

STIC-Biotech/ChemLib

170813

11/9

From: Swope, Sheridan
Sent: Friday, November 04, 2005 7:20 PM
To: STIC-Biotech/ChemLib
Subject: FW: 10/791,980

Jan De Groot

-----Original Message-----

From: Low, Christopher
Sent: Friday, November 04, 2005 7:19 PM
To: Swope, Sheridan; Woodward, Michael
Cc: Page, Thurman; Richter, Johann
Subject: RE: 10/791,980

RECEIVED
NOV - 7 2005
STIC/BIOTECH/CHM LIB
(STIC)

Rush approved.

-----Original Message-----

From: Swope, Sheridan
Sent: Fri 11/4/2005 4:42 PM
To: Woodward, Michael
Cc: Low, Christopher; Page, Thurman; Richter, Johann
Subject: FW: 10/791,980

Please reply all, so we know there's been a response.
Thanks,

-----Original Message-----

From: Swope, Sheridan
Sent: Friday, November 04, 2005 4:41 PM
To: Chan, Christina
Subject: 10/791,980

*Jan, 22504
11/7 - 11/14*

Chris, May I have this rushed for an allowance?
Not enough hits were retrieved to cover the recited scope.

For 10/791,980, pls search--only the requested databases:

SID 6 against the Published Applications (.rnpb) database.
Collect the top 250 alignments.

SID 6 against the N_Geneseq_16Dec04 (.rng) database.
Collect the top 250 alignments.

Sheridan Swope, Ph.D.
Patent Examiner, AU 1656
Recombinant Enzymes
571-272-0943 (voice)

11/7/2005

THIS PAGE BLANK (USPTO)

E02B71 Remsen Bld (Office)
E03C70 Remsen Bld (Mailbox)

11/7/2005

THIS PAGE BLANK (USPTO)

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: November 14, 2005, 11:19:51 ; Search time 695 Seconds

(without alignments)
4429.159 Million cell updates/sec

Title: US-10-791-980-6

Perfect score: 2834

Sequence: 1 MVARYGLLRLLQLLLWGHLL.....WATLPMGWCWANGSGSALF 520

Scoring table: BLOSUM62

Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 8780412

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 300 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp
-Q/cgn2_1/USPTO_spoor_p/US10791980/runat_09112005_121055_27725/app_query.fasta_1.711
-DB=N Geneseq 16Dec04 -QFMT=fastcap -SUFFIX=ring -MINMATCH=0.1 -LOOPEL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=300 -DOALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=250
-MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US10791980 @CGN_1.1.708 @runat_09112005_121055_27725 -NCPU=6 -ICPU=3
-NO_WMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THRAIDS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : N Geneseq 16Dec04:*

1: Geneseqn1980s:.*
2: Geneseqn1990s:.*
3: Geneseqn2000s:.*
4: Geneseqn2001as:.*
5: Geneseqn2001bs:.*
6: Geneseqn2002as:.*
7: Geneseqn2002bs:.*
8: Geneseqn2003as:.*
9: Geneseqn2003bs:.*
10: Geneseqn2003cs:.*
11: Geneseqn2003ds:.*
12: Geneseqn2004as:.*
13: Geneseqn2004bs:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2834	100.0	1597	6	AAD23965 Human mat
2	2792	98.5	1563	4	AAD23373 Human MPR
3	2792	98.5	1985	4	AA21315 Human CDN
4	2792	98.5	1985	8	ACA03674 cDNA enco
5	2792	98.5	1985	8	ABX89212 DNA encod

6	2792	98.5	1985	8	ACD41866	ACD41866 Human sec
7	2792	98.5	1985	8	ACA04095	ACA04095 Human CDN
8	2792	98.5	1985	9	ADA45662	ADA45662 Novel hum
9	2792	98.5	1985	9	ADA76093	ADA76093 Human PRO
10	2792	98.5	1985	9	ADA18743	ADA18743 Human PRO
11	2792	98.5	1985	9	ADA61366	ADA61366 Homo sapi
12	2792	98.5	1985	9	ADB19151	ADB19151 Novel hum
13	2792	98.5	1985	9	ADB27692	ADB27692 cDNA enco
14	2792	98.5	1985	9	ADA86171	ADA86171 Novel hum
15	2792	98.5	1985	9	ADB15735	ADB15735 Human PRO
16	2792	98.5	1985	9	ADA47521	ADA47521 Human PRO
17	2792	98.5	1985	9	ADA67316	ADA67316 Human PRO
18	2792	98.5	1985	9	ADB30323	ADB30323 cDNA enco
19	2792	98.5	1985	9	ADA85619	ADA85619 Novel hum
20	2792	98.5	1985	9	ADA96831	ADA96831 Human PRO
21	2792	98.5	1985	9	ADA79135	ADA79135 Human PRO
22	2792	98.5	1985	9	ADA87274	ADA87274 Novel hum
23	2792	98.5	1985	9	ADB16476	ADB16476 Human PRO
24	2792	98.5	1985	9	ADA91568	ADA91568 Novel hum
25	2792	98.5	1985	9	ADB14631	ADB14631 Human PRO
26	2792	98.5	1985	9	ADB18592	ADB18592 Novel hum
27	2792	98.5	1985	9	ADA93807	ADA93807 Human PRO
28	2792	98.5	1985	9	ADB19703	ADB19703 Novel hum
29	2792	98.5	1985	9	ADB13015	ADB13015 Human PRO
30	2792	98.5	1985	9	ACD98495	ACD98495 Novel hum
31	2792	98.5	1985	9	ADA74269	ADA74269 Human PRO
32	2792	98.5	1985	9	ADB24502	ADB24502 Human PRO
33	2792	98.5	1985	9	ADA82026	ADA82026 Human PRO
34	2792	98.5	1985	9	ADA74989	ADA74989 Human PRO
35	2792	98.5	1985	9	ADA85067	ADA85067 Novel hum
36	2792	98.5	1985	9	ADA84515	ADA84515 Novel hum
37	2792	98.5	1985	9	ADB29771	ADB29771 cDNA enco
38	2792	98.5	1985	9	ADA80299	ADA80299 Human PRO
39	2792	98.5	1985	9	ADA75541	ADA75541 Human PRO
40	2792	98.5	1985	9	ADA46766	ADA46766 Human PRO
41	2792	98.5	1985	9	ADB25062	ADB25062 Human PRO
42	2792	98.5	1985	9	ADA93238	ADA93238 Human PRO
43	2792	98.5	1985	9	ADB26588	ADB26588 cDNA enco
44	2792	98.5	1985	9	ADB30875	ADB30875 cDNA enco
45	2792	98.5	1985	9	ADA60803	ADA60803 Homo sapi
46	2792	98.5	1985	9	ADB23950	ADB23950 Human PRO
47	2792	98.5	1985	9	ADA96279	ADA96279 Human PRO
48	2792	98.5	1985	9	ADA80851	ADA80851 Human PRO
49	2792	98.5	1985	9	ADA95727	ADA95727 Human PRO
50	2792	98.5	1985	9	ADB26036	ADB26036 cDNA enco
51	2792	98.5	1985	9	ADB21521	ADB21521 Novel hum
52	2792	98.5	1985	9	ADA77300	ADA77300 Human PRO
53	2792	98.5	1985	9	ADB18040	ADB18040 cDNA enco
54	2792	98.5	1985	9	ADA86723	ADA86723 Novel hum
55	2792	98.5	1985	9	ADA87826	ADA87826 Novel hum
56	2792	98.5	1985	9	ADA46214	ADA46214 Novel hum
57	2792	98.5	1985	9	ADB28244	ADB28244 cDNA enco
58	2792	98.5	1985	9	ADB28796	ADB28796 cDNA enco
59	2792	98.5	1985	9	ADA76748	ADA76748 Human PRO
60	2792	98.5	1985	9	ADA88378	ADA88378 Novel hum
61	2792	98.5	1985	9	ADA97383	ADA97383 Human PRO
62	2792	98.5	1985	9	ADB27140	ADB27140 cDNA enco
63	2792	98.5	1985	9	ADB22073	ADB22073 Novel hum
64	2792	98.5	1985	9	ADA66764	ADA66764 Human PRO
65	2792	98.5	1985	9	ADB22625	ADB22625 Human PRO
66	2792	98.5	1985	9	ADB23398	ADB23398 Human PRO
67	2792	98.5	1985	9	ADA92120	ADA92120 Novel hum
68	2792	98.5	1985	9	ADB15183	ADB15183 Human PRO
69	2792	98.5	1985	9	ADB38435	ADB38435 Novel hum
70	2792	98.5	1985	9	ADB37883	ADB37883 Novel hum
71	2792	98.5	1985	9	ADB66355	ADB66355 Novel hum
72	2792	98.5	1985	10	ADB89435	ADB89435 Human PRO
73	2792	98.5	1985	10	ADB90167	ADB90167 Human PRO
74	2792	98.5	1985	10	ADB39268	ADB39268 Novel hum
75	2792	98.5	1985	10	ADB46891	ADB46891 Novel hum
76	2792	98.5	1985	10	ADB86498	ADB86498 Human PRO
77	2792	98.5	1985	10	ADB77103	ADB77103 Novel hum
78	2792	98.5	1985	10	ADB34260	ADB34260 Human PRO

[illegible]

XX

AAS21315
 ID AAS21315 standard; cDNA; 1985 BP.
 XX
 AC AAS21315;
 XX
 DT 24-OCT-2001 (first entry)
 XX
 DE Human cDNA sequence encoding for PRO4339 polypeptide.
 XX
 KW Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
 KW prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
 KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
 KW A-peptide; factor VIIa; gene therapy; ss.
 XX
 OS Homo sapiens.
 PN WO200140466-A2.
 XX
 PD 07-JUN-2001.
 XX
 PF 01-DEC-2000; 2000WO-US032678.
 XX
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 09-DEC-1999; 99US-0170262P.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000US-0187202P.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 05-JUN-2000; 2000US-0209832P.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
 XX
 WPI: 2001-408281/43.
 DR P-PSDB; AAU12243.
 DR
 XX Isolated , secretory and transmembrane PRO polypeptide used to detect
 PT other PRO polypeptides, link bioactive molecules to cells expressing PRO

polypeptides, and detect the presence of mammalian tumors e.g. lung,
 breast, prostate, cervical.
 Claim 3; Fig 143; 813pp; English.
 AAS21244-AAS21518 encode for novel human secretory and transmembrane PRO
 polypeptides. The PRO polypeptides are useful to detect other PRO
 polypeptides, to link bioactive molecules to cells expressing PRO
 polypeptides, to modulate biological activities of cells expressing PRO
 polypeptides, and to detect the presence of mammalian lung, colon,
 breast, prostate, rectal, cervical or liver tumours by comparing PRO
 polypeptide expression in a cell sample to that in a control sample. Some
 of the 275 sequences are also useful to stimulate the release of tumour
 necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
 differentiation of chondrocytes, the proliferation or gene expression in
 pericyte cells, the release of proteoglycans from cartilage, the
 proliferation of inner ear utricular supporting cells or of T-
 lymphocytes, the release of a cytokine from peripheral blood monocytes
 (PBMCs), or the proliferation of endothelial cells. Some of the PRO
 polypeptides may modulate glucose or free fatty acid uptake by skeletal
 muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
 VIIa. The PRO polypeptides can be used in assays to identify molecules
 involved in binding interactions. The polynucleotides encoding PRO
 polypeptides can be used to generate probes, antisense RNA/DNA,
 transgenic or knock out animals and can be used in gene therapy
 SQ Sequence 1985 BP; 403 A; 646 C; 504 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 4 Gaps: 0

US-10-791-980-6 (1-520) x AAS21315 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB ATGGTCGCGCGTGGGCTCTCTGCGGCCCTGCAGCTGCTACTGTGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB GACGCCAGCCCGCGGAGCGCGGAGCGAGCTGCGCAAGAGGCGGAGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCGATTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB GATGCCATCAGCGGTTTCAGTGGGTGTCAGCTACTGTTCAGCGGGGTGTTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATAGCGGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB AAGCGCTTGGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTTACCGCTGTGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB AACTGGCTGAGCATCTGCCGAGCCGCGAGTTCGGGGCGCGTGGCGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCCGCAGCCAGGCGCCGCTGAC 745

PR 27-JAN-2000; 2000GB-00001898.
XX (SMIK) SMITHKLINE BEECHAM PLC.
XX
XX Southern CD, Hughes AS;
XX
XX WPI; 2001-457732/49.
DR P-PSDB; AAB85427.
XX
XX An isolated polypeptide treatment of diseases relating to MPROT45
PT polypeptide including arthritis, respiratory diseases, thrombosis,
PT diabetes, cancer.
XX
PS Claim 4; Page 22; 28pp; English.
XX
XX This cDNA encodes a human MPROT45 polypeptide. The polypeptide can be
CC expressed by standard recombinant methodology. The MPROT45 polypeptide,
CC antibodies and their agonists or antagonists are useful in the treatment
CC of diseases relating to MPROT45 polypeptide including arthritis,
CC respiratory diseases, thrombosis, diabetes, cancer, inflammatory
CC disorders, osteoporosis, cardiovascular disorders, hypertension, stroke,
CC asthma, neurodegenerative diseases such as Alzheimer's, Parkinson's,
CC depression and other CNS disorders or as a vaccine. They are also useful
CC for diagnosis or determining susceptibility
XX
XX Sequence 1563 BP; 283 A; 519 C; 484 G; 277 T; 0 U; 0 Other;
SQ

Alignment Scores:
Pred. No.: 1.5e-149 Length: 1563
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 4 Gaps: 0

US-10-791-980-6 (1-520) x AAH23373 (1-1563)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 1 ATGGTCGCGCGGTCGCGCTCTGCTGCGCGGCTGACGTGCTACTGTGGGGCCACCTG 60
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 61 GAGCCCGAGCCCGGAGCGCGAGCGCAGGAGCTGCGCAAGGAGCGGAGCAATTCCTA 120
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 121 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 180
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 181 GATGCCATCAGACGGTTTCAGTGGGTGTCACAGCTACCTGTCAGCGCGGTGTGGACCC 240
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 241 GCCACCTCGCCAGATGACTGTCTCCCGCTGCGGGGTACAGATACCAACAGTTATGG 300
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 301 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGGCTAAG 360
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 361 AAACGCTTTGCAAGCAGAGTAACAAATGGTACAGCAGCACCTCTCTACCGCCTGGTG 420
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 421 AACTGGCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGGCTTCCAG 480
QY 160 rCysGlyAlaThrSerClnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 481 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCTCGTAC 540

RESULT 3

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 541 ATCCGGCTCACCTTCTTCCAGAGGGACACACCATGGCTGGGCATATGCTTTGATGGC 600
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 601 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 659
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 660 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTTCTGGTGGTGGCGCA 719
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 720 CGAATCGGTCAACAGCTTGGCCTCACCCACTCCCGCGCGCGCGCTCATGGCGCC 779
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 780 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 839
QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 840 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 899
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 900 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGACGG 959
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 960 CCCTAAATATCTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACGCAACTGTA 1019
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1020 CATTTTAAAGGGAGCCCAITTTCTGGAGGTGGAGCTGATGGCAACGCTCAGAGCCCG 1079
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
DB 1080 TCCACTGCAGGAAGATGGTGGGTCGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCAAT 1139
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys 400
DB 1140 GAATGATGGAGATTTCTACTTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGGCCCAA 1199
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1200 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCCGCCATCTGTAGCG 1259
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1260 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGCT 1319
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1320 SCTGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGCTGACAGACTGGGG 1379
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1380 AGGCATCTCTGAGGAGGTGAGCGGCGCTTCCCGAGGCCGATGCTCATCATCTTCTT 1439
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1440 CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAAACTGCAAGGCAACACCTCGGGCG 1499
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1500 CTGGGCGCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1559
QY 520 e 520
DB 1560 C 1560


```
QY 180 rSerGlySerProSerSerIysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGCTGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGGGCCCTGGCGCACGCTTC-CTGGCCCGCGCGCGCAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTyrSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHis 240
Db 865 AGATGAGCGCTGGTCTCTGAGCCCGCGCGCGCAACCTGTTCTGTTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTTGGCTCACCCCACTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTyrAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTTGATGGAAAGCCCTAGGGGGCTCAGTGGCGGCTCCAGCTCCCAAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCGCAAGGAGCGCCCTGAAACGCAAGG 1164
QY 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAAATATGCTCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrTyrGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCATTTCTGGGAGGTGGCGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAenIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGAGTGGTGGGCTGCCCCCAACATTGAGGTGGCGCACTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTyrTrpArgPheArgGlyProIy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgIleGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCCAAGCTGTGCCGGCAGGGGGCCCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGTGGCGGTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGGGGGCCCTGCCGAGGGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTTGACCAAGGCCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrPheHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGAGTGGCTGCTGGCATGCCAACTCGGGAGGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
```

```
RESULT 4
ACA03674
ID ACA03674 standard; cDNA; 1985 BP.
XX
AC ACA03674;
XX
DT 23-MAY-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
differentialiation; chondrocyte; tumour; genetic disorder; cytostatic; gene;
KW
XX
OS Homo sapiens.
XX
PN US2003036180-A1.
XX
PD 20-FEB-2003.
XX
PF 09-MAY-2002; 2002US-00143114.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003431.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
```


Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCCCGCGCGCGCTCATCGCGCC 984
Qy 260 oTyrTyrlsArLeuGlyArAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAAGAGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGA 1044
Qy 280 nSerLeuTyrlsArLeuGlyArAspValLeuValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrlsSerProGlnGlyArGArgProGluThrGlnGI 320
Db 1105 GACTGACTTTAGACTGGAGCTCTTACAGCCCAAGAGCGCCCTGAAACGAGGG 1164
Qy 320 yProLysTyrlsArLeuGlyArAspAlaLeuValLeuValGlnGlnLeuTy 340
Db 1165 CCCTAAATACGCACTCTTCTTCGATGCTCATCTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaLeuValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCACTTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProHsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGATGGTCCGGCTGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrlsPhePheLysGlyArGArgTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuGlyArGAlaGlyLeuProArGHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCGCCGCACTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrlsVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGGTGCCGCTACTACGT 1524
Qy 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrlsTrpArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGNAGCTGCGAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCTGCGAGGCGGATGCTCATCTCTTCTT 1644
Qy 480 eArgAspAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGGCAAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAAGAGCTGCTGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 5
ID ABX89212
XX ID ABX89212 standard; cDNA; 1985 BP.
XX AC
XX ABX89212;
XX DT 13-MAY-2003 (first entry)
DE DNA encoding novel secreted and transmembrane protein PRO4339.
DE Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;

KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney meangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ss.
XX Homo sapiens.
OS US2003017563-A1.
XX PN 23-JAN-2003.
XX PD 07-MAY-2002; 2002US-00140808.
XX PF 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028651.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.

```
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854280.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
XX WPI; 2003-148238/14.
XX P-PSDB; ABU59722.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; Fig 143; 659pp; English.
XX
XX The invention describes an isolated human PRO polypeptide. The PRO
XX polypeptides are useful in detecting PRO polypeptides in a sample, in
XX linking a bioactive molecule to a cell expressing a PRO polypeptide, and
XX in modulating at least one biological activity of a cell expressing a PRO
XX polypeptide. PRO312 stimulates hypertrophy of neonatal heart and is thus
XX useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
XX stimulate adrenal cortical capillary endothelial growth, and PRO536,
XX PRO943, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
XX PRO3360 and PRO1387 induce c-fos in endothelial cells, and are thus
XX useful for treating conditions or disorders where angiogenesis would be
XX beneficial, e.g. wound healing and antagonist of this polypeptide are
XX useful for treating cancerous tumours. PRO812 inhibits vascular
XX endothelial growth factor (VEGF) stimulated proliferation of endothelial
XX cells and is thus useful for inhibiting endothelial cell growth in
XX mammals which would be beneficial in inhibiting tumour growth. PRO826,
XX PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
XX stimulated T-lymphocytes and are therapeutically useful for enhancing
```

```
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are
CC thus useful for treating sports injuries, and arthritis. This sequence
CC encodes a novel human PRO protein
XX
```

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

```
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 8 Gaps: 0
```

US-10-791-980-6 (1-520) x ABX89212 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGCGCTCTCTGCTGCGGCCCTCAGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGGAGCGGAGCTGCGAAGGAGCGGAGGCGGATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCTTTCAGTGGGTGTCCAGAGTACTGTTCAGCGGGCGTGTTCGACGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTTCGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrrpTrrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCGCAAGGATTAACAATGGTACAGCAGCACCTCTCTACCGCTGTGTG 625
Qy 141 AsnTrrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGAGCGGAGCTTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTAGCCCTCAGGCTTCGGGAGGGCCCGCCAGCCAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGGCTGCGGCGACGCTTC-CTGCCCCCGCGCGGAGCGGCACTTCGACCA 864
Qy 220 nAspGluArgTrrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTTGAGCCCGCGCGGCGGCGCAACTGTTCGTGGTGTGCTGGCGCA 924
```

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrtTyrtLysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGCGCGCTGCA 1044
Qy 280 nSerLeuTyrtGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrtSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAG 1164
Qy 320 yProLysTyrtCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATAACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGCATT 1344
Qy 380 uAsnAspGlyAspPheTyrtPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTCAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCGAGTGTGGGTCTCCCAAGCTGTGGCGGGGGGCGCTGCCCGCCATCTCGAGCG 1464
Qy 420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrtTyrtVa 440
Db 1465 CGCCCTCTTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrtTyrtProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGACTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCTCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCTCTT 1644
Qy 480 eArgAspAspArgTyrtTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGACCGAGTGGCGCTGGATGGGTCTGGCATGCCAACTCGGGAGCGCGCTGT 1764
Qy 520 e 520
Db 1765 c 1765
RESULT 6
ACD41866
ID ACD41866 standard; cDNA; 1985 BP.
XX ACD41866;
AC ACD41866;
XX
DT 05-SEP-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #72.
XX Human; ss; gene; PRO; secreted protein; transmembrane protein; tumour;
KW cytostatic; gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;
KW proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;

KW PBMC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;
KW chondrocyte cell proliferation; chondrocyte cell differentiation;
KW pericyte cell; inner ear usricular supporting cell; T-lymphocyte cell;
KW endothelial cell; A-peptide; factor VIIA.

OS Homo sapiens.

XX US2003036179-A1.

XX 20-FEB-2003.

PF 10-MAY-2002; 2002US-00142431.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 10-MAR-2000; 2000WO-US006319.

PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.


```
QY 200 aGlnGlyAlaProTrrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCCCTGAGCGCGCGCGCGCAACCTGTTCTGGTGGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProAtqAlaLeuMetAlaPr 260
Db 925 CGGATCGGTACACGCTGGCGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 tTyrrLyArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAAGAGCTGGCGCGCGCGCTGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
QY 280 nSerLeuTyrrGlyLyProLeuGlyGlySerValAlaValGlnLeuProGlyLyLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCGTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCCTAGAGCCCGCGGAGGCGCCCTGAAACGCGAGG 1164
QY 320 yProLyTyrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLyGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGAGCCATTTCTGGGAGGTGGCGCTGATGGCAACGTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrrValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
Db 1285 TCACCTGCGAAGAAAGATGGTGGCTGCCCGCCCAACATGAGGCTGGCGGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrrPhePheLyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCATCTCTAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLyGlyAlaAtqTyrrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCACTCCCTAGAGAGGTGAGCGGGCGCTGCGGAGGCGCGATGGCTCATCTCTTCTT 1644
QY 480 eArgAspAspArgTyrrTrpArgLeuAspGlnAlaIleLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGGCGCTCGACAGGCGCAAACTGCAGGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 7
ACA04095
ID ACA04095 standard; cDNA; 1985 BP.
XX
AC ACA04095;
```

```
XX
DT 27-MAY-2003 (first entry)
XX
DE Human cDNA encoding a secreted/transmembrane protein, SEQ ID 143.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defects; premature aging; AIDS; biosensor;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW bioindicator; tumour.
XX
OS Homo sapiens.
XX
PN US2003032155-A1.
XX
PD 13-FEB-2003.
XX
PF 03-MAY-2002; 2002US-00137865.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
```


Db 806 CAGGGGGGCGCTGGCGACGCTTC-CTGCCCCCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAepGluArgTTPSerSerArgArgGlyArgAsnLeuPheValValLeuAlaIh 240
Db 865 AGATGAGCGCTGGTCTCCAGCGCGCGCGCGCAACCTGTTCTGTTGGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGGCGC 984
Qy 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAAGAGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGGCCCTTAGGGGCTCAGTGGCGGTCCAGCTCCACAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACTGGGACTCCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATATGCTCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCATTTCTGGGAGGTGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTTCGGCTGCCCCCAACATTGAGGCTGGCGAGTCTCAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGGGACGGGGGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGCGCGTACTACTGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTAGCGGGCGCTTCCGAGGCCGATGCTCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGGCTCTGCACGAGGCCAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 8
ADA45662
ID ADA45662 standard; cDNA; 1985 BP.
XX
AC ADA45662;
XX

DT 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO4339 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003022328-A1.

XX 30-JAN-2003.

XX 16-APR-2002; 2002US-00123904.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022291.

PR 20-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 11-FEB-2000; 2000WO-US000376.

PR 18-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 22-FEB-2000; 2000WO-US004342.

PR 24-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 01-MAR-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

Db 806 CCAGGGGGCCCTGGCGCACGCCCTTC-CTGCCCCCGCCGCGGAGCGCCTTCGACCA 864
Qy 220 nAepGluArgTfPsrLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGCAACCTGTTCTGGTCTCGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCCCGCGCGCGCTCATGCGCGC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGAGCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGACGG 1164
Qy 320 yProlystTyrCysHisSerSerPheAspAlaThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCACTTTCTGGAGGTGGCAGCTGATGGCAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTfPValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTCTACTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCyArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCTGCCCCGCCATCTTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTCTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGGCCCTTACCCCCGAGCTTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGGCCCTGCGAGGGCCGATGGCTCATCACTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTGCGCGCTCGACCAGGCCAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 9
ADA76093
ID ADA76093 standard; cDNA; 1985 BP.
XX
AC ADA76093;
XX
DT 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #72.

DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

XX US2003073212-A1.

PD 17-APR-2003.

XX 16-APR-2002; 2002US-00123903.

PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 200WO-US005746.
PR 02-MAR-2000; 200WO-US005841.
PR 10-MAR-2000; 200WO-US006319.
PR 15-MAR-2000; 200WO-US006884.
PR 20-MAR-2000; 200WO-US007377.
PR 21-MAR-2000; 200WO-US007532.
PR 30-MAR-2000; 200WO-US008439.
PR 17-MAY-2000; 200WO-US013705.
PR 22-MAY-2000; 200WO-US014042.
PR 30-MAY-2000; 200WO-US014941.
PR 02-JUN-2000; 200WO-US015264.
PR 28-JUL-2000; 200WO-US020710.
PR 11-AUG-2000; 200WO-US022031.
PR 23-AUG-2000; 200WO-US023522.
PR 24-AUG-2000; 200WO-US023328.
PR 08-NOV-2000; 200WO-US030932.
PR 10-NOV-2000; 200WO-US030873.
PR 01-DEC-2000; 200WO-US032678.
PR 20-DEC-2000; 200WO-US074259.
PR 20-DEC-2000; 200WO-US034956.
PR 28-FEB-2001; 200IUS-00736498.
PR 28-FEB-2001; 200IUS-00760520.
PR 01-MAR-2001; 200IWO-US006666.
PR 09-MAR-2001; 200IUS-00802706.
PR 14-MAR-2001; 200IUS-00808689.
PR 22-MAR-2001; 200IUS-00816744.
PR 05-APR-2001; 200IUS-00828366.
PR 10-MAY-2001; 200IUS-00854208.
PR 10-MAY-2001; 200IUS-00854280.
PR 18-MAY-2001; 200IUS-00860216.
PR 25-MAY-2001; 200IUS-00866028.
PR 25-MAY-2001; 200IUS-00866034.
PR 25-MAY-2001; 200IWO-US017092.
PR 01-JUN-2001; 200IUS-00872035.
PR 01-JUN-2001; 200IWO-US017800.
PR 05-JUN-2001; 200IUS-00874503.
PR 14-JUN-2001; 200IUS-00882636.
PR 19-JUN-2001; 200IUS-00886342.
PR 20-JUN-2001; 200IWO-US019692.
PR 21-JUN-2001; 200IUS-00887879.
PR 22-JUN-2001; 200IWO-US020116.
PR 29-JUN-2001; 200IWO-US021066.
PR 09-JUL-2001; 200IWO-US021735.
PR 18-JUL-2001; 200IUS-00908827.
PR 06-AUG-2001; 200IUS-00924419.
PR 09-AUG-2001; 200IUS-00927796.
PR 16-AUG-2001; 200IUS-00931836.
PR 19-DEC-2001; 200IUS-00028072.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-687639/65.
DR P-PSDB; ADA76094.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 143; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as

hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA76093 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrrGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGCGCCCTCTGCTGCGCGCCCTGCAGCTGTCTACTGTGGGGCCACTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCCAGCCCGGAGCGCGGAGGCCAGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTGAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCCATCAGAGCGTTTCAGTGGGTGTCAGTCTCTGTCAGCGCGGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATAGGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrrTrrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAATAATGGTACAAAGCAGCACCTCTCTACCGGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCGCGCGCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACCTCTCAGCGCTGGAGTTCTTGGAGAGCCCGCAGCCAGGCCCCGCTGAC 745

QY 180 rSerGlySerProSerSerlyseGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
DB 806 CCAGGGGGGGCCCTGGCGACGCTTC-CTGGCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTyrSerLeuSerArgArgArgGlyArgAenLeuPheValValAlaHis 240
DB 865 AGATGAGCGCTGTCTCTGAGCCCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACAGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGACAGG 1164
QY 320 yProlystTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAAATACTGCACACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTyrProGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGACATTTCTGGGAGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAenIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCCCAACATTTAGGCTGCGGCACTGTCTATT 1344
QY 380 uAenAspGlyAspPheTyrPhePheLysGlyArgCysTyrProArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGGGGGCGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGCCTGCTACTACTGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
DB 1525 GCTGGCGCCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGCAAGTCTCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGCTCAGCGGGCGCTTGGCGAGGCGCGATGGCTCATCTCTTCT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAGGCGCAAACTGCGAGGCACCACTTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCGCCAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 a 520
DB 1765 c 1765
RESULT 10

ADA18743
ID ADA18743 standard; cDNA; 1985 BP.
XX
AC ADA18743;
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
OS Homo sapiens.
XX
PN US2003054517-A1.
XX
PD 20-MAR-2003.
XX
PF 08-MAY-2002; 2002US-00141755.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 13-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.


```
Db      806  C C A G G G G G C C C T G T G C G C A C G C C T T C - C T G C C C C G C G C G A G C G C A C T T C G A C C A 864
Qy      220  n A p G l u A r g T r p S e r L e u S e r A r g A r g G l y A r g A s n L e u P h e V a l V a l L e u A l a h i 240
Db      865  A G A T G A G C G C T G T C C T G A G C G C G C G C G C G C A A C C T G T T C G T G T G T C G T G C G C A 924
Qy      240  s G l u l e G l y H i s T h r L e u G l y L e u T h r H i s S e r P r o A l a P r o A r g A l a L e u M e t A l a P r 260
Db      925  C G A G A T C G G T C A C A C G T T G G C C T C A C C C A C T C G C C G C G C G C G C G C T C A T G C G C G C 984
Qy      260  o f T r T y r L y s A r g L e u G l y A r g A s p A l a L e u L e u S e r T r p A s p V a l L e u A l a V a l G l 280
Db      985  C T A C T A C A A G A G C T G G G C G C G A C G C G T G C T A G C T G G G A C G A C G T G C T G C G C G T G C A 1044
Qy      280  n S e r L e u T y r G l y L y s P r o L e u G l y L y s S e r V a l A l a V a l G l n L e u P r o G l y L y s L e u P h 300
Db      1045  G A G C C T G T A T G G A G C C C T A G G G G C T C A G T G C C G T C C A G C T C C C A G G A A A G C T G T T 1104
Qy      300  e T h r A s p P h e G l u T h r T r p A s p S e r T y r S e r P r o G l n G l y A r g A r g P r o G l u T h r G l n G l 320
Db      1105  C A C T G A C T T T G A G A C T G G G A C T C C T A C A G C C C C A A G A G C G C C C T G A A A C G C A G G G 1164
Qy      320  y P r o L y s T y r C y s H i s S e r S e r P h e A s p A l a l e T h r V a l A s p A r g G l n G l n L e u T y 340
Db      1165  C C C T A A A T A C T G C C A C T C T T C C T T C G A T G C C A T C A C T G T A G A C A G C A A C A G C A A C T G T A 1224
Qy      340  r l e P h e L y s G l y S e r H i s P h e T r p G l u V a l A l a A l a A s p G l y A s n V a l S e r G l u P r o A r 360
Db      1225  C A T T T T T A A G G A G C C A T T C T G G A G G T G C A G C T G A T G C A A C G T C T C A G A G C C C G G 1284
Qy      360  g P r o L e u G l n G l u A r g T r p V a l G l y L e u P r o P r o A e n l l e G l u A l a A l a V a l S e r L e 380
Db      1285  T C C A C T G C A G A A A G A T G G T C G G G C T G C C C C C A A C A T T G A G G C T G C G G C A G T C T C A T T 1344
Qy      380  u A s n A s p G l y A s p P h e T y r P h e P h e L y s G l y A r g C y s T r p A r g P h e A r g G l y P r o L y 400
Db      1345  G A A T G A T G G A G A T T T C T A C T T C T C A A G G G G T C G A T G C T G A G G T T C C G G G G C C C A A 1404
Qy      400  s P r o V a l T r p G l y L e u P r o G l n L e u C y s A r g A l a G l y L y s L e u P r o A r g H i s P r o A s p A l 420
Db      1405  G C C A G T G G G G T C T C C C A C A C T G T G C G G C A G G G G C C T G C C C C G C A T C C T G A G C G C 1464
Qy      420  a A l a L e u P h e P r o P r o L e u A r g A r g L e u l l e L e u P h e L y s G l y A l a A r g T y r T y r V a 440
Db      1465  C G C C C T C T T C C C T C C T G C G C G C C T C A T C C T T C A A G G G T G C C G C T A C T A C G T 1524
Qy      440  l l e u A l a A r g G l y L e u G l n V a l G l u P r o T y r T y r P r o A r g S e r L e u G l n A s p T r p G l 460
Db      1525  G C T G C C C G A G G G G A C T G C A A G T G G A G C C C T A C C C C G A A G T C T G C A G G A C T G G G G 1584
Qy      460  y G l y l e P r o G l u G l u V a l S e r G l y A l a L e u P r o A r g P r o A s p G l y S e r l l e l l e P h e P h 480
Db      1585  A G G C A T C C C T A G A G G T C A G G G G C C C T G C C G A G G C C G A T G C T C C A T C A T C T T C T T 1644
Qy      480  e A r g A s p A r g T y r T r p A r g L e u A s p G l n A l a L y s L e u G l n A l a T h r T h r S e r G l y A r 500
Db      1645  C C G A G A T G A C C G T A C T G G C G C T C G A C A G G C C A A C T G C A G G C A A C A C C T C G G G C G G 1704
Qy      500  g T r p A l a T h r G l u L e u P r o T r p M e t G l y C y s T r p H i s A l a A s n S e r G l y S e r A l a L e u P h 520
Db      1705  C T G G C C C A C C G A G T G C C T G G A T G G G T G C T G G C A T G C C A A C T C G G G A G C G C C T G T T 1764
Qy      520  e 520
Db      1765  C 1765
RESULT 11
ID ADA61366
XX ADA61366 standard; cDNA; 1985 BP.
AC ADA61366;
XX
```



```
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004343.
PR 22-FEB-2000; 2000WO-US004344.
PR 24-FEB-2000; 2000WO-US004345.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023322.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
XX WPI; 2003-695892/66.
XX
XX P-PSDB; ADA61367.
XX
XX New PRO nucleic acid and encode polypeptides, are useful for
PT manufacturing a medicament for diagnosing or treating cancer.
XX
XX Claim 2; Fig 143; 660pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
```

```
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear uricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
SQ
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
US-10-791-980-6 (1-520) x ADA61366 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCGGGCTCTCTGCGCGCCCTGAGCTGTCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG 325
Qy 41 GlulysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCTCCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGTGTCCAGCTACTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGGTGGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTTGTGTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTGCACCAAGGTAAACAAATGGTACAAAGCAGACACCTCTCTCCGCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGCGGAGCTTGGGGCGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTCTCTGGGAGGCGCCCGGAGGCGCCCGCTGAC 745
```



```
QY 180 rSerGlySerProSerSerSerGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCCTTTGATGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTyrSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCAGCGCGCGCGCGGCGCAACCTGTTCGTGGTCTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCTCACCCCTACCCCTCGCCCGCGCGCGCTCATGGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGAGCTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACCTTTGAGACTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATATCTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGAGCTGATGGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGGCGAGTGCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCGCGGGGCCCA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCACAGCTGTGGCGGAGGGGCGCTGCCCCCGCATCCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
Db 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGGGGCGCTGCGGAGGCGCGATGGCTTCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGGCAAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGCCGAGCTGCCCTGGATGGCTGCTGGCATGCCAATCGGGGAGCGCGCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 12
```

```
ADB19151
ID ADB19151 standard; cDNA; 1985 BP.
XX
AC ADB19151;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokin.
XX
OS Homo sapiens.
XX
PN US2003068796-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123261.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 29-OCT-1999; 99WO-US021547.
PR 05-NOV-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
```



```
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATAGTCCCACTTCTCTCGATGCACTAGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheTysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCATTTCTGGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheTysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCCAAGCTGTGCCGGCAGGGGCCCTGCCCCGCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheTysGlyValAlaArgTyrVa 440
Db 1465 CGCCCTCTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGCCCGCTACTAGT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
QY 460 yClyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleAlaPhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGGCCCTGCCGAGGCCGATGCGTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVa 500
Db 1645 CCGAGATGACCCCTACTGCGGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGCTGCTGGCATGCCAATCGGAGGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 13
ID ADB27692 standard; cDNA; 1985 BP.
AC ADB27692;
XX 20-NOV-2003 (first entry)
DE cDNA encoding human PRO polypeptide #72.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082704-A1.
XX
PD 01-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131819.
XX
```

```
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-765415/72.
DR P-PSDB; ADB27693.
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX Claim 2; Fig 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
```

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADB27692 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

Db 206 ATGGTCGCGCGTCCCTCTGTCGCCCTCTGTCAGCTGCTACTTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40

Db 266 GACGCCAGCCCGCGGAGCCGAGGAGCTGGCAAGGAGGCGGAGGATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60

Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACCTGATTACAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGGGGGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTAGAGGATCAGTCACTTGTGTGACACCGCGACCAAAATGAGGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCCTCAGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGACATCTCCGAGCGCGGAGTTCCGGGGCGCGTCCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCACCAACGATGGGCTGGGCAATGSCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CAGGGGGCGCCCTGGCGACCGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCCTCAGCGCGCGCGCGGCGCAACCTGTTGCTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CAGATTCGCTCACGCTTGGCTCACCACCTCGCCCCCGCGCGCGCTCATGCGCGCC 984
Qy 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGAGCGCTGCTCAGCTGGAGCGAGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGCCCCCAAGAAAGCGCCCTGAAACGCGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCATAAATACTGCCACTCTCTTCGATGCCATCAGTGTAGCAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGGAGGTTCGGGCCCCCAA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCGGGCCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCATCCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGCGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCAACCTGCAGGCAACCCACTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCATGCCAACTTCGGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 14
ADA86171
ID ADA86171 standard; cDNA; 1985 BP.
XX
AC ADA86171;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082711-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147508.
XX
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUN-1999; 99WO-US012252.
PR 07-JUL-1999; 99WO-0143048P.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Deenoysers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786914/74.
DR P-PSDB; ADA86172.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX

PS Claim 2; Fig 143; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF- α from human blood, for modulating the uptake of glucose or PFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA86171 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGCGCGGCTCTCTGCTGCGCGCTCTGAGCTGCTACTGTGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCACGCCGCGAGCGCGGAGGCTGCGCAAGGCGCGGAGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCAATGAACAGGTGCCCAAGTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCTCCAGCTACTGTTCAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGATCAGTACTGTTGCTAGACACCGGACCCAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTGGACCAAGGTACAAATGGTACAGCAGCACCTCTCTCCCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTCGCACTGGCACTCGGGGAGCGCCCTGTT 1764

DB 626 AACTGGCCTGAGCATCTCTCGCGAGCGCGGAGTTTCGGGCGCGCTGCGGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGACAACGCTCTCAGCGCTGGAGTTCGGGAGGCCCCAGCCACAGGCCCTCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCGGCTCACCTTCTTCCAAAGGAGCACCAACGATGGCTGGCAATGCTTTCATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 DB 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCGCGCGCGCGCGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGTCCACGCTTGGCCTCACCCACTTCGCCCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
 DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTCTCAGCTGGGACGACGCTGCGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCGTGTATGGGAAGCGCCCTAGTGGGCGCTCAGTGGCGCTCCAGTCCAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCNAGAGAGCGCCCTGAACCGCAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAAATACTGCGCACTCTTCTTCGATGCGCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGAGCTGATGGCAACGCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTCGAGAAAGATGGGTGGGCTGCGGCTGCCCCCAACATTTAGGCTGCGGCGAGTGTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTCGATGCTGGAGGTTCCGGGCCCCCA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGGGGTCTCCACAGCTGTCCGCGGAGGGGCGCTGCCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCTCTTCTTCCCTCTCTGGCGCCCTCATCTCTTCAAGGGTGGCCCTACTACT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCCGAAGTCTGCAGGACTGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
 DB 1585 AGGCATCCCTGAGAGGTACGCGCGCTGCGGAGCGCCGCTGAGGCTCCATCTCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCAGATGACCGCTACTTGGCGCTTCGACAGGCGCAAACTGCAGGCAACACCTCGGGCCG 1704
 QY 500 gTTPAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTCGCACTGGCACTCGGGGAGCGCCCTGTT 1764


```
Db      865  |||||AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGGTCTGCGGCA 924
Qy      240  sGIuIlleGIyHieThrLeuClYleuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTGCACACGCTTGCGCTCACCACTCGCGCGCGCGCGCGCTCATGCGCGC 984
Qy      260  oTyTyTyLysATgLeuGIyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db      985  CTACTACAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGAGCAGTCTGCGCGCTGCA 1044
Qy      280  nSerLeuTyTyGIyLeuProLeuGIyGIySerValAlaValGlnLeuProGIyLysLeuPh 300
Db      1045  GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTrpAsnSerTyTySerProGlnGIyArgAtqProGluThrClnGI 320
Db      1105  CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGCGCGCCCTGAACGCGAGG 1164
Qy      320  yProLysTyTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTAATAACTGCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy      340  rIlePheLysGIySerHisPheTrpGluValAlaIaAspGIyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGTCTCAGAGCCCG 1284
Qy      360  gProLeuGlnGluArgTrpValGIyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
Db      1285  TCCACTGCAAGGAAGATGGTGGGCTGCGGCCCAACATTGAGGCTCGCGGCAATGTCATT 1344
Qy      380  uAsnAspGIyAspPheTyTyPhePheLysGIyArgCysTrpArgPheArgGIyProLy 400
Db      1345  GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy      400  sProValTrpGIyLeuProGlnLeuCysArgAlaGIyGIyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGGCATCCTGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgGluIleLeuPheLysGIyAlaArgTyTyrVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy      440  lLeuAlaArgGIyGIyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTrpGI 460
Db      1525  GTGGCCCGAGGGGAGTCAAGTGGAGGCGCTACTACCCCGAGTCTGCAGGACTGGGG 1584
Qy      460  yGIyIleProGIuGluValSerGIyAlaLeuProArgProAspGIySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy      480  eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGIyAr 500
Db      1645  CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAACTGCAGGCAACACCTCGGGCGG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGIyCysTrpHisAlaAsnSerGIySerAlaLeuPh 520
Db      1705  CTGGGCCACGAGTGGCTTGGATGGGCTGCTGGCATGGCAACTGGGGAGGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 16
ADA47521
ID ADA47521 standard; cDNA; 1985 BP.
XX
AC ADA47521;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
```

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX Homo sapiens.

OS US2003073215-A1.

PN 17-APR-2003.

PD 07-MAY-2002; 2002US-00140925.

PF 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 05-SEP-1999; 99WO-US021547.

PR 15-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 10-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.

```

PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006666.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
XX WPI; 2003-644801/61.
XX P-PSDB; ADA47522.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, detecting the presence of tumor in a mammal, or
XX modulating the uptake of glucose or free fatty acid by skeletal muscle
XX cells or adipocyte cells.
XX
XX Claim 2; Fig 143; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

```

```

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

```

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA47521 (1-1985)

```

Qy 1 MetValAlaArgValGlyLeuLeuAlaLeuGlnLeuLeuTrrGlyHisLeu 20
Db 206 ATGTCGCGCGGTCGCGCCCTCTGTCGCGCCCTCTGTCAGCTGTGGAGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAphaLeu 40
Db 266 GAGCCCGAGCGCGGAGCGCGAGGCTGCGCAAGGAGGCGGAGGCGGAGGCGGAGG 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGCTCCACCTCCACCTCGATTG 385
Qy 61 AspAlaIleArgAlaPheGlnTrrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCAGCTACCTGTACAGCGCGGTGTGGAGCCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATGACTGTCGCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTGACTTGTGTTTGTAGACACCGGACCAAAATGAGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrrTrrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGGTTTCCAAAGCAGAGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTCAGCATCTGCGGAGCGGCGGAGTTCGGGGCGCCGTCGCGCGGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACCTCTCAGCGCTGGAGTTCCTGGAGGCGCCCGCCAGCCAGCCCGCGTGC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrrAlaMetProLeuMetAl 200

```



```

PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015284.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866038.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695926/66.
DR P-PSDB; ADA67317.
XX
XX Novel isolated PRO secreted and transmembrane polypeptides useful for
PT stimulating the release of tumor necrosis factor-alpha from human blood
PT and detecting the presence of a tumor in a mammal.
XX
PS Claim 2; Fig 143; 660pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

```

```

CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA67316 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGCGCCTCTGTCGCGCGCCTGCTACTGCTGCGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGGAGCGCAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuLeuAenGluInValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACGACTACTGTCAGCGCGGTTTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGGATCATGACTGTGTTGTTCTAGACACCGGACCAAAATGAGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGCGAGCGCGAGTTCGGGGCGCGCGTGCAGCGCGCTTCCAG 685

```

Qy	160	rCyGlyAlaThrSerGlnAtrGTrpSerSerGlyArgProGlnProGlnAlaProLeu	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGGAGGCCCCAGGCACAGAGCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSerLeuGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCAGAGGGAGCCACAACGATGGCTTGGGCAATGCCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpAtrGTrpProPheLeuProArgArgGlyGlnAlaHisPheAspG	220
Db	806	CCAGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCGCGCGCGCGAAGCGCATCTTCGACCA	864
Qy	220	nAspGluAtrGTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTCGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTCTGGGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTTCACACGCTTGGCCTCACCACTTCGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyTrpIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGCTGGCGCGCGCGCTCTCAGCTGGGACGACGCTGCTGGCGCGTGCA	1044
Qy	280	nSerLeuTrpGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGTCTAGTGGCGCTCAGCTCCAGCTCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAGG	1164
Qy	320	yProIysTyrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCCAAGCAGCACTGTA	1224
Qy	340	rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCAATTTCTGGGAGTGGCAGCTGATGGCAACGCTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluAtrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGCGCAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrrPhePheIysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAAAGGGGTGATGTGTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACACAGCTGTCCGGGCGAGGGGGCTGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrrVa	440
Db	1465	CGCCCTCTTCTTCCTCTCTCGCCCGCCTCATCTCTTCAAGGGTGCCTGCTACGCT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCGCGAGGGGACTGCAGGTGGAGCCCTACTACCCCGAAGTCTGCAGGAGTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGTTCAGCGCGCCCTGCCGAGGCCGATGGCTCCCATCTCTCTT	1644
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTCTGGCGCTCTCGACCAAGGCCAAACTGCAGGCAACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGGCTGCTGGCATGCCCAACTCGGGGAGCGCCCTGT	1764
Qy	520	e	520

DB	1765 C 1765	
RESULT 18		
ADB30323		
ID	ADB30323 standard; cDNA; 1985 BP.	
XX		
AC	ADB30323;	
XX		
DT	20-NOV-2003 (first entry)	
XX		
DE	cDNA encoding human PRO polypeptide #72.	
XX		
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	
KW	liver; microvascular endothelial cell; glucose; FFA;	
KW	skeletal muscle cell; adipocyte cell; pericyte cell;	
KW	inner ear utricular supporting cell; T-lymphocyte cell;	
KW	endothelial cell tube formation; bone disorder; cartilage disorder;	
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;	
KW	immune system cell infiltration.	
OS		
XX	Homo sapiens.	
XX		
PN	US2003068794-A1.	
XX		
PD	10-APR-2003.	
XX		
PF	15-APR-2002; 2002US-00123155.	
XX		
PR	31-MAR-1997; 97WO-US0005230.	
PR	12-JUN-1998; 98WO-US012456.	
PR	14-JUL-1998; 98WO-US014552.	
PR	28-AUG-1998; 98WO-US017888.	
PR	10-SEP-1998; 98WO-US018824.	
PR	14-SEP-1998; 98WO-US019093.	
PR	14-SEP-1998; 98WO-US019094.	
PR	14-SEP-1998; 98WO-US019177.	
PR	16-SEP-1998; 98WO-US019330.	
PR	17-SEP-1998; 98WO-US019437.	
PR	07-OCT-1998; 98WO-US021141.	
PR	29-OCT-1998; 98WO-US022991.	
PR	29-OCT-1998; 98WO-US022992.	
PR	20-NOV-1998; 98WO-US024855.	
PR	01-DEC-1998; 98WO-US025108.	
PR	05-JAN-1999; 99WO-US000106.	
PR	08-MAR-1999; 99WO-US005028.	
PR	10-MAR-1999; 99WO-US005190.	
PR	20-APR-1999; 99WO-US008615.	
PR	14-MAY-1999; 99WO-US010733.	
PR	02-JUN-1999; 99WO-US012252.	
PR	01-SEP-1999; 99WO-US020111.	
PR	08-SEP-1999; 99WO-US020594.	
PR	13-SEP-1999; 99WO-US020944.	
PR	15-SEP-1999; 99WO-US021090.	
PR	15-SEP-1999; 99WO-US021547.	
PR	03-OCT-1999; 99WO-US023089.	
PR	20-NOV-1999; 99WO-US028214.	
PR	30-NOV-1999; 99WO-US028313.	
PR	30-NOV-1999; 99WO-US028409.	
PR	01-DEC-1999; 99WO-US028301.	
PR	01-DEC-1999; 99WO-US028634.	
PR	02-DEC-1999; 99WO-US028551.	
PR	02-DEC-1999; 99WO-US028564.	
PR	02-DEC-1999; 99WO-US028565.	
PR	16-DEC-1999; 99WO-US030095.	
PR	20-DEC-1999; 99WO-US030911.	
PR	20-DEC-1999; 99WO-US030999.	
PR	22-DEC-1999; 99WO-US030720.	
PR	30-DEC-1999; 99WO-US031243.	
PR	30-DEC-1999; 99WO-US031274.	

Db 566 AACCGCTTTCAGCAAGCAAGTAAACAATGGTACACGACGACCTCTCTACCGCCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGCGGAGTTCTGGGGCGCGTGGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCTGGCGCACGCTTC-CTGCCCCCGCGGGGAGCGCACTTCGACCA 864
Qy 220 nAepGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGCTCCAGCGCGCGCGGCGCAACCTGTTGCTGCTGCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCACCCACTCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpLeuArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGGCGCGGACCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGA 1044
Qy 280 nSerLeuTrpGlyLeuPheProLeuGlyGlySerValAlaValGlnLeuProGlyLeuPh 300
Db 1045 GAGCCTGTATGGAGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGACTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCGCCAAGGAGCGCCCTGMAAACGAGG 1164
Qy 320 yProLysTrpCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAATACTGCCACTTCTTCTTGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGACCCCG 1284
Qy 360 gProLeuGlnAlaArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGGTCGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGTGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCAGCGC 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTrpTyVa 440
Db 1465 CCGCCCTCTTCTTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCCGAGGGGACTGCAAGTGGAGCCCTTACCCCCGAACTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGGGCGCTGCGGAGGCCGAGTGGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAACTGCGAGGCCAACCACTCGGGCGC 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 19

ADAB5619
ID ADAB5619 standard; cDNA; 1985 BP.
XX
AC ADAB5619;
DT 20-NOV-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX Human; secreted and transmembrane protein; PRO; Gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003082693-A1.

XX 01-MAY-2003.

XX 22-APR-2002; 2002US-00127843.

XX 05-JUN-2000; 2000US-0209832P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786907/74.

DR P-ESDB; ADA85620.

XX New PRO nucleic acid, useful for preparing a composition for treating
e.g., tumor or for tissue typing.

XX Claim 2; Fig 143; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage, for
stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from BMC cells, for inhibiting the binding of
A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the

CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA85619 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGCGCGCTCGCGCTCTCTGTCGCGCGCTCGAGCTGCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCGCGGAGCGCGGAGCGCAGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGNTACTCTCAATGACAGAGTCCCCAAGTCCCACTCCACTCGATTACG 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGACCGCTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGCTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTGGCGCAGATCACTCGTCCCGCTGCGGGGTTCAGATACCACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGCGCTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGTGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCAATCTCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGACCAAGCTCTCAGCGCTGGAGTTCCTGGGAGGCGCCACAGCGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGCTCAGCTTCTTCCAAAGGGGACCAACACGATGGGCTGGGCAATGCTTTGTGGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 806 CCAGGGGGCGGCTTGGCGACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGTCCTGAGCGCGCGCGGGGCGCACTGTTCGTGGTGTCTGGCGCA 924
 Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCTCACCCTGCGCGCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 Db 985 CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACACGTGCTGGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGAGAAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCAAGGAAGGCGCCCTGAAACGCGAGG 1164
 Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAAATATCTGCCACACTCTTCCTTCGATGCCATCCTGTGTAGACAGGCAACAGCACTGT 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGTATGGCAACGCTCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGAAAGATGGGTTCGGCTGCCCCCAACATTCAGGCTCGCGCAGTGTCAAT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
 Db 1405 GCCAGTCTGGGTCTCCACAGCTGTCGGGGCAGGGGGCTGCGCCGCCATCTCTGACGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAAGGGTGCCTGCTACTACGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGGCTGGG 1584
 Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGTCAAGCGCGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCGGCGCAAACTCAGGCAACCCACTCGGGCCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCATGCCAATCTCGGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 20
 ADA96831
 ID ADA96831 standard; cDNA; 1985 BP.
 XX
 AC ADA96831;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;

endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

Homo sapiens.

US2003082705-A1.

01-MAY-2003.

24-APR-2002; 2002US-00131829.

09-DEC-1999; 99US-0170262P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755112/71.

P-PSDB; ADA96832.

New PRO nucleic acid, useful for preparing a composition for treating

e.g., tumor or for tissue typing.

Claim 2; Flg 143; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note:

The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1-93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2

DB:	9	Gaps:	0
US-10-791-980-6 (1-520) x ADA96831 (1-1985)			
QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTCGGCGCGTCTCTGCTGGCGCGCCCTGCAGCTCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlnGlnGlnLeuArgGlyGluAlaGluAlaPheLeu	40
DB	266	GAGCCCGAGCCCGGAGCGGAGAGCTGGCAAGAGCGCGGTGTGGACCG	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	336	GAGAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCATCGATTACG	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCATCAGAGCGTTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGGTGTGGACCG	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCACCAAGTATTGG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCCTGGGCTGAGAGATCAGTGACTTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGGTAAACAAATGTGTACAGCAGCACCTCTCTCCATCGCGTGG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe	160
DB	626	AACTGGCTGAGCATCTCCCGAGCGCGAGTTCGGGGCGCGGTGGCGCGCCCTTCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAAGTCTCAGCGCTGGAGTTCCTGGAGGCGCCCGCCACAGGCGCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCGCGCTCACCTTTCTTCAAGGGGACCAACATGGGCTGGGCAATGCGCTTGTATGGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
DB	806	CCAGGGGCGCGCTGGCGGACGCTTC-CTGCCCGCGCGCGGCGGCGGCGCTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCAACCTGTTCTGTGGTGTGGCGCA	924
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTACACGCTTGGCTTCAGCTCCCGCGCGCGCGCGCGCTCATGGCGCC	984
QY	260	oTyrTyrIleArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
DB	985	CTACTACAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGAGCGGCGCTGGCGCGTGA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyLysValAlaValAlaGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlnGlyArgArgProGluThrGlnGl	320
DB	1105	CACCTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAGGCGCGCTGAAGCGCAGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
DB	1165	CCCTAAATATGTCACCTCTCTTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360

```
Db 1225 |||||TAAGGAGCATTCTGGAGGTGCACGTGATGCACAGTCTAGAGCCCG 1284
Qy 360 gProLeuGlnAArgTTPValGlyLeuProProHenileGluAlaAaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGCTGCGGCCCAACATTGAGGCTGCGGCAGTGTCAAT 1344
Qy 380 uAenAepGlyAapPheTyPhePheIleGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTTACTCTTCAAAGGGGGTGCATGCTGAGAGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACACAGCTGTGCGGSCAGGGGCGCTGCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTCAAGGGTGCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAapTrpGl 460
Db 1525 GTGCGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAepGlySerIleIlePhePh 480
Db 1585 AGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGGCCGATGGCTCCATCACTCTTT 1644
Qy 480 eAArgAepAArgTyrTrpArgLeuApsGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCTACTGCGGCTCGACGAGGCCAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGCACCGAGTGCCTGGATGGCTGTGTGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 21
ADA79135
ID ADA79135 standard; cDNA; 1985 BP.
XX
AC ADA79135;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082763-A1.
XX
XX 01-MAY-2003.
XX
PF 17-APR-2002; 2002US-00124818.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028501.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US007532.
PR 17-MAY-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US013705.
PR 30-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
```



```
QY      320 yProlystYrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
          |||
Db      1165 CCTAAATACTGCCACTTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
          |||
QY      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
          |||
Db      1225 CATTTTAAAGGAGCCATTTCTGGAGGTGCAGCTGATGCCACAGTCTCAGAGCCCG 1284
          |||
QY      360 gProLeuGlnGluArGTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
          |||
Db      1285 TCCACTGCAGGAAGATGGTGGCTGCCGCCCAACATTGAGCTGCGGAGTGTCTATT 1344
          |||
QY      380 uAsnAspGlyAspPheTyPhePheLysGlyClyArgCysTrpArgPheArgGlyProly 400
          |||
Db      1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
          |||
QY      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
          |||
Db      1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGTCCCCGCCATCTTGACGC 1464
          |||
QY      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
          |||
Db      1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGCCTACTAGT 1524
          |||
QY      440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
          |||
Db      1525 GCTGCGCCGAGGGGACTGCAAGTGGAGCCCTTACCCCCGAAGTGCAGGACTGGGG 1584
          |||
QY      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
          |||
Db      1585 AGGCATCCCTGAGGAGTTCAGCGGCGCTGCGGAGGCGCGATGCTCATCACTTCTT 1644
          |||
QY      480 eArgPheAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
          |||
Db      1645 CCGAGATCACCGCTACTGCGCGCTCGACAGGCCAACTGCAGGCCAACCACTCGGGCG 1704
          |||
QY      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
          |||
Db      1705 CTGGGCCACCGAGTCCCTGTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
          |||
QY      520 e 520
          |||
Db      1765 C 1765

RESULT 22
ADA87274
ID ADA87274 standard; cDNA; 1985 BP.
XX
AC ADA87274;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087345-A1.
XX
PD 08-MAY-2003.
XX
PF 16-APR-2002; 2002US-00123907.
XX
PR 31-MAR-1997; 97WO-US005230.
```


Db	1165		CCCTAAATACATGCCACTCTCTTCGATGCGATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyValSerGluProAr	360	
Db	1225	CATTTTAAAGGAGGCCATTCTTGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG	1284	
Qy	360	gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	
Db	1285	TCCACTGCGAAGATGGGTCTGGGCTGCCGCCCAACATTGAGGCTCGGCAGTGTCATT	1344	
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrPheArgPheArgGlyProLy	400	
Db	1345	GAATGATGCAGATTCTACTCTTCAAAAGGGGGTCTGATGGAGGTTCGGGGCCCCAA	1404	
Qy	400	sProValTyrGlyLeuProGlnLeuCysArgAlaGlyVgLyLeuProArgHisProAspAl	420	
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCATCTCTGACGC	1464	
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440	
Db	1465	CGCCCTCTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTACTACTAGT	1524	
Qy	440	lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrog1	460	
Db	1525	GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584	
Qy	460	vGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh	480	
Db	1585	AGGCATCCCTGAGGAGGTGAGGGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT	1644	
Qy	480	eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysIleuGlnAlaThrThrSerGlyAr	500	
Db	1645	CCGAGATGACCGCTACTGCGCGCTCGACCAGGCCAAATGCGAGGCAACCACTCGGGCCG	1704	
Qy	500	gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaSerGlySerAlaLeuPh	520	
Db	1705	CTGGGCCACCGAGTCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT	1764	
Qy	520	e 520		
Db	1765	C 1765		
RESULT 23				
ID	ADB16476	standard; cDNA; 1985 BP.		
AC	ADB16476;			
XX	ADB16476;			
DT	20-NOV-2003	(first entry)		
DE	Human PRO polynucleotide #72.			
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;			
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;			
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;			
KW	liver; microvascular endothelial cell; glucose; FFA;			
KW	skeletal muscle cell; adipocyte cell; pericyte cell;			
KW	inner ear utricular supporting cell; T-lymphocyte cell;			
KW	endothelial cell tube formation; bone disorder; cartilage disorder;			
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;			
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;			
KW	immune system cell infiltration.			
XX	Homo sapiens.			
OS	US2003087349-A1.			
PN	08-MAY-2003.			
PD	19-APR-2002; 2002US-00125928.			
PF	19-JUN-1998; 98US-0089947P.			
PR				

PR	02-JUN-1999;	99WO-US012252.		
PR	25-AUG-1999;	99US-00380137.		
PR	02-MAR-2000;	2000WO-US005841.		
PR	01-DEC-2000;	2000WO-US032678.		
PR	19-DEC-2001;	2001US-00028072.		
XX	(GETH) GENENTECH INC.			
PA	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;			
XX	Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;			
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;			
XX	WPI; 2003-786940/7A.			
DR	P-PSDB; ADB16477.			
XX	New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,			
PT	and for manufacturing a medicament for diagnosing or treating tumor.			
PT	Claim 2; Fig 143; 637pp; English.			
XX	The invention relates to isolated human PRO polypeptides (secreted and			
CC	transmembrane polypeptides) and the polynucleotides encoding them. The			
CC	invention also relates to an antibody which specifically binds to a PRO			
CC	polypeptide, a method for stimulating the release of tumour necrosis			
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the			
CC	proliferation or differentiation of chondrocyte cells and a method for			
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,			
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The			
CC	polynucleotides are useful in molecular biology, including uses as			
CC	hybridisation probes, in chromosome and gene mapping, in generating			
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also			
CC	be used in preparing PRO polypeptides by recombinant techniques and in			
CC	generating either transgenic animals or knock-out animals which are			
CC	useful in the development and screening of therapeutically useful			
CC	reagents. The PRO polypeptides or antibodies are used in preparing a			
CC	medicament for treating a condition responsive to the polypeptides or			
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation			
CC	of human microvascular endothelial cells, for modulating the uptake of			
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for			
CC	stimulating differentiation of adipocyte cells, for stimulating			
CC	proliferation of or gene expression in pericyte cells, for stimulating			
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte			
CC	cells, for inducing endothelial cell tube formation and for treating			
CC	various bone and/or cartilage disorders such as sports injuries and			
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans			
CC	from cartilage are useful for treating sports-related joint problems,			
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO			
CC	polypeptides are also useful for treating various mammalian haemoglobin-			
CC	associated disorders such as various thalassemias and conditions which			
CC	may benefit from enhanced local immune system cell infiltration. This			
CC	sequence represents a human PRO polynucleotide of the invention. Note:			
CC	The sequence data for this patent is also available in electronic format			
CC	from USPTO at seqdata.uspto.gov/sequence.html.			
XX	Sequence 1985 BP; 403 A; 646 C; 504 G; 332 T; 0 U; 0 Other;			
SQ				
Alignment Scores:				
Pred. No.:	1.93e-149	Length:	1985	
Score:	2792.00	Matches:	519	
Percent Similarity:	99.62%	Conservative:	0	
Best Local Similarity:	99.82%	Mismatches:	1	
Query Match:	98.52%	Indels:	2	
DB:	9	Gaps:	0	
US-10-791-980-6 (1-520) x ADB16476 (1-1985)				
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20	
Db	206	ATGGTCGGCGGTGGGCTCTCTGCTGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG	265	
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40	
Db	266	GACGCCACCGCCCGGAGCGCGGAGCTGCCAGAGCTGCCAGAGGGCGGAGGCATTCTTA	325	

```
Qy 41 GluYsYrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAAAGCTCCCACTCCATCGATTGACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTGCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTGTGTAGACACCGGACCAAAATGAGGCGTAA 565
Qy 121 LysArgPheAlaLysGlnLysAsnLysTyrTrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTTCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCCGAGCGCGAGTTGCGGGCGCGGTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCCAGCCACGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCACACGATGGGGTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGGCCCTTGGCGCACGCTTC-CTGCCCGCGCGCGCGGAGCGCACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGTGGTCTCTGAGCGCGCGCGCGCGCGCACTGTTGTGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTGGCTCCTCACCACCTCGCGCGCGCGCGCTCATGGCGC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGACGCGCTGCTCAGCTGGGACGAGCTGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCTGMAACGACAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATATGCGCACTTCTCTTCGATGCGCATCTGCTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGAGGTGGGAGCTGATGGCAAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGCTGGCTGCCCCCAACATTGAGGCTGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGAGGTTCCGGGGGCCCCAA 1404
```

400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCGCTGCCCGCCATCTGACGC 1464
420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
1465 CGCCCTTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGGCTTACTACCCCGAAGTCTCGAGACTGGGG 1584
460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
1585 AGGCATCTCTGAGGAGTCAAGGGCGCTTCCGAGGCGCGATGGCTCCATCTCTCTT 1644
480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645 CCGAGATGACCGCTACTGGCGCTCGACCCAGGCCAACTGCAGGCAACACCTCGGGCGC 1704
500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
1705 CTGGGCGCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
520 e 520
1765 C 1765

RESULT 24
ADA91568
ID ADA91568 standard; cDNA; 1985 BP.
XX
AC ADA91568;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX Gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003082694-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127845.
XX
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Pylvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786908/74.
DR
P-PSDB; ADA91569.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT or a composition for treating e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 143; 637pp; English.
XX

CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear intracellular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA91568 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGGCGCGTGGGCTCTCTGTGCGCGCTCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGGAGCGCGAGCGCAGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGGTCCCACTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGACGTTTCAGTGGGTGTCCAGCTACCTGTGAGGGGTGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgProCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTCGGGGTGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGGCTGAGGAGTACGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTGTCAAGCAAGGTAACTAATGTGTACAGACGACACTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTGGCGCGCCCTTCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTTCTAGCGCTGTGAGTTCCTGGGAGGCCCCCAGGCCACAGGCCCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCCAAAGGGGACACCAACGATGGCTGGGCAATGCCCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGAGCGCTGGTCCCTAGCGCGCGCGCGGCGCAACTGTTCTGGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
Db 985 CTACTACAAGAGGTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAACTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAGGAGGCCAATTTCTGGAGGTGGAGCTGATGGCAACGCTCAGAGCCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTTTCTTCAAAGGGGGTTCGATGTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGCAAGGGGGCTGCCCGGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCTCTCTTCTCTCTCTCGCGCTCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpProArgSerLeuGlnAspTrpG 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCGCTACTACCCCGCAAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTACAGCGCGCTCTGCCGAGGCGCATGGCTCCTCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGGCCAAACTGCGAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520

Db 1765 C 1765
 RESULT 25
 ADB14631
 ID ADB14631 standard; cDNA; 1985 BP.
 XX
 AC ADB14631;
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003087351-A1.
 XX
 XX 08-MAY-2003.
 XX
 XX 22-APR-2002; 2002US-00127822.
 XX
 XX 17-JUN-1998; 98US-0089532P.
 XX
 XX 02-JUN-1999; 99WO-US012252.
 XX
 XX 25-AUG-1999; 99US-00380137.
 XX
 XX 30-NOV-1999; 99WO-US028313.
 XX
 XX 01-DEC-2000; 2000WO-US032678.
 XX
 XX 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-786942/74.
 DR P-PSDB; ADB14632.
 XX
 PT New PRO nucleic acid, useful for manufacturing a medicament for
 diagnosing or treating tumor.
 XX
 XX Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-in-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservatives: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0
 US-10-791-980-6 (1-520) x ADB14631 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGTCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCACAGCCCGCGAGCGCGAGCGCTGCCACAGGAGCGCGGCATTCTCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCATTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTGCGCGGTGTGGACCC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTTGAGCATCTCCCGAGCGCGCAGTTCGGGGCGCGCTCGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGACAAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCGCCACGACAGGCGCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 DB 806 CCAGGGGCGCGCTTGGCGCACGCTTC-CTGCCCGCGCGCGGAGGCGCATTCCGACCA 864
 QY 220 rAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCGTGGTGTGCTGGCGCA 924

glucose uptake modulator; FFA uptake modulator;
cell proliferation stimulator; cell differentiation stimulator;
cell differentiation inhibitor; cytokin.

Homo sapiens.

US2003073211-A1.

17-APR-2003.

15-APR-2002; 2002US-00123292.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US021141.

29-OCT-1998; 98WO-US022991.

20-NOV-1998; 98WO-US022992.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 98WO-US000106.

08-MAR-1999; 99WO-US005028.

10-MAR-1999; 99WO-US005190.

20-APR-1999; 99WO-US008615.

14-MAY-1999; 99WO-US010733.

02-JUN-1999; 99WO-US012252.

01-SEP-1999; 99WO-US020111.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

01-DEC-1999; 99WO-US028301.

02-DEC-1999; 99WO-US028634.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028564.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.

KW

KW

KW

XX

OS

XX

PN

XX

PD

XX

PF

XX

XX

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

Db 925 CAGATCGGTCAACGCTGGCCTCACCACTCGCCCGCGCGCTCATGGCC 984

QY 260 ofYrYrYsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280

Db 985 CFACCTACAAGAGCGCTGGCCGCGACGCGCTGTCTAGCTGGGACGACGTCTGGCCGTGCA 1044

QY 280 nSerLeuTyrGlyYsProLeuGlyGlySerValAlaValGlnLeuProGlyYsLeuPh 300

Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320

Db 1105 CACTACATTTGAGACTGGGACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1164

QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340

Db 1165 CCCTAAATACCTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224

QY 340 rIlePheYsGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr 360

Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284

QY 360 gProLeuGlnGluArgTTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380

Db 1285 TCACCTGACGAAAGATGGGTGGGCTGCCCTCCCAACATTGAGGCTGGCGAGTGTCA 1344

QY 380 uAsnAspGlyAspPheTyrPhePheGlyGlyValArgCysTrpArgPheArgGlyProLy 400

Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGTTCCGGGGCCCA 1404

QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCGCCCATCTGACGC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheYsGlyAlaArgTyrTyVa 440

Db 1465 CGCCCTCTTCTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524

QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460

Db 1525 GCTGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTGTGAGGCTGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480

Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaYsLeuGlnAlaThrThrSerGlyAr 500

Db 1645 CCGAGTACCGCTACTGCGCTCGACAGGCCAACTGACGGCAACCACTCGGGCG 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGTGGCATGCCAATCGGGAGCGCCCTGTT 1764

QY 520 e 520

Db 1765 c 1765

RESULT 26

ADBI8592

ID ADBI8592 standard; cDNA; 1985 BP.

XX AC ADBI8592;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;


```
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyVgLyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCCGCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
DB 1465 CGCCCTCTTCTCCCTCTGCGCGGCTCATCTCTTCAAGGGTGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTGTGCAAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGGGGCGCTGCCGAGGGCCGATGGCTCCATCTCTT 1644
QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAAACTGCAAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCCCAGAGCTGCCCCGTGATGGGCTGTGGCATGCCAACTCGGGGAGGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 27
ADA93807
ID ADA93807 standard; cdNA; 1985 BP.
XX
AC ADA93807;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077722-A1.
XX
PD 24-APR-2003.
XX
PF 03-MAY-2002; 2002US-00137872.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-0032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WI 1; 2003-755077/71.
DR P-PSDB; ADA93808.
```

```
XX
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA93807 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGTCGGCCTCCTGCTGGCGCCCTGCAGCTGTCTACTGTGGGGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGGCCCGCGGAGCGCGGAGCCAGAGCTGCGAAGGAGGGCGGCGCATTTCTCTA 325
QY 41 GlulysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGTCTCCCAAGCTCCACCTCCGATTCCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACTCTGTACGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTCTGTCCTCCGCTGCGGGGTACAGATACCAACAGATTATCGG 505
```

101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHieArgThrLysMetArgArgLys 120
Db GCCTGGGCTGAGAGGATCAGTACTGTTTGTCTAGACACCGGACCAAAATGAGCGCTAAG 565
121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db AAACGGCTTTTCAAGCAAGGTAAACAAATGGTATACAGCAGCACCTCTCTACCGCTGGTG 625
141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db AACTGGCCCTGAGCATCTGCGGAGCGGACAGTTCGGGGGCGCCCTGGCGCGCCCTTCCAG 685
160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGCGCCCGACAGCCAGCCCGCTGAC 745
180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTCATGGC 805
200 aGlnGlyAlaProTrpArgTrpPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db CAGGGGGGCGCCCTGGCGCACGCTTC - CTGCCCGCGCGCGGAGGAGCGACTTCGACCA 864
220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGGTGGCGCA 924
240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db CGAGATCGGTTCACACCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGC 984
260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
Db CTACTACAGAGGCTGGGCGCGACCGCTGCTCAGCTGGGACGAGCTGGCGGTGCA 1044
280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db GAGCGTGTATGGAGAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db CACTGACTTTGAGACCTGGGACTCTCTACAGCGCCCAAGGAGCGCGCTGAAACGAGG 1164
320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db CCTAAATACTGCCACTCTTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db CATTTTAAAGGAGGAGCCATTTCTGGGAGTGGAGCTGATGGCAACGTTCTCAGAGCCCG 1284
360 gProLeuGlnGluArgTrpValGlyLeuProProHennilleGluAlaAlaAlaValSerLe 380
Db TCCACTGCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTAGGCTGGCGCATGTGCT 1344
380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCCAA 1404
400 sProValTspGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db GCCAGTGTGGGTCTTCCACAGCTGTGGCGGAGGGGGCTGCCCGCCATCTCTGAGCG 1464
420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db CGCCCTCTTCTTCTCTCTGCGCGCTCTATCTCTTCAAGGTGGCGCTACTAGT 1524
440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG 460
Db GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGCAGGACTGGG 1584
460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480

1585 AGGCATCCTCGAGGAGTTCAGCGCGCTTCGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCCAGGCCAACTGCAGGCAACACCTCGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 28
ADBI9703
ID ADBI9703 standard; cDNA; 1985 BP.
XX
AC ADBI9703;
XX 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082691-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127838.
XX
PR 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755108/71.
DR P-PSDB; ADBI9704.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; FFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; T-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

XX Homo sapiens.

XX US2003082710-A1.

XX 01-MAY-2003.

XX 16-MAY-2002; 2002US-00147484.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gertsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786913/74.

XX P-PSDB; ADB13016.

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,

XX preparing a composition for treating e.g., tumor, or for tissue typing.

XX Claim 2; Fig 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX antibodies, such as tumours, for stimulating and inhibiting proliferation

XX of human microvascular endothelial cells, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX stimulating differentiation of adipocyte cells, for stimulating

XX proliferation of or gene expression in pericyte cells, for stimulating

XX the proliferation of inner ear utricular supporting cells or T-lymphocyte

XX cells, for inducing endothelial cell tube formation and for treating

XX various bone and/or cartilage disorders such as sports injuries and

XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

XX from cartilage are useful for treating sports-related joint problems,

XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

XX polypeptides are also useful for treating various mammalian haemoglobin-

XX associated disorders such as various thalassaemias and conditions which

XX may benefit from enhanced local immune system cell infiltration. This

XX sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format

CC from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1-93e-149 Length: 1985

Score: 2792.00 Matches: 519

Percent Similarity: 99.62% Conservative: 0

Best Local Similarity: 99.82% Mismatches: 1

Query Match: 98.52% Indels: 2

DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB13015 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

DB 206 ATGTCGCGCGCGTCTCTCTGCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40

DB 266 GACGCCAGCCCGCGGAGCGGAGCCAGAGCTGCGCAGGAGCGGAGGCGGAGCTTCTTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60

DB 326 GAGAAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCCACTCCACTCGATTGAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuArg 80

DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCTGAGTACCTGTGAGCGCGGTGTGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100

DB 446 GCCACCTGCGCCAGATGACTCTGTCCTCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

DB 506 GCCTGGGCTGAGAGATCAGTGACTTGTGCTAGACACCGACCAAAATGAGGCGTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

DB 566 AACCGCTTGCAGAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160

DB 626 AACTGGCTGAGCATCTGCGGAGCGCGCAGTTGCGGGCGCGCTGCGGCGCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180

DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCCTGGAGGCGCCAGCCACAGGCGCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200

DB 746 ATCCGGCTCACCTCTTCCAGGGGACCAACATGGGCTGGGCAATGCTTTTGTATGCG 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220

DB 806 CCAGGGGGCGCTTGGCGCACGCTTC-CTGCCCGCGCGCGGAGGAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHis 240

DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTGCGCGCA 924

QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

DB 925 CGAGATCGGTCAACAGCTTGGCTCACCCTGCGCGCGCGCGCGCGCTCATGCGCGC 984

QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280

DB 985 CTACTACAGAGGTGGGCGCGCGCGCTGCTCAGCTGGGAGCGAGCTGTGGCGCGTCA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

```
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTCGGACTCTACAGCCCCCAAGGAAGCGCCCTGAACGCGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTCCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCACCACTGTA 1284
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGTGCAACGCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGAATGGTGGGCTGCGGCTGCCCAACATTGAGGTGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTCTTCTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGCTCTCCACAGCTGTGCCGGCAGGGGCTGCCCGGCCCATCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGTGCGCGCTACTAGCT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTTCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGGCGGCGCTGCCGAGGCGCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACAGGCCAACTGCAGGCCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGSCATGCCAACTCGGAGGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 30
ACD98495
ID ACD98495 standard; cDNA; 1985 BP.
XX
AC ACD98495;
XX
DT 26-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene therapy;
KW chromosome identification; tissue typing; gene; ss.
XX
OS Homo sapiens.
XX
PN US200304945-A1.
XX
PD 06-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00142419.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003376.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
```


PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00871092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001US-008717800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001US-00919692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001US-00920116.
 PR 29-JUN-2001; 2001US-00921066.
 PR 09-JUL-2001; 2001US-00921735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Deenoyers L, Pilvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-492275/46.
 PS P-PSDB; ABO43220.
 XX
 DR New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, or in generating probes.
 XX
 XX Claim 2; Fig 143; 660pp; English.
 XX
 CC The invention describes an isolated nucleic acid encoding a PRO (secreted
 CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
 CC used to generate either transgenic animals or knock-out animals useful in
 CC developing and screening of therapeutically useful reagents. The nucleic
 CC acids may also be used in gene therapy, in chromosome identification, as
 CC chromosome markers, or in generating probes. The PRO polypeptides are
 CC useful as molecular markers for protein electrophoresis, and the isolated
 CC nucleic acids may be used for recombinantly expressing those markers. The
 CC PRO polypeptides and nucleic acids may also be used in tissue typing.
 CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. This sequence encodes a novel human secreted and transmembrane
 CC PRO polypeptide
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1,938-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0
 US-10-791-980-6 (1-520) x ACD98495 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGCGCGGCTCGGCTCTCTGTCGCGGCTCGAGCTGCTACTGTGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
 Db 266 GACGCCCGCCGCGGAGCGCGGAGGCCAGGAGCTGCGCAAGGAGCGGAGGACATTCCTA 325


```
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGGTCTCCACAGCTGTGCCGGCAGGGGCTGCCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCCTCCTCTGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTCAGGAGGTACAGGGGCGCTGCCAGGCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAAACTGCAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGCCTGGATGGGCTGTGGATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 31
ADA74269
ID ADA74269 standard; cDNA; 1985 BP.
XX
XX ADA74269;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human PRO polynucleotide #72.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003068798-A1.
XX
XX 10-APR-2003.
XX
XX
XX 07-MAY-2002; 2002US-00140928.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 30-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 16-DEC-1999; 99WO-US028565.
XX 20-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 11-FEB-2000; 2000WO-US00376.
XX 18-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 22-FEB-2000; 2000WO-US004342.
XX 24-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 01-MAR-2000; 2000WO-US005004.
XX 02-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 10-MAR-2000; 2000WO-US005841.
XX 15-MAR-2000; 2000WO-US006319.
XX 20-MAR-2000; 2000WO-US007377.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUL-2000; 2000WO-US020710.
XX 11-AUG-2000; 2000WO-US022031.
XX 23-AUG-2000; 2000WO-US023522.
XX 24-AUG-2000; 2000WO-US023328.
XX 08-NOV-2000; 2000WO-US030952.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032578.
XX 20-DEC-2000; 2000US-00747259.
XX 28-FEB-2001; 2001US-00796498.
XX 28-FEB-2001; 2001US-00834956.
XX 01-MAR-2001; 2001WO-US006520.
XX 09-MAR-2001; 2001US-00802706.
XX 14-MAR-2001; 2001US-00808689.
XX 22-MAR-2001; 2001US-00816744.
XX 05-APR-2001; 2001US-00828366.
XX 10-MAY-2001; 2001US-00854208.
XX 10-MAY-2001; 2001US-00854280.
XX 18-MAY-2001; 2001US-00860216.
XX 25-MAY-2001; 2001US-00866028.
XX 25-MAY-2001; 2001US-00866034.
XX 01-JUN-2001; 2001US-00872035.
XX 01-JUN-2001; 2001US-00872035.
XX 05-JUN-2001; 2001WO-US017800.
XX 14-JUN-2001; 2001US-00874503.
XX 19-JUN-2001; 2001US-00886342.
```

PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924415.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-625490/59.
 DR P-PSDB; ADA74270.
 XX
 Novel secreted and transmembrane PRO polypeptides and polynucleotides
 PT encoding them, useful for treating bone disorders, arthritis, heart
 PT attack, injuries, tumors, and stimulating release of Tumor Necrosis
 PT Factor-alpha from human blood.
 XX
 Claim 2; Fig 143; 659pp; English.
 XX
 The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,936-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA74269 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGCTCGGCTCTCTGCTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGCGGAGCGCGGAGGAGCTGCGCAAGGAGGCGGAGGCAATTCCTTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTACGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCACGCTACCTGTCCAGCGGCTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCAAAATGAGGGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCANAGCAAGGTAACAAATGGTACAGCAGCAGCTCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCAGTCTCGCGAGCGCGCAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCGGGAGGCGCCAGCCAGGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCNAGGGGACCAACAGATGGCTGGGCAATGCTTGTATGCG 805
 QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGCGCGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGCGAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGCAACCTGTTCTGTGTGCTCGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGCGCTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
 DB 1165 CCCTAAATACTGCCCACTCTCTCTTCGATGCTCCTCAGTACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
 DB 1225 CATTTTTAAGGGAGGCCATTTCTGGAGGTGGCGAGCTGATGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380

Db 1285 TCCACTGACGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGGGAGTGTCAAT 1344
Qy 380 uAaAaPGLyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGGGGCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGGCGGACGGGGCCCTGCCCCGCCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCCTGAGAGGTCAGCGGCGCCCTGCCGAGGCGCCATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
Db 1645 CCGAGATGACCGCTACTGGGCGCTCGACGAGCCAACTGCAGGCAACCACTGGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLysSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 32
ADB24502
ID ADB24502 standard; cDNA; 1985 BP.
AC ADB24502;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 143.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US200307713-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127839.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX
DR WPI; 2003-755068/71.
DR P-PSDB; ADB24503.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
US-10-791-980-6 (1-520) x ADB24502 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCGTCGGCCCTCCTGTCGCGCGCGCTGCAGCTGTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGGAGCGGAGCGGAGCTGCGAAGGAGCGGAGGACCTTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGCCAGCTACCTGTGACGCGCGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTCGGGGTACAGATACCAACAGTTATGG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTCGGCTGAGAGGATCAGTACCTGTTTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnLysValThrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGTAAACAAATGTTAAAGCAGCACTCTCTTACCGCTGGTG 625
Qy 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGACATCTCGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCGGAGGGCCCGAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTCTTCCAAAGGGACCAACAGATGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTCGCGCACGCTTC-CTGCCCCCGCGGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgGlyArgGlnPheValValLeuAlaHi 240
Db 865 AGATGAGGGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGTTGGTGTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGCGGCC 984
Qy 260 rTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGAGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCGAGGAGGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAAATCTGCCACTCTTCTTCGATGCCATCTACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCACTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnLysArgTTPValGlyProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCNA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGGGAGGGGCGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460

Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProArgProArgGlySerIleIlePhePh 480
Db 1585 AGGCATCTCCTGAGGAGGTGAGCGGGCGCTGCCAGAGGCCGATGGCTCATCTCTTCT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 33
ADA82026
ID ADA82026 standard; cDNA; 1985 BP.
XX
AC ADA82026;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082701-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128686.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755110/71.
XX
DR P-PSDB; ADA82027.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
XX tumor or for tissue typing.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 99.52% Indels: 2
Gaps: 0

US-10-791-980-6 (1-520) x ADA82026 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGCTCGCGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGCGAGCCAGAGGCTGCCAGAGGAGCGCGAGGCAATTCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCACCTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACCGTTTCAGTGGGTGTCCAGACTACCTGTGACGGCGGTGTGGACGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGCACAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGCTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTGGCAAGCAGAGGTACAAATGGTACAGAGCAGCACTCTCTCCCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160

DB 626 AACGGGCTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGATTCTGGAGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACTTCTTCCAAAGGGGACACCAACATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGGCTGCGCGCACGCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCGCAACTGTTCGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGCGCTTACCCACTCGCCCGCGCGCGCGCTCATGGGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGAGGCGCGCTGAAACGCGAGG 1164
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTAAATATGCGCACTCTTCTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGAAAGATGGGTGCGGCTGCCCCCAACATTTGAGGCTGCGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAAGGGTGGCGCTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGGAAGTCTCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTCTGAGAGGTACGCGCGCTGCGGAGGCCCGGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCAGATGACCGCTACTTGGCGCTTCGACAGGCCAAACTCGAGGCCAACCACTTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

Db 1705 CTGGGCCACCGAGCTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 34
ID ADA74989 standard; cDNA; 1985 BP.
XX
AC ADA74989;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; as; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XN US2003073216-A1.
XX
PD 17-APR-2003.
XX
PF 30-MAY-2002; 2002US-00160498.
XX

31-MAR-1997; 97WO-US05230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012253.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.

22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US020231.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX
DR WPI; 2003-765392/72.
DR P-PSDB; ADA74990.
XX
PT New secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha in human blood and detecting

the presence of tumor in a mammal.

Claim 2; Fig 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA74989 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGTTGCGCGCGTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu	40
DB	266	GACGCCACCGCGGAGCGCGGAGCCAGAGCTGCGCAGAGGCGGCGGATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAA CAGGTGCCCAAGCTCCACCTCCACTCGATTACG	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCTGCTGACCTGCTGACGGCGGTGTGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCCCTGCGCCAGATCACTCGTCCCGCTGCGGGTTACAGATACCACACAGTTATCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG	565

QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCCTTTGCAAGCAAGGTAA CAAATGGTACAGCAGACACCTCTCTCCACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACCTGGCTGAGCATCTGCCGAGCCGCGAGTTCGGGGCGCGTGGCGCCCTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAACGCTCAGCGCTGAGTTCCTGGGAGGCCCGCAGCCACAGGCCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACTTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCTTGTATGGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
DB	806	CCAGGGGGCGCCCTGGCGCAGCCTTC-CTGCCCGCGCGCGCGCAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTCCCTGAGCCGCGCGCGCGCAACCTGTTCTGTTGCTGGCGCA	924
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTACACAGCTTGCCCTCACCACTGCCCGCGCGCGCGCTCATGGCGCC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
DB	985	CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
DB	1105	CATGACTTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTGAACGAGGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
DB	1165	CCCTAAATACTGCCACCTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284
QY	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
DB	1285	TCCACTCAGAAAGATGGGTGGGCTGCCCTGCCCTCCCACTTGAAGCTCGGCGCATGTCATT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgGlyArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATGATGGAGATTCTTACTTCTTCAAAGGGGTGCGATGCTGGAGGTTCCGGGGCCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGTGGGGTCTCCACAGCTGTCCGCGGAGGGGGCTGCCCGGCCCATCTCGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
DB	1465	CGCCTCTTCTTCCCTCTCTGGCCCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
DB	1525	GCTGGCCGAGGGGACCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
QY	460	yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCCCTGAGAGGTGAGCGCGCCCTGCCGAGGCCGATGGCTCCATCTCTTCT	1644

QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCAGATGACCGCTACTGGCGCTCGACCAAGGCAAACTGCAGGCAACCACTCGGGCGG 1704
 QY 500 gTTPAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCGACCGAGCTCGCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 35
 ADA85067
 ID ADA85067 standard; cDNA; 1985 BP.
 XX
 AC ADA85067;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; as;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2003082695-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127846.
 XX
 PR 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-05032678.
 PR 19-DEC-2001; 2000MO-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI: 2003-786909/74.
 DR P-PSDB; ADA85068.
 XX
 XX New nucleic acid encoding a PRO polypeptide, useful for preparing a
 PT composition for treating e.g. tumor by gene therapy, or for tissue
 PT typing.
 XX
 XX Claim 2; Fig 143; 637pp; English.
 PS
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or

CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0
 US-10-791-980-6 (1-520) x ADA85067 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGCGCGCTCGGCTCTCTGCTGGCGCCCTGCAGCTCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GAGCGCCAGCCCGGAGCGGCGGAGCTGCCGAGGAGCGGAGGAGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGACAGGTGCCAAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 Db 386 GATGCCATCAGAGCGGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGGTGTGTGACCC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTGGCCAGATGACTCTGTCCTCCGCTGCGGGGTTCAGATACCAACAGTTATGG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCCAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTCCCGGAGCCCGGAGTTCGGGGCGCGCGTCCGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAAGTCTCAGCGCTGGAGTTCCTGGGAGGCGCCACGACAGGCCCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTTCACCTCTTCCAAAGGGGACCAACATGAGTGGGCTGGGCAATGCCCTTATGG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 Db 806 CCAGGGGGCGCCCTGGCGCACCCCTTC-CTGCCCGCGCGCGGAGGCGCATCTTGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHis 240
 Db 865 AGATGAGCGCTGGTCCCTTGAGCCCGCGCGCGGCGCAACCTGTTCTGGTGGTGGCGCA 924

```
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCTCACCACTCGCGCGCGCGCGCTCATGGGGCC 984
Qy 260 oTyTyTlyyArgLeuGlyArgAlaLeuLeuSerTrpApepValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGAGCGCTGCTCAGCTGGGACGACGTGCGCGTGA 1044
Qy 280 nSerLeuTyrrGlyLySProLeuGlyGlySerValAlaValGlnLeuProGlyLySLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCCGCTCCAGTCCCGAAGAGCTGT 1104
Qy 300 eThrApepPheGluThrTrpApepSerTyrrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCCTCAGCCCCCAAGAAAGGCGCCCTGAACGCGAGG 1164
Qy 320 yProLySTyrrCyHHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTTCTTCGATGCGCATCTCTGTAGACGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLySgLySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTCATGGCAAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTCGGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyApepPheTyrrPhePheLySgLyGlyArgCysTrpArgPheArgGlyLyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCATGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 gProValTrpGlyLeuProGlnLeuCyeArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGCGAGGGGCGCTGCCCGCCCATCTCCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLySgLyAlaArgTyrrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGTGCGCCGCTACTAGT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgApepArgTyrrTrpArgLeuAspGlnAlaLySLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCGCTACTGGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCGTGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 36
ID ADA84515 standard; cDNA; 1985 BP.
XX AC ADA84515;
XX DT 20-NOV-2003 (first entry)
XX TT
XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
```

```
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003082708-A1.
XX 01-MAY-2003.
XX 15-MAY-2002; 2002US-00146729.
XX 05-JUN-2000; 2000US-0209832P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786911/74.
XX P-PSDB; ADA84515.
XX New PRO nucleic acid, useful for preparing a composition for treating
XX e.g. tumor or for tissue typing.
XX Claim 2; Fig 143; 637pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PMBC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
XX Alignment Scores:
XX Pred. No.: 1.93e-149 Length: 1985
XX Score: 2792.00 Matches: 519
XX Percent Similarity: 99.62% Conservative: 0
XX Best Local Similarity: 99.62% Mismatches: 1
XX Query Match: 98.52% Indels: 2
XX DB: 9 Gaps: 0
XX US-10-791-980-6 (1-520) x ADA84515 (1-1985)
```

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGCTGGCGCGCGTTCGGCTCCTGCTGGCGCGCTGCAGTGTACTGTGTGGCGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCGCCGCGAGCGGAGCCAGGAGCTGCGCAGGAGCGGAGGCAATTCCTA	325
Qy	41	GluLysTrpGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTCAAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGSTAACAATGGTACAGCAGCACCTCTCTACCGCTGTGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer	160
Db	626	AACTGGCCTGAGCATCTCCCGAGCGCGCAGTTTCGGGCGCGCTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTACGCGCTGAGTTCGTGGAGGCGCCAGCCACAGGCGCGCTGC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGCTCACCTTCTTCCAGGGGACCCACCAACGATGGCTGGGCAATGCCTTTGATGC	805
Qy	200	gGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGCGCGCTGGCGACGCTTC-CTGCCCCGCGCGCGAAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTTGAGCGCGCGCGCGGCGCAACTGTTCGTGGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGTCAACGCTTGCCCTCACCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
Db	985	CTACTACAAGAGGTGGGCCCGACGCGCTGCTCAGCTGGGACGACGCTGTGGCGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
Db	1105	CACGTACTTTGAGACCTGGGACTCCTACAGCCCCCNAGGAAGGCGCTTGAAACGACGG	1164
Qy	320	YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGGAGCCATTTCTGGGAGGTGGCACTGATGGCAACGCTTCAGAGCCCGC	1284

QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnileGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAAGATGGGTTCGGGCTGCCCCCAACATTGAGGCTCGGCAGTGTCTATT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLys	400
Db	1345	GAATGATGGAGATTCTTACTTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGGCCCA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTTCTCCACACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrpVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTCCCGCTACTACGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGATGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
QY	460	yGlylLeProGluGluValSerGlyAlaLeuProArgProAspGlySerllellePhePh	480
Db	1585	AGGCATCCCTGAGAGAGTTCAGCGGCGCCCTGCCGAGGCCCGATGGCTCCATCATCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTCGACACAGGCCAAACTGCAGGCACACCTCGGGCGG	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGTGCCTTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
QY	520	e	520
Db	1765	C	1765
RESULT 37			
ID	ADB29771		
XX	ADB29771	standard; cDNA; 1985 BP.	
AC	ADB29771;		
XX	ADB29771		
DT	20-NOV-2003	(first entry)	
XX	cDNA encoding human PRO polypeptide #72.		
DE			
XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;		
KW	immune system cell infiltration.		
OS	Homo sapiens.		
XX			
FN	US2003073214-A1.		
XX			
PD	17-APR-2003.		
XX			
PF	17-APR-2002; 2002US-00124822.		
XX			
PR	31-MAR-1997;	97WO-US005230.	
PR	12-JUN-1998;	98WO-US012456.	
PR	14-JUL-1998;	98WO-US014552.	
PR	28-AUG-1998;	98WO-US017888.	
PR	10-SEP-1998;	98WO-US018824.	
PR	14-SEP-1998;	98WO-US019093.	
PR	14-SEP-1998;	98WO-US019094.	
PR	14-SEP-1998;	98WO-US019177.	

PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005094.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US032759.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-720081/68.

P-FSDB; ADB9772.

Novel secreted and transmembrane PRO polypeptides useful for stimulating the release of tumor necrosis factor alpha and detecting the presence of a tumor in a mammal.

Claim 2; Fig 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumor necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519

```
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Indels: 2
Query Match: 98.52%
DB: 9 Gaps: 0
```

US-10-791-980-6 (1-520) x ADB29771 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTTCGCGCGTTCCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCCCGCGAGCGCGAGCCAGGAGCTGGCNAAGGAGCGGAGGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAGCTCCCACTCCACTCCGATTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCCACTACTGTCTCAGCGGGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCAGATGACTCGTCCCGCTTCGGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTTGGGCTGAGAGGATCAGTGACTGTGTTCGTAGACACCCGAGCCAAATGAGGCGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAGGTAAACAATGGTTACAAGCAGCACCTCTCTCTACCGCCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTCCCGAGCGCGCAGTTTCGGGGCGCGCTCGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCACGCGCTGGAGTTCTTGGGAGGGCCCCCAGCCACAGGCCCCCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCAGCTTCTTCCAAAGGGAGCCACAACCATGGCTGGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCCCGCGCGCGAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCGCGCGCGCGCGCAACCTGTTTCGTGGTCTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTTACCACCTTCGCCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACNAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGAGACGACGTGCTGGCGCTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGGCTCCCAAGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTTGAGACCTGGGACTCTCTACGCGCCCCCAAGAGGGCGCCCTGAAACGCAGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeu	340

Db	1165	CCCTAAATACTGCCACACTCTCTCCCTTCGATGCCATCATCTGTAGACAGGCAACAGCAACTGTGA	1224
Qy	340	rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGACCATTTCTGGGAGGTGGCAGCTGATGSCAACGTCCTCAGAGCCCCG	1284
Qy	360	gProIeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTGCGCAGTGTCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheIysGlyIleArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProIeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTrpVa	440
Db	1465	CGCCCTCTTCTCTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGCCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyIleuGlnValGluProTyrTyrProArgSerIeuGlnAspTrpGl	460
Db	1525	GCTGGCCCCGAGGGGAGATGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGACACTGGGG	1584
Qy	460	YGIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTTCAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGGTACTTGGCGCCTCGACACAGGCCAAACTGCAGSCAACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 38			
ADA80299			
ID	ADA80299 standard; cDNA; 1985 BP.		
XX	ADA80299;		
AC	ADA80299;		
XX	20-NOV-2003 (first entry)		
DT	Human PRO polynucleotide #72.		
DE	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;		
KW	immune system cell infiltration.		
OS	Homo sapiens.		
XX	US2003082761-A1.		
PN	01-MAY-2003.		
PD	12-APR-2002; 2002US-00121061.		
XX	31-MAR-1997; 97WO-US0005230.		
PR	12-JUN-1998; 98WO-US012456.		

PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005130.
PR 20-APR-1999; 98WO-US010733.
PR 14-MAY-1999; 98WO-US0108615.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 05-OCT-1999; 98WO-US021547.
PR 29-NOV-1999; 98WO-US023089.
PR 30-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028584.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00823366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882536.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755115/71.
DR P-PSDB; ADA80300.
XX
XX New PRO polypeptides useful for treating diabetes, hyper- or hypo-
PT insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,
PT various coagulation disorders and tumors.
XX
PS Claim 2; Fig 143; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA80299 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 206 ATGGTCGGCGGCTGGCCCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGGAGCGCGGAGGCGCAGGAGCTGGCAAGGAGGCGGAGGCAATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGAGTCCCAAGAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTGAGCGGCGGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTCGGGGTACAGATACCAACAGTTATGG 505
Qy 101 AlaTyrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgGly 120
Db 506 GCCTGGGTGAGGATCAGTCACTTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAAAGCAGCCTCTCTCTACCGCTGGTG 625
Qy 141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGACATCTGCCGAGCGCGAGTTCCGGGCGCGTCCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTACCTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGACGCTTC-CTGCCCCCGCGGCGGCAACCTGTTCGTGGTGTGGCGCA 864
Qy 220 nAspGluArgTyrSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 aGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTGGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysrValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCAGAGAGGCCCTTGAACCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCGCACTCTCTCTCGATGCATCACTAGTACAGCGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAGATGGGTGGGCTGCCCGCCCAACATTTGAGGTGGGCACTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTyrAspArgPheArgGlyProly 400
Db 1345 GAATGATCGAGATTTCTACTTTCTTCAAGGGGTGCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCCCTGAGGAGGTGAGCGCGCTCCGAGGCGCGATGCGTCCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCCAACTGCGAGGCAACCTCTCGGGCGG 1704
Qy 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrPheHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGATGGGCTGTGGCATGCCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 39
ADA75541
ID ADA75541 standard; cDNA; 1985 BP.
XX
AC ADA75541;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082703-A1.
XX

PD 01-MAY-2003.

XX 23-APR-2002; 2002US-00128691.

XX 09-DEC-1999; 99US-0170262P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zharg Z; WPI; 2003-765414/72.

DR P-PSDB; ADA75542.

XX New PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.

PT Claim 2; Fig 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA75541 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20

Db 206 ATGTCTGGCGCGCTCTCTGCTGGCGCCCTGACGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GAGCCCGAGCCGCGGAGCCGCGAGGCTGCGAAGGAGCGGAGGCAATTCCTA 325

Qy 41 GluLysTrpGlyTrpLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60

Db 326 GAGAAGTACGAGTACCTCAATGAACAGGTCCCAAGCTCCACCTCCACCTCGATTGAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValIleuAspArg 80

Db 386 GATGCCATCAGAGGTTTCAGTGGGTGTCCAGCTACTGTACGCGGCGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100

Db 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrlsGlnHisLeuSerTrpArgLeuVal 140

Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCGCTGTGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValAlaProCysAlaProProSerSe 160

Db 626 AACTGGCTTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180

Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCGCCAGCAGCGCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200

Db 746 ATCGGCTTCACTCTTCCAAAGGGGACCAACGATGGGTGGGCAATGCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220

Db 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240

Db 865 AGATAGCGGTGGTCTCTCAGCGCGCGCGCGCGCGCACTGTTCGTGGTGTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

Db 925 CGAGATCGGTCAACGCTTGGCTTCCACTCGCCCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrlsLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280

Db 985 CTACTACAAGAGGTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044

Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320

Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAACGCGAGG 1164

Qy 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340

Db 1165 CCCTAAATACTGCGCACCTCTCTTCGTATGGCATCACTGTAGACAGGCAACAGCACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360

Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGGAGCTGTATGGCAACGCTCAGAGCCCCG 1284

Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380

Db 1285 TCCACTCAGGAAGAATGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGT 1344

Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400

Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTtpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGGCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCTCCCTCTTGGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTtpGl 460
Db 1525 GTTGGCCCGAGGGGGACTGCAAGTGGAGCGCTACTACCCCGAAGTCTCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGAGCGCGCCCTGCGAGCGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCCAATGTCAGGCAACCACTCGGGCG 1704
QY 500 gTtpAlaThrGluLeuProTtpMetGlyCysTtpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 40
ADA46766
ID ADA46766 standard; cdna; 1985 BP.
XX
AC ADA46766;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; r-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073210-A1.
XX
PD 17-APR-2003.
XX
PF 11-APR-2002; 2002US-00121045.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00870932.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-644800/61.
 DR P-PSDB; ADA46767.
 DR
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; Fig 143; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC the sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA46766 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCGTCGCGCTCTCTGTCGCGCCCTGCTACTGTCGCGGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCGCGGAGCGCGGAGCGCAGAGCTGCGAAGAGGCGGAGGCATTCTTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCATTCGATTGAC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGTACTCTGTACGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACACACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgLleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGCTGAGAGATCAGTCACTTCTTCTAGACACCGGACCAAAATGAGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGGAGGCCCGCAGCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACTTCCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCCCTTGTATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGGCGACATTGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGCCCTCACCCACTGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTCTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CATGACTTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAACGACTCTCAGAGCCCCG	1284

QY 360 gProLeuGlnGluArgTrrpValGlyLeuProProAsnIleGluAlaAaValSerIe 380
 DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGCTGCGGCGATGTCATT 1344
 QY 380 uAnAspGlyAspPheTyrPhePheLysGlyArgCysTrrpArgPheArgGlyProly 400
 DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCCAACAGCTGTGCCGGGAGGGGCGCTGCCCGGCATCTCGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrrVa 440
 DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTACTACTCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrrTyrProArgSerLeuGlnAspTrrpGl 460
 DB 1525 GTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
 QY 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGCATCTCTGAGAGGTGAGCGGCCCTGCGAGGCCGATGCTCATCTCTCTCTCT 1644
 QY 480 eArgAspAspArgTrrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
 DB 1645 CCGAGATGACCGCTACTGCGGCTCGACCAGGCCAACTGACGCAACCACTCGGGCG 1704
 QY 500 gTrrpAlaThrGluLeuProTrrpMetGlyCysTrrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCTGTT 1764
 QY 520 e 520
 DB 1765 c 1765
 RESULT 41
 ADB25062
 ID ADB25062 standard; cDNA; 1985 BP.
 XX
 AC ADB25062;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide SEQ ID NO 143.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; Glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; r-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003077715-A1;
 XX
 PD 24-APR-2003.
 XX
 PF 23-APR-2002; 2002US-00128693.
 XX
 PR 31-AUG-1998; 98US-0098525P.
 PR 16-SEP-1998; 98US-0100634P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.

XX
 PA
 PI
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI: 2003-755070/71.
 P-PSDB; ADB25063.
 New isolated, secreted and transmembrane PRO nucleic acids, useful for
 the diagnosis, prevention and/or treatment of tumors, such as lung,
 colon, breast, prostate, rectal, cervical and/or liver tumors.
 Claim 2; Fig 143; 637pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems,
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassaemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polynucleotide of the invention. Note:
 The sequence data for this patent is also available in electronic format
 from USPTO at seqdata.uspto.gov/sequence.html.
 SQ Sequence 1985 BP; 403 A; 546 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservatives: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB25062 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGTCGGCTCTCTGCGGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACCCCCAGCCCCCGAGCGCGGAGGCTGCGCAAGAGCGCGGAGCATTCCTA 325
 QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGATACCTCAATGACAGGTCCCCAAAGCTCCCACTCCACTCGATTGAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCATCAGAGCGTTTCAGTGGGTGTCCTAGCTACCTGTGAGCGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGGCCAGATGACTGCTCCCGCTGCGGGTTACAGATACCACACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTCGGGCTGAGAGGATCAGTACTGTTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAACAGTAAGTAACAAATGGTACAGCAGACCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGCAGTTCCGGGGCGCGTGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAGCTCTCAGCGCTGGAGTTCTGGGAGGCCCGCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCCAGAGGAGCACCAACGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpPheLeuProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTCTGTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACCTTGGCTCACCCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGCAGCGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTCTTCGATGCCATCTAGTGGAGGCGCCCTGAAACGCGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTCTCGATGCCATCTAGTGGAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTANT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGGCGAGGGGGCTGCCCGCCATCTCTGAGCG 1464

QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 GCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGCCTACTAGCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGCGCGCGCTGCCGAGGCCGATGGCTCCATCATCTCTT 1644
QY 480 eAtqAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCCAAACTGCAGGCACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAATCGGGAGCGCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 42
ADA93238
ID ADA93238 standard; cDNA; 1985 BP.
XX AC ADA93238;
XX DT 20-NOV-2003 (first entry)
XX DE Human PRO polynucleotide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003077721-A1.
XX PD 24-APR-2003.
XX PF 24-APR-2002; 2002US-00131837.
XX PR 09-DEC-1999; 99US-0170262P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755076/71.
XX P-PSDB; ADA93239.
XX DR
XX PT New PRO nucleic acid, useful for recombinantly producing a PRO
XX polypeptide and for manufacturing a medicament for diagnosing or treating
XX tumor.
XX PS Claim 2; Fig 143; 637pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and

Db 1705 CTGGGCCAGAGCTGCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 43
 ADB26588
 ID ADB26588 standard; cDNA; 1985 BP.
 XX
 AC ADB26588;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE cDNA encoding human PRO polypeptide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; r-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003092147-A1.
 XX
 PD 15-MAY-2003.
 XX
 PF 11-APR-2002; 2002US-00121051.
 XX
 PR 31-MAR-1997; 97WO-US052230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028213.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-FEB-2001; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 01-MAR-2001; 2001WO-US006520.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI: 2003-777245/73.
 DR P-PSDB; ADB26589.
 DR
 XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or

Qy	1	MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGTGGCTCTCTGTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgIysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCCAGCCCGAGCGCGAGGCCAGAGACTGCGCAAGAGGGCGAGGACATTCCTCA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCCACTCCACTCCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTTCAGTGGGTGTCCCAAGTACTGTGTACGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTCGCCGACATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGGC	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120

```
OY 480 eArGhSpAArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGCCAACTGCAGGCAACACCTCGGGCCG 1704

OY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGTGCTGGATGCCAACTCGGGGAGGCGCCTGTT 1764

OY 520 e 520
Db 1765 C 1765

RESULT 44
ADB30875
ID ADB30875 standard; cDNA; 1985 BP.
XX
AC ADB30875;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003096386-A1.
XX
PD 22-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121042.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US000508.
PR 10-MAR-1999; 98WO-US005130.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005501.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
```

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-786990/74.
P-PSDB; ADB30876.

Novel isolated PRO polypeptide useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders, tumors.

Claim 2; Fig 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other

Alignment Scores:			
Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0
US-110-791-980-6 (1-520) x ADB30875 (1-1985)			
Qy	i	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGGTGGCCCTCTGTGTGGCGCCCTGCAGCTGTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgIysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCCAGCCCGGAGCGCGGAGGCCAGAGACTGCGCAAGGAGCGGAGGCATTCCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCATTCGATTCAGC	395
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGGTTTCAGTGGGTGTCCAGGTACTCTGTACAGCGCGTGTGGACCGC	445

Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTGGCCAGATAGACTCGTCCGCGCTGCGGGGTACAGATACCAACAGATTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisargThrLysMetArgArgLys	120
Db	506	GCCTGGGCTCAGAGGATCAGTGACTTGTTGCTAGACACCGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTCGAAGCAAGGTACAAATGGTACAAAGCAGCACCTCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGGCTCAGCATCTGCGGAGCGCGCAGTTCGGGGCGCGTGCCTCCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCCTGGAGAGGCCCGCAGCCAGGCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTCTCTCCAAAGGGACCAACAAGATGGGCTGGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCTTGGCGCAGCGCTTC-CTGCCCGCGCGCGGGAAGCGCACTTCGACCA	864
Qy	220	naSpGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGACGCTGGTCCCTGAGCGCGCCCGCGGGCGCAACTGTGTCGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGCGCTCACCCACTTGCGCCCGCGCGCGGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGCGTGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGACTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTACACGCCCCCAAGAAAGCGGCCCTGAAACCGCAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACCTGCCACTCTTCTTCGATGCGCATCTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTGCGCAGTGTCA	1344
Qy	380	uaenAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTCTTCAAAGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCCAAGCTGTGCCGGGAGGGGGCTGCCCCGCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa	440
Db	1465	CGCCCTCTCTTCCCCTCTCTGCGCGCGCTCATCTCTCTTCAAGGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460

Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGCGGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIyLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCCTCGACCGCCAACTGCAGGCAACCCCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTCTGTCGATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 45
ADA60803
ID ADA60803 standard; cDNA; 1985 BP.
XX
AC ADA60803;
XX
DT 20-NOV-2003 (first entry)
XX
DE Homo sapiens.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO4339.
OS cDNA.
XX
FN US2003049817-A1.
XX
PD 13-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00142423.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806889.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.

PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PR 10-MAR-2009; 2000WO-US006319.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart JA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-695893/66.
 DR P-PSDB; ADA60804.
 XX
 PT New secreted and transmembrane PRO polypeptide and nucleic acid, useful
 PT for manufacturing a medicament for diagnosing or treating tumor.
 XX
 PS Claim 2; Fig 143; 658pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA60803 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ARGGTGCGCGCGGTGGCGCTCTCTGTCGCGCGCCCTGACGTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaAlaPheLeu 40
 DB 266 GAGCCCGACCGCGGAGCGCGGAGCCAGAGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGGTCCCAACCTCCACTCGATTGACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACCGTTTCAGTGGGTGTCCACAGCTACCTGTGTAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGGC 505
 QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCTTGGGCTGAGAGGATCAGTGTGTTGTGTACACCGGACCAAAATGAGGGGTAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACCGCTTTCDAAGCAAGTAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTCGGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCGGAGAGGCCCCAGCCAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACTTCTCCAGGGGACCAACAGATGGGTGGGCAATGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGCGCGCTGGCGCACGCCTTC-CTGCCCCGCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACAGCGCTTGGCTTCCACCATCTGCGCGCGCGCGCGGCTCATGGCGGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGTCTAGCTGGGAGCAGCTGTGCGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAGAGAGCGCCCTGAAACCGCAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATACCTGCGCACTCTCTCTTCGATGCGCATCTAGTAGAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGACCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGAGGAGAGATGGGTGGGCTGCGGCTGCCCCCAACATTGAGGGTGGGCGAGTGTCT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTCAATGCTGGAGGTTCGGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGCGGAGGGGGCTGGCCCCGCCCATCTCTGACG 1464

QY 121 LysArgPheAlaLysGlnGlyAenLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGGCTTTGCAAGCAAGTAAACAATGGTACAGCAGCACTCTCCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTCAGCATCTGCGGAGCGCGAGTTCGGGGCGCGGTGGCGCGCTTCACG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGGCGCCACAGCCCGCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCGCGCGCGCTCATGGCGCC 984
QY 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCGTGGCGCGCGCGCTGTCTGAGTGGGACGCTGTCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyCysSerValalValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGAGCGCGCTTGAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValalalalalalalalalalalalalalal 360
Db 1225 CATTTTAAAGGAGGACCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGTGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGTGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACACAGCTGTGCGGGCAGGGGCGCTGCCCGGCCATCTCTGACGC 1464
QY 420 alAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CGCCCTCTCTTCTCTCTGCGCGCTCTATCTCTTCAAGGGTGGCGGCTCTACTAGT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAACTCTGCGAGGCTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCGCTGCGAGGGCGCGATGCTCCATCATCTTCT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 47
ADA96279
ID ADA96279 standard; cDNA; 1985 BP.
XX
AC ADA96279;
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone cartilage defect; osteoarthritis;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082690-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127837.
XX
PR 01-SEP-1998; 98US-0098750P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WP1; 2003-755107/71.
DR P-PSDB; ADA96280.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
XX tumor or for tissue typing.
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA96279 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu 20
Db 206 ATGTTCGGCGCGTCGGCTCTCTGCTGCGGCCCTGACGTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGCGAGCGGAGGCTGCGCAAGGAGCGGAGGCGATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCTCCCAAGCTCCCACTCCACATCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGGCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTTCAGGGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCAAAATGAGCGGTAAG 565
Qy 121 LysArgPheAlaLysGlnLysAsnLysTrrpTrrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCANAGCAGGTAAACNAATGGTACAGCAGCCTCTCTCCACCGCTGGTG 625
Qy 141 AsnTrrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCGAGCGCGGAGTTCGGGGCGCGTTCGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrrpSerSerGlyArgProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCAGCGCTGAGGTCTGGGAGGCCCCAGGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrMetGlyTrrpAlaMetProLeuMetAl 200

Db 746 ATCCGGCTACCTTCTTCCNAGGGGACCAACAGATGGGCTGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrrpArgThrProPheLeuProArGArgGlyGlyAlaHisPheAspG 220
Db 806 CCAGGGGGCGCTTGGCGCACGCTTC-CTGCCCGCGCGCGAGCGCACATTCGACCA 864
Qy 220 nAspGluArgTrrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTGAGCGCGCGCGCGCGCACTGTTCGTGTGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTTCACGCTTGGCTCACCACTCGCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrrpLysArgLeuGlyArgAspAlaLeuLeuSerTrrpAspAspValLeuAlaValG 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGTCTCAGCTGGAGCAGACGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTrrpGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrrpAspSerTyrSerProGlnGlyArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTTGGGACTCTTACAGCCCCCAAGGAGCGCTGAAACGCAAGG 1164
Qy 320 yProLysTrrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrr 340
Db 1165 CCCTAAATACTGCGCACTCTTCTTCGATGCGCATCACTGTAGACAGGCAACGCACTGTA 1224
Qy 340 rLlePheLysGlySerHisPheTrrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTCTGGGAGGTGGGAGCTGTGGCAACGTCTCAGAGGCCCG 1284
Qy 360 gProLeuGlnGluArgTrrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATGATGGGCTCGGCAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTrrpPhePheLysGlyLysArgCysTrrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCAAGGGGCTGCCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrrpYrVa 440
Db 1465 CGCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrrpTrrpProArgSerLeuGlnAspTrrpG 460
Db 1525 GCTGGCGCGAGGGGAGTCAAGTGGAGCGCTACTACCCCGAAGTGTGACGAGTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTTGAGAGGTGAGCGCGCTGCGGAGCGCGCGATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTrrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCCCAACTGCAGGCAACACACCTCGGGCG 1704
Qy 500 gTrrpAlaThrGluLeuProTrrpMetGlyCysTrrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 48
ADA80851

ADA80851 standard; cDNA; 1985 BP.
ADA80851; .
20-NOV-2003 (first entry)
Human PRO polynucleotide #72.
Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
Homo sapiens.
US2003082702-A1.
01-MAY-2003.
23-APR-2002; 2002US-00128690.
02-MAR-2000; 2000WO-US005841.
30-MAY-2000; 2000WO-US014941.
01-DEC-2000; 2000WO-US032678.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-755111/71.
P-PSDB; ADA80852.
New PRO nucleic acid, useful for preparing a composition for treating
e.g., tumor or for tissue typing.
Claim 2; Fig 143; 637pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor- α (TNF- α) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridization probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
SQ
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
US-10-791-980-6 (1-520) x ADA80851 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
DB 206 ATGGTCGGCGCGCTCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGCGAGAGCTGCCCAAGAGCGCGAGCGGCGGCGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCATCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTyrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnLysGlnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTCAGACAGGTAAACAAATGGTACAGCAGCAGCCTCTCTTACCGCCTGGTG 625
QY 141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTCGCGAGCGCGGCGAGTTCGGGGCGCGCTGCGCGCGCTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGGCAACAGCTCTACGCGTGGAGTTCCTGGGAGGCGCCCGACAGGCGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCGGGCTCAGCTTCTTCAAGGGGAGCCACAAACGATGGGCTGGGCAATGCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGCGGCGGCGGCGGCGGCG 864
QY 220 nAspGluArgTyrSerLeuSerArgArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTCGAGCCCGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCG 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACAGCTTGGGCTTCCACCTTCCGCGCGCGCGGCGGCGGCGGCGGCGG 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspValLeuAlaValG 280

Db	985	CTACTACAAGAGGCTGGCGCGAGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGCA	1044	KW	immune system cell infiltration.
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValaValGlnLeuProGlyLysLeuPh	300	XX	Homo sapiens.
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT	1104	XX	US2003082759-A1.
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG	320	XX	01-MAY-2003.
Db	1105	CACGTACTTTCAGACCTGGGACTCTCAGACCCCAAGGAGGGCCCTGAAACGCGGG	1164	XX	11-APR-2002; 2002US-00121040.
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	XX	31-MAR-1997; 97WO-US005230.
Db	1165	CCCTAAATACCTCCCACTCTTCCTTCGATGCCATCAGTACAGCAAGCAACAGTGA	1224	PR	12-JUN-1998; 98WO-US012456.
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	PR	14-JUL-1998; 98WO-US014552.
Db	1225	CATTTTAAAGGGAGCCATTTCGGAGGTGGACGTGATGGCAACGCTCTCAGAGCCCCG	1284	PR	28-AUG-1998; 98WO-US017888.
Qy	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	PR	10-SEP-1998; 98WO-US018824.
Db	1285	TCCACTGAGGAAGATGGGTGGGCTGCCCCCAACATTGAGGCTGGGCGAGTGTCA	1344	PR	14-SEP-1998; 98WO-US019093.
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400	PR	14-SEP-1998; 98WO-US019094.
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGTCGATGCTGGAGGTTCCGGGGCCCAA	1404	PR	16-SEP-1998; 98WO-US019177.
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	PR	17-SEP-1998; 98WO-US019437.
Db	1405	GCCAGTGGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGGCCATCTCGACGC	1464	PR	07-OCT-1998; 98WO-US021141.
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440	PR	29-OCT-1998; 98WO-US022991.
Db	1465	CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT	1524	PR	20-OCT-1998; 98WO-US022992.
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460	PR	01-DEC-1998; 98WO-US024855.
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG	1584	PR	05-JAN-1999; 99WO-US000106.
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	PR	08-MAR-1999; 99WO-US005028.
Db	1585	AGGCATCCCTGAGGAGGTACGGCGCCCTCCCGAGGGCCGATGGCTCCATCTCTCTT	1644	PR	10-MAR-1999; 99WO-US005190.
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	PR	20-APR-1999; 99WO-US008615.
Db	1645	CCGAGATGACCGCTACTGCGCGCTCGACCGCCAAACTGCAGGCAACCACTCGGGCCG	1704	PR	14-MAY-1999; 99WO-US010733.
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	PR	02-JUN-1999; 99WO-US012252.
Db	1705	CTGGCCCAACGAGTGGCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764	PR	08-SEP-1999; 99WO-US020594.
Qy	520 e 520			PR	13-SEP-1999; 99WO-US020944.
Db	1765 c 1765			PR	15-SEP-1999; 99WO-US021090.
RESULT 49				PR	05-OCT-1999; 99WO-US021547.
ADA95727				PR	29-NOV-1999; 99WO-US028214.
ID ADA95727 standard; cDNA; 1985 BP.				PR	30-NOV-1999; 99WO-US028313.
XX ADA95727;				PR	30-NOV-1999; 99WO-US028409.
AC ADA95727;				PR	01-DEC-1999; 99WO-US028301.
XX 20-NOV-2003 (first entry)				PR	02-DEC-1999; 99WO-US028551.
XX Human PRO polynucleotide #72.				PR	02-DEC-1999; 99WO-US028565.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;				PR	16-DEC-1999; 99WO-US030095.
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;				PR	20-DEC-1999; 99WO-US030911.
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;				PR	20-DEC-1999; 99WO-US030999.
KW liver; microvascular endothelial cell; glucose; FFA;				PR	30-DEC-1999; 99WO-US031274.
KW skeletal muscle cell; adipocyte cell; pericyte cell;				PR	05-JAN-2000; 2000WO-US000219.
KW inner ear utricular supporting cell; T-lymphocyte cell;				PR	06-JAN-2000; 2000WO-US000277.
KW endothelial cell tube formation; bone disorder; cartilage disorder;				PR	06-JAN-2000; 2000WO-US000376.
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;				PR	11-FEB-2000; 2000WO-US003565.
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;				PR	18-FEB-2000; 2000WO-US004341.
				PR	18-FEB-2000; 2000WO-US004342.
				PR	22-FEB-2000; 2000WO-US004414.
				PR	24-FEB-2000; 2000WO-US004914.
				PR	01-MAR-2000; 2000WO-US005004.
				PR	02-MAR-2000; 2000WO-US005561.
				PR	02-MAR-2000; 2000WO-US005746.
				PR	10-MAR-2000; 2000WO-US006319.
				PR	15-MAR-2000; 2000WO-US006884.
				PR	20-MAR-2000; 2000WO-US007377.
				PR	21-MAR-2000; 2000WO-US007532.
				PR	30-MAR-2000; 2000WO-US008439.
				PR	17-MAY-2000; 2000WO-US013705.
				PR	22-MAY-2000; 2000WO-US014042.
				PR	30-MAY-2000; 2000WO-US014941.
				PR	02-JUN-2000; 2000WO-US015264.
				PR	28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US065520.
PR 01-MAR-2001; 2001WO-US066666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828166.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00865028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goodard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-755114/71.
DR P-PSDB; ADA95728.
XX
PT New isolated PRO polypeptides, useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders and tumors.
XX
PS Claim 2; Fig 143; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: Gaps: 9

US-10-791-980-6 (1-520) x ADA95727 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
DB	206	ATFGTGGCGCGCTGGCTCTCTGCTGGCGGCTGACAGTCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GAGCCCCAGCCGCGGAGCGGAGGCTGCGCAAGGAGCGGAGGCGGACATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGGCGGTGTGGACCC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
DB	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGAGGAAGTAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGGTGCGGCGGCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTTGGGACCAAGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCAGCCAGCCAGGCGCCGCTGAC	745
QY	180	rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTTCTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTTGTGCG	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
DB	806	CCAGGGGGCGGCTTGGCGACGCGCTTC-CTGCCCGCGCGCGGAGGCGGACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgPheLeuValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTGGTCTGAGCCCGCGCGGCGGCAACCTGTTCTGTTGGTGGCGCA	924

QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACACTGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrlsArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAAGAGCTGGCGCGCGCTGTCTAGCTGGGACGACGTCTGGCGGTGCA 1044
QY 280 nSerLeuTyrlsGlyProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyxSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTTGGACTCTCTACAGCCCCCAGGAAGGCCCTGAAACGCAGGG 1164
QY 320 yProLysTyrlsCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCATTCTGGAGGTGGCAGCTATGGCAACGCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGCTGCCCCCCCAACATTGAGGCTGGGGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrlsPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGGGCAGGGGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrlsVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrlsTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTATCCCGCAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGACGGGGCTTCCCGAGGCCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCCAACGAGCTGCCCTGGATGGGTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 50
ADB26036
ID ADB26036 standard; cDNA; 1985 BP.
XX AC ADB26036;
XX DT 20-NOV-2003 (first entry)
XX DE cDNA encoding human PRO polypeptide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX FN US2003082760-A1.
XX PD 01-MAY-2003.
XX PF 12-APR-2002; 2002US-00121056.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.

Db 806 CCAGGGGGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACTGTTCTGGTGTCTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaPProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTCAACGCTGGCCCTCACCACTCCCGCGCGCGCGCTCATGTGGCGCC 984
Qy 260 oTyTyTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACGAGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCGCCAAGGAAGCGCCCTGAAACGCAAGG 1164
Qy 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACGGCAACAGCAACTGTA 1224
Qy 340 rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaIleValSerLe 380
Db 1285 TCACACTGAGGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheIysGlyVcIlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTCTGATGCTGGAGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCGCCCATCTGTAGCG 1464
Qy 420 alAlaLeuPheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCTGTT 1764
Qy 520 e 520
Db 1765 c 1765
RESULT 51
ADB21521
ID ADB21521 standard; cDNA; 1985 BP.
XX
AC ADB21521;
XX

DT 20-NOV-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss;
XX Humour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS
XX US2003082765-A1.
XX 01-MAY-2003.
XX 17-MAY-2002; 2002US-00147492.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022391.
PR 29-OCT-1998; 98WO-US022392.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US0005841.
 PR 10-MAR-2000; 2000WO-US0006319.
 PR 15-MAR-2000; 2000WO-US0006884.
 PR 20-MAR-2000; 2000WO-US0007377.
 PR 21-MAR-2000; 2000WO-US0007532.
 PR 30-MAR-2000; 2000WO-US0008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00806889.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
 XX WPI; 2003-786920/74.
 DR P-PSDB; ADB21522.
 XX
 PT New secreted and transmembrane PRO polypeptide useful for detecting the
 PT presence of tumor in a mammal, or modulating the uptake of glucose or
 PT free fatty acid by skeletal muscle cells or adipocyte cells.
 XX
 PS Claim 2; Fig 143; 638pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear intracicular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumor in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB21521 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 |||||
 DB 206 ATGTCGCGCGCTCGGCTCTCTGTGCGGCCCTGAGCTGCTACTGTGGGGCCACCTG 265
 |||||
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
 |||||
 DB 266 GACGCCAGCCCGCGAGCGCGGAGCCAGGAGCTGCGCAAGAGCGCGAGGCATTTCCTA 325
 |||||
 QY 41 GluLysTyrglyTyrglyLeuAsnGluGlnValPheGlyAlaProThrSerThrArgPheSer 60
 |||||
 DB 326 GAGAAATACGGATACCTCAATGAACAGCTGCCAAAGTCCCACTCCATCGATTCAGC 385
 |||||
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 |||||
 DB 386 GATGCATCAGAGCGTTTCAGTGGGTGTCACAGTACCTGTCTGAGCGGGGTGTGGACCCG 445
 |||||
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 |||||
 DB 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 |||||
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 |||||
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGCTAGACACCGGACCCAAATAGGCGGTAA 565
 |||||
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrglyGlnHisLeuSerTyrArgLeuVal 140
 |||||
 DB 566 AAACGCTTGCAAAGCAGGTAAACAAATGGTACAGCAGCAGCCTCTCTCCGCGCTGGTG 625
 |||||
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 |||||
 DB 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTCTGGGGGCGCGTGGCGCGCGCTTCCAG 685
 |||||
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 |||||
 DB 686 TTGTGGAGCAACGCTCTAGCCCTGGAGTTCCTGGAGGCGCCAGCCAGCAGGCCCCCTCAC 745
 |||||
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 |||||
 DB 746 ATCCGGCTCACCTTCTTCCAAAGGGGAGCACCAACGATGGGCTGGGCATGCTTGTGATGGC 805
 |||||
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 |||||

Db	806	CCAGGGGGCCCTGGCGCACGCCTTC-CTGCCCCGGCGCGGCGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrrpSerLeuSerArgArgGlyAArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTCGAGCGCGCGCGCGCAACCTGTTGCTGGTGGCGCA	924
Qy	240	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPrr	260
Db	925	CGAGATCGGTACACAGCTTGGCCTCACCACTCGCCCCGGCGCGCGCTCATGGCGCC	984
Qy	260	oTrrYrlyysArgLeuGlyAArgAspAlaLeuSerTrpAspValLeuAlaValG1	280
Db	995	CTACTACAAGAGGCTGGCGCGACGCGCTGCTCAGCTGGGACGCGTGGCCGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyAArgProGluThrGlnG1	320
Db	1105	CACTGACTTTGAGACTTGGGACTCTCTACAGCCCCCAAGAAAGCGCCCTGAAACGCGAGG	1164
Qy	320	yProlyseTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGTCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	xIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGGCCATTTCTGGGAGTGCGAGCTGATGGCAACGCTCTCAGAGCCCCG	1284
Qy	360	gProleuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGAGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyAArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTCGATGCTGGAGTTTCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCGCTGCCCGCCATCCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGGCCCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTACGCGCGCCCTGCCAGGCGCCGATGGCTCCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCyTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGCCCAACGAGTGCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	c 1765	
RESULT 52			
ADA77300			
XX	ADA77300 standard; cDNA; 1985 BP.		
AC	ADA77300;		
XX			
DT	20-NOV-2003 (first entry)		

XX	Human PRO polynucleotide #72.		
DE			
XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; PFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
XX	immune system cell infiltration.		
OS	Homo sapiens.		
XX	US2003068797-A1.		
PN	10-APR-2003.		
XX	07-MAY-2002; 2002US-00140921.		
PD			
XX			
PF			
XX			
PR	31-MAR-1997;	97WO-US005230.	
PR	12-JUN-1998;	98WO-US012456.	
PR	14-JUL-1998;	98WO-US014552.	
PR	28-AUG-1998;	98WO-US017888.	
PR	10-SEP-1998;	98WO-US018824.	
PR	14-SEP-1998;	98WO-US019093.	
PR	14-SEP-1998;	98WO-US019094.	
PR	14-SEP-1998;	98WO-US019177.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98WO-US019437.	
PR	07-OCT-1998;	98WO-US021141.	
PR	29-OCT-1998;	98WO-US022991.	
PR	29-OCT-1998;	98WO-US022992.	
PR	20-NOV-1998;	98WO-US024855.	
PR	01-DEC-1998;	98WO-US025108.	
PR	05-JAN-1999;	99WO-US000106.	
PR	08-MAR-1999;	99WO-US005028.	
PR	10-MAR-1999;	99WO-US005190.	
PR	20-APR-1999;	99WO-US008615.	
PR	14-MAY-1999;	99WO-US010733.	
PR	02-JUN-1999;	99WO-US012252.	
PR	01-SEP-1999;	99WO-US020111.	
PR	08-SEP-1999;	99WO-US020594.	
PR	13-SEP-1999;	99WO-US020944.	
PR	15-SEP-1999;	99WO-US021090.	
PR	15-SEP-1999;	99WO-US021547.	
PR	05-OCT-1999;	99WO-US023089.	
PR	29-NOV-1999;	99WO-US028214.	
PR	30-NOV-1999;	99WO-US028313.	
PR	30-NOV-1999;	99WO-US028409.	
PR	01-DEC-1999;	99WO-US028301.	
PR	01-DEC-1999;	99WO-US028634.	
PR	02-DEC-1999;	99WO-US028551.	
PR	02-DEC-1999;	99WO-US028564.	
PR	02-DEC-1999;	99WO-US028565.	
PR	16-DEC-1999;	99WO-US030095.	
PR	20-DEC-1999;	99WO-US030911.	
PR	20-DEC-1999;	99WO-US030999.	
PR	22-DEC-1999;	99WO-US030720.	
PR	30-DEC-1999;	99WO-US031243.	
PR	30-DEC-1999;	99WO-US031274.	
PR	05-JAN-2000;	2000WO-US000219.	
PR	06-JAN-2000;	2000WO-US000277.	
PR	06-JAN-2000;	2000WO-US000376.	
PR	11-FEB-2000;	2000WO-US003565.	
PR	18-FEB-2000;	2000WO-US004341.	
PR	22-FEB-2000;	2000WO-US004342.	
PR	24-FEB-2000;	2000WO-US004414.	
PR	24-FEB-2000;	2000WO-US005004.	
PR	01-MAR-2000;	2000WO-US005601.	

02-MAR-2000; 2000WO-US005746.
02-MAR-2000; 2000WO-US005841.
10-MAR-2000; 2000WO-US006319.
15-MAR-2000; 2000WO-US006884.
20-MAR-2000; 2000WO-US007377.
21-MAR-2000; 2000WO-US007532.
30-MAR-2000; 2000WO-US008433.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00860238.
25-MAY-2001; 2001US-00866034.
01-JUN-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
05-JUN-2001; 2001WO-US017800.
14-JUN-2001; 2001US-00874503.
19-JUN-2001; 2001US-00882636.
20-JUN-2001; 2001US-00886342.
21-JUN-2001; 2001WO-US019692.
22-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-625489/59.
P-PSDB; ADA77301.
Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801
and PRO1114, useful in the preparation of a medicament for treating a
condition responsive to PRO polypeptide, and as therapeutic agents e.g.
vaccines.
Claim 2; Fig 143; 659pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
US-10-791-980-6 (1-520) x ADA77300 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCGTCGGCCCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCCAGCCCGCGAGCGCGGAGCCAGAGCTGCCAAGAGCGCGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrArgPThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATCGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTTCGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGACCTCTCTCCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGACCGCGAGTTCGGGGCGCGTGGCGCGCCCTCCAG 685
QY 160 rCyGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGGAGGCGCCCGACGACAGGCGCGCTGAC 745

```
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CACAGGGGGCCCTGGGCGACGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAepGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCAACCTGTTGCTGGTGGTGGCGCA 924
QY 240 sduileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CAGATCGGTACACGCTTGGCTTCCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 ofYrYrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAepAepValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGTGCA 1044
QY 280 nSerLeuYrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAepPheGluThrTrpAepSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTCAGCGCCCAAGGAGGGCGCCCTGAAACGCAAGG 1164
QY 320 yProLysYrCyHisSerSerPheAlaIleThrValAepArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCATGTCATCACTGTACACAGCGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAepGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGGCGGAGTGTCAAT 1344
QY 380 uAenAepGlyAepPheYrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACACAGCTGTGCCGGGCAAGGGGCGCTGCCCGCCCATCTGCACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpYrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTACGT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTrpYrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAepGlySerIlellePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTCAGCGGGCGCTTCCCGAGGCGCGATGGCTCATCATCTTCTT 1644
QY 480 eArgAepAepArgTrpTrpArgLeuAepGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGGCTCGACAGGCCAATGACGAGCAACACCTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGCCCAACGAGCTGCCCTGGTGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

```
RESULT 53
ADB18040
ID ADB18040 standard; cDNA; 1985 BP.
XX
AC ADB18040;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077710-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127825.
XX
PR 22-OCT-1998; 98US-0105169P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
( GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WI: 2003-755065/71.
DR P-PSDB; ADB18041.
XX
New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, in chromosome and gene mapping, as chromosome markers,
in tissue typing, and in identifying chromosomes.
XX
Claim 2; Fig 143; 637pp; English.
XX
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
```

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2752.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB18040 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGCGCGGTGGCCCTCTGTCGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGCGAGCGCGAGCCAGGAGCTGGCAGAGCGCGGAGGCAATTCCTTA 325
 QY 41 GluLeuTrpGlyLeuLeuGlnGlnValProLysAlaProHisAlaProHisSer 60
 DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACATCGATTACAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTCAGTGGGTGTCCTCAGCTACCTGTGAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGATCAGTACTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTGCAGACGAGTAAACAAATGTTACAGACGACACCTCTCTACGCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 NAATGGCTTGCATCTGCGGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGGTGAGTTCGGAGGCGCCACAGCCAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCNAGGGGACCAACAGATGGCTGGGCATGCTTCCTTGTATGGC 805
 QY 200 sGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCTGCGCACGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCAACCTGTTGTCGTGGTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTTCCACCTTCGCGCGCGCGCGCTCATGGCGGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTATCTACAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCGCGCTGCA 1044
 QY 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGAAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCCAAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACCTTGGAGCTTGGGACTCTACAGCCCCCAAGGAGCGCCCTGAAACGACGAG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
 DB 1165 CCTTAATACCTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGCGGAGGGGGCTGCCCCCGCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCTCTCTTCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGCTGTCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGCGCGCTGCGGAGGCGCGATGGCTCCATCATCTCTTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCTGACAGCGCCAACTGACGAGCAACACCTCGGGCGC 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCGCTGGATGGGTGCTGGCATGCCAACTCGGAGGAGCGCCCTGT 1764
 QY 520 e 520
 DB 1765 c 1765

RESULT 54

ID ADA86723 standard; cDNA; 1985 BP.
 XX ADA86723;
 AC ADA86723;
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 XX US2003082709-A1.
 XX
 XX 01-MAY-2003.
 XX
 XX 15-MAY-2002; 2002US-00146791.
 XX
 XX 17-AUG-1998; 98US-0096895P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvatoff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-786912/74.
 DR P-PSDB; ADA86724.
 XX
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
 PT for preparing a composition for treating e.g., tumor, or for tissue
 PT typing.
 XX
 XX Claim 2; Fig 143; 637pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMC cells, for inhibiting the binding of
 CC A-peptide to factor VITA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 SQ

Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2

DB: 9 Gaps: 0
 US-10-791-980-6 (1-520) x ADA86723 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGCTCGGCCCTCTCTGCGCGCCCTCAGCTGCTACTGTGGGCGCACTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCCCGGAGCGGAGCGGAGCTGCGCAAGGAGGAGGCGGAGCATTCCTA 325
 QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACTGTGAGCGCGGTGTTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTCGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGCGGTAA 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLysSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysValaProProSerSe 160
 DB 626 AACTGGCCTGAGCATCTGCGGAGCGCGAGTTGCGGGCGCGCGCGCGCTTCCAG 685
 QY 160 rCysGlyValThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCCGCCAGCCAGCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACTTCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGGC 805
 QY 200 aGlnGlyValaProTrpArgThrProPheLeuProArgArgGlyGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGGCGCCCTGGGCGCAGCCCTTC-CTGCCCGCGCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGACGCTGGTCTCCCTGAGCGCGCGCGCGCGCAACCTGTTGCTGGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCCTCACCCATCTCCCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGluVArgaspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGCTGGGCGCGCGCGCGCGCTGCTGAGTGGGACGAGCTGCTGGCGGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCAAGGAGGCGCGCTGAAACGCGAGG 1164
 QY 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
 DB 1165 CCCTAAATACTGCCACTCTCTTCATGTCATCATCTGTAGACAGGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360


```
Db 1225 CATTGTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAACGTCCTCAGAGCCCG 1284
QY 360 GProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGAAGATGGTCCGGCTGCCCCCAACATGAGCTGGCGCAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGAGAGTTTCGGGGCCCCAA 1404
QY 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 alAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTTGGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 GCTGGCCCGAGGGGACTGCNAGTGGAGCCCTACTACCCCCGAGTCTCAGAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGCATCTCTGAGGAGTCCAGCGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAAGCCAACTGCAAGGCAACCACTTCGGGCG 1704
QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGTGCCTTGGATGGGCTGTGGCATGCCAATCGGGGAGGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 55
ADA87826
ID ADA87826 standard; cDNA; 1985 BP.
AC ADA87826;
XX AC
XX AC
DT 20-NOV-2003 (first entry)
XX DT
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX DE
KW Human; secreted and transmembrane protein; PRO; Gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX KW
OS Homo sapiens.
XX OS
XX US2003082700-A1.
PN US
XX PN
XX 01-MAY-2003.
PD 01
XX PD
XX 23-APR-2002; 2002US-00128684.
PF 23
XX PF
XX 05-JUN-2000; 2000US-0209832P.
PR 05
XX PR
XX 01-DEC-2000; 2000WO-US032678.
PR 01
XX PR
XX 19-DEC-2001; 2001US-00028072.
PR 19
XX PR
XX (GETH ) GENENTECH INC.
PA (GETH
XX PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
```

```
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX
XX WPI; 2003-786910/74.
XX P-PSDB; ADA87827.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA87826 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
Db 206 ATGTGTCGGCGCGTCCGGCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGGAGCGGAGCCGAGAGCTGGCCAGAGGAGCGGAGGAGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGNACAGGTCCCAAGCTCCCACTCCATCGATTACGC 385
QY 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGAGTACCTGTCTCAGCGGCTGTGTGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCGGTGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
```

Db	506	GCCTGGGCTGAGAGATCAGTGA	CTTGTCTTAGACACCGACCAAAATGAGCGCTAAG	565	Db	1585	AGGCATCCTCAGGAGGTCAGCGGGCCCTCGCGAGGCCCGATGGCTCCATCATCTTCTT	1644
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140		Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	566	AAACGCCTTGCACAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTTACCCGCTGGTG	625		Db	1645	CCGAGATCAGCGCTACTGGCGCTCGACCGGCCAACTGCAGGCCAACCACTCGGGCCG	1704
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe	160		Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLeuSerGlySerAlaLeuPh	520
Db	626	AACGTGGCTGAGCATCTGCCGAGCGCCGAGCTTCGGGGCGCCGTGCGCGCGCTTCCAG	685		Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180		Qy	520 e	520	
Db	686	TTGTGGACCAAGCTCTCAGCGCTGAGTTCTGGGAGGCCCGACAGCACAGGCCCGCTGAC	745		Db	1765 C	1765	
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200					
Db	746	ATCCCGCTCACCTCTTCCAAAGGGGACCCACAAACGATGGGCTGGGCAATGCCCTTGTATGGC	805		RESULT 56			
Qy	200	aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl	220		ADA46214			
Db	806	CCAGGGGGCGCCTGGCGCACGCTTC-CTGCCCGCGCGCGCAAGCGCACTTCGACCA	864		ID	ADA46214	standard; cDNA; 1995 BP.	
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240		XX	ADA46214;		
Db	865	AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGCAACTGTTCGTGGTGTCTGGCGCA	924		AC			
Qy	240	sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260		XX			
Db	925	CCAGATCGGTCAACGCTTGGCTTCAACCATCGGCCGCGCGCGCTCATGGCGCC	984		DT	20-NOV-2003	(first entry)	
Qy	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280		DE		Novel human secreted and transmembrane protein PRO4339 cDNA.	
Db	985	CTACTACAAGAGCGCTGGCGCGCGCTGCTCTAGCTGGGACGACGTCTGGCGGTGCA	1044		XX		Human; secreted and transmembrane protein; PRO; gene; ss;	
Qy	280	nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300		KW		Tumour necrosis factor alpha release; TNF-alpha release;	
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGGNAAGCTGT	1104		KW		glucose uptake modulator; FFA uptake modulator;	
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320		KW		cell proliferation stimulator; cell differentiation stimulator;	
Db	1105	CACGTACTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGACGGG	1164		KW		cell differentiation inhibitor; cytokine release stimulator; tumour;	
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340		KW		lung tumore; colon tumour; breast tumour; prostate tumour; rectal tumour;	
Db	1165	CCCTAAATATCGCCACTCTCTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGT	1224		KW		cervical tumour; liver tumour; chromosome mapping; gene mapping;	
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360		KW		gene therapy; chromosome identification; chromosome marker.	
Db	1225	CATTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG	1284		XX		Homo sapiens.	
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle	380		OS	US2003054516-A1.		
Db	1285	TCCACTGCAGAAAGATGGTTCGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAIT	1344		XX	20-MAR-2003.		
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly	400		XX			
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404		XX			
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl	420		XX			
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCTGCCCGCCATCTCTGACGC	1464		XX			
Qy	420	aAlaLeuPhePheProPheLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440		XX			
Db	1465	CGCCCTCTTCTCCCTCTTGGCGCCCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524		XX			
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl	460		XX			
Db	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG	1584		XX			
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480		XX			

PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 02-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US000356.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000US-0074259.
 PR 20-DEC-2000; 2000US-0074259.
 PR 28-FEB-2001; 2001US-00796496.
 PR 28-FEB-2001; 2001US-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-US0082706.
 PR 14-MAR-2001; 2001US-US0080689.
 PR 22-MAR-2001; 2001US-US016744.
 PR 05-APR-2001; 2001US-US028366.
 PR 10-MAY-2001; 2001US-US0084208.
 PR 10-MAY-2001; 2001US-US00854280.
 PR 18-MAY-2001; 2001US-US00860216.
 PR 25-MAY-2001; 2001US-US00866034.
 PR 25-MAY-2001; 2001US-US017092.
 PR 01-JUN-2001; 2001US-US00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-US00874503.
 PR 14-JUN-2001; 2001US-US0082636.
 PR 19-JUN-2001; 2001US-US0086342.
 PR 20-JUN-2001; 2001US-US019692.
 PR 21-JUN-2001; 2001US-US00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-US00908827.
 PR 06-AUG-2001; 2001US-US024419.
 PR 09-AUG-2001; 2001US-US00927796.
 PR 16-AUG-2001; 2001US-US00931836.
 PR 19-DEC-2001; 2001US-US0028072.
 XX (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI; 2003-521853/49.
 DR P-PSDB; ADA46215.
 XX
 PT New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g., tumor.
 XX
 PS Claim 2; Fig 143; 200pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in paricycle
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear intracellular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0
 US-10-791-980-6 (1-520) x ADA46214 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB 206 ATGTGCGCGCGTCGCGCTCTCTGTCGCGCCCTGACAGTGTACTGTGGGCGACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGCGAGCGCGGAGCGGAGGTCGCGCAGAGGAGCGGAGGCGCATTCCTA 325
 QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAATACGGATACCTCAATGAACAGTCTCCCAAGCTCCACCTCCACCTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACTGTCCAGCGCGGTGTGGACGCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTACTGTTGTTGCTAGACACCGGACCAAAATGAGCGCTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGGTACAGCAGCACCTCTCTACTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCGAGCGCGAGTTCGGGGCGCGTGGCGCCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCCTGGAGGCCACAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTCTTCCAGAGGAGCACCAACATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGAGGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTGTGCTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 COAGATCGGTACACGCTTGGCTTACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGCGTCTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValalaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCAAGAGGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaileThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTCTCTTCGATGCTCCTCAGTACAGGCAACAGCAACTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnileGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGGAGTGTGATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTCGATGCTGGAGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGAGGAGGGGCGCTGCCCGCCCATCTCGAGC 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGTGCGCCCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGCGCGCTCCGAGGGCCGATGGCTCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCTGACCGAGCCAAACTGCAGGCAACCTCGGGCG 1704
QY 500 gTtpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTCGATGGGCTGTCGATGCCCACTCGGGAGCGCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 57
ADB28244
ID ADB28244 standard; cDNA; 1985 BP.
XX
AC ADB28244;
XX
XX 20-NOV-2003 (first entry)
XX
DB cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003082699-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127851.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-777202/73.
XX P-PSDB; ADB28245.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
XX e.g., tumor or for tissue typing.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating

antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Prod. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADB28244 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTCGGCGCGTCTGGCTCTCTGCTGCGGCGCTGCAGCTGCTACTGTGGGCGCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu	40
DB	266	GAGCCCGACCGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG	325
QY	41	GluLeuTyrGlyTyrLeuLeuGlnGlnValProLeuAlaProThrSerThrArgPheSer	60
DB	326	GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
DB	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGTACCTGTGTCAGCGCGGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTCGCCGAGATGACTGTCTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgGly	120
DB	506	GCTTGGGCTGAGAGGATCAGTACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGGTAACTAATGGTACACCGGACCAAAATGAGGGGTAAAG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCCTGAGCATCTGCGGAGCGGAGTTGCGGGCGCGCTGCGCGCGCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGAGGAGGAGGAGGAGGAGGAGGAG	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200

RESULT 58
ADB28796

DB	746	ATCCGCGCTCACCTCTTCCAAAGGGGACACACACGATGGCTGGCAATGCCCTTGTATGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
DB	806	CCAGGGGGCGGCTCGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaH	240
DB	865	AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTCTGGCGCA	924
QY	240	sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTACACGCTGGCGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC	984
QY	260	OTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
DB	985	CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGTGGGACGAGCTGCTGGCCGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCGAGGAAAGTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
DB	1105	CACTGACTTTGAGACTCGGACTCTCAGACCCCAAGGAGCGCGCTGAAACGCGAGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
DB	1165	CCCTAAATACCTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACACGAACTG	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAAGCTCTCAGAGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
DB	1285	TCCACTGCAGGAAGATGGGTGGGTGCGGCTGCCCCCAACATTAGGTGCGCGAGTGTCA	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLys	400
DB	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCC	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCCGCCATCTCTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
DB	1465	CGCCCTCTTCT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG	460
DB	1525	GCTGCGCGGAGGGGACTGCAAGTGGAGGCCCTTACCCCCGAAAGTCTCAGAGCTGGGG	1584
QY	460	yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCTCTGAGGAGGTTCAGCGGCGCTGCGGAGGCGCGGATGGCTCATCTCTCTT	1644
QY	480	sArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
DB	1645	CCGAGATGACCGCTACTGCGCGCTCGACCGAGGCCAACTGCAGGCAACACCCCTCGGGCG	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
DB	1705	CTGGGCCCAACGAGCTGCGCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCGCTGT	1764
QY	520	e 520	
DB	1765	C 1765	


```
Db      985 CTACTACAAGAGCGCTGGGCGCGAGCGCTGCTCAGCTGGGACGACGTCGTGCGCCGTGCA 1044
Qy      280 nSerLeuTyRgLyLeuProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045 GAGCGTGATGGAGAGCCCTAGGGGGCTCAGTGGCGGTCCAGCTCCAGAGAAAGCTGTT 1104
Qy      300 eThrAspPheGluThrTyrAspSerTyRserProGlnGlyArgArgProGluThrGlnG 320
Db      1105 CACTGACTTGAGACCTGGAGACTCCTACAGCGCCCAAGAGGCGCCCTGAACGCGAGG 1164
Qy      320 yProLysTyRcYeHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165 CCTTAATAACTGCCACTCTTCCTTCGATGCCATCACTAGTAGACGAGCAACACCAACTGTA 1224
Qy      340 rIlePheLysGlySerHisPheTyrGluValAlaAspGlyAsnValSerGluProAr 360
Db      1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGCCAGCTCTCAGAGCCCG 1284
Qy      360 gProLeuGlnGluArgTyrValGlyLeuProProAniIleGluAlaAlaValSerIe 380
Db      1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAATT 1344
Qy      380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTyrProArgPheArgGlyProLy 400
Db      1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGGGCCCAA 1404
Qy      400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGTGGGTCTCCACACACTGTCCGGGAGGGGCCCTGCCCGGCATCCTGAGCG 1464
Qy      420 alAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyRva 440
Db      1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy      440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyRProArgSerLeuGlnAspTyrGl 460
Db      1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGGCTTACTACCCCGAAGCTTGCAGGACTGGGG 1584
Qy      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585 AGGCATCTCTGAGAGGTGAGCGGCGCTTCCGAGGCGCGATGGCTCCATCTTCTT 1644
Qy      480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645 CCGAGATGACCGCTACTGCGCGCTCGACCAGGSCCAACTGCAGGCAACCACTCGGGCG 1704
Qy      500 gTyrAlaThrGluLeuProTyrPheGlyCysTyrPheHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy      520 e 520
Db      1765 C 1765

RESULT S9
ADA76748
ID ADA76748 standard; cDNA; 1985 BP.
XX
AC ADA76748;
XX
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
```

immune system cell infiltration.

Homo sapiens.

US2003059909-A1.

27-MAR-2003.

10-MAY-2002; 2002US-00143032.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

14-SEP-1998; 98WO-US019177.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US021141.

29-OCT-1998; 98WO-US022991.

29-OCT-1998; 98WO-US022992.

20-NOV-1998; 98WO-US024855.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 99WO-US000106.

08-MAR-1999; 99WO-US005028.

10-MAR-1999; 99WO-US005190.

20-APR-1999; 99WO-US008615.

14-MAY-1999; 99WO-US010733.

02-JUN-1999; 99WO-US012252.

01-SEP-1999; 99WO-US020111.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

30-NOV-1999; 99WO-US028409.

01-DEC-1999; 99WO-US028301.

01-DEC-1999; 99WO-US028634.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028564.

02-DEC-1999; 99WO-US028565.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.

22-DEC-1999; 99WO-US030720.

30-DEC-1999; 99WO-US031243.

30-DEC-1999; 99WO-US031274.

05-JAN-2000; 2000WO-US000219.

06-JAN-2000; 2000WO-US000277.

06-JAN-2000; 2000WO-US000376.

11-FEB-2000; 2000WO-US003565.

18-FEB-2000; 2000WO-US004341.

18-FEB-2000; 2000WO-US004342.

24-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US004914.

01-MAR-2000; 2000WO-US005004.

01-MAR-2000; 2000WO-US005601.

02-MAR-2000; 2000WO-US005746.

02-MAR-2000; 2000WO-US005841.

10-MAR-2000; 2000WO-US006319.

15-MAR-2000; 2000WO-US006884.

20-MAR-2000; 2000WO-US007377.

21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.

17-MAY-2000; 2000WO-US013705.

22-MAY-2000; 2000WO-US014042.

30-MAY-2000; 2000WO-US014941.

02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000WO-US020710.

11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006656.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-540684/51.
P-FSDB; ADA76749.
New secreted and transmembrane nucleic acids and polypeptides, designated
as PRO, useful for treating inflammation, organ failure, atherosclerosis,
cardiac injury, infertility, birth defects, premature aging, AIDS, or
cancer.
Claim 2; Fig 143; 660pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTGGCTCACCACCTGCGCGCGCGCGGCTCATGGCGCC 984
QY 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTAATAAGAGGCTGGGCGCGCACGCGCTGCTCAGTGGGACGACGTGCTGCGCGGTGCA 1044
QY 280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCATGGCGCTCCAGTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGGAGCGCCCTGAACCGCAGGG 1164
QY 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCGG 1284
QY 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGAGGAAGAATGGTGGGCTGCCGCCCAACATTGAGGTGGCGACTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheIysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGCCCATCTCGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTTACCCCGAGCTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTTCCGAGGCGCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCCCTACTTGGCGCTCGACAGGCCAACTGACAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 60

ADA88378

ID ADA88378 standard; cDNA; 1985 BP.

XX AC

ADA88378;

XX DT 20-NOV-2003 (first entry)

XX DE

DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX KW

KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
OS Homo sapiens.

XX OS

XX US2003073213-A1.

XX PD 17-APR-2003.

XX PF 17-APR-2002; 2002US-00124819.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 29-OCT-1998; 98WO-US022992.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 99WO-US000106.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 10-MAR-1999; 99WO-US005190.

XX PR 20-APR-1999; 99WO-US008615.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 08-SEP-1999; 99WO-US020594.

XX PR 13-SEP-1999; 99WO-US020944.

XX PR 15-SEP-1999; 99WO-US021090.

XX PR 15-SEP-1999; 99WO-US021547.

XX PR 05-OCT-1999; 99WO-US023089.

XX PR 29-NOV-1999; 99WO-US028214.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 30-NOV-1999; 99WO-US028409.

XX PR 01-DEC-1999; 99WO-US028301.

XX PR 01-DEC-1999; 99WO-US028634.

XX PR 02-DEC-1999; 99WO-US028551.

XX PR 02-DEC-1999; 99WO-US028564.

XX PR 02-DEC-1999; 99WO-US028565.

XX PR 16-DEC-1999; 99WO-US030095.

XX PR 20-DEC-1999; 99WO-US030911.

XX PR 22-DEC-1999; 99WO-US030999.

XX PR 22-DEC-1999; 99WO-US030720.

XX PR 30-DEC-1999; 99WO-US031243.

XX PR 30-DEC-1999; 99WO-US031274.

XX PR 05-JAN-2000; 2000WO-US000219.

XX PR 06-JAN-2000; 2000WO-US000277.

XX PR 06-JAN-2000; 2000WO-US000376.

XX PR 11-FEB-2000; 2000WO-US003565.

XX PR 18-FEB-2000; 2000WO-US004341.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 22-FEB-2000; 2000WO-US004414.

XX PR 24-FEB-2000; 2000WO-US004514.

XX PR 24-FEB-2000; 2000WO-US005004.

XX PR 01-MAR-2000; 2000WO-US005601.

XX PR 02-MAR-2000; 2000WO-US005746.

XX PR 02-MAR-2000; 2000WO-US005841.

XX PR 10-MAR-2000; 2000WO-US006319.

XX PR 15-MAR-2000; 2000WO-US006884.

XX PR 20-MAR-2000; 2000WO-US007377.

XX PR 21-MAR-2000; 2000WO-US007532.

XX PR 30-MAR-2000; 2000WO-US008439.


```
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaBr 260
Db 925 CGAGATCGGTCAACAGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTyrlsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACGACGTGTCGGCGCTGCA 1044
QY 280 nSerLeuTyrlsGlyProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGGCCCTAGGGGCTCAGTGGCCGTCCAGCTCCCAAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrlsProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGACGG 1164
QY 320 yProLysTyrlsCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCATAATATCTCCACTCTCTCCATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGCAACGTTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrlsPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAAGGGGTGCTGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGGCGGAGGGGCTGCCCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrlsVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrlsTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCGCGGAGGGGACTGCAAGTGGAGGCTTACTACCCCGCAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCCGATGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTCGCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 61

ADA97383

ID ADA97383 standard; cDNA; 1985 BP.

XX AC ADA97383;

XX XX ADA97383;

DT 20-NOV-2003 (first entry)

XX XX Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FPA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082686-A1.

XX 01-MAY-2003.

XX 19-APR-2002; 2002US-00125926.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755106/71.

XX P-FSDB; ADA97384.

XX Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.

XX Claim 2; Fig 143; 666pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting the proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

XX Alignment Scores:

PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 18-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 31-MAR-1998; 98US-0079728P.
PR 09-APR-1998; 98US-008165P.
PR 14-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089595P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096771P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 14-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 15-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 13-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.

```
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US02485S.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113298P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.

Alignment Scores:
Pred. No.: 1,936-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB27140 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTCGCGCGCTGGCGCTCTGTCGCGCGCTGCGAGCTGCTACTGTGGGGCCACTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCAAGCCCGGAGCGGAGCCAGAGCTGCGCAGAGGAGCGGAGCATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCGATTTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGAGTACCCTGTGACGGCGGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATCACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCCTACCGCTGTGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTCCGAGCGGCGAGTTCGGGGCGCGGTGGCGCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGATTCTGGGAGGCGCCAGGCCAGAGGCCGCTGAC 745
```

```
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACTTCCTTCCAAAGGGGACCAACAACATGGCTGGCAATGCTTTGATGGC 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGGCTGGGGCGACGCCCTTC-CTGCCCGCGCGCGGCGAAGGGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCAACCTGTTCGTGGTCTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCCGCCCGCGCGCGCTCAATGGCGGCC 984

QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGGGCGCGGCGCTGCTCAGCTGGGACGACGCTGTGGCGCTGCA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGTCCAGAAAAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGGCGCTCGAAACGCGAGG 1164

QY 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
DB 1165 CCTAATACTGCGACATCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTCAGAAAGATGGGTGCGGCTGCCCCCAACATTTAGGCTCGGCAGTGTCAATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCAAGGGGGCTGCCCGGCCATCTCGACGC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584

QY 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCAGATGACCGCTACTTGGCGCTCGACCAAGGCCAATACTGCAGGCAACACCTCGGGCGC 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGTGCAACTCGGAGGAGCGGCCCTGTT 1764

QY 520 e 520
DB 1765 C 1765
```

RESULT 63
ADB22073
ID ADB22073 standard; cDNA; 1985 BP.
XX AC
AC ADB22073;
XX DT 20-NOV-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN
PN US2003087344-A1.
XX PD
PD 08-MAY-2003.
XX PF 16-APR-2002; 2002US-00123905.
XX PR 18-JUN-1997; 97US-0049511P.
PR 26-AUG-1997; 97US-0056574P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0068212P.
PR 11-DEC-1997; 97US-0068278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 12-MAY-1998; 98US-0084637P.
PR 13-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 26-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 30-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.

PR	14-SEP-1998;	98US-0100263P.	Db	266	GACGCCAGCCCGCGGAGCGCGGAGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCCTA	325
PR	14-SEP-1998;	98WO-US019033.	Qy	41	GlulysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer	60
PR	14-SEP-1998;	98WO-US019094.	Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC	385
PR	15-SEP-1998;	98US-0100390P.	Qy	61	AspAlaIleArgAlaPheGlnTrrpValSerGlnLeuProValSerGlyValLeuAenArg	80
PR	16-SEP-1998;	98US-0100634P.	Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGGTACTCTGTACGCGGCGTGTGGACGC	445
PR	16-SEP-1998;	98WO-US019330.	Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
PR	17-SEP-1998;	98US-0100710P.	Db	446	GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
PR	17-SEP-1998;	98US-0100858P.	Qy	101	AlaTrrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
PR	17-SEP-1998;	98WO-US019437.	Db	506	GCCTGGGCTGAGAGATCAGTACTTGTTCGTAGACACCGGACCAAAATGAGCGTAAAG	565
PR	23-SEP-1998;	98US-0101474P.	Qy	121	LysArgPheAlaLysGlnGlyAenLysTrrpTrrLysGlnHisLeuSerTyrArgLeuVal	140
PR	23-SEP-1998;	98US-0101477P.	Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCTCCGCTGGTG	625
PR	24-SEP-1998;	98US-0101741P.	Qy	141	AsnTrrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
PR	07-OCT-1998;	98US-0103315P.	Db	626	AACCTGGCTGAGCATCTGCCGAGCGCGAGTTCCGGGCGCGCTGCGCGCTTCCAG	685
PR	07-OCT-1998;	98WO-US03288P.	Qy	160	rCysGlyAlaThrSerGlnArgTrrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
PR	13-OCT-1998;	98US-0104080P.	Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGGAGGCCCCAGCCACAGGCCCGCTGAC	745
PR	20-OCT-1998;	98US-0104987P.	Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrpAlaMetProLeuMetAl	200
PR	22-OCT-1998;	98US-0105169P.	Db	746	ATCCGGCTCACCTTCTTCCAAAGGGGACCACAACTGGGCTGGGCAATGCCCTTTGATGGC	805
PR	28-OCT-1998;	98US-0106030P.	Qy	200	aGlnGlyAlaProTrrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
PR	29-OCT-1998;	98WO-US022931.	Db	806	CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAGCGCACTTCGACCA	864
PR	30-OCT-1998;	98US-0106464P.	Qy	220	nAspGluArgTrrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
PR	03-NOV-1998;	98US-0106856P.	Db	865	AGATGAGCGTGGTCCCTGAGCCGCGCGCGCGGCGCAACTGTTCTGGTGGTGGCGCA	924
PR	10-NOV-1998;	98US-0107783P.	Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
PR	17-NOV-1998;	98US-0108775P.	Db	925	CGAGATCGGTACACGCTTGGCCCTCACCACTGCCCGCGCGCGCGCTCATGGGGCC	984
PR	17-NOV-1998;	98US-0108801P.	Qy	260	oTyrTrrLysArgLeuGlyArgAspAlaLeuLeuSerTrrpAspAspValLeuAlaValGl	280
PR	17-NOV-1998;	98US-0108802P.	Db	985	CTACTACAAGAGGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA	1044
PR	20-NOV-1998;	98US-0109304P.	Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
PR	01-DEC-1998;	98WO-US025108.	Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104
PR	15-DEC-1998;	98US-0112743P.	Qy	300	eThrAspPheGluThrTrrpAspSerTyrSerProGlnGlyVarArgProGluThrGlnGl	320
PR	16-DEC-1998;	98US-0112850P.	Db	1105	CACAGCTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGGCGCCCTGAAACGCGAGG	1164
PR	22-DEC-1998;	98US-0113311P.	Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
PR	22-DEC-1998;	98US-0113313P.	Db	1165	CCCTAAATATCGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA	1224
PR	22-DEC-1998;	98US-0113315P.	Qy	340	rIlePheLysGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr	360
PR	22-DEC-1998;	98US-0113510P.	Db	1225	CATTTTAAAGGGAGGCCATTCTTGGGAGGTGGGACGTGTATGGGCAACGTCTCAGAGCCCCG	1284
PR	22-DEC-1998;	98US-0113510P.	Qy	360	gProLeuGlnGluArgTrrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
PR	23-DEC-1998;	98US-0113511P.	Db	1285	TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTTAGGCTGGGCGAGTGCATT	1344
PR	23-DEC-1998;	98US-0113621P.	Qy	380	uAenAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrrpArgPheArgGlyProLy	400
PR	05-JAN-1999;	98WO-US000106.	Db	1345	GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADB22073 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGGTTCGCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40

```
QY 400 sProValTTPGlyLeuProGlnLeuCyArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCAGTGTGGGTCTCCACAGCTGTGCGGAGGGGCGCTGCCCCGCATCTTGAGCG 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGAGCTCAAGTGGAGCGCTACTACCCCGAAGTGTGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProArgGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGGATGGCTCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGAGCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCGCACCGAGTGCCTGGAGTGGCTGCTGGCATGCCAACTCGGGAGCGCGCTGT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 64
IDA666764
XX ADA66764 standard; cDNA; 1985 BP.
XX ADA66764;
XX
XX 20-NOV-2003 (first entry)
XX Human PRO polynucleotide #72.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003068793-A1.
XX
XX 10-APR-2003.
XX
XX 15-APR-2002; 2002US-00123108.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
```



```

Db      1285  TCCACTGCAAGGAAGATGGGTGCGGCTGCCCCCAACATTGAGCGTCGCGCATTCATT 1344
Qy      380  uAanAspGlyVAspPheTyrPhePheLysGlyArgCysTyrAtqPheArgGlyProly 400
Db      1345  GAATGATGAGATTTCTACTCTTCAAGGGGTGCATGCTGGAGGTTCGGGGCCCCAA 1404
Qy      400  sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGGCATCTTGACGC 1464
Qy      420  alAlaLeuPheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGGCCCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGAAGTCTCGAGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGTTCAGCGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy      480  eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTCGCGCTCGACCAAGGCAAACTGCAGGCAACCACTCGGGCG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAanSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 65
ADB22625
ID      ADB22625 standard; cDNA; 1985 BP.
AC      ADB22625;
XX      20-NOV-2003 (first entry)
XX      Human PRO polynucleotide #72.
KW      Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW      tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW      cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW      liver; microvascular endothelial cell; glucose; FFA;
KW      skeletal muscle cell; adipocyte cell; pericyte cell;
KW      inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW      immune system cell infiltration.
OS      Homo sapiens.
XX      US2003077711-A1.
PN      24-APR-2003.
XX      22-APR-2002; 2002US-00127829.
XX      22-OCT-1998; 98US-0105169P.
PR      01-SEP-1999; 99WO-US020111.
PR      18-OCT-1999; 99US-00403297.
PR      30-NOV-1999; 99WO-US028313.
PR      18-FEB-2000; 2000WO-US004342.
PR      01-DEC-2000; 2000WO-US032678.
PR      19-DEC-2001; 2001US-00028072.
XX      (GETH ) GENENTECH INC.

```

```

XX      Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI      Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI      Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX      WPI; 2003-755066/71.
DR      P-PSDB; ADB22626.
XX      New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT      in gene therapy, as diagnostic markers for the presence of a disease,
PT      condition, or as therapeutic targets for treating tumors, diabetes,
PT      obesity or arthritis.
XX      Claim 2; Fig 143; 637pp; English.
XX      The invention relates to isolated human PRO polypeptides (secreted and
CC      transmembrane polypeptides) and the polynucleotides encoding them. The
CC      invention also relates to an antibody which specifically binds to a PRO
CC      polypeptide, a method for stimulating the release of tumour necrosis
CC      factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC      proliferation or differentiation of chondrocyte cells and a method for
CC      detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC      colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC      polynucleotides are useful in molecular biology, including uses as
CC      hybridisation probes, in chromosome and gene mapping, in generating
CC      antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC      be used in preparing PRO polypeptides by recombinant techniques and in
CC      generating either transgenic animals or knock-out animals which are
CC      useful in the development and screening of therapeutically useful
CC      reagents. The PRO polypeptides or antibodies are used in preparing a
CC      medicament for treating a condition responsive to the polypeptides or
CC      antibodies, such as tumours, for stimulating and inhibiting proliferation
CC      of human microvascular endothelial cells, for modulating the uptake of
CC      glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC      stimulating differentiation of adipocyte cells, for stimulating
CC      proliferation of or gene expression in pericyte cells, for stimulating
CC      the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC      cells, for inducing endothelial cell tube formation and for treating
CC      various bone and/or cartilage disorders such as sports injuries and
CC      arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC      from cartilage are useful for treating sports-related joint problems,
CC      articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC      polypeptides are also useful for treating various mammalian haemoglobin-
CC      associated disorders such as various thalassaemias and conditions which
CC      may benefit from enhanced local immune system cell infiltration. This
CC      sequence represents a human PRO polynucleotide of the invention. Note:
CC      The sequence data for this patent is also available in electronic format
CC      from USPTO at seqdata.uspto.gov/sequence.html.
XX      Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
SQ      Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
US-10-791-980-6 (1-520) x ADB22625 (1-1985)
Qy      1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db      206 ATGTCTCGCGCGGTTCGGCTCTCTGTGCGCCCTTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy      21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266 GACGCCACAGCCCGGAGCGCGGAGCCAGAGCTGCCAAGAGCGCGAGGACATTCCTA 325
Qy      41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGTCCACCTCCACTCGATTACG 385

```


QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaSerGlySerAlaLeuPh 520
 Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 67
 ADA92120
 ID ADA92120 standard; cDNA; 1985 BP.
 XX
 AC ADA92120;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 OS US2003082712-A1.
 PN
 PN 01-MAY-2003.
 PD
 XX
 PF 16-MAY-2002; 2002US-00147512.
 XX
 PR 15-MAY-1998; 98US-0085697P.
 PR 08-MAR-1999; 99WO-US005028.
 PR 25-AUG-1999; 99US-00380138.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786915/74.
 DR P-PSDB; ADA92121.
 XX
 PT New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g., tumor or for tissue typing.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding

CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservatve: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA92120 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
 Db 206 ATGTGTCCGGCGGTGCGCCCTCTGCTGCGCGCCCTGCAGCTGTCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCCCGGAGCGCGGAGCGCCAGAGCTGCGAAGGAGCGGAGGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGTGTCCCAAGCTCCCACTCCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCCATCAGAGGTTCAGTGGGTGTCCAGCTACTGTGACGGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCCCTGCGCCAGATGACTGCTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
 QY 101 AlaTTPAlaGluArgLleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTCTAGACACCGGACCAAAATGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTTPTrpLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyValAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCCTGAGCATCTGCGGAGCGGCAGTTCGGGGCGCCGCTGCGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGAGCCCCAGCCAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACTTCTTCCAGGGGACCAACATGGCTGGGTGGCAATGCTTTGTATGGC 805
 QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATAGCGCTGGTCTCCCTGAGCGCGCGCGCGCAACCTGTGTGTGGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

Alignment Scores:

Pred. No.:	1,936-149	Length:	1985
Argument Scores:		Matches:	519
Score:	2792.00	Conservative:	0
Percent Similarity:	99.62%	Mismatches:	1
Best Local Similarity:	99.62%	Indels:	0
Query Match:	99.52%	Gaps:	2
DB:	9		

US-10-791-980-6 (1-520) X ADB15183 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuAArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTGCGCGCGTCTCTGTGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu	40
Db	266	GACGCCCAGCCCGCGAGCGCGGAGCGCAGAGCTGCGCAAGSAGGCGGAGGCATTCTTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTTCGATTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCCAAGTACTCTGTGACGGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGGCCAGATGACTCTGTCGCCGTGCGGGGTTCAGATATCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTTGCTAGACACCGGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAATGGTTACAAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGGCTTGAGCATCTGCGGAGCGCGGAGTTCTCGGGCGCGGTGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGGCCCGCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCCCGCGCGCGCAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerAspArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATAGCGGTGGTCCCTGAGCCCGCGCGCGGCGGCAACTGTGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACGCTTGGCTTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGGGCGGACGCGCTGCTCAGCTGGGACACGAGCTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGACTCAGTGGCGGTCCAGCTCCGAGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCTCTGAACGCGAGGG	1164

PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022591.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025106.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010731.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 05-OCT-1999; 98WO-US021547.
PR 29-NOV-1999; 98WO-US023089.
PR 30-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013709.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-786921/74.
DR P-PSDB; ADB38436.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
XX Claim 2; Fig 143; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBM cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I) -antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Argument Scores:			
Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.6%	Conservative:	0
Best Local Similarity:	99.6%	Mismatches:	1
Query Match:	99.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADB38435 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuAArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCTCGCGCGCTCTCTGCTGCGCCCTGACGTGCTACTGTGGGGCACCTG	265
Qy	21	AspAlaGlnProAlaGluAArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu	40
Db	266	GACGCCCAGCCCGGAGCGCGGAGGCAGAGCTGCGCAAGGAGGGAGGCAATCCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTACGTGGGTGTCCAGCTACTCTGTACGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTGTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATATCAACAGTTATTGCG	505
Qy	101	AlaTrpAlaGluAArgIleSerAspLeuPheAlaAArgHisAArgThrLysMetArgArgLys	120
Db	506	GCCTGGCTGAGAGGATCAGTACTTGTGTCTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAACAAAATGGTATCAAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AAC'TGGCTTGAGCATCTGCCGAGACCGCGCAGTTCGGGGCGCGCGCGCTTCGAG	685
Qy	160	rCysGlyValAThr-SerGlnAArgTrpSerSer-GlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTTGGGAGGCGCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTTTCCAAGGGAGCACCAACGATGGGCTGGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpAArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCCCGCGCGCGGCAAGCGACTTCGACCA	864
Qy	220	nAspGluAArgTrpSerLeuSerArgAArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGACGCTGGTCCCTGAGCCCGCCCGCGGCGCAACCTGTTCGTGGTGTGGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTTCACCCACTCGCCCGCGCGCGCGCTCATGGCGGC	984
Qy	260	oTyrTyrLysAArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAAGGCTGGGCGCGACGCGCTGCTCAGCTGGGACACGCTGTGGCGCGTGCA	1044
Qy	280	nSerLeuTyr-GlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGNAGCCCTTAGGGGCTCAGTGGCCGTCCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTTTGACACTTGGGACTCTTACAGCCCCCAAGGAGGGCGCTCGAAACGCAAGG	1164

Qy	320	yProLysTyrCy	HisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATAC	TGCGCACTTCTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySer	HisPheTrpGluuValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGAGGAGCATTTCTGTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGGCCCG		1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluuAlaAlaValSerLe		380
Db	1285	TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGCTGCGCAGTGTCAAT		1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy		400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA		1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl		420
Db	1405	GCCAGTGTGGGGTCTCCCAAGCTGTGCCGGGAGGGGCGCTGCCCGCCATCCTGACGC		1464
Qy	420	aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyValaArgTyrTyrVa		440
Db	1465	CGCCCTCTTCTTCCCTCCTCTGGCGCGCTCATCTCTTCAAGGGTGCCCGTACTACGT		1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl		460
Db	1525	GCTGGCCGAGGGGAGCTGCAAGTGGAGCGCTACTACCCCGGAAAGTCTCAGAGACTGGGG		1584
Qy	460	yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh		480
Db	1585	AGGCATCCCTTGAGAGAGGTGAGGGCGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT		1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr		500
Db	1645	CCGAGATGACCGCTACTGCGGCGCTCGACCAGGCCAACTGCAGGCCAACCCACCTCGGGCG		1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh		520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGGCTGTGGCATGCGCAACTCGGGAGGCCCTGTT		1764
Qy	520	e	520	
Db	1765	C	1765	
RESULT 70				
ADB37883				
ID ADB37883 standard; cDNA; 1985 BP.				
XX	AC	ADB37883;		
XX	DT	04-DEC-2003 (first entry)		
XX	DE	Novel human secreted and transmembrane protein PRO4339 cDNA.		
XX	KW	Human; secreted and transmembrane protein; PRO; gene; ss;		
KW	KW	tumour necrosis factor alpha release; TNF-alpha release;		
KW	KW	glucose uptake modulator; FFA uptake modulator;		
KW	KW	cell proliferation stimulator; cell differentiation stimulator;		
KW	KW	cell differentiation inhibitor; cytokine release stimulator; tumour;		
KW	KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW	KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;		
XX	XX	gene therapy; chromosome identification; chromosome marker.		
OS	OS	Homo sapiens.		
XX	XX	US2003087347-A1.		
PN	XX	08-MAY-2003.		
PD	XX	19-APR-2002; 2002US-00125921.		
PF	XX	17-AUG-1998; 98US-0096791P.		
PR	XX			

PR 02-JUN-1999; 99WO-US011252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
 PI Gerritson ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786938/74.
 DR P-PSDB; ADB37884.
 XX
 PR New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 PT
 XX
 XX Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (II) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,938-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB37883 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTGGCGGGTGGGCTCTCTGGCGGCGCTGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GAGCCCGAGCGCGAGCGGAGCCAGGAGCTGGCAAGGAGCGGAGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAAGTACGATACCTCAATGAACAGGTGCCCAAGGTCCCAACCTCCATCGATTGAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCACAGCTACCTGTTCAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTATTATGG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTAGACACCGGACCAAAATAGGGCGTAAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGCAGCTCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
 DB 626 AACTGGCTTGAGCATCTCGCGAGCGGCGAGTTCGGGGCGCGCTGCGGGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGACCAACGCTCTAGCGCTGGAGTCTGGGAGGCGCCAGCCAGGCGCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCCTTCTTCAAGGGGACCAACAAGATGGCTGGGCAATGCTTTCATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 DB 806 CCAGGGGCGGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHis 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCGCAACCTGTTGCTGGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
 DB 985 CTACTACAAGAGGTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCGCCCGAGGAGGCGCCCTGAAACGCGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATACCTGCCACTCTCTTCGTGATGCCATCCTCAGTACAGCGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCGAGCTGATGGCAACGCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTCAGGCTGGCGGAGTGTCTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440

Db	1465	CGCCCTCTTCTTCCTCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyr:ProArgSerLeuGlnAspTtpG1	460
Db	1525	GCTGGCCGAGGGGACATGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTCAGGAGGTTCAGCGCGCCCTGCGGAGGCCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACAGGCCAACTGCAGGCAACCACTCGGGCGG	1704
Qy	500	gTrpAlaThrCluLeuProTtpMetGlyCyeTtpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 71			
ADB66355			
ID	ADB66355 standard; cDNA; 1985 BP.		
XX			
AC	ADB66355;		
XX			
DT	04-DEC-2003 (first entry)		
XX			
DE	Novel human secreted and transmembrane protein PRO4339 cDNA.		
XX			
KW	Human; secreted and transmembrane protein; PRO; gene; ss;		
KW	Tumour necrosis factor alpha release; TNF-alpha release;		
KW	Glucose uptake modulator; FFA uptake modulator;		
KW	cell proliferation stimulator; cytokine release stimulator; tumour;		
KW	cell differentiation inhibitor; cell differentiation stimulator;		
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;		
XX	gene therapy; chromosome identification; chromosome marker.		
OS	Homo sapiens.		
XX			
PN	US2003082689-A1.		
XX			
PD	01-MAY-2003.		
XX			
PF	22-APR-2002; 2002US-00127831.		
XX			
PR	31-MAR-1997; 97WO-US005230.		
PR	12-JUN-1998; 98WO-US012456.		
PR	14-JUL-1998; 98WO-US014552.		
PR	28-AUG-1998; 98WO-US017888.		
PR	10-SEP-1998; 98WO-US018824.		
PR	14-SEP-1998; 98WO-US019093.		
PR	14-SEP-1998; 98WO-US019094.		
PR	14-SEP-1998; 98WO-US019177.		
PR	16-SEP-1998; 98WO-US019330.		
PR	17-SEP-1998; 98WO-US019437.		
PR	07-OCT-1998; 98WO-US021141.		
PR	29-OCT-1998; 98WO-US022991.		
PR	29-OCT-1998; 98WO-US022992.		
PR	20-NOV-1998; 98WO-US024855.		
PR	01-DEC-1998; 98WO-US025108.		
PR	05-JAN-1999; 99WO-US000106.		
PR	08-MAR-1999; 99WO-US005028.		
PR	10-MAR-1999; 99WO-US005190.		
PR	20-APR-1999; 99WO-US008615.		
PR	14-MAY-1999; 99WO-US010733.		
PR	02-JUN-1999; 99WO-US012252.		
PR	01-SEP-1999; 99WO-US020111.		
PR	08-SEP-1999; 99WO-US020594.		

PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786905/74.
DR P-P8DB; ADB66356.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g. tumor or for tissue typing.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,938-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB66355 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGGCCCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACCGCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCCACTCGATCTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

DB 386 GATGCCATCAGACGCGTTTTCAGTGGGTGTCACAGTACCTGTTCAGCGGCGGTGTGGACCCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCCCTGGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTGTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTACACACCGGACCACAAATGAGGGGTAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGACCTCTCTCACCCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCGGAGCGGAGTTCGGGGCGCGTTCGGCGGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCCCCAGCCACAGGCCCTGTAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTGTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGGCGCAACCTGTTCTGGTGG 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGGTGGTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGG 984
QY 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
DB 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGAGCAGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGMAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACGTGCCACTCTCTCTCGATGCGCATCTCTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCCATTTCTGGAGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
DB 1285 TCCACTGCAGGAAGATGGGTGGGTGCGGCTGCCCCCAACATTGAGGCTGGCGGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCCGCCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524

```
Qy 440 lleuAlaargGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Cc |||||
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Cc |||||
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Cc |||||
Db 1585 AGGCATCCCTGAGGAGGTGACGGGCGCCCTGCCGAGGCCCATGGCTCCATCATCTTCTT 1644
Cc |||||
Qy 480 eArgAspAspArgTyrTrpAArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Cc |||||
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCGCCAACTGCAGGCCAACCACTCGGGCGG 1704
Cc |||||
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
Cc |||||
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Cc |||||
Qy 520 e 520
Cc |
Db 1765 C 1765

RESULT 72
ADB89435
ID ADB89435 standard; cDNA; 1985 BP.
XX
XX
AC ADB89435;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX
XX US2003082698-A1.
XX
XX PD 01-MAY-2003.
XX
XX PF 22-APR-2002; 2002US-00127850.
XX
XX PR 20-AUG-1998; 98US-0097218P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 02-MAR-2000; 2000WO-US005841.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX
XX PA (GETH ) GENENTECH INC.
XX
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-743896/70.
XX DR P-PSDB; ADB89436.
XX
XX PT New PRO nucleic acids and encoded polypeptides, useful in the treatment
XX of cancer.
XX
XX PS Claim 2; Fig 143; 637pp; English.
XX
XX CC The invention relates to isolated human PRO polypeptides (secreted and
```

```
Cc transmembrane polypeptides) and the polynucleotides encoding them. The
Cc invention also relates to an antibody which specifically binds to a PRO
Cc polypeptide, a method for stimulating the release of tumour necrosis
Cc factor-alpha (TNF-alpha) from human blood, a method for stimulating the
Cc proliferation or differentiation of chondrocyte cells and a method for
Cc detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
Cc colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
Cc polynucleotides are useful in molecular biology, including uses as
Cc hybridisation probes, in chromosome and gene mapping, in generating
Cc antisense RNA and DNA and in gene therapy. The polynucleotides may also
Cc be used in preparing PRO polypeptides by recombinant techniques and in
Cc generating either transgenic animals or knock-out animals which are
Cc useful in the development and screening of therapeutically useful
Cc reagents. The PRO polypeptides or antibodies are used in preparing a
Cc medicament for treating a condition responsive to the polypeptides or
Cc antibodies, such as tumours, for stimulating and inhibiting proliferation
Cc of human microvascular endothelial cells, for modulating the uptake of
Cc glucose or FFA by skeletal muscle cells or adipocyte cells, for
Cc stimulating differentiation of adipocyte cells, for stimulating
Cc proliferation of or gene expression in pericyte cells, for stimulating
Cc the proliferation of inner ear utricular supporting cells or T-lymphocyte
Cc cells, for inducing endothelial cell tube formation and for treating
Cc various bone and/or cartilage disorders such as sports injuries and
Cc arthritis. PRO polypeptides which stimulate the release of proteoglycans
Cc from cartilage are useful for treating sports-related joint problems,
Cc articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
Cc polypeptides are also useful for treating various mammalian haemoglobin-
Cc associated disorders such as various thalassaemias and conditions which
Cc may benefit from enhanced local immune system cell infiltration. This
Cc sequence represents a human PRO polynucleotide of the invention. Note:
Cc The sequence data for this patent is also available in electronic format
Cc from USPTO at seqdata.uspto.gov/sequence.html.
Cc
XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB89435 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Cc |||||
Db 206 ATGGTCGCGCGCGTCGGCCCTCCTGCTGCGGCGCCCTGCAGCTGTACTGTGGGGCACCTG 265
Cc |||||
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Cc |||||
Db 266 GAGCCCCAGCCCGCGGAGCGCGGAGCCAGAGCTGCGAAGAGCGGAGGCAATTCTTA 325
Cc |||||
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Cc |||||
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCATTCGATTTCAGC 385
Cc |||||
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Cc |||||
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTCTGCAGCGCGGTGTTCGAGCGCG 445
Cc |||||
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Cc |||||
Db 446 GCACACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
Cc |||||
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Cc |||||
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTTGCTTAGACACCGGACCAAAATGAGCGCTAAG 565
Cc |||||
Qy 121 LysArgPheAlaLysGlnGlyAsnLysGlnLysGlnHisLeuSerTyrArgLeuVal 140
Cc |||||
Db 566 AAACGCTTTTCAAGCAAGGTAACAATGGTTACAAGCAGCACCTCTCTCCGCGCTGGTG 625
```


QY 141 AenTrrProGluHisLeu-ArsSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCCGAGCGCGAGTTGGGGCGCGTGGCGCGCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGGAGGCCCGCCAGCCAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCCGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAAGCGCACTTCGACCA 864
QY 220 nAepGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGGTGTCTGGCGCA 924
QY 240 eGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTrrTrrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTrrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGACTCTCTCAGAGCGCGCGCGCGCGCGCGCGCGCGCGG 1164
QY 320 yProLysTrrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGACGAGNAGATGGTGGCGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAIT 1344
QY 380 uAsnAspGlyAspPheTrrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTTCTTCAAGGGGGTCTGATGCTGGAGTTCCGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTTCCACAGCTGTGCCGGGAGGGGGCGCTGCCCGCCCATCTCGAGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTrrTrrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrrTrrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGGAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGATCTCTGAGGAGGTTCAGCGCGCGCTTCCCGAGGCGCGATGCTCATCATCTTCT 1644
QY 480 eArgAspAspArgTrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATACCGCTACTTGGCGCGCTCGACACGGCCAAATGACGGCAACCACTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 73
ADB90167
ID ADB90167 standard; cDNA; 1985 BP.
XX
AC ADB90167;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082762-A1.
XX
PD 01-MAY-2003.
XX
PF 15-APR-2002; 2002US-00123235.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.

QY	121	LysArgPheAlaLysGlnGlySerLysTyrLysGlnHisLeuSerTyrArgLeuVal	140	QY	480	eAsgPheArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	566	AAACGGCTTTGCAAGCAAGGTAACTGTTACAGCAGCAGCTCTCTCTACCGCTGGTG	625	Db	1645	CCGAGATGACCGCTACTGCGGCTCGACGAGCCAACTGACAGGCAACACCTCGGGCG	1704
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160	QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	626	AACTGGCCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCTTCAG	685	Db	1705	CTGGCCACCGAGCTGCCCTGGATGGCTGTGGCTGCGATGCCAATCGGGAGCGCTGTT	1764
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	QY	520	e 520	
Db	686	TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCCCCCAGCCACAGCGCCGCTGAC	745	Db	1765	C 1765	
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200	RESULT 74			
Db	746	ATCCGGCTCACCTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGGC	805	ADB39268			
QY	200	aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl	220	ID	ADB39268	standard; cDNA; 1985 BP.	
Db	806	CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGAGCGCACTTCGACCA	864	XX	ADB39268;		
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240	AC	ADB39268;		
Db	865	AGATGAGCGCTGGTCTCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGTCTGGCGCA	924	DT	04-DEC-2003 (first entry)		
QY	240	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260	DE	Novel human secreted and transmembrane protein PRO4339 cDNA.		
Db	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGCGGCC	984	KW	Human; secreted and transmembrane protein; PRO; gene; ss;		
QY	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl	280	KW	Tumour necrosis factor alpha release; TNF-alpha release;		
Db	985	CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA	1044	KW	glucose uptake modulator; FFA uptake modulator;		
QY	280	nSerLeuTyrgLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	KW	cell proliferation stimulator; cell differentiation stimulator;		
Db	1045	GAGCTGTATGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT	1104	KW	cell proliferation inhibitor; cytokine release stimulator;		
QY	300	eThrAspPheGluThrTrpAspSerTy-SerProGlnGlyArgArgProGluThrGlnGl	320	KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;		
Db	1105	CACCTGACTTTGAGACTTGGGACTCTACAGCCCCCAAGNAGCGCCCTGAAACGACGG	1164	KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;		
QY	320	yProLysTyrgLysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	OS	gene therapy; chromosome identification; chromosome marker.		
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCATCTAGACAGGCAACAGCAACTGTA	1224	XX	Homo sapiens.		
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	XX	US2003082764-A1.		
Db	1225	CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284	XX	01-MAY-2003.		
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	XX	03-MAY-2002; 2002US-00137868.		
Db	1285	TCCACTGCAGGAAGATGGGTGGGCTGGGCTGCCCCCAACATTGAGGTGCGGAGTGTATT	1344	PR	31-MAR-1997; 97WO-US005230.		
QY	380	uAsnAspGlyAspPheTyPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400	PR	12-JUN-1998; 98WO-US012456.		
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGTTCGGGGGCCCCAA	1404	PR	14-JUL-1998; 98WO-US014552.		
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420	PR	28-AUG-1998; 98WO-US017888.		
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCTGCCCGGCCCATCTCGACGC	1464	PR	10-SEP-1998; 98WO-US018824.		
QY	420	aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa	440	PR	14-SEP-1998; 98WO-US019093.		
Db	1465	CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT	1524	PR	14-SEP-1998; 98WO-US019094.		
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl	460	PR	14-SEP-1998; 98WO-US019177.		
Db	1525	GCTGGCCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGGAAAGTCTGACGAGCTGGG	1584	PR	17-SEP-1998; 98WO-US019437.		
QY	460	yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	PR	07-OCT-1998; 98WO-US021141.		
Db	1585	AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGGCCGATGCTCATCTCTTCTT	1644	PR	29-OCT-1998; 98WO-US022991.		

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGGCTTTGCAAAAGCAAGTAACAAATGGTACACGACGACCTCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCCTGAGCATCTGCGGAGCGGAGTTCGGGGGCGCGCTGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTACGCGCTGGAGTTCGGAGGCGCCCGACACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCGCTGGCGCACGCTTC-CTGGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCCCTGCTCTCAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluLleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCCACCTACCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysPheProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCGCTGTATGGGAAGCCCTCAGGGGCTCAGTGGCGGCTCCAGCTCCCAAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTGAAACGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTCTCTCCATGCCATCCTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCGAGGAAGATGGGTGGGCTGCCCCCAACATTGAGGTGGCGCATGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTCTACTTCTTCAAGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCAGTGTGGGTCTCCACAGCTGTGGCGGAGGGGCGCTGCCCCGCCATCTTCGACGC 1464
QY 420 aAlaLeuPheProProLeuArgArgLleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGGTACTAGT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCGCCGAGCTGCGAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGCGCGCTGCGGAGGCGCGATGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

DB 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGCCCAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCCAACGAGCTGCGCTGCGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 75
ASB46891
ID ADB46891 standard; cDNA; 1985 BP.
XX ADB46891;
AC ADB46891;
XX 04-DEC-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; as;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003082687-A1.
XX 01-MAY-2003.
XX 19-APR-2002; 2002US-00125930.
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Bresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786904/74.
DR P-PSDB; ADB46892.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 143; 627pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (ii) encoding (i) is useful in chromosome mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(i)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (i) and (ii) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB46891 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGGCTCGGCTCTCGTGGCGGCTCGACGCTACTGTGGGGGCACCTG	265
QY	21	AspAlaGlnProAlaGlyGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCGCCAGCGCGGAGCGGAGCGGAGGCTGCCAAGAGCGCGAGGCAATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACGGATCACTCAATGAACAGGTCGCCCAAGCTCCACCTCGATTACG	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGGTTTCAGTGGGTGTCCTAGCTACCTGTGAGCGGGTGTGGAC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCACCTCGCCAGATGACTCGTCCCGCTCGGGGTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspPheAlaArgHisArgThrLysMetArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaIleGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAACTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGTTCGCGCGCTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCGCCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl	200
Db	746	ATCCGGCTACCTTCTCCAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGCG	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCCCGCGCGGAGAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGGCGCAACTGTTCTGTGTGTGGCGCA	924

QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTTCCACCTCGCGCGCGCGCGCGCTCATGGCGCC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAGAGGCTGGGCGGACGCGCTGTCTAGCTGGAGCAGCTGTGGCGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGAAGCCCTAGGGGCTTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTGTAGACCTGGGACTCTTACAGCCCCCAAGAGAGCGCCCTGAAACGCGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCTGATGCCATCACTGTAGACAGCAACAGCACTGA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGACCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCAGAGGCGG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCACCTGACAGAAAGATGGGTGGGCTGCCCCCAACATTTAGGCTGCGGAGTGTCA	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGG	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa	440
Db	1465	CGCCTCTTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerLeilePhePh	480
Db	1585	AGGATCTCTGAGGAGGTACAGCGCGCTGCGGAGCGCGATGGCTCCATCTCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGCGCTTCGACCAAGGCGCAAACTGCAGGCAACCACTCGG	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCAACCGAGCTGCCCTGGATGGGCTGTGTCATGCCCACTCGGGAGCGCCCTGT	1764
QY	520	e	520
Db	1765	C	1765

RESULT 76

ADB86498

ID ADB86498 standard; cDNA; 1985 BP.

XX AC ADB86498;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polynucleotide #72.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;

liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

Homo sapiens.

OS

XX

PN

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

Homo sapiens.

OS

XX

PN

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

Homo sapiens.

OS

XX

PN

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

Homo sapiens.

OS

XX

PN

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

Homo sapiens.

OS

XX

PN

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

Homo sapiens.

OS

XX

PN

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

Homo sapiens.

OS

XX

PN

XX

XX

XX

XX

XX

XX

XX

XX

XX

```
QY 320 yProLysTyrCYsHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTTCTTCCTCGATGCCATCACTGTAGACGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATCTGGAGGTTCGGGGCCCA 1404
QY 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCGCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 GCGCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTACTACTAGT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTTCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGACGGCGCTGCCGAGGCCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCTCGACACGGCCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTTPAlaThrGluLeuProTTPMetGlyCYsTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 77
ADB77103
ID ADB77103 standard; cDNA; 1985 BP.
XX
AC ADB77103;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082696-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127848.
XX
PR 03-NOV-1998; 98US-0106934P.
```

```
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Deaneyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755109/71.
XX P-PSDE; ADB77104.
XX
XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
XX tumor or for tissue typing.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from BMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
```

```
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
```

US-10-791-980-6 (1-520) x ADB77103 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuTTPGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGGCGCCCTGCAGCTGTACTGTGGGGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGGAGCGGAGCCAGAGCTGCGAAGGAGGCGGAGGAGGAGGAGGAGGAG 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```

Db 326 GAGAGTACGGATACCTCAATGAAACAGGTCCTCCCAAGCTCCACCTCCACTCGATTGACG 385
 QY 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTGAGTACCTGTCAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
 Db 446 GCCACCCTCGCCAGATGACTCGTCCCGCTGGGGTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgLys 120
 Db 506 GCTCGGCTCGAGAGATCAGTGAATTGTTGTAGACACCGGACCAAAAATGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAenLysTTPValSerGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAGGTAACAAATGGTACAGCAGCACTCTCTACCGCTTGGTG 625
 QY 141 AenTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTCGCGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGGCCCAAGCAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAAGATGGGCTGGGCAATGCCITTTGATGC 805
 QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 Db 806 CCAGGGGGCGCTGCGCAGCGCTTC-CTGCCCCCGCGGGCGAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTTPSerSerArgArgArgGlyArgAenLeuPheValLeuAlaHi 240
 Db 865 AGATGAGCGTGTCTCAGCGCGCGCGCGGCAACCTGTTCTGTTGGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CCAGATCGGTACACGCTTGGCTTCAACCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG 280
 Db 985 CTACTACAGAGCTGGCGCGGACGCGTGTCTAGCTGGAGCAGTGTCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGGTCCAGTCCCAGGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
 Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGGAACGCGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCTAAATACTGCCACTTCTCTTCATGCCATCACTGTAGACGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAenValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTTPValGlyLeuProProAenIleGluAlaAlaValSerIle 380
 Db 1285 TCCACTGCAAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
 QY 380 uAenAspGlyAspPheTyrPhePheLysGlyArgCysTTPArgPheArgGlyProly 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCA 1404
 QY 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCGCTGCCCGCCATCTCTGACG 1464

QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT 1524
 QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTCAGAGCTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCTCTGAGAGGTGAGCGCGCCCTGCGAGGGCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACGAGGCCAAACTGCGAGGCACCACTCGGGCCG 1704
 QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAenSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 78
 ID ADB34260
 AC ADB34260 standard; cDNA; 1985 BP.
 XX ADB34260;
 DT 04-DEC-2003 (first entry)
 XX Human PRO polynucleotide SEQ ID NO 143.
 DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 OS US2003077717-A1.
 XX 24-APR-2003.
 XX 24-APR-2002; 2002US-00131818.
 XX 07-OCT-1998; 98US-0103328P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 30-NOV-1999; 99WO-US028313.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755072/71.
 DR P-PSDB; ADB34261.
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,

PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.

XX Claim 2; Fig 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB34260 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGTCCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCACGCGCGGAGCGGGAGCCAGGAGCTGCGCAAGGAGGGCGGCGATTCTCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCAATGACAGAGTCCCAAGCTCCACCTCCATCGATTGAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGGTGTGGACGCG 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCGGACATGACTCGTCCCGCTGCGGGGTATACAGATACCACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 1585 AGGCATCCCTGAGGAGGTACGCGGCGCCCTGCGGAGGCCCGATGGCTCCATCATCTTCTT 1644

DB 506 GCCTGGGCTGAGGAGATCAGTGACTTGTCTTTAGACACACCGACCAAAATGAGCGGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCATCGGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlnValaProCysAlaProProSerSe 160
 DB 626 AACTGGGCTGAGCATCTGCGGACCGGCGAGTTCGGGGCGCGGTCGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTCTCTGGGAGGCCCCAGCCACAGGCCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACTTTTCCAAAGGGGACACAAACATGGGCTGGGCAATGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGGCGCCCTGGGCGCACGCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTTCCACCTCGCGCGCGCGCGCTCATGTGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCACAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACGCAAGG 1164
 QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAAATATGCACTCTTCTTCGATGCACTCAGTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTCAGAGAAAGATGGGTGCGGCTGCCCGCCCAACATTTGAGGCTCGGCGAGTGTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGCGGAGGGGCTGCCCCCGCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
 DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGGTGCGCGCTACTAGT 1524
 QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGGCCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTCGAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
 DB 1585 AGGCATCCCTGAGGAGGTACGCGGCGCCCTGCGGAGGCCCGATGGCTCCATCATCTTCTT 1644

Db 746 ATCCGGCTCACCTTCTTCAAGGGGACACACAGATGGCTGGGCAATGCCTTTGATGCG 805
Qy 200 adInGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CAGGGGGCGCCCTGGCGACGCTTC-CTGCCCCCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyValArgLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTAGCCCGCGCGGGCGCAACTGTTCTGGTGGCTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspLeuValLeuAlaValG1 280
Db 985 CTACTACAAAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCCGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyValSerGluProAr 360
Db 1225 CATTTTAAAGAGGCCATTCTGGAGGTGGAGCTGATGCAACGCTCAGAGCCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCCGCCATCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTACGGCGGCCCTGCCGAGGCCGATGCTCCATCACTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGCCCAATCGCAGGCCAACCCCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 80
ADB33708

ID XX
AC XX
DT XX
XX
DB XX
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.
OS Homo sapiens.
XX
XX US2003077716-A1.
XX
XX 24-APR-2003.
XX
XX 24-APR-2002; 2002US-00131813.
XX
XX 07-OCT-1998; 98US-0103315P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 18-FEB-2000; 2000WO-US004342.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755071/71.
XX P-PSDB; ADB33709.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful in gene therapy, in chromosome and gene mapping, as chromosome markers, in tissue typing, and in identifying chromosomes.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating

KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003077718-A1.

PD 24-APR-2003.

XX 24-APR-2002; 2002US-00131823.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022291.

PR 29-OCT-1998; 98WO-US022292.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010732.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023322.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001WO-US006520.

PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.

PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00860216.

PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.

PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001US-00886342.

PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.

PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755073/71.

XX P-PSDB; ADB34813.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic

XX acids, useful for the diagnosis, prevention and/or treatment of tumors,

XX such as lung, colon, breast, prostate, rectal, cervical and/or liver

XX tumors.

XX Claim 2; Fig 143; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB34812 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGCGCGCGGTCTCGGCTCTCTGTCGCGCGCTCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACGCCGCGAGCGCGAGCGCGAGAGCTGCGCAAGGAGCGCGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGACCGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTGCGCAGATCACTGTCGCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTpaAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTACCTGTTGTGTAGACCCGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACCGCTTTCGAACCAAGGTAAACAAATGGTACACAGACGACCTCTCTCCGCTGTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGCTGCGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGATTCTGGAGAGGCCCAACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCNAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 eGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGGCTTGGCGCAGCCCTTC-CTGCCCCCGCGCGGAGGCGACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlyArgGlyArgGlyArgGlyArgGly 240
DB 865 AGATGAGCGCTGTCTCCCTGAGCGCGCGCGCGCGCGCAACCTGTTCGTGTGTGTGTGTGT 924
QY 240 eGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACAGCTTGCGCTCACCACTCGCGCGCGCGCGCGCGCTCATGGCGGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCACAGGAACCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCACTCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGAAAGATGGGTGCGGTGCCGCCCAACATTGAGGCTGCGGCGAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys 400
DB 1345 GAATGATGGAGATTCTACTTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGAGCTGTGCCGGGCGAGGGGGCTTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAAGTCTGCAAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCCGTAGAGAGGTACGCGCGCGCTGCCGAGGGCCGATGGCTCCATCATCTTTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACACGCGCAAACTGCGAGGCAACACCTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGTGGGCTGTGTCATGCCCAACTCGGGGAGGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 82,

ADB35916

ID ADB35916 standard; cDNA; 1985 BP.

XX ADB35916;

AC ADB35916;

DT 04-DEC-2003 (first entry)

XX

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCACGCTACCTGTTCAGCGCGTGTGTGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTGGCCAGATGACTCTCCCGCTCGGGGGTTACAGATACCACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCTCGGGCTGAGAGGATCAGTGACTTGTGTGTCAGACCGGACCAAAATGAGGCGTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACTCTCCTCAGCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTCCCGGAGCGCGAGTTCCGGGGCGCGTCCGCGCCGCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGGCCACAGGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTTCAGCTTCTTCCAAAGGGGACCACCAACGATGGGCTGGGCAATGCGCTTTGATGGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 806 CCAGGGGGCGCTTGGCCACGCGCTTC-CTGCCCGCGCGCGGCGCAACTGTTGCTGGTGGCGCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGCGCAACCTGTTGCTGGTGGTGGCGCA 924
 Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCCGTTCACAGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGGCGCC 984
 Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
 Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTCAGCCCCCAAGGAAGGCGCTTGAACGCGCAGGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAATCTGCCACTCTTCTTCGATGCCATCACTGTACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGAGATTCTACTTCTTCARAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCGCTGCCCGCCATCTCTGACGC 1464

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCCGAGGGGAGTGCAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGTCTCAGCGCGCGCTGCCGAGCCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCTTCGACCGAGCCCAACTCAGGCAACCACTCGGGCCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCTGGATGGGCTGTCGCAATGCCAATCGGGGAGCGCTTGT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 84
 ADC50184
 ID ADC50184 standard; cDNA; 1985 BP.
 XX
 AC ADC50184;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker; gene; ss.
 XX
 OS Homo sapiens.
 XX
 US2003092106-A1.
 XX
 PD 15-MAY-2003.
 XX
 PF 24-APR-2002; 2002US-00131822.
 XX
 PF 19-AUG-1998; 98US-0097141P.
 XX
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, DeForge L, Deenoers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-801171/75.
 DR P-PSDB; ADC50185.
 XX
 PT New secreted and transmembrane nucleic acid useful for treating
 PT inflammation, organ failure, atherosclerosis, cardiac injury,

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATACCGCTACTGGCGCTCGACCGCCAACTGACGGCAACCACTCGGGCGG 1704
 Qy 500 gTrpAlaThrGluLeuProTTPMetGlyCYeTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 85
 ADCT71731
 ID ADCT71731 standard; cDNA; 1985 BP.
 XX
 AC ADCT71731;
 XX
 XX 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PR04339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003092107-A1.
 XX
 PD 15-MAY-2003.
 XX
 PF 24-APR-2002; 2002US-00131828.
 XX
 PR 07-OCT-1998; 98US-0103315P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
 XX
 DR WPI; 2003-801172/75.
 DR P-PSDB; ADCT71732.
 XX
 XX New secreted and transmembrane nucleic acids and polypeptides, designated
 PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
 PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
 XX cancer.
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon,
 CC breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells, for
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC71731 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGCGCGCTGCGGCTCTCTGTCGCGCGCTGTCAGCTGTACTGTGGGGCCACTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgIysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCGCGGAGCGCGAGGCTGCGCAAGGAGCGGAGGCATTCTTA 325
 Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
 Db 326 GAGNAGTACGGATACCTCAATGAACAGTGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGGTTTTCAGTGGTGTCTCCAGCTACTGTTCAGCGCGGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIlysMetArgArgIys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTACTGTGTTGCTAGACACCGGACCAAAATCAGCGGTAA 565
 Qy 121 LysArgPheAlaIysGlnGlyAsnLysTyrTyrIlysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTCAAAGCAAGGTACAAATGCTACAAAGCAGCACCTCTCTCTACCGCTGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCCTGAGCATCTGCCGGAGCCGCGAGTTCGGGGCGCGCGTTCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerGlyThrThrThrMetGlyTTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGACGCCCTTC-CTGCCCGCCCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGCTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGGCTTACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpLyAsArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCTGGCGCGCGACCGCTGCTCAGCTGGAGCAGCTGCTGCGCGTGA 1044
Qy 280 nSerLeuTyGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyfSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTAGAGCTGGGACTCTACAGCCGCCAAGGAAGCGCCCTGAAACAGCGG 1164
Qy 320 yProLyfTyCysHisSerSerPheAspAlaileThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTTCTTCGTGTCGATCTGAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerle 380
Db 1285 TCACCTGCAGGAAGAATGGTGGGCTGCCGCCCAACATTTAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyPProly 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyTrpVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCGAGGGGAGCTGCAAGTGAGCCCTTACCCCCGAGTCTGCGAGACTGGG 1584
Qy 460 yGlyleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCCCTGCGAGGCGCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCGCTACTGCGGCTCGACAGGCCAACTGACGGAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGTGATGGGCTGTGGCATGCCAACTCGGGAGGCCCTGTT 1764
Qy 520 e 520

Db 1765 C 1765

RESULT 86

ADCS9710

ID ADCS9710 standard; cDNA; 1985 BP.

XX AC ADCS9710;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;

XX KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;

XX KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;

XX KW rectum; kidney; cervix; liver; microvascular endothelial cell;

XX KW glucose uptake modulator; FFA uptake modulator; cell proliferation;

XX KW cell differentiation; skeletal muscle cell; adipocyte cell;

XX KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;

XX KW immune system cell infiltration; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker; gene; ss.

XX OS Homo sapiens.

XX PN US2003092105-A1.

XX PD 15-MAY-2003.

XX PF 24-APR-2002; 2002US-00131821.

XX PR 09-DEC-1999; 99US-0170262P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;

XX DR WPI; 2003-801170/75.

XX DR P-P8DB; ADCS9711.

XX PT New secreted and transmembrane nucleic acids and polypeptides, designated

XX PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,

XX PT cardiac injury, infertility, birth defects, premature aging, AIDS, or

XX PT cancer.

XX PS Claim 2; Fig 143; 637pp; English.

XX PS The invention relates to isolated human PRO polypeptides (secreted and

XX PS transmembrane polypeptides) and the polynucleotides encoding them. The

XX PS invention also relates to an antibody which specifically binds to a PRO

XX PS polypeptide, a method for stimulating the release of tumour necrosis

XX PS factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX PS proliferation or differentiation of chondrocyte cells and a method for

XX PS detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX PS colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX PS polynucleotides are useful in molecular biology, including uses as

XX PS hybridisation probes, in chromosome and gene mapping, in generating

XX PS antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX PS be used in preparing PRO polypeptides by recombinant techniques and in

XX PS generating either transgenic animals or knock-out animals which are

XX PS useful in the development and screening of therapeutically useful

XX PS reagents. The PRO polypeptides or antibodies are used in preparing a

XX PS medicament for treating a condition responsive to the polypeptides or

XX PS antibodies, such as tumours, for stimulating and inhibiting proliferation

XX PS of human microvascular endothelial cells, for modulating the uptake of

XX PS glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte

KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophic factor; hormones; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX US2003087365-A1.
PN
XX
PD 08-MAY-2003.
XX
XX
PF 23-APR-2002; 2002US-00128689.
XX

31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 20-NOV-1998; 98WO-US025108.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 29-OCT-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004411.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart JA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801150/75.
DR P-PSDB; ABC52718.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present

CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC52717 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGGAGCGGAGGCTGGCGAAGGAGCGGAGGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGCGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATCACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGTACGATGACTTTGTTGCTAGACACCGGACCAAAATGAGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCCGAGCGGACACCAACATGGGCGCGTGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACACAGTCTCAGCGCTGGAGTTCTGGGAGGCCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACACCAACATGGGCTGGGCAATGGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGCGGCTTGGCGACGCTTC-CTGCCCCCGCGCGCGGCAAGCGACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTGTTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGG 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG 280
Db 985 CTACTACAGAGGCTGGGCGCGGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300

Db 1045 GAGCCTGTATGGAGCCCTCAGGGGCTCAGTGGCGTCCAGTCCACGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGCGCTCTGAAACGACGGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGTCATCAGTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaIleValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGCGGCTGCCCCCAACATTTGAGGCTCGGCAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTCTGATGCTGGAGTTCCGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGGTGCGCTACTACTGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTACAGCGCGCTCGCGAGGCCGATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTTACTTGGCGCTCGACAGGCCCAACTCGAGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCTGGATGGCTGCTGTCATGCCAATCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 88
ADC57071
ID ADC57071 standard; cDNA; 1985 BP.
XX
AC ADC57071;
XX
XX 18-DEC-2003 (first entry)
DT
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID143.
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuro peptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
OS Homo sapiens.
XX
XX US2003087366-A1.
XX
PD 08-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128694.

XX 02-MAR-2000; 2000WO-US005841.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801151/75.
 DR P-PSDB; ADC57072.
 XX
 XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 PT
 XX
 XX Claim 2; SEQ ID NO 143; 637pp; English.
 XX
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0
 US-10-791-980-6 (1-520) x ADC57071 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGCTCGGCTCTCTGTCGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCACGCGCGCGAGCGCGAGCGCGAGAGCTGCGCAAGGAGCGCGGCAATTCCTA 325
 QY 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCATGACACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCACGCTACCTGTGCGCGGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCCTCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCCTGAGCATCTCGGAGCGGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAGACTCTCAGCGCTGGAGTTCGTGGAGGCCCCAGCCAGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCACAAACGATGGCTGGGCAATGCCTTTGATGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGCGCGCTTGGCGCAGCCCTTC-CTGCCCGCGCGCGCGGCGGCGCTCATCGGCC 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGTGCTCCCTGAGCGCGCGCGCGGCGGCAACCTGTTCTGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGTTCACAGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATCGGCC 984
 QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
 QY 280 nSerLeuTrpGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAACTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACCGCAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAAATACTGCGCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
 DB 1225 CATTTTTAAGGGAGGCCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTCAGGAAAGATGGGTGCGGGCTGCCCGCCCAACATTCGAGGCTGCGGCGAGTGTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGGCTGCCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCCTCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCGCGCTACTAGT 1524
 QY 440 lLeuAlaArgGlyClyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCCGAGGGGAGTGCAGAGTGGAGCGCTACTACCCCGGAAAGTCTGCAGGAGCTGGG 1584

```
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGACGGCGCCCTGCCAGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACCAAGCCCAACTGCAGGCAACCACTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 89
ID ADC60262
ID ADC60262 standard; cDNA; 1985 BP.
AC ADC60262;
XX
XX
XX 18-DEC-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003087367-A1.
XX
XX
XX 08-MAY-2003.
XX
XX 24-APR-2002; 2002US-00131825.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 98WO-US000106.
XX 08-MAR-1999; 98WO-US005028.
XX 10-MAR-1999; 98WO-US005190.
XX 10-MAR-1999; 2000WO-US006319.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007177.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
```

XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX WPI; 2003-801152/75.
DR P-PSDB; ADC60263.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 2; Fig 143; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proteoglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various
XX mammalian haemoglobin-associated disorders such as various thalassaemias
XX and conditions which may benefit from enhanced local immune system cell
XX infiltration. This sequence represents a human PRO polynucleotide of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC60262 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGGCTGGGCTCTCTGTGGCGCCCTCGAGCTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCGCGAGCGCGAGGCGCAGGAGCTGCGCAAGAGGCGGAGGCGGCAATTCCTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTAGCGGATACCTCAATGAACAGGTGCCAAAGCTCCCAACCTCCACCTCGATTACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCGTTTTCAGTGGGTGTCCAGCTACCTGTCTCAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCGCCAGATGCTCTCCCGCTGCGGGGTGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGGGGTAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGCACCTCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTGTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnAlaTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGACCAACGCTCTAGCGCTGAGTTCGGGAGGCCCCAGCCACAGGCCCTGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTCATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGCGAAGCGCATCTTCACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGCGCAACCTGTGTGTGGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCCACCTCGCCCGCGCGCGCGCTCATGGCGC 984
QY 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGGCGCTCGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACCTGCACCTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTGCGATGCTGGAGGTTCGCGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCCGGCGAGGGGCTGCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440

Db 1465 GCCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAGGTGCGCCCTACTAGT 1524
QY 440 lIeuAlaHrgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPgI 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTCAAGCGCGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACGCTACTGCGCCCTCGACGAGCCAACTGAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 90
ADC50737

ID ADC50737 standard; cDNA; 1985 BP.

AC ADC50737;

XX 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PR04339 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; as.

XX OS Homo sapiens.

XX PN US2003087361-A1.

XX PD 08-MAY-2003.

XX 22-APR-2002; 2002US-00127841.

XX PF 09-SEP-1998; 98US-0099536P.

XX PR 01-SEP-1999; 98WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI: 2003-801146/75.

XX DR P-FSDB; ADC50738.

XX PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX PT and for manufacturing a medicament for diagnosing or treating tumor.

PS Claim 2; Fig 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC50737 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 206 ATGTCTCGCGCGTCTCGGCCTCTCTGCTCGCGCCCTGAGCTGTACTGTGGGGCCACTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCCAGAGCTGCGAAGGAGCGGAGGCATTCTTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGGTGTCCAGCTACTGTACGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCTGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGCTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

Db 566 AAACGCTTTGCAAGCAAGTAACTGATCAAGCAGCAGCTCTCTCTACCGCTGGTG 625
QY 141 AenTtpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSe 160
Db 626 AACTGGCCCTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTpsSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGGCCCCAGCCACAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerGlyThrThrThrMetGlyTtpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACGATGGCTGGGCAATGCCCTTGTATGC 805
QY 200 aGlnGlyAlaProTtpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGACCTTCACCA 864
QY 220 nAspGluArgTtpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTTGTGTGTCTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrtYrLyArgLeuGlyArgAspAlaLeuLeuSerTtpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCGCTGGCGCGCGACGCGCTGTCTAGCTGGGACGACGTCTGCGCGTGA 1044
QY 280 nSerLeuTyrtYrLyArgProLeuGlySerValAlaValGlnLeuProGlyLyLeuPh 300
Db 1045 GAGCCTGTATGGAGAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTtpAspSerTyrtSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGACGG 1164
QY 320 yProLySerTyrtCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATATCTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCGCAACACACTGTA 1224
QY 340 rIlePheLyGlySerHisPheTtpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAGGAGGACATTTCTGGAGGTGCAGCTGATGCCACGCTCTCAGACCCCG 1284
QY 360 gProLeuGlnGluArgTtpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrtPhePheLyGlyGlyArgCysTtpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTtpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCACACTGTGCGGCGAGGGGCTGCCCCGCACTCTCGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLyGlyAlaArgTyrtYrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrtYrProArgSerLeuGlnAspTtpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCCGAAGCTGCGAGGCTGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCTCTGAGGAGGTGAGGGGCGCTGCGAGGGCCGATGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTtpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCCAGGCCCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTtpAlaThrGluLeuProTtpMetGlyCysTtpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 91
ID ADC65264
XX ADC65264 standard; cDNA; 1985 BP.
XX AC ADC65264;
XX DT 18-DEC-2003 (first entry)
XX DE Human PRO polynucleotide #72.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003087362-A1.
XX PD 08-MAY-2003.
XX PF 22-APR-2002; 2002US-00127844.
XX PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801147/75.
DR P-PSDB; ADC65265.
XX New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
XX Claim 2; Fig 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC65264 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGTCGGCGCTCGGCTCTCTGTCGGCGCTTCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCGCGAGCGGAGCGGAGCGCTGCGCAAGGAGGCGGAGGCTTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCACCTCCAGTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGCTTCAGTGGGTGCCAGTACCTGTACGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyzala 100
DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTACTGTGTGCTAGACACCGGACCAAAATGAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGAAACAGAGTAAACAAATGGTACAGAGCACCTCTCTCCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTCCGAGCGCGCAGTTTGGGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGACCAACGTCTCAGCGCTGAGGTCTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACTTCTTCCAGAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCGCGCGCGCAAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGACGCTGTGTCCTTGGCCGCGCGCGCAACCTGTTCGTGTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACAGCTTGGCTTACCCACTCCCGCGCGCGCGCTCATGTGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyValArgArgProGluThrGlnG 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCGCACCTCTTCTTCGATGCCATCCTCATGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCNACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTTGAGGCTCGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTCTACTTCTCAAAGGGGTGATGCTGGAGGTTCGCGGCGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCAGTGTGGGGTCTCCCAAGCTGTGCGGGAGGGGGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGGTACGCGCGCGCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCAGATGACCGCTACTGGGCGCTTCGACAGGCGCCAACTGCAGGCAACACCTCGGCGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACGAGCTGCCCTGGATGGCTGCTGCATGCGCAACTCGGGGAGCGCGCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 92
ADC54362
ID ADC54362 standard; cDNA; 1985 BP.
XX
AC ADC54362;
XX
DT 18-DEC-2003 (first entry)
XX

QY 380 uasnAspGlyaspPheTyrPhePheLysGlyVArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAAGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCybArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTTGACGC 1484
QY 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 GCGCTCTTCTCCCTCTCTGGCGGCTCATCTCTTCAAGGGTGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAATCTGCAAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTACGGGGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgHspAepArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCCAAACTGCAGGCCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 93
ADCS3323
ID ADCS3323 standard; cDNA; 1985 BP.
XX AC ADCS3323;
XX AC ADCS3323;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein cDNA Seq ID143.
XX KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuroptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX OS Homo sapiens.
XX PN US2003087364-A1.
XX PD 08-MAY-2003.
XX PF 23-APR-2002; 2002US-00128688.
XX PR 09-FEB-1999; 99US-0119341P.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
DR WPI; 2003-801149/75.
DR P-PSDB; ADCS3324.
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.

XX Claim 2; SEQ ID NO 143; 637pp; English.
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuroptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADCS3323 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTGCTGCGCGCTGCAGCTGTCTACTGTGGGGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGGCCAGAGCTGCGCAAGGAGGGGGGACATCTCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTACGCGGCGGTTCGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAATAATGGTACAAAGCAGCACCTCTCTACCGGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCCGTCGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTTGGAGAGCCCCAGCCACAGGCCCGCTGAC 745

```
Qy 180 rSerGlySerProSerSerGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCCCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGGGCCCTGGCGCACGCTTC-CTGGCCCGCGCGCGCAAGCGCACTTCGACCA 864
Qy 220 nAepGluAArgTyrSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCTGAGCCCGCGCGGCGCAACCTGTTCTGTGGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspValLeuAlaValG1 280
Db 985 CTACTACAAAGAGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATATGCTCACTTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGACATTTCTGGAGGTGGGAGCTGATGCCACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProAenLeuGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGAAGATGGTGGGCTGCCCCCAACATGAGGTGGCGAGTGTCAAT 1344
Qy 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyProLy 400
Db 1345 CAATGATGAGATTTCTACTTCTCAAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 eProValTyrGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGAGGGGCGCTGCCCGCCCAATCCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTGCGCGGCTCATCTCTTCAGGGGTGGCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCGCGAGGGGACTCAAGTGGAGGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTGGGCTCTGACAGGCGCAACCTGACAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTCTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 94
```

```
ADC58846
ID ADC58846 standard; cDNA; 1985 BP.
XX
AC ADC58846;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID143.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003087359-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127834.
XX
PR 17-SEP-1998; 98US-0100710P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US012678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801144/75.
XX P-PSDB; ADC58847.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides or hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
XX invention.
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
```

```
Alignment Scores:
Pred. NO.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
```



```
QY 300 eThraPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCGCCAAGAGGCGCCCTGAACACGAGGG 1164
QY 320 yProLysTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCATTTCTGGAGGTGCGACTGATGCCAACGCTCTCAGAGCCCGG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProPheAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAenAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTCTTCAAGGGGCTCGATCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCACGTGTGGGTCTCTCCACAGCTGTGCGGCGAGGGGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CCGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCTGAGGAGGTGAGCGGGCCCTGCGGAGGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaValSerLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGCGGCTCGACCGGCAAACTGACGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 97
ADD02968
ID ADD02968 standard; cDNA; 1995 BP.
XX
AC ADD02968;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW pericyte cell; inner ear utricular supporting cell; adipocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
OS Homo sapiens.
```

```
XX
PN US2003092104-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131817.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR
```

PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001US-00066666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
 XX WPI; 2003-801169/75.
 DR P-PSDB; ADD02969.
 XX
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; Fig 143; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries

CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0
 US-10-791-980-6 (1-520) x ADD02968 (1-1985)
 Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGTGTCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGAGCCGCGAGCGCGAGCGAGCTGCGAAGGAGGCGGAGGCAATTCCTA 325
 Qy 41 GlulysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCATCGATTGAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGCTACTGTGAGCGCGGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAnserSyrAla 100
 Db 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTTTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTTCGTAGACACCGGACCAAAATGAGCGGTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTrpLysGlnHisLysSerTyrArgLeuVal 140
 Db 566 AAAGCGTTTCAAGCAAGGTAACAATGGTACAAGCAGCACCTCTCTACCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAAGATCTGCGCGAGCGGAGTTTCGGGGCGCGGTGCGCGCGCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGAGAACCAAGCTCTCAGCGCTGGAGTTCTGGAGAGCCCCAGCCACAGGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTACCTTCTTCAAGGGGACCAACAGTGGGTGGGCAATGCTTTGATGGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAAGGGGCGCCCTGGCGCAGCCTTC-CTGCCCGCGCGCGGAGCGACATTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATAGCGCTGTCTCCCTGAGCGCGCGCGCGGGGCGCACTGTTCGTGGTGTGGCGCA 924
 Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTCAACGCTTGGCTTCAACCACTGCCCGCGCGCGCGCTCATGGCGCC 984

```
QY 260 oTyrTyrlYsAArgLeuGlyAAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACAGCTGCTGGCGCGTGA 1044
QY 280 nSerLeuTyrlYsProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyAArgProGluThrGlnG1 320
Db 1105 CACTGACATTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGAGGG 1164
QY 320 yProLysTyrlYsHisSerSerPheAspAlaIleThrValAspAArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTTCTTCATGCCATCATCTGTAGACGGAACACCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrTrpGluValAlaAlaAspGlyAAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluAArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerle 380
Db 1285 TCCACTGCAAGGAAGATGGGTGGGGCTGCCCGCCCAACATTGAGGCTGGCGGCACTGCAAT 1344
QY 380 uAenAspGlyAspPheTyrlPhePheLysGlyGlyArgCysTrpAArgPheArgGlyProly 400
Db 1345 GATGATGGAGATTTCTACTTCTTCNAGGGGGTGTGATGCTGGAGGTTCGGGGCCCCNA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProAArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGGCAGGGGGCTGCCCGCCATCTCTGACGC 1464
QY 420 alaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaAArgTyrlTyVa 440
Db 1465 CCCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCCGCTACTACGT 1524
QY 440 lLeuAlaAArgGlyGlyLeuGlnValGluProTyrlTyrlProAArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGGAGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAGTGTGAGGACTGGGG 1584
QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTCGCGAGGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspAArgTyrlTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAAGCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 98

ADC89960
ID ADC89960 standard; cDNA; 1985 BP.

XX
AC ADC89960;

DT 01-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX Human; secreted and transmembrane protein; PRO; Gene: ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003087348-A1.
XX 08-MAY-2003.
XX 19-APR-2002; 2002US-00125923.
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786939/74.
DR P-PsDB; ADC89961.
XX New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
PT Claim 2; SEQ ID NO 143; 637pp; English.

CC The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage, for
stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from PWM cells, for inhibiting the binding of
A-peptide to factor VITA, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or
knockout animals which in turn are useful in the development and
screening of therapeutically useful reagents, in gene therapy, for
chromosome identification, as chromosome marker, and for generating
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
detecting its expression in specific cells, tissues or serum, and for
affinity purification of PRO from recombinant cell culture or natural
sources. (I) and (II) are useful for tissue typing. This sequence encodes
a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC89960 (1-1985)

QY 1 MetValAlaAArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

Db 206 ATGGTCGGCGCGTCGGCTCTGCTGCGCGCCTGCGAGCTGCTACTGTGGGCCACCTG 265

Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACACAGCCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATCCCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTTPArThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGGCCCCCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTCCTCAGCGCGCGCGCGGCAACCTGTGTGTGTGTGTGTGTGTGT 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTACACGCTTGGCTTCCACCTCTGCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGTCTCAGCTGGGACGAGTGTCTGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAGGAGGCGCCCTGAAACGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAATACTGCCACTCTTCTCGATGCGCTGATGCGAGCAACGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGAGGTGGCGAGCTGATGCAACGCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProHennileGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGCTCTCCACAGCTGTGCGCGGCGAGGGGCTGCCCCCGCATCTCGAGCG 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GTGGCCCCGAGGGGACTGCAAGTGGAGGCTTACTACCCCCGAGTCTGCGAGACTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTATGCGCGCTCGACAGGCGCAACTGCAAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTTPMetGlyCysTrpHisAlaAnSerGlySerAlaLeuPh 520
Db 1705 CTGGGGCCACGAGTGGCTTGGATGGGCTGTGGCATGCCAACTCGGGAGGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 101

ADD09797

XX ID ADD09797 standard; cDNA; 1985 BP.

XX AC ADD09797;

XX DT 01-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #72.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003194776-A1.

XX PD 16-OCT-2003.

XX PF 29-MAY-2002; 2002US-00157785.

XX PR 05-JUN-2000; 2000US-0209832P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-852596/79.

XX DR P-PSDB; ADD09798.

XX CC Claim 2; Fig 143; 637pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD09797 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGTCTGGCTCTCTGGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCGCGCGGAGCGGAGCGGAGAGCTGCGCAAGAGGCGGAGGCGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAACTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCGTTTCAGTGGGTGTCCAGCTTACCTGTCCAGCGCGGTGTGGACGCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGCGCCAGATCACTCGTCCCGCTGCGGGGTACAGATACCACAAAGTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACGGCTGAGACATCTCCGGAGCGCGAGTGTGGGGCGCGTGGCGCGCTTCGAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGACCAACGTTCTCAGCGTGGAGTTCTGGGAGGCCCCAGCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGGCTGGCGACGCTTC-CTGCCCGCGCGGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCGCACTGTGTGTGTGTGGCGCA	924
Qy	240	sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGGCTCATGGGCGCC	984

Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAGAGGCTGGCCCGCAGCGCTGCTCAGCTGGGACACGCTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCTCTGAACGCGAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCGCACCTCTCTTCGATGCCATCCTGTAGACAGGACACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTGGGCTGCCGCCCAACATTTGAGGCTGCGGCGAGTGTATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyValArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTACTTCTTCAAGGGGTGATGTGGAGGTTCGCGGCGCCCA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTTCT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTCTGCGAGGCTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGTCTCAGCGCGCCCTGCCGAGGCCGATGGCTCCATCTCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACCAAGGCCAAACTGCAGGCAACCACTCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCATGCCNACTCGGGGAGCGCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 102			
ID	ADD04372	standard; cDNA; 1985 BP.	
XX	XX	ADD04372;	
XX	XX	01-JAN-2004 (first entry)	
DT	XX	Novel human secreted and transmembrane protein PRO4339 cDNA.	
DE	XX	Human; secreted and transmembrane protein; PRO; secreted polypeptide;	
KW	XX	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;	
KW	XX	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;	
KW	XX	rectum; kidney; cervix; liver; microvascular endothelial cell;	
KW	XX	glucose uptake modulator; FFA uptake modulator; cell proliferation;	
KW	XX	cell differentiation; skeletal muscle cell; adipocyte cell;	

pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 endothelial cell tube formation; bone disorder; cartilage disorder;
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
 immune system cell infiltration; chromosome mapping; gene mapping;
 gene therapy; chromosome identification; chromosome marker; gene; ss.
 OS
 XX Homo sapiens.
 XX US2003087354-A1.
 XX 08-MAY-2003.
 XX 22-APR-2002; 2002US-00127827.
 XX 17-AUG-1998; 98US-0096891P.
 XX 02-JUN-1999; 99WO-US012252.
 XX 25-AUG-1999; 99US-00380137.
 XX 30-MAR-2000; 2000WO-US008439.
 XX 30-MAY-2000; 2000WO-US014941.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801139/75.
 DR P-PSDB; ADD04373.
 XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 XX Claim 2; Fig 143; 637pp; English.
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proinflammatory cytokines are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:				
Pred. No.:	1.93e-149	Length:	1985	
Score:	2792.00	Matches:	519	
Percent Similarity:	99.62%	Conservative:	0	
Best Local Similarity:	99.62%	Mismatches:	1	
Query Match:	98.52%	Indels:	2	
DB:	10	Gaps:	0	
US-10-791-980-6 (1-520) x ADD04372 (1-1985)				
QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20	
DB	206	ATGGTCGGCGCGCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265	
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu	40	
DB	266	GAGCCCCAGCCCGCGAGCGCGGAGGCCAGAGAGCTGCCAAGGAGGCGGAGGCAATTCCTA	325	
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60	
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC	385	
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80	
DB	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTGACGGCGGTGTGGACCGC	445	
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100	
DB	446	GCCACCTGCGCCAGATGACTCTGTCGCCGCTGCGGGGTTCAGATACCAACAGTTATGCG	505	
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	
DB	506	GCTTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG	565	
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	
DB	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCCTGGTG	625	
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160	
DB	626	AACTGGGCTGAGCATCTGCCGAGCGCGGAGTTCGGGGCGCGTGGCGCGCGCTCCAG	685	
QY	160	rCyGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	
DB	686	TTGTGGAGCAACGCTCAGCGCTGGAGTTCCTGGGAGGCGCCAGCCACAGGCGCCGCTGCAC	745	
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200	
DB	746	ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTCTTTCATGGC	805	
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220	
DB	806	CCAGGGGGCGCCCTGGCGACCGCCCTTC-CTGCCCGCGCGCGGCGAGGCGCATTCGACCA	864	
QY	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240	
DB	865	AGATGAGCGCTGGTCCCTGAGCGCCCGCGCGGCGCAACCTGTTCTGTGGTGTCTGGCGCA	924	
QY	240	sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260	
DB	925	CGAGATCGGTACACGCTTGGGCTTCAGCCCATCGCCCGCGCGCGCGGCTCATGGCGCC	984	
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280	
DB	985	CTACTACAAGAGGCTGGGCGCGGACGCGCTGCTCAGCTGGGACGACAGCTGCTGGCGCGTGA	1044	
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	
DB	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104	
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320	
DB	1105	CACCTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGAGGCGCGCTGAAACGACGG	1164	

QY 320 yProlystYrCyvSHisSerSerPheAspAlaIlethrValaspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCTACTTCTTCGATGCCATCACTGTAGACAGCGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArTrpValGlyLeuProProAsenIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAGATGGTGGCTGCCGCCCAACATTAGGCTGGCGAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyVlyArgCystrPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCyvArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTGAGCG 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaAArgTyrTyVa 440
Db 1465 GCGCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGCT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCGCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGAAGTGTGCAAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGGGGGCTTCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCGCAAACTGCAGGCAACCACTCTGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCystrPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCCAACGAGCTGCCCTGATGGGTCTGGCATGCCAACTCGGGGAGGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 103
ADC80328
ID ADC80328 standard; cDNA; 1985 BP.
XX
AC ADC80328;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; haemoglobin-associated disorder; thalassemia;
KW gene therapy; chromosome identification; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
OS Homo sapiens.
XX
PN US20003092103-A1.
XX
PD 15-MAY-2003.

XX 24-APR-2002; 2002US-00131815.
PF 22-DEC-1998; 98US-0113511P.
XX 01-DEC-1999; 99WO-US028634.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
PI
XX WPI; 2003-801168/75.
DR P-PSDB; ADC80329.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
FT generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 143; 637bp; English.
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred No.: 1-93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADC80328 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGGCGGTGCGCCCTCCTGCGGCCCTGCAGCTGCTACTGTGGGGCCACTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCACCGCCGAGCGCGGAGCGGAGGAGCTGCGCAAGAGCGGAGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACACCTCCACTCGATTGACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGGCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGGTGTGTGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCGAGATGACTGTCCCGCTCGGGGTTCAGATACCAACAGATTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGGATCAGTCACTTGTGTGTAGACACCGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnClyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAGCAGCACTCTCCTACCGCCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCGCGAGCGCGGAGTTCGGGGCGCGTCCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCGGAGGCGCCACAGCCAGGCCCTGCAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGCGCAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATCAGCGCTGTCTCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTGCGGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerThrAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGGGCGCGAGCGCTGTCTCAGCTGGGACGACGTGTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysrValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAGAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCCTAGACCCCAAGAGCGCGCTCGAAACGACGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACGTCCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCGAGGAAGATGGTGGGCTGGCGTGGCCCCCAACATTGAGGTGGCGGAGTGTCA 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGTTCCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
DB 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAGCTTCAGGACTGGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTCAGGAGGTGAGCGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGGCAAACTGCAGGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCCAACGAGCTGCCGTGGTGGCTGTGGCATGCCAACTCGGGGAGGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 104
ADD10835
ID ADD10835 standard; cDNA; 1985 BP.
AC ADD10835;
XX
XX 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003194774-A1.
XX
XX 16-OCT-2003.
XX
XX 21-MAY-2002; 2002US-00152399.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000MO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood W, Zhang Z;
XX WPI; 2003-852594/79.
XX P-PSDB; ADD10836.

XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the proliferation or differentiation
PT of chondrocyte cells and stimulating the release of tumor necrosis factor
PT alpha.

PS Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear uricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADD10835 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGGCGCGCTCTGCTGCGCCCTGACGTCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGGAGCCAGAGCTGCGCAAGAGGCGCGGACATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACCTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGGTTTCAGTGGGTGCCACGACTACCTGTCAGCGGGCTGTGGACGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGATTATGCG	505

Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTTGGGCTGAGAGGATCAGTGTGTTTGTAGACACCGGACCAAAATGAGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGGTTTGCNAAGCNAAGGTAACTAATGGTACAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACCTGGCTCAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnhArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCCTGGAGGCCCCCAGCCAGCGCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCGGCTCACCTTCTTCCAAAGGGGACCAACGATGGGCTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGCGACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCCCGCGGGCGCACTGTTCGTGTGCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGACGTGCTGGCGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAGCCCTAGGGGGCTCAGTGGCGCTCAGGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACCTGCTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCTGAAACGCAAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCGACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGCCATTTCTGGGAGGTGGGAGCTGATGGGACGCTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCAGAGAAAGATGGGTGCGGCTGCCCCCAACTTGGAGCTGCGGCGAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GATATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGTCTGGAGGTTCGCGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCGCGGCGAGGGGCTGCCCCGCCATCTCGAGCG	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCCCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGAGCTGCAAGTGGAGGCCCTACTACCCCGGAAAGTCTGAGGAGTGGG	1584

QY 460 yGlylleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePhe 480
 Db 1585 AGGCATCCCTGAGAGGTGAGCGCGCTGCGAGCGCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgSepAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAAGGCAAACTGCAAGGCAACCACTCGGCGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAATCGGGAGGCGCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 105
 ADC47716
 ID ADC47716 standard; cDNA; 1985 BP.
 AC ADC47716;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003194771-A1.
 XX
 PD 16-OCT-2003.
 XX
 PF 21-MAY-2002; 2002US-00152377.
 XX
 PR 09-DEC-1999; 99US-0170262P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Gurney SL, Smith V;
 PI Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-844454/78.
 DR P-PSDB; ADC47717.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids useful
 PT for detecting a tumor, stimulating the release of proteoglycans from
 PT cartilage and stimulating the proliferation of endothelial cells.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC47716 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTTCGGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GAGCCCAAGCCCGCGAGCGCGAGGCGAGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATCAACAGGTCCCAAGGCTCCCACTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTTACCTGTGAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGATTATCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGAGCAGACCTCTCTTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTGCCGAGCGCGGCACTTCGGGGCGCGGTGCGCGCGCTTCCAG 685
 QY 160 rCyGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCAGCCAGGCCCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db |||||
746 ATCCGGCTCACTCTTCAAGGGGACCACAAACGATGGGCTGGGCAATGCCTTTTGATGGC 805

QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db |||||
806 CCAGGGGGCCCTGGCGACGCCTTC-CTGCCCGCGCGCGGAGGCGACTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db |||||
865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGGGCGCAACCTGTTCGTGCTGGCGCA 924

QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db |||||
925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGGCTCATGGCGCC 984

QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db |||||
985 CTACTACAAGAGGCTGGCGCGGACGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db |||||
1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGTT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db |||||
1105 CACTGACTTTGAGACCTGGGACTCTCAGCCCCCAAGAAAGGGCGCCTGAAACGCGAGGG 1164

QY 320 yProLysTyrCySHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db |||||
1165 CCTTAANTACTGCCACTCTCTTCGATGCCCATCTGTAGACAGGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db |||||
1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTCATGCCAACGCTCTCAGAGCCCCG 1284

QY 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db |||||
1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCCCAACATTCAGGCTGGCGAGTGTCAAT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyGlyProLy 400
Db |||||
1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCyAspAlaGlyGlyLeuProArgHisProAspAl 420
Db |||||
1405 GCCAGTGTGGGTCTCCACACAGCTGTGCCGGGCGAGGGGCGCTGCCCGCCATCCTGACGC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db |||||
1465 GCCTCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGCT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db |||||
1525 GCTGGCCCGAGGGGACTGCAAGTGAGGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584

QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db |||||
1585 AGGCATCCCTGAGGAGGTGAGCGGGCGCCTGCCGAGGCGCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db |||||
1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGAGGCAACCACTCGGGCGG 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCyeTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db |||||
1705 CTGGSCCACCAGGCTGCCCTGGATGGGCTGCTGGCATGCCAACCTCGGGGCGGCCCTGTT 1764

QY 520 e 520
Db 1765 C 1765
RESULT 106

ADC79776
ID ADC79776 standard; cDNA; 1985 BP.
XX
AC ADC79776;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;
KW sports injury; proteoglycan; articular cartilage defect; thalassemia;
KW rheumatoid arthritis; haemoglobin-associated disorder; gene mapping;
KW immune system cell infiltration; chromosome mapping; gene mapping; ss.
XX
OS Homo sapiens.
XX
XX US2003087358-A1.
XX
PD 08-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127833.
XX
XX 01-SEP-1998; 98US-0098750P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801143/75.
DR P-PSDB; ADC79777.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
cells, for stimulating differentiation of adipocyte cells, for
stimulating proliferation of or gene expression in pericyte cells, for

stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC79776 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTCGCGCGGTGGCCCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GAGCCCGAGCCCGGAGCGCGAGCCAGGAGCTGGCAAGGAGCGGAGGCAATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTACG	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
DB	386	GATGCCATCAGACGGTTTCAGTGGGTGTCACAGTACCTGTGACGGCGGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgProCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTCGCGCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCCTGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGGTAACTGGTAAAGAGCAGCACTCTCCACCGCTGTGGT	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCGCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAAGGTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACAGGCGCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGCAATGCCCTTTGATGGC	805
QY	200	gGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
DB	806	CCAGGGGGCGCCCTGGCGACCGCTTC-CTGCCCCCGCGCGGAGGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLysSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTGTCGTGTCGTGGCGCA	924

QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTACACAGCTTGGCCTCACCCACTCGCGCGCGCGCGCTCATGGCGGC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1	280
DB	985	CTACTACAAGAGGCTGGCGCGCGAGCTGTCTCAGCTGGGACGACGTGCTGGCGGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCACGAAAGCTGTT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320
DB	1105	CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACACAGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
DB	1165	CCCTAAATACCTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGAGGACCAATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
DB	1285	TCCACTGAGGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAATT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLys	400
DB	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGCTGGAGGTTCCGGGGCCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGGGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCATCTTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
DB	1465	CGCCCTCTTCTTCT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
DB	1525	GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGAAGCTGTGAGGAGCTGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePhe	480
DB	1585	AGGATCCCTGAGGAGGTGAGCGCGCGCTGCGAGGCGCGGATGGCTCCATCTCTTCT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
DB	1645	CCGAGATGACCGCTACTGCGCGCTCGACAGGCGCAAACTGCGAGGCAACACCTCGGCGC	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLeuSerGlySerAlaLeuPh	520
DB	1705	CTGGGCCACCGAGTGCCTGAGTGGGTGCTGGCATGCCAACTCGGAGGAGCGCTGTT	1764
QY	520	e 520	
DB	1765	C 1765	
RESULT 107			
ID	ADD09245	standard; cDNA; 1985 BP.	
XX	ADD09245		
AC	ADD09245		
DT	01-JAN-2004	(first entry)	
XX			
DE	Human PRO polynucleotide #72.		
XX			
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		

QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCTAAATAGTGCACCTCTCTCTCGATGATCCATCATCTGTAGACAGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheThrTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluAArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCGAGAAAGATTTCTACTTTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGAGATTTCTACTTTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GGCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCCCGCATCTCTGAGCG 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 Db 1465 CGCCCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCGAGCTGGGG 1584
 QY 460 gGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGAGGGCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGTATGCCCTACTGCGGCTCTGACAGGCCAACTGCGAGGCAACACCTCGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 108
 ADD40958
 ID ADD40958 standard; cDNA; 1985 BP.
 AC ADD40958;
 XX
 XX 15-JAN-2004 (first entry)
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW Cell proliferation stimulator; cell differentiation stimulator;
 KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 FN US2003203438-A1.
 XX
 XX 30-OCT-2003.
 XX
 PF 15-MAY-2002; 2002US-00146786.
 XX
 XX 24-NOV-1997; 97US-0066511P.
 PR 16-SEP-1998; 98WO-US019330.

PR 25-AUG-1999; 99US-00380139.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Pilvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-875645/81.
 DR P-PSDB; ADD40959.
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; SEQ ID NO 143; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD40958 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGCTCGCGCGCTCGCGCTCTCTCTGCGGCCCTCTGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGAGGCTGCGAAGGAGCGGAGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATCATCAATGAACAGGTCCCAAGCTCCACCTCCATCGATTTCAGC 385


```
|||||
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGATGCCCACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 110
ADD52837
ID ADD52837 standard; cDNA; 1985 BP.
XX
AC ADD52837;
XX
DT 15-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003194792-A1.
PN 16-OCT-2003.
XX
XX 15-APR-2002; 2002US-00123156.
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019033.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US0000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032578.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882536.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-852595/79.
DR
DR P-PSDB; ADD52838.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT
```

PRO4978, useful in chromosome and gene mapping, in generating antisense RNA and DNA, and in the treatment of cancer.

Claim 2; Fig 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) .x ADD52837 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTGGCGCGGTGGCGCTCTGCTGGCGGCTTGCAGCTGCTACTGTGGGCGCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GACGCCACAGCCCGGAGCGCGGAGCCAGAGCTGGCAGGAGCGGAGGCATTCTCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCCTCCACTCGATTACG	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGACCGTTTCAGTGGGTGTCCACGCTACCTGTGAGCGGCGTGTGGACGCG	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTTGGCGCAGATGACTCGTCCCGCTGGGGGTTCATGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120

DB	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCACGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCCTGAGCATCTCCCGAGCGCGGAGTTCGGGGCGCGTGGCGGCGCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGACAAAGCTCTAGCGCTGGAGTTCCTGGGAGGCGCCAGGCACAGGCGCCGCTGAC	745
QY	180	rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCGGCTTCACCTCTTCCAAAGGGGACCACACAGATGGGTGGGCAATGCCCTTTGATGGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
DB	806	CCAGGGGCGGCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTGTGGCGCA	924
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTCAACAGCTTGGCCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaVal	280
DB	985	CTACTACAAGAGGCTGGGCGCGCGCGCTCTCAGCTGGGAGCGAGCTGTGGCGGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
DB	1105	CACGTACTTTGAGACCTGGGACTCTACAGCCCCCAAGAAAGGCGCTCTGAACCCAGGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
DB	1165	CCCTAAATACTGCACCTCTCTTCGTGATGCTCCTCAGTACAGCAGCAACAGCACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
DB	1285	TCCACTGGAGAAAGATGGGTGGGCTGCCCGGCTCCCAACATTGAGGCTGGCAGGTGCTAT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGTTCGGGGCCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGGGGTCTCCACACAGCTGTGCGGGGAGGGGGCTGCCCGCCCATCTCTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
DB	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAANGGTGCGCGCTACTAGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
DB	1525	GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCCCTGAGGAGGTTCAGCGCGCGCTGCGCGAGGCGCGATGGCTCCATCATCTTCT	1644

QY 480 eARGspAsgArgTyrTrpArgLeuAsgAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAACTGAGGCAACACCTCGGGCGG 1704
 QY 500 gTPAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGGCTGT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 111
 ADD53389
 ID ADD53389 standard; cDNA; 1985 BP.
 XX
 AC ADD53389;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; PFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2003203437-A1.
 XX
 PD 30-OCT-2003.
 XX
 PF 15-MAY-2002; 2002US-00146728.
 XX
 PR 01-JUL-1998; 98US-0091360P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-DEC-2000; 2000US-00380137.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-875644/81.
 DR P-PSDB; ADD53390.
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; SEQ ID NO 143; 659pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor V17A, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADD53389 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTGGCGGCGTGGCCCTCTCTGCTGGCGGCCCTGCAGCTGTACTGTGGGGCCACTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCGCGGAGCGGAGCGCAGAGCTGGCGAAGGAGCGGAGGCAATTCCTA	325
Qy	41	GluIysTyrGlyTyrLeuAsnGluInValproIysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTGAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACTGTACGGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGCGCCAGATGACTCGTCCCGCTGGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgAtgLys	120
Db	506	GCTTGGGCTGAGAGGATCAGTGACTTGTTTGTAGACACCGGACCAAAATGAGCGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTTCAAGCAAGGTAACTAATGGTGTACAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTGCGGAGCGGAGGTTTGGGGCGCGCTGGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTCTTGGAGGCCCCAGCAGCGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCGGCTCACCTTCTTCCAAGGGGACCAACAGTGGGTGGGCAATGCTTTTGTATGCG	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGGCGCCCTGGCGCA CGCCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA	864

Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTTCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyVGLyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480
Db 1585 AGGATCCCTAGGAGGTGACGGGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCCAAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCTGTCGAACCTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 114
ADD01778
ID ADD01778 standard; cDNA; 1985 BP.
XX AC ADD01778;
XX DE 15-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #72.
KW Human; gene; ss: PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003203430-A1.
XX PD 30-OCT-2003.
XX PF 23-APR-2002; 2002US-00128685.
XX PR 11-AUG-1998; 98US-0096143P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 30-MAR-2000; 2000US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-875637/81.
DR P-PSDB; ADD01779.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 143; 637bp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADD01778 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTGTCGCGGCCCTGCAGCTGTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGGAGCGCAGAGCTGCGAAGGAGGGAGGCAATCTCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGTGTGGACCGC 445

```
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerIvAla 100
DB 446 GCCACCCTCGCCAGATGACTCGTCCCGCTGGGGTTACAGATACCAACAGTATGCG 505
QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgIlys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTGTTGTTGTCTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenIysTrpIysGlnHisLeuSerIvArgLeuVal 140
DB 566 AAACGCTTTCGAAGCAAGGTACAAATGTTACAGCAGCAGTCTCTCTACCGCTGGTG 625
QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTGCGGAGCGGCGAGTTCGGGAGCGCTGCGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCCTTCTTCAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTGGCGCACGCCCTTC-CTGCGCGCGCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGCAACCTGTTCGTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlApr 260
DB 925 CAGATCGGTACAGCTTGGCTCACCACCTCGCGCGCGCGCGGCTCATGGCGCC 984
QY 260 oTrpIvArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGCGCTGGCGCGCGCGCTGTCTAGCTGGGACGAGCTGTGCGCGTGA 1044
QY 280 nSerLeuTyArgLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGAGCGCGCTGAAACCGCAGGG 1164
QY 320 yProLysTyArgHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
QY 360 pProLeuGlnArgTrpValGlyLeuProProLeuIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCTACTGAGGAAGATGGTGGGGCTGCGGCCCTGCCCCCAACATTGAGGCTGGCGAGTGTCT 1344
QY 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyIvProLy 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAGAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 pProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGCGCTGCGCCGCCATCTGTAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyTrpVa 440
DB 1465 CGCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1524
```

```
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCCAAGTCTGCAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTCAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGCTCCATCATCTCTTT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGATGACCGCTACTGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGCGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 115
ADD53960
ID ADD53960 standard; cDNA; 1985 BP.
XX
AC ADD53960;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203432-A1.
XX
PD 30-OCT-2003.
XX
PF 10-MAY-2002; 2002US-00142886.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-875639/81.
DR P-FSDB; ADD53961.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
```


Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	OS
Ds	1045	GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGTCCAGCTCCCAAGAAAGCTGTT	1104	XX
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyValArgProGluThrGlnG	320	XX
Ds	1105	CACGTACTTTGAGACCTGGGACTCCTACAGCCCCAAGGAAGGCCCTGAAACGACGGG	1164	XX
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	XX
Ds	1165	CCCTAAATACATGCCACTCTCTCTTCGATGCTCCTAGACAGCAACAGCAACTGTA	1224	XX
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	XX
Ds	1225	CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284	XX
Qy	360	gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	XX
Ds	1285	TCCACTGCAGGAAGATGGTGGGCTGGGCTGCCCCCAACATTGAGGCTGGGCGAGTCA	1344	XX
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400	XX
Ds	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGTCTGATGCTGGAGTTCCGGGGCCCAA	1404	XX
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	XX
Ds	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGGCCATCTGACGC	1464	XX
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440	XX
Ds	1465	CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524	XX
Qy	440	lIleAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl	460	XX
Ds	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584	XX
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	XX
Ds	1585	AGGCATCCCTGAGAGGTTCAGCGGGCGCTGCCGAGGGCCGATGGCTCCATCATCTTCT	1644	XX
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	XX
Ds	1645	CCGAGATGACCGCTACTTGGCGCTCGACCAGGCCAACTGCAGGCAACACACTCGGGCGG	1704	XX
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	XX
Ds	1705	CTGGGCCACCGAGTGCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT	1764	XX
Qy	520	e	520	XX
Ds	1765	C	1765	XX
DE	RESULT 117			
XX	ADD91173			
XX	ID ADD91173 standard; cDNA; 1985 BP.			
AC	ADD91173;			
XX	29-JAN-2004 (first entry)			
DE	Human PRO polynucleotide #72.			
XX	Human; gene; s; PRO; secreted polypeptide; transmembrane polypeptide;			
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;			
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;			
KW	liver; microvascular endothelial cell; Glucose; FFA;			
KW	skeletal muscle cell; adipocyte cell; pericyte cell;			
KW	inner ear utricular supporting cell; T-lymphocyte cell;			
KW	endothelial cell tube formation; bone disorder; cartilage disorder;			
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;			
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;			
XX	immune system cell infiltration.			

OS	Homo sapiens.	7WO-US005230.
XX	US2003199055-A1.	98WO-US012456.
PN	23-OCT-2003.	98WO-US014552.
XX		98WO-US017888.
XX		98WO-US018824.
XX		98WO-US019093.
XX		98WO-US019094.
XX		98WO-US019177.
XX		98WO-US019330.
XX		98WO-US019437.
XX		98WO-US021141.
XX		98WO-US022991.
XX		98WO-US022992.
XX		98WO-US024855.
XX		98WO-US025108.
XX		98WO-US000106.
XX		98WO-US005028.
XX		98WO-US005190.
XX		98WO-US006319.
XX		98WO-US008615.
XX		98WO-US010733.
XX		98WO-US012252.
XX		98WO-US020111.
XX		98WO-US020594.
XX		98WO-US020944.
XX		98WO-US021090.
XX		98WO-US021547.
XX		98WO-US023089.
XX		98WO-US028214.
XX		98WO-US028313.
XX		98WO-US028409.
XX		98WO-US028301.
XX		98WO-US028634.
XX		98WO-US028551.
XX		98WO-US028564.
XX		98WO-US028565.
XX		98WO-US030095.
XX		98WO-US030911.
XX		98WO-US030999.
XX		98WO-US030720.
XX		98WO-US031243.
XX		98WO-US031274.
XX		2000WO-US000219.
XX		2000WO-US000277.
XX		2000WO-US000376.
XX		2000WO-US003565.
XX		2000WO-US004341.
XX		2000WO-US004342.
XX		2000WO-US004414.
XX		2000WO-US004914.
XX		2000WO-US005004.
XX		2000WO-US005601.
XX		2000WO-US005746.
XX		2000WO-US005841.
XX		2000WO-US006884.
XX		2000WO-US007377.
XX		2000WO-US007532.
XX		2000WO-US008439.
XX		2000WO-US013705.
XX		2000WO-US014042.
XX		2000WO-US014941.
XX		2000WO-US015264.
XX		2000WO-US020710.
XX		2000WO-US022031.
XX		2000WO-US023522.

Db 925 CGAGATCGGTACACGCTGGCGCTCACCCACTCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrlsArgLeuGlyAraAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCGTGGCGCGACGCGTGTCTAGCTGGGACGACGTCTGGCGGTCA 1044
Qy 280 nSerLeuTyrlsArgLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGACCCCTTAGGGGGCTCAGTGGCGCTCCAGTCCAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyxserProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrlsCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGACCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTCCGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrlsPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAGGGGGTGCATCTCTCAAGGTGGCGCTACTACGT 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrlsVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGGCGCTACTACGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrlsTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGACGGCGCTTCCCGAGGGCCGATGGCTCCATCTCTT 1644
Qy 480 eArgAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTTGGCGCTCGACAGGCCAAACTGCAGGCCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaIleSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGATGCCAACCTCGGGGCGGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 118
ADE03787
ID ADE03787 standard; cDNA; 1985 BP.
XX
AC ADE03787;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

PN US2003199057-A1.

PD 23-OCT-2003.

PF 15-APR-2002; 2002US-00123213.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022391.

PR 29-OCT-1998; 98WO-US022392.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US006319.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 30-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 05-JAN-2000; 99WO-US031274.

PR 08-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 11-FEB-2000; 2000WO-US000376.

PR 18-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 24-FEB-2000; 2000WO-US004342.

PR 24-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 01-MAR-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 15-MAR-2000; 2000WO-US005841.

PR 20-MAR-2000; 2000WO-US006884.

PR 21-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US007532.

PR 17-MAY-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US033678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006660.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-009098827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritteen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900167/82.
DR P-PSDB; ADE03788.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADE03787 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTACTGTGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GACGCCACGCCGCGAGCGCGGAGGCTGCGCAAGCGGCGGAGGCATTCCTTA	325
QY	41	GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCATGAACAGGTCCCCAAGCTCCACCCTCCACTCGATTACGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGCGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	CCCTGGGCTGAGAGATCAGTGACTTGTTCAGACACCGGACCCAAATAGGGCGTAGG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCGCTGAGCATCTGCGGAGCGCGGACGTTCGGGGCGCGCTGCGCGCTTCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGGAACAGTCTCAGCGCTGGAGTTCTGGGAGGCGCCGACGACAGGCCCCCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTTCTCCAGAGGGGACACACAGATGGGCTGGGCAATGCTTTGATGCG	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
DB	806	CCAGGGGCGCGCTTGGGCGACGCTTC-CTGCCCGCGCGGCGGAGGCGACTTCGACCA	864

Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGTGGTCCCTGAGCCGCGCGGGCGCAACCTGTTCGTGGTGGTGGCGCA	924
Qy	240	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGGCCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyIysArgLeuGlyArgAspAlaLeuLeuSerTirAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCCCGGACGCGTCTCAGCTGGGACGACGTGCTGGCGCTGCA	1044
Qy	280	nSerLeuTyIcIyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGGCTCAGCTCCAGCTCCAGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTGACTTTGAGACCTTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAACACGACGG	1164
Qy	320	yProLyTyIcYHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTTTCCTTCGATGCCATCAGTGTAGACAGGCCAACAGCAACTGT	1224
Qy	340	rIlePheLySglySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTTCGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTTCGGGCTGCCCCCAAATTGAGGCTCGCGACGTGCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLySGLyGLyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGCACAGGGGGCTGCCCGCCCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLySGLyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTTCCTCTCGCCCGGCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGCATGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh	480
Db	1585	AGGCATCCCTGAGAGGTCAAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLyLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGGCTTCGACAGGCCAAACTCGAGGCAACACCTCGGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCNACTCGGGGAGGCCCTGT	1764
Qy	520	e 520	
Db	1765	c 1765	

REF ID: A61197

RESOLUTION
ADE32084

ADE32084
ID ADE32084 standard; cDNA: 1985 BP.

2 XX

AC ADE32084;

XX

DT 29-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO4339 cDNA.

Human; secreted and transmembrane protein; PRO; gene; ss;
tumour necrosis factor alpha release; TNF-alpha release;
glucose uptake modulator; PFA uptake modulator;
cell proliferation stimulator; cell differentiation stimulator;
cell differentiation inhibitor; cytokine release stimulator;
lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
cervical tumour; liver tumour; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker.

Homo sapiens.

U.S. 2003 194765-A1

16-00T-2003

09-MAY-2002: 2002UIS-00142889

03-MAY-2000. 200005-010720ZB

03-MAR-2000; 2000US-018/202P.
01-DEC-2000; 2000WO-150313357801=DEC=2000; 2000WO=US032678.
19=DEC=2001; 2001US=00028072

(CFT) (CENTECH INC)

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-899784/82

P-PSDB: ADE32085.

Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders. e.g. arthritis.

Claim 2: SEO ID NO 143: 636pp: English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNP-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear articular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PMNC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1985 BP: 403 A: 646 C: 604 G: 332 T: 0 U: 0 Other:

Alignment Scores:

1.93e-149

Length: 1985

Score: 2792.00

Matches: 519

Percent Similarity: 99.62%

Conservative: 0

Best Local Similarity: 99.62%

Mismatches: 1

Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0
US-10-791-980-6 (1-520) x ADE32084 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpClyHisLeu	20
Db	206	ATGGTTCGGCGCGTTCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCCGGAGCGCGGAGCCAGNGCTGCCNAGGAGCGGAGGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAGCTCCACCTCCACTCGATTCCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTCAAGCGGGGTGTGGACGCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTGCGCCAGATGACTGCTCCCGCTCGGGGGTTACAGATACCACAGTTATTCGG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGATCAGTGACTGTTTCTGACACACCGGACCCAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAGAGTAAACAAATGGTACAAAGCAGCACCTCTCTACGCGCTGGT	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTTGAGCATCTGCCGAGCGCGCAGTTCCGGGCGCGCTGCGCGCGCTTCACG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCACGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGCGCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGTGGGCTGGGCAATTCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCCCGCGCGGCAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTGTTGGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGGGCTTCACCCACTCGCGCGCGCGCGCTCATGGGGGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGCTGGCGCGTGA	1044
Qy	280	nSerLeuTyrClyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCCTACAGCGCCCAAGGAGGCGCCTGAAACGCAGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCCACTCTCTCTTCGATGCCATCAGCTGTAGACAGGCAACAGCAACTGTA	1234

PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US024855.
PR 20-NOV-1998; 98WO-US025108.
PR 01-DEC-1998; 98WO-US000106.
PR 05-JAN-1999; 98WO-US0005028.
PR 08-MAR-1999; 98WO-US0005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 16-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020231.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 03-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 10-SEP-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00882636.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900166/82.
DR P-PSDB; ADE22017.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 143; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells and for treating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:				
Pred. No.:	1.93e-149	Length:	1985	
Score:	2792.00	Matches:	519	
Percent Similarity:	99.62%	Conservative:	0	
Best Local Similarity:	99.62%	Mismatches:	1	
Query Match:	98.52%	Indels:	2	
DB:	10	Gaps:	0	
US-10-791-980-6 (1-520) x ADE22016 (1-1985)				
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20	
Db	206	ATGGTCGGCGCGCTCGGCTCTCTGCTGGCGCCCTGCAGCTCTACTGTGGGGCCACCTG	265	
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40	
Db	266	GACGCCACCGCCGCGAGCGGAGCCAGGAGCTGCACAGGAGCGGAGGCATTCCTA	325	
Qy	41	GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60	
Db	326	GAGAAGTACGATACCTCAATGAACAGGTCCCAAAGCTCCACACTCCACTCGATTACG	385	
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80	
Db	386	GATGCCATCAGACGGTTTCAGTGGGTGTCCCAAGCTTACTGTCTCAGCGGGGTGTGGACCGC	445	
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100	
Db	446	GCCACCCCTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTTATGCG	505	
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	
Db	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTTCGTAGACACCCGACCCANAATGAGGCGTAAG	565	
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	
Db	566	ANAACGTTTGCACAGCAGGTAAACNAATGGTACAGCAGCACCTCTCTCTACCGCTCGTG	625	
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160	
Db	626	AACTGGCCGTAGCATCTCCCGAGCGCGCAGTTCGGGGCGCGCTCGCGCGCGCTTCAG	685	
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	
Db	686	TTGTGGAGCAACGCTCTACGCGCTGGAGTTCGTGGAGGGCCCCAGCCACAGGCCCGCTGAC	745	
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200	
Db	746	ATCCGGCTCACCTCTTCCAGGGGAGCACCAACGATGGGCTGGGCATGCCCTTTGATGGC	805	
Qy	200	agLnglyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220	
Db	806	CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCCGCGCGCGAAGCGCACTTCGACCA	864	
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValLeuAlaHis	240	
Db	865	AGATGAGCGCTGGTCCCTTGAGCGCGCGCGGGCGCAACCTGTTCGTGGTGTCTGGCGCA	924	
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260	
Db	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC	984	
Qy	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaVal	280	
Db	985	CTACTACAAGAGGCTGGGCGCGAGCGCGCTGTCTAGCTGGGACGACGCTGCTGGCGTGA	1044	
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	
Db	1045	GAGCTGTATGGGAAGCCCCCTAGGGGGCTCAAGTGGCCCTCAGCTTCCACGGAAGACTGT	1104	
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320	

PF 22-APR-2002; 2002US-00127852.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875635/81.
XX P-PSDB; ADD79241.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD79240 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GACGCCCGCGCGGAGCGGAGCGAGAGCTGCGCAAGAGGCGGAGGCAATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProlysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACACTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTTCAGCTACTGTGTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCCTGGGAGGCCCGCAGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyValaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGCGCACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGACGCTGGTTCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGCCCTCACCCACTCCCGCGCGCGCGCTCATGGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGACGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCGCCTCTCTTCGATGTCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAAAGATGGGTGGGCTGCCCGCTGCCCACTTGGAGCTCGGGCAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400

```
Db 1345 GAATGATGGAGATTCTACTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGACAGGGGGCTGCCCCCGCATCTGACGC 1464
Qy 420 alaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTTCAAGGGTGCCCGCTACTACGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCAGGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTCAGAGCTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGACGGCGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAGGCCAACTGCAGGCCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetClyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCGCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 122
ADE41776
ID ADE41776 standard; cDNA; 1985 BP.
XX
AC ADE41776;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003194772-A1.
XX
XX 16-OCT-2003.
XX
XX 21-MAY-2002; 2002US-00152386.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-899788/82.
XX
XX P-PSDB; ADE41777.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
```

PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.

XX Claim 2; Fig 143; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

1.93e-149 Length: 1985
Pred. No.: 2792.00 Matches: 519
Score: 2792.00
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADE41776 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCGCTGCGCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGGAGCGCGAGGCTGCCAAGAGGAGCGGAGGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 336 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTCCTGAGTGGGTGTCACGAGTACCTGTGTCAGCGGCGGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCGCAGATGACTCGTCCCGCGCTGCGGGTTACAGATACCACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCCTTGGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCCGAGAGCCGCGAGTTTGGGGCGCGGTGGCGCCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCAGCGCTGGAGTTCTGGGAGGCCCCAGGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCACACGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCTGGCCGACGCCCTTC-CTGCCCGCGCCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTACCCACTCGCCCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGGACCGCGCTGCTCAGTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGGGCGCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGCTGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 GCCTCTTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCCGAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCTGCGGAGGCCGATGGCTCATCATCTTCTT 1644

Qy 480 eAtgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACCGAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTtpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTCGATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 123
ADE17593
ID ADE17593 standard; cDNA; 1985 BP.
XX
AC ADE17593;
XX 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #72.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear cellular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
FN US2003199023-A1.
XX
XX 23-OCT-2003.
XX
PF 17-APR-2002; 2002US-00124821.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020940.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.

```

PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00870992.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-900155/82.
DR P-PSDB; ADE17594.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADE17593 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGTCTCTCTGTCGGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGCGAGAGCTGCGCAAGAGCGCGAGGCGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCATCAACAGGTGCCCCAAAGGTCCACCCTCCATCGATTCCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCCCAGCTACCTGTGTCAGCGCGGTGTGTGACCGC 445
```

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Dbb|||||
446 GCCACCCCTGCCCCAGATACCTGCTCCCGCTGCGGGGTACAGATACCACACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Dbb|||||
506 GCCTGGGCTGAGAGGATCAGTGACTTGTTGCTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Dbb|||||
566 AAACGCCTTGCAAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Dbb|||||
626 AACTGGGCTGAGCATCTCCCGGAGCGGCACTTCTGGGGCGCGCTGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyVArgProGlnProGlnAlaProLeuTh 180
Dbb|||||
686 TTGTGGAGCAAGCTCAGCGCTGGAGTTCTGGGAGGCCCCCAGCCAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Dbb|||||
746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCCACAAACATGGGCTGGGCAATGCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Dbb|||||
806 CCAGGGGCGGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyVArgAsnLeuPheValValLeuAlaHi 240
Dbb|||||
865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGGCGCACTGTTCTGGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Dbb|||||
925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyVArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Dbb|||||
985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyVArgSerValAlaValGlnLeuProGlyLysLeuPh 300
Dbb|||||
1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Dbb|||||
1105 CACTGACTTTGAGACCTGGGACTCTCCTACAGCCCCCAAGAAAGCGCGCTGAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Dbb|||||
1165 CCTTAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Dbb|||||
1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGAGCTCATGGCAAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Dbb|||||
1285 TCCACTGCGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyVArgCysTrpArgPheArgGlyProLy 400
Dbb|||||
1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCATGCTGGAGGTTCCGGGGCCCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Dbb|||||
1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Dbb|||||
1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460

Dbb|||||
1525 CTTGGGCCCGAGGGGGAAGTGCAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Dbb|||||
1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTCGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Dbb|||||
1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCCAACTGCAGGCCAACCCCTCGGGCGC 1704
Qy 500 gTTPAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Dbb|||||
1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCAATGCCNACTCGGGGAGCGCTCTT 1764
Qy 520 e 520
Dbb 1765 C 1765
RESULT 124
ADD91725
ID ADD91725 standard; cDNA; 1985 BP.
XX
AC ADD91725;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199053-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121053.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 14-SEP-1998; 98WO-US018824.
PR 10-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.


```
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005745.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00867092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-AUG-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX
DR WPI; 2003-900164/82.
DR P-PSDB; ADD91726.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 143; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD91725 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
|
Db 206 ATGGTCGGCGCGTCGGCCTCTCTGCGGCCCTCGACGTGCTACTGTGGGCCACCTG 265
|
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
|
Db 266 GACGCCACGCCGCGAGCGCGAGCGAGCTGCCAAGAGCGCGAGGCATTCCTA 325
|
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
|
```

Db 326 GAGAAAGTACGGATACCTCAATGAAACAGGTCCCAAAGCTCCACACCTCCACCTCGATTACG 385
Qy 61 AspAlaIleAraAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCATCAGACCGTTTTCAGTGGGTGTCCACGCTACCTGTCTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGACCCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCCCTTGCACAGCAAGTAACAAATGGTACAGACGACCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCCGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCCTGGAGGCGCCACAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTCTCAGCGCTGAGTTCCTGGAGGCGCCACAGTGGGCTGGCAATGCTTGGTGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCTCGCGCGCGCGCGCGCTCATYGGCGCC 984
Qy 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGACGACGCTGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTGTAGACCTGGACTCCTCAGCGCCCGCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAAATACGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCGCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTCAAGGGGGTTCGATGCTGGAGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGGCGAGGGGCGCTGCCCGCCCATCTCTGACG 1464

Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTTCTTCTCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCTCAGCGCGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCCTCGACCGCGCCAACTGCAGGCAACCCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 125
ADE33188
ID ADE33188 standard; cDNA; 1985 BP.
XX
AC ADE33188;
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003194767-A1.
XX 16-OCT-2003.
XX 16-MAY-2002; 2002US-00147497.
XX 26-AUG-1998; 98US-0097951P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-899786/82.
DR P-PSDB; ADE33189.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 143; 636pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADE33188 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGFTGGGGCGCTGGGCTCTGCTGGCGCCCTGCAGCTGCTACTGTGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCGCGGAGCGGAGGCGCCAGGAGCTGCGCAAGGAGGCGGAGGCAATTCCTA	325
Qy	41	GluLysTyrGlyTyrIleuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGGTGCCAAAGCTCCACCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
Db	386	GATGCCANTCAGACCGTTTCAGTGGGTGTCCAGCTACCTGTGACGGGGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTATACAGATACCAACAGATTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspIleuPheAlaArgHisArgThrIlyMetArgArgLys	120
Db	506	GCTCGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGTGTAACAGACACCTCTCTTACCGCCCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTGCCGGAGCCGCGAGTTTCGGGGCGCGTTCGCGCCGCTTCCAG	685

Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTTCTAGCCCTGGAGTTCTGGGAGGGCCCGCCAGCCAGGCCCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGACACCAACGATGGCTGGGCAATGCCTTTCATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAGGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGACCGCGCGCGGCGCAACTGTTCGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGGCCTCACCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrIlySArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAGGCGCCCTGAAACGACAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCGCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAGGAGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle	380
Db	1285	TCCACTCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTCAGGCTGGCGCAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	GGCCCTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTCCCGCGAAAGTCTGCGAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCTCTGAGGAGGTACGCGCGCGCTGCCGAGGGCCCATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGCGCCTCGACCGAGCCAAACTGCAGGCAACACCTCGGGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCGTGGTGGGTGCTGGCATGCCCAACTCGGGAGCGCCCTGTT	1764

Qy	520 e 520	PR	05-JAN-2000; 2000WO-US000219.	XX
Db	1765 C 1765	PR	06-JAN-2000; 2000WO-US000277.	XX
RESULT 126		PR	06-JAN-2000; 2000WO-US000376.	XX
ADE33740		PR	11-FEB-2000; 2000WO-US003565.	XX
ID ADE33740 standard; cDNA; 1985 BP.		PR	18-FEB-2000; 2000WO-US004341.	XX
XX		PR	22-FEB-2000; 2000WO-US004414.	XX
AC ADE33740;		PR	24-FEB-2000; 2000WO-US004914.	XX
XX		PR	24-FEB-2000; 2000WO-US005004.	XX
DT 29-JAN-2004 (first entry)		PR	01-MAR-2000; 2000WO-US005601.	XX
XX		PR	02-MAR-2000; 2000WO-US005746.	XX
DE	Novel human secreted and transmembrane protein PRO4339 cDNA.	PR	02-MAR-2000; 2000WO-US005841.	XX
XX	Human; secreted and transmembrane protein; PRO; gene; ss;	PR	15-MAR-2000; 2000WO-US006884.	XX
KW	Tumour necrosis factor alpha release; TNF-alpha release;	PR	20-MAR-2000; 2000WO-US007377.	XX
KW	glucose uptake modulator; FFA uptake modulator;	PR	21-MAR-2000; 2000WO-US007532.	XX
KW	cell proliferation stimulator; cell differentiation stimulator;	PR	30-MAR-2000; 2000WO-US008439.	XX
KW	cell differentiation inhibitor; cytokine release stimulator; tumour;	PR	17-MAY-2000; 2000WO-US013705.	XX
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	PR	22-MAY-2000; 2000WO-US014042.	XX
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;	PR	30-MAY-2000; 2000WO-US014941.	XX
KW	gene therapy; chromosome identification; chromosome marker.	PR	02-JUN-2000; 2000WO-US015264.	XX
XX		PR	28-JUL-2000; 2000WO-US020710.	XX
OS	Homo sapiens.	PR	11-AUG-2000; 2000WO-US022031.	XX
XX		PR	23-AUG-2000; 2000WO-US023522.	XX
PN	US2003194791-A1.	PR	24-AUG-2000; 2000WO-US023328.	XX
XX		PR	08-NOV-2000; 2000WO-US030952.	XX
XX		PR	10-NOV-2000; 2000WO-US030873.	XX
PD	16-OCT-2003.	PR	01-DEC-2000; 2000WO-US032678.	XX
XX		PR	20-DEC-2000; 2000US-00747259.	XX
XX		PR	20-DEC-2000; 2000WO-US034956.	XX
XX		PR	28-FEB-2001; 2001US-00796498.	XX
XX		PR	28-FEB-2001; 2001WO-US006520.	XX
XX		PR	01-MAR-2001; 2001WO-US006666.	XX
PR	31-MAR-1997; 97WO-US005230.	PR	09-MAR-2001; 2001US-00802706.	XX
PR	12-JUN-1998; 98WO-US012456.	PR	14-MAR-2001; 2001US-00808689.	XX
PR	14-JUL-1998; 98WO-US014552.	PR	22-MAR-2001; 2001US-00816744.	XX
PR	28-AUG-1998; 98WO-US017888.	PR	05-APR-2001; 2001US-00828366.	XX
PR	10-SEP-1998; 98WO-US018824.	PR	10-MAY-2001; 2001US-00854208.	XX
PR	14-SEP-1998; 98WO-US019093.	PR	18-MAY-2001; 2001US-00860216.	XX
PR	14-SEP-1998; 98WO-US019094.	PR	25-MAY-2001; 2001US-00866028.	XX
PR	14-SEP-1998; 98WO-US019177.	PR	25-MAY-2001; 2001US-00866034.	XX
PR	16-SEP-1998; 98WO-US019330.	PR	01-JUN-2001; 2001US-00872035.	XX
PR	17-SEP-1998; 98WO-US019437.	PR	01-JUN-2001; 2001WO-US017800.	XX
PR	07-OCT-1998; 98WO-US021141.	PR	14-JUN-2001; 2001US-00882536.	XX
PR	29-OCT-1998; 98WO-US022991.	PR	19-JUN-2001; 2001US-00886342.	XX
PR	20-NOV-1998; 98WO-US024855.	PR	20-JUN-2001; 2001WO-US019692.	XX
PR	01-DEC-1998; 98WO-US025108.	PR	21-JUN-2001; 2001US-00887879.	XX
PR	05-JAN-1999; 99WO-US000106.	PR	22-JUN-2001; 2001WO-US020116.	XX
PR	08-MAR-1999; 99WO-US005028.	PR	29-JUN-2001; 2001WO-US021066.	XX
PR	10-MAR-1999; 2000WO-US006319.	PR	09-JUL-2001; 2001WO-US021735.	XX
PR	20-APR-1999; 99WO-US008615.	PR	18-JUL-2001; 2001US-00908827.	XX
PR	02-JUN-1999; 99WO-US010733.	PR	06-AUG-2001; 2001US-00924419.	XX
PR	01-SEP-1999; 99WO-US012252.	PR	09-AUG-2001; 2001US-00927796.	XX
PR	08-SEP-1999; 99WO-US020594.	PR	16-AUG-2001; 2001US-00931836.	XX
PR	13-SEP-1999; 99WO-US020944.	PR	19-DEC-2001; 2001US-00028072.	XX
PR	15-SEP-1999; 99WO-US021090.	XX	(GETH) GENENTECH INC.	XX
PR	15-SEP-1999; 99WO-US021547.	XX	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	XX
PR	05-OCT-1999; 99WO-US023089.	XX	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	XX
PR	29-NOV-1999; 99WO-US028214.	XX	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	XX
PR	30-NOV-1999; 99WO-US028313.	XX	WPI; 2003-899790/82.	XX
PR	30-NOV-1999; 99WO-US028409.	XX	P-ESDB; ADE33741.	XX
PR	01-DEC-1999; 99WO-US028301.	XX	Two hundred and seventy five nucleic acids encoding PRO polypeptides,	XX
PR	01-DEC-1999; 99WO-US028634.	XX	useful for treating pericyte-associated tumors, diabetes and various bone	XX
PR	02-DEC-1999; 99WO-US028531.	XX	and/or cartilage disorders, e.g. arthritis.	XX
PR	02-DEC-1999; 99WO-US028564.	XX	Claim 2; SEQ ID NO 143; 636pp; English.	XX
PR	16-DEC-1999; 99WO-US028565.	XX		XX
PR	20-DEC-1999; 99WO-US030095.	XX		XX
PR	20-DEC-1999; 99WO-US030911.	XX		XX
PR	20-DEC-1999; 99WO-US030999.	XX		XX
PR	22-DEC-1999; 99WO-US030720.	XX		XX
PR	30-DEC-1999; 99WO-US031243.	XX		XX
PR	30-DEC-1999; 99WO-US031274.	XX		XX

CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF- α from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in binding
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1-93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADE33740 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACGCCCGAGCGCGAGGCCAGAGCTGCGCAAGGAGCGGAGGCAATTCCTTA 325
QY 41 GluLysTrpGlyTrpLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGACAGGTCCTCCCAAGCTCCACCTCCATCCATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTCAGTGGGTGTCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
DB 446 GCCACCTTCGCCCATGATGCTCTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTACCTTGTTGCTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAGACCGGACCAAAATGAGGGCTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTCGGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCGCTTCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCCCGCGTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTCCAGAGGACACACACAGATGGCTGGCAATGCCCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CAGGGGGGGCGCTGGCGACGCCCTTC-CTGCCCGCGCGCGAGCGCATTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTCTGTGGTCTGGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGTCTGCGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTTGGGACTCTCAGAGCCCGCGCGCGCGCGCTGAAACAGCGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
DB 1165 CCCTAAATACTGCGCACTCTCTCCGATGCCATCATCTGTAGACAGCGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGAGGAAAGATGGTGGGCTGCCGCCCAACATTGAGGTGGCGCATGTGTCATT 1344
QY 380 uAsnAspClyAspPheTrpPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTTCTACTTTCTTAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTTGCCCCGCCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTrpTrpVa 440
DB 1465 CGCCCT 1524
QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCGGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGAGGTGAGCGCGCTGCCGAGGCCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCCCAACATGCGAGGCAACCACTCGGGCGC 1704
QY 500 gTrpAlaThrGlnLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGCATGTCACCACTCGGGGAGCGCGCTGTT 1764
QY 520 e 520

Db 1765 C 1765
RESULT 127
ADD79792
ID ADD79792 standard; cDNA; 1985 BP.
XX AC ADD79792;
XX DT 29-JAN-2004 (first entry)
XX DE cDNA encoding human PRO polypeptide #72.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX US2003207417-A1.
XX PD 06-NOV-2003.
XX PF 07-MAY-2002; 2002US-00140805.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022921.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020534.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Debnovers L, Filvaroff E, Gao W;
PI Geriksen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-875867/81.
DR P-PSDB; ADD79793.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
XX Claim 2; Fig 143; 638pp; English.
PS

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:			
Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0
US-10-791-980-6 (1-520) x ADD79792 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGAGCGGAGCCAGGAGCTGCGCAGAGGCGGAGGCATTCTCTA	325
Qy	41	GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAGCTCCCACTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATCCCATCAGAGCGTTTCAGTGGGTGTCGCCAGCTACCTGTGCAGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTCGGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGGCGTTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140

CC from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADE19249 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCTGTCGCGCGCTTCCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGGGAGGCCAGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
Qy 41 GluIysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
Db 446 GCCACCTTGGCCAGATCACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCGAGCGCGCAGTTCGGGGCGCGTCCGCGCGCTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGAGGGCCCGCAGCCACAGGCGCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCGTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGGGGCGCAACCTGTTGCTGGTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCATCTGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGTT 1104
```

```
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGGCCCTTGAACGCAGGG 1164
Qy 320 YProLysTrpCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
Db 1165 CCCTAATACTGCCACTCTTCTTCGATGTCATCACTGTAGACAGGCACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGCGGGCTGCCCCCAACATTGAGGCTGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCATCCTCGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpTrpVa 440
Db 1465 CGCCTCTTCTTCCCTCTCTGCGCCCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGAGCGCGCTGCCGAGCGCCGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGTACTTGGCGCTCGACCGAGCCAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765
RESULT 130
ADE18697
ID ADE18697 standard; cDNA; 1985 BP.
XX ADE18697;
AC
XX 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #72.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003199026-A1.
XX FN
```

XX PD 23-OCT-2003.
 XX PF 20-MAY-2002; 2002US-00152393.
 XX PR 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-900157/82.
 DR P-PSDB; ADE18698.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 143; 636pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,938-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADE18697 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB ATGGTGGCGGGCTGGGCTCTGCTGGCGGCTTGCAGTGTCTACTGTGGGGCCACCTG 265

QY	21	ApAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGlyGluAlaGluAlaPheLeu	40
DB	266	GACGCCAGCCCGCGAGCGCGAGGAGCTGGCGAAGGAGCGGAGGAGGATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCATCGATTGACG	385
QY	61	ApAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuArg	80
DB	386	CATGCCATCAGACCGCTTTCAGTGGGTGCCAGTACCTGTCCAGCGCGGTGTGGACCG	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTTGGCCAGATGACTGCTCCCGCTGCGGGGTACAGATACCAACAGTATTGCG	505
QY	101	AlaTrpAlaGluArgGlnSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCAAAATGAGCGGTAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTGGCAAGCAAGGTAAACAAATGGTACAAGCAGACCTCTCTTACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTGAGCATCTCCCGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAGCTCTCAGCGCTGGAGTTCGGGAGGCGCCGACAGGCGCCCGCTGAC	745
QY	180	rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGCG	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
DB	806	CGAGGGGCGGCTGGCGCGACGCTTC-CTGCGCGCGCGCGCGGCGGAGCGGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCGCAACCTGTTCTGTTGGTGGCGCA	924
QY	240	sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTCAACGCTTGGCTCACCACTCGCGCGCGCGCGCGCGCTCATGGCGCG	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
DB	985	CTACTACAAGAGGTGGGCGCGCGCGCGCTCTCTAGCTGGGACGACGCTGGCGCGTGA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
DB	1105	CACGTACTTTCAGACCTGGGACTCTCTACAGCCCCCAAGAGGGCGCTGAAACGCGGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
DB	1165	CCCTAAATACCTGCGCACCTCTCTCTTCGATGCGCATCCTCTGTAGACAGGCAACAGCACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGAGCTGATGGCAACGTCTCAGAGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
DB	1285	TCCACTGCGGAAAGATGGGTGGGCTGCCGCCCAACATTCAGGTGGCGGAGTGTCTATT	1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCybArAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTTCAGCG 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCCCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTAGGAGGTGACGGGGCCCTGCCGAGGCCCATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATCACCGCTACTGCGCGCTCGACAGGCCAAACTGCAGGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCCGAGCTGCGCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 131
ADE42893
ID ADE42893 standard; cDNA; 1985 BP.
XX
AC ADE42893;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX
PN US2003199033-A1.
XX
PD 23-OCT-2003.
XX
XX
PF 28-MAY-2002; 2002US-00156845.
XX
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX
DR WPI; 2003-900162/82.
P-PSDB; ADE42894.

XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 143; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADE42893 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGGGCGGTTCGGCCCTCTGCTGGGGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCGCAGAGCTGGCGAAGGAGCGGAGGCATTCTCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACATTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGGTGTCCAGAGTACTGTTCAGGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGGGCCAGATGACTCGTCCCGGTGTCGGGGTTACAGATACACACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTCGGCTCAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACCGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACTCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCGGAGCGGAGCTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrPheAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACGATGGGCTGGGCAATGCTTTCATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CAGGGGGCGCTGGCGCACCGCTTC-CTGGCCCGCGCGGGGCAACCTGTTCTGCTGCTGCGCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGCGGCAACCTGTTCTGCTGCTGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 ofTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGCTGGGCGCGAGCGCTGCTCAGCTGGGAGCAGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGCTGGGACTCTTACAGCCCGCAAGGAGCGCGCTTGAAACGAGGG 1164
QY 320 vProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTAAATACTGCCACTCTCTTCATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnArgTrpValGlyLeuProProLeuIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCGGCTGCCCGCCCAACATTGAGGCTCGCGCACTGCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGAGATTTCTACTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPheProProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCCGCTACTAGCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGAAGCTGCGAGGCTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480

DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCCGATGGCTCCATCATCTCTTT 1644
QY 480 eArgAspPheArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCGAGGCAACCCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 132
ADD95682
ID ADD95682 standard; cDNA; 1985 BP.
XX
AC ADD95682;
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear cellular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199059-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123322.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.

Db 386 GATGCCATCAGACGGCTTTCAGTGGGTGTCCTCCAGCTACCTGTCCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyraLa 100
Db 446 GCCACCTCGCCAGATGACTGCTCCCGCTCGGGGTTCAGATACCAACAGATTATGGC 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTGAGAGGATCAGTCACTGTTGTTGTAGACACCGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnClyAsnLysTrpTyrlLysGlnHisLeuSerTyrlArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTAAGTCAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCAGTCTCGGAGCGGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCGGAGGCGCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCCGCTCACCCTTCTTCCAGGGGACCAACGATGGGCTGGGCAATGCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTCGGCGCACGCTTC-CTGGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCCTCGAGCGCGCGCGCGCAACCTGTTGTTGCTGTCGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrlLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCGTGGCGCGGACCGCTGCTCAGCTGGAGACGAGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrlLysProLeuGlyLysrValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrlSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTTGGACTCTTACAGCCCCCAAGAGGCGCCCTGMAAACGACGG 1164
Qy 320 yProLysTyrlCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTTCCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGACGCTGATGGCAAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrlPhePheLysGlyLysrValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTCAAGGGGGTGCATGCTGGAGGTTCGGGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGACGGGGCGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrlTyraVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCGCGCGCTCATCTCTTCAAGGGGTGCGCGCTACTAGCT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrlTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGCTTCGACGACTGGGG 1584
Qy 460 yGlyIleProGluGlnValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrlTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTCGAGGCAACCCCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 133
ADE22568
ID ADE22568 standard; cDNA; 1985 BP.
XX AC ADE22568;
XX XX
XX 29-JAN-2004 (first entry)
XX DE cDNA encoding human PRO polypeptide #72.
XX KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003199064-Al.
XX PD 23-OCT-2003.
XX PF 19-APR-2002; 2002US-00125932.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012452.
PR 01-SEP-1999; 99WO-US020111.

QY 41 GluLysTyrGlyTyrLeuAenGluInValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTACGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAseArg 80
 DB 386 GATGCCATCAGACGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
 DB 446 GCACCTCTGGCAGATGACTCGTCCCGCTCGGGGTTCACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGCTGAGAGATCAGTACATTGTTTGTAGACACCGACCAAAATGAGCGTAAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTTGAAGCAAGGTAAACAAATGGTAAACAGCACCTCTCTTACCGCTGTGTG 625
 QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTTGACATCTGCCGAGCGCGCAGTTTCGGGGCGCGCTGCGCGCCCTTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTACGCGCTCGAGTTCTGGAGGGCCCCAGCCAGGCCCTCGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCTTTCATGCGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGGCGCTGCGGCACGCTTC-CTGCCCCCGCGCGGAGCGACCTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGTTCCCTGAGCGCGCGCGCGCGCAACCTGTTGTTGCTGCGCA 924
 QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValCl 280
 DB 985 CTACTACAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGACGG 1164
 QY 320 vProLysTyrCysHisSerPheAspAlaIleThrValLeuPheArgGlnGlnLeuTy 340
 DB 1165 CCTTAATACTCCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
 DB 1225 CATTTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerIle 380
 DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCGCGCCCAACATTCAGGCTGCGGCGAGTGTCTAT 1344
 QY 380 uAenAspGlyAspPheThrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys 400
 DB 1345 GAATGATGAGATTTCTACTCTTCAAGGGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGNACTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProArgProArgGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGACGGCGCTGCGAGGGCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACGAGCCCAACTGCAGGCAACACCTCGGGCGC 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCGCAACTCGGGGAGCGCCCTGT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 134
 ADD78686
 ID ADD78686 standard; cDNA; 1985 BP.
 XX
 AC ADD78686;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE CDNA encoding human PRO polypeptide #72.
 DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 XX OS
 XX PN
 XX US2003203429-A1.
 XX
 PD 30-OCT-2003.
 XX
 PF 22-APR-2002; 2002US-00127900.
 XX
 PR 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Borensini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-875636/81.
 DR P-PSDB; ADD78687.
 XX
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.

Db 1645 CCGAGATACCGCTACTGGCGCTCGACAGGCCAACATGCAAGCAACCTCGGGCGG 1704
Qy 500 gtrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 135
ADE32636
ID ADE32636 standard; cDNA; 1985 BP.
XX
AC ADE32636;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
FN US2003194766-A1.
XX
PD 16-OCT-2003.
XX
PF 14-MAY-2002; 2002US-00145874.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-899785/82.
DR P-PSDB; ADE32637.
XX
XX Two hundred and seventy five nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PBMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADE32636 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGGAGCGGAGCGGAGCTGCGCAAGAGCGGAGGCATTCCTTA 325
Qy 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCATGAACAGGTCCCAAGCTCCACCCTCCACTGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTGCAGAGCAAGGTAAACAAATGGTTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGCTGCGCGCGCTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGAACAGTCTCAGCGCTCGAGTTCGGAGAGGCCCCAGCCACAGGCCCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTCCAGAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGCGCGCTGCGGCGACGCCCTTC-CTGCCCGCGCGCGGAGCGCAATTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCCCTAGAGCCCGCGCGGCGCAACCTGTTCTGCTGGTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB |||||
DB 925 CGAGATCGGTACACAGCTTGGCCTCACCATCTGCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 ofTyrTyrIysArgLeuGlyAraGAspAlaLeuSerTrpAspValLeuAlaValG1 280
DB |||||
DB 985 CTACTACAAGAGGCTGGCGCGGAGCGCTGCTCAGCTGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB |||||
DB 1045 GAGCGTGATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThraSpPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG1 320
DB |||||
DB 1105 CACTGACATTTGAGACCTGGGACTCTCAGAGCCCGCAAGGAGGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCySHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
DB |||||
DB 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB |||||
DB 1225 CATTTTAAAGGAGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
DB |||||
DB 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLeuGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB |||||
DB 1345 GAATGATCGAGATTCTACTTCTTCNAAAGGGGTGATGCTGGAGGTTCGGGGCCCCNA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB |||||
DB 1405 GCGAGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCTGCCCGCCCATCTCGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB |||||
DB 1465 GCGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
DB |||||
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
DB |||||
DB 1585 AGGCATCCTGAGGAGGTGAGCGGCGGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB |||||
DB 1645 CCGAGATGACCGCTACTGGCGGCTCGACAGGCGCAAACTGCAGGCAACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB |||||
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGATCCCAACTCGGGGAGCGGCTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 136
ADE42328
ID ADE42328 standard; cDNA; 1985 BP.
XX
AC ADE42328;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear cellular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199032-A1.
XX
PD 23-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156844.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
DR WPI; 2003-900161/82.
DR P-PSDB; ADE42329.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 143; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985

Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0
US-10-791-980-6 (1-520) x ADE42328 (1-1985)			
QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGTCGCGCGGTGGGCTCTCTGTCGCGGCTCGAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GAGCCCGCCGCGGAGCGCGAGGCGCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
DB	386	GATGCCATCAGACGGTTTCAGTGGGTGTCCTAGCTACCTGTGAGCGGCGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTCGCCAGATGACTGTCCTCCGCTGGGGGTTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCCTGGCTGAGAGGATCAGTGACTGTTTGTGTAGACACCGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGGTAACTGTTACAAAGTACAGACACCTCTCTACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTGAGCATCTGCGGAGCGCGAGTTGCGGGCGCGTGCGCGCCCTTCNAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTTCTTCAAGGGGACCAACGATGGGCTGGGCAATGCCCTTTGATGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
DB	806	CCAGGGGGCGCTGGCGACCGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGCTGCTGCGCA	924
QY	240	sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CCAGATCGGTACACGCTTGGCTCACCCACTGCGCGCGCGCGCGCTCATGCGCGC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1	280
DB	985	CTACTACAGAGGCTGGGCGCGGACCGCGTGTCTAGCTGGGACGAGCTGCTGCGCGTGA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGAGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAAGCTGTT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320
DB	1105	CACCTGACTTTGAGCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACGAGGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340

DB	1165	CCCTAAATACTGCCACTCTCTCTCGATGCCATCATCTGTAGACGCGCAACAGCACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe	380
DB	1285	TCCACTGCAAGAAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTGCGGCAAGTGCATT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATCATGGAGATTTCTACTCTTCAAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC	1464
QY	420	aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
DB	1465	CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
DB	1525	GCTGSCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGCTCCATCATCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVa	500
DB	1645	CGAGATGACCGCTACTGCGCTCGACAGGCCAAACTGCAGGCAACCCCTCGGGCGG	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
DB	1705	CTGGSCCACCAGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCGCTGT	1764
QY	520	e 520	
DB	1765	C 1765	
RESULT 137			
ADD80344			
ID	ADD80344 standard; cDNA; 1985 BP.		
XX	AC ADD80344;		
DT	29-JAN-2004 (first entry)		
DE	cDNA encoding human PRO polypeptide #72.		
XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
XX	immune system cell infiltration.		
OS	Homo sapiens.		
XX	US2003207418-A1.		
XX	06-NOV-2003.		
XX	07-MAY-2002; 2002US-00140809.		
XX	31-MAR-1997; 97WO-US005230.		

PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018834.
PR 14-SEP-1998; 98WO-US019033.
PR 14-SEP-1998; 98WO-US019034.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 16-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030939.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882836.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
FA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875868/81.
DR P-PSDB; ADD80345.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
PS Claim 2; Fig 143; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from

CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD80344 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTTCGGCGGCTGGCCCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGCGGAGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuHsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGAGTACCTCAATGAACAGAGTCCCAAGAGCTCCACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTCAGCTACCTGTGAGCGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACCTGTTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaValGlnGlyHsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGAGCAAGTAACTGTTAAAGCAGCAGTCTCTCTACCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCACTCTCGCGAGCGGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGGCCCGGACACAGGCCCGCGTGCAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGGCTCACCTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGGCGACCGCTTC-CTGCCCCCGCGCGGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgHsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCAACCTGTTCTGTTGCTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTACAGCTTGGGCTTACCACCTCGCCCGCGCGCGCGGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGCTGGGCGCGGCGCGCTGTCTCAGCTGGGACGAGCTGCTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGCTCAGCTCCCGAGGAAGCTGTT 1104
```

```
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTTGGGACTCTCTACAGCCCCCAGGAGGCGCCCTTAAACGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCGCACTCTTCTTCGATGCATCACTAGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
QY 360 pProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGTCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGTGCGGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGAGGTTCCGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGACAGGGGGCGCTGCCCGCCATCTCTGAC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCCGTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAGCTTCGAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGCATCTCTGAGGAGGTGAGCGGCGCTGCGAGGGCCGATGCGTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCGAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaHsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGAGGCGCGCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 138
ADD89372
ID ADD89372 standard; cDNA; 1985 BP.
XX AC ADD89372;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #72.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX Homo sapiens.
OS
XX
PN US2003199028-A1.
```

XX 23-OCT-2003.
PD 22-MAY-2002; 2002US-00153552.
PF 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900158/82.
DR P-PSDB; ADD89373.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX Claim 2; Fig 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD89372 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTGGCGCGTCTCTGCTGCGCGCCTGCAGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCTGCGCAAGAGGCGGAGGCATTCTCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGNAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCATCGATTGAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCACTGGGTGCTCCAGCTACCTGTCCAGCGCGCTGTTCGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCCGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCCGAGCCGCGAGTTCTGGGGCGCGCTGCCGCGCTTCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCGCCAGCACAGGCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAAGGGGACACAAACATGGGTGGGCAATGCTTGTATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGGCGGAGCGCACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGTTGCTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCCTCACCTCCCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACACGCTGTGGCGGTGCA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGAGAAAGTGT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCGCTGAAAGCGAGGG 1164

Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCCACTCTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAGGGAGGCATTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAGAAAGATGGGTGGGCTCGGCGTCCGCCCCCAACATTGAGGCTGGCGCAGTGTCA 1344


```
QY 380 uAenAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGAGATTCTTCTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCAGTGTGGGGTCTCCCAAGCTGTGCCGGGAGGGGGCCCTGCCCGGCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTTGGCCGCTCATCTCTTCAAGGGTGGCCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCCGAGTCTGCAGGACTGGGG 1584
QY 460 yGlylleProGluGluValSerGlyAlaLeuProArgProAspGlySerlleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGGGGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCCCTCGACCAGGCCAAACTGCAGGCCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGTGCCTTGGATGGGCTGTGGCATGCCAATCTCGGGAGGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 139
ID ADE40656 standard; cdNA; 1985 BP.
XX AC ADE40656;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX SS US2003199031-Al.
XX PN 23-OCT-2003.
XX PF 28-MAY-2002; 2002US-00156842.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-05032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S,
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX WPI; 2003-900160/82.
XX DR P-PSDB; ADE40657.
```

Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 143; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADE40656 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTGGCGCGGTGCGGCTCTCTGCTGGCGGCCCTGACAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu	40
DB	266	GACGCCACGCCCGGAGCGCGGAGCCAGAGCTGGCAAGGAGGAGGAGGCAATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCATCGATTCAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGAGGCTTCAGTGGGTGTCCACAGCTACCTGTGACGGCGGTGTGTGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGATTATCGG	505

Qy 101 AlaTpaAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 CCTGGGCTGAGAGATCAGTACTTGTGTTCTAGACACCGGACCAAAATAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCCTTGCAAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCCTAGACATCTCCCGAGCCGCGAGTTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACACAGTCTCAGCGCTGGAGTTCCTGGAGGCCCCCAGCCAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAAGGGACCAACAACATGGCTGGCAATGCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCCTAGCGCGCGCGCGGCGCAACTGTTCTGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCT 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAAGAGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCCTCAGCGCCCAAGGAAGGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCyHisHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTGCCACTTCTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATCGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGCTCTCCACAGCTGTGCGGGCAGGGGCTGCGCCGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGTGGCGCTGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGAGTGCAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480

Db 1585 AGCATCCTCGAGAGGTGAGCGGCGCTCGCGAGCCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGGCAAACTGCAGGCAACCACTCGGCGC 1704
Qy 500 gTpaAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 140
ADE04455
ID ADE04455 standard; cDNA; 1985 BP.
AC ADE04455;
XX 29-JAN-2004 (first entry)
DT Human PRO polynucleotide #72.
DE
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalasassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX US2003199034-A1.
PN
XX 23-OCT-2003.
PD
XX 28-MAY-2001; 2001US-00156846.
PF
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900163/82.
DR P-PSDB; ADE04456.
DR
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating

Db 985 CTACTACAAGAGCTGGCGCGACGCGCTGCTCAGCTGGGACGAGCTGCTGCCCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTTAGGGGCTCAGTGGCCGTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCGCCCAAGGAGCGCCCTGNAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACCTCCACTCTCTCCATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyClyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCGCTGCCCGCCATCTCGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCCGTACTAGT 1524
Qy 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGGAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGGGGCGCTGCCGAGGGCCGATGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGGCCAACTGCGAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAATCGGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 142
ADG21293
ID ADG21293 standard; cDNA; 1985 BP.
AC ADG21293;
XX
DT 26-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker; gene; ss.
OS Homo sapiens.
XX US2003207355-A1.
XX 06-NOV-2003.
XX 07-MAY-2002; 2002US-00140923.
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-901058/82.
DR P-PSDB; ADG21294.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2

DB:	10	Gaps:	0	
US-10-791-980-6 (1-520) x	ADG21293 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu	20	
Db	206	ATGTCGCGCGCGTCTCGCTGCGCGCTCTGCGCGCTGCTACTGTGGGGCCACCTG	265	
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40	
Db	266	GACGCCACCGCGCGAGCGCGAGCGCAGGAGCTGCGCAAGAGGCGGAGGCAATTCCTA	325	
Qy	41	GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer	60	
Db	326	GAGAAAGTACGGATACCTCATGAAACAGGTCCCAAGCTCCCACTCCACATCGATTTCAGC	385	
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80	
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGACGGCGTGTGGACCGC	445	
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100	
Db	446	GCCACCTCGCGCAGATCACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG	505	
Qy	101	AlaTTPAlaGluAtqIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	
Db	506	GCCTGGGCTGAGAGATCAGTGACTTGTTGCTAGACACCGGACCAAAANTGAGGCGTAAG	565	
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	
Db	566	AAACGCTTTGCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG	625	
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160	
Db	626	AACTGGCTGAGCAATCTCCGAGCGCGCATGTTGCGGGCGCGCTGCGCGCGCTTCCAG	685	
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	
Db	686	TTGTGGACACGTCCTCAGCGCTGAGTTCCTGGGAGGCGCCACGACAGGCGCCGCTGAC	745	
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200	
Db	746	ATCCGGCTCACCTTCTCCAGGGGACCAACAGATGGCTGGGCAATGCTCTTTGATGGC	805	
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220	
Db	806	CCAGGGGCGCGCTGGCGACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA	864	
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240	
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACTGTTCGTGGTGTGGCGCA	924	
Qy	240	eGluIleGlyHisThrLeuGlyLeuThrHiserProAlaProArgAlaLeuMetAlaPr	260	
Db	925	CGAGATCGGTACACGCTTGCGCTCACCACTCGCGCGCGCGCGCTCATGGCGCC	984	
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1	280	
Db	985	CTACTACAAAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA	1044	
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGTCCAGAAAGCTGTT	1104	
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320	
Db	1105	CACCTGACTTTGAGACTGGGACTCTACAGCCCCCAAGAGGCGCCCTGAAACGCGAGG	1164	
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	
Db	1165	CCCTAAATACGCGCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA	1224	
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	
Db	1225	CATTTTAAAGGAGCCATTTCTGGGAGGTGGAGCTGTATGGCAACGCTCTCAGAGCCCCG	1284	
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	
Db	1285	TCCACTCAGAAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTGCGGCAGTGTCAAT	1344	
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400	
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404	
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTCTGACGC	1464	
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440	
Db	1465	CGCCCTCTCTTCT	1524	
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460	
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG	1584	
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	
Db	1585	AGGATCCCTGAGAGGTGACGGCGCGCTGCCAGGCGCCGATGCTCCATCATCTTCTT	1644	
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	
Db	1645	CCGAGATGACCGCTACTTGGGCGCTCGACCGGCGCAAACTGCAGGCAACCACTCGGGCG	1704	
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	
Db	1705	CTGGGCCACCGAGTCCCTGGATGGGTGCTGTGCTGCAACCTCGGGAGCGCCCTGTT	1764	
Qy	520	e 520		
Db	1765	C 1765		
RESULT 143				
ADG22934				
ID	ADG22934	standard; cDNA; 1985 BP.		
XX	AC	ADG22934;		
XX	DT	26-FEB-2004 (first entry)		
XX	DE	Novel human secreted and transmembrane protein PRO4339 cDNA.		
XX	KW	Human; secreted and transmembrane protein; PRO; secreted polypeptide;		
KW	KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;		
KW	KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;		
KW	KW	rectum; kidney; cervix; liver; microvascular endothelial cell;		
KW	KW	glucose uptake modulator; FFA uptake modulator; cell proliferation;		
KW	KW	cell differentiation; skeletal muscle cell; adipocyte cell;		
KW	KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;		
KW	KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;		
KW	KW	immune system cell infiltration; chromosome mapping; gene mapping;		
KW	KW	gene therapy; chromosome identification; chromosome marker; gene; ss.		
XX	OS	Homo sapiens.		
XX	US	US2003207384-A1.		
FN	XX	06-NOV-2003.		
PD	XX	22-MAY-2002; 2002US-00153585.		
XX	PF	03-MAR-2000; 2000US-0187202P.		
XX	PR	01-DEC-2000; 2000WO-US032678.		
PR	PR	19-DEC-2001; 2001US-00028072.		

XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-901065/82.
 XX P-PSDB; ADG22935.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, bone
 XX useful for treating pericyte-associated tumors, diabetes and various
 XX and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 143; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 XX polynucleotides are useful in molecular biology, including uses as
 XX hybridisation probes, in chromosome and gene mapping, in generating
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
 XX be used in preparing PRO polypeptides by recombinant techniques and in
 XX generating either transgenic animals or knock-out animals which are
 XX useful in the development and screening of therapeutically useful
 XX reagents. The PRO polypeptides or antibodies are used in preparing a
 XX medicament for treating a condition responsive to the polypeptides or
 XX antibodies, such as tumours, for stimulating and inhibiting proliferation
 XX of human microvascular endothelial cells, for modulating the uptake of
 XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 XX cells, for stimulating differentiation of adipocyte cells, for
 XX stimulating proliferation of or gene expression in pericyte cells, for
 XX stimulating the proliferation of inner ear utricular supporting cells or
 XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
 XX treating various bone and/or cartilage disorders such as sports injuries
 XX and arthritis. PRO polypeptides which stimulate the release of
 XX proteoglycans from cartilage are useful for treating sports-related joint
 XX problems, articular cartilage defects, osteoarthritis and rheumatoid
 XX arthritis. PRO polypeptides are also useful for treating various
 XX mammalian haemoglobin-associated disorders such as various thalassaemias
 XX and conditions which may benefit from enhanced local immune system cell
 XX infiltration. This sequence represents a human PRO polynucleotide of the
 XX invention. Note: The sequence data for this patent is also available in
 XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 XX
 XX Alignment Scores:
 XX Pred. No.: 1.93e-149 Length: 1985
 XX Score: 2792.00 Matches: 519
 XX Percent Similarity: 99.62% Conservative: 0
 XX Best Local Similarity: 99.62% Mismatches: 1
 XX Query Match: 98.52% Indels: 2
 XX DB: 10 Gaps: 0
 XX
 XX US-10-791-980-6 (1-520) x ADG22934 (1-1985)
 XX
 XX 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
 XX 206 ATGGTCGGCGGCTGGCGCTCTGCTGGCGCGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265
 XX 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 XX 266 GAGCCACCCCGGAGCGCGGAGCCAGAGCTGGCGCAAGAGGCGGAGGACATTCCTA 325
 XX 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 XX 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCCAAAGGTCCCAACCTCCACTCCATTACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCAGAGCTACCTGTCAAGCGCGCTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCTCGCCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGATTATGG 505
 QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCTTGGGCTGAGAGGATCAGTGTGTGTGTAGACACCGACCAAAATGAGCGGTAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
 DB 566 AAACGCTTTCAAAGCAGGTAAACAAATGGTACAGCAGCAGCTCTCTCCACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTAGCATCTGCGGAGCGGCAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGGCGCCCGACAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCCTTTCAGAGGAGCACCAACAGATGGGCTGGGCATATGCTTGTATGGC 805
 QY 200 gGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGCGCGCTCGCGCAGCCCTTC-CTGCCCCGCGCGCGAGGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTTCACAGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGGC 984
 QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGTGGGACGAGCTGTCGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACCTTGGACCTGGGACTCTCAGCGCCCGAGAGGCGCCCTCTGAAGCGCAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATACCTGCCACTCTCTCTTCGATGCCATCAGCTAGACAGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLys 380
 DB 1285 TCCACTCAGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGGCTGGGCGAGTGTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys 400
 DB 1345 GAATGATGAGATTCTTACTTCTTCAAGGGGGTTCGATGTGGAGTTCGGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCGAGGGGCGCTGCGCCCGCCCATCTCTGACGC 1464

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLeuPhelysGlyAlaAxtgTyrTyrVa 440
Db 1465 CGCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 CTGGCCGAGGGAGTGCAGTGGAGCTTACTACCCCGGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyLeProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGCGGCCCTCCGAGGCCGATGCCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTCGCCCTCGACCGCCAACTGCAGGCAACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTTPMetGlyCyseTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAATCGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 144
ADF97269
ID ADF97269 standard; cDNA; 1985 BP.
XX
AC ADF97269;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207370-A1.
XX
PD 06-NOV-2003.
XX
PF 14-MAY-2002; 2002US-00145632.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-901059/82.
DR P-PSDB; ADF97270.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

xx SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADF97269 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGTCGCGCGCTCGCGCTCTCTGTCGCGCGCTGTCAGCTGCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGCGCGAGCTGCGAAGGAGGAGGCGGCGGCGGCGGCG 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGNAGTACGGATACCTCAATGACAGGTCCCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCTGTCAGCTACTGTGTCAGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTGCTCCCGCTGCGGGGGTTACAGATACCAACAGTTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTCTTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCTACCGCTGTGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCCTGAGCATCTGCGGAGCGCGAGTTGCGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCGTGAC 745
QY 180 rSerGlySerProSerSerSerGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCCTTCTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCGCTGGCGCACGCCCTTC -CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCAACCTGTGTGTGTGTGTGTGTGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAAGAGCTGGGCGCGCGAGCGCGTGTCTAGCTGGGAGCGTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAGAGTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGACGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCCG 1284
QY 360 qProLeuGlnGluArgTrpValGlyLeuProProLeuIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGAGTGGTGGCGCTGCCCGCCCAACATTGAGGTGGCGGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATCATGGAGATTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCGCTGCCCGCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GTGGCCCGGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGTTCAGCGCGCGCTGCCGAGGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGAGCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 145
ADG80333
ID ADG80333 standard; cDNA; 1985 BP.
XX
AC ADG80333;
DT 11-MAR-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207373-A1.
XX
PD 06-NOV-2003.
XX
PF 14-MAY-2002; 2002US-00145871.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-901061/82.
DR P-PSDB; ADG80334.
XX
PT New secreted and transmembrane PRO polypeptides useful for inhibiting the
differentiation of adipocyte cells, stimulating the proliferation of T-
lymphocyte cells and detecting the presence of a tumor in a mammal.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. Note:
 CC sequence represents a human PRO polynucleotide of the invention. This
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADG80333 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCTGCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyClyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCGCGGAGCGGAGCGGAGCTGCGCAAGAGGCGGAGGCAATCTCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGATACCTCANTGACAGGTCCCAAGGCTCCACCTCCACTCGATTGAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTCAGTGGGTGTCCTGAGTACCTGTCAGCGGCGGTGTGGACGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTGCGCCAGATCACTGCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTGGGCTGAGAGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCAATCTCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGACACAGTCTCAGCGCTGAGTCTTGGGAGGCGCCACGACAGGCCCCGCTGAC	745
Qy	180	rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTCAAGGGGACCAACAAATGGCTGGGCAATGCTTGTATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGGCGGCTGGCGACGCTTC-CTGCCCCGCGCGGAGCGACATCTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240

Db	865	AGATAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACACGCTTGGCTTCCACTCGCCCGCGCGCGCTCAATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
Db	985	CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAGGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGAGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
Db	1105	CACAGCTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGGCGCTGAAAGCGCAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACCTGCGCACCTTCTTCTGATGCCATCCTGTAGACAGGCAACAGCACTGT	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCAGAGAAAGATGGGTGCGGCTGCCGCCCAACATTTGAGGCTCGGCGAGTGTATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCGAGCG	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCGCGCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG	460
Db	1525	GCTGGCGGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGACAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTACGCGCGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTTACTGGGCGCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCG	1704
Qy	500	qTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCGCACCGAGCTGCCCTGGATGGGCTGTGTGCTGTCAGCAACTCGGGGAGCGCCCTGT	1764
Qy	520	e 520	
Db	1765	C 1765	

RESULT 146

ADG79781	
ID	ADG79781 standard; cDNA; 1985 BP.
XX	
AC	ADG79781;
XX	
DT	11-MAR-2004 (first entry)
XX	
DE	Human PRO polynucleotide #72.
XX	

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

Homo sapiens.

US2003207372-A1.

06-NOV-2003.

14-MAY-2002; 2002US-00145753.

03-NOV-1997; 97US-0064248P.

16-SEP-1998; 98WO-US019330.

13-OCT-1998; 98US-0104080P.

25-AUG-1999; 99US-00380139.

05-OCT-1999; 99WO-US023089.

22-FEB-2000; 2000WO-US004414.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;

Geritense ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-901060/82.

P-PSDB; ADG79782.

New PRO nucleic acid, useful for manufacturing a medicament for

diagnosing or treating tumor, for chromosome mapping or for tissue

typing.

Claim 2; SEQ ID NO 143; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This

Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCCCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThraspPheGluThrTrrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCTCAAGGAAAGGGCCCTGAAGCGCAGGG 1164
Qy 320 yProlyserTyrCyvHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTGCCACTCTTCTTCGATGCCATCACTGTACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrrValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAATT 1344
Qy 380 uAsnAspGlyVAspPheTyrPhePheLysGlyGlyVArgCysTrpArgPheArgGlyVProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrrPgluLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGCTGCCCGCCATCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTrrProArgSerLeuGlnAspTrrG 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGAAGTGTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTCAGGGCGCTCTGCCAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTrrTrrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAACTGAGGCAACACCTCGGGCGG 1704
Qy 500 gTrrAlaThrGluLeuProTrrMetGlyCysTrrHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCTGGATGGGCTCTGGCATGCCAACTCGGGAGCGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 147
ID ADH55073 standard; cDNA; 1985 BP.
XX
AC ADH55073;
XX
DT 25-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.

XX OS Homo sapiens.
XX US2003207381-A1.
XX 06-NOV-2003.
XX 21-MAY-2002; 2002US-00152376.
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Deenoysers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-901064/82.
DR P-PSDB; ADH55074.
XX New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor, for chromosome mapping or for tissue
typing.
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
cells, for stimulating differentiation of adipocyte cells, for
stimulating proliferation of or gene expression in pericyte cells, for
stimulating the proliferation of inner ear utricular supporting cells or
T-lymphocyte cells, for inducing endothelial cell tube formation and for
treating various bone and/or cartilage disorders such as sports injuries
and arthritis. PRO polypeptides which stimulate the release of
proteoglycans from cartilage are useful for treating sports-related joint
problems, articular cartilage defects, osteoarthritis and rheumatoid
arthritis. PRO polypeptides are also useful for treating various
mammalian haemoglobin-associated disorders such as various thalassemias
and conditions which may benefit from enhanced local immune system cell
infiltration. This sequence represents a human PRO polynucleotide of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
SQ
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADH55073 (1-1985)

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;

XX WPI; 2003-901063/82.

DR P-PsDB; ADH55626.

XX New PRO nucleic acid, useful for manufacturing a medicament for

PT diagnosing or treating tumor, for chromosome mapping or for tissue

PT typing.

XX Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte

CC cells, for stimulating differentiation of adipocyte cells, for

CC stimulating proliferation of or gene expression in pericyte cells, for

CC stimulating the proliferation of inner ear utricular supporting cells or

CC T-lymphocyte cells, for inducing endothelial cell tube formation and for

CC treating various bone and/or cartilage disorders such as sports injuries

CC and arthritis. PRO polypeptides which stimulate the release of

CC proteoglycans from cartilage are useful for treating sports-related joint

CC problems, articular cartilage defects, osteoarthritis and rheumatoid

CC arthritis. PRO polypeptides are also useful for treating various

CC mammalian haemoglobin-associated disorders such as various thalassemias

CC and conditions which may benefit from enhanced local immune system cell

CC infiltration. This sequence represents a human PRO polynucleotide of the

CC invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADH55625 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20

DB 206 ATGTTCGCGCGGTGGGCTCTCTGCGCGCCCTGCAGCTGCTACTGTGTGGGGCCACTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40

DB 266 GACGCCACGCCCGGACGGGAGCCAGAGCTGCGCAGAGGCGGAGGCAATTCCTA 325

QY 41 GlulysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60

DB 326 GAGAAGTACGGATACCTCAATGAAACAGGTCCCAAGGCTCCACCTCCACTCGATTTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTCCAGCGCGTGTTCGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100

DB 446 GCCACCCTGCGCCAGATGACTCGTCCCCTGCGGGGTTCAGATACCAACAGATTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

DB 566 AAACGCTTTTCAAGCAAGGTAAATAATGGTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160

DB 626 AACTGGCTTGAGCATTCTCCGAGCCCGCAGTTTCGGGGCGCGGTGCGCGCGCTTCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180

DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTCTCTGGAGGCCCCCAGCCACAGGCCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200

DB 746 ATCCGGCTCACTCTTCTCAAGGGGACCAACAGATGGGTGGGCAATGCTTTGTATGGC 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220

DB 806 CCAGGGGGGCGCCCTGGCGCGACGCTTC-CTGCCCCGCGCGGGCGAGCGGCACTTCGACCA 864

QY 220 nAspGluArTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240

DB 865 AGATGAGCGTGTGTCTGAGCGCGCGCGCGCAACCTGTGTGTGTGTGTGTGTGTGTGTGT 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

DB 925 CGAGATCGGTACACGCTTGGCTTCCCTCACCTCCGCGCGCGCGCGCTCAATGGCGGCC 984

QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280

DB 985 CTACTACAGAGGCTGGGCGCGCGCGCTGTCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300

DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGTCCAGGAAAGCTGTT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320

DB 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGGCGCTTGAACGCGAGGG 1164

QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340

DB 1165 CCCTAATACTGCCACTCTTCTTCGATGCCATCCTCAGTAGACAGGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360

DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380

DB 1285 TCCACTCGAGAAAGATGGGTGCGGCTGCGCCCCCAACATTGAGGCTCGGCAGTGTCAAT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400

DB 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGGCTGCCCGGCCCATCTCTGACGC 1464

Qy	420	aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheIysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTCCCTCTCTGGCGCCCTCATCTCTTCAAGGGTGCCTACTACGT	1524
Qy	440	lLeuAlaArgGlyVGLyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTtpGl	460
Db	1525	GCTGGCCCGAGGGGAGCTGCAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGCTCAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTtpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCCTCGACCAAGGCCAATCTGCAGCAACCACTCGGGCG	1704
Qy	500	gTtpAlaThrGluLeuProTtpMetGlyCysTtpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAATCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 149			
ADI63292			
XX	ID	ADI63292 standard; cDNA; 1985 BP.	
XX	AC	ADI63292;	
XX	XX	22-APR-2004 (first entry)	
XX	XX	Novel human secreted and transmembrane protein PRO4339 cDNA.	
XX	XX	Human; secreted and transmembrane protein; PRO; secreted polypeptide;	
KW	KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;	
KW	KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;	
KW	KW	rectum; kidney; cervix; liver; microvascular endothelial cell;	
KW	KW	glucose uptake modulator; FFA uptake modulator; cell proliferation;	
KW	KW	cell differentiation; skeletal muscle cell; adipocyte cell;	
KW	KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;	
KW	KW	endothelial cell tube formation; bone disorder; cartilage disorder;	
KW	KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	
KW	KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;	
KW	KW	immune system cell infiltration; chromosome mapping; gene mapping;	
XX	XX	gene therapy; chromosome identification; chromosome marker; gene; ss.	
OS	XX	Homo sapiens.	
XX	XX	US2003207387-A1.	
XX	XX	06-NOV-2003.	
XX	XX	29-MAY-2002; 2002US-00157801.	
XX	XX	05-JUN-2000; 2000US-0209832P.	
PR	PR	01-DEC-2000; 2000WO-US032678.	
PR	PR	19-DEC-2001; 2001US-00028072.	
XX	XX	(GETH) GENENTECH INC.	
PA	PA	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;	
PI	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
DR	DR	WPI; 2003-901068/82.	
DR	DR	P-PSDB; ADI63293.	
XX	XX	Two hundred and seventy five nucleic acids encoding PRO polypeptides,	
PT	PT	useful for treating paricyte-associated tumors, diabetes and various bone	
PT	PT	and/or cartilage disorders, e.g. arthritis.	
XX	XX	Claim 2; SEQ ID NO 143; 637pp; English.	

Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTCTACCGCCTGGTG 625
Qy 141 AsnTrrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCGCGAGCGCGAGTCTGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArGTrpSerSerGlyVArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGAGCAACGTCCTGAGCTGAGTCTTGGAGAGCCCGCAGCCAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCCAAAGGGACCAACAACGATGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArGTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyVArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCTGAGCGCGCGCGGGCGCAACTGTTCTGTGTCTGGCGCA 924
Qy 240 eGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrrLyysArgLeuGlyVArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAAGAGCGTGGCGCGCGCTGCTCAGCTGGAGCGACGCTGCGCGGTGCA 1044
Qy 280 nSerLeuTyrrGlyLyysProLeuGlyLyysSerValAlaValGlnLeuProGlyLyysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGCGGCCCTGAAACGCAGGG 1164
Qy 320 yProLyssTyrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCACACGCAACTGT 1224
Qy 340 rIlePheLyssGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrrPhePheLyssGlyLyysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLyysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCGCCCATCTCAGCG 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLyssGlyAlaArgTyrrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGCGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyLyysLeuGlnValGluProTyrrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCGCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGCGCGCTTCCCGAGGGCCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLyssLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACGAGGCCAAACTGCGAGGCAACCACTCGGGCGG 1704

Qy 500 gTrrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCAGCTGCCCTGGATGGGCTGCTGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 150
ADH81706
ID ADH81706 standard; cDNA; 1985 BP.
XX AC ADH81706;
XX AC
DT 22-APR-2004 (first entry)
XX XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
XX US2003207388-A1.
XX XX
XX 06-NOV-2003.
XX XX
XX 29-MAY-2002; 2002US-00157802.
XX XX
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-901069/82.
DR P-PSDB; ADH81707.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 143; 648pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells, for
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADH81706 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTropGlyHisLeu 20
 DB 206 ATGGTCGCGCGGTGCGGCTCTCTGTCGCGCGGCTCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGGAGCGCGGAGCCAGGAGCTGCGCAAGAGCGGAGGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGGTTTCAGTGGGGTGTCCAGCTACCTGTGAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTGCGCCAGATGACTGTCTCCCGCTCGGGGTGTACAGATACCAACAGTTATGG 505
 QY 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 DB 506 GCTGGGCTGAGAGGATCAGTACATGTTGTGTAGACCGGACCAAAATGAGCGGTAAG 565
 QY 121 LysArgPheAlaLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 NAATGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGTGGAGTTCTGGAGGCGCCAGCCAGCCAGCGCCCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGCAATGCCCTTTATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgGlyGluAlaHisPheAspG1 220

DB 806 CACGGGGGGCGCTCTGGCGACGCTTC-CTGCGCGCGCGCGGAGCGCCTCTTCACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGGTGGCGCA 924
 QY 240 eGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CAGATCGGTACACGCTTGGCTCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLyservAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCACGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCAGCCCCCAAGAAAGCGCCCTTGAACCGCAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGTGGCGAGTGTCAFT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGCGGCGAGGGGCGCTGCCCGCCATCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTCTTCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAGCTGTGAGGACTGGGG 1584
 QY 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCCCTGAGGAGGTGAGCGCGCTCTCCAGGCGCGAGTGGCTCATCTCTTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGGCAACATGCGAGGCAACACCTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGTGGCATCGCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 151
 ADH81154
 ID ADH81154 standard; cDNA; 1985 BP.
 XX
 AC ADH81154;
 XX


```
Qy 280 nserLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGAGCCCTAGGCGGCTCAGTGGCGTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThraspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTTGGAGCTCCTCAGAGCCCAAGAGGCGCCCTGAAACGACGGG 1164
Qy 320 yProLysTyrCyvHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGCGAGCTGATGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyVlVArgCyvTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCyvArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGCTGCCGCCCATCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaAArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCCTCTCGCGCGGCTCATCTCTTCAAGGGTGCCTGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCGAGGATGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGGGGCGCTCGCGAGGCGCGATGGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCCAACTGCGAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCyvTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 152
ACD23924
ID ACD23924 standard; cDNA; 1985 BP.
XX
XX ACD23924;
AC ACD23924;
DT 26-AUG-2003 (first entry)
DE
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cycostatic;
KW antididiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing; gene; ss.
XX
```

```
OS Homo sapiens.
XX US2003032156-A1.
PN
XX
PD 13-FEB-2003.
XX
PF 06-MAY-2002; 2002US-00140474.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
```



```
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACCTTGGAGACTGGGACTCTCTACAGCCCCCAAGAGAGCGCCCTGAAACGACGG 1164
QY 320 yProlystYrCyseHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCGATGCCATCACTGTAGACAGGCCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGCCAGCTCTAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCACCTGCAGGAAGATGGTCCGGCTGCCGCCCAACATTGAGGCTGCCGCAGTGTCATT 1344
QY 380 uAsnAspGlyAspPheThrPhePheLysGlyValArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTCTTACTCTTCAAAGGGGGTCCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCyseArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCATCTCTAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGAGGTGAGCGGGCCCTGCCGAGGCCCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLenSerGlySerAlaLeuPh 520
Db 1705 CTGGCCCAACGAGCTGCCCTGGATGGGCTGCTGGCATGCACACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 153
ID ACA67065 standard; cDNA; 1985 BP.
XX ACA67065;
AC ACA67065;
XX
DT 23-JUN-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
anti-PRO antibody; diagnostic assay; gene expression; diabetes;
bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
hearing loss; coagulation disorder; stroke; heart attack; cardiast;
KW antidiabetic; anorectic; vulnerable; antithratic; osteopathic;
XX antirheumatic; auditory; cerebroprotective; angiogenic; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003004311-A1.
XX
PD 02-JAN-2003.
XX
PF 19-DEC-2001; 2001US-00028072.
XX
18-JUN-1997; 97US-0049911P.
PR
26-AUG-1997; 97US-0056974P.
PR
17-SEP-1997; 97US-0059113P.
PR
17-SEP-1997; 97US-0059115P.
PR
17-SEP-1997; 97US-0059117P.
PR
17-SEP-1997; 97US-0059122P.
PR
17-SEP-1997; 97US-0059184P.
PR
18-SEP-1997; 97US-0059263P.
PR
19-SEP-1997; 97US-0059352P.
PR
19-SEP-1997; 97US-0059588P.
PR
24-SEP-1997; 97US-0059836P.
PR
17-OCT-1997; 97US-0062250P.
PR
17-OCT-1997; 97US-0062285P.
PR
17-OCT-1997; 97US-0062287P.
PR
17-OCT-1997; 97US-0063755P.
PR
24-OCT-1997; 97US-0062814P.
PR
24-OCT-1997; 97US-0062816P.
PR
24-OCT-1997; 97US-0063045P.
PR
24-OCT-1997; 97US-0063082P.
PR
24-OCT-1997; 97US-0063127P.
PR
27-OCT-1997; 97US-0063327P.
PR
27-OCT-1997; 97US-0063329P.
PR
28-OCT-1997; 97US-0063550P.
PR
28-OCT-1997; 97US-0063561P.
PR
29-OCT-1997; 97US-0063704P.
PR
29-OCT-1997; 97US-0063733P.
PR
29-OCT-1997; 97US-0063735P.
PR
29-OCT-1997; 97US-0063738P.
PR
03-NOV-1997; 97US-0064248P.
PR
07-NOV-1997; 97US-0064809P.
PR
12-NOV-1997; 97US-0065186P.
PR
17-NOV-1997; 97US-0065846P.
PR
21-NOV-1997; 97US-0066364P.
PR
24-NOV-1997; 97US-0066453P.
PR
24-NOV-1997; 97US-0066511P.
PR
24-NOV-1997; 97US-0066770P.
PR
11-DEC-1997; 97US-0069212P.
PR
11-DEC-1997; 97US-0069278P.
PR
11-DEC-1997; 97US-0069334P.
PR
16-DEC-1997; 97US-0069694P.
PR
23-JAN-1998; 98US-0072320P.
PR
04-FEB-1998; 98US-0073612P.
PR
09-FEB-1998; 98US-0074086P.
PR
09-FEB-1998; 98US-0074092P.
PR
12-MAR-1998; 98US-0077791P.
PR
20-MAR-1998; 98US-0078910P.
PR
25-MAR-1998; 98US-0079294P.
PR
27-MAR-1998; 98US-0079663P.
PR
31-MAR-1998; 98US-0079728P.
PR
12-JUN-1998; 98WO-US012456.
PR
14-JUL-1998; 98WO-US014552.
PR
28-AUG-1998; 98WO-US017888.
PR
10-SEP-1998; 98WO-US018824.
PR
14-SEP-1998; 98WO-US019093.
PR
14-SEP-1998; 98WO-US019094.
PR
14-SEP-1998; 98WO-US019177.
PR
16-SEP-1998; 98WO-US019330.
PR
17-SEP-1998; 98WO-US019437.
PR
07-OCT-1998; 98WO-US021141.
PR
29-OCT-1998; 98WO-US022991.
PR
29-OCT-1998; 98WO-US022992.
PR
20-NOV-1998; 98WO-US024855.
PR
01-DEC-1998; 98WO-US025108.
PR
05-JAN-1999; 99WO-US000106.
PR
08-MAR-1999; 99WO-US005028.
PR
10-MAR-1999; 99WO-US005190.
PR
20-APR-1999; 99WO-US008615.
PR
14-MAY-1999; 99WO-US010733.
PR
02-JUN-1999; 99WO-US012252.
PR
01-SEP-1999; 99WO-US020111.
PR
08-SEP-1999; 99WO-US020594.
PR
```

```

PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-352836/33.
DR P-PSDB; ABU80941.
XX
PT New isolated PRO polypeptide useful for treating diabetes, rheumatoid
PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
PT heart attack.
XX
PS Claim 2; Fig 143; 643pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the treatment of diabetes, bone and/or cartilage disorders
CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
CC assays for PRO, by detecting its expression in specific cells, tissues or
CC serum, and for affinity purification of PRO from recombinant cell culture
CC or natural sources. ACA66994-ACA67268 represent cDNA sequences encoding
CC the human PRO polypeptides of the invention. Note: The sequence data for
CC this patent was obtained in electronic format directly from the USPTO web
CC site at seqdata.uspto.gov/psipdbEntry.html
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

```

```

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

```

US-10-791-980-6 (1-520) x ACA67065 (1-1985)

```

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
|||||

```

```

Db 206 ATGCTCGCGCGCTCGCTCTCTGCTCGCGCCCTGCTACTGTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
|||
Db 266 GACGCCAGCCGCGGAGCGCGGAGCTGGCGCAAGGAGGCGGAGGCAATTCCTA 325
|||
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
|||
Db 326 GAGAGTACGATACCTCAATGAACAGTCCCCAAGCTCCACCTCCACTCGATTGAGC 385
|||
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
|||
Db 386 GATGCCATCAGAGCGTTTCAGTGGTGTCCAGCTACTGTGACGCGGTGTGGACCGC 445
|||
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
|||
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
|||
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
|||
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTGCTAGACACCGGACCAAAATGAGCGGTAA 565
|||
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
|||
Db 566 AACCGCTTTCAAAGCAAGGTAACTAATGTGTACAAAGCAGCACCTCTCTACCGCTGTG 625
|||
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
|||
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTGTGGGGCGCGCGCTTCCAG 685
|||
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
|||
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGACCCCGGACACAGGCCCGCTGAC 745
|||
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrTrpAlaMetProLeuMetAl 200
|||
Db 746 ATCGGCTCACTTCTTCCAAAGGGGACACAAACGATGGGTGGGCAATGCTTTGTATGCG 805
|||
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
|||
Db 806 CCAGGGGGCGCCCTGGCGGACGCGCTTC-CTGCCCGCGCGGCGGAGCGCACTTCGACCA 864
|||
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
|||
Db 865 AGATGACGCTGTGTCCTCGAGCGCGCGCGGGCGCACTGTTCGTGTGTGGCGCA 924
|||
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
|||
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
|||
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
|||
Db 985 CTACTCAAGAGGCTGGCGCGCGGAGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044
|||
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
|||
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGCAAGAGTGT 1104
|||
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
|||
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCGCTGAAAGCGCAGG 1164
|||
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
|||
Db 1165 CCCTAAATATCTGCCACTCTCTTCGTATGTCATCCTGTAGACAGGCAACAGCAACTGTA 1224
|||
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
|||
Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
|||
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
|||
Db 1285 TCCACTGCAGAAAGATGGGTGCGGCTGCCCGCCCAACATTTGAGGCTGCGGCGAGTGTCA 1344
|||

```


Db 446 GCCACCCCTGCCAGATGACTGCTCCCGCTGCGGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTpaAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTGCTAGACACCGGACCAAAATAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGGCTTGTCAAAAGCAGAGTAAACAAATGGTACAGCAGACCTCTCTCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheValAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCCTGAGCATCTGCCGAGCCGCGCATTTGGGGGCGCGTGGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTTTCCCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGCTGGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 tTyrTrpLysArgLeuGlyArgAspAlaLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAGAGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTTACTCTTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 gProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGGGAGGGGGGCTGCCCCGCCATCTCGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
Qy 440 lleuAlaArgGlyLysLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGGCCCTTACTACCCCCGAACTCTGCGAGGATGGG 1584

Qy 460 yGlyIleProGluValSerGlyAlaLeuPurArgProAspGlySerIlelePhePh 480
Db 1585 AGGCATCCCTTGAGAGGTACAGCGCGCCCTGCGGAGCGCGATGGCTCCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGAGACCGCTACTGGCGCTTCGACACGAGGCAAACTCGAGCAACACCTCGGCGCG 1704
Qy 500 gTTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGACCGAGCTGCCCTGGATGGCTGCTGCGATGCGCAACTCGGGGAGCGCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 155
ADN15722
ID ADN15722 standard; cDNA; 1985 BP.
XX AC ADN15722;
XX 17-JUN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003087353-A1.
XX 08-MAY-2003.
XX 22-APR-2002; 2002US-00127826.
XX 17-JUN-1998; 98US-0089532P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801138/75.
DR P-PSDB; ADN15723.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (i) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (ii) encoding (i) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(i)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (i) and (ii) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 11 Gaps: 0

US-10-791-980-6 (1-520) x ADN15722 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGCGCGGTGGCTCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCACGCCCGGAGCGCGGAGCCAGAGCTGCGCAAGGAGCGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCACTCGATTGACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGGTGTCCAGCTACCTGTGAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 DB 506 GCCTGGCTGAGAGGATCAGTGACTGTTTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnLysAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAACTGGTTACAGACGACACTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTTGACATCTGCGGAGCGCGGAGTTGCGGGCGCTGCGGGCGCCCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGCG 805

QY 200 aGlnGlyAlaProTrpArgThrPrpPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGGCGCTCTGGCGCACGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgLenLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGTGTCCTCGAGCGCGCGCGGCGCAACCTGTTCTGTGTGTGCGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCACCACTCTGCGCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 tTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGCGTGGCGCGCGCGCTGCTCAGTGGGACGAGCTGCTGGCCGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACTTGGACTCTCTACAGCCCCCAGAGGCGCCCTGAAACGCGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCTCATCTGTAGACAGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCCAATTTCTGGAGGTGGCAGCTGTATGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLeu 380
 DB 1285 TCCACTGAGGAAGATGGTGGCTGCCCCCCAACATTGAGGCTGGGCGAGTGCATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCCATCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCCTCTCTTCTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAACTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGCGGGCTGCGCGAGGCCGATGGCTGCATCATCTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATACCGCTACTTGGCGCTCGACAGGCCAAATCGCAGGCAACACCTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGTGCCTGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765

RESULT 156

ADN16351

ID ADN16351 standard; cDNA; 1985 BP.

XX

AC ADN16351;

XX 17-JUN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss;
XX Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS US2003087385-A1.
XX PN 08-MAY-2003.
XX PD 28-AUG-2002; 2002US-00230417.
XX PF 09-DEC-1999; 99US-0170262P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-801153/75.
DR P-P5DB; ADN16352.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; SEQ ID NO 143; 644pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (II) and (I) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1-93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	11	Gaps:	0

US-10-791-980-6 (1-520) x ADN16351 (1-1985)

Qy	1	MetValalaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCGCGCTCTCTGTCGCGCCCTCTGTCGAGCTGCTACTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCCGCGGAGCGGAGCCAGAGCTGCGCAAGAGGCGGAGGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGNAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACTGTGACGGCGGTGTTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTACTTGTCTTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTCCAAAGCAAGGTAACAATGGTACAAAGCAGCACCTCTCTACCGCTGCTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACGTGGCTGAGCATCTGCCGAGCGCGAGTTCCGGGGCGCCGTCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCCGCGCGGCGGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGACGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCCTCACCTGCTGCCCGCGCGCGCGCTCATGGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGGCGCGGACGCGCTGCTCAGCTGGAGACGAGCTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGTCCAGCTCCACAGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGGG	1164

```
QY 320 yProlystYrCyseHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATAGTCCCACTCTCTCCATGATGCATCACTGTAGACAGGCAACAGCTGTA 1224
QY 340 rIlePheLyGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTTGGAGAGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGTGCGGCTGCCCCACACATTGAGCTGCGGAGTGCATT 1344
QY 380 uAsnAspGlyAspPheTyPhePheLyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTCAAGAGGGGTGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCCAAGCTGTGCCGGCAGGGGGCCCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLyGlyAlaArgTrpTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGTGCGCGTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCGCGATGGCTCCATCTCTT 1644
QY 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLyLeuGlnAlaThrThrSerGlyVa 500
Db 1645 CCGAGATACCGCTACTGCGCTCGACCAGGCCAACTGCAGGCAACCACTTCGGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 157
ADN15170
ID ADN15170 standard; cDNA; 1985 BP.
XX
AC ADN15170;
DT 17-JUN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
OS
PN US2003087356-A1.
XX
XX 08-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127830.
XX
XX 15-SEP-1998; 98US-0100390P.
PR 01-SEP-1999; 99WO-US020111.
```

```
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
```

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-801141/75.

P-PSDB; ADN15171.

New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
and for manufacturing a medicament for diagnosing or treating tumor.

Claim 2; SEQ ID NO 143; 637pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in paricycle
cells, for stimulating the release of proteoglycans from cartilage, for
stimulating the proliferation of inner ear intracellular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from BMC cells, for inhibiting the binding of
A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or
knockout animals which in turn are useful in the development and
screening of therapeutically useful reagents, in gene therapy, for
chromosome identification, as chromosome marker, and for generating
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
detecting its expression in specific cells, tissues or serum, and for
affinity purification of PRO from recombinant cell culture or natural
sources. (I) and (II) are useful for tissue typing. This sequence encodes
a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	11	Gaps:	0

US-10-791-980-6 (1-520) x ADN15170 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db	206	ATGTCGCGCGCGTCTCTCTGCGCCCTGTCAGCTGCTACTGTGGGCGCCACCTG 265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLyGluAlaGluAlaPheLeu 40
Db	266	GACGCCAGCCCGCGGAGCGCGGAGCGAGCTGCGCAGAGGCGCGGAGCATTCCTA 325
QY	41	GluLySerGlyTyrLeuAsnGluGlnValProLyAlaProThrSerThrArgPheSer 60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCCACTCCGATTCAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db |||||
386 GATGCCATCAGACCGCTTTTCAGTGGGTGTCACAGCTACCTGTTCAGCGGGCTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db |||||
446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGATTATGCG 505

Qy 101 AlanTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db |||||
506 GCGTGGGCTGAGAGGATCAGTGACTTGTTCAGACACCGGACCAAAATGAGGGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db |||||
566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACTCTCCTCAGCGCGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db |||||
626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db |||||
686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCCTGGGAGGCCACAGGCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db |||||
746 ATCCGGCTTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db |||||
806 CCAGGGGGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db |||||
865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db |||||
925 CGAGATCGGTACACGCTTGGCTTCCACCATCGCCCGCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db |||||
985 CTACTACAGAGGCTGGCGCGGACGCGCTGCTCAGCTGGGACGCGTGTGGCGGTGCA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db |||||
1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db |||||
1105 CACTGACTTTGAGACCTGGGACTCTCAGCCCCCAAGAAAGGCGCCCTGAAACGCAAGG 1164

Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLey 340
Db |||||
1165 CCTAAATACTGCCACTCTCTCTTCGATGCCACTCAGTACAGGCAACAGCACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db |||||
1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284

Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db |||||
1285 TCCACTGAGAAAGATGGTGGGGTGCCTCCCAACATTGAGGCTGGCGAGGTGTCATT 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db |||||
1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db |||||
1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCGCTGCCCGCCATCTCAGCGC 1464

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db |||||
1465 CGCCCTCTTCTTCTCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTACTACGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db |||||
1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCGAGGACTGGG 1584

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db |||||
1585 AGGCATCCCTGAGGAGGTGAGCGCGCCTGCCGAGGCCGATGCTCCATCATCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db |||||
1645 CCGAGATGACCGCTACTGGCGCCTCGACGAGGCCAACTGCGAGCAACCCACTCGGGCG 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db |||||
1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCATGCCAACTCGGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db |
1765 C 1765

RESULT 158
ADN14618
ID ADN14618 standard; cDNA; 1985 BP.
AC ADN14618;
XX
DT 17-JUN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087357-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127832.
XX
PR 09-SEP-1998; 98US-0099536P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801142/75.
DR P-PSDB; ADN14619.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and


```
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACACGCTTGGCCCTACCCACTCGCCGCGCGCTCATGCGGCC 984
Qy 260 oTyTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAGAGCTGGCGCGACCGCTGCTCAGCTGGAGCAGCTGCTGCGCGTGA 1044
Qy 280 nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTCACTTTGAGACTGGGACTCTTACAGCCGCCCAAGGAGCGCCTGAAACGCGAGG 1164
Qy 320 yProLysTyTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATATCTGCCACTTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCATT 1344
Qy 380 uAsnAspGlyAspPheTyTyPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGCCCTGCCCGCCATCTCGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGAGCTCAAGTGGAGCCCTACTACCCCGAAGCTGTCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTTCCGAGGCCCGGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGCCAAACTGCAGGCAACCCACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 c 1765
RESULT 160
ADI64793
XX ADI64793 standard; cDNA; 1985 BP.
XX ADI64793;
XX ADI64793;
XX 16-DEC-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
```

```
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
OS US2003207386-A1.
XX PN 06-NOV-2003.
XX PD 29-MAY-2002; 2002US-00157800.
XX PF 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX XX (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2003-901067/82.
XX DR P-PSDB; ADI64794.
XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX PS Claim 2; SEQ ID NO 143; 636pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or PFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proteoglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various
XX mammalian haemoglobin-associated disorders such as various thalassemias
XX and conditions which may benefit from enhanced local immune system cell
XX infiltration. This sequence represents a human PRO polynucleotide of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
```



```
Db      1345  GAAATGATGGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGTTCGGGGCCCCAA 1404
QY      400  pProValTrpGlyLeuProGlnLeuCyeArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCAGGGGCTGCCCGCCCATCTCTGACGC 1464
QY      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheGlyAlaArgTyrTyrVa 440
Db      1465  GCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
QY      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGCCCGAGGGGACTGCAAGTGAGGCCCTACTACCCCGCAAGCTGCAAGACTGGGG 1584
QY      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCTCAGGAGGTTCAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaIleGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAACTGCAGGCCAACCTCGGGCGG 1704
QY      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGTGCCTGGATGGGCTGTGGCATGCCAACTCGGAGCGGCTTGTT 1764
QY      520  e 520
Db      1765  C 1765

RESULT 162
ADD76328
ID  ADD76328 standard; cDNA; 1985 BP.
XX
AC  ADD76328;
XX
DT  29-JAN-2004 (first entry)
XX
DE  Human PRO polynucleotide #72.
XX
KW  Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW  tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW  cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW  liver; microvascular endothelial cell; glucose; FFA;
KW  skeletal muscle cell; adipocyte cell; pericyte cell;
KW  inner ear utricular supporting cell; T-lymphocyte cell;
KW  endothelial cell tube formation; bone disorder; cartilage disorder;
KW  sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW  rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW  immune system cell infiltration.
XX
OS  Homo sapiens.
XX
PN  US2003100087-A1.
XX
PD  29-MAY-2003.
XX
PF  16-APR-2002; 2002US-00123912.
XX
PP  31-MAR-1997; 97WO-US005230.
PR  12-JUN-1998; 98WO-US012456.
PR  14-JUL-1998; 98WO-US014552.
PR  28-AUG-1998; 98WO-US017888.
PR  10-SEP-1998; 98WO-US018824.
PR  14-SEP-1998; 98WO-US019033.
PR  14-SEP-1998; 98WO-US019094.
PR  14-SEP-1998; 98WO-US019177.
PR  16-SEP-1998; 98WO-US019330.
PR  17-SEP-1998; 98WO-US019437.
PR  07-OCT-1998; 98WO-US021141.
PR  29-OCT-1998; 98WO-US022991.
PR  29-OCT-1998; 98WO-US022992.
PR  20-NOV-1998; 98WO-US024855.
PR  01-DEC-1998; 98WO-US025108.
PR  05-JAN-1999; 99WO-US000106.
PR  08-MAR-1999; 99WO-US005028.
PR  10-MAR-1999; 99WO-US005190.
PR  20-APR-1999; 99WO-US008615.
PR  14-MAY-1999; 99WO-US010733.
PR  02-JUN-1999; 99WO-US012252.
PR  01-SEP-1999; 99WO-US020111.
PR  08-SEP-1999; 99WO-US020594.
PR  13-SEP-1999; 99WO-US020944.
PR  15-SEP-1999; 99WO-US021090.
PR  15-SEP-1999; 99WO-US021547.
PR  05-OCT-1999; 99WO-US023089.
PR  29-NOV-1999; 99WO-US028214.
PR  30-NOV-1999; 99WO-US028313.
PR  01-DEC-1999; 99WO-US028409.
PR  01-DEC-1999; 99WO-US028301.
PR  01-DEC-1999; 99WO-US028634.
PR  02-DEC-1999; 99WO-US028551.
PR  02-DEC-1999; 99WO-US028564.
PR  16-DEC-1999; 99WO-US028565.
PR  20-DEC-1999; 99WO-US030095.
PR  20-DEC-1999; 99WO-US030911.
PR  20-DEC-1999; 99WO-US030599.
PR  22-DEC-1999; 99WO-US030720.
PR  30-DEC-1999; 99WO-US031243.
PR  30-DEC-1999; 99WO-US031274.
PR  05-JAN-2000; 2000WO-US000219.
PR  06-JAN-2000; 2000WO-US000277.
PR  11-FEB-2000; 2000WO-US000376.
PR  18-FEB-2000; 2000WO-US004341.
PR  22-FEB-2000; 2000WO-US004414.
PR  24-FEB-2000; 2000WO-US004914.
PR  01-MAR-2000; 2000WO-US005004.
PR  02-MAR-2000; 2000WO-US005501.
PR  02-MAR-2000; 2000WO-US005746.
PR  10-MAR-2000; 2000WO-US005841.
PR  15-MAR-2000; 2000WO-US006319.
PR  20-MAR-2000; 2000WO-US006884.
PR  21-MAR-2000; 2000WO-US007377.
PR  30-MAR-2000; 2000WO-US008439.
PR  17-MAY-2000; 2000WO-US013705.
PR  22-MAY-2000; 2000WO-US014042.
PR  30-MAY-2000; 2000WO-US014941.
PR  02-JUN-2000; 2000WO-US015264.
PR  28-JUL-2000; 2000WO-US020710.
PR  11-AUG-2000; 2000WO-US022031.
PR  23-AUG-2000; 2000WO-US023522.
PR  24-AUG-2000; 2000WO-US023328.
PR  08-NOV-2000; 2000WO-US030952.
PR  10-NOV-2000; 2000WO-US030873.
PR  01-DEC-2000; 2000WO-US032578.
PR  20-DEC-2000; 2000US-00747259.
PR  20-DEC-2000; 2000WO-US034956.
PR  28-FEB-2001; 2001US-00796498.
PR  01-MAR-2001; 2001WO-US006520.
PR  09-MAR-2001; 2001US-00802706.
PR  14-MAR-2001; 2001US-00808689.
PR  22-MAR-2001; 2001US-00816744.
PR  05-APR-2001; 2001US-00828366.
PR  10-MAY-2001; 2001US-00854208.
PR  10-MAY-2001; 2001US-00854280.
PR  18-MAY-2001; 2001US-00860216.
PR  25-MAY-2001; 2001US-00866028.
PR  25-MAY-2001; 2001US-00866034.
PR  25-MAY-2001; 2001WO-US017092.
PR  01-JUN-2001; 2001US-00872035.
PR  01-JUN-2001; 2001WO-US017800.
```



```
Qy 360 gProLeuGlnGluArgTrrpValGlyLeuProProAenlleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyVAspPheTyrPhePheLeVgGlyVgYstrPArgPheArgGlyVProLy 400
Db 1345 GAATGATGGAGATTTCATTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCyAAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGCTGCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPhePhyGlyAlaArgTyrVa 440
Db 1465 GCGCTCTTCTTCCTCTCGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 CTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGACTGGGG 1584
Qy 460 yGlyLeProGluGlnValSerGlyAlaLeuProProArgProAspGlySerllePhePh 480
Db 1585 AGGCATCCTGAGGAGTTCAGCGGCGCTGCGAGGCGCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTrrpArgLeuAspGlnAlaValSerGlyLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGTACTCGCGGCTCGACCGGCCAACTGACGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGCCTGGATGGGTGCTGGCATGCCAATCGGGAGCGGCGCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 163
ADD87692
ID ADD87692 standard; cDNA; 1985 BP.
AC
XX
XX
XX 29-JAN-2004 (first entry)
XX
XX Human PRO polynucleotide #72.
DE
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX
XX US2003092113-A1.
PN
XX
XX 15-MAY-2003.
PD
XX
XX 16-MAY-2002; 2002US-00147523.
PF
XX
XX 09-DEC-1999; 99US-0170262P.
PR
XX 01-DEC-2000; 2000WO-US032678.
PR
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
```

```
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-020237/02.
DR P-PSDB; ADD87693.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
SQ
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0
US-10-791-980-6 (1-520) x ADD87692 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGGTGGGCTCTCTGTCGGCCCTCTGTCGGCCCTGCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGCTGCGAGAGCTGCGAAGAGCGGAGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAATACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACCTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
```


Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTCTCCAGCTACCTGTGCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCGAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTCAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCTACCGCCCTGGTG 625
QY 141 AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGCAGTTTCGGGGCGCCGTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACAGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
Db 865 AGATGAGCGCTGTCCTCCTGAGCGCGCGCGGCGCAACCTGTTCTGGTGTGCGGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGGCGCGACGCGTGTCTAGCTGGGACGACGCTGCGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGACCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCACAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATAATGCGCACTCTCTCTCGATGCCATCACTGTGAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGTATGCAACGTTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProHennileGluAlaAlaAlaValSerIe 380
Db 1285 TCCACTGCAAGAAAGATGGTGGGCTGCGGCCCAACATTGAGGCTGCGGCAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTCGAGGTTCCCGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTTGGCCCGCCATCTTGACGC 1464
QY 420 alaLeuPhePheProProLeuArgGluIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCCTCATCTCTTCAAGGGGTGCGCGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCAGGGGAGTCAAGTGGAGCCCTACTACCCCCCGAGTCTGCAGAGCTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGCGGCGCCCTGCGAGGCCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCAAGGCCAACTGCAGGCAACCACTTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 164
ADD86096
ID ADD86096 standard; cDNA; 1985 BP.
XX
AC ADD86096;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203440-A1.
XX
PD 30-OCT-2003.
XX
PF 29-MAY-2002; 2002US-00157798.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-021363/02.
DR P-PSDB; ADD86097.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,936-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADD86096 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGGCGCGTCTCTGTCGCGCCCTGACGTGCTACTGTGGGCGCACCTG	265
Qy	21	AepAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCCGCGAGCGCGGAGCGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGGTGCCAAAGCTCCACCTCCACTCGATTCAGC	385
Qy	61	AepAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGGGGTGTGGACGCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCGCAGATCACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATCGC	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTTGGGCTGAGAGGATCAGTGACTGTGTGTAGACACCGGACCAAAATGAGGGGTAAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCCAAGCAAGGTAAACAAATGGTTACAGACGAGCACCTCTCTCCACCGCCTGTG	625
Qy	141	AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTCCGAGCGCGAGTTCGGGGCGCGGTGCGCGCCGCTTCCAG	685

Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCGGCTCACCTTCTTCCAAGGGGACACACGATGGGCTGGGCATGCTTGTATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAGCGACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGTGGTCCCTGAGCGCGCCCGCGGGCGCAACTGTTCTGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTCACCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGCTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAACGCGAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCGCACTCTCTTCGATGCGCATCACTGTAGACAGGAACAACGACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAGGGAGGCCATTTCTGGGAGGTGGGAGCTGTAGGCCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTTCGGGCTGCCCCCAACATTGAGGCTCGCGCAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCGGGGCAGGGGGCTGCCCGCCCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTCTTCCTCTCTCGCGCGCTCATCTCTTCAAGGGGTGCCCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCCGAGGGGAGCTGCAAGTGGAGCGCTACTACCCCGAAGTCTGCGAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCTCTGAGGAGGTGAGCGCGCTCGCCGAGGCCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACGCTACTTGGCGCTTCGACCGAGGCCAAACTGCAGGCAACCACTCTGGGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGTGCCTTGGATGGGCTGCTGCGTCCCACTCGGGGAGCGCCCTGTT	1764

Pred. No.:	1-93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0
US-10-791-980-6 (1-520) x ADE23120 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGGCTCGGCTCTCTGCTGCGCGCTCGACGTGCTACTGTGGGCGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCGACCGCGGAGCGCGAGGCCAGGAGCTGCGCAGGAGCGCGGCGCATTCCTA	325
Qy	41	GluLysTyGlyTyzLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTAGCGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTCAGTGGGTGTCACAGCTACCTGTGAGCGCGGTGTGGACGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyraLa	100
Db	446	GCCACCTCGCCGACGATGACTGCTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAenLysTrpTyzLysGlnHisLysSerTyzArgLeuVal	140
Db	566	AAACGCTTTGGCAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTACCGCTGTTG	625
Qy	141	AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCACTCTGCGGAGCGCGAGTTTCGGGGCGCGCTGCGCGCCCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCCGCCCTGCAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCCGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGCTCCCTCAGCGCGCGCGCGCGCAACCTGTTCTGCTGCTCGCGCA	924
Qy	240	aGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CCAGATCGGTCAACGCTTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGCGGCC	984
Qy	260	oTyzTyzLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAGAGCGTGGGCGCGAGCGCGTCTCAGCTGGGACAGCTGCTGGCGCGTGA	1044
Qy	280	nSerLeuTyzGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGAGACCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyzSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CAGTACTTTGAGCTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTGAAACAGCGG	1164

Qy	320	yProLysTyzCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTGATGCCATCACTGTAGACAGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGCACAGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaAlaValSerLe	380
Db	1285	TCCACTGTCAGGAAGAATGGTCCGGCTGCCCCCAACATTGAGGCTGCGGCACTGTCATT	1344
Qy	380	uAenAspGlyAspPheTyzPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	gProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCCGGGACAGGGGCTGCCCGCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyzTyra	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyzTyzProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGAGCTGCAGTGTGAGCCCTTACCCCCGAAAGTTCAGAGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCTCTGAGGAGGTGAGCGCGCTGCGAGGCGCGATGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyzTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATCACCGCTACTGGCGCTCGACCGCCAACTGCAGGCAACACCATCTCGGGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCGCTGGATGGGCTGTGGCATGGCAACTCGGGGAGCGCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 167			
ADE23672			
ID	ADE23672 standard; cDNA; 1985 BP.		
XX	AC ADE23672;		
XX	29-JAN-2004 (first entry)		
DE	cDNA encoding human PRO polypeptide #72.		
KW	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; PFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
OS	Homo sapiens.		
PN	US2003092110-A1.		
XX	15-MAY-2003.		
PD	03-MAY-2002; 2002US-00137864.		
XX			

PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-020235/02.
DR P-PSDB; ADE23673.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; Fig 143; 637pp; English.
PS
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
XX the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,938-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADE23672 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTGGCCCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCCAAGCCCGAGCGCGAGGCCAGGAGCTGCCAAGGAGCGGAGCGGCATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACATTCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCACTGGGTGTCAGCTACTGTACGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
DB 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAGCGTTTGCNAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGTGGAGGCCCGCAGCCAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTTATGTCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCGCTTGGCGCAGCGCTTC-CTGCCCGCGCGCGCGCGCGCTCATGGGCCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCTCTAGCGCCCGCGCGCGCGCGCGCGCGCTGTGTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACGCTTGGCCTCACCACTCGCCCGCGCGCGCGCGCTCATGGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCGCTGAAAGCGCAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATATCTGCGCACCTCTCTTCGATGTCATCCTCCTGTAGACAGGCAACAGCAACTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGAGCCATTTCTGGAGAGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
DB 1285 TCCACTCGAGGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTGCGGCGAGTTCATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCCA 1404

antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADB87140 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGGCTCTGCTGCGCGCCCTGCGAGCTGCTACTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCCGGAGCGCGGAGCGGAGCTGCGCAAGGAGCGGCGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTCTGTACGCGGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGATTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGMAAGCAAGGTAAACAAATGGTACAGAGCAGCACCTCTCCATCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCATCTGCGGAGCGCGCAGTTTCGGGCGCGCTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCGCCACAGCGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200

Db	746	ATCCGGCTCACTTCTCCAAAGGGGACCAACAACATGGGCTGGCAATGCCTTTGATGCG	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
Db	806	CCAGGGGGCGCCCTGGGGCGACGCTTC-CTGCCCCCGCGCGGCAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATAGCGCTGGTCCCTGAGCCCGCGCGGGGCGCACTGTTCGTGGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACGCTTGGCCTCACCACTCGCCCGCGCGCGCTCATCGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1	280
Db	985	CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGGCGCGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGACGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCGCACTCTCTCTTCGATGCTCCTCAGTACAGGCAACAGCAACTGT	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGCCATTTCTGGAGGTGGAGCTGATGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGAAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGCATGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCCGGGCCCA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
Db	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCTCTGAGAGGTACGCGCGCGCTGCCGAGGCCCGTGGCTCCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGGCGCTCGACCGGCCAAACTGCGAGGCAACCACTCGGGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheIleAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGTCATGCCAACTCGGGGAGCGCCCTGT	1764
Qy	520	e 520	
Db	1765	c 1765	

RESULT 170
ADEB9006

ID ADEB9006 standard; cDNA; 1985 BP.
XX
AC ADEB9006;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199062-A1.
XX
XX 23-OCT-2003.
XX
PF 17-APR-2002; 2002US-00124823.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019033.
PR 14-SEP-1998; 98WO-US019034.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028554.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005501.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Deansoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-041360/04.
XX P-PSDB; ADEB9007.
XX
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
XX hypo-insulinemia, sports injuries, arthritis, obesity, heart
XX attack, various coagulation disorders, tumors.
XX
XX Claim 2; SEQ ID NO 143; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems.
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,938-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADE89006 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGTGCGCGCGCTCGGCTCTCTGTCGCGCGCTCTGCTACTGTGGGCGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCCGCGCGAGCGCGGAGCCAGGAGCTGCGCAAGGAGCGCGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTCAGTGGGTGTCACGACTACCTGTGAGCGGCGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgProCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCGCCAGATCACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgLys 120
 DB 506 GCTCGGGCTGAGAGGATCAGTACTGTTGTGTAGACACCGGACCAAAATGAGCGGTAA 565
 QY 121 LysArgPheAlaLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 ANAOCCTTTCANAGCNAGGTAAACAAATGGTACAGACGACCTCTCTACCGCCCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 NAATGGCCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCCCTTCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAAGCTCTCAGCGCTGAGGTTCTGGAGGGCCCCAGCACAGGCCCGCGTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTCCAAGGGGACCAACAGATGGCTGGCAATGCCCTTTGATGGC 805
 QY 200 acInGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CAGGGGGCGGCTTGGCGACGCCCTTC-CTGCCCGCGCGCGGAGCGACATTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGCTCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGCTGGCGCA 924
 QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACAGCTTGGCTCACCACCTCGCGCGCGCGCTCATGCGCGC 984
 QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGTGCTGCGCGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
 QY 300 eThAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAAATACTGCGCACTCTCTTCGATGCCATCACTGTAGACAGGCAACACGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGTGGGCGAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGGAGCTCTGACGAGCTGGGG 1584
 QY 460 yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
 DB 1585 AGGCATCTCAGGAGGTGACGGCGCCCTGCCGAGGCCGATGGCTCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGCGCCAAACCTGAGGCAACCCACCTCGGGCGC 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGCCGACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 171
ADE18145
ID ADE18145 standard; cDNA; 1985 BP.
XX
AC ADE18145;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194794-A1.
XX
PD 16-OCT-2003.
XX
PF 17-APR-2002; 2002US-00125805.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018894.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US0008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 15-SEP-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030929.
PR 22-DEC-1999; 99WO-US030799.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-021079/02.
DR P-PSDB; ADE18146.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, for use in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX

Db 1645 CCGAGATGACCGCTACTGCGCCCTCGACCGCCAAACTGCGAGCAACCTCGGCGCG 1704

Qy 500 gTTPAlaThrGluLeuPrtPpMetGlyCytrPheAlaAAsnSerGlySerAlaLeuPh 520
|||||

Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

Qy 520 e 520

Db 1765 C 1765

RESULT 172

AD888454

ID AD888454 standard; cdNA; 1985 BP.

XX AC AD888454;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; PFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; r-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

XX US2003199054-A1.

XX 23-OCT-2003.

XX 12-APR-2002; 2002US-00121054.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 10-MAR-1999; 2000WO-US006319.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 03-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US005841.

PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001WO-US006520.

PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.

PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.

PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.

PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.

PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritken ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2004-041356/04.

DR P-PSDB; ADE88455.

XX Novel secreted and transmembrane polypeptides, PRO useful for treating
PT bone disorders, arthritis, heart attack, injuries, tumors, and
PT stimulating release of TNF-alpha from human blood.

XX Claim 2; SEQ ID NO 143; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADE88454 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGGCGCGCTCGCTCTCTGTCGGCCCTCGAGCTGCTACTGTGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGAGCGCGGAGGCGGAGGAGTGCACAGGAGGCGGAGGCGATTCTTA	325
Qy	41	GluysrTyGlyTyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACCGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGGCGGTGTGGACCCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505

Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTCCGAGCGGAGTTCGGGGCGCGCTGCGGCGCCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyVArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGACAACGCTCTCAGCGCTGGAGTCTGGGAGGCCCCCAGCCAGGCCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGCGAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyVArgHisLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTTGAGCGCGCGCGCGCAACCTGTTCTGGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGCGGCC	984
Qy	260	oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATATCTGCGCACTCTCTTCGATGCGCATCACTGTAGACAGGCAACAGCACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyValSerGluProAr	360
Db	1225	CATTTTTAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGGTGGGCTGGCGCTGCCCCCAACATTCGAGGCTGGCGCAGTGT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCCGCCATCTCTGAGCG	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGAGTGCAGAGTGGAGCGCTACTAGCCCCCAAGTCTGCGAGGACTGGG	1584

Qy 460 yGlylleProGluValSerGlyAlaLeuProArgProAspGlySerllellePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTACGGCGCCCTCCGAGGCCGATGCTCCATCATCTCTTT 1644
 Qy 480 eARAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATACCGCTACTGGCCCTCGACCAAGCCCAACTGCGAGCAACCACTCGGCGG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGATGCCCAACTCGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 173
 ADE94474
 ID ADE94474 standard; cDNA; 1985 BP.
 XX AC ADE94474;
 XX DT 12-FEB-2004 (first entry)
 XX DE cDNA encoding human PRO polypeptide #72.
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX OS Homo sapiens.
 XX PN US2003199027-A1.
 XX PD 23-OCT-2003.
 XX PF 20-MAY-2002; 2002US-00152396.
 XX PR 01-MAR-2000; 2000WO-US005601.
 XX PR 01-DEC-2000; 2000WO-US032678.
 XX PR 19-DEC-2001; 2001US-00028072.
 XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2004-059538/06.
 XX P-PSDB; ADE94475.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 XX useful for treating pericyte-associated tumors, diabetes and various bone
 XX and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; Fig 143; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 XX polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0
 US-10-791-980-6 (1-520) x ADE94474 (1-1985)
 Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGCGCGGTTCAGTGGTGTCCAGCTACCTGTGCGGCTGCTACTGTGGGCCACTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCGCGGAGCGCGAGCGCAGGAGCTGCGCAAGGAGGCGGAGGCGATTCTTA 325
 Qy 41 GlutylsTyrGlyTyrLeuAsnGluValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGGGTTTCAGTGGTGTCCAGCTACCTGTGCGGCGGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGATTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTACCTTTGCTAGACACCGGACCAAAATCAGGCGTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTrpLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGTGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysValaProProSerSe 160
 Db 626 AACTGGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGCTGCGGCGCGCTTCAG 685
 Qy 160 rCysGlyValaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGACACAGTCTCAGCGCTGAGGTTCCTGGGAGGCGCCCGCAGCCAGGCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACACACAGATGGCTGGCAATCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTGTCGCGACGCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValAlaHis 240
DB 865 AGATGAGCCTGCTGCTCAGCGCGCGCGCGCAACCTGTTGCTGCTGCGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACAGCTTGGCTCACCCACTCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGTGCTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAGACCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCGCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCGCTGATGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGTGCGGCACTGCTAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTCAAGGGGTGATGCTGGAGGTTCGCGGGCCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCCCGCATCTCGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
DB 1525 GCTGGCGCGAGGGGACTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 vGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGCATCTCTGAGGAGGTGAGGGGCGCTGCGGAGGCGCGATGGCTCCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACCAGGCCAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTyrPheMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCGACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 c 1765
RESULT 174

ABE90885
ID ADE90885 standard; cDNA; 1985 BP.
XX
AC ADE90885;
DT 12-FEB-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199061-Al.
XX
PD 23-OCT-2003.
XX
PF 16-APR-2002; 2002US-00123911.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00838366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-08602116.
PR 25-MAY-2001; 2001US-08660238.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001US-00210666.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2004-041359/04.
DR P-PSDB; AD90886.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; SEQ ID NO 143; 638pp; English.
PS
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADE90885 (1-1985)

Qy 1 MerValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCGCCCTCCCTGCGGCCCTGCGAGTGTACTGTGGGGCCACTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGAGCGCGAGGCGAGGCTGCGCAAGGAGGCGGAGGCAATCTCTA 325

Qy 41 GluLysTyrGlyTyrLeuArgGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCCATCAGAGGTTTCAGTGGGTGCCAGTACTGTGACGGCGGTGTTCGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGATTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisGlnThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGTCTTCTAGACACCGGACCAAAATGAGGCGTAAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAAACAATGGTTACAAGCAGCACCTCTCTCTACCGCTGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160

Db 626 AACTGGCCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCCCTGCGCGCCCTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCGCCAGCCACAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLeuGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTCTGCTGCTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTACACCTTGGCTTACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpLeuArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGTCTCAGCTGGGACGCTGCTGCGCGTGA 1044
Qy 280 nSerLeuTyGlyLeuProLeuGlySerValAlaValGlnLeuProGlyLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCGCAAGAGCGCCCTCGAAACGCGGG 1164
Qy 320 yProLysTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTTCTCTCGATGCCATCACTGTAGACGCAACACCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerle 380
Db 1285 TCACATGCAAGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCATGTCAAT 1344
Qy 380 uAenAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCNA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGCGGCGAGGGGCTGCCCGCCCATCTTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGGTGGCGCCGTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGAGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCTCTGACCGAGCCCAACTGCAAGGCAACCCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520

Db 1705 CTGGCCACCAGAGCTCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 175
ADE95026
ID ADE95026 standard; cDNA; 1985 BP.
XX
AC ADE95026;
XX
DT 12-FEB-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199052-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121052.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US024855.
PR 20-NOV-1998; 98WO-US025108.
PR 01-DEC-1998; 98WO-US000106.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.

Db 506 GCTGGGCTGAGAGGATCAGTGACTGTTGTTGTAGACACGGACCAAAAATGAGGCGTAAG 565
Qy 121 LyAArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACACAGCAGCACTCTCTACCGCCTGGTG 625
Qy 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaPProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACACACAGATGGGCTGGGCANTGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpPheLeuProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTGCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTACACGCTTGGCTTCCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAAGAGCTGGGCGCGAGCGCTGCTCAGCTGGAGCAGCTGCTGCGCGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAGAGGCGGCTGAAACCGAGGG 1164
Qy 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
Db 1165 CCCTAAATACTGCCACTTCTCTCGATGCCATCATCTGTAGACAGCAACACCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 pProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
Db 1285 TCACATGCAAGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 pProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCGGGGCAGGGGCGCTGCCCCCGCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTTACTACCCCCGAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCGCTGCGGAGGCCGATGGCTGCATCATCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTTGACCAAGGCCAAACTGACAGGCCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 176
ADE93136
ID ADE93136 standard; cDNA; 1985 BP.
XX
AC ADE93136;
DT 12-FEB-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199060-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123771.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.

```

PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028851.
PR 02-DEC-1999; 99WO-US028856.
PR 02-DEC-1999; 99WO-US028856.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030873.
PR 10-NOV-2000; 2000WO-US030878.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US0796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
FA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI
```

```

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-041358/04.
DR P-PSDB; ADE93137.
XX
XX Novel PRO polypeptide useful for treating diabetes, hyper or hypo
PT insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,
PT various coagulation disorders, tumors.
XX
XX Claim 2; Fig 143; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or for treating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
D: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADE93136 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGGCGCGGTCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGGAGGTCGCGAGGTCGCCAAGGAGGCGGAGGAGCATTCCTA 325
QY 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCATTCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGCGGTGTGTGACCGC 445
```

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
DB 446 GCCACCTCGCGCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGTATGCG 505
QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIlysMetArgArgIys 120
DB 506 GCTGGGCTGAGAGGATCAAGTGAATTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTTPtYrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTCGAAGCAGAGTAACAATGGTACAGCAGCACTCTCTACCGCCCTGGTG 625
QY 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSe 160
DB 626 AACTGGCCTGAGCATCTCGCGAGCCGCGAGTTTCGGGGCGCGTGCAGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCAAGCCACAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
DB 746 ATCCGCTCACCCTTCTCAAGGGGACCAACAGATGGGCTGGCAATGCCCTTTGATGC 805
QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCTGGAGCAGCCCTTC-CTGCCCCCGCGGGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTTPSerSerSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGCTCCTCAGCGCGCGCGGCGCAACCTGTTGCTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGGCGCGGCGCGCTGCTCAGCTGGGACGAGTGTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGTCCCAAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAGCGCGCTGNAACGCGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCAATTTCTGGAGGTGGCAGCTGATGCAACGCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaAlaValSerie 380
DB 1285 TCCACTGCAAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCATGTCAAT 1344
QY 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProly 400
DB 1345 GAATGATGAGATTTCTACTTTCTTAAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGAGGGGCGCTGCCCGCCATCCTGACGC 1464
QY 420 alaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460

DB 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAGTCTCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGGAGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGGCCAACTGCGAGGCACCACTCGGGCGG 1704
QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 177
ADF34717
ID ADF34717 standard; cDNA; 1985 BP.
XX ADF34717;
AC ADF34717;
DT 12-FEB-2004 (first entry)
XX cDNA encoding human PRO polypeptide #72.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS US2003199029-A1.
XX
XX
XX 23-OCT-2003.
XX
XX 22-MAY-2002; 2002US-00153840.
XX
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000MO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-041352/04.
DR P-PSDB; ADF34718.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful for molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,938-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADF34717 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGCTCTCGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGCGAGCGGAGAGCTGCGCAAGAGGCGGAGGCGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAAAGTACGGATACCTCAATGACAGGTCCCAAGCTCCACCTCCACTCGATTACGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTCAGTGGGTGTCGCCAGCTACCTGTGCGGGGTGTGGACGCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCAGATGACTGCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCCAAATGAGGGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACGCGCTGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTTGACATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180

Db	686	TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTGGAGAGCCCCCAGCACAGGCCCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA	864
Qy	220	nasGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATAGCGCTGGTCCCTGAGCCCCCGCGGGCGCAACTGTGTGTGTGTGTGTGTGTGTGT	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACACGCTTGGCCTCACCCACTGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACCTGCTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCGCTGAAGCGCAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTTAAATACCTGCCACCTCTCTTCGATGCGCATCCTGTAGACAGGCAACAGCAACTGT	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCAGGAAAGATGGGTGCGGCTGCCCGCGCGCGCGCTGCGGCGAGTGTCTATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCGCTGCCCGCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCT	1524
Qy	440	lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGGCTGGGG	1584
Qy	460	yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCCGAGGCGCGCGATGGCTCATCTCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTCGACCGAGGCGCAAACTGCAGGCAACCACTCGGGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCGCACCGAGTGCCTGGATGGGCTGTGCGATGCCAACTCGGGGAGGCGCGCTGT	1764
Qy	520	e 520	

Db 1765 C 1765
RESULT 178
ADE92032
ID ADE92032 standard; cDNA; 1985 BP.
XX AC ADE92032;
XX DT 12-FEB-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW Cell proliferation stimulator; cell differentiation stimulator;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX US2003199051-A1.
XX 23-OCT-2003.
XX 12-APR-2002; 2002US-00121048.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000108.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012254.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028651.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerriksen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-041354/04.
DR P-PSDB; ADE92033.
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX Claim 2; SEQ ID NO 143; 638pp; English.
PS The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBM cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1, 93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADE92032 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGTGTCGGCGCGTCCGCTCTCGTGGCGCGCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCCCGGAGCGCGGAGCCGAGGAGCTGCGCAAGAGCGCGAGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACCGCTTTTCAGTGGGTGTCCACAGCTACCTGTGAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCACACNGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGCTGAGAGGATCAGTCACTTTGTTGTAGACACCGGACCAAAATGAGGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAAAGCAGACCTCTCCTACCGCCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGACATCTGCCGAGCGCGCAGTGTGGGGCGCGTGGCGGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180

DB 586 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACTCTTCTCCAAAGGGGACCAACAGATGGCTGGGCAATGGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAGGAGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGACGGCTGTCTCCAGCGCGCGCGGGCGCAACCTGTTCGTGGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTCAACGCTTGGCCTCACCACTCGCGCGCGCGCGCTCATGGCGGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAAGAGCTGGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTCTATGGGAAGCCCTTAGGGGCTCAGTGGCGTCCAGCTCCAGGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGGCGCTGAAACGCGAGG 1164
 QY 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
 DB 1165 CCCTAATAATCTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTCTCAGAAAGATGGGTGGGCTGCGCCCCCAACATTAGAGCTCGGCAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGCTGGAGGTTCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGGCCGCTACTAGCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGATCCCTGAGGAGGTACGCGCGCCCTGCCAGGCCCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTTGGCGCCTTCGACGAGGCCAACTGCAGGCAACCACTCGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheAlaHisSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGTGTGGCATGTCCAACTCGGGAGCGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765

RESULT 179
ADE90333
ID ADE90333 standard; cDNA; 1985 BP.
XX AC ADE90333;
XX DT 12-FEB-2004 (first entry)
XX DE Human PRO polynucleotide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; prostate; breast; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003199063-A1.
XX PD 23-OCT-2003.
XX PF 19-APR-2002; 2002US-00125931.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-041361/04.
DR P-PSDB; ADE90334.
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX Claim 2; SEQ ID NO 143; 636pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADE90333 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTTCGCGCGGTGCGCTCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGGCCACGCCCGCGAGCGCGAGCCGAGGAGCTGCGCAGGCGGAGGCGGAGCATTCCTTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCTCCCAAGCTCCACCTCCATCGATTACG	385
Qy	61	AspAlaAlaArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTCAGTGGGTGTCCTCACTACCTGTGAGCGGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAAGATTATGCG	505
Qy	101	AlaTrpAlaGluArgTleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
Db	506	GCCTGGCTGAGAGGATCAGTGCTTGTGTGCTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisSerTyrArgLeuVal	140
Db	566	AAACCGCTTTGCCAAGCAAGGTAAACAATGGTACAGCAGCACTCTCTCCCTGGCTGGTG	625

Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACCTGGCTGAGCATTCGCCGAGCGCGAGTTCTGGGGCGCCCTGCGCGCCCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGAGCCCCAGCCACAGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGACCAACAGATGGGTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGGAAGCGACCTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACCTGTTCGTGGTGGCGCA	924
Qy	240	sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCGCGCGCGCGCTCATATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCCGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAGGGCCCTGAAGACGACGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAATATCTGCCACTCTTCTTCGATGCCATCCTCCTGTAGACAGCAACAGCACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGTATGGCAACGTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCAACATTTGAGGCTGGCGAGGTGTCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTCTTCTTCAAGGGGTGCGATGCTGGAGGTTCCGGGGCCCA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGCCCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTATCCCGCAAGTCTGCGAGGCTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCTCTGAGGAGGTACGGCGCCCTGCCGAGGCGCCGATGGCTCCATCATCTTCT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGTACCGCTACTGGCGCTCGACAGCCGCAAACTGCGAGGCAACCACTCTCGGGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520

```
|||||
Db 1705 CTGGCCACCGAGTGCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 180
ADE91480
ID ADE91480 standard; cDNA; 1985 BP.
XX
AC ADE91480;
XX
DT 12-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003199058-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123291.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
```

```
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020231.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-041357/04.
DR P-PSDB; ADE91481.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
```


Db 1705 CTGGGCCACCGAGCTGCCTCGATGGCGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 181
 ADG02059
 ID ADG02059 standard; cDNA; 1985 BP.
 XX
 AC ADG02059;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003207352-A1.
 XX
 PD 06-NOV-2003.
 XX
 PF 07-MAY-2002; 2002US-00140806.
 XX
 PR 03-MAR-2000; 2000US-0187202P.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, DeForge L, Deanoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI; 2004-051514/05.
 DR P-PSDB; ADG02060.
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; SEQ ID NO 143; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of

Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACTGTTCTGGTGGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACAGCTTGGCTTCCCTCACCCTCGCCCGCGCGCGGCTCATGGCGCC 984
Qy 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGAGTCTGGCGGTCA 1044
Qy 280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCNAGNAGGCGCTTGAACGCAGGG 1164
Qy 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCATGCTCATCTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCCATTCTGGGAGGTGGCAGCTGATGGCAACGTCCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheIysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGGAGGGGCTTGGCCCCCATCTTCGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGCTGCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGCAAGTCTCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGGCGCCCTTCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCCAACTGCAGGCCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 182
ID ADG21845
XX ADG21845 standard; cDNA; 1985 BP.
AC ADG21845;
XX
DT 26-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX

KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
XX US2003207360-A1.
XX 06-NOV-2003.
XX 08-MAY-2002; 2002US-00141757.
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-010596/01.
XX P-PSDB; ADG21846.
XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
XX useful for stimulating the release of tumor necrosis factor alpha from
XX human blood and in treating and detecting a tumor.
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proteoglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various
XX mammalian haemoglobin-associated disorders such as various thalassemias
XX and conditions which may benefit from enhanced local immune system cell
XX infiltration. This sequence represents a human PRO polynucleotide of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,938-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG21845 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGCTCGGCTCTGCTGGCGGCTCGAGCTGTACTGTGGGCGCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCGCGGAGCGGAGCGCAGAGCTCGCAAGGAGCGGAGGCATTCTCTA 325

QY 41 GluLysTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGAGCTCCACCTCCACTCGATTTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGCGCGGCTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCGCAGATGACTCTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCTTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGGGTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAGGTAAACAAATGGTACAGCAGCAGCTCTCTCCACCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTGCGGGCGCGTGGCGCGCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGCGCCCGTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACTCTTCCAGGGGACCAACAGATGGGCTGGGCATGCTTGTATGGC 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTGGCGCACGCTTC - CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTGTGTGTGTGTGTGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CAGATCGGTACACGCTTGGCTTACCCTCTGCGCGCGCGCGCGCGCTCATGGCGCC 984

QY 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGGCGCGAGCGCGCTGTCTCAGCTGGGAGCAGCTGTGCGCGTGA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCGTCCAGCTCCCGAGGAAGCTGTT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTTCCTACAGCCCCCAAGAGGCGCCCTTGAACGAGGG 1164

QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGCGAGCTGATGGCAACGTCTCGAGGCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCACCTGCAAGAAAGATGGTGGCTGCCCCCAACATTGAGGCTGCGGAGTGTCAATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGGCATCTCGACGC 1464

QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGCCCGAGGGGACTGCAAGTGGAGGCGCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGGCCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CGAGATGACCGCTACTTGGCGCTCGACAGGCGCAAACTGCAAGGCAACCACTCGGGCGG 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACAGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

QY 520 e 520
DB 1765 C 1765

RESULT 183
ADG19915
ID ADG19915 standard; cDNA; 1985 BP.
XX
AC ADG19915;
XX
DT 26-FEB-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207376-A1.
XX


```
Db 1285 TCCACTGCAGGAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTGCGCGCATGTTCATT 1344
Qy 380 uAenAspGlyVAspPheTyrPhePheLysGlyGlyAiqCysTirArgPheArgGlyProLys 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTTCATGCTGGAGGTTCGGGGCCCCCAA 1404
Qy 400 sProValTirGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCAGGGGCTGCCCGCCCATCTTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuLleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTGCGCGCCCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTirG 460
Db 1525 GCTGGCCCGAGGGGACTGCAGTGGAGGCTTACTACCCCGGAGTCTGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGCGGCTGCGGCGCCCTGCGGAGCGGCTGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTirArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTTGGCGCTCGACCAAGGCAAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTirAlaThrGluLeuProTirMetGlyCysTirHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCAACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 184
ADF97821
ID ADF97821 standard; cDNA; 1985 BP.
XX AC
XX ADF97821;
XX AC
DT 26-FEB-2004 (first entry)
XX XX
DE Human PRO polynucleotide #72.
XX XX
KW Human; gene; as; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS
XX Homo sapiens.
XX XX
PN US2003207422-A1.
XX XX
PD 06-NOV-2003.
XX XX
PF 08-MAY-2002; 2002US-00141754.
XX XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023328.
PR 24-AUG-2000; 2000WO-US023522.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806889.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
```



```
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAGAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACTTGGACTTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAATACTGCCACTCTTCTTCGATGCCATCTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 sProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCACATGCAAGAAAGATGGGTGGGCTGCCCCCAACATTGAGGCTGCGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCTGCCCGCCATCTGACGC 1464
Qy 420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTAG 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG 460
Db 1525 GTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTCAGAGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGGCGCCCTGCCAGGCGCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspArgArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCAACTCGGGAGGCGCCCTG 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 186
ADF98392
ID ADF98392 standard; cDNA; 1985 BP.
XX
AC ADF98392;
XX
DT 26-FEB-2004 (first entry)
DE
XX Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; Glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
```


Qy 260 oTyTyTyTyArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGI 280
 Db 985 CTACTCAAGAGGCTGGCGCGGAGCGCTGCTCAGCTGGAGCAGCTGCTGGCGCTGCA 1044
 Qy 280 nSerLeuTyTyGlyysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyValArgProGlnThrGlnGI 320
 Db 1105 CACTGACTTTGAGACCTTGGGACTCTACAGCCCTCAAGAGGCGCCCTCAAGACGAGGG 1164
 Qy 320 yProLysTyTyCyHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAAATAGTCCACTTCTTCGATGCCATCCTAGTACAGGCAACAGCACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGTAGCAAGCTCTCAGAGCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGGAAGATGGTGGCTGGCTGCCCCCAACATTGAGGCTCGGCGCATCTTCATT 1344
 Qy 380 uAsnAspGlyAspPheTyTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGAGGGCTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGAGGGGGCTGCCCCGCGCATCTCTGACGC 1464
 Qy 420 aAlaLeuPhePheProLeuArgGlyLeuIleLeuPheLysGlyAlaArgTyTrpVa 440
 Db 1465 CGCCCTTCTTCTCCCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTTACTACCT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGI 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGACGACCTGGGG 1584
 Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTTCCGAGGCGCGATGGCTCCATCATCTTCT 1644
 Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGIyAr 500
 Db 1645 CCAGATGACCGCTACTTGGCGCTTCAGCAGGCGCAACTGCAGGCAACCACTTCGGGCGG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGTCCCTGGATGGCTGCTGGCATGCCNACTCGGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 c 1765

RESULT 187

ADG03223

ID ADG03223 standard; cDNA; 1985 BP.

XX AC ADG03223;

XX XT ADG03223;

XX DT 26-FEB-2004 (first entry)

XX DE Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; PFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX US2003207351-A1.

XX 06-NOV-2003.

XX 06-MAY-2002; 2002US-00140473.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2004-010589/01.

XX DR P-PSDB; ADG03224.

XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
 PT useful in stimulating the proliferation or differentiation of chondrocyte
 PT cells and detecting a tumor.

XX Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0


```
QY      440 lleulaargglyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
Db      1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGCTCTGCAGGACTGGGG 1584
QY      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCCGAGGCCGATGGCTCAATCACTTCTT 1644
QY      480 eArghepAepArgTyrTyrArgLeuAAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645 CCGAGATGACCGCTACTGCGCGCTCGACCGAGCCAACTGCAGGCAACCACTCGGGCGG 1704
QY      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705 CTTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY      520 e 520
Db      1765 C 1765

RESULT 189
ADG16529
ID      ADG16529 standard; cdNA; 1985 BP.
XX
AC      ADG16529;
XX
DT      26-FEB-2004 (first entry)
XX
DE      cDNA encoding human PRO polypeptide #72.
KW      Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW      tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW      cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW      liver; microvascular endothelial cell; glucose; FFA;
KW      skeletal muscle cell; adipocyte cell; pericyte cell;
KW      inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW      immune system cell infiltration.
XX
OS      Homo sapiens.
XX
PN      US2003207359-A1.
XX
PD      06-NOV-2003.
XX
PF      08-MAY-2002; 2002US-00141756.
XX
PR      31-MAR-1997; 97WO-US005230.
PR      12-JUN-1998; 98WO-US012456.
PR      14-JUL-1998; 98WO-US014552.
PR      28-AUG-1998; 98WO-US017888.
PR      10-SEP-1998; 98WO-US018824.
PR      14-SEP-1998; 98WO-US019093.
PR      14-SEP-1998; 98WO-US019094.
PR      14-SEP-1998; 98WO-US019177.
PR      16-SEP-1998; 98WO-US019330.
PR      17-SEP-1998; 98WO-US019437.
PR      07-OCT-1998; 98WO-US021141.
PR      29-OCT-1998; 98WO-US022991.
PR      29-OCT-1998; 98WO-US022992.
PR      20-NOV-1998; 98WO-US024855.
PR      01-DEC-1998; 98WO-US025108.
PR      05-JAN-1999; 99WO-US000106.
PR      08-MAR-1999; 99WO-US005028.
PR      10-MAR-1999; 99WO-US005190.
PR      20-APR-1999; 99WO-US008615.
PR      14-MAY-1999; 99WO-US010733.
PR      02-JUN-1999; 99WO-US012252.
PR      01-SEP-1999; 99WO-US020111.
PR      08-SEP-1999; 99WO-US020594.
PR      13-SEP-1999; 99WO-US020944.
PR      15-SEP-1999; 99WO-US021090.
PR      15-SEP-1999; 99WO-US021547.
PR      05-OCT-1999; 99WO-US023089.
PR      29-NOV-1999; 99WO-US028214.
PR      30-NOV-1999; 99WO-US028313.
PR      30-NOV-1999; 99WO-US028409.
PR      01-DEC-1999; 99WO-US028301.
PR      01-DEC-1999; 99WO-US028634.
PR      02-DEC-1999; 99WO-US028551.
PR      02-DEC-1999; 99WO-US028564.
PR      16-DEC-1999; 99WO-US028565.
PR      20-DEC-1999; 99WO-US030095.
PR      20-DEC-1999; 99WO-US030311.
PR      20-DEC-1999; 99WO-US030999.
PR      22-DEC-1999; 99WO-US030720.
PR      30-DEC-1999; 99WO-US031243.
PR      30-DEC-1999; 99WO-US031274.
PR      05-JAN-2000; 2000WO-US000219.
PR      06-JAN-2000; 2000WO-US000277.
PR      06-JAN-2000; 2000WO-US000376.
PR      11-FEB-2000; 2000WO-US003565.
PR      18-FEB-2000; 2000WO-US004341.
PR      18-FEB-2000; 2000WO-US004342.
PR      22-FEB-2000; 2000WO-US004414.
PR      24-FEB-2000; 2000WO-US004914.
PR      24-FEB-2000; 2000WO-US005004.
PR      01-MAR-2000; 2000WO-US005601.
PR      02-MAR-2000; 2000WO-US005746.
PR      02-MAR-2000; 2000WO-US005841.
PR      10-MAR-2000; 2000WO-US006319.
PR      15-MAR-2000; 2000WO-US006884.
PR      20-MAR-2000; 2000WO-US007377.
PR      21-MAR-2000; 2000WO-US007532.
PR      30-MAR-2000; 2000WO-US008439.
PR      17-MAY-2000; 2000WO-US013705.
PR      22-MAY-2000; 2000WO-US014042.
PR      30-MAY-2000; 2000WO-US014941.
PR      02-JUN-2000; 2000WO-US015264.
PR      28-JUL-2000; 2000WO-US020710.
PR      11-AUG-2000; 2000WO-US022031.
PR      23-AUG-2000; 2000WO-US023522.
PR      24-AUG-2000; 2000WO-US023328.
PR      08-NOV-2000; 2000WO-US030952.
PR      10-NOV-2000; 2000WO-US030873.
PR      01-DEC-2000; 2000WO-US032678.
PR      20-DEC-2000; 2000US-00747259.
PR      20-DEC-2000; 2000WO-US034956.
PR      28-FEB-2001; 2001US-00796498.
PR      28-FEB-2001; 2001WO-US006520.
PR      01-MAR-2001; 2001WO-US006666.
PR      09-MAR-2001; 2001US-00802706.
PR      14-MAR-2001; 2001US-00808689.
PR      22-MAR-2001; 2001US-00816744.
PR      05-APR-2001; 2001US-00828366.
PR      10-MAY-2001; 2001US-00854208.
PR      10-MAY-2001; 2001US-00854208.
PR      18-MAY-2001; 2001US-00860216.
PR      25-MAY-2001; 2001US-00866028.
PR      25-MAY-2001; 2001US-00866034.
PR      25-MAY-2001; 2001WO-US017092.
PR      01-JUN-2001; 2001US-00872035.
PR      01-JUN-2001; 2001WO-US017800.
PR      05-JUN-2001; 2001US-00874503.
PR      14-JUN-2001; 2001US-00882636.
PR      19-JUN-2001; 2001US-00886342.
PR      20-JUN-2001; 2001WO-US019692.
PR      21-JUN-2001; 2001US-00887879.
PR      22-JUN-2001; 2001WO-US020116.
PR      29-JUN-2001; 2001WO-US021066.
PR      09-JUL-2001; 2001WO-US021735.
PR      18-JUL-2001; 2001US-00908827.
PR      06-AUG-2001; 2001US-00924419.
```

PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2004-010595/01.
 DR P-PSDB; ADG16530.

XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
 PT useful for stimulating the release of tumor necrosis factor-alpha from
 PT human blood and for detecting the presence of a tumor.

XX Claim 2; Fig 143; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as:
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADG16529 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTGGCGCGGTGGCCCTCTGCTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGlnArgGlyGlyGlnGlnLeuLeuArgGlyGlnAlaGlnAlaPheLeu	40
DB	266	GACGCCAGCCCGCGAGCGCGAGGCCAGGAGTGGCGCAAGAGCGGAGGCATTCCTTA	325

QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTCAGC	395
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
DB	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGTACCTGTCCAGCGCGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCCCTGGCCAGATGCTCTCCCGCTCCGGGGTTACAGATACCACAGTATTATGCG	505
QY	101	AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCTTGGGCTGAGAGGATCAGTGACTTGTGTGTACACCGGACCAAAATGAGGCGTAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACCGTTTGCAAAGCAAGGTAAACAATGGTACAAGCAGCACCTCTCTTACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTTGAGCATCTGCCGAGCGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAAGCTCTCAGCGCTGGAGTCTGGGAGGCCCCCAGCCAGGCCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTTCTCCAAAGGACCAACAGATGGGTGGGCAATGCCTTTGATGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
DB	806	CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCAAGCGCACTTGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATAGGCGCTGGTCCCTGAGCCGCGCGCGGGGCAACCTGTTCTGTTGCTGGCGCA	924
QY	240	sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTCAACGCTTGGCTCACCACTCGCCGCGCGCGCGCTCATGCGCGCC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
DB	985	CTACTACAAGAGGCTGGGCGCGCGAGCGCTGCTCAGCTGGGACGAGTGTGGCGGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCACAGGAAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
DB	1105	CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGCGCCCTGAAACGCGAGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
DB	1165	CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
QY	360	gProLeuGlnGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLeu	380
DB	1285	TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTCAGGCTGGCGGAGTGTCTATT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly	400
DB	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCAGTCTGGAGGTTCGGGGGCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420

Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCGGGCGAGGGGCGCTGCCCGCCATCTGAGCG 1464
QY 420 aAlaLeuPheProLeuArgLeuLeuPheGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGGCTCATCTCTTCAAGGTGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGTCAAGCGGCGCTGCGAGGCGGATGCTCCATCATCTTCT 1644
QY 480 eArgPhePheArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTGCGCGCTCGACAGGCCAAATGTCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGGCGCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 190
ADG04988
ID ADG04988 standard; cdNA; 1985 BP.
AC ADG04988;
XX
DT 26-FEB-2004 (first entry)
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207375-Al.
XX
PD 06-NOV-2003.
XX
PF 15-MAY-2002; 2002US-00146794.
XX
PR 24-OCT-1997; 97US-0062814P.
PR 16-SEP-1998; 98WO-US019330.
PR 25-AUG-1999; 99US-00380139.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2004-069291/07.
DR P-PSDB; ADG04989.
XX
PT New PRO nucleic acid, useful for diagnosing or treating cancer, for

PT chromosome mapping or for tissue typing.
XX Claim 2; SEQ ID NO 143; 637bp; English.
PS
XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 546 C; 504 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 12 Indels: 2
DB: Gaps: 0
US-10-791-980-6 (1-520) x ADG04988 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGCTCGCGCGCTCGCCCTCTCTGCGGCCCTGCAGCTGCTACTGTGGGGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGAGTGGCAGAGGAGCGGAGGCATTCCTA 325
QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGTGTCCCAAAAGTCCCACTTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTACGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCACAGATTATCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565

```
QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGGCTTTGCAAGCAAGTAACTAATGTTACAGCAGCACTCTCTACCGCTGGTG 625
QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCCTGAGCATCTGCGGAGCGGAGTTTCGGGGCGCGCTGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGGACACTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCGCTGGCGCACGCTTC-CTGGCCCGCGCGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnPheValValLeuAlaHi 240
Db 865 AGATGAGCCCTGGTCTCAGCGCGCGCGCGCGCAACCTGTTGTTGGTGGTGGCGCA 924
QY 240 sGluLleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTTCACAGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGCTGCGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCCATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenlleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGCTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTATT 1344
QY 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGCATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTTCCACAGCTGTGGCGGAGGGGCGCTGCCCCCGCATCTTGAGCGC 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTGCGCGCTCTACTCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGCGAGGGCCGATGGCTCCATCATCTTCT 1644
```

480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGGCCAACTGCGAGGCACACCTCGGGCGG 1704
500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
520 e 520
1765 c 1765

RESULT 191
ADG19255
ID ADG19255 standard; cDNA; 1985 BP.
XX
AC ADG19255;
DT 26-FEB-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207425-A1.
XX
XX 06-NOV-2003.
PF 09-MAY-2002; 2002US-00142430.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.

Db 446 GCCACCTCGCCGAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgLys 120
 Db 506 GCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
 Qy 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSe 160
 Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGGCCCCGTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCCAGGGGACACACAGATGGCTGGGCATGCTTGTATGGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLysSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCTCTAGCGCGCGCGCGGCGCAACCTGTTCGTGTGTCTGGCGCA 924
 Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 tTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
 Db 985 CTACTACAAAGAGCTGGCGCGGACGCGCTGTCTCAGCTGGGACGACGTCTGGCGTGCA 1044
 Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGAGGCCCTTAGGGGGCTCAGTGGCGGCTCCAGCTCCCAAGAAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGCGAGG 1164
 Qy 320 yProLysTyrCysHisSerPheAspAlaLeThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGCGAGCTGATGCAACGTCTCAGAGCCCCG 1284
 Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAenLleGluAlaAlaAvalSerle 380
 Db 1285 TCACCTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTAGGCTGGCGAGTGTCAAT 1344
 Qy 380 uAenAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGGGGTCTCCCAACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
 Qy 420 aAlaLeuPheProProLeuArgArgLeuLleLeuPheLysGlyAlaArgTyrTrpVa 440
 Db 1465 CGCCCTCTTCTTCT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460

Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTCGAGACTGGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCCCTACTGGCGCTCGACACAGGCCAAACTGCAGGCAACCACTCGGGCGG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 c 1765
 RESULT 192
 ADG13092
 ID ADG13092 standard; cDNA; 1985 BP.
 XX
 AC ADG13092;
 DT 26-FEB-2004 (first entry)
 XX
 DE cDNA encoding human PRO polypeptide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; Glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003207357-Al.
 XX
 PD 06-NOV-2003.
 XX
 PF 08-MAY-2002; 2002US-00141703.
 XX
 PR 10-MAR-1999; 99US-0123618P.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 (GETH) GENENTECH INC.
 PA
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-010593/01.
 DR P-PSDB; ADG13093.
 XX
 PT New nucleic acid encoding a secreted and transmembrane PRO polypeptide
 PT useful in detecting the presence of a tumor in a mammal, in treating
 PT cancer, and stimulating the proliferation of inner ear utricular
 PT supporting cells.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO

Qy 520 e 520
 Db 1765 C 1765
 RESULT 193
 ADG08149
 ID ADG08149 standard; cdna; 1985 BP.
 AC
 AC ADG08149;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cdna.
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation inhibitor; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2003207424-A1.
 XX
 PD 06-NOV-2003.
 XX
 PF 09-MAY-2002; 2002US-00142425.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US006319.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 14-MAY-1999; 99WO-US008615.
 PR 02-JUN-1999; 99WO-US010733.
 PR 01-SEP-1999; 99WO-US012252.
 PR 08-SEP-1999; 99WO-US020111.
 PR 13-SEP-1999; 99WO-US020594.
 PR 15-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2004-051521/05.
 DR P-PSDB; ADG08150.
 DR
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, cervical and/or liver
 XX tumors.
 XX

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGACATCTCGGAGCGCGAGTTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTCTTCAAGGGGACACCAACGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCAACCTGTTTGGTGGTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGGCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTAGCTGGGACGAGCTGTGGCGTGCA 1044
QY 280 nSerLeuTyTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGATGGAAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTACAGCTCCAGAGGCGCGCGCGCTGAAAGCAGGG 1164
QY 320 yProLysTyCysHisSerSerPheAlaIleThrValAspArgGlnGlnGlnLeuTy 340
DB 1165 CCTTAANTACTGCCACTCTTCTTCATGTCATCTAGTACAGCAACGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCACCTGAGGAAAGATGGTGGGCTGCCCGCGCGCGCGCGCGCGCGCGCGCGCGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrpVa 440
DB 1465 CGCCCTCTTTCCTCTCTCGCGCGCTCATCTCTTCAAGGTGGCGCGCGCTACTAGT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGGCCCTACTACCCCCGAAGCTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGGAGGCGCGCATGGCTCCATCTTCTT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCGCTCGACCGAGGCAAACTGCAGGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGSCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 195
ADF96717
ID ADF96717 standard; cDNA; 1985 BP.
XX AC ADF96717;
XX 26-FEB-2004 (first entry)
XX Human PRO polynucleotide #72.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; EPA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX US2003207371-A1.
XX 06-NOV-2003.
XX 14-MAY-2002; 2002US-00145749.
XX 22-MAY-2000; 2000WO-US014042.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-069290/07.
DR P-ESDB; ADF96718.
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservativeness: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADF96717 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTGGCGCGGTGGCTCTGCTGGCGCGCTGCAGCTCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCCCGGAGCGCGGAGCGCAGAGCTGGCGAAGGCGGAGGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACACCTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACCGCTTTTCAGTGGGTGTCCACAGCTACCTGTGAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCCAGATGACTCGTCCCGCTCGGGGGTTACAGATACCACCAAGTATATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTTTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACCGCTTGCNAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCAGCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTCCCGGAGCGCGGAGTTCGGGGCGCGCTCGCGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAAGTCTCAGCGCTGGAGTTCTGGAGGGCCCCCAGCCACAGGCCCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCCGCTCACCTTCTTCAAGGGACCAACACGATGGGCTGGGCAATGCGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCCCTGGCGACCGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHis 240

DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTGTTGGTGTGCGCGCA 924
 QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACAGCTTGGCCTCACCACTCGCGCGCGCGCGCTCATCGCGCGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAAGAGGTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGTGCTGCGCGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACACGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTTAATACTGCCACACTCTTCTTCGATGCCATCTACTGTAGACAGGCAACAGCAACTGT 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCGC 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerie 380
 DB 1285 TCCACTGTCAGGAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGGCGAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyYpProly 400
 DB 1345 GAATGATGGAGATTCTACTTTCTTCAAGGGGTGCTGCTGGAGGTTCGGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTCTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTCTACTAGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGCTCTGCAAGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
 DB 1585 AGGCATCCCTGAGGAGGTTCAGCGCGCGCTTCCCGAGGGCGCGATGGCTCCATCATCTTCT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAAGCCAACTGCAGGCAACCACTCTCGGGCGC 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGGCTGGATGGCTGCTGGCATGCCAATCTCGGGAGCGCGCTGT 1764
 QY 520 e 520
 DB 1765 C 1765

RESULT 196

ADG05902
 ID ADG05902 standard; cDNA; 1985 BP.

XX AC ADG05902;

XX XX 26-FEB-2004 (first entry)

XX DE Human PRO polynucleotide #72.

XX XX

QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GA CGCC CAG CCG CGG AGC GCG AGG AGC TGC CAAG GAG GCG GGC ATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuLeuGlnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACATCGATTACGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGGCCAGATAGTCTGCTCCCGCTCGGGGTTACAGATACCAACAGTTATCGC	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTTGGGCTGAGAGATCAGTGTCTGTTGTGTAGACACGGACCCAAATGAGGGCTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCTCTCTCCACCGCTGTG	625
QY	141	AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGGCTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGGTGCGCGCCCTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCCGCTGAC	745
QY	180	rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTCATGGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGGCGCAGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATAGAGCGCTGGTCCCTGAGCCCGCGCGGCGGCACTGTTGTGGTCTGGCGCA	924
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGTACACGCTTGCCCTCACCACTGCCCGCGCGCGCGCTCATGCGCGC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGGACGCGCTGCTCAGCTGGGAGCAGCTGTGGCCGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGAGAACCCCTAGGGGCTCAGTGGCGTCCAGCTCCAGAAAGCTGTT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTGTAGACCTCGGACTCTCAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCGCACTCTTCTTCGATGCCATCAGTGTAGACAGGCAACAGCACTGT	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGAGCTGATGGCAACGTCTCAGAGCCCGC	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCACATGACAGGAAGATGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLys	400

```
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808699.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX MPI; 2004-051520/05.
XX P-PSDB; ADG03776.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy for treating e.g. tumors, obesity, diabetes, hypo- or
PT hyperinsulinemia, bone and/or cartilage disorders, stroke, or heart
PT attack.
XX
XX Claim 2; SEQ ID NO 143; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0
```


PR 10-SEP-1998; 98WO-US018924.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019337.
 PR 07-OCT-1998; 98WO-US021141.
 PR 23-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 03-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US0005028.
 PR 10-MAR-1999; 99WO-US0005190.
 PR 10-MAR-1999; 2000WO-US0006319.
 PR 20-APR-1999; 99WO-US0008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US022089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US028565.
 PR 20-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 22-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 05-JAN-2000; 99WO-US031274.
 PR 06-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US0003565.
 PR 18-FEB-2000; 2000WO-US0004341.
 PR 22-FEB-2000; 2000WO-US0004342.
 PR 24-FEB-2000; 2000WO-US0004914.
 PR 24-FEB-2000; 2000WO-US0004914.
 PR 01-MAR-2000; 2000WO-US0005004.
 PR 02-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 15-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 28-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001WO-US0082706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-051523/05.
 DR P-PSDB; ADG24677.
 XX
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.
 XX
 PS Claim 2; SEQ ID NO 143; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SO Sequence 1985 BP: 403 A: 646 C: 604 G: 332 T: 0 U: 0 Other:

Alignment Scores:		1,938-149	Length:	1985
Pred. No.:	Score:	2,792.00	Matches:	519
	Percent Similarity:	99.63%	Conservative:	0
	Best Local Similarity:	99.63%	Mismatches:	1
	Query Match:	98.53%	Indels:	2
DB:		12	Gaps:	0

US-10-791-980-6 (1-520) x ADG24676 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGTTCGGCGCGCTCTCTCTCGCGCCCTCGAGCTGCTACTGTGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GACGCCACGCCCGGAGCGCGAGCGACGAGCTGCGAAGGAGCGGAGGCATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGATACCTCAATGAACACAGTCCCCAAAGCTCCCACTCCATCGATTACG	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACTCTGTCAGCGCGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTTCGCCACAGATACACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgGlnLeuSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCCTGGCTGAGAGATCAGTGACTTGTTCGCTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCTACCGCTGGT	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer	160
DB	626	AACTGGCTGAGACACTCTCCCGAGCGCGCAGTTGCGGCGCCGTGCGCGCCCTTCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuThr	180
DB	686	ITGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCGCCGCTGCAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTTCTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln	220
DB	806	CCAGGGGGCGCCTGGCGCACGCCCTTC-CTGCCCGCCCGCGCGAGCGCATTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
DB	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTGTGTGTGTGGCGCA	924
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln	280
DB	985	CTACTACAAGAGCTGGGGCGCGACCGCTGCTCAGCTGGGACGACGTGCTGGCGCTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPhe	300
DB	1045	GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCCTGCTCAGCTCCCAAGAAAGCTGTT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGln	320

D	b	1105	CAC	TGACTTTGGAGCTTGGGACTCCTACAGCCCGCCCAAGGAAGGCCTCAAACGCCAGG	1164
Q	y	320	yP	rLyTyTyrCySHisSerSerpHeAspAlalleThrValaspArgGlnGlnGlnLeuTy	340
D	b	1165	CCCTAAATACTGCCACATCTTCCTTCGATGCATCACCTGTATAGACAGGCAACAGCAACTGTGA	1224	
Q	y	340	rI	ePhelysGlySerHisSHeTrpGluValAlaAAspGlyAsnValSerGluProAr	360
D	b	1225	CAITTTTAAGGGAGCCATTCTCTGGGAGGTGGCGCTGATGCCAACGCTCTCAGAGCCCCG	1284	
Q	y	360	gP	rLeuGlnGlnuargTrpValGlyLeuProProAsnilleGluAlaAlaValSerle	380
D	b	1285	TCCACTGCAGGAAGAATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGCGCATGTCAATT	1344	
Q	y	380	uAsnAspGlyAsppHeTyrPhePheYsGlyVatqCysTrpArgPheArgGlyProLY	400	
D	b	1345	GAAATGATGGAGATTCTACTCTTCTCAAGGGGGTGATGCTGGAGGTTCCGGGSCCCCA	1404	
Q	y	400	sP	rValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
D	b	1405	GCCAGTGTGGGCTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCCATCTCTGACGC	1464	
Q	y	420	aAlaLeuPhePheProLeuArgArgLeuileuPheYsGlyAlaargTYrTYrVa	440	
D	b	1465	CGCCCTCTTCTTCGCTCTCTGCGCCGCCTCATCTCTTCAAGGGTGCCGCTACTACGT	1524	
Q	y	440	lLeuAlaArgGlyGlyLeuGlnValGluProTYrTYrProArgSerLeuGlnAspTrpGl	460	
D	b	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGCTCTGCAGGACTGGG	1584	
Q	y	460	yGlyileProGluGluValSerGlyAlaLeuProArgProaspGlySerllellePhePh	480	
D	b	1585	AGGCATCCCTGAGGAGGTCAAGCGCGCCCTCGCGAGGCCCAGTGGCTCCATCATCTTCTT	1644	
Q	y	480	eArgAspAspargTYrTrpArgLeuAspGlnAlalyeLeuGlnAlaThrThrSerGlyAr	500	
D	b	1645	CGAGATACCCGCTACTGCGCCCTCGACCAGGCCAACTGCAGGCAACCACTCTGGGCGG	1704	
Q	y	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	
D	b	1705	CTGGGCCACCGAGCTGCCCTTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT	1764	
Q	y	520 e	520		
D	b	1765 c	1765		
RESULT 200					
ADG06973					
ID		ADG06973 standard; cdNA; 1985 BP.			
AC		ADG06973;			
XX					
DT		26-FEB-2004 (first entry)			
XX					
DE		Novel human secreted and transmembrane protein PRO4339 cdNA.			
XX					
KW		Human; secreted and transmembrane protein; PRO; gene; ss;			
KW		Tumour necrosis factor alpha release; TNF-alpha release;			
KW		glucose uptake modulator; FFA uptake modulator;			
KW		cell proliferation stimulator; cell differentiation stimulator;			
KW		cell differentiation inhibitor; cytokine release stimulator; tumour;			
KW		lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;			
KW		cervical tumour; liver tumour; chromosome mapping; gene mapping;			
KW		gene therapy; chromosome identification; chromosome marker.			
OS		Homo sapiens.			
XX					
PN		US2003207350-A1.			
XX					
PD		06-NOV-2003.			
PX					
PF		03-MAY-2002; 2002US-00137871.			

Novel human secreted and transmembrane protein PRO4339 cDNA.

Human; secreted and transmembrane protein; PRO; gene; ss;
Tumour; nuclear factor alpha release; TNF-alpha release;
Tumour; nuclear factor alpha release; TNF-alpha release;
Salivary gland; modulator; FFA uptake modulator;
Cell differentiation stimulator; cell differentiation stimulator;
Cell differentiation inhibitor; cytokine release stimulator; tumour;
lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
cervical tumour; liver tumour; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker.

Homo sapiens.

US2003207350-A1.

06-NOV-2003.

03-MAY-2002; 2002US-00137871.

XX 09-DEC-1999; 99US-0170262P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2004-010588/01.
 DR P-PSDB; ADG06974.
 XX
 XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
 PT useful in stimulating the proliferation of inner ear utricular supporting
 PT cells and detecting a tumor.
 XX
 XX Claim 2; SEQ ID NO 143; 637pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG06973 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTGTCGCGCGCTGGCCCTCTCTGTCGCGCCCTCTGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GAGCCCGAGCCCGGAGCGCGAGGCCAGGAGCTGGCAAGAGGCGGAGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGGTCCCAAGCTCCACCTCCATCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTCTCAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTACACCCGACCAAAATAGGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnIleAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCANAGCAAGGTAAACAAATGGTACAGACAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
 Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTACGCGCTGGAGTTCGGGAGGCGCCAGCCAGGCGCCCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCAGCTTCTTCANAGGGGACCAACAGATGGCTGGGCAATGCCCTTTCATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTCGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACAGCGCTTGGCTCACCCTCGCCCGCGCGCGCGCTCATGCGGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTCGCGCGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGGAGGCGCCCTGAAACGACGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCCTAAATATCTGCACCTCTCTCTTCATGCTCCCTCAGTGCCTCAGTACAGGCAACAGCACTGA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGGCGTCCCGCCCAACATTCAGGCTGGCGGAGTGTCTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys 400
 Db 1345 GAATGATGGAGATTCTACTTCTCAAAGGGGTGATGCTGGAGGTTCGCGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGGGGTCTCCACACAGCTGTCCCGGGCAGGGGGCTGCCCGCCCATCTCCAGCGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440

Db 1465 CGCCCTCTTCCCTCTGCGCGCGCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
Qy 440 lIeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGAGGCCGATGGCTCATCTCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACGAGCCAACTGCGGCAACCACTCGGGCGG 1704
Qy 500 gTrrAlaThrGluLeuProTrrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGATGCGCACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 201

ADG07525
ID ADG07525 standard; cDNA; 1985 BP.

XX AC ADG07525;
XX 26-FEB-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; Cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN US2003207356-A1.
XX PD 06-NOV-2003.
XX PF 08-MAY-2002; 2002US-00141699.
XX PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Bersesini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-010592/01.
DR P-PSDB; ADG07526.
XX PT New nucleic acid encoding a secreted and transmembrane PRO polypeptide
PT useful in detecting the presence of a tumor in a mammal and stimulating
PT the proliferation or differentiation of chondrocyte cells.
XX PS Claim 2; SEQ ID NO 143; 637bp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of T-lymphocyte cells, for stimulating
CC for stimulating the proliferation of PBMC cells, for inhibiting the binding of
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG07525 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTGCGCTCTGTCGCGCGCTGCTACTGTGTGGGCGACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGGAGCGAGAGTGCAGAGGCGGAGGCGGAGGCGATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCATGACAGGTCCCCAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlathrLeuArgGlnMetThrArgProArgCysGlyValThrArgThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCCGCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGGCTGAGAGGATCAGTGACTTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGCGGAGCGGCGAGTTCGGGGCGCGTTCGCGCGCGCTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCGGCCAGGCACAGGCCCGCTGAC 745

QY 180 rSerGlySerProSerSerGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGCAATGCCCTTGGATGC 805
 QY 200 aGlnGlyAlaProTyrArgThrProHelLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGGGCCCTGGCGCACCGCTTC - CTGCCCGCCCGCGGCGAAGCGCACTTCGACCA 864
 QY 220 nAspGluAArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
 DB 865 AGATGAGCGCTGGTCTCGAGCGCCCGCGGCGCAACCTGTTCTGTGTGTGGTGGCGCA 924
 QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTCAACAGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLygArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAGAGGCTGGCGCGGACCGCTGCTCAGCTGGGACGACGCTGCGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLygProLeuGlyGlySerValAlaValGlnLeuProGlyLygLeuPh 300
 DB 1045 GAGCTGTATGGAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCTGAAACGACGG 1164
 QY 320 yProLygTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTTAATAATGCTCACTCTCTCTGATGCTCATCTAGTACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLygLygSerHisPheThrGluValAlaAlaAspGlyAenValSerGluProAr 360
 DB 1225 CATTTTTAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
 DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGGCGAGTGTCTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLygGlyGlyArgCysTyrTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
 QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCGCTGCCCGCCATCTCTGAGCG 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLygGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGGCGCTACTACGT 1524
 QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
 DB 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGGGGGCGCTGCCGAGGGCCGATGGCTCATCTCTT 1644
 QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLygLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGCGCAACTGCGAGGCACCACTCGGGCGG 1704
 QY 500 gTyrAlaThrGluLeuProTyrPheGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGCGCCAGGCTGCTGAGTGGGTGCTGGCATGCCAATCTGGGAGGCGCGCTGT 1764
 QY 520 e 520
 DB 1765 c 1765
 RESULT 202

ADG55020
 ID ADG55020 standard; cDNA; 1985 BP.
 XX
 AC ADG55020;
 DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuroptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
 XX
 OS Homo sapiens.
 XX
 PN US2003194778-A1.
 XX
 PD 16-OCT-2003.
 XX
 PF 29-MAY-2002; 2002US-00157796.
 XX
 PR 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-113266/12.
 DR P-PSDB; ADG55021.
 XX
 PT New secreted and transmembrane nucleic acids and polypeptides useful for
 PT detecting the presence of a tumor, stimulating the release of tumor
 PT necrosis factor alpha from human blood and treating inflammation.
 XX
 PS Claim 2; SEQ ID NO 143; 637pp; English.
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.82% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

DR P-PSDB; ADG60685.

XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor, for chromosome mapping or for tissue
 PT typing.

XX Claim 2; SEQ ID NO 143; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,936-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG60684 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGTGCGCGCGTGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCACGCCCGCGAGCGCGGAGGAGCTGCGCAAGGAGCGGCGGAGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCATGAAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTCAGTGGGTGTCACAGCTACCTGTCCAGCGGCGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCGCAGATGACTGTCTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
 QY 101 AlaTpaAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGTGAGAGATCATGTGACTTGTGTAGACACCGGACCAAAATGAGGGGTAAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAACCAAGGTAAACAAATGTTACAGACGACACCTCTCTCAGCGCTGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTCCGAGCGCGCAGTTTCGGGGCGCGTTCGCGCGCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyValArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCCGACAGCCACAGCGCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTCTTCCAAGGGGACCCACACAGATGGCTGGGCAATGCTTGTATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGGCGCTCGCGCACGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyValArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTCCTAGCGCGCGCGCGGCGCAACCTTGTGCTGGTGGCGCA 924
 QY 240 aGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGSGCGC 984
 QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACCGCGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAAATACCTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
 DB 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTCTACTTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGGCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyValLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTTGCCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGAGAGGTACGCGCGCTGCCGAGGCCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCAAACAGGCGCAACACCTCGGGCGC 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACAGCTGCGCTGGATGGGTGTCATGCCAATCTCGGCAGCGCGCTGTT 1764

Oy 520 e 520
Db 1765 C 1765
RESULT 204
ADG61788
ID ADG61788 standard; cDNA; 1985 BP.
XX
XX
AC ADG61788;
XX
DT 11-MAR-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
DE human; PRO; membrane bound protein; membrane bound receptor;
XX cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
XX US2003207428-A1.
PN
XX
PD 06-NOV-2003.
XX
XX 15-MAY-2002; 2002US-00146792.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US012252.
PR 02-JUN-1999; 98WO-US020111.
PR 01-SEP-1999; 98WO-US020594.
PR 08-SEP-1999; 98WO-US020944.
PR 13-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001WO-US020116.
PR 09-JUL-2001; 2001WO-US021066.
PR 18-JUL-2001; 2001WO-US021735.
PR 06-AUG-2001; 2001US-00908827.
PR 09-AUG-2001; 2001US-00924419.
PR 16-AUG-2001; 2001US-00927796.
PR 19-DEC-2001; 2001US-00931836.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-021503/02.
DR P-PSDB; ADG61789.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, cervical and/or liver
PT tumors.
XX
XX Claim 2; SEQ ID NO 143; 638pp; English.
PS
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC

CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides or hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytosolic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC invention is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG61788 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGTGTCGGCGCGTGGCCCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGCGAGCGCGAGGCCAGGAGCTGCGCAAGAGCGGCGGAGGCATTTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAACCTCCACCTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuPheArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTGCGCCAGATGACTGTCCTCCCGCTCGGGGTTCACAGATACCAACAGTTATGGC 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGCTGAGAGGATCAGTACTGTTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCANAGCAAGGTAAACAAATGGTAAACAGCGACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTCGCGAGCGCGCAGTTTCGGGGCGCGTTCGGCGCCCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCTGGAGGGGCCACAGCCACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCCCTTTATGGC 805
 QY 200 aglnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyGluAlaHisPheAspG1 220

DB 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCCGCGCGGAGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGCTGCTCTGAGCGCGCGCGGCGCAACCTGTTGTTGTTGTTGCGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTTCCACACTTGGCCCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTGCTAGCTGGAGCAGCTGCTGGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACTCGGACTCTCAGACCCCAAGAGGCGCCCTGAAACGCGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGCAGGAAGATGGTGGCTGCCCTCCCAACATTTAGGCTGGCGAGTGTCTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGCGGCGAGGGGCGCTGCCCGCCATCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 GCCTCTTCTTCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAGTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGCGCGCTTCCCGAGGCGCGATGGCTCATCTCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCAACATGCGAGGCAACACCTTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGGCGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 XX RESULT 205
 ADG81989
 ID ADG81989 standard; cDNA; 1985 BP.
 XX
 AC ADG81989;
 XX

DT 11-MAR-2004 (first entry)
XX Human PRO polynucleotide #72.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX US2003207358-A1.
XX
XX 06-NOV-2003.
XX
XX 08-MAY-2002; 2002US-00141706.
XX
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-010594/01.
DR P-PSDB; ADG81990.
XX
XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
PT useful in stimulating the proliferation of inner ear utricular supporting
PT cell, detecting the presence of a tumor and in treating cancer.
PT
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG81989 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGGTGCGCTCTCTGCTGCGCGCTCAGCTGCTACTGTGGGCGCACTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGGAGGCTGCCAAGAGGCGGAGGCGGATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGATACCTCAATGACAGGTCCCAAGAGTCCCACTCCACTCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGACGTTTTCAGTGGGTGTCCTGCTGCTGCTGCTGCTGCTGCTGCTG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTGTCCTCCGCTGCGGGGTTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTTGTAGACACCGGACCAAAATGAGCGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTCGAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTGGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGTCTTGGGAGGCGCCAGCCAGGCCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCGGCTCAGCTTCTTCCAAAGGGGACCAACAGTGGCTGGGCTGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGCGGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGGCGGCAACTGTTCTGTTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCTGCTGCGCGCGCGCGGCTCATGCGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG 280
DB 985 CTACTACAGAGGCTGGGCGCGGACGCGCTGCTCAGCTGGGAGCAGCTGCTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

```
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTTGGAGCTTCCCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATAGTCCACTTCTTCCTTCGATGCCATCACTAGACAGGCACACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerIle 380
Db 1285 TCACCTGCAGGAAGATGGGTGGGCTGGCGCTGCCCCCAACATTTAGAGCTGGCGCAT 1344
Qy 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGGCTGCCCGGCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG 460
Db 1525 GCTGGCCCGAGGGGACTGCAGTGGAGCCCTACTACCCCGAGAGTTCGACGACTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGGGGGCCCTGCCGAGGCCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgPheAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCCAAACTGCAGGCCAACCCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAATCTGGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 206
ADGS7228
ID ADGS7228 standard; cDNA; 1985 BP.
AC
XX
XX ADGS7228;
XX
XX 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophin; hormone; cell
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
XX US2003207362-A1.
XX
XX 06-NOV-2003.
XX
XX 08-MAY-2002; 2002US-00141762.
```

```
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-010598/01.
DR P-PSDB; ADGS7229.
XX
XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide,
PT useful for detecting a tumor and inhibiting the differentiation of
PT adipocyte cells.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
XX
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0
US-10-791-980-6 (1-520) x ADGS7228 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGCGCGCTGGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGCCGAGAGCTGCGCAAGAGCGGAGGCAATTCCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGCTCCACCTCCATCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGAGGCTTTCAGTGGGTGTCCAGGACTCTGTCCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGATTATCG 505
```

QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	506	CCCTGGGCTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGTAAG	565	Db	1585	AGGCATCCCTGAGGAGGTGAGCGGCCCTCGCAGGCCCGGATGGCTCATCATCTTCTT	1644
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	566	AAACGCTTGTCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTTACCGCTGGTG	625	Db	1645	CCGAGATGACCGCTACTGCGGCTCGACCCAGGCCAAACTGCAGGCAACCCACCTCGGGCG	1704
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe	160	QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	626	AACGGCTGAGCATCTCCCGAGCCGCGCATTTGGGGCGCGTGGCGCGCTTCCAG	685	Db	1705	CTGGGCCACGAGCTCCCTGGATGGCTGGCTGGCATGCAACTCGGAGCGCCCTGT	1764
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	QY	520	e 520	
Db	686	TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC	745	Db	1765	c 1765	
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200	RESULT 207			
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGACACACATGGGCTGGGCAATGCCCTTTGATGGC	805	ADG56676			
QY	200	agLInGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220	ID	ADG56676	standard; cDNA; 1985 BP.	
Db	806	CAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA	864	XX	ADG56676;		
QY	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240	XX	11-MAR-2004	(first entry)	
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGTGTCTGGCGCA	924	XX	Novel human secreted and transmembrane protein PRO4339 cDNA.		
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260	KW	human; PRO; membrane bound protein; membrane bound receptor;		
Db	925	CGAGATCGGTACACGCTTGGCTTCCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984	KW	cell proliferation; cell migration; cell differentiation;		
QY	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280	KW	mitogenic factor; survival factor; cytotoxic factor;		
Db	985	CTACTACAGAGCGCTGGGCGCGACGCGCTGTCTAGCTGGGACGAGTGTGGCGGTGA	1044	KW	differentiation factor; neuroptide; hormone; cell receptor;		
QY	280	nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	XX	receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.		
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT	1104	OS	Homo sapiens.		
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320	XX	US2003207364-A1.		
Db	1105	CACTGACTTTGAGACTGGGACTCTCAGCCCCCAAGAGCGCGCTGAAACCGCAGGG	1164	XX	06-NOV-2003.		
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	XX	10-MAY-2002; 2002US-00142429.		
Db	1165	CCCTAAATACTGCCACTTCTTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGA	1224	XX	05-JUN-2000; 2000US-0209832P.		
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	PR	01-DEC-2000; 2000WO-US032678.		
Db	1225	CATTTTAAAGGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGACCCCG	1284	PR	19-DEC-2001; 2001US-00028072.		
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	XX	(GETH) GENENTECH INC.		
Db	1285	TCCACTGCGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCA	1344	XX	Baker KP, Beresini M, DeForge L, Deanovers L, Filvaroff E, Gao W;		
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly	400	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGCTGGAGGTTCGGGGGCCCAA	1404	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	XX	WPI; 2004-051515/05.		
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGGGGCTTCCCGCCATCTTGACGC	1464	XX	P-PSDB; ADG56677.		
QY	420	aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa	440	XX	New PRO nucleic acid, useful for manufacturing a medicament for		
Db	1465	CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524	XX	diagnosing or treating tumor, for chromosome mapping or for tissue		
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460	XX	typing.		
Db	1525	GCTGGCCCCGAGGAGTGCAGTGGAGGCCCTACTACCCCCGAAGTGTGAGGACTGGGG	1584	PS	Claim 2; SEQ ID NO 143; 637pp; English.		
				CC	This invention relates to novel nucleic acids encoding human PRO secreted		
				CC	and transmembrane proteins. Extracellular proteins play important roles		
				CC	in the formation, differentiation and maintenance of multicellular		
				CC	organisms. The fate of many individual cells (for example proliferation,		
				CC	migration or differentiation) is typically governed by information		
				CC	received from other cells and the immediate environment. The information		
				CC	is often transmitted by secreted polypeptides (for example mitogenic		
				CC	factors, survival factors, cytotoxic factors, differentiation factors,		
				CC	neuropeptides and hormones) which are received and interpreted by diverse		
				CC	cell receptors or membrane bound proteins. These membrane bound proteins		
				CC	as in the blocking of receptor-ligand interactions. The current invention		
				CC	provides the amino acid sequences of novel human membrane bound receptors		
				CC	and proteins, along with the cDNA sequences encoding them. The novel		

CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG56676 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGCGCGGTGGCCCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCCGCGAGCGCGAGGCCAGGAGCTGCGCAAGGCGGCGGAGGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCCAACCTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTGCGGGGTTTACAGATACCAACAGTTATGG 505
 QY 101 AlaThrAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 DB 506 GCTCGGGCTGAGAGGATCAGTACTTGTGTGTAGACACCGACCAAAATGAGGGGTAAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGACCTCTCTACCGCCCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTGCGGGCGCGTGGCGCGCCCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACGACACAGGCCCTTCAG 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCCCTGGCGACGCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 DB 865 AGATAGCGCTGGTCCCTCAGCGCGCGCGGCGCAACCTGTTGCTGGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CAGATTCGGTCAACGCTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280

DB 985 CTACTACAGAGGCTGGCGCGAGCGCTGCTAGCTGGGACGAGTGTGCGCGTGA 1044
 QY nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCCAAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGAAAGCGCCCTTGAACGCGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATATCGCACTCTCTCTCGATGCCATCACTAGACAGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGTGCAACGCTCTCAGAGCCCCG 1284
 QY 360 pProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGCAAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGGCAAGTGTCTAT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGCGGCGAGGGGCTGCCCCCGCATCTGACGC 1464
 QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAGCTGTCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCCTCAGAGAGGTGAGCGCGGCTGCGGAGGCGCGATGGCTCCATCATCTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGCCCAACTGCGGCAACACCTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 208
 ADG55572
 ID ADG55572 standard; cDNA; 1985 BP.
 XX
 AC ADG55572;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuropeptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
 XX Homo sapiens.
 OS
 XX

Qy 240 sglurleGlyHisThrLeuGlyLeuThrHisSerProAlaPProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCTTCAACCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTyrlsYsGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAAGAGGCTGGCGCGCGCGCTCTCAGCTGGGACGACGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrglyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLeuPh 300
Db 1045 GAGCTGTATGGAGAGCCCTAGGGGCTCAGTGGCGCTCCAGTCCAGGAAAGCTGTT 1104
Qy 300 eThraPheGluThrTrpAspSerTrpProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTCAGACCTGGGACTCTCTTCGATGCCATCTCTGTAGACGGCAACAGCTGTA 1164
Qy 320 yProlyTyrcyVehHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCTCTGTAGACGGCAACAGCTGTA 1224
Qy 340 rIlePheLySgLySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGCTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGGAGTGTCTATT 1344
Qy 380 uAenAspGlyAspPheTyPhePheLySgLyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGCTGATGCTGGAGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGCTCTCCACAGCTGTGGCGGAGGGGCTGCCCCGCCATCCTGACGC 1464
Qy 420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLySgLyAlaAlaGlyTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGGCTCTATCTTCTTCAAGGCTGGGCTGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCTCTGAGGAGTCCAGCGGCGCTTGGCGGCGCTGCGAGGCGGATGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLySLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTGGCGCTTCCAGCGGCGGCAACTGCGAGGCAACCCACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAATCTGGGGAGCGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 210
ADG70698
ID ADG70698 standard; cDNA; 1985 BP.
XX
AC ADG70698;
XX
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;

KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
XX US2003207420-A1.
XX 06-NOV-2003.
XX 07-MAY-2002; 2002US-00140865.
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 98WO-US000106.
XX 08-MAR-1999; 98WO-US005028.
XX 10-MAR-1999; 98WO-US005190.
XX 20-APR-1999; 98WO-US008615.
XX 14-MAY-1999; 98WO-US010733.
XX 02-JUN-1999; 98WO-US012252.
XX 01-SEP-1999; 98WO-US020111.
XX 08-SEP-1999; 98WO-US020594.
XX 13-SEP-1999; 98WO-US020944.
XX 15-SEP-1999; 98WO-US021090.
XX 15-SEP-1999; 98WO-US021547.
XX 05-OCT-1999; 98WO-US023089.
XX 29-NOV-1999; 98WO-US028214.
XX 30-NOV-1999; 98WO-US028313.
XX 30-NOV-1999; 98WO-US028409.
XX 01-DEC-1999; 98WO-US028301.
XX 01-DEC-1999; 98WO-US028634.
XX 02-DEC-1999; 98WO-US028551.
XX 02-DEC-1999; 98WO-US028564.
XX 02-DEC-1999; 98WO-US028565.
XX 16-DEC-1999; 98WO-US030095.
XX 20-DEC-1999; 98WO-US030911.
XX 20-DEC-1999; 98WO-US030999.
XX 22-DEC-1999; 98WO-US030720.
XX 30-DEC-1999; 98WO-US031243.
XX 30-DEC-1999; 98WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 02-MAR-2000; 2000WO-US005841.
XX 10-MAR-2000; 2000WO-US006319.
XX 15-MAR-2000; 2000WO-US006884.

rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; PFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.

20-MAR-2000; 2000WO-US007377.
 21-MAR-2000; 2000WO-US007532.
 30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US0113705.
 22-MAY-2000; 2000WO-US011042.
 30-MAY-2000; 2000WO-US0114941.
 02-JUN-2000; 2000WO-US015264.
 28-JUL-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US022031.
 23-AUG-2000; 2000WO-US023522.
 24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030873.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000US-00747259.
 20-DEC-2000; 2000WO-US034956.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 10-MAY-2001; 2001US-00854280.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924413.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI: 2004-021499/02.
 P-PSDB; ADG70699.
 New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 in gene therapy for treating e.g. tumors, obesity, diabetes, hypo- or
 hyperinsulinemia, bone and/or cartilage disorders, stroke, or heart
 attack.
 Claim 2; SEQ ID NO 143; 638pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in

generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 cells, or stimulating differentiation of adipocyte cells, for
 stimulating proliferation of or gene expression in pericyte cells, for
 stimulating the proliferation of inner ear utricular supporting cells or
 T-lymphocyte cells, for inducing endothelial cell tube formation and for
 treating various bone and/or cartilage disorders such as sports injuries
 and arthritis. PRO polypeptides which stimulate the release of
 proteoglycans from cartilage are useful for treating sports-related joint
 problems, articular cartilage defects, osteoarthritis and rheumatoid
 arthritis. PRO polypeptides are also useful for treating various
 mammalian haemoglobin-associated disorders such as various thalassaemias
 and conditions which may benefit from enhanced local immune system cell
 infiltration. This sequence represents a human PRO polynucleotide of the
 invention. Note: The sequence data for this patent is also available in
 electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0
 US-10-791-980-6 (1-520) x ADG70698 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 20
 Db 206 ATGGTCGGCGCGTCGGCTCTCTGTCGGCGCGCTGTCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCCCGGAGCGCGGAGCGCAGAGCTGCCAAGGAGCGCGGAGCATTCCTCA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGTACCTCAATGACAGCTCCCAAGCTCCACCTCCATTCGATTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCCCTGCCCGCAGATGACTCGTCCCGCGGTTCAGATACCAACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTCTGTAGACACCGGACCAAAATGAGGGGTAA 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCACCTCTCTACCGCGCTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGGCTGAGCATCTGCCCGGAGCGCGAGTTCGGGGCGCGCGTCCGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGAGGCCAGCAGCCAGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACTTCTCCAAAGGGGAGCACCAACGATGGGCTGGGCAATGCTTGTGATGCG 805

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGCGGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCGACAGATGCTGCTCCCGCTCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgGly 120
DB 506 GCTTGGCTGAGAGGATCAGTGTGTTGTGTAGACACCGGACCAAAATGAGGGGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGTAAACAATGGTACACAGCACCACTCTCTACCGCTGGTG 525
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTGTATGCC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTGGCGACGCTTC-CTGCCCCGCGCGGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCTGAGCGCGCGCGGGCGCAACCTGTGTGTGTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGGCTCATGCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGCTGGGCGCGGACGCGCTGTCTAGCTGGGACGAGCTGTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyCysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTTCATGATGTCATCTCAGCCCGCCAGGAGCGCCCTGAAACCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCATGATGTCATCTCAGAGCGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGAGGAAAGATGGTGGCTGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAIT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCCATCTCTGAGCG 1464

QY 420 aAlaLeuPhePheProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTTGAGGAGGTGAGCGCGCTTCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTTCGACGAGGCCAACTGCAGGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

QY 520 e 520
DB 1765 C 1765

RESULT 213
ADG71250
ID ADG71250 standard; cDNA; 1985 BP.
XX
AC ADG71250;
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
US2003207421-A1.
XX
PD 06-NOV-2003.
XX
PF 08-MAY-2002; 2002US-00141701.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.

PR	20-APR-1999;	99WO-US0008615;
PR	12-JUN-1999;	99WO-US010733;
PR	04-JUN-1999;	99WO-US012252;
PR	01-SEP-1999;	99WO-US020111;
PR	08-SEP-1999;	99WO-US020594;
PR	13-SEP-1999;	99WO-US020944;
PR	15-SEP-1999;	99WO-US021090;
PR	15-SEP-1999;	99WO-US021547;
PR	05-OCT-1999;	99WO-US023089;
PR	29-NOV-1999;	99WO-US028214;
PR	30-NOV-1999;	99WO-US028313;
PR	30-NOV-1999;	99WO-US028409;
PR	01-DEC-1999;	99WO-US028301;
PR	01-DEC-1999;	99WO-US028304;
PR	02-DEC-1999;	99WO-US028851;
PR	02-DEC-1999;	99WO-US028864;
PR	02-DEC-1999;	99WO-US028565;
PR	16-DEC-1999;	99WO-US030095;
PR	20-DEC-1999;	99WO-US030911;
PR	20-DEC-1999;	99WO-US030720;
PR	22-DEC-1999;	99WO-US030720;
PR	30-DEC-1999;	99WO-US031243;
PR	05-JAN-2000;	99WO-US031274;
PR	05-JAN-2000;	2000WO-US000219;
PR	06-JAN-2000;	2000WO-US000277;
PR	06-JAN-2000;	2000WO-US000376;
PR	11-FEB-2000;	2000WO-US000365;
PR	18-FEB-2000;	2000WO-US004341;
PR	18-FEB-2000;	2000WO-US004342;
PR	22-FEB-2000;	2000WO-US004414;
PR	24-FEB-2000;	2000WO-US004914;
PR	24-FEB-2000;	2000WO-US005004;
PR	01-MAR-2000;	2000WO-US005601;
PR	02-MAR-2000;	2000WO-US005746;
PR	02-MAR-2000;	2000WO-US006319;
PR	15-MAR-2000;	2000WO-US006884;
PR	20-MAR-2000;	2000WO-US007377;
PR	21-MAR-2000;	2000WO-US007532;
PR	21-MAR-2000;	2000WO-US008439;
PR	17-MAY-2000;	2000WO-US013705;
PR	22-MAY-2000;	2000WO-US014042;
PR	30-MAY-2000;	2000WO-US014941;
PR	28-JUN-2000;	2000WO-US015264;
PR	28-JUL-2000;	2000WO-US020710;
PR	11-AUG-2000;	2000WO-US020231;
PR	24-AUG-2000;	2000WO-US023522;
PR	08-NOV-2000;	2000WO-US030952;
PR	10-NOV-2000;	2000WO-US030873;
PR	01-DEC-2000;	2000WO-US032678;
PR	20-DEC-2000;	2000US-U0747259;
PR	28-DEC-2000;	2000WO-US034956;
PR	28-FEB-2001;	2001US-U0796498;
PR	28-FEB-2001;	2001WO-US006520;
PR	01-MAR-2001;	2001WO-US006666;
PR	09-MAR-2001;	2001WO-US006706;
PR	14-MAR-2001;	2001US-U0802766;
PR	22-MAR-2001;	2001US-U0816744;
PR	05-APR-2001;	2001US-U0828366;
PR	10-MAY-2001;	2001US-U0854208;
PR	18-MAY-2001;	2001US-U0860216;
PR	25-MAY-2001;	2001US-U086028;
PR	25-MAY-2001;	2001US-U0866034;
PR	25-MAY-2001;	2001WO-US017092;
PR	01-JUN-2001;	2001US-U0872035;
PR	01-JUN-2001;	2001WO-US017800;
PR	05-JUN-2001;	2001US-U0874503;
PR	14-JUN-2001;	2001US-U0882636;
PR	19-JUN-2001;	2001US-U0886342;
PR	21-JUN-2001;	2001WO-US019692;
PR	21-JUN-2001;	2001US-U0887879;

22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-021500/02.
P-PSDB; ADG71251.

New secreted and transmembrane PRO nucleic acid, useful in gene therapy
for treating e.g. tumors, obesity, diabetes, hypo- or hyperinsulinemia,
bone and/or cartilage disorders, stroke, or heart attack.

Claim 2; SEQ ID NO 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumors, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
cells, for stimulating differentiation of adipocyte cells, for
stimulating proliferation of or gene expression in pericyte cells, for
stimulating the proliferation of inner ear utricular supporting cells or
T-lymphocyte cells, for inducing endothelial cell tube formation and for
treating various bone and/or cartilage disorders such as sports injuries
and arthritis. PRO polypeptides which stimulate the release of
proteoglycans from cartilage are useful for treating sports-related joint
problems, articular cartilage defects, osteoarthritis and rheumatoid
arthritis. PRO polypeptides are also useful for treating various
mammalian haemoglobin-associated disorders such as various thalassemias
and conditions which may benefit from enhanced local immune system cell
infiltration. This sequence represents a human PRO polynucleotide of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP: 403 A: 646 C: 604 G: 332 T: 0 U: 0 Other:

Alignment Scores:		
Pred. No.:	1.93e-149	Length:
Score:	2792.00	Matches:
Percent Similarity:	99.62%	Conservative:
Best Local Similarity:	99.62%	Mismatches:
Query Match:	98.52%	Indels:
DR:	12	Gaps:
		1985
		519

UUS-10-791-980-6 (1-520) x ADG71250 (1-1985)

Qy	1	M	e	t	V	a	l	a	a	r	g	v	a	l	g	l	y	l	e	u	l	e	u	a	r	g	a	l	e	u	g	i	n	l	e	u	t	r	p	g	l	y	h	i	s	t	e	u	20					
Db	206	A	T	G	T	C	G	C	G	C	G	T	C	T	G	C	T	T	C	T	G	C	T	T	G	C	G	C	C	C	T	G	C	A	G	T	G	C	T	A	C	T	G	T	G	G	G	C	C	A	C	C	T	G

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCCCGGAGCGCGAGCCAGAGCTGGCGAAGGGGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCCACTCCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCACTGGGTGCTCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
DB 446 GCCACCCCTCGCCAGATGCTGCTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTGGGCTGAGAGGATCAGTGAATGTTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAATGATACAGCAGACCTCTCTACCGCCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGSCCTGAGCATCTGCGGAGCGGCAGTTCTGGGGCGCGCTGGCGCGCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCCGCGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGACCGCCTTC-CTGCCCCCGCGCGGCAAGCGCACTTCACCA 864
QY 220 nAspGluArgTrpSerLysArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
DB 865 AGATGAGCGCTGCTCCTCAGCGCGCGCGCGCAACCTGTTCTGTGCTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGGCGCGGACCGCTGTCTAGCTGGGACGAGCTGCTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTCGAAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCAATTTCTGGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerie 380
DB 1285 TCCACTGCGAAGAAATGGTGGGCTGCGGCTGCCCCCAACATTAGGCTGCGGCACTGTCTATT 1344

QY 380 uAenAspGlyAspPheTyrPhePheLysGlyArgCysTyrArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTTTCAAGGGGCTGATGCTGGAGGTTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisPheAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCGGCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CCCCCTCTTTCTTCCCTCTCTCGCGGCTCATCTCTTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTCTTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCCCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 214
ADG81437
ID ADG81437 standard; cDNA; 1985 BP.
XX
AC ADG81437;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003207805-A1.
XX
PD 06-NOV-2003.
XX
PF 28-MAY-2002; 2002US-00156843.
XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.

PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 12-NOV-1997; 97US-0064809P.
PR 17-NOV-1997; 97US-0065186P.
PR 21-NOV-1997; 97US-0065846P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-00692112P.
PR 11-DEC-1997; 97US-0069278P.
PR 16-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0073220P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077919P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085523P.
PR 13-MAY-1998; 98US-0085538P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089539P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.

PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 15-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.


```
Db      1105  ||||| CACTGACTTTGAGACCTGGGACTCCTACAGCCCGCCAAAGGAAGCGCCCTGAAACCGAGGG 1164
Qy      320  YProLyVeTyCyEHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTTAATACTGCACACTCTTCCTTCGATGCGCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy      340  rIlePheLyGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGCCATTTCGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy      360  gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCGAAGAAGATGGGTGGGCTGCCCGCCCAACATTGAGCGCTCGCGACGTGCA 1344
Qy      380  uAsnAspGlyAspPheTyPhePheLyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy      420  alaLeuPhePheProLeuArgArgLeuIleLeuPheLyGlyAlaArgTyTrVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyTrTyProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGGCCCGAGGGGAGACTGCAAGTGGAGGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy      480  eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTTGGCGCCTCGACAGGCCAACTGCAGGCAACCACTCGGGCCG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 216
ADH11766
ID      ADH11766 standard; cDNA; 1985 BP.
XX
AC      ADH11766;
XX
DT      11-MAR-2004 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW      Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW      transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW      chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW      rectum; kidney; cervix; liver; microvascular endothelial cell;
KW      glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW      cell differentiation; skeletal muscle cell; adipocyte cell;
KW      pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW      immune system cell infiltration; chromosome mapping; gene mapping;
KW      gene therapy; chromosome identification; chromosome marker; gene, ss.
XX
OS      Homo sapiens.
XX
PN      US2003207419-A1.
```



```
Db      985  |||||CTACTACAGAGCGTGGCGCGACGCGTGTCTCAGCTGGACGAGTGTGCGCCGTGCA 1044
Qy      280  nSerLeuTyrGlyValProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyValArgProGluThrGlnG 320
Db      1105  CACTGACTTTGAGACCTTGGACTCTTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db      1165  CCTTAAATACGCACTTCTCTTCGATGCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
Qy      360  gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCGAGGAAGATGGTGGGCTGCCGCCCAACATTGAGCTGCGGCGAGTGTCAT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyPro 400
Db      1345  GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy      400  sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCCAAGCTGTGCCGGGCGAGGGGCTGCCCGCCATCCTGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyValArgTyrTyrVa 440
Db      1465  CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTCAGGAGCTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCGAGGCGCGATGGCTCCATCATCTTCT 1644
Qy      480  eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAACTGCAGGCAACCACTCGGGCGG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 217
ADGS2188
ID  ADGS2188 standard; cDNA; 1985 BP.
XX
AC  ADGS2188;
XX
DT  11-MAR-2004 (first entry)
XX
DE  Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW  human; PRO; membrane bound protein; membrane bound receptor;
KW  cell proliferation; cell migration; cell differentiation;
KW  mitogenic factor; survival factor; cytotoxic factor;
KW  differentiation factor; neuropeptide; hormone; cell receptor;
KW  receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS  Homo sapiens.
XX
```



```
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATAGTGCACCTCTTCCTTCGATGCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGCTGGGCTGCGCCCAACATTGAGGCTGGCGCATGTCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyA-gCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGTCGAGGTTCGGGGCCCCAA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCCAAGCTGTGCGGGGAGGGGGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCCTCTCTGCGCGCTCATCTCTTCAAGGTGCGCGCTACTACGT 1524
Qy 440 lLeuAlaA-gGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGCCAACTGACAGCAACCACTTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTCGATGGCTGCTGGCATGCCAATCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 218
ADGS3916
ID ADGS3916 standard; cDNA; 1985 BP.
XX
AC ADGS3916;
XX
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytosstatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003207416-A1.
XX
PD 06-NOV-2003.
XX
PF 06-MAY-2002; 2002US-00140023.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
```

PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00860208.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00870192.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001US-00872035.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001US-0019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001US-0020116.
 PR 29-JUN-2001; 2001US-00201066.
 PR 09-JUL-2001; 2001US-0021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI; 2004-059757/06.
 DR P-PSDB; ADG53917.
 XX
 PT New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor, for chromosome mapping, or for tissue
 PT typing.
 XX
 PS Claim 2; SEQ ID NO 143; 637pp; English.
 XX
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 XX

Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG53916 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20

Db 206 ATGTCGGCGCGCTCGGCTCTCTGCTGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCGCGGAGCGGAGCGGAGCTGCGCAAGGAGCGGAGCATTCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACATTCAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCCACAGTACTCTGTACAGGGCGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATCGC 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTCTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAAAGCTTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTCTGGGGCGCGTGGCGCGCGCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGTCTCAGCGCTGAGTCTTGGAGAGGCCCCAGCACAGGCCCCGCTGAC 745
 Qy 180 rSerGlySerProSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCAGCTTCTTCCAAGGGGACCAACAATGGGCTGGGCAATGCCCTTGTATGCG 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 Db 806 CCAGGGGCGCGCTTGGGGCGAGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGGCGCAACCTGTTCGTGGTGGTGGCGCA 924
 Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACAGCTTGGGCTCAGCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
 Db 985 CTACTACAAGAGGCTGGGCGCGAGCGGCTGCTCAGCTGGGAGCAGCGTGTGGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCGCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGAAAGCTGT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAGGAAGGCGCTGAAACGACGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCCTAAATATCTGCCCATCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGGAGGCAATTTCTGGAGGTGGAGCTGTATGGCAACGCTTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGGAGTGTCTATT 1344

```

QY      380 uAenAspGlyAspPheTyr:PhePheLysGlyArgCysTyrArgPheArgGlyProLy 400
      |||||
Db      1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
      |||||
Db      1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464

QY      420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
      |||||
Db      1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAAGGGTGCCTCTACTACGT 1524

QY      440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
      |||||
Db      1525 GCTGGCCCGGAGGAGTGCNAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584

QY      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
      |||||
Db      1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCGAGGCGCATGGCTCCATCATCTTCTT 1644

QY      480 eArgAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
      |||||
Db      1645 CCGAGATGACCGCTACTGCGGCTCGACCGAGCCAACTGCAGGCAACCACTCGGGCGG 1704

QY      500 gTrpAlaThrGluLeuProTyrMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
      |||||
Db      1705 CTGGGGCACGAGTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

QY      520 e 520
Db      1765 C 1765

RESULT 219
ADG80885
ID      ADG80885 standard; cDNA; 1985 BP.
XX
AC      ADG80885;
XX
DT      11-MAR-2004 (first entry)
XX
DE      Human PRO polynucleotide #72.
XX
KW      Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW      tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW      cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW      liver; microvascular endothelial cell; glucose; FFA;
KW      skeletal muscle cell; adipocyte cell; pericyte cell;
KW      inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW      immune system cell infiltration.
XX
OS      Homo sapiens.
XX
PN      US2003194793-A1.
XX
PD      16-OCT-2003.
XX
PF      15-APR-2002; 2002US-00123214.
XX
PR      31-MAR-1997; 97WO-US005230.
PR      12-JUN-1998; 98WO-US02456.
PR      14-JUL-1998; 98WO-US014552.
PR      28-AUG-1998; 98WO-US017888.
PR      10-SEP-1998; 98WO-US018824.
PR      14-SEP-1998; 98WO-US019093.
PR      14-SEP-1998; 98WO-US019094.
PR      14-SEP-1998; 98WO-US019177.
PR      16-SEP-1998; 98WO-US019330.
PR      17-SEP-1998; 98WO-US019437.
PR      07-OCT-1998; 98WO-US021141.
PR      29-OCT-1998; 98WO-US022991.
PR      29-OCT-1998; 98WO-US022992.
PR      30-NOV-1998; 98WO-US024855.
PR      01-DEC-1998; 98WO-US025108.
PR      05-JAN-1999; 99WO-US000106.
PR      08-MAR-1999; 99WO-US005028.
PR      10-MAR-1999; 99WO-US005190.
PR      10-MAR-1999; 2000WO-US006319.
PR      20-APR-1999; 99WO-US008615.
PR      14-MAY-1999; 99WO-US010733.
PR      02-JUN-1999; 99WO-US012252.
PR      01-SEP-1999; 99WO-US020111.
PR      08-SEP-1999; 99WO-US020594.
PR      13-SEP-1999; 99WO-US020944.
PR      15-SEP-1999; 99WO-US021090.
PR      15-SEP-1999; 99WO-US021547.
PR      05-OCT-1999; 99WO-US023089.
PR      29-NOV-1999; 99WO-US028214.
PR      30-NOV-1999; 99WO-US028313.
PR      30-NOV-1999; 99WO-US028409.
PR      01-DEC-1999; 99WO-US028301.
PR      01-DEC-1999; 99WO-US028634.
PR      02-DEC-1999; 99WO-US028551.
PR      02-DEC-1999; 99WO-US028564.
PR      02-DEC-1999; 99WO-US028565.
PR      16-DEC-1999; 99WO-US030095.
PR      20-DEC-1999; 99WO-US030911.
PR      20-DEC-1999; 99WO-US030999.
PR      22-DEC-1999; 99WO-US030720.
PR      30-DEC-1999; 99WO-US031243.
PR      30-DEC-1999; 99WO-US031274.
PR      05-JAN-2000; 2000WO-US000219.
PR      06-JAN-2000; 2000WO-US000277.
PR      06-JAN-2000; 2000WO-US000376.
PR      11-FEB-2000; 2000WO-US003565.
PR      18-FEB-2000; 2000WO-US004341.
PR      18-FEB-2000; 2000WO-US004342.
PR      22-FEB-2000; 2000WO-US004414.
PR      24-FEB-2000; 2000WO-US004914.
PR      24-FEB-2000; 2000WO-US005004.
PR      01-MAR-2000; 2000WO-US005601.
PR      02-MAR-2000; 2000WO-US005746.
PR      02-MAR-2000; 2000WO-US005841.
PR      15-MAR-2000; 2000WO-US006884.
PR      20-MAR-2000; 2000WO-US007377.
PR      21-MAR-2000; 2000WO-US007532.
PR      30-MAR-2000; 2000WO-US008439.
PR      17-MAY-2000; 2000WO-US013705.
PR      22-MAY-2000; 2000WO-US014042.
PR      30-MAY-2000; 2000WO-US014941.
PR      02-JUN-2000; 2000WO-US015264.
PR      28-JUN-2000; 2000WO-US020710.
PR      11-AUG-2000; 2000WO-US022031.
PR      23-AUG-2000; 2000WO-US023522.
PR      24-AUG-2000; 2000WO-US023328.
PR      08-NOV-2000; 2000WO-US030952.
PR      10-NOV-2000; 2000WO-US030873.
PR      01-DEC-2000; 2000WO-US032678.
PR      20-DEC-2000; 2000US-0074259.
PR      20-DEC-2000; 2000WO-US034956.
PR      28-FEB-2001; 2001US-00796498.
PR      28-FEB-2001; 2001WO-US006520.
PR      01-MAR-2001; 2001WO-US006666.
PR      09-MAR-2001; 2001US-00802706.
PR      14-MAR-2001; 2001US-00808689.
PR      22-MAR-2001; 2001US-00816744.
PR      05-APR-2001; 2001US-00828366.
PR      10-MAY-2001; 2001US-00854208.
PR      10-MAY-2001; 2001US-00854280.
PR      18-MAY-2001; 2001US-00860216.
PR      25-MAY-2001; 2001US-00866028.
PR      25-MAY-2001; 2001US-00866034.
PR      25-MAY-2001; 2001WO-US017092.

```

PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874530.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2004-106646/11.
 DR P-PSDB; ADG80886.
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX Claim 2; SEQ ID NO 143; 638pp; English.
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems.
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2

DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG80885 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGGCGCGTGGCGCTCTGCTGGCGCCCTCAGCTGCTACTGTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCCCGCGAGCGCGAGCGCAGAGCTGCGCAAGAGGCGGAGGCAATTCCTA 325
 QY 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAAGTACGGATACCTCAATGAACAGTCCCAAGAGCTCCCACTCCACATCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCACGACTCTGTCTCAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGGTAA 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTCCACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGGCTGAGCATCTCGCGAGCGCGAGTCTCGGGCGCGTTCGGCGCGCTTCAG 685
 QY 160 rCvsGlyValaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGACACGTCTCAGCGCTGGAGTTCGTGGAGGCGCCCGACACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACTCTTCTTCAAGGGGACACAAACGATGGCTGGGCAATGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCGCTTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTTCCTTGAGCCCGCGCGGGCGCAACCTGTTGTGTGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGTCCACACGCTTGGCCCTCACCCACTGCCCGCGCGCGCTCATGGCGCC 984
 QY 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGGTCCAGAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCAAGGAAGGCGCCCTGAACGCGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCCTAAATACATGCGCACCTCTCTTCATGTCATCCTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360

Db 1225 CATTTTAAAGGAGGAGCTTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProAenlleGluAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGATGGTTCGGCTGCCCCCAACATTGAGGCTGCGGCGATGTCATT 1344
Qy 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGCGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCGCTGCCCGGCCATCTCCAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTTCTTCTCCCTCTCTGGCCGCTCTATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
Db 1525 GCTGGCCCGAGGGGAGTGAAGTGGAGCCCTACTACCCCGAGGCTGCAGAGCTGGGG 1584
Qy 460 yGlylleProGluGluValSerGlyAlaLeuProArgProAspGlySerllePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCGCAAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 220
ADG56124
ID ADG56124 standard; cDNA; 1985 BP.
XX AC ADG56124;
XX AC
XX DT 11-MAR-2004 (first entry)
XX XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell
KW receptor-ligand interaction; cytotatic; chondrocyte; tumour; ss; gene.
XX OS Homo sapiens.
XX XX
XX PN US2003207366-A1.
XX XX
XX PD 06-NOV-2003.
XX XX
XX PF 09-MAY-2002; 2002US-00143027.
XX XX
XX PR 03-MAR-2000; 2000US-0187202P.
XX PR 01-DEC-2000; 2000WO-05032678.
XX PR 19-DEC-2001; 2001WO-00028072.
XX XX
XX PA (GETH) GENENTECH INC.
XX XX
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski FU, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2004-051516/05.
XX P-PSDB; ADG56125.
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The fate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neuropeptides and hormones) which are received and interpreted by diverse
XX cell receptors or membrane bound proteins. These membrane bound proteins
XX as in the blocking of receptor-ligand interactions. The current invention
XX provides the amino acid sequences of novel human membrane bound receptors
XX and proteins, along with the cDNA sequences encoding them. The novel
XX proteins of the invention may have cytostatic activities through the
XX stimulation of chondrocytes. The nucleic acids of the invention may be
XX useful for the manufacture of a medicament for diagnosing or treating a
XX tumour in a mammal. In addition, they may be useful for measuring or
XX detecting the expression of a tumour associated gene. The present
XX sequence is a cDNA sequence which encodes a human PRO protein of the
XX invention.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG56124 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 206 ATGTTCGGCGCGCTCGGCTCTCTGCTCGCGCCCTGCAGCTCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGAGCGCGAGCGCGAGCTGCGCAAGGAGCGCGGAGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCATCAGAGCGTTTCAGTGGGTGCCAGCTACTCTGCAGCGCGGTGTGGACCGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTyrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTTGTTCCTAGACACCGGACCCAAATGAGGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAGCTTTGCAAGCAAGGATTAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160

Db 626 AACTGGCCTGAGCATCTCGCGAGCGGCAGTTTCGGGCGCGCTGCGCGCCCTTCACG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCCTGGAGAGGCCACAGGCCACAGGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGAGCACCAACAGATGGCTGGGCAATGCCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGAGCGCTGTCTCCTGAGCGCGCGCGGGCGCAACCTGTTGCTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaApr 260
Db 925 CCGAGATCGGTACACGCTTGGCTCACCCACTGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCCGAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGACACTGGGACTCTACAGCCCCCAAGAGGCGCCCTGAAACCGCAGGG 1164
Qy 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAGAAAGTGGTGGGCTGCCCCCCCAACATTGAGGTGGGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGGGGAGGGGGCCCTGCCCCGCCATCTCCAGCGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpTrpVa 440
Db 1465 CGCCCTCTCTTCCTCTCTGCGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCCCTGCGGAGGCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAATGCGAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 221

ADH12390

ID ADH12390 standard; cDNA; 1985 BP.

XX

AC ADH12390;

DT 11-MAR-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
XX transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
XX rectum; kidney; cervix; liver; microvascular endothelial cell;
XX glucose uptake modulator; FFA uptake modulator; cell proliferation;
XX cell differentiation; skeletal muscle cell; adipocyte cell;
XX pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
XX immune system cell infiltration; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker; gene; ss.

OS Homo sapiens.

XX US2003207378-A1.

XX 06-NOV-2003.

PD

XX

XX 17-MAY-2002; 2002US-00147535.

XX

XX 05-JUN-2000; 2000US-0209832P.

XX

XX 01-DEC-2000; 2000WO-US032678.

XX

XX 19-DEC-2001; 2001US-00028072.

XX

XX (GETH) GENENTECH INC.

XX

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2004-069292/07.

XX P-PSDB; ADH12391.

XX

PT New PRO nucleic acids, useful in diagnosis and treatment of cancer, for

XX chromosome mapping or for tissue typing.

XX

PS Claim 2; SEQ ID NO 143; 637pp; English.

XX

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte

KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003207429-A1.
XX
PD 06-NOV-2003.
XX
PF 30-MAY-2002; 2002US-00158791.
XX
31-MAR-1997; 97WO-US0052230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019177.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 08-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 20-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 08-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US0004341.
PR 18-FEB-2000; 2000WO-US0004342.
PR 23-FEB-2000; 2000WO-US0004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882536.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-021504/02.
DR P-PSDB; ADG61237.
XX
DR New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX Claim 2; SEQ ID NO 143; 638pp; English.
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or hormone bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADH28323 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB 206 ATGTTGCGCGGCTCGGCTCTCTGTCGCGCGCTCGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCCCGGAGCGGAGGCCAGGAGCTGGCGAAGGCGGCGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCAATCAGACGTTTCAGTGGGTGTCCTGAGCTACCTGTGAGCGGCGGTGTGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCCAGATGACTGTCCTCCGCTCGCGGGTTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCTTGGGCTGAGAGGATCAGTACTGTTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAANAGCAAGGTAAATGTTAAAGACGACCTCTCTTACCCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 NAATGGCTGAGCANTCTGCGGAGCGCGGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGCAATGCTTTGATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCTGGCGACGCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGCTCCTGAGCGCGCGCGGGGCAACCTGTTCTGTTGTTGTTGTTGTTG 924
 QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

DB 925 CGAGATCGTCCACACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAGAGGCTGGGCGCGCGCTGTCTAGCTGGGACGACGTCTGGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACTTGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACCGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTAGAGCCCCG 1284
 QY 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGGCACTGTCATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGTGGAGGTTCCGGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGGGGTCTTCCACAGCTGTGCGCGGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCTTACTTACCCCGGAGCTCTGACGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGATCCTCAGGAGGTGAGCGGCGCTTCCGAGGGCGGATGGCTCCATCTTCTTCT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCCCAACTGACAGGCAACCACTCGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGGGCGCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 224
 ADG54468
 ID ADG54468 standard; cDNA; 1985 BP.
 XX
 AC ADG54468;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuropeptide; hormone; cell receptor;

KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX Homo sapiens.
OS US2003207367-A1.
XX
PN 06-NOV-2003.
XX
PD 09-MAY-2002; 2002US-00143115.
XX
PF 03-MAR-2000; 2000US-0187202P.
XX
PR 01-DEC-2000; 2000WO-US032678.
PR
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-051517/05.
DR P-PSDB; ADG54469.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
PS
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG54468 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTTCGGCGGTGGCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCCGAGCCCGAGCGCGAGGAGCTGCGCAGGAGCGCGAGCATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60

Db 326 GAGAACTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTCCTGTACGGCGGTGTGGACCGC 445
QY 81 AlaThrIleuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTTGTGTGTAGACACCGACCAAAATCAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGAGCCGCGAGTTCTGGGCGCCGCTGCGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTTCTCAGCGCTGAGTCTCTGGGAGGCCCCAGCCACAGGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAGGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGCTCCCTGAGCCCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTTCACACGCTTGGCCCTCAGCCCACTCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACGCCACCTCTTCTTCATGTCATCCTCAGTACAGAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCGC 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGAGAAAGATGGGTGGGCTCGCGCTGCCCCCCCAACATTGAGGCTGGCGAGTGTCAIT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATCTGGAGGTTCGCGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCCAACAGCTGTGCGGGGAGGGGCGCTGCGCCGCTCCTGACGC 1464


```
QY 220 nAspGluAArgTrrSerLeuSerArgArgGlyAArgAanLeuPheValValLeuAlaHi 240
|
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTGCTGGTGGCGCA 924
|
QY 240 sGluileGlyHsrThrLeuGlyLeuThrHisSerProAlaProAargAlaLeuMetAlaPr 260
|
Db 925 CGAGATCCGTACACGCTGGCCTCACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
|
QY 260 oTrrTrrLysArgLeuGlyAArgAspAlaLeuSerTrpAspValLeuAlaValGI 280
|
Db 985 CTACTACAAGAGCTGGCGCGCGCGCTGCTCAGCTGGCAGCAGCTGCTGGCGGTGCA 1044
|
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
|
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAGCTGTT 1104
|
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyAArgProGluThrGlnGI 320
|
Db 1105 CACTGACITTTAGACCTGGGACTCTCAGCCCCCAGAGGCCCTGAAACGCGAGG 1164
|
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
|
Db 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
|
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAanValSerGluProAr 360
|
Db 1225 CATTTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
|
QY 360 gProLeuGlnGluAArgTrrValGlyLeuProProAenlleGluAlaAlaValSerLe 380
|
Db 1285 TCACCTGCAGGAAGAATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
|
QY 380 uAenAspGlyAspPheTrrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
|
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCCGGGGCCCA 1404
|
QY 400 sProValTrrGlyLeuProGlnLeuCysAArgAlaGlyGlyLeuProAArgHisProAspAl 420
|
Db 1405 GCAGTGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCTGCCCGGCCATCTCTGAGCG 1464
|
QY 420 aAlaLeuPheProProLeuAArgLeuIleLeuPheTysGlyAlaAArgTrrTrrVa 440
|
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
|
QY 440 lLeuAlaAArgGlyGlyLeuGlnValGluProTrrTrrProAArgSerLeuGlnAspTrpGI 460
|
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
|
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
|
Db 1585 AGGCATCCCTGAGGAGTCAAGGGCCCTGCGAGGCCCGATGGCTCCATCATCTTCTT 1644
|
QY 480 eArgAspAspAArgTrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
|
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAAGGCCAACTGCAGGCCAACCACTCGGGCGG 1704
|
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAanSerGlySerAlaLeuPh 520
|
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
|
QY 520 e 520
|
Db 1765 C 1765

RESULT 226
ADI80932
ID ADI80932 standard; cDNA; 1985 BP.
XX
AC ADI80932;
XX
DT 15-APR-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
```

XX KW Human, gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003207361-A1.

XX XX 06-NOV-2003.

XX XX 08-MAY-2002; 2002US-00141759.

XX XX 03-MAR-2000; 2000US-0187202P.

XX XX 30-MAY-2000; 2000WO-US014941.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX XX (GETH) GENENTECH INC.

XX PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2004-010597/01.

XX DR P-PSDB; ADI80933.

XX XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide useful for stimulating the release of tumor necrosis factor alpha from human blood and in treating and detecting a tumor.

XX PT Claim 2; Fig 143; 637pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumor necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1 93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADI80932 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGCGCGCTCGGCTCTCTGCTCGCGCTCGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGlnArgGlyGlnGlnLeuLeuArgGlyGlnAlaGlnAlaPheLeu 40
 DB 266 GACGCCAGCCCGGAGCGCGAGGCGCAGAGCTGCGCAAGGAGCGGCGGCAATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCATCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 DB 386 GATGCCATCAGAGGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGGCTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgProArgGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgLys 120
 DB 506 GCTTGGGCTGAGAGGATCAGTACCTGTTGTGTAGACACCGGACCAAAATGAGGGGTAAG 565
 QY 121 LysArgPheAlaLysGlnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGTAAACAAATGATACAGCAGCACCTCTCTACCGCTGTGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGGCCCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACTCTTCCAGGGGACCAACAGATGGGCTGGGCATATGCTTGTATGGC 805
 QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
 DB 806 CCAGGGGGCGCTGCGGCAAGCTTC-CTGCCCCCGCGCGGCGCAACCTGTGTGTGTGCTGCGGCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTGTGTGTGCTGCGGCA 924
 QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCCCGCGCGCGGCTCATGCGGCGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGTGGGACGACGCTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGACTGTT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACITTTGAGACTTGGACTCTCTACAGCCCCCAAGGAAGGCGCTTAAACGAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGCAGGAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTGCGGCACTGTCATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGGCTTGCCTCCGCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTTCCCTCTCTGCGGCGCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
 QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
 DB 1585 AGCATCTCTGAGGAGGTGACGCGGCGCTTGCAGGGCCGATGCTCCATCATCTCTTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCTGTT 1764
 QY 520 e 520
 DB 1765 c 1765
 RESULT 227
 ADG09675
 ID ADG09675 standard; cDNA, 1985 BP.
 XX ADG09675;
 AC ADG09675;
 DT 22-APR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; PFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2004009548-A1.
 XX
 PD 15-JAN-2004.
 XX

PF 07-MAY-2002; 2002US-00140927.
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2004-090467/09.
DR P-PSDB; ADG09676.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG09675 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTGGCGGGTGGCGCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCCGCCCGAGCGCGAGCGCCAGGAGCTGCGCAGAGCGCGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCCAAGCTCCCACTCGATTTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGAGTACCTGTTCAGCGCGTGTTCGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAspSerTyrAla 100
DB 446 GCCACCCCTGCCCCAGATGACTGTCGCCGCTGCGGGGTTCAGATACCAACAGTTATCGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATCAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGACCTCTCCTACCGCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCCGGAGCCGCGAGTTTCGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyValaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCCTCAGCGCTCGAGTTCCTGGGAGGCCCCCAGCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTCCAAAGGGGACCAACACATGGGCTGGGCAATGCTCTTTGATGGC 805
QY 200 aGlnGlyValaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCCCTGGGCGACGCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTAGCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACGCTTGGCCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTCAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTTAATATCTGCCACTCTTCTTCGATGCCATCCTCCTAGACAGAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCCGCGCTGCCCGCAACATTGAGGCTCGGCAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACACAGCTGTGCCGGCAGGGGGCGCTGCCCGCCCATCTCTGACGC 1464

QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuLeuPheLeuGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGCCCGTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTCAGGACTGGGG 1584
 QY 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTAGCGCGCCCTGCGAGGCCGATGGCTCATCATCTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGCGCCCTCGACCGGCCAACTGCAGGCAACCACTCGGGCG 1704
 QY 500 GTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 228
 ADI15146
 ID ADI15146 standard; cDNA; 1985 BP.
 XX AC ADI15146;
 XX DT 22-APR-2004 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker; gene; ss.
 XX OS Homo sapiens.
 XX PN US2003207382-A1.
 XX PD 06-NOV-2003.
 XX PF 21-MAY-2002; 2002US-00152381.
 XX PR 03-MAR-2000; 2000US-0187202P.
 XX PR 01-DEC-2000; 2000WO-US032678.
 XX PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2004-032742/03.
 XX DR P-PSDB; ADI15147.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 143; 647pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 SQ
 Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0
 US-10-791-980-6 (1-520) x ADI15146 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGCGCGCTCGGCTCTCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
 Db 266 GACGCCCGAGCCGCGAGCGCGGAGGAGCTGCGCAAGAGGCGGAGGAGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCCACTGTACCTGTCCAGCGCGTGTGTGGACCCG 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTATATGGG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCCAAATAGGGCGTAA 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACTCTCTACCGCTGGTG 625
Qy 141 AenTrrProGluHiSieu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGGAGCATCTGCGGAGCGCGCAGTTCGGGGCGCGTTCGGCGCGCTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnAtrgTrrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCGGAGGCCCAACAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLySgLyThrThrMetGlyTrrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGAGCACCACAGATGGCTGGCAATGGCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCGCTGGCGACGCCCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAepGluArgTrrSerLeuSerArgArgGlyVArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGTGGCGCC 984
Qy 260 oTyrTrrLySArgLeuGlyArgAspAlaLeuLeuSerTrrPaspValLeuAlaValG1 280
Db 985 TCTACTACAGAGGCTGGCGCGCGCGCTGTCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
Qy 280 nSerLeuTrrGlyLySProLeuGlyGlySerValAlaValGlnLeuProGlyLyLeuPh 300
Db 1045 GAGCCTGTATGGAGAGCCCTCAGGGGGCTCAGTGGCGGTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrrPaspSerTySxerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCCCAAGGAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLySrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATAATCGCCACTCTCTCCATGCGCATCACTGTAGACAGGCAACGCACTGTA 1224
Qy 340 rIlePheLySgLySerHisPheTrrPgluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrrValGlyLeuProProAsenIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTrrPhePheLySgLyGlyArgCysTrrPargPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrrPgluLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCCGCCATCTCAGCGC 1464
Qy 420 alalaLeuPhePheProProLeuArgArgLeuLeuPheLySgLyAlaArgTrrTyVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGTGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrrTyrrProArgSerLeuGlnAspTrrG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGCAAGCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTTGGAGAGGTGAGCGGCGCTGCGGAGGCCGATGCTCATCATCTCTT 1644
Qy 480 eArgAspAspArgTrrTyrrArgLeuAspGlnAlaLySLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGACAGGCCAAACACACTCGGGCGG 1704

Qy 500 gTrrAlaThrGluLeuProTrrMetGlyCysTrrPheHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765
RESULT 229
ADG09023
ID ADG09023 standard; cDNA; 1985 BP.
XX
AC ADG09023;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2004009547-A1.
XX
PD 15-JAN-2004.
XX
PF 23-APR-2002; 2002US-00128692.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032878.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WP1; 2004-090466/09.
DR P-ESDB; ADG09024.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
PS Claim 2; SEQ ID NO 143; 658pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for treating
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome

Db	1165	CCCTAAATACGCCCACTTCCTCTCGAGGCATCAGTGTAGACGAGCAACAGCAACTGTA	1224
Qy	340	rilePheIysGlySerHisPheTrpGluValAlaAAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCACATTCTCGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAGAAGATGGGTCCGGCTGCCGCCCAAATTGAGGCTCGCGCAGTGTCATT	1344
Qy	380	wAsnAspGlyAspPheTyrrPhePheIysGlyItyrGlyCysTrpArgPheArgGlyProLy	400
Db	1345	GAAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyItyrLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCCAACAGCTGTGCCGGGAGGGGGCTGCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLgLeuIleLeuPheIysGlyAlaHArgTyrrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyItyrLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCAGAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGAGGGCCGATGGCTTCATCATCTTCCT	1644
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrserGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACCAGGCGAACACTGCAGGCAACCACTCGGSCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGTGCCTGGATGGGCTGTGTCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520 e	520	
Db	1765 c	1765	
RESULT 231			
ID	ADI18073 standard; cDNA; 1985 BP.		
XX	ADI18073;		
XX	ADI18073;		
DT	22-APR-2004 (first entry)		
DE	Novel human secreted and transmembrane protein PRO4339 cDNA.		
KW	Human; secreted and transmembrane protein; PRO; secreted polypeptide;		
KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;		
KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;		
KW	rectum; kidney; cervix; liver; microvascular endothelial cell;		
KW	glucose uptake modulator; FFA uptake modulator; cell proliferation;		
KW	cell differentiation; skeletal muscle cell; adipocyte cell;		
KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;		
KW	immune system cell infiltration; chromosome mapping; gene mapping;		
KW	gene therapy; chromosome identification; chromosome marker; gene; ss.		
OS	Homo sapiens.		
PN	US2003207349-A1.		
PD	06-NOV-2003.		
PF	03-MAY-2002; 2002US-00137867.		


```

Db      1045  |||||GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy      300  eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db      1105  CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTTAATAGTGCACCTCTCTTCGATGCCATCACTGTAGACAGCAAGCACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheThrPGLuValAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGTCTCAGAGCCCG 1284
Qy      360  gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCAGGAAGAAGATGGTGGGCTGCCCCCAACATTTAGGCTGCGGCAGTGCA 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTTPArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400  sProValTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCATCTCTGACG 1464
Qy      420  alaLeuPhePheProProLeuArgArgLeulleLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGGTGCCCGCTACTAC 1524
Qy      440  lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG 460
Db      1525  GCTGGCCCCGAGGGGACTGCAAGTGAGCCCTACTACCCCGGAGTCTCGAGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGGTGAGGGGCGCCCTGCCGAGGCGCGATGGCTCATCTCTTCT 1644
Qy      480  eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGCGCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704
Qy      500  gTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCAACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCCCTGT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 232
ID      ADJ63354 standard; cDNA; 1985 BP.
XX
AC      ADJ63354;
XX
DT      20-MAY-2004 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW      Human; secreted and transmembrane protein; PRO; gene; as;
KW      Glucose uptake modulator; FFA uptake modulator;
KW      cell proliferation stimulator; cell differentiation stimulator;
KW      cell differentiation inhibitor; cytokine release stimulator; tumour;
KW      lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW      cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW      gene therapy; chromosome identification; chromosome marker.
XX
OS      Homo sapiens.
XX
PN      US2004039164-A1.

```

```

XX      26-FEB-2004.
PD
XX      30-MAY-2002; 2002US-00158787.
PF
XX      05-JUN-2000; 2000US-0209832P.
PR      01-DEC-2000; 2000WO-US032678.
PR      19-DEC-2001; 2001US-00028072.
XX
XX      (GETH ) GENENTECH INC.
XX
XX      Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI      Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI      Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR      WPI; 2004-203291/19.
XX      P-PSDB; ADJ63355.
XX
XX      New PRO polypeptides and nucleic acids, useful in gene therapy, as
PT      molecular weight markers for protein electrophoresis, as hybridization
PT      probes or as therapeutic agents.
XX
PS      Claim 2; SEQ ID NO 143; 650pp; English.
XX
XX      The invention describes 305 nucleic acids encoding PRO (secreted and
CC      transmembrane) polypeptides (I). (I) is useful for stimulating the
CC      release of TNF-alpha from human blood, for modulating the uptake of
CC      glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC      stimulating the proliferation or differentiation of chondrocyte cells,
CC      for stimulating the proliferation of or gene expression in pericyte
CC      cells, for stimulating the release of proteoglycans from cartilage, for
CC      stimulating the proliferation of inner ear utricular supporting cells,
CC      for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC      the release of a cytokine from PBMC cells, for inhibiting the binding of
CC      A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC      cells, for stimulating proliferation of endothelial cells, for detecting
CC      the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC      prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC      are useful for isolating genomic and cDNA nucleotide sequences or
CC      antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC      in assays to identify other proteins or molecules involved in binding
CC      interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC      and gene mapping, in generation of antisense RNA and DNA, in the
CC      preparation of PRO polypeptide, for generating transgenic animals or
CC      knockout animals which in turn are useful in the development and
CC      screening of therapeutically useful reagents, in gene therapy, for
CC      chromosome identification, as chromosome marker, and for generating
CC      probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC      detecting its expression in specific cells, tissues or serum, and for
CC      affinity purification of PRO from recombinant cell culture or natural
CC      sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC      a novel human secreted and transmembrane PRO polypeptide.
XX
SQ      Sequence 1985 BP; 403 A; 646 C; 332 T; 0 U; 0 Other;

```

```

Alignment Scores:
Pred. No.:      1,938-149      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              12      Gaps:      0

US-10-791-980-6 (1-520) x ADJ63354 (1-1985)

Qy      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db      206  ATGTGCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACGCCCGCGCGAGCGGAGCGGAGGAGCTGCGCAAGGAGCGGAGGATTCCTTA 325

```

QY 41 GluLysTyrGlyTyrLeuAsnGluInValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAAGCTCCACACCTCCATCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGTTTCAGTGGGTGTCCAGACTACCTGTGAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCGCAGATGACTCGTCCCGCTCGGGGTTTACAGATACCAACAGTTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTCGGGCTGAGAGATCAGTACTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCNAAGCAGGTAAACAAATGGTACAGCAGCAGCTTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCGCGAGCGCGCAGTTTCGGGGCGCGTTCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGAGATTCTGGGAGGCCCCACGACAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCTCGCGCACGCCCTTC-CTGCCCGCGCGCGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi 240
DB 865 AGATAGGCGCTGGTCCCTAGCGCGCGCGCGGCGCAACCTGTGTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTGGCTCACCACCTCGCGCGCGCGCGCTCATGTGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGAGCGCTGTCTAGCTGGGACGAGTGTCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCCTACAGCCCCCAGGAAGCGCCCTGAAACCGCAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTCTCCGTGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGGCAACGTTCTAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
DB 1285 TCCACTCGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGCGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyClyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTTCTACTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420

DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCGCCCATCTCGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTCAGAGAGTCAAGCGGCTCGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyYAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 233
ADJ77249
ID ADJ77249 standard; cDNA; 1985 BP.
XX ADJ77249;
AC ADJ77249;
XX 20-MAY-2004 (first entry)
XX Human PRO polynucleotide #72.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS US2004038336-A1.
XX 26-FEB-2004.
XX 13-MAY-2002; 2002US-00144993.
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2004-203226/19.
DR P-PSDB; ADJ77250.
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT for detecting the presence of a tumor in a mammal or as therapeutic
PT targets for treating cancer, diabetes, obesity or arthritis.
XX

Claim 2; SEQ ID NO 143; 637bp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADJ77249 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTTCGGCGCGTGGCCCTCTGTCGCGCCCTGACGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GAGCCCGACCGCGGAGCGCGGAGCCAGGAGCTGGCGAAGGCGGAGGCATTTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGAGCTCCACCTCCACCTGATTCAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
DB	386	GATGCCATCAGACGGTTTCAGTGGGTGTCCTGCTACCTGTCAGCGGGGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
DB	506	GCTGGGCTGAGAGGATCAGTACTGTTTGTGTAGACACCGGACCAAAATGAGGGCTAAG	565
QY	121	LysArgPheAlaLysGlnLysAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140

DB	566	AAACCGCTTGTGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTGAGCATCTGCGGAGCGCGCAGTTCGGGGCGCGTGGCGCGCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCCTGGAGGGCCCCAGCAGCCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTCTTCCAAAGGGGACCAACAGATGGCTGGCAATGCCCTTGTATGC	805
QY	200	aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG	220
DB	806	CCAGGGGGCGGCTTGGCGCAGCCCTTC-CTGGCCCGCGCGCGGAGCGCAGCTTCGACCA	864
QY	220	naSpGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGGCGCAACCTTGTGTGGTGGCGCA	924
QY	240	eGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGTCCACACGCTTGGCTCACCCAGCTCGCCCGCGCGCGCTCATGGCGC	984
QY	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
DB	985	CTACTACAAGAGGCTGGGCGCGCAGCGCTGTCTAGCTGGGACGACGCTGCGCGCTGA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
DB	1105	CAGTACCTTTCAGACCTGGGACTCTCAGCCCCCAAGGAGCGCCCTGAAACGACGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
DB	1165	CCCTAAATACTGCCACTCTCTCTCGATGCCATCATCTGTAGACAGCAACAGCAACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTATGCAACAGTCTCAGAGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe	380
DB	1285	TCCACTGAGGAGAGATGGTGGGCTGCCCTGCCCCCAACATTGAGGCTGGCGCAGTGTATT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGCTGGAGGTTCGGGGGCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGGGGTCTTCCACAGCTGTGCCGGGAGGGGGCTGCCCGCCATCTCTGAGCGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
DB	1465	CGCCCTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG	460
DB	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGCTGCGAGGACTGGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCCCTGAGGAGGTACGCGCGGCTGCCGAGGGCCGATGGCTCCATCATCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADM42231 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGGTCTGGCTCTCTGTCGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGGAGCGCGAGGCGCAGAGCTGCGCAAGGAGCGGAGGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATCCTCAATGAACAGGTGCCCAAGCTCCACCTCCACATCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTTCAGTGGGTGCCAGCTACCTGTTCAGCGCGGTGTGACGCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTCGCCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGCTGAGAGGATCAGTCACTGTTGTTGTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACTCTCCTACCGCCCTGGT	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	NACTGGCTGAGCATCTGCCGAGCGCGGAGTTTCGGGGCGCGTCCGCGCCCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGTGGAGTTCTGGGAGGCCACAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCCGGCTACCTCTTCCAGGGGAGCCACACAGATGGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200	aglnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
Db	806	CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGGAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTCAGCGCGCGCGGCGCAACCTGTTGTTGGTGTGCGGCA	924
Qy	240	sgluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATTCGGTCAACGCTTGGCTCACCACACTCGCCGCGCGCGCTCATGCGGCC	984
Qy	260	ofTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1	280

Db	985	CTACTACAAGAGGTGGGCGCGAGCGGTCTCTAGCTGGGACGACGTCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCGTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCCGAGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320
Db	1105	CACGTGACTTTGAGACCTGGGACTCCTACGCCCCCAAGGAAGGCGCCCTGAAGACGACGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTCTTCGATGCCATCTACTGTAGACAGGCAACAGCACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGAAAGATGGGTGGGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACACAGCTGTGCCGGCAGGGGGCTGCCCGCCCATCCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGCCTACTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
Db	1525	GCTGGCCCGAGGGGAGTGCAGAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlylProGluGluValSerGlyAlaLeuProArgProAspGlySerllePhePh	480
Db	1585	AGGCATCCTCAGGAGGTTCAGCGCGCTCCCGAGGCCGCTCCATCATCTCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGCGCCCTCGACCGCCCAACTGCAGGCAACCACTCGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGTCACCACTCGGGGAGGCCCTGT	1764
Qy	520	e 520	
Db	1765	c 1765	
RESULT 237			
ADM28093			
ID	ADM28093	standard; cDNA; 1985 BP.	
XX	XX	ADM28093;	
XX	XX	15-JUL-2004 (first entry)	
XX	XX	cDNA encoding human PRO polypeptide #72.	
DE	XX	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
KW	XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
KW	XX	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	
KW	XX	liver; microvascular endothelial cell; glucose; FFA;	
KW	XX	skeletal muscle cell; adipocyte cell; pericyte cell;	
KW	XX	inner ear utricular supporting cell; T-lymphocyte cell;	
KW	XX	endothelial cell tube formation; bone disorder; cartilage disorder;	
KW	XX	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 XX immune system cell infiltration.

OS Homo sapiens.

PN US2004077064-A1.

XX 22-APR-2004.

XX 17-MAY-2002; 2002US-00147536.

XX 31-MAR-1997; 97WO-US0005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US019437.

PR 29-OCT-1998; 98WO-US021141.

PR 20-NOV-1998; 98WO-US022991.

PR 01-DEC-1998; 98WO-US024855.

PR 05-JAN-1999; 98WO-US025108.

PR 08-MAR-1999; 98WO-US000106.

PR 10-MAR-1999; 98WO-US005028.

PR 10-MAR-1999; 98WO-US005190.

PR 20-APR-1999; 2000WO-US006319.

PR 14-MAY-1999; 99WO-US008615.

PR 02-JUN-1999; 99WO-US010733.

PR 01-SEP-1999; 99WO-US012252.

PR 08-SEP-1999; 99WO-US020111.

PR 13-SEP-1999; 99WO-US020594.

PR 15-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 05-OCT-1999; 99WO-US021547.

PR 29-NOV-1999; 99WO-US023089.

PR 30-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US028565.

PR 20-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US005841.

PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001US-0080520.

PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.

PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854208.

PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001US-00870992.

PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.

PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.

PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.

PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2004-340004/31.
 DR P-PSDB; ADM28094.

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PRO4978, useful in molecular biology, chromosome and gene mapping, in
 generating antisense RNA and DNA, and in gene therapy.

PS Claim 2; Fig 143; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADM28093 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTGGCGCGCTGGCTCTGTCGCGCGCTGCAGCTCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GAGCGCCAGCCCGAGCGCGGAGCGCCAGGAGCTGCGCAAGAGCGGAGGACATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAACAGAGTCCCCAAAGCTCCACCTCCACTCGATTACG	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACCTGTGTCAGCGCGGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTCGCCAGATGACTCGTCCCGCTCGGGGTGTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCCTGGCTGAGAGGATCAGTACATTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCCTCTCCTACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTTACAGCACTGCGGAGCGCGGAGTTCGGGGCGCGTGGCGCCCTTCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCGCCAGCCACAGCGCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC	805
QY	200	aGlnGlyAlaProTrpAlaThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
DB	806	CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGCTGCGCGCA	924

QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTACACAGCTTGCGCTTCCACCACTCCCGCGCGCGCGCTCATATGGCGCC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1	280
DB	985	CTACTACAGAGGTGGCGCGGACGGCTGCTCAGTGGGACGACGTGCTGGCGGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320
DB	1105	CACGTACTTTGAGACCTGGGACTCTCTACGCCCCCAAGGAAGGCGCCCTGAAAGCGCAGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
DB	1165	CCCTAATATCTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
DB	1285	TCCACTGAGGAAAGATGGGTGGGGTGGCCCCCAACATTGAGGCTGGCGAGTGTCAAT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyVGLYArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATGATGGAGATTCTACTTCTTCAAGGGGTGCGTCTGGAGGTTCGGGGCCCCCA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGGCCATCTCTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
DB	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
DB	1525	GCTGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCAGGACTGGGG	1584
QY	460	yGlyIleProGluGlnValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCCCTGAGGAGGTGAGCGCGCTCTCCGAGGCCGATGGCTCCATCATCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
DB	1645	CCGAGATGACCGCTACTGGCGCTCGACCGGCCAATCGAGGCCAACCACTCGGGCGG	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaHisSerGlySerAlaLeuPh	520
DB	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGT	1764
QY	520	e 520	
DB	1765	C 1765	
RESULT	238		
ADI95575			
ID	ADI95575	standard; cDNA; 1985 BP.	
XX			
AC	ADI95575;		
DT	04-NOV-2004	(first entry)	
XX			
DE	cDNA encoding human PRO polypeptide #72.		
XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.

XX Homo sapiens.
 OS
 XX
 XX US2003077659-A1.
 XX
 PD 24-APR-2003.
 XX
 PF 17-APR-2002; 2002US-00124824.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US019824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022992.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-020216/02.
 XX P-PSDB; ADI95576.
 PT Isolated nucleic acid used, e.g. on gene therapy, for chromosome
 PT identification, and for generating probes for polymerase chain reaction,
 PT has nucleic acid sequence identity to nucleotide sequence that encodes
 PT specific amino acid sequence.
 XX
 PS Claim 2; Fig 143; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are

useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Alignment Scores:	
Pred. No.:	1,93e-149
Score:	2792.00
Percent Similarity:	99.62%
Best Local Similarity:	99.62%
Query Match:	98.52%
DB:	13
Length:	1985
Matches:	519
Conservative:	0
Mismatches:	1
Indels:	2
Gaps:	0

ITS-10-791-990-6 (1-520) x ANT95575 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCTGGCCCTCTCTGTCGCGCCCTGCAGCTGCCTACTCTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCCAGCCCGGAGCGCGAGGACGAGGAGCTTGGCNAAGGAGGGCGGAGGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCGCCAAAGCTCCACCTCCACTCGATTCCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCCACTACCTGTACGCGCGGTGTTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTTGCAAGCAGGATACAAATGGTACACAGCAGCAGCTCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTGCCGGAGCCCGGAGTTTCGGGGCGCGTTCGGCGCGCCCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGACCAACGCTCAGCGCTGGAGTTCTTGGGAGGCCCCAGGCACAGGCCCGCTCAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGGCTCACCTTCTTCCAAAGGGGACCCAAAGATGGGCTGGGCATATCTTTGATGGC	805

Qy	200	aGlnGlyAlaProTrrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
Db	806	CMAGGGGGGCCCTGGCGACGCGCTTC-CTGCCCGCGCGGAAGCGCACTTCGACCA	864
Qy	220	nAspGluuArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGTGCTCCTGAGCGCGCGCGGCGCAACCTGTTCTGGTGGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTTCACACCTTTGGCTCACCCACTCGCCGCGCGCGCGCTCATGCGCC	984
Qy	260	oTyrrTyrsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1	280
Db	985	CTACTACAAGAGCTGGCGCGACGCGTGTCTAGCTGGGACGACGCTCTGGCGGTGA	1044
Qy	280	nSerLeuTyrrGlyAspProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGTCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnG1	320
Db	1105	CACTGACTTTTGAGACTGGGACTCTCTACAGCCCGCAAGGAAGCGCGCTGAAACGCA	1164
Qy	320	yProLysTyrrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATATCGGCACCTTCTTCGATGGCATCTCTGTAGACAGGCAACAGCACTGT	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CAITTTTAAAGGGAGCCATTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGACGAAGATGGGTGGGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGG	1344
Qy	380	uAsnAspGlyAspPheTyrrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGCGCCCA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGGCTGCGCGCGCCATCTGAG	1464
Qy	420	aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrrVa	440
Db	1465	CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTTCGCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpG1	460
Db	1525	GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGAGGACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh	480
Db	1585	AGGCATCCCTCAGGAGGTTCAGCGCGCTGCGCGAGGCGCGATGGCTCCATCATCTT	1644
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATCACCGCTACTGGCGCTCTGACAGCGCCAACTGCGAGGCAACCACTCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGT	1764
Qy	520	e 520	
Db	1765	c 1765	

RESULT 239
ADI96127
ID ADI96127 standard; cDNA; 1985 BP.
XX
AC AC ADI96127:

XX
DT 04-NOV-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003207354-A1.
XX
XX 06-NOV-2003.
XX
XX 07-MAY-2002; 2002US-00140863.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z,
XX
XX WPI; 2004-010591/01.
XX
XX P-PSDB; ADI96128.
XX
XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
XX useful for detecting the presence of a tumor and stimulating the
XX proliferation of inner ear utricular supporting cells.
XX
XX Claim 2; SEQ ID NO 143; 637bp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as:
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proteoglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various

```
QY      280 nserLeuTyrcGlyLysProLeuGlyGlySerValaValGlnLeuProGlyLysLeuPh 300
Db      1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCCTCCAGTCCCGAGAAAGCTGTT 1104

QY      300 eThrAspPheGluThrTrpAspSerTyrcProGlnGlyArgArgProGluThrGlnG1 320
Db      1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAAAGGGGCCCTGAAGACGACGG 1164

QY      320 yProLysTyrcHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165 CCCTAAATACCTCCACTCTCTTCGATGCCATCACTGTAGACAGCCACAGCAACTGTA 1224

QY      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGCCAACGTCTCAGAGCCCCG 1284

QY      360 gProLeuGlnGluArgTrpValGlyLeuProProHsnIleGluAlaAlaValSerLe 380
Db      1285 TCACCTGCCAAGAAAGATGGTGGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAIT 1344

QY      380 uAsnAspGlyAspPheTyrcPheLysGlyArgCysTrpArgPheArGlyProLy 400
Db      1345 GAATGATGAGATTCTACTCTTCCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404

QY      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGGCAGGGGGCTTGCCCCGCCATCTCTGACGC 1464

QY      420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrcTyrcVa 440
Db      1465 CGCCCTCTTCTTCCCTCTCTCGCCCGCCCTCATCTCTTCAAGGGTGCCCGCTACTACTGT 1524

QY      440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrcTrpArgSerLeuGlnAspTrpGl 460
Db      1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGAGAGTCTGCAGGACTGGGG 1584

QY      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585 AGGCATCTCTGAGGAGTGCAGCGGCCCTGCGAGGCCGATGGCTCATCATCTTCTT 1644

QY      480 eArgAspAspArgTyrcTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645 CCGAGATGACCGGTACTTGGGCTCTGACGAGCCCAACTGCAGGCAACCACTCGGGCG 1704

QY      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCGCAACTCGGGGAGCGCCCTGTT 1764

QY      520 e 520
Db      1765 C 1765
```

RESULT 240

AAF81736
ID AAF81736 standard; cDNA; 2241 BP.

XX AAF81736;

XX AAF81736;

DT 12-JUN-2001 (first entry)

XX Human protease and protease inhibitor PPIM-23 encoding cDNA.

XX Human; protease; protease inhibitor; protease and protease inhibitor;
KW PPIM; identification; diagnosis; anti-human immunodeficiency virus; HIV;
KW antidiabetic; immunostimulant; immunomodulator; antiinflammatory;
KW antithyroid; immunosuppressive; nephrotropic; antitox; thyromimetic;
KW cytostatic; antibacterial; fungicide; protozoicide; antiarteriosclerotic;
KW antiatherosclerotic; antipsoriatic; virucide; hepatotropic; gene therapy;
KW autoimmune disorder; inflammatory disease; AIDS; Digeorge's syndrome;
KW severe combined immunodeficiency disease; SCID; Chediak-Higashi syndrome;
KW Cushing's disease; Addison's disease; autoimmune thyroiditis; gout;
KW Crohn's disease; diabetes mellitus; Good pasture's syndrome; infection;

KW Grave's disease; Hashimoto's thyroiditis; Sjogren's syndrome; cancer;
KW Werner's syndrome; cell proliferative disorder; arteriosclerosis;
KW atherosclerosis; cirrhosis; hepatitis; psoriasis; ss.
OS Homo sapiens.

XX W0200110903-A2.

XX 15-FEB-2001.

XX 09-AUG-2000; 2000WO-US021878.

XX 09-AUG-1999; 99US-0147986P.

XX 21-OCT-1999; 99US-0160807P.

XX (INCY-) INCYTE GENOMICS INC.

XX Yue H, Lal P, Tang YT, Bandman O, Baughn MR, Azimzai Y, Lu DAM;
PI Yang J;

XX WPI; 2001-202760/20.

XX P-PSDB; AAB74690.

XX New protease (inhibitors) useful for diagnosis and treatment of
PT autoimmune/inflammatory disorders such as acquired immunodeficiency
PT syndrome, Cushing's disease, Addison's disease and cell proliferative
PT disorders such as cancer.

XX Claim 5; Page 131; 134pp; English.

XX AAF81714 to AAF81740 encode the human proteases and protease inhibitors
CC (PPIMs) given in AAB74668 to AAB74694. The PPIMs can have activities such
CC as: anti-human immunodeficiency virus (HIV); antidiabetic; antithyroid;
CC immunostimulant; immunomodulator; antiinflammatory; immunosuppressive;
CC nephrotropic; antitox; thyromimetic; cytostatic; antibacterial;
CC fungicide; protozoicide; antiarteriosclerotic; antiatherosclerotic;
CC virucide; antipsoriatic; and hepatotropic. PPIM polynucleotide and
CC protein sequences can be used in the diagnosis, treatment and prevention
CC of autoimmune/inflammatory disorders such as AIDS, Digeorge's syndrome,
CC severe combined immunodeficiency disease (SCID), Chediak-Higashi
CC syndrome, Cushing's disease, Addison's disease, autoimmune thyroiditis,
CC Crohn's disease, diabetes mellitus, Good pasture's syndrome, gout,
CC Grave's diseases, Hashimoto's thyroiditis, Sjogren's syndrome, Werner's
CC syndrome, viral, bacterial, fungal, parasitic, protozoal, and helminthic
CC infections and cell proliferative disorder such as arteriosclerosis,
CC atherosclerosis, cirrhosis, hepatitis, psoriasis and cancer. PPIM
CC polynucleotide sequences can be used in somatic or germline gene therapy
CC and in diagnosis of diseases. They can also be used in generating
CC hybridisation probes useful in mapping the naturally occurring genomic
CC sequences and in molecular biology techniques

XX SQ Sequence 2241 BP; 444 A; 705 C; 673 G; 419 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	2,19e-149	Length:	2241
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	4	Gaps:	0

US-10-791-980-6 (1-520) x AAF81736 (1-2241)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	35	ATGTTGGCGCGCGCTCGGCTCTCTGTCGGCCCTCGAGCTGCTACTGTGGGGCCACCTG	94
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	95	GAGCCCCAGCCCGGAGCGCGAGGCCAGGAGTGCAGGAGGCGGAGGAGCATTCCTTA	154
QY	41	GluLysTyrcGlyTyrcLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60

Db 155 GAGAACTACGGATACCTCAATGACACAGGTCCTCCCAAGCTCCACCTCCACTCCGATTCCAGC 214
Qy 61 AspAlaileAraPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 215 GATGCCATCAGACGGTTTCACTGGGTGTCCAGCTACCTGTGAGCGCGTGTGGACCGC 274
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 275 GCCACCTCGCCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 334
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaAraGHisArgThrIlysMetArgArgIys 120
Db 335 GCGTGGGCTGAGAGGATCAGTCACTTGTGTGTAGACACCGGACCAAAATGAGCGGTAAG 394
Qy 121 LysArgPheAlaIysGlnGlyAsnIysTrpTyrLysGlnHisIleSerTyrArgLeuVal 140
Db 395 AAACGCTTTTGAAAGACAGGTACAAATGGTACAGCAGCACCTCTCCACCGCTGGTG 454
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 455 AACTGGCCTGAGCATCTGCGGAGCGCGCAGTTTCGGGGCGCGTTCGGCGCGCTTCAG 514
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 515 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGCGCCGCTGAC 574
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 575 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTATGGC 634
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 635 CCAGGGGGCGCTGGCGACGCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 693
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 694 AGATGAGCGCTGCTCCCTCAGCGCGCGCGGGGCAACCTGTTCGTGGTCTGGCGCA 753
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 754 CCAGATCGGTACACGCTTGGGCTCACCCACCTGCGCGCGCGCGCGCTCATGGCGCC 813
Qy 260 tTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 814 CTACTACAGAGCGTGGCGCGCGACGCGCTGTCTAGCTGGGACGAGCTGTGCGCGTGA 873
Qy 280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db 874 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGTT 933
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 934 CACTGACTTTGAGACTGGGACTCTCTACAGCCCAAGGAAGCGCGCTCGAAACGCGGG 993
Qy 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 994 CCTTAATACTGCCACTCTTCTTGTAGTCCATCTCTGTAGACAGCAACAGCACTGTA 1053
Qy 340 rIlePheIysGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1054 CATTTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1113
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1114 TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATGAGGTGGCGCATGCTCAT 1173
Qy 380 uAsnAspGlyAspPheTyrPhePheIysGlyIysGlyArgCysTrpArgPheArgGlyProly 400
Db 1174 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTAGTCTGGAGGTTCGGGGGCCCCA 1233
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1234 GCCAGTGTGGGTCTCCCCACACAGCTGTGGCGGCGAGGGGCGCTGCCCGCATCTTCGCGC 1293

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa 440
Db 1294 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT 1353
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1354 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTCAGGACTGGGG 1413
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1414 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1473
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyVar 500
Db 1474 CCGAGATGACCCCTACTGGCGCTCGACGAGCCAACTGCGAGCAACCACTCGGGCGC 1533
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1534 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1593
Qy 520 e 520
Db 1594 C 1594
RESULT 241
ASK48980
ID ASK48980 standard; cDNA; 2527 BP.
XX AC ASK48980;
XX DT 02-JUL-2002 (first entry)
XX DE cDNA encoding novel matrix metalloproteinase 46798, long form.
XX KW Matrix metalloproteinase; MMP; 46798 long form; heart failure; tumour;
XX KW extracellular matrix degradation; cardiovascular disease; metastasis;
XX KW atherosclerosis; arthritis; nephritis; neurological disease; ischaemia;
XX KW periodontal disease; skin ulceration; liver fibrosis; emphysema; trauma;
XX KW fibrotic lung disease; bacterial infection; viral infection; psoriasis;
XX KW wound healing; chronic injury; autoimmune disorder; angiogenesis;
XX KW tissue invasion; gene; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX CDS 300..1862
XX FT /*tag= a
XX FT /product= "46798"
XX FT /note= "Novel matrix metalloproteinase. Specifically
XX claimed in claim 1."
XX PN WO200220739-A2.
XX PD 14-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028260.
XX PR 08-SEP-2000; 2000US-0231136P.
XX PA (MILL-) MILLENNIUM PHARM INC.
XX PI Curtis RAJ;
XX XX WPI; 2002-351776/38.
XX DR P-PSDB; AAU79810.
XX XX New human matrix metalloproteinase and polynucleotides useful for
XX PT diagnosing and treating atherosclerosis, bacterial and viral infections,
XX PT wound healing, chronic injury, traumatic, ischemia and psoriasis.
XX PS Claim 1; Fig 1A-D; 133pp; English.
XX XX

DT 29-NOV-2002 (first entry)
 XX cDNA encoding human matrix metalloproteinase (MMP) 46798 #2.
 DE Human; matrix metalloproteinase; MMP 46798; cell proliferation disorder;
 XX cell differentiation disorder; carcinoma; sarcoma; leukaemia;
 KW breast cancer; lung cancer; neurological disorder; schizophrenia;
 KW ischaemia; infarction; Parkinson's disease; Huntington's disease;
 KW inflammatory disorder; Crohn's disease; immune disorder; arthritis;
 KW diabetes mellitus; cardiovascular disorder; restenosis; tachycardia;
 KW rheumatic heart disease; motility disorder; developmental disorder;
 KW lung disorder; chronic bronchitis; pulmonary congestion; oedema;
 KW blood disorder; blood clotting disorder; cytostatic; immunomodulator;
 KW anti-inflammatory; cardiatic; antiparkinsonian; nootropic; thrombolytic;
 KW neuroprotective; antidiabetic; antirheumatic; antiarthritic; vasotropic;
 XX gene; ss.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 300..1862
 FT /*tag= a
 FT /product= "MMP 46798 #2"
 FT /note= "The coding region is specifically claimed in
 FT Claim 6"
 FT
 XX WO200266670-A2.
 PN 29-AUG-2002.
 XX
 XX 16-JAN-2002; 2002WO-US0001546.
 XX
 XX 16-JAN-2001; 2001US-0262252P.
 XX (MILL-) MILLENNIUM PHARM INC.
 PA
 XX Curtis RAJ, Lora JM;
 PI
 XX WPI: 2002-674955/72.
 DR P-PSDB; ABG31460.
 XX
 XX New human matrix metalloproteinase nucleic acid and polypeptide
 PT molecules, designated 46798, useful for diagnosing, preventing or
 PT treating cancers, ischemia, Parkinson's disease heart disease or edema.
 XX
 PS Claim 6; Page 110-113; 117pp: English.
 XX
 CC The present invention relates to the isolation of novel human matrix
 CC metalloproteinases (MMP), designated 46798, and the polynucleotide
 CC sequences encoding them. The MMP 46798 polypeptide and polynucleotide
 CC sequences are useful for diagnosing, preventing, alleviating or treating
 CC metalloproteinase-associated disorders such as cell proliferation and/or
 CC differentiation disorders (e.g. carcinoma, sarcoma, leukaemia, breast
 CC cancer, or lung cancer), neurological disorders (e.g. schizophrenia,
 CC ischaemia, infarction, Parkinson's disease or Huntington's disease),
 CC inflammatory disorders (e.g. Crohn's disease), immune disorders (e.g.
 CC diabetes mellitus or arthritis), cardiovascular disorders (e.g.
 CC restenosis, tachycardia or rheumatic heart disease), motility disorders,
 CC developmental disorders, lung disorders (e.g. chronic bronchitis,
 CC pulmonary congestion or oedema), and blood/blood clotting disorders. The
 CC present sequence encodes human MMP 46798 #2
 XX
 SQ Sequence 2527 BP; 480 A; 817 C; 773 G; 457 T; 0 U; 0 Other;
 XX
 Alignment Scores:
 Pred. No.: 2,49e-149 Length: 2527
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 6 Gaps: 0
 US-10-791-980-6 (1-520) x ABK91096 (1-2527)

```
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1379 TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGAGTGTCAAT 1438
QY 380 uAsnAspGlyAspPheTyrPhePheLeuGlyGlyArgCysTyrPheArgPheArgGlyProLy 400
Db 1439 GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1498
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1499 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCCCTGCCCGCCATCTCTGAGCG 1558
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLeuGlyAlaArgTyrTyrVa 440
Db 1559 GSCCTCTTCTTCCCTCTCTGGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1618
QY 440 lleuAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
Db 1619 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1678
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1679 AGGCATCCCTGAGGAGTTCAGCGGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1738
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1739 CCGAGATGACCGCTACTTGGCGCTCGACCGAGGCCAACTGCAGGCCAACCACTCGGGCG 1798
QY 500 gTyrPalaThrGluLeuProTyrMetGlyCysTyrPheHisAlaAsnSerGlySerAlaLeuPh 520
Db 1799 CTGGGCCACCGAGTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1858
QY 520 e 520
Db 1859 C 1859
RESULT 243
ABL57676
ID ABL57676 standard; DNA; 2275 BP.
XX
AC ABL57676;
XX
XX 15-JUL-2002 (first entry)
XX
DE Human matrix metalloprotease protein MMP-ABT gene.
XX
KW Human; MMP-ABT; matrix metalloprotease; cytostatic; anti-inflammatory;
KW anti-arthritis; gene therapy; cancer; inflammatory disease; arthritis;
KW gene; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 46..1608
FT /*tag= a
FT /product= "MMP-ABT"
FT polyA_signal 2203..2208
FT /*tag= b
XX
US2002031817-A1.
XX
XX 14-MAR-2002.
XX
XX 07-SEP-1999; 99US-00391104.
XX
XX 11-MAR-1997; 97US-00814394.
XX
PA (FALD/) FALDUTO M T.
PA (MAGN/) MAGNUSON S R.
PA (MORG/) MORGAN D W.
XX
XX Falduto MT, Magnuson SR, Morgan DW;
```

```
DR WPI; 2002-361182/39.
DR P-PSDB; ABB77182.
XX
XX New human matrix metalloprotease gene and protein, useful for diagnosing,
PT staging, preventing or treating cancer or inflammatory diseases (e.g.
PT arthritis), as well as in screening drugs for treating these diseases.
XX
XX Claim 11; Fig 4; 44pp; English.
XX
XX The sequence encodes a human matrix metalloprotease protein. The
CC invention relates to a novel polynucleotide, which comprises a nucleotide
CC sequence encoding a human matrix metalloprotease protein (designated MMP-
CC ABT). The protein of the invention has cytostatic, anti-inflammatory, and
CC anti-arthritis activity. The polynucleotide may have a use in gene
CC therapy. The MMP-ABT polynucleotides and proteins are useful for
CC detecting, diagnosing, staging, monitoring, prognosing, preventing or
CC treating cancer or inflammatory diseases (e.g. arthritis). The MMP-ABT
CC proteins and polynucleotides are also useful developing therapeutic
CC agents that affect MMP function
XX
XX Sequence 2275 BP; 466 A; 707 C; 677 G; 425 T; 0 U; 0 Other;
XX
Alignment Scores:
Pred. No.: 8.62e-148 Length: 2275
Score: 2764.00 Matches: 514
Percent Similarity: 99.23% Conservative: 3
Best Local Similarity: 98.66% Mismatches: 3
Query Match: 97.53% Indels: 2
DB: 6 Gaps: 0
US-10-791-980-6 (1-520) x ABL57676 (1-2275)
QY 1 MetValalaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 46 ATGGTCGGCGCGTCGGCCCTTCTGCTGGCGCCCTGCAGTGTCTACTGTGGGGCCACTG 105
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 106 GACGCCCGAGCCCGCGAGCGCGAAGCGCAGAGCTGCGCAAGAGCGCGAGGCATTCTTA 165
QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 166 GAGAAGTACGGATACCTCAATGAA CAGGTCCCCAAAGCTCCCACTCCACATGATTACG 225
QY 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 226 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGTACTCTGTCCAGCGCGGTGTGGACCGC 285
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 286 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGTTATCGC 345
QY 101 AlaTyrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 346 GCCTGGGTGAGAGGATCAGTACTTGTTCAGACACCGGACCAAAATGAGGCGTAAG 405
QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 406 AAACGCTTTGCAAGCAAGGTGACAAATGGTACAGCAGCACCTCTCTACCGCCTGGTG 465
QY 141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 466 AACTGGCCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 525
QY 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 526 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCCTGGGAGGGCCCCAGCCACAGGCCCTGAC 585
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 586 ATCCGGCTCACCTTCTTCAAGGGGACCCACACGATGGCTGGGCAATGCCTTGTATGCG 645
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
```

```
Db 646 CCAGGGGGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCAATTTTACTTCGACCA 704
Qy 220 AAspGluAArgTTPSerLeuSerArgArgGlyArgAAspLeuPheValValLeuAlaHi 240
Db 705 AGATGAGCGTGTGCTCTGAGCGCGCCCGCGCGGCAACCTGTTGTTGTTGCTGGCGCA 764
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 765 CGAGATCGGTCAACAGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 824
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 825 CTACTACAAGAGCGTGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGCTGGCGCTGCA 884
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 885 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 944
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnGI 320
Db 945 CACTGACTTTGAGACCTGGGACTCTACAGCCCGCCCAAGGAGCGCCCTGAAACGCGGG 1004
Qy 320 yProLysTyrCyHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
Db 1005 CCCTAAATAGTGCACCTTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1064
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1065 CATTTTAAAGGAGGAGCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1124
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1125 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCACTTGGCTGGCGCAGTGTCTATT 1184
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCytsTrpArgPheArgGlyProby 400
Db 1185 GAATGATGAGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1244
Qy 400 sProValTTPGlyLeuProGlnLeuCybArgAlaGlyLeuProArgHisProAspAl 420
Db 1245 GCAGTGTGGGGTCTCCCAAGCTGTGGCGGGCAGGGGGCGCTGCCCGCCCATCTCTGACG 1304
Qy 420 aAlaLeuPhePheProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1305 CGCCCTCTTCTTCTCTCTGTCGGCGCCCTCATCTCTTCAAGGGTGGCGCTACTACT 1364
Qy 440 lLeuAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
Db 1365 GCTGGCCCGAGGGGAGTGCAGTGGAGCGCTACTACCCCGAAGTCTGCAGAGCTGGGG 1424
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleilePhePh 480
Db 1425 AGGCATCTCTGAGGAGGTGAGCGGGCGCTGCGAGGCGCGATGGCTCCATCTCTTCTT 1484
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1485 CCGAGATGACCGCTACTTGGCGCTTCGACGAGGCCAATTCGAGGCCAACCACTTCGGGCG 1544
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCytsTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1545 CTGGGCCACCGAGCTGCTGATGGCTGCTGGCATGCCAATCTGGGAGCGCCCTGTT 1604
Qy 520 e 520
Db 1605 c 1605
RESULT 244
ADQ63889
ID ADQ63889 standard; cDNA; 2336 BP.
XX
AC ADQ63889;
XX
```

```
DT 07-OCT-2004 (first entry)
XX Novel human cDNA sequence #1050.
XX ss; gene; osteopathic; neuroprotective; nootropic; antiparkinsonian;
KW cytostatic; gene therapy; diagnostic marker; morbid state; osteoporosis;
KW neurological disease; Alzheimer's disease; Parkinson's disease; dementia;
KW cancer.
XX OS Homo sapiens.
XX PF1440981-A2.
XX 28-JUL-2004.
XX 21-JAN-2004; 2004EP-00001196.
XX 21-JAN-2003; 2003JP-00102206.
XX 09-MAY-2003; 2003JP-00131392.
XX (REAS-) RES ASSOC BIOTECHNOLOGY.
XX Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Nagai K, Irie R;
XX WPI: 2004-535376/52.
DR P-PSDB; ADQ66077.
XX Novel 2495 cDNA, useful for treating osteoporosis, neurological diseases,
PT Alzheimer's diseases, Parkinson's diseases, dementia and various cancers.
XX Claim 1; SEQ ID NO 1050; 2449pp; English.
XX The invention relates to 2495 novel polynucleotides (I) and their encoded
CC polypeptides, sequences hybridizing to these nucleotides, sequences
CC encoding partial polypeptides and sequences having 70% or 90% identity to
CC the nucleotide and protein sequences. The nucleotides and polypeptides
CC are useful as diagnostic markers or therapeutic target for the diseases
CC or morbid states. They are also useful for treating osteoporosis,
CC neurological diseases, Alzheimer's diseases, Parkinson's diseases,
CC dementia and various cancers. This sequence corresponds to a nucleotide
CC sequence of the invention.
XX SQ Sequence 2336 BP; 423 A; 764 C; 728 G; 421 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 2,448-145 Length: 2336
Score: 2721.00 Matches: 508
Percent Similarity: 97.70% Conservative: 1
Best Local Similarity: 97.50% Mismatches: 1
Query Match: 96.01% Indels: 12
DB: 12 Gaps: 1
US-10-791-980-6 (1-520) x ADQ63889 (1-2336)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 331 ATGTTCGGCGCGCTGGCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 390
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 391 GAGGCCAGCCCGCGAGCGCGGAGAGCTGGCAAGAGCGCGGAGGCGGATTCCTTA 450
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 451 GAGAAGTACGGATACCTCAATGAACAGGTGCCAAAGTCCCACTCCACTCGATTCAGC 510
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 511 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTCTGTGAGCGGCGGTGTGGACCG 570
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCytsGlyValThrAspThrAsnSerTyrAla 100
```

Db 571 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 630
 Qy 101 AlatrAlaGluAArgIleSerAspLeuPheAlaAArgHisArgThrLysMetArgArgLys 120
 Db 631 GCCTGGGCTGAGAGGATCAGTGAATGTTGTTCTAGACACCGACCAAAATGAGCGTAAG 690
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 691 AAACGCTTTGCAACAGAGTAAACAAATGTTACAGACGACACTCTCTTACCGCTGCTG 750
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 751 NACTGGCTGAGCACTGCGGAGCGCGGGTTCTGGGCGCGCTGCGCGCGCTTCAG 810
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 811 TTGTGGAGCAACGTCACAGCGTGGAGTTCGGAGGAGCCACAGCCAGGCGCCGCTGAC 870
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 871 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTGTATGCG 930
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 931 CCAGGGGGCGCTGCGGACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 989
 Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
 Db 990 AGATGAGCGTGTCTCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTGCGCA 1049
 Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 1050 CGAGATCGGTCAACAGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGCC 1109
 Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 Db 1110 CTACTACAAGAGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCGCGCTGCA 1169
 Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1170 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1229
 Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1230 CACTGACTTTGAGACCTGGAGCTCTACAGCCCCCAAGGAGCGCCCTGAACCGCAGGG 1289
 Qy 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1290 CCTTAATATGCACTCTTCTTCGATGCCATCACTGTA----- 1329
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1330 -----GGAGGCAATTTCTGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCG 1379
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1380 TCCACTGCAGAAAGATGGTTCGGGCTGCCCCCAACATTGAGCTGGCGCATGTCATT 1439
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCyeTrpArgPheArgGlyProLy 400
 Db 1440 GAATGATGAGATTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCGGGGGCCCCAA 1499
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1500 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGCTGCCCCCGCATCTCTGACGC 1559
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 Db 1560 GCGCTCTTCTTCTCTCTGCGCGGCTCATCTCTTCAAGGGTTCGCGCTACTACGT 1619
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
 Db 1620 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCCCAAGTCTGCGAGGACTGGG 1679

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1680 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCATCATCTTCTT 1739
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1740 CCGAGATGACCGCTACTGCGGCTCGACCAGGCCAACTGCGAGGCACACCTCGGGCG 1799
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1800 CTGGGCCACCGAGCTCCCTGGATGGCTGCTGGCATGCAACTCGGGAGGCGCTGTT 1859
 Qy 520 e 520
 Db 1860 C 1860
 RESULT 245
 ADE07322 standard; DNA; 1983 BP.
 ID ADE07322 standard; DNA; 1983 BP.
 XX AC ADE07322;
 XX 29-JAN-2004 (first entry)
 XX Novel coding sequence (useful for identifying genetic disorders) #388.
 DE novel gene; novel protein; tissue marker; molecular weight marker;
 KW chromosome marker; genetic disorder; gene; ds.
 KW Unidentified.
 OS WO2003054152-A2.
 XX 03-JUL-2003.
 PD 10-DEC-2002; 2002WO-US039555.
 XX 10-DEC-2001; 2001US-0339739P.
 PR 11-DEC-2001; 2001US-0339453P.
 PR 14-MAR-2002; 2002US-0365091P.
 PR 14-MAR-2002; 2002US-0365384P.
 PR 12-APR-2002; 2002US-0372381P.
 PR 12-APR-2002; 2002US-0372615P.
 PR 22-APR-2002; 2002US-00128558.
 PR 24-APR-2002; 2002US-0376045P.
 XX (HYSE-) HYSEQ INC.
 XX Tang YT, Asundi V, Goodrich RW, Ren F, Zhang J, Zhao QA, Wang J;
 PI Ghosh M, Xue AJ, Wehrman T, Weng G, Zhou P, Drmanac RI, Wang Z;
 PI Ma Y, Wang D, Chen R, Xu C, Boyle BU;
 XX WPI; 2003-569235/53.
 DR P-PSDB; ADE08233.
 XX New polynucleotides, useful for expressing recombinant proteins for
 PT analysis, characterization or therapeutic use, or as markers for tissues
 PT in which the corresponding protein is preferentially expressed.
 XX Claim 1; SEQ ID NO 388; 1177pp; English.
 CC The invention comprises the amino acid and coding sequences of novel
 CC proteins. The DNA and protein sequences of the invention are useful as:
 CC markers for tissues in which the corresponding protein is preferentially
 CC expressed; as molecular weight markers on gels; as chromosome markers or
 CC tags; to identify chromosomes or to map related gene positions; and to
 CC compare with endogenous DNA sequences in patients to identify potential
 CC genetic disorders. The present DNA sequence represents a gene of the
 CC invention.
 XX Sequence 1983 BP; 357 A; 640 C; 610 G; 376 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.27e-136 Length: 1983
 Score: 2566.00 Matches: 507
 Percent Similarity: 94.61% Conservative: 2
 Best Local Similarity: 94.24% Mismatches: 6
 Query Match: 90.54% Indels: 25
 DB: 10 Gaps: 3

US-10-791-980-6 (1-520) x ADE07322 (1-1983)

QY 1 MetValAlaArg-ValGlyLeuLeuLeuArgAla-LeuGlnLeuLeuLeuTrp-GlyHis 19
 DB 266 ATGGTCGGCGCTGTGGGCTCTCTGTGGCGCCCTTGAGCTGTCTACTGTGGGCCAC 325
 QY 20 LeuAspAlaGlnProAlaGluArgGlyGlyGln-GluLeuArgLysGluAlaGluAlaPh 39
 DB 326 CTGGAGCCCGAGCCCGGAGCGCGAGGCCAGTGAAGCTGGCGAGAGCGGAGGCAIT 385
 QY 39 eLeuGlu-----lysTyrGlyTyrLeuAsnGluGlnValPr 51
 DB 386 CCTAGAGATGTACTGTGATAGCTCAAGTGAAGCATGGTCC-----CC 429
 QY 51 olysAlaProThrSerThrArgPheSer-AspAlaIleArgAla-PheGlnTrpValSer 70
 DB 430 AAATGCTCCACCTCCACTCGATTTCAGCTGATGCCATCAGAGCTGTTTCAGTGGGTGCC 489
 QY 71 GlnLeu-ProValSer-GlyValLeu---AspArgAlaThrLeuArgGlnMetThrArgP 89
 DB 490 CAGTACCTCTGTCAGCTGGCTGTTGTTGGACCTGCGCCACCCTGCGCCAGATGACTCGTC 549
 QY 89 roArgCysGlyValThrAspThrAsnSerTyrAlaAlaTrpAlaGluArgIleSerAspL 109
 DB 550 CCGCTGCGGGTTACAGATACCAACAGTTATGCGGCTGGCTGAGAGATCAGTGACT 609
 QY 109 euPheAlaArgHisArgThrLysMetArgArgLysLysArgPheAlaLysGlnGlyAsnL 129
 DB 610 TGTGTTCTAGACCCCGGACCAAAATGAGCGCTAAGAAACGCTTTGCAAGCAAGGTAA 669
 QY 129 ysTyrTyrLysGlnHisLeuSerTyrArgLeuValAsnTrpProGluHisLeu-ArgSer 148
 DB 670 AATGTTAAGCAGCAGCACTCTCTACCGCTGCTGTAACCTGGCTGAGCATCTGCCGAGC 729
 QY 149 ArgGlnPheGlyAlaProCysAlaProProSerSerCysGlyValaThrSerGlnArgTrp 168
 DB 730 CGGAGTTCCGGGCGCGCTGCGCGCCCTTCAGTTGTGGAGCAACGCTCTCAGCGCTGG 789
 QY 169 SerSerGlyArgProGlnProGlnAlaProLeuThrSerGlySerProSerSerLysGly 188
 DB 790 AGTTCTGGGAGGCCCCAGCCAGGCCCCGCTGACATCCGGCTCACCTTCTTCCAAGGG 849
 QY 189 ThrThrThrMetGlyTrpAlaMetProLeuMetAlaGlnGlyValaProTrpArgTrpPro 208
 DB 850 ACCAACACATGGCTGGGCAATGCCCTTGTATGGCCAGGGGCGCCCTGGCGCACGCT 909
 QY 209 PheLeuProArgArgGlyGluAlaHisPheAspGlnAspGluArgTrpSerLeuSerArg 228
 DB 910 TC-CTGCCCCCGCGCGGCAAGCGCACTTCGACCAAGATGAGGCGTGGTCCCTGAGCGCG 968
 QY 229 ArgArgGlyArgAsnLeuPheValValLeuAlaHisGluIleGlyHisThrLeuGlyLeu 248
 DB 969 CGCCCGGGCGCAACCTGTTCTGTTGCTGGCGCACGAGATCGGTACACGCTTGGCCTC 1028
 QY 249 ThrHisSerProAlaProArgAlaLeuMetAlaProTyrTyrLysArgLeuGlyArgAsp 268
 DB 1029 ACCCACTCGCCCGCGCGCGCTCATGGCGCCCTACTACAGAGGCTGGCGCGCGAC 1088
 QY 269 AlaLeuLeuSerTrpAspAspValLeuAlaValGlnSerLeuTyrGlyLysProLeuGly 288
 DB 1089 GCGCTGCTCAGCTGGGACACGCTGCTGGCGCTGCAGAGCGCTGTATGGGAGGCCCTTAGGG 1148
 QY 289 GlySerValAlaValGlnLeuProGlyLysLeuPheThrAspPheGluThrTrpAspSer 308
 DB 1149 GGTCTAGTGGCGCTCCAGCTCCAGGAAAGCTGTTCACTGACTTTTGGAGACCTGGGACTCC 1208

QY 309 TyrSerProGlnGlyArgArgProGluThrGlnGlnGlyProLysTyrCysHisSerSerPhe 328
 DB 1209 TACAGCCCCAAGGAAGGGCCCTGAACGAGGGGCCCTAAATACTATGACCTTCTCTTC 1268
 QY 329 AspAlaIleThrValAspArgGlnGlnGlnLeuTyrIlePheLysGlySerHisPheTrp 348
 DB 1269 GATGCCATCAGCTGTAGACAGGCAACAGCAACTGTACATTTTAAAGGGAGCCATTCTCG 1328
 QY 349 GluValAlaAlaAspGlyAsnValSerGluProAspGluProLeuGlnGluArgTrpValGly 368
 DB 1329 GAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGCTCCATCGCAGGAAAGATGGGTGG 1388
 QY 369 LeuProProAsnIleGluAlaAlaValSerLeuAsnAspGlyAspPheTyrPhePhe 388
 DB 1389 CTGCCCCCCCACTTATGAGGCTCGGCAGTGTATTGAAATGAGGAGATTTCTACTTCTTC 1448
 QY 389 LysGlyGlyArgCysTrpArgPheArgGlyProLysProValTrpGlyLeuProGlnLeu 408
 DB 1449 AAAGGGGTGATGCTGGAGGTTCCGGGGCCCAAGCCAGTGTGGGGTCTCCCAAGCTG 1508
 QY 409 CysArgAlaGlyGlyLeuProArgHisProAspAlaAlaLeuPhePheProProLeuArg 428
 DB 1509 TGCCGGGCGAGGGGGCTGCCCCCATCTCGACGCCCTCTCTTCTTCTCTCTCTCTGCG 1568
 QY 429 ArgLeuIleLeuPheLysGlyAlaArgTyrTyrValLeuAlaArgGlyGlyLeuGlnVal 448
 DB 1569 CCGCTCATCTCTTTNAGGGTGGCGCTACTACGTGTGGCCCGAGGGGAGATGCAAGTG 1628
 QY 449 GluProTyrTyrProArgSerLeuGlnAspTrpGlyGlyIleProGluGluValSerGly 468
 DB 1629 GAGCCCTACTACCCCGAAGTTTTCAGGACTGGGGAGGCATCCCTGAGGAGGTGAGCGG 1688
 QY 469 AlaLeuProArgProAspGlySerIlelePhePheArgAspAspArgTyrTrpArgLeu 488
 DB 1689 GCGCTGCGGAGCGCGATGGCTCCATCATCTTCTTCGAGATGACCGCTACTGGCGCTC 1748
 QY 489 AspGlnAlaLysLeuGlnAlaThrThrSerGlyArgTrpAlaThrGluLeuProTrpMet 508
 DB 1749 GACCAAGGCANAACTCAGGCAACCACTCGGGCCGTTGGGCCACCGAGCTGCGCTGGATG 1808
 QY 509 GlyCysTrpHisAlaAsnSerGlySerAlaLeuPhe 520
 DB 1809 GGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTTT 1844

RESULT 246

AAV08170

ID AAV08170 standard; DNA; 1717 BP.

XX AAV08170;

XX 25-JAN-1999 (first entry)

XX MMP19 coding sequence.

XX MMP19; matrix metalloprotease 19; human; cancer; arthritis; inflammation;
 XX therapy; diagnosis; ds.
 XX Homo sapiens.
 XX WO9840475-A1.
 XX 17-SEP-1998.
 XX 11-MAR-1998; 98WO-US004694.
 XX 11-MAR-1997; 97US-00814394.
 XX (ABBO) ABBOTT LAB.
 XX Faiduto M, Magnuson SR, Morgan DW;
 XX WPI, 1998-531521/45.

DR P-PSDB; AAW73211.
 XX New isolated human matrix metalloproteinase gene - used to develop products
 PT for the diagnosis, prevention and treatment of e.g. cancer, arthritis or
 PT inflammation.
 XX
 XX
 PS Claim 1; Page 56; 11pp; English.

XX This sequence encodes the human matrix metalloproteinase 19 (MMP19) of the
 CC invention. The DNA, protein, and antibodies against MMP19 can be used in
 CC the diagnosis, prognosis, prevention or treatment of individuals with
 CC conditions associated with the expression of the MMP19 gene, such as
 CC cancer, arthritis or inflammation, or to identify a predisposition to
 CC these conditions. The DNA can be fixed to a substrate and used to detect
 CC the presence of MMP19 in a sample. The sequences can be used to make
 CC primers for use in reverse transcription PCR to detect MMP19, they can
 CC also be used to identify inhibitors of MMP19

XX Sequence 1717 BP; 361 A; 547 C; 494 G; 315 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1-78e-134 Length: 1717
 Score: 2527.00 Matches: 467
 Percent Similarity: 99.36% Conservative: 0
 Best Local Similarity: 99.36% Mismatches: 2
 Query Match: 89.17% Indels: 2
 DB: Gaps: 0

US-10-791-980-6 (1-520) x AAW08170 (1-1717)

QY	52	LysAlaProThrSerThrArgPheSerAspAlaIleArgAlaPheGlnTrpValSerGln	71
DB	1	AAAGCTCCACCTCCACTCGATTACGCGATGCGCATCAGAGCGTTTCAGTGGGTGCCAG	60
QY	72	LeuProValSerGlyValLeuAspArgAlaThrLeuArgGlnMetThrArgProArgCys	91
DB	61	CTACCTGTGAGCGCGTGTGGACCGCGCAACCTGGCCAGATGACTCGTCCCGCTGC	120
QY	92	GlyValThrAspThrAsnSerTyrAlaAlaTrpAlaGluArgIleSerAspLeuPheAla	111
DB	121	GGGGTTTACAGATACCAACAGTTATGCGGCTGCGGCTGAGAGGATCAGTGACTTGTGCT	180
QY	112	ArgHisArgThrIleMetArgArgLysLysArgPheAlaLysGlnGlnValAsnLysTrpTyr	131
DB	181	AGACACCGGACCAAAATAGGCGGTAAAGAACCGCTTTGCAAGCAGGTAAACAATGGTAC	240
QY	132	LysGlnHisLeuSerTyrArgLeuValAsnTrpProGluHisLeu-ArgSerArgGlnPh	151
DB	241	AAGCAGACCTCTCTACCGCCTGGTGAACCTGGCCTGAGCATCTGCGGAGCGGCAGTT	300
QY	151	eGlyAlaProCysAlaProSerSerCysGlyAlaThrSerGlnArgTrpSerSerGln	171
DB	301	CGGGGGCGCGTGGCGCGCGCTTCCAGTTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGG	360
QY	171	YArgProGlnProGlnAlaProLeuThrSerGlySerProSerSerLysGlyThrThrTh	191
DB	361	GAGGCCCCCAGCACAGCCCCCGCTGACATCCGCGCTACCTTCTCCAGGGGACCAACA	420
QY	191	rMetGlyTrpAlaMetProLeuMetAlaGlnGlyAlaProTrpArgThrProPheLeuPr	211
DB	421	GATGGGCTGGCAATGCTTTGATGGCCAGGGGGCGCCCTGGCGCAGCGCTTTC-CTGCC	479
QY	211	oArgArgGlyGluAlaHisPheAspGlnAspGluArgTrpSerLeuSerArgArgGln	231
DB	480	CCGCGCGCGGGAAGCGACCTTCGACCAAGATAGCGCTGTCTCCTGAGCCCGCGCGCGG	539
QY	231	YArgAsnLeuPheValValLeuAlaHisGluIleGlyHisThrLeuGlyLeuThrHis	251
DB	540	GCGCAACCTGTTCTGTGTGTGGCGCAGAGATCGGTACACGCTTGGCCCTCACCCACTC	599
QY	251	rProAlaProArgAlaLeuMetAlaProTyrTyrLysArgLeuGlyArgAspAlaLeuLe	271
DB	600	GCCCGCGCGCGCGCTCATGTGGCGCCCTACTACAGAGGCTGGGCGCGCGCGCTGCT	659

QY	271	uSerTrpAspAspValLeuAlaValGlnSerLeuTyrGlyLysPheProLeuGlyGlySerVa	291
DB	660	CAGCTGGGACGAGTCTGCGCGTGCAGAGCCCTGTATGAGAGCCCTCCTAGGGGCTCAGT	719
QY	291	lAlaValGlnLeuProGlyLysLeuPheThrAspPheGluThrTrpAspSerTyrSerPr	311
DB	720	GGCGTCCAGTCCAGGAAAGCTGTTCACTGACTTTGAGACTGGGACTCTCTACAGCCC	779
QY	311	oGlnGlyArgArgProGluThrGlnGlyProLysTyrCysHisSerSerPheAspAlaI	331
DB	780	CCAAGGAAGCGCCCTGAAACGAGGCGCCCTAAATACTGCCACTCTTCTTTCATGCCAT	839
QY	331	eThrValAspArgGlnGlnLeuTyrIlePheLysGlySerHisPheThrGluValAl	351
DB	840	CATGTAGACAGGCAACAGCACTGTACATTTTAAAGGAGGAGCACTTCTGGGAGGTGC	899
QY	351	aAlaAspGlyAsnValSerGluProArgProLeuGlnGluArgTrpValGlyLeuProPr	371
DB	900	AGCTGATGCAACGTTCTCAGAGCCCGCTCCACTGCAGGAAAGATGGGTGCGGCTGCC	959
QY	371	oAsnIleGluAlaAlaValSerLeuAsnAspGlyAspPheTyrPhePheLysGlyG	391
DB	960	CAACATTGAGCGTGGCGCAGTGTCAATGAATGATGAGAGATTTCTACTTCTTCAAGGGG	1019
QY	391	YArgCysTrpArgPheArgGlyProLysProValTrpGlyLeuProGlnLeuCysArgAl	411
DB	1020	TCGATGCTGGAGGTTCGCGGCGCCCAAGCCAGTGTGGGTCTCCACAGCTGTGCCGGC	1079
QY	411	aglyGlyLeuProArgHisProAspAlaAlaLeuPhePheProLeuArgLeuI	431
DB	1080	AGGGGCGTGGCGCCCATCTCAGCGCGCCCTTCTTCTTCTTCTTCTTCTTCTTCTTCT	1139
QY	431	eLeuPheLysGlyAlaArgTyrTrpValLeuAlaArgGlyGlyLeuGlnValGluPrTy	451
DB	1140	CCTTTCAAGGTGCCCGCTACTACGTCGTGGCCCGGAGGAGTGCNAGTGGAGCCCTA	1199
QY	451	rTyrProArgSerLeuGlnAspTrpGlyIleProGluGluValSerGlyAlaLeuPr	471
DB	1200	CTACCCCGAGTCTGCGGAGCTGGGAGGCATCCCTGAGGAGGTGACGCGCGCCCTGCC	1259
QY	471	oArgProAspGlySerIlePhePheArgAspAspArgTyrTrpArgLeuAspGlnAl	491
DB	1260	GAGGCGCGATGGCTCCATCATCTTCTCCGAGATGACCGCTACTGGCGCCCTCGACCCAGC	1319
QY	491	alysLeuGlnAlaThrThrSerGlyArgTrpAlaThrGluLeuProTrpMetGlyCysTr	511
DB	1320	CAAACTGGAGCAACCACTCGGCGCGCTGGGCCACCGAGCTGCCCTGGATGGGCTGCTG	1379
QY	511	pHisAlaAsnSerGlySerAlaLeuPhe	520
DB	1380	GCATGCCAACTCGGGGAGCGCCCTGTTC	1407

RESULT 247

ABK48982

ID ABK48982 standard; cDNA; 2310 BP.

XX AC ABK48982;

XX DT 02-JUL-2002 (first entry)

XX DE cDNA encoding novel matrix metalloproteinase 46798, short form.

XX Matrix metalloproteinase; MMP; 46798 short form; heart failure; tumour;
 KW extracellular matrix degradation; cardiovascular disease; metastasis;
 KW atherosclerosis; arthritis; nephritis; liver fibrosis; emphysema; trauma;
 KW periodontal disease; skin ulceration; viral infection; psoriasis;
 KW fibrotic lung disease; bacterial infection; autoimmune disorder; angiogenesis;
 KW wound healing; chronic injury; tissue invasion; gene; ss.
 XX Homo sapiens.

Db	1351	CGCCCTCTTCTCCCTCCTCTGCGCGCCGCTCATCCTCTTCAAGGGTGCCCGCTACTACGT	1411
Qy	440	lLeuAlaAArgGlyVcGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
Db	1411	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG	1470
Qy	460	YGlyTleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh	480
Db	1471	AGGCATCCCTGAGAGAGTCAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT	1530
Qy	480	eArGAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1531	CCGAGATGACCGCTACTTGGCGCCTCGACAGGCCAATCTGCAGGCACCACTCGGGCCG	1590
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAAsnSerGlySerAlaLeuPh	520
Db	1591	CTGGCCACCGAGCTGCCCTTGGATGGGTCTGGCATGCCAACTCGGGGAGCGCCTGTT	1650
Qy	520	e 520	
Db	1651	C 1651	
	RESULT 248		
	ABK91095		
ID	ABK91095	standard; cDNA; 2310 BP.	
AC	ABK91095;		
XX	29-NOV-2002	(first entry)	
XX	cDNA encoding human matrix metalloproteinase (MMP) 46798 #1.		
XX	Human; matrix metalloproteinase; MMP 46798; cell proliferation disorder;		
KW	cell differentiation disorder; carcinoma; sarcoma; leukaemia;		
KW	breast cancer; lung cancer; neurological disorder; schizophrenia;		
KW	ischaemia; infarction; Parkinson's disease; Huntington's disease;		
KW	inflammatory disorder; Crohn's disease; immune disorder; arthritis;		
KW	diabetes mellitus; cardiovascular disorder; restenosis; tachycardia;		
KW	rheumatic heart disease; motility disorder; developmental disorder;		
KW	lung disorder; chronic bronchitis; pulmonary congestion; oedema;		
KW	blood disorder; blood clotting disorder; cytostatic; immunomodulator;		
KW	anti-inflammatory; cardiant; antiparkinsonian; nootropic; thrombolytic;		
KW	neuroprotective; antidiabetic; antirheumatic; antiarthritic; vasotropic;		
KW	gene; ss.		
XX	Homo sapiens.		
OS			
XX	Key	Location/Qualifiers	
FT	CDS	317..1654	
FT		/*tag= a	
FT		/product= "MMP 46798 #1"	
FT		/note= "The coding region is specifically claimed in	
FT		Claim 6"	
XX			
XX	WO200266670-A2.		
PN			
XX			
XX	29-AUG-2002.		
PD			
XX			
PF	16-JAN-2002; 2002WO-US001546.		
XX			
PR	16-JAN-2001; 2001US-0262252P.		
XX			
XX	(MILL-) MILLENNIUM PHARM INC.		
PA			
XX	Curtis RAJ, Lora JM;		
PI			
XX	WPI; 2002-674955/72.		
XX	P-PSDB; ABG31458.		
DR			
DR			
XX			
XX	New human matrix metalloproteinase nucleic acid and polypeptide		
PT	molecules, designated 46798, useful for diagnosing, preventing or		
PT	treating cancers, ischemia, Parkinson's disease heart disease or edema.		
XX			

QY 220 nAspGluArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 751 AGATGAGCGCTGGTCTCTGAGCGCGCGCGCGCGCAACCTGTTGGTGTGTGGCGCA 810
 QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 811 CGAGATCGGTACACGCTGGCGCTCCACCTCGCGCGCGCGCGCTCATGTCGGCGC 870
 QY 260 oTyrtTyrtLeuArgLeuGlyArgSerPheAlaLeuLeuSerTrpAspValLeuAlaValGI 280
 DB 871 CTACTACAGAGCGCTGGCGCGCGCGCTGGCGCTGGCGCTGGCGCTGGCGCTGGCA 930
 QY 280 nSerLeuTyrtGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 931 GAGCCTGTATGGAGCGCTTACGGCGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 990
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
 DB 991 CACTGACTTTTGACCTGGGACTCTTACAGCGCGCGCGCGCGCGCTGMAACGCGCG 1050
 QY 320 yProLysTyrtCysHisSerSerPheAlaLeuThrValAspArgGlnGlnLeuTy 340
 DB 1051 CCTTAATATCTGCCT 1110
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1111 CATTTTAAAGGAGGCAATTTCTGGAGGTGGCGCTGATGCAAGCTCTCAGAGCCCG 1170
 QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1171 TCCACTGCAGGAAGATGGTGGCGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1230
 QY 380 uAenAspGlyAspPheTyrtPhePheLysGlyArgGlyArgGlyArgGlyArgGlyProLy 400
 DB 1231 GAATGATGAGATTTCTACTTCTTCAAGGGGGTCCGATGCTGGAGGTTCGGGGCGCCAA 1290
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1291 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCGCGCGCGCGCGCGCG 1350
 QY 420 alAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrtVa 440
 DB 1351 CGCCCTCTTCT 1410
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrtTyrtProArgSerLeuGlnAspTrpGI 460
 DB 1411 GTGGCGCGCGGGGAGCTCAAGTGGAGCGCTTACCTACCGCGCGCGCGCGCGCGCGCG 1470
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleilePhePh 480
 DB 1471 AGGCATCTCTGAGGAGTTCAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1530
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1531 CCGAGATGACCGCTACTGCGCGCTCGACCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1590
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1591 CTGGGCCACCGAGTCTGCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 1650
 QY 520 e 520
 DB 1651 C 1651

RESULT 249

ADJ72039

ID ADJ72039 standard; DNA; 1355 BP.

XX AC ADJ72039;

XX DT 06-MAY-2004 (first entry)

XX DE Human PMMM protein gene sequence SeqID99.

XX protein modification and maintenance molecule; PMMM; cytostatic;
 KW cerbroprotective; anticonvulsant; nootropic; neuroprotective;
 KW antinflammatory; endocrine-Gen; antiallergic; antimicrobial;
 KW cell proliferative disorder; cancer; atherosclerosis;
 KW neurological disorder; epilepsy; Huntington's disease; stroke;
 KW immune disorder; inflammatory disorder; AIDS; allergy;
 KW developmental disorder; Hypothyroidism; Cushing's syndrome; infection;
 KW human; gene; ds.
 XX Homo sapiens.
 XX WO2004009797-A2.
 XX 29-JAN-2004.
 XX 23-JUL-2003; 2003WO-US023249.
 XX 23-JUL-2002; 2002US-0398143P.
 PR 09-AUG-2002; 2002US-0402458P.
 PR 12-AUG-2002; 2002US-0403289P.
 PR 27-AUG-2002; 2002US-0406472P.
 PR 06-SEP-2002; 2002US-0409354P.
 XX (INCY-) INCYTE CORP.
 XX Elliott VS, Swarnakar A, Griffin JA, Lee EA, Sprague WW;
 PI Hafalia AJA, Lee SY, Kabie AE, Ison CH, Khare R, Chawla NK;
 PI Marquis JP, Jiang X, Jackson AA, Becha SD, Emerling BM, Jin P;
 PI Wilson AD, Richardson TW, Yang J, Baughn MR, Gandhi AR, Nguyen DB;
 PI Ramkumar J, Kallick DA, Kearney L, Lu DAM, Gietzen KJ, Tribouley CN;
 PI Lal PG, Blake JJ, Lu Y, Arvizu LS;
 XX WPI; 2004-123392/12.
 DR P-PSDB; ADJ71977.
 XX New human protein modification and maintenance molecules (PMMM), useful
 PT for diagnosing, treating and preventing diseases or conditions associated
 PT with the aberrant PMMM expression e.g. cancer, AIDS, epilepsy, or
 PT infections.
 XX Claim 5; SEQ ID NO 99; 387pp; English.
 XX This invention relates to novel protein modification and maintenance
 CC molecules (PMMM) and polynucleotides which identify and encode PMMM. The
 CC invention may be useful for the development of compositions with a
 CC cytostatic, antiarteriosclerotic, anticonvulsant, nootropic,
 CC neuroprotective, cerbroprotective, vasotropic, anti-HIV, antiallergic,
 CC antimicrobial, antiinflammatory, endocrine-Gen or thymometric activity.
 CC The polypeptides and polynucleotides are useful in diagnosing, treating
 CC and preventing diseases or conditions associated with the decreased
 CC expression or overexpression of PMMM, such as cell proliferative (for
 CC example cancer, atherosclerosis), neurological (for example epilepsy,
 CC Huntington's disease, stroke), immune/inflammatory (for example AIDS,
 CC allergies) and developmental (for example hypothyroidism, Cushing's
 CC syndrome) disorders, or infections. These are also useful in assessing
 CC the effects of exogenous compounds on the expression of nucleic acid and
 CC amino acid sequences of PMMM. The present sequence is that of a gene
 CC which encodes a human PMMM protein of the invention.
 XX SQ Sequence 1355 BP; 259 A; 440 C; 422 G; 234 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1.29e-103 Length: 1355
 Score: 1981.00 Matches: 397
 Percent Similarity: 76.05% Conservative: 0
 Best Local Similarity: 76.05% Mismatches: 3
 Query Match: 69.90% Indels: 124
 DB: 12 Gaps: 2
 US-10-791-980-6 (1-520) x ADJ72039 (1-1355)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	65	ATGTCGCGCGCGTCTCTCTGTCGCGCCCTCAGCTGCTACTGTGGGCGACCTG	124
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	125	GACGCCAGCCGCGAGCGGAGCGGAGCGGAGCTGCGCAAGAGGCGGAGCATTCCTA	184
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	185	GAGAAAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC	244
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	245	GATGCCATCAGACGCTTCAGTGGGTGCCAGCTACCTGTGACGGCGTGTGGACCGC	304
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	305	GCCACCTCGCGCAGATGACTGCTCCCGCTGCGGGTTACAGATACCACCAAGTTATGCG	364
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	365	GCTTGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG	424
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	425	AAACGCTTTGCAAG	439
QY	141	AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSer	160
Db	439	-----	439
QY	161	CysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuThr	180
Db	439	-----	439
QY	181	SerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAla	200
Db	439	-----	439
QY	201	Gln-GlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln	220
Db	440	CAGGGGGCGCCCTGGCGACAGCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA	498
QY	220	AspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	499	AGATGAGCGTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA	558
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	559	CGAGATCGGTACACAGCTTGGCTTCACCTCCGCGCGCGCGCGCGCTCATGGCGCC	618
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln	280
Db	619	CTACTACAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGAGCGAGCTGTGGCGCTGCA	678
QY	280	nSerLeuTyrLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	679	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTCCAGAAAAGCTGTT	738
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGln	320
Db	739	CACGTACTTGGACCTGGGACTCTACAGCCCCCAAGGAAGCGCGCTGAAACGCGAGGG	798
QY	320	YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	799	CCCTAAATACCTGCCACTTCTCTCGATGCCATCCTGTGACAGGCGCAACAGCAACTGTA	858
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	859	CATTTTTTAAAGGAGCCATTTCTGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG	918
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	919	TCACATGTCAGGAAAGATGGTCTGGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCAAT	978
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly	400
Db	979	GAATGATGGAGATTCTACTTC	1000
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1000	-----	1000
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPhe-LysGlyAlaArgTyrTyrV	440
Db	1001	-----TTCAAGGGTGGCGCTACTACG	1023
QY	440	AlaLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG	460
Db	1024	TGCGCGCGGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTGTGCAAGGACTGGG	1083
QY	460	lyGlyIleProGluGluValSerGlyAlaLeuProArgProArgProArgGlySerIleLeuPheP	480
Db	1084	GAGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGGAGGCCGCGATGCTCATCATCTTCT	1143
QY	480	heArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyA	500
Db	1144	TCCGAGATGACCGCTACTGGCGCTCGACCCAGGCCAAACTGCGAGGCAACCACTCGGGCC	1203
QY	500	rgTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuP	520
Db	1204	GCTGGGCCACCGAGCTGCC-TGGATGGGCTGTGGCATGTCCTCAACTCGGGAGCGCCCTGT	1262
QY	520	he 520	
Db	1263	TC 1264	
RESULT 250			
ADJ72037			
ID	ADJ72037 standard; DNA; 1144 BP.		
XX	AC ADJ72037;		
XX	06-MAY-2004 (first entry)		
DE	Human PMM protein gene sequence SeqID97.		
XX	protein modification and maintenance molecule; PMM; cytostatic;		
KW	antiarteriosclerotic; anticonvulsant; nootropic; neuroprotective;		
KW	cerebroprotective; vasotropic; anti-HIV; antiallergic; antimicrobial;		
KW	antiinflammatory; endocrine-Gen; thyromimetic;		
KW	cell proliferative disorder; cancer; atherosclerosis;		
KW	neurological disorder; epilepsy; Huntington's disease; stroke;		
KW	immune disorder; inflammatory disorder; AIDS; allergy;		
KW	developmental disorder; Hypothyroidism; Cushing's syndrome; infection;		
XX	human; gene; ds.		
OS	Homo sapiens.		
XX	WO2004009797-A2.		
PN	29-JAN-2004.		
XX	23-JUL-2003; 2003WO-US023249.		
PF	23-JUL-2002; 2002US-0398143P.		
XX	09-AUG-2002; 2002US-0402458P.		
PR	12-AUG-2002; 2002US-0403289P.		
PR	27-AUG-2002; 2002US-0406472P.		
PR	06-SEP-2002; 2002US-0409354P.		
XX	(INCY-) INCYTE CORP.		
PA	Elliott VS, Swarnakar A, Griffin JA, Lee EA, Sprague WW;		
XX	Hafalia AJA, Lee SY, Kable AE, Ison CH, Khare R, Chawla NK;		

Db 1042 TGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTTTC 1101

Search completed: November 14, 2005, 14:27:05
Job time : 1442 secs

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: November 14, 2005, 12:42:27 ; Search time 1008 Seconds
(without alignments)
4266.177 Million cell updates/sec

Title: US-10-791-980-6
Perfect score: 2834
Sequence: 1 MVARVGLLRLLQLLWGH.....WATELPWMCWHANSGLSF 520

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 9794790 seqs, 4134909567 residues

Total number of hits satisfying chosen parameters: 19589580

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 300 summaries

Command line parameters:
-MODEL=frame_p2n.model -DEV=xlp
-Q=/cgn2_1/USPTO_spool_p/US10791980/runat_09112005_121056_27734/app_query.fasta_1.711
-DB=Published Applications NA -QFMT=fastap -SUFFIX=rnpb -MINMATCH=0.1
-LOOPCL=0 -LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blousum62
-TRANS=human40.cdi -LIST=300 -DOCALLIGN=200 -THR SCORE=pct -THR MAX=100
-THR MIN=0 -ALIGN=250 -MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZ=500
-MINLEN=0 -MAXLEN=2000000000
-USER=US10791980@cgn_1_1_723 @runat_09112005_121056_27734 -NCPU=6 -ICPU=3
-NO MMAP -LARGQUERY -NEG SCORE=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV_TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : Published Applications_NA:
1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq.*
2: /cgn2_6/ptodata/2/pubpna/PCT_NEW_PUB.seq.*
3: /cgn2_6/ptodata/2/pubpna/US06_NEW_PUB.seq.*
4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq.*
5: /cgn2_6/ptodata/2/pubpna/US07_NEW_PUB.seq.*
6: /cgn2_6/ptodata/2/pubpna/PCTUS_PUBCOMB.seq.*
7: /cgn2_6/ptodata/2/pubpna/US08_NEW_PUB.seq.*
8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq.*
9: /cgn2_6/ptodata/2/pubpna/US09A_PUBCOMB.seq.*
10: /cgn2_6/ptodata/2/pubpna/US09B_PUBCOMB.seq.*
11: /cgn2_6/ptodata/2/pubpna/US09C_PUBCOMB.seq.*
12: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq.*
13: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq.*
14: /cgn2_6/ptodata/2/pubpna/US10A_PUBCOMB.seq.*
15: /cgn2_6/ptodata/2/pubpna/US10B_PUBCOMB.seq.*
16: /cgn2_6/ptodata/2/pubpna/US10C_PUBCOMB.seq.*
17: /cgn2_6/ptodata/2/pubpna/US10D_PUBCOMB.seq.*
18: /cgn2_6/ptodata/2/pubpna/US10E_PUBCOMB.seq.*
19: /cgn2_6/ptodata/2/pubpna/US10F_PUBCOMB.seq.*
20: /cgn2_6/ptodata/2/pubpna/US10G_PUBCOMB.seq.*
21: /cgn2_6/ptodata/2/pubpna/US10H_PUBCOMB.seq.*
22: /cgn2_6/ptodata/2/pubpna/US10I_PUBCOMB.seq.*
23: /cgn2_6/ptodata/2/pubpna/US10_NEW_PUB.seq.*
24: /cgn2_6/ptodata/2/pubpna/US10A_NEW_PUB.seq.*
25: /cgn2_6/ptodata/2/pubpna/US11A_PUBCOMB.seq.*
26: /cgn2_6/ptodata/2/pubpna/US11_NEW_PUB.seq.*
27: /cgn2_6/ptodata/2/pubpna/US60_NEW_PUB.seq.*

28: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	2834	100.0	1597	10	US-09-862-631-3	Sequence 3, Appli
2	2834	100.0	1597	24	US-10-791-980-3	Sequence 3, Appli
3	2792	98.5	1560	9	US-09-950-510-3	Sequence 3, Appli
4	2792	98.5	1560	20	US-10-744-033-3	Sequence 3, Appli
5	2792	98.5	1563	9	US-09-737-353-1	Sequence 1, Appli
6	2792	98.5	1563	15	US-10-050-216B-10	Sequence 10, Appl
7	2792	98.5	1585	15	US-10-028-072-143	Sequence 143, App
8	2792	98.5	1585	15	US-10-140-808-143	Sequence 143, App
9	2792	98.5	1585	15	US-10-121-049-143	Sequence 143, App
10	2792	98.5	1585	15	US-10-123-904-143	Sequence 143, App
11	2792	98.5	1585	15	US-10-140-470-143	Sequence 143, App
12	2792	98.5	1585	15	US-10-175-746-143	Sequence 143, App
13	2792	98.5	1585	15	US-10-176-918-143	Sequence 143, App
14	2792	98.5	1585	15	US-10-176-921-143	Sequence 143, App
15	2792	98.5	1585	15	US-10-137-865-143	Sequence 143, App
16	2792	98.5	1585	15	US-10-140-474-143	Sequence 143, App
17	2792	98.5	1585	15	US-10-142-431-143	Sequence 143, App
18	2792	98.5	1585	15	US-10-143-114-143	Sequence 143, App
19	2792	98.5	1585	15	US-10-142-419-143	Sequence 143, App
20	2792	98.5	1585	15	US-10-123-262-143	Sequence 143, App
21	2792	98.5	1585	15	US-10-142-423-143	Sequence 143, App
22	2792	98.5	1585	15	US-10-121-050-143	Sequence 143, App
23	2792	98.5	1585	15	US-10-141-755-143	Sequence 143, App
24	2792	98.5	1585	15	US-10-143-032-143	Sequence 143, App
25	2792	98.5	1585	15	US-10-123-108-143	Sequence 143, App
26	2792	98.5	1585	15	US-10-123-236-143	Sequence 143, App
27	2792	98.5	1585	15	US-10-123-261-143	Sequence 143, App
28	2792	98.5	1585	15	US-10-140-921-143	Sequence 143, App
29	2792	98.5	1585	15	US-10-140-928-143	Sequence 143, App
30	2792	98.5	1585	15	US-10-121-045-143	Sequence 143, App
31	2792	98.5	1585	15	US-10-123-292-143	Sequence 143, App
32	2792	98.5	1585	15	US-10-123-903-143	Sequence 143, App
33	2792	98.5	1585	15	US-10-124-819-143	Sequence 143, App
34	2792	98.5	1585	15	US-10-124-822-143	Sequence 143, App
35	2792	98.5	1585	15	US-10-140-925-143	Sequence 143, App
36	2792	98.5	1585	15	US-10-160-498-143	Sequence 143, App
37	2792	98.5	1585	15	US-10-124-824-143	Sequence 143, App
38	2792	98.5	1585	15	US-10-127-825A-143	Sequence 143, App
39	2792	98.5	1585	15	US-10-127-829A-143	Sequence 143, App
40	2792	98.5	1585	15	US-10-127-835A-143	Sequence 143, App
41	2792	98.5	1585	15	US-10-127-839A-143	Sequence 143, App
42	2792	98.5	1585	15	US-10-127-901A-143	Sequence 143, App
43	2792	98.5	1585	15	US-10-128-693A-143	Sequence 143, App
44	2792	98.5	1585	15	US-10-131-813A-143	Sequence 143, App
45	2792	98.5	1585	15	US-10-131-818A-143	Sequence 143, App
46	2792	98.5	1585	15	US-10-131-823A-143	Sequence 143, App
47	2792	98.5	1585	15	US-10-131-824A-143	Sequence 143, App
48	2792	98.5	1585	15	US-10-131-830A-143	Sequence 143, App
49	2792	98.5	1585	15	US-10-131-837A-143	Sequence 143, App
50	2792	98.5	1585	15	US-10-137-872A-143	Sequence 143, App
51	2792	98.5	1585	15	US-10-147-500-143	Sequence 143, App
52	2792	98.5	1585	15	US-10-147-502-143	Sequence 143, App
53	2792	98.5	1585	15	US-10-147-515-143	Sequence 143, App
54	2792	98.5	1585	15	US-10-147-517-143	Sequence 143, App
55	2792	98.5	1585	15	US-10-147-526-143	Sequence 143, App
56	2792	98.5	1585	15	US-10-147-527-143	Sequence 143, App
57	2792	98.5	1585	15	US-10-121-041-143	Sequence 143, App
58	2792	98.5	1585	15	US-10-121-043-143	Sequence 143, App
59	2792	98.5	1585	15	US-10-121-047-143	Sequence 143, App
60	2792	98.5	1585	15	US-10-123-215-143	Sequence 143, App
61	2792	98.5	1585	15	US-10-123-902-143	Sequence 143, App
62	2792	98.5	1585	15	US-10-123-908-143	Sequence 143, App

209	2792	98.5	1985	16	US-10-142-760-143	Sequence 143, App
210	2792	98.5	1985	16	US-10-145-821-143	Sequence 143, App
211	2792	98.5	1985	16	US-10-152-531-143	Sequence 143, App
212	2792	98.5	1985	17	US-10-127-840A-143	Sequence 143, App
213	2792	98.5	1985	17	US-10-142-424-143	Sequence 143, App
214	2792	98.5	1985	17	US-10-142-761-143	Sequence 143, App
215	2792	98.5	1985	17	US-10-142-763-143	Sequence 143, App
216	2792	98.5	1985	17	US-10-142-765-143	Sequence 143, App
217	2792	98.5	1985	17	US-10-142-887-143	Sequence 143, App
218	2792	98.5	1985	17	US-10-142-888-143	Sequence 143, App
219	2792	98.5	1985	17	US-10-143-034-143	Sequence 143, App
220	2792	98.5	1985	17	US-10-143-116-143	Sequence 143, App
221	2792	98.5	1985	17	US-10-143-117-143	Sequence 143, App
222	2792	98.5	1985	17	US-10-144-957-143	Sequence 143, App
223	2792	98.5	1985	17	US-10-144-992-143	Sequence 143, App
224	2792	98.5	1985	17	US-10-145-015-143	Sequence 143, App
225	2792	98.5	1985	17	US-10-145-090-143	Sequence 143, App
226	2792	98.5	1985	17	US-10-145-091-143	Sequence 143, App
227	2792	98.5	1985	17	US-10-145-629-143	Sequence 143, App
228	2792	98.5	1985	17	US-10-145-630-143	Sequence 143, App
229	2792	98.5	1985	17	US-10-145-747-143	Sequence 143, App
230	2792	98.5	1985	17	US-10-145-752-143	Sequence 143, App
231	2792	98.5	1985	17	US-10-145-754-143	Sequence 143, App
232	2792	98.5	1985	17	US-10-145-755-143	Sequence 143, App
233	2792	98.5	1985	17	US-10-145-818-143	Sequence 143, App
234	2792	98.5	1985	17	US-10-145-820-143	Sequence 143, App
235	2792	98.5	1985	17	US-10-145-872-143	Sequence 143, App
236	2792	98.5	1985	17	US-10-145-873-143	Sequence 143, App
237	2792	98.5	1985	17	US-10-147-481-143	Sequence 143, App
238	2792	98.5	1985	17	US-10-147-482-143	Sequence 143, App
239	2792	98.5	1985	17	US-10-147-503-143	Sequence 143, App
240	2792	98.5	1985	17	US-10-147-522-143	Sequence 143, App
241	2792	98.5	1985	17	US-10-152-401-143	Sequence 143, App
242	2792	98.5	1985	17	US-10-157-783-143	Sequence 143, App
243	2792	98.5	1985	17	US-10-158-792-143	Sequence 143, App
244	2792	98.5	1985	17	US-10-158-462-143	Sequence 143, App
245	2792	98.5	1985	17	US-10-143-035-143	Sequence 143, App
246	2792	98.5	1985	17	US-10-145-751-143	Sequence 143, App
247	2792	98.5	1985	17	US-10-145-822-143	Sequence 143, App
248	2792	98.5	1985	17	US-10-145-824-143	Sequence 143, App
249	2792	98.5	1985	17	US-10-145-827-143	Sequence 143, App
250	2792	98.5	1985	17	US-10-145-869-143	Sequence 143, App
251	2792	98.5	1985	17	US-10-145-875-143	Sequence 143, App
252	2792	98.5	1985	17	US-10-145-877-143	Sequence 143, App
253	2792	98.5	1985	17	US-10-145-958-143	Sequence 143, App
254	2792	98.5	1985	17	US-10-146-787-143	Sequence 143, App
255	2792	98.5	1985	17	US-10-146-790-143	Sequence 143, App
256	2792	98.5	1985	17	US-10-146-793-143	Sequence 143, App
257	2792	98.5	1985	17	US-10-147-480-143	Sequence 143, App
258	2792	98.5	1985	17	US-10-147-485-143	Sequence 143, App
259	2792	98.5	1985	17	US-10-147-486-143	Sequence 143, App
260	2792	98.5	1985	17	US-10-147-487-143	Sequence 143, App
261	2792	98.5	1985	17	US-10-147-490-143	Sequence 143, App
262	2792	98.5	1985	17	US-10-147-494-143	Sequence 143, App
263	2792	98.5	1985	17	US-10-147-498-143	Sequence 143, App
264	2792	98.5	1985	17	US-10-147-514-143	Sequence 143, App
265	2792	98.5	1985	17	US-10-147-524-143	Sequence 143, App
266	2792	98.5	1985	17	US-10-152-379-143	Sequence 143, App
267	2792	98.5	1985	17	US-10-152-394-143	Sequence 143, App
268	2792	98.5	1985	17	US-10-152-406-143	Sequence 143, App
269	2792	98.5	1985	17	US-10-156-847-143	Sequence 143, App
270	2792	98.5	1985	17	US-10-157-778-143	Sequence 143, App
271	2792	98.5	1985	17	US-10-157-799-143	Sequence 143, App
272	2792	98.5	1985	17	US-10-160-504-143	Sequence 143, App
273	2792	98.5	1985	17	US-10-145-634-143	Sequence 143, App
274	2792	98.5	1985	17	US-10-147-520-143	Sequence 143, App
275	2792	98.5	1985	17	US-10-157-781-143	Sequence 143, App
276	2792	98.5	1985	17	US-10-176-989-143	Sequence 143, App
277	2792	98.5	1985	17	US-10-147-491-143	Sequence 143, App
278	2792	98.5	1985	17	US-10-152-378-143	Sequence 143, App
279	2792	98.5	1985	17	US-10-152-382-143	Sequence 143, App
280	2792	98.5	1985	17	US-10-152-383-143	Sequence 143, App
281	2792	98.5	1985	17	US-10-152-384-143	Sequence 143, App
ALIGNMENTS						
RESULT 1						
US-09-862-631-3						
; Sequence 3, Application US/09862631						
; Publication No. US20030032164A1						
; GENERAL INFORMATION:						
; APPLICANT: Holmgren, Erik						
; APPLICANT: Kihlen, Mats						
; APPLICANT: Wood, Tim						
; APPLICANT: Ekblom, Jonas						
; TITLE OF INVENTION: No. US20030032164A1el Matrix Metalloproteinases						
; FILE REFERENCE: 00014regus						
; CURRENT APPLICATION NUMBER: US/09/862,631						
; CURRENT FILING DATE: 2001-05-22						
; PRIOR APPLICATION NUMBER: 206119						
; PRIOR FILING DATE: 2000-05-22						
; NUMBER OF SEQ ID NOS: 8						
; SOFTWARE: PatentIn version 3.0						
; SEQ ID NO 3						
; LENGTH: 1597						
; TYPE: DNA						
; ORGANISM: Homo sapiens						
US-09-862-631-3						
Alignment Scores:						
Pred. No.: 2.06e-266 Length: 1597						
Score: 2834.00 Matches: 520						
Percent Similarity: 100.00% Conservative: 0						
Best Local Similarity: 100.00% Mismatches: 0						
Query Match: 100.00% Indels: 0						
DB: 10 Gaps: 0						
US-10-791-980-6 (1-520) x US-09-862-631-3 (1-1597)						
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20			
Db	35	ATGTTCGCGCGCTCGCCCTCTCTGCGCCCTCTGCGAGCTGCTACTGTGGGCCACCTG	94			
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40			
Db	95	GACGCCAGCCCGGAGCGCGGAGGCGGAGGCTGGCAGAGGCGGAGGCATTCCTA	154			
Qy	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60			
Db	155	GAGAAGTACGATACCTCAATGAACAGTCCCAAGCTCCCACTCCATTCAGC	214			
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80			
Db	215	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACCTACCTCGAGCGCGGTGTGACCGC	274			
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100			

Db	275	GCACCCCTGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG	334	Db	1355	CTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGTCTGCAGGACTGGGA	1414
Qy	101	AlaTrpAlaGluArgIleSerAspIeuPheAlaArgHisArgThrLysMetArgArgLys	120	Qy	461	GlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePhe	480
Db	335	GCCTGGGCTGAGAGGATCAGTGACTGTGTTCTAGACACCGGACCAAAATGAGCGTAAG	394	Db	1415	GGCATCCCTGAGGAGTCAAGCGCGCTTCCGAGGCCGATGGCTCCATCATCTTCTTC	1474
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal	140	Qy	481	ArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyArg	500
Db	395	AAACGCTTTGCAAGCAAGTAACAAATGGTACAGACGACCTCTCTACCGCGCTGGTG	454	Db	1475	CGAGATGACCGCTACTGGCGCTCGACCAAGGCCAAATCTGCAGGCAACCACTCGGCGCG	1534
Qy	141	AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSer	160	Qy	501	TrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPhe	520
Db	455	AACTGGCTGAGCATCTCCGAGCGCGCAGTTCCGGGGCGCGTGCAGCTTCCAGT	514	Db	1535	TGGGCACCGAGTGCCTGGATGGCTGTCGATGCCAACTCGGGAGCGCCTGTTC	1594
Qy	161	CysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuThr	180	RESULT 2			
Db	515	TGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCTGACA	574	US-10-791-980-3			
Qy	181	SerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAla	200	; Sequence 3, Application US/10791980			
Db	575	TCCGCTTACCTTCTCCAAAGGGACCAACAGATGGCTGGCAATGCCCTTGTATGCC	634	; Publication No. US20040146499A1			
Qy	201	GlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln	220	; GENERAL INFORMATION:			
Db	635	CAGGGGGCGCCCTGGCGCAGCGCTTCTGTCGCCCGCGCGGCGAAGCGACTTCGACCA	694	; APPLICANT: Holmgren, Erik			
Qy	221	AspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValLeuAlaHis	240	; APPLICANT: Kihlen, Mats			
Db	695	GATGAGCGTGTGTCTGAGCGCGCGCGCGCGCGAACCCTGTTCTGTGTCTGGCGAC	754	; APPLICANT: Wood, Tim			
Qy	241	GluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPro	260	; APPLICANT: Ekblom, Jonas			
Db	755	GAGATCGGTACACGCTTGGCTCCACCTCGCCCGCGCGCGCGCTCATGCGCGCC	814	; TITLE OF INVENTION: Novel Matrix Metalloproteinases			
Qy	261	TyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln	280	; FILE REFERENCE: 00014regUS			
Db	815	TACTACAGAGGTGGCGCGCAGCGCGTCTCAGCTGGGACGAGTGTGGCGCTGCGAG	874	; CURRENT APPLICATION NUMBER: US/10791,980			
Qy	281	SerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPhe	300	; PRIOR FILING DATE: 2004-03-03			
Db	875	AGCCTGTATGGGAGCCCTAGGGGCTCAGTGGCGTCCAGTCCAGGAAAGCTGTTC	934	; PRIOR APPLICATION NUMBER: US/09/862,631			
Qy	301	ThrAspPheGluThrTrpAspSerTrpProGlnGlyArgArgProGluThrGlnGly	320	; PRIOR FILING DATE: 2000-05-22			
Db	935	ACTGACTTTGAGACCTGGGACTCCTACAGCCCGCCAGGAAGCGCGCTGAAACGAGGGC	994	; PRIOR FILING DATE: 2000-05-22			
Qy	321	ProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp	340	; NUMBER OF SEQ ID NOS: 8			
Db	995	CCTAAATACGCCACTCTCTTCGATGCCATCAGTGTAGACAGGCAACGACTGTAC	1054	; SOFTWARE: PatentIn version 3.0			
Qy	341	IlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProArg	360	; SEQ ID NO 3			
Db	1055	ATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCGT	1114	; LENGTH: 1597			
Qy	361	ProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLeu	380	; TYPE: DNA			
Db	1115	CCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGCGAGTGCATTG	1174	; ORGANISM: Homo sapiens			
Qy	381	AsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLys	400	US-10-791-980-3			
Db	1175	AAATGATGGAGATTCTACTCTTCTTCAAGGGGTGATGTGGAGGTTCGGGGCCCCAAG	1234	Alignment Scores:			
Qy	401	ProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAla	420	Pred. No.: 2,06e-266			
Db	1235	CCAGTGTGGGTCTCCACAGCTGTGCGCGGCGAGGGCGCTGCGCGCCATCCTGACGCG	1294	Score: 2834.00			
Qy	421	AlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpVal	440	Percent Similarity: 100.00%			
Db	1295	GCCT	1354	Best Local Similarity: 100.00%			
Qy	441	LeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpGly	460	Query Match: 100.00%			
				DB: 24			
				US-10-791-980-6 (1-520) x US-10-791-980-3 (1-1597)			
				Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20			
				Db 35 ATGTGCGCGCGTCCGCTCTCTGTCGCGCCCTGCAGCTGTACTGTGGGGCCACCTG 94			
				Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40			
				Db 95 GAGCCCGAGCGCGAGCGGAGCGGAGCTGCGCAAGAGGCGGAGGCGCATTCCTA 154			
				Qy 41 GlnLysTrpGlyTrpLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60			
				Db 155 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCATCGATTGAGC 214			
				Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80			
				Db 215 GATGCCATCAGACGCTTTCAGTGGGTGTCCTCCAGCTACCTGTCCAGCGGCTGTGGACCGC 274			
				Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100			
				Db 275 GCCACCTGCGCAGATGACTGTCCTCCCGCTGCGGGGTACAGATACCAACAGTATGCG 334			
				Qy 101 AlaTrpAlaGluArgGlySerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120			
				Db 335 GCCTGGGCTGAGAGGATCAGTGTCTTTTGTAGACACCGGACCCAAATGAGGGCTAAG 394			

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 395 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCGCTGGTG 454
QY 141 AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
DB 455 AACTGGCCTCAGCATCTCCGAGCCGCGACGTTCCGGGCGCGCTCCAGTTCAGT 514
QY 161 CysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuThr 180
DB 515 TGTGGAGCAACGCTCAGCCCTGGAGTTCTGGAGAGCCCGCAGCCAGGCCCCGCTGACA 574
QY 181 SerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAla 200
DB 575 TCCGGCTCACCTTCTCCAGGGGACACAAACGATGGCTGGGCAATGCTTTGATGGCC 634
QY 201 GlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln 220
DB 635 CAGGGGGCGCCCTGGCGCAGCCCTTCTGCCCCCGCGCGGAGCGCACTTCGACCAA 694
QY 221 AspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
DB 695 GATAGCGCTGGTCTCCAGCCCGCGCGCGGCGCAACTGTTCGTGGTGTGGCGCAC 754
QY 241 GluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPro 260
DB 755 GAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCCC 814
QY 261 TyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln 280
DB 815 TACTACAAGAGGTGGCGCGCAGCGCGCTCTCAGCTGGGACGACGCTGGCGGTGAC 874
QY 281 SerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPhe 300
DB 875 AGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 934
QY 301 ThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGly 320
DB 935 ACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAGGAGGGCGCTGAAAGCGAGGC 994
QY 321 ProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 995 CCTAAATACTGGCACCTCTCTTCGATGCGCATCTGTAGACAGGCAACAGCACTGTAC 1054
QY 341 IlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProArg 360
DB 1055 ATTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGTATGGCAACGCTCTCAGAGCCCGT 1114
QY 361 ProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLeu 380
DB 1115 CCACTGCAGGAAAGATGGGTGGGCTGCCCCCACCATTGAGGCTGGCGCAGTGTATGT 1174
QY 381 AsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLys 400
DB 1175 AATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGAGGTTCCGGGCCCCAAG 1234
QY 401 ProValTrpGlnLeuProGlnCysArgAlaGlyGlyLeuProArgHisProAspAla 420
DB 1235 CCAAGTGTGGGGTCTCCACAGCTGTCCGGGAGGGGGCTGCCCGCCCATCTCAGCGCC 1294
QY 421 AlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVal 440
DB 1295 GCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGTG 1354
QY 441 LeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGly 460
DB 1355 CTGGCCCGAGGGGAGTGAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGA 1414
QY 461 GlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePhe 480
DB 1415 GGCATCCCTTCAGGAGGTACGGCGCCCTCTGCCGAGCCCGATGGGTCCATCATCTTCT 1474
QY 481 ArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyArg 500

DB 1475 CGAGATGACCGCTACTGGCGCTCGACCGAGCCAAACTGCAGCAACACCTCGGGCCG 1534
QY 501 TrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPhe 520
DB 1535 TGGGCCACCGAGTGGCTGGATGGCTGTCGATGCCAACTCGGGAGCGCCCTGTTTC 1594
RESULT 3
US-09-950-510-3
; Sequence 3, Application US/09950510
; Patent No. US20020150978A1
; GENERAL INFORMATION:
; APPLICANT: Curtis, Rory
; TITLE OF INVENTION: 46798, A No. US20020150978A1el Human Matrix Metalloproteinase An
; FILE REFERENCE: 10147-45U1
; CURRENT APPLICATION NUMBER: US/09/950,510
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/251,156
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
; LENGTH: 1560
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-950-510-3
Alignment Scores:
Pred. No.: 2,53e-262 Length: 1560
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
US-10-791-980-6 (1-520) x US-09-950-510-3 (1-1560)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 1 ATGTGTCGGCGCGCTCGGCTCTCTGTGCGCGCTCTGTCAGCTCTACTGTGGGGCCACCTG 60
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 61 GAGGCCACGCGCGGAGCGCGGAGGAGCTGCCGAGGAGCGGAGGAGGATTCCTA 120
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 121 GAGAAATACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTTCAG 180
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 181 GATGCCATCAGAGCGCTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 240
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 241 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGGC 300
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 301 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCCAAATAGAGCGGTAA 360
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 361 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCAGCTCTCTCCCGCTGGTG 420
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 421 AACTGGCTTGAGCATCTGCCGAGCGCGCAGTTCGGGGCGCGCTGCGGCGCCCTTCAG 480
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 481 TTGTGGAGCAACGCTCTCAGCGCTGTCTGGAGGTTCTGGGAGGCCCCCAGGCCACAGGCCCGCTGAC 540

180	Qy	rSerGlySerProSerSerIysGlyThrThrMetGlyTrpAlaMetProIeuMetAl	200
181	Db		
182	Db		
541	Db	ATCGGCTCACCTTCTTCCAAGGGGACCAACACGATGGCTGGGCAATGCTTGTATGGC	600
200	Qy	aGlnGlyAlaProTyrPheLeuProArgArgGlyGluAlaHisPheAspG1	220
201	Db		
601	Db	CCAGGGGGCCCTTGGCGCACGCTTC-CTGCCCCCGCGGGGACGCACTTCGACCA	659
220	Qy	nAspGluArgTrpSerIeuSerArgArgGlyArgAsnLeuPheValValIeuAlaHi	240
221	Db		
660	Db	AGATGACGCTGTGCTCCCTGAGCCGCGCGCGCGCAACTCTTCTGCTGGTGGCGCA	719
240	Qy	sGluIleGlyHisThrIeuGlyIeuThrHisSerProAlaProArgAlaIeuMetAlaPr	260
241	Db		
720	Db	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC	779
260	Qy	oTyrTyLysArgIeuGlyArgAspAlaLeuLeuSerTrpAspAspValIeuAlaValG1	280
261	Db		
780	Db	CTACTACAGAGGCTGGGCCGCGACGCGCTGCTCAGCTGGGACGACGTGTCGGCCGTGA	839
280	Qy	nSerLeuTyGlyIysProIeuGlyGlySerValAlaValGlnIeuProGlyIysIeuPh	300
281	Db		
840	Db	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT	899
300	Qy	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320
301	Db		
900	Db	CACGTGACTTTTGAACCTTGGGACTCTTACAGCCCCCAAGGAAGGCGCCTGAAACGCA	959
320	Qy	yProLeuTyrcysHisSerPheAspAlaIleThrValAspArgGlnGlnIeuTy	340
321	Db		
960	Db	CCCTAAATACTGCCACTCTTCTTCGATGCATCACTGTAGACAGGCAACAGCAACTGA	1019
340	Qy	rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
341	Db		
1020	Db	CATTTTAAAGGGAGCCATTCTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG	1079
360	Qy	gProIeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
361	Db		
1080	Db	TCCACTGCAGGAAGATGGTTCGGCTGCCCCCAACATTTAGGCTGCGGCACTGTCA	1139
380	Qy	uasnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
381	Db		
1140	Db	GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA	1199
400	Qy	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
401	Db		
1200	Db	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCCCGCATCTCTGACGC	1259
420	Qy	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTrVa	440
421	Db		
1260	Db	CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTGCTACTACGT	1319
440	Qy	lIeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
441	Db		
1320	Db	GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGAGGACTGGG	1379
460	Qy	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
461	Db		
1380	Db	AGGCATCTCTGAGGAGGTACGCGCGCCCTGCCGAGGCGCGCATGGCTCCATCTCTTCT	1439
480	Qy	eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysIeuClnAlaThrThrSerGlyAr	500
481	Db		
1440	Db	CCGAGATACCGCTACTGGCGCTCGACGAGCCAACTGCAGGCAACACCTCGGGCCG	1499
500	Qy	gTrpAlaThrGluLeuProTrpMetGlycTyrPheHisAlaAsnSerGlySerAlaLeuPh	520
501	Db		
1500	Db	CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGT	1559
520	Qy	e	520
521	Db		
1560	Db	C	1560

Db	601	CGAGGGGGCGCCTGTGGCCAGCGCCTTC--CTGCCCCCGCGCGGAGAGCGCACTTCGACCA	659
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	660	AGATGAGCGCTGGTCCCTTGAGCCGCGCGGCGCAACCTGTTCTGTGGTGTCTGGCGCA	719
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	720	CGAGATCGGTACACAGCTTGGCCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	779
Qy	260	oTyrtTyrlsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI	280
Db	780	CTACTACAGAGGCTGGGCCGCGAGCGCTGCTCAGCTGGGACGACGTGCTGGCCGTGCA	839
Qy	280	nSerLeuTyrglyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	840	GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT	899
Qy	300	eThrAspPheGluThrTrpAspSerTyrsSerProGlnGlyArgArgProGluThrGlnGI	320
Db	900	CACGTGACTTTGAGACCTTGGGACTCTCAAGCCCCCAAGGAGGGCCCTGAAACGCGAGG	959
Qy	320	yProLysTyrcysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	960	CCCTAAATACTGCCACCTCTCTTCGATGCCATCACTGTACAGGCAACAGCAACTGTGA	1019
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1020	CATTTTTAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCACAGAGCCCG	1079
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaIalValSerLe	380
Db	1080	TCCACTCGAGAAAGATGGGTGGGGCTGCCCCCAACATTTAGAGCTCGGGCAGTGTCA	1139
Qy	380	uAsnAspGlyAspPheTyrlPhePheLysGlyValArgCysTrpArgPheArgGlyProLy	400
Db	1140	GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCAA	1199
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1200	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCCGCATCTCTGACGC	1259
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrlrVa	440
Db	1260	CGCCCTCTTCTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTCCCGCTACTACGT	1319
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrlTyrlProArgSerLeuGlnAspTrpGI	460
Db	1320	GCTGGCCCCGAGGGGACTGACAGTGGAGGCCCTACTACCCCCGAAGTCTGCAGGACTGGG	1379
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1380	AGGCATCCCTGAGAGGTTCAGCGCGCCCTGCGAGGCCCGATGGCTCCATCATCTTCTT	1439
Qy	480	eArgAspAspArgTyrlTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1440	CCGAGATGACCGCTACTTGGCGCCTCGACACAGGCCAAACTCGAGGCACACCACTCGGGCGG	1499
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1500	CTGGGCCACCGAGCTGCGCTTGGATGGGCTGCTGGCATGCCAACTCGGGGGAGCGCCCTGT	1559
Qy	520	a 520	
Db	1560	c 1560	

RESULT 5

```

US-09-737-353-1
; Sequence 1, Application US/09737353
; Patent No. US20010036648A1
; GENERAL INFORMATION:
; APPLICANT: Christopher Donald Southan
; APPLICANT: Stephen Anthony Hughes

```

```
Db 720 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 779
Qy 260 oTyrTyrlsArgLeuGlyArGspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 760 CTACTACAAGAGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGACGCTGGCGTGCA 839
Qy 280 nSerLeuTyrlsGlyProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 840 GAGCGCTGATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 899
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgProGluThrGlnGl 320
Db 900 CACTGACTTTGAGACTGGGACTCTCAGACCCCAAGAGCGGCCCTGAAACGACGG 959
Qy 320 yProLysTyrlsCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 960 CCCTAAATACTGCCACTCTTCTTCGATGTCATCACTGTAGACAGGCAACAGCAACTGTA 1019
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1020 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCC 1079
Qy 360 gProLeuGlnGluArgTvpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1080 TCCACTGCAGGNAAGATGGTCCGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1139
Qy 380 uAsnAspGlyAspPheTyrlsPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1140 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCA 1199
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgnIleGlyLeuProArgHisProAspAl 420
Db 1200 GCCAGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGGCTGCCCGGCCATCTCTGACGC 1259
Qy 420 aAlaLeuPheProProLeuArgArgLeuPheLysGlyAlaArgTyrlsVa 440
Db 1260 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGT 1319
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrlsTrpProArgSerLeuGlnAspTrpGl 460
Db 1320 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGCTCTGCAGGACTGGGG 1379
Qy 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1380 AGGCATCCCTGAGGAGGTGAGCGCGCTCCCGAGGGCCGATGGCTCCATCATCTTCTT 1439
Qy 480 eArgAspAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1440 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACCACTGGGCGC 1499
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1500 CTGGGCGACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1559
Qy 520 e 520
Db 1560 c 1560
```

RESULT 6

```
US-10-050-216B-10
; Sequence 10, Application US/10050216B
; Publication No. US2003003991A1
; GENERAL INFORMATION:
; APPLICANT: Curtis, Rory A.J., Lora, Jose M.
; TITLE OF INVENTION: 46798, A Human Matrix Metalloprotease and
; TITLE OF INVENTION: Uses Thereof
; FILE REFERENCE: MPI2001-014PIRNM
; CURRENT APPLICATION NUMBER: US/10/050,216B
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 60/262,252
; PRIOR FILING DATE: 2001-01-16
; NUMBER OF SEQ ID NOS: 10
```

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 10

; LENGTH: 1563

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (1)...(1563)

US-10-050-216B-10

Alignment Scores:

Pred. No.:	2,53e-262	Length:	1563
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-050-216B-10 (1-1563)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	1	ATGGTCGCGCGCTCGGCCCTCTCTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	60
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	61	GACGCCACGCCCGCGGAGCGGAGGCTGGCAAGGAGGGGCGGAGGCATTCTCTA	120
Qy	41	GluLysTyrlsGlyTyrlsLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	121	GAGAAGTACGGATACCTCAATGAACAGTCCCCAAAGCTCCACCTCCACCTCGATTTCAGC	180
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	181	GATCCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTCTGTACGGCGGTGTGGACCGC	240
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrlsAla	100
Db	241	GCCACCTTGCGCCAGATGACTCGTCCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	300
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	301	GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCAAAATCAGGCGTAAG	360
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrlsGlnHisLeuSerTyrlsArgLeuVal	140
Db	361	AAACGCTTTGCAAGCAAGGTAACAAAATGGTACAGCAGACCTCTCTCCCGCTGTGTG	420
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	421	AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG	480
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	481	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCCCGCCAGCCACAGGCCCGCTGAC	540
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	541	ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAAATGGGCTGGGCAATGCCCTTTGATGGC	600
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	601	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA	659
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	660	AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTTCGTGGGTGCTGGCGCA	719
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	720	CGAGATCGTCAACGCTTGGCCCTCACCCACTCGCCCGCGCGCGGCGCTCATCGCGCC	779
Qy	260	oTyrTyrlsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280

Db 780 CTACTACAAGAGGCTGGCGCGACGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 839
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 840 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGCAAGAGCTGTT 899
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG 320
Db 900 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGGCGCTCGAAGCGAGG 959
Qy 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 960 CCCTAAATACTGCCACCTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1019
Qy 340 rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1020 CATTTTAAAGGAGGCCATTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCC 1079
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1080 TCCACTCAGGAAGATGGTGGGCTGCCCCCNACATTTAGGCTGGCGACGTGTCAAT 1139
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTyrArgPheArgGlyProLy 400
Db 1140 GAATGATGAGAGATTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1199
Qy 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1200 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGCCATCTCTGACGC 1259
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1260 CGCCCTCTTCTTCTCTCTCTGGCCGCTCTACCTCTTCAAGGGTGGCCGCTACTACGT 1319
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1320 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1379
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1380 AGGCATCCCTGAGGAGGTCAGCGGCGCCCTGCGGAGCGCGCTGCCATCATCTTCTT 1439
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaValLeuGlnAlaThrThrSerGlyAr 500
Db 1440 CCGAGATGACCGTACTTGGCCCTCGACCAAGGCCAACTGCAGGCAACCACTCGGGCCG 1499
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1500 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1559
Qy 520 e 520
Db 1560 c 1560
RESULT 7
US-10-028-072-143
; Sequence 143, Application US/10028072
; Publication No. US20030004311A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang
; TITLE OF INVENTION:
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/028,072
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059836
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062285
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062814
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063127
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063327
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063550
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063561
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063704
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063735
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063738
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064248
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364

1	PRIOR FILING DATE: 1997-11-21	
2	PRIOR APPLICATION NUMBER: 60/066643	
3	PRIOR FILING DATE: 1997-11-24	
4	PRIOR APPLICATION NUMBER: 60/066511	
5	PRIOR FILING DATE: 1997-11-24	
6	PRIOR APPLICATION NUMBER: 60/066770	
7	PRIOR FILING DATE: 1997-11-24	
8	PRIOR APPLICATION NUMBER: 60/069212	
9	PRIOR FILING DATE: 1997-12-11	
10	PRIOR APPLICATION NUMBER: 60/069278	
11	PRIOR FILING DATE: 1997-12-11	
12	PRIOR APPLICATION NUMBER: 60/069334	
13	PRIOR FILING DATE: 1997-12-11	
14	PRIOR APPLICATION NUMBER: 60/069694	
15	PRIOR FILING DATE: 1997-12-16	
16	PRIOR APPLICATION NUMBER: 60/072320	
17	PRIOR FILING DATE: 1998-01-23	
18	PRIOR APPLICATION NUMBER: 60/073612	
19	PRIOR FILING DATE: 1998-02-04	
20	PRIOR APPLICATION NUMBER: 60/074086	
21	PRIOR FILING DATE: 1998-02-09	
22	PRIOR APPLICATION NUMBER: 60/074092	
23	PRIOR FILING DATE: 1998-02-09	
24	PRIOR APPLICATION NUMBER: 60/077791	
25	PRIOR FILING DATE: 1998-03-12	
26	PRIOR APPLICATION NUMBER: 60/078910	
27	PRIOR FILING DATE: 1998-03-20	
28	PRIOR APPLICATION NUMBER: 60/079294	
29	PRIOR FILING DATE: 1998-03-25	
30	PRIOR APPLICATION NUMBER: 60/079663	
31	PRIOR FILING DATE: 1998-03-27	
32	PRIOR APPLICATION NUMBER: 60/079728	
33	PRIOR FILING DATE: 1998-03-27	
34	PRIOR APPLICATION NUMBER: 60/080165	
35	PRIOR FILING DATE: 1998-03-31	
36	PRIOR APPLICATION NUMBER: 60/081203	
37	PRIOR FILING DATE: 1998-04-09	
38	PRIOR APPLICATION NUMBER: 60/081229	
39	PRIOR FILING DATE: 1998-04-09	
40	PRIOR APPLICATION NUMBER: 60/081695	
41	PRIOR FILING DATE: 1998-04-14	
42	PRIOR APPLICATION NUMBER: 60/081817	
43	PRIOR FILING DATE: 1998-04-15	
44	PRIOR APPLICATION NUMBER: 60/081818	
45	PRIOR FILING DATE: 1998-04-15	
46	PRIOR APPLICATION NUMBER: 60/082999	
47	PRIOR FILING DATE: 1998-04-24	
48	PRIOR APPLICATION NUMBER: 60/083322	
49	PRIOR FILING DATE: 1998-04-28	
50	PRIOR APPLICATION NUMBER: 60/083545	
51	PRIOR FILING DATE: 1998-04-29	
52	PRIOR APPLICATION NUMBER: 60/084600	
53	PRIOR FILING DATE: 1998-05-07	
54	PRIOR APPLICATION NUMBER: 60/084627	
55	PRIOR FILING DATE: 1998-05-07	
56	PRIOR APPLICATION NUMBER: 60/084637	
57	PRIOR FILING DATE: 1998-05-07	
58	PRIOR APPLICATION NUMBER: 60/085149	
59	PRIOR FILING DATE: 1998-05-12	
60	PRIOR APPLICATION NUMBER: 60/085323	
61	PRIOR FILING DATE: 1998-05-13	
62	PRIOR APPLICATION NUMBER: 60/085338	
63	PRIOR FILING DATE: 1998-05-13	
64	PRIOR APPLICATION NUMBER: 60/085339	
65	PRIOR FILING DATE: 1998-05-13	
66	PRIOR APPLICATION NUMBER: 60/085579	
67	PRIOR FILING DATE: 1998-05-15	
68	PRIOR APPLICATION NUMBER: 60/085697	
69	PRIOR FILING DATE: 1998-05-15	
70	PRIOR APPLICATION NUMBER: 60/085704	
71	PRIOR FILING DATE: 1998-05-15	
72	PRIOR APPLICATION NUMBER: 60/086414	
73	PRIOR FILING DATE: 1998-05-22	

QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGGCTTTGCAAGCAAGGTATCAAAATGGTACAAGCAGCACCTCTCTCTACCGCTGGTG 625
QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCCGCGAGTTTCGGGGCGCCGTGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAAGGGGACACACAGATGGCTGGGCAATGCCITTTGATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCTTTC - CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGGCGCAACCTGTTCTGTGTCTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTCAACGCTTGGCTTGGCTCACCCACTCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGCTGGGCGCGAGCGCTGTCTAGCTGGGAGCGAGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCGCTGATGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTTAATACTGCCACTCTTCTTCATGTCATCACTGTAGACAGCGCAACACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluPrBar 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGACGCTGATGGCAACGCTCTAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAAGATGGCTCGGCTGCCCCCAACATTGAGGCTGCGGCGAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyCysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 aProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACACAGCTGTGCGGCGAGGGGGCTTGGCCCCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGGGCGCTTCCGAGGGCCCATGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGAGCAAACTGCAGGCAACACCACTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCCAACGAGCTGCGCTTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 8

US-10-140-808-143
; Sequence 143, Application US/10140808
; Publication No. US20030017563A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C182
; CURRENT APPLICATION NUMBER: US/10/140,808
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-808-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-808-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTTCGCGCGCTGCGGCTCTCTGTCGCGCCCTGACGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGGAGCGCGGAGCCAGAGCTGCGCAAGAGCGCGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100

```

Db      446  GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
Qy      101  AlatrPalGluArgIleSerAspLeuPheAlaargHisargThrLysMetArgAtgLys 120
Db      506  GCCTGGGCTGAGAGGATCAGTGTGTCTAGACACCGGACCAAAATGAGCGTAAAG 565
Qy      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGCTTTGCAAGCAAGGTAAACAATGGTTACAAGCAGCACCTCTCTCCACCGCTGGTG 625
Qy      141  AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCTTGAGCATCTCCGAGCGCGCAGTCTCGGGCGCGCTGCGCGCGCTTCAG 685
Qy      160  rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686  TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGGCCCCCAGCCAGGCCCGCTGAC 745
Qy      180  rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db      746  ATCCGGCTCACCTTCTTCAAGGGGACCAACAACATGGCTGGGCAATGCTGATGGC 805
Qy      200  aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db      806  CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGCGCAAGCGCACTTCGACCA 864
Qy      220  nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGGTGGTGCGCA 924
Qy      240  sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTCAACAGCTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy      260  oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db      985  CTTACTACAAGAGCGCTGGGCGCGCGAGCGCTGCTCAGCTGGGACGACGTGTGGCGCTGCA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
Qy      300  eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db      1105  CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGAGCGCGCTTGAACCGCAGGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTTAATACTGCACACTCTCTCTTCATGCGCATCTGTAGACAGCAACAGCAACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy      360  gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCAGGAAGATGGGTGCGGCTGCCCGCCCAACATTGAGCTCGCGCAGTGTATT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTCTACTTCTTCAAGGGGTTCGATGCTGGAGGTTCCGGGGGCCCAA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGCGCATCTCTGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaargTyrTrpVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTGGCGCCCTCATCTCTTCAAGGCTGCCCGCTACTACGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
1525  GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGCAAGACTGGGG 1584
460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
1585  AGGCATCTCTGAGGAGGTGAGGGCGCCCTGCGGAGGCCGATGGCTTCATCTCTTCTT 1644
480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645  CCAGATGACCGCTACTTGGCGCTCGACAGGCAAACTGCGAGCAACCACTCGGGCGG 1704
500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
1705  CTGGCCACCAGACTGCCCTGGATGGCTGCTGGCATGCACTCGGGAGCGCCCTGT 1764
520  e 520
1765  C 1765
RESULT 9
US-10-121-049-143
; Sequence 143, Application US/10121049
; Publication No. US20030022239A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C17
; CURRENT APPLICATION NUMBER: US/10/121.049
; CURRENT FILING DATE: 2002-04-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-121-049-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-121-049-143 (1-1985)
Qy      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db      206  ATGTGTCGCGCGCTCGCTCTCTGCGCGCCCTGCACTGCTACTGTGGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACGCCCAAGCCCGGAGCGCGGAGGCTGCGCAAGGAGCGGAGGCATTCCTA 325
Qy      41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```

```
Db 326 GAGAACTACCGATACCTCAATGAACAGGTCCCAAAAGCTCCCACTCCACTCCGATTACG 385
Qy 61 ApsAlaileArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTCCAGCTACCTGTGAGCGCGGTGTGGACCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCGACAGATACCTCGTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgIys 120
Db 506 GCTCGGCTGAGAGGATCAGTACCTGTTTGTAGACACCGGACCAAAATGAGGCGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACCGCTTGGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAGAGGAGCACCAACAGATGGGCTGGGCAATGCCCTTTGATGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTC-CTGCCCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGCTGTCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAAGGAAGCGCCCTGAAACGACAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATAGCTCACTCTCTTCATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheThrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAAGGGGTGATCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCGCCCGCCCATCTCTGACGC 1464
```

```
Qy 420 aAlaLeuPhePheProLeuArgArgIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CCCCCCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAAGGGTGCCCCGTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCCGAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGCGTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVa 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCGCAACTGCAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAATCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 10

```
US-10-123-904-143
; Sequence 143, Application US/10123904
; Publication No. US20030022328A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C54
; CURRENT APPLICATION NUMBER: US/10/123,904
; PRIORITY FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-904-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-123-904-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCGGCGCTCTGTCGGCGCCCTGCGAGCTGCTACTGTGGGGCCACTG 265
```

```
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 CACGCCACAGCCGCGAGCGGAGCGGCGAGGCTGCGCAAGAGGAGCGGAGGCAATTCCTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGAATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCACGAGTACCTGTGACGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATCACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGGCTGAGAGGATCAGTGACTTGTGCTAGACACCGGACCAAAATGAGCGGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCGCTTTCGAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTTCTAGCCGCTGAGGTTCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGCGGCAAGCGCATCTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGAGCGCTGCTCAAGTGGGACGACGCTGCGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGGCCCTTAGGGGCTCATGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgA-gProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTTGAAACGACGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCATAATATCGCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACACACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAGAAATGGGTGGGCTGCCCCCAACATTGAGGCTGCGCGCATGTGCATT 1344
```

```
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTTACTTTCTTAAAGGGGTTCATGCTGAGAGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTGTACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrPrArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCCCTGAGAGGTACGGCGCCCTGCGAGCGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGAGATGACCGCTACTGCGCGCTCGACACGAGGCAAACTGCAGGCAACACCTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGCTGCTGGCATGCCAATCGGAGGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 11
US-10-140-470-143
; Sequence 143, Application US/10140470
; Publication No. US20030022331A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C160
; CURRENT APPLICATION NUMBER: US/10/140,470
; PRIORITY FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-470-143
Alignment Scores: 3.35e-262 Length: 1985
Pred. No.: 2792.00 Matches: 519
Score: 99.62% Conservative: 0
Percent Similarity: 99.62% Mismatches: 1
Best Local Similarity: 99.62% Indels: 2
Query Match:
```



```

; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-176-918-143

```

Alignment Scores:

Pred. No.:	3,358-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-176-918-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTTGCGCGCGTCTGCTGCGCGCCCTGCAGCTGCTACTGTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCCGGAGCGCGAGCCAGAGCTGCGCAAGGAGCGGAGGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAAGCTCCACCTCCACTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCACAGCTACCTGTACGGCGGTGTGTACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGCGCCAGATGACTCGTCCCGCTGCGGGTTACGATACCACACGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTCTAGACACCGGACCCAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGACAAAGTAAACAATGGTACAAGCAGCACCTCTCTCTACGCGCTGGT	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTTGAGCATCTGCCGAGCGGCGAGTTCGGGGCGCGTGTGCGCGCCCTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTCGAGTTCCTGGGAGGCCACGACAGGCCCTGCAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAGGGACCAACAAGATGGGCTGGGGCAATGCCCTTTGATGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCCCGCGCGGGAAGCGCATTCGACCA	864
Qy	220	naSpGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGCAACCTGTGTGTGTGTGTGTGTGTGTGT	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGTGGCTCACCCACTCGCGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
Db	985	CTACTACAAGAGGTGGGCGCGCACGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA	1044

Qy	280	nSerLeuTyrgLylySProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGGGCTCCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG1	320
Db	1105	CATGACTTTGAGACCTGGGACCTCTACAGCCCCAAGGAGGGCCCTGAAACGAGGG	1164
Qy	320	yProLysTyrcyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATAGTCCCACTTCTCCATCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGACCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGGTGGGTGCCCCCAACATTGAGGCTGGCGCAGTGTCATT	1344
Qy	380	aAsnAspGlyAspPheTyrrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTCTTCAAAGGGGCTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGGGGCAGGGGGCTGCCCGCGGCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProLeuArgGluIleLeuPheLysGlyAlaArgTyrrVa	440
Db	1465	CGCCCTCTCTCCCTCTCTGGCGCGCTCATCTCTCAAGGGTGGCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpG1	460
Db	1525	GCTGGCCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCCGAAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGTCAAGCGGCCCTGCCGAGGGCCGATGGGTCCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGGTACTTGGCGCTTCAGACAGGGCAAACTGCAGGCAACACCTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGACTGCCCTGGATGGGTGCTGGCATGCCNACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	

RESULT 14

```

US-10-176-921-143
; Sequence 143, Application US/10176921
; Publication No. US2003002726A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Baregin, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K

```

```
; APPLICANT: Wood,William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C288
; CURRENT APPLICATION NUMBER: US/10/176,921
; CURRENT FILING DATE: 2002-06-20
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-176-921-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 99.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-176-921-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
DB 206 ARGTCGGCGGGTCTGGCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCGCGAGCGCGGAGCGCAGGAGCTGCCAAGAGGCGGAGGCATTCTTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTCGCCAAAGCTCCACCTCGATTTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGACGGCGGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGATTATGG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCCAAATGAGCGCTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 ANACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGACCTCTCTCCCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTCGCTGAGCATCTGCCGAGCCGCGAGTTTCGGGGCGCGTTCGCGCGCTTCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCAGCCACAGGCGCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAGAGGGGACCACAAACGATGGGCTGGGCAATGCCCTTTGATGG 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCCCTGGCGACGCTTC-CTGCCCCGCGCGCGGAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHis 240
DB 865 AGATAGCGCTGGTCCCTGAGCGCCGCGCGGCGCAACCTGTTCTGGTGGTGGCGCA 924
```

```
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAATCGGTACACAGCTTGGCCCTCACCCACTCCCGCGCGCGCGCTCATGGCCGCC 984

QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGCGGGCTCAGTGGCGCTCCAGCTCCAGAAAAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyValArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGAAAGGCGCTGAAACGCGAGG 1164

QY 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTyr 340
DB 1165 CCCTAAATACCTGCCACTCTTCTTCGATGCCACTCACTGTAGACAGGCAACAGCAACTGA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

QY 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTCGAGAAAGATGGGTGGGCTGCCCGCCCAATTTGAGGCTGGGCGAGTGTCAAT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCGATGCTGGAGGTTCGGGGGCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGCTCTCCACAGCTGTCCGCGGCGAGGGCGCTGCCCGCCATCTCGACGC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
DB 1465 CGCCCTCTTCTTCTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGGCCCTACTAGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGGCACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584

QY 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGGTACAGCGCGCCCTGCCGAGGCCGATGGCTCCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGGCGCTCGACGAGGCCAANAATGCAGGCAACCCACTCGGGCG 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACAGCTGCCCTGGATGGGTGTGTGGCATGTGTCAGTGCACAACTCGGGAGCGCCCTGT 1764

QY 520 e 520
DB 1765 c 1765

RESULT 15
US-10-137-865-143
; Sequence 143, Application US/10137865
; Publication No. US20030032155A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deonoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
```



```
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C162
; CURRENT APPLICATION NUMBER: US/10/140,474
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-474-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservativity: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-474-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGGCTCTCTGCTGCGCGCTGACGTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCCGGAGCGCGAGCGCGAGGAGTGGCAAGAGCGGAGGAGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGGTACGGATACCTCAATGACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGGTTTACGTGGGTGTCCAGCTACCTGTGCAGCGCGCTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCACACCTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCCCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSe 160
DB 626 AACTGGGCTGAGCATCTGCCGGAGCCGCGAGTTCGGGGCGCGCTGGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
```

```
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
DB 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGCTGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCACCGCTTC-CTGCCCGCCCGCGGCGAAGCGCATCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHis 240
DB 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCGCAACCTGCTTCTGCTGCTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTTCACACGCTTGGCCTCACCCACCTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGCTGGCGCGCGACCGGCTGCTCAGCTGGGACGACGTGCTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGCTCCCAAGNAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCCTACACCCCCCAAGGAAGGGCCCTGAAACGCGAGG 1164
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTAATACTGCGACCTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGACATTTCTGGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTCAGAAAGATGGGTGCGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGCGGCGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyVgLyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACACAGCTGTGCCGGGCHAGGGGCTGCCCGCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTGTGCGAGGCTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTGAGGAGGTACAGGGCGCTGCCGAGGGCCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAAACTGCAGGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCCAACCGAGCTGCCCTGGATGGGCTGTGGATGCCAACTCGGGAGGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
```


QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

QY 520 e 520
Db 1765 c 1765

RESULT 18
US-10-143-114-143
; Sequence 143, Application US/10143114
; Publication No. US20030036180A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC211
; CURRENT APPLICATION NUMBER: US/10/143,114
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-143-114-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-143-114-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGGCTCGGCTCTCTGCTGGCGGCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTTCCTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGGTGCCAGCTACCTGTGTCAGCGCGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCTGGCCAGATGACTCGCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAG 555
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAGGTACAAATGGTACACGACGACCTCTCTACGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGGAGTTTCGGGGCGCGCTTCCTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACGCCACAGGCCCCGTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGGCTTGGCGCACGCTTTC-CTGCCCGCGCGGCGGAGCGCACCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGCGCTGGTCTCTGAGCGCGCGCGCGCGCAACCTGTTGTTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCCTCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGAGACAGCTGTGCGCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCACAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCTAAATATCTGCCACCTCTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCATCTCAGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTGCGGCGAGTCTNT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAGGGGGTTCGATCTGGAGGTTCCTCCGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCCATCTCTGAGCGC 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGAGCCCTACTACCCCCCAAGCTGTGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProaspGlySerIleIlePhePh 480

Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCGGAGCCGATGCCATCATCTTCTT 1644
Qy 480 eArgAspArgArgTrrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
Db 1645 CCGAGATGACCGGTACTGCGGCTCGACGAGCCCAACTGACGAGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGCTGCTGGCATGCCAACTCGGGAGGCGCCCTGTT 1764
Qy 520 a 520
Db 1765 C 1765

RESULT 19

US-10-142-419-143
; Sequence 143, Application US/10142419
; Publication No. US2003004945A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RLC244
; CURRENT APPLICATION NUMBER: US/10/142,419
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-419-143

Alignment Scores:

Pred. No.:	3.35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-142-419-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGTCGGCGCGTGGGCTCTGCTGCGCGCCCTGACAGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGCGAGGCGAGGCTGGCAAGGAGCGGAGGCATTCTTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCAGCTTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCACAGCTACCTGTCCAGCGCGTGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCCAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACCGCTTGCAAAGCAAGGTAACAATGGTACAAAGCAGCACCTCTCTACCGCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGGCACTTCGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyVarGProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCGTGGAGGCCCCCAGCCACAGGCCCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCCAAAGGGGACCAACATGGGCTGGCAATGCCCTTGTATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGGCGACGCCCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyVarGAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTTCGTGGTGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCCTCACCCACTCCCGCGCGCGCGCTCATGCGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyVarArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTTCTTCGTATGCGCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGTGCGGCGCGCCCAACATTGAGGCTCGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGCGGAGGGGCGCTGCCCGCGCATCTCGTACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440

Db 1465 GCCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTCCCCCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
Db 1525 GCTGGCGGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGluLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTCAGGAGGTCACGCGCGCCTGCCAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACACGGCCAACTGCAGGCAACCACTCTGGGCG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaLysSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 20

US-10-123-262-143
; Sequence 143, Application US/10123262
; Publication No. US20030049816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; CURRENT APPLICATION NUMBER: US/10/123,262
; CURRENT FILING DATE: 2002-04-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-262-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-262-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTTPGlyHisLeu 20
Db 206 ATGGTGGCGCGGTCTCTGCTGCGCGCCCTGACAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GACGCCACGCGCGGAGCGGAGCCAGAGCTGGCAGGAGCGGAGGCGGATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTGAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTCTTGTCTAGACACCGGACCAAAATGAGCGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAACAATGGTACAGCAGCACCTCTCTACCGGCTGTG 625
Qy 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGAGCCCGCAGCACAGGCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGTGGGCAATGCTTTGTATGGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGTGGTTCCTGAGCCCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCAGCGGCTGCTCAGCTGGGACACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTCCAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCTGAAACGCGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACCTCTCTTCGATGCGCTCCTACAGTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGAGGAAGATGGGTGGGCTGCCGCCCAACATTCATGAGGTGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGTGGAGGTTCCTCGGGGGCCCCAA 1404

```
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGCAGGGGCGCTGCCCGCATCTCTGACGC 1464
QY 420 alaLeuPheProProLeuArgArgLeuLeuPheGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCAGGGGGACTCAAGTGGAGCCCTACTACCCCCGAAAGTCTCAGGACTGGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGCGCTGCGAGGCCCGATGCTCATCATCTCTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAAGGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTCGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 21

```
US-10-142-423-143
; Sequence 143, Application US/10142423
; Publication No. US20030049817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC249
; CURRENT APPLICATION NUMBER: US/10/142,423
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-423-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-142-423-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGGCGCGCTCGGCTCTCTGCTGCGCGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGCAAGAGGCGCGAGGCAATTCCTTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCTCATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGCCAGCTACTCTGTTCAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCTGTCCTCCGCTGCGGGTTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCCAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAGCTTTGCAAGCAAGGTAACAATGGTACAGACGACACCTCTCTCCGCTCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACGGCCTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCGCCAGCCACAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACGATGGGCTGGGCATATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGGCGACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCAACCTGTTGCTGGTGTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGCGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGGCGCTGAAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
```

```
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaValSerLe 380
Db 1285 TCACCTGAGGAAAGATGGTTCGGCTGCCGCCCAACATTGAGGCTCGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLeuGlyGlyArgCysTyrPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGSGCAGGGGGCTGCCCCGCCATCCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLeuPheLeuGlyArgTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
Db 1525 GGTGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCCGAAAGTCTGCAAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTCAAGTGGAGGCCCTGCGAGGGCCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGCGGCTCTGACCGAGGCCAAACATGACGCGCAACCACTCGGGCGG 1704
QY 500 gTrrAlaThrGluLeuProTrrMetGlyCysTrrHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGTGCTGGCATGCGCAACTCGGGAGGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 22
US-10-121-050-143
; Sequence 143, Application US/10121050
; Publication No. US20030054516A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C20
; CURRENT APPLICATION NUMBER: US/10/121,050
; CURRENT FILING DATE: 2002-04-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-121-050-143
Alignment Scores: 3.35e-262 Length: 1985
Pred. No.:
```

```
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-121-050-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrGlyHisLeu 20
Db 206 ATGGTCGCGCGGTTCGGCTCTCTGCTGCGCGCTTCTGAGCTGCTACTGTTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGGAGCGCGAGGCCAGGAGCTGCGCAGGAGCGCGGAGGCAATTCCTTA 325
QY 41 GluLyTyTyGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCAACCTCCACTCGATTTCAG 385
QY 61 AspAlaIleArgAlaPheGlnTrrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTCAGTGGGTGCCAGCTACCTGTCTAGCGCGCTGTTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGTTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrrAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGTGTACAGCAGCACCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTCAGCATCTGCGGAGCGGCAAGTTTCGGGGCGCGCTGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCCCCCAGCACGCCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAGGGGACCACACAGATGGGCTGGGCAATGCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGGCTTGGCGCACGCCCTTC-CTGCCCCCGCGCGGCGAAAGCGCACCTTCGACCA 864
QY 220 nAspGluArgTrrSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTTGAGCCCCCGCGCGCGGCGCAACCTGTTCTGTTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCCTACCCACTCGCCCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTrrLysArgLeuGlyArgAspAlaLeuLeuSerTrrAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGAGCGCGCTCTCAGCTGGGAGCAGCGTGTGGCGGTGCA 1044
QY 280 nSerLeuTrrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrrAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTCAGACCTGGGACTTCCTACAGCCCCCAAGAGAGGCGCCCTGAAACGACGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
```

Db 1165 CCCTAAATAGTCCACTTCTTCGATGCCATCATCTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rtlePheLysGlySerHisPheHtrpGluValAlaAAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArGTrpValGlyLeuProAsnIleGluAlaAAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTCCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGGTCTCCCAAGCTGTGCCGGGAGGGGCCCTGCCCGGCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGCCCGCTACTACGT 1524
Qy 440 lleuAlaArgGlyLeuGlnValGluProTyrTrpTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTCAGGACTGGGG 1584
Qy 460 vGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGTACTGGCGCTCGACCAGGCCAACTGCGAGGCACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765

RESULT 23
US-10-141-755-143
; Sequence 143, Application US/10141755
; Publication No. US20030054517A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C192
; CURRENT APPLICATION NUMBER: US/10/141,755
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143

; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-755-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-141-755-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTTCTGCTGCGCGCTTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGGAGGCCAGGAGCTGCCGAGGAGCGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACCTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCCCTGCGGGGTTCAGATACCAACAGTTATGGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCGCCGAGTTCGGGGCGCGCTGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTCGAGTTCCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCACAAACATGGGCTGGGCAATGCCCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCCCGCGGCAACCTGTTCTGTTGGTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCAACCTGTTCTGTTGGTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGCGTCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

```
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTAGTGGCGGTCAGCTCCAGTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCAAGGAAGGCCCTGAAACGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTCGATGCCATCACTGTAGACAGGCAACGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCCATCTGAGGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACAGCGCGCCCTGCCGAGGGCCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysIleuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCGAGCCAAACTGCAAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 24
US-10-143-032-143
; Sequence 143, Application US/10143032
; Publication No. US2003005990A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
```

```
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC245
; CURRENT APPLICATION NUMBER: US/10/143, 032
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-143-032-143
Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-143-032-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGGCGCTCGGCCCTCTGCTGCGCGCGCTGCGAGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGGAGCGCGGAGCGCGAGCTGCGAAGGAGGCGGAGGCAATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCTCCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTACGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGATCTGTCCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACCGCTTTGCAAGCAAGGTAACTAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCGCGAGTTTCGGGGCGCGTGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCCTGGGAGGCCCCAGCCACAGGCCCCGTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCCAAAGGGGACCAACCATGGGCTGGGCAATGCCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACTGTGTCTGGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCCTCACCACTCTGCCCGCGCGCGCGCTCATGGCGCC 984
```


QY 260 oTyrtYrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGI 280
Db 985 CTACTACAAGAGGCTGGCGCGACCGCGTCTGCTCAGCTGGACGAGTCTGGCCGTGCA 1044
QY 280 nSerLeuTyrgLylyPProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrClnGI 320
Db 1105 CACTGACTTTGAGACTTGGACTCTTACAGCCCCCAAGGAGGCGCCCTGAAACGCGGG 1164
QY 320 yProLysTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTTCTTCTCGATGCCATCTGTAGACGCGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAAGTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerIle 380
Db 1285 TCACCTGCAGGAAGATGGGTGGCTGCCGCCCAACATTGAGGCTGCCGCGCATCTCAT 1344
QY 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProby 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGGGGCCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTrpProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAGTGGAGCCCTACTACCCCGAGAGTCTGCAGGATGGGG 1584
QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCGAGGCGCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspClnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAAGGCGCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGTGGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 25

US-10-123-108-143

; Sequence 143, Application US/10123108

; Publication No. US20030068793A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C36
; CURRENT APPLICATION NUMBER: US/10/123,108
; CURRENT FILING DATE: 2002-04-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059836
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062285
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062814
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063127
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063327
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063550
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063561
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063704
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063735
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063738
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064248
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12

;
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066453
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069212
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069278
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069334
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-15
; PRIOR APPLICATION NUMBER: 60/072320
; PRIOR FILING DATE: 1998-01-23
; PRIOR APPLICATION NUMBER: 60/073612
; PRIOR FILING DATE: 1998-02-04
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081695
; PRIOR FILING DATE: 1998-04-14
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081818
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082999
; PRIOR FILING DATE: 1998-04-24
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/083545
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085149
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704

;
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086414
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/086430
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088730
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088741
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090538
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091982

Alignment Scores:

Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-108-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGGCGCGCTCGGCCCTCTCTGCGGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGGAGCGGAGCTGGCGAGGCGGAGGCGGAGGCGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGCTCCCAAGCTCCACCTCCACTCGATTACGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGCGCTTCAGTGGGTGTCACGAGCTACCTGTCCAGCGGCGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120

Db 506 GCTGGGCTGAGAGGATCACTGTTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAenLysTyrTrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTAATGGTACNAGCAGCACTCTCTTACCGCCTGGTG 625
Qy 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGGGCGCGTGGCGCCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGAGCAACGCTCTAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCCCGCGTGC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCCAGGGGACACACAGATGGCTGGGCANTGCCCTTGNATGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC - CTGCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLysSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGTGCTGGCGCA 924
Qy 240 eGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGAGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAGGAGCGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTrpCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTrp 340
Db 1165 CCCTAAATACTGCCACTCTTCTTGTGATGCCATCACTGTAGACAGCAACACCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAenLleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCCCAGCAATGAGGTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGGAGGGGCTTCGCCCGCATCTCAGCGC 1464
Qy 420 aAlaLeuPheProProLeuArgGluLeuLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAAGGGTGGCGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTCAAGTGGAGCCCTTACTACCCCCGAGTCTCGAGGACTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGCGGGCGCTGCGCGAGGGCCGATGGCTCCATCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTTGGCGCTCGACCGAGCCAAACTGCGAGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCGCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 26
US-10-123-236-143
; Sequence 143, Application US/10123236
; Publication No. US20030068795A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C33
; CURRENT APPLICATION NUMBER: US/10/123,236
; CURRENT FILING DATE: 2002-04-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-236-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-123-236-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCCGCGGAGCGCGGAGCTGGCGAAGGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTrpGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGGCGGTGTGGACGCG 445

Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	CCACCCCTGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTGGGCTGAGAGGATCAGTGACTTGTGTTTCTAGACACCGGACCAAAATGAGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCMAACAAGATTAACAAATGGTACAGACGACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	NACTGGCCTGAGCATCTGCCGAGCCGCGAGTTCGGGGCGCGTCCGCGCCCTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCACAGCGCTGGAGTTCGGGAGGCCCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAGGGGACCCACACGATGGCTGGGCAATGCTTGTATGGC	805
Qy	200	aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAGGCGACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGGGCGCACTGTTCGTGGTGTGGCGCA	924
Qy	240	sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTTCAACCCTCGCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGCTGGGGCGCGAGCGCTGTCTACAGCTGGGACGAGCTGGCGGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGAAAGCCCTAGGGGGCTCAGTGGCGTCCAGCTCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGCGCCCTGAAACGAGGG	1164
Qy	320	yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATCTGCACCTCTTCTTCATGCGCATCTGTAGACAGGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CAITTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGTTCGGGCTGCCCCCAACATTGAGGCTGCGGCACTGTCAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTCTCCCGCCCATCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCTCTGCGCCGCTCATCTCTTCAAGGGTTCGCGCTTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GTTGGCCCCAGGGGGAGTCAAGTGGAGCCCTACTACCCCGAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGTTCAGCGGGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar	500
Db	1645	CCGAGATGACCGCTACTGCGCCTCGACCGAGGCAAACTGCAGGCAACCACTCTGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCACCGAGTCTGGCTGGATGGCTGTGGCATGCCAACTCGGGGAGGCGCCCTGT	1764
Qy	520	e 520	
Db	1765	c 1765	
RESULT 27			
US-10-123-261-143			
; Sequence 143, Application US/10123261			
; Publication No. US20030068796A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Desnoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tamas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; FILE REFERENCE: P3330R1C42			
; CURRENT APPLICATION NUMBER: US/10/123,261			
; CURRENT FILING DATE: 2002-04-15			
; Prior Application removed - See File Wrapper or Palm			
; NUMBER OF SEQ ID NOS: 550			
; SEQ ID NO 143			
; LENGTH: 1985			
; TYPE: DNA			
; ORGANISM: Homo Sapien			
US-10-123-261-143			
Alignment Scores:			
Pred. No.: 3.35e-262 Length: 1985			
Score: 2792.00 Matches: 519			
Percent Similarity: 99.62% Conservative: 0			
Best Local Similarity: 99.62% Mismatches: 1			
Query Match: 98.52% Indels: 2			
DB: 15 Gaps: 0			
US-10-791-980-6 (1-520) x US-10-123-261-143 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGTCGCGCGCTCGGCTCTCTCTGCGCCCTGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCCGCCGCGGAGCGGGAGGCGCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA	325

```
QY 41 GluLysTyrGlyTyrLeuAenGluInValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
DB 446 GCCACCTGGCCAGATGACTGTCCTCCGTCGGGGTTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGGTAAG 565
QY 121 LysArgPheAlaLysGlnLysTrpValSerGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTGGCAAGCAAGGTAAACAAATGGTATACAGCAGCAGCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCGGAGCGGAGTTCGGGGCGGCTGCGCGCCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCCCTTGTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CAGGGGGGGCGCTGCGGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
DB 865 AGATGAGCGCTGCTCCCTCAGCGCGCGCGCGCGCAACCTGTTCTGGTCTCGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGCTGGGCGCGAGCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTACAGCCGCCCAAGGAGCGCGCTTGAACACGAGGG 1164
QY 320 vProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAAATACTGCCACTCTCTCTGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGCAACGCTCCAGAGCCCG 1284
QY 360 gProLeuGlnLysArgTrpValGlyLeuProProLeuIleGluAlaAlaValSerIle 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCGGCCCAACATTAGGCTGGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheThrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTCTACTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
```

```
DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAGTCTGCAGACTGGGG 1584
QY 460 vGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
DB 1585 AGGCATCTCCAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATACCGCTACTGCGCGCTCGACAGCGCAAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 28
US-10-140-921-143
; Sequence 143, Application US/10140921
; Publication No. US20030068797A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C175
; CURRENT APPLICATION NUMBER: US/10/140,921
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-921-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-921-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
```

Db 206 ATGTCGCGCGCTGGCGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyVglnGluLeuArgGlyGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACAGCCCGGAGCGCGAGGCCAGAGCTGGCGAAGGAGCGGAGCATTCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCACCTCCGATTCGATC 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGACCGCTTCAGTGGGTGTCACAGTACCTCTGTCAGCGGGCTGTGGACGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTGGCCAGATGACTGCTCCCGCTGGCGGGTTACAGATACCACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCTCGGCTGAGAGATCAGTACTTGTGTCTAGACACCGGACCAAAATGAGCGCTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGTACAAATGGTACAGCAGCACCTCTCTACCGCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 NAATGGCTTGGATCTGCGGAGCGCGAGTTCCGGGCGCGCTGCGCGCGCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTACGCGCTGGAGTTCGGAGGCGCCACAGCCAGGCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGCTCACCTTCTTCCAGGGGACCCACACAGATGGCTGGGCAATGCCTTTGATGCG 805
 Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCTGGCGCACGCCCTTC-CTGCGCGCGCGCGGCGAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGGCGCAACCTGTTGTTGGTGGTGGCGCA 924
 Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGAGCGTGGGCGCGGACGCGTGTCTAGCTGGGACGAGCTGCGCGCGTGA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyVglnSerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACTGGACTCTCTACAGCCCCCAAGGAAGCGCGCTGAAACACGAGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCTAAATATCTGCACCTTCTCTTCATGCCATCTAGTGTAGACGAGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380

Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCGCCGCCAACATTGAGGCTGCGCAGTGTCAATT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGAGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCGACGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
 Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
 Qy 440 lLeuAlaArgGlyVglnGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGGCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGCATCCCTGAGAGGTGACGGCGCCCTGCGAGGCCGATGGCTCCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACACGAGGCAAACTCGAGGCAACACCTCGGGCCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGTGGCTGGATGGCTGTCATGTCGCACTGCCAACTCGGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765

RESULT 29

US-10-140-928-143
 ; Sequence 143, Application US/10140928
 ; Publication No. US20030068798A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330P1C186
 ; CURRENT APPLICATION NUMBER: US/10/140,928
 ; CURRENT FILING DATE: 2002-05-07
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 ; US-10-140-928-143
 Alignment Scores:
 Pred. No.: 3.35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0

Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0
US-10-791-980-6 (1-520) x US-10-140-928-143 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCGTCTGCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGCGGAGCCAGAGCTGCCGAGGAGCGAGCATTCCTTA	325
Qy	41	GluYstYrGlyTyLeuAsnGluGlnValProTysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAAGCTCCACCTCCACTCGATT	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGGGGTGT	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAppThrAsnSerTyxAla	100
Db	446	GCCACCTTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTAT	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCCAAATGAGG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTryLysGlnHisLeuSerTyxArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAGCAGCACCTCTCTCTACCG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGGCTGAGCATCTGCCGGAGCCGCGAGTTGCGGGCGCGCTGCCGCTTC	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGGCC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGAGCCACACCATGGCTGGGCAATGCCTTT	805
Qy	200	gGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGCGCAAGCGCACT	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGGGCTGGTCCCTGAGCCCGCGCGCGGGGCNAACCTGTCTGTGTGTG	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCACACGCTTGGCCTCACCCACTCGCCCCGCGCGCGCTCATGGCG	984
Qy	260	oTyTryLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGGCGCGCAGCGGCTGCTCAGCTGGGAGCAGCGTGTCTG	1044
Qy	280	nSerLeuTyxGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGGTCTCAGCTCCGAGNA	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyxSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTACAGCCCCCAGGAAGGCGCCCTGAAA	1164
Qy	320	yProLysTyxIleCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACCTCTCTTCGATGCCATCACTGTAGCAGGCAACAGCACTGT	1224

Qy	340	rIlePheYlsGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CAITTTTAAAGGGAGCCATTTCCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG	1284
Qy	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCNCTGCAGGAAGAATGGGTGGGCTGGCCCCCACATTGAGGCTCGGAGTGTGATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheYlsGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGGCTGCCCGCCATCCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheYlsGlyAlaArgTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGGCCGCTCATCTCTTTCAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTTCAGCGCGCCCTGCGCAGGCGCGCATGGCTTCCATCATCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCAGATGACCGGTACTTGGGCGCTCGACNAGGCGCAACTGCAGGCAACCACTTCGGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCGACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAATCTCGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	c 1765	
RESULT 30			
US-10-121-045-143			
; Sequence 143, Application US/10121045			
; Publication No. US20030073210A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Deenoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; FILE REFERENCE: P33301C8			
; CURRENT APPLICATION NUMBER: US/10/121,045			
; CURRENT FILING DATE: 2002-04-11			
; Prior Application removed - See File Wrapper or Palm			
; NUMBER OF SEQ ID NOS: 550			
; SEQ ID NO 143			
; LENGTH: 1985			
; TYPE: DNA			

; ORGANISM: Homo Sapien
US-10-121-045-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-121-045-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGTCTGGCTCTCTGGCGCCCTGCGAGCTGCTACTGTGGGGCCACTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGCGGAGCCGAGAGCTGCCAAGAGGCGGAGGCATTCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGAGTCCCAAAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCACAGCTACCTGTGAGCGGCGTGTGGACGCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTGCTCCCGCTGGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGGATCAGTCACTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGACCTCTCTCCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCATGCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLysSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCTCAGCGCGCGCGCGCGGCGCAACCTGTGTGGTGTCTGGCGCA 924
QY 240 sGluTlleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCACCCACTCGCCCGCGCGCGCGCTCATCGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAAGAGCGCTGGGCGCGAGCGCGCTGTCTCAGCTGGGACGAGCTGCGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGCTCCAGCTCCCAAGAAAGCTGTT 1104
```

```
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnGl 320
DB 1105 CACTGACTTGGAGACCTGGGACTCTTACAGCCCCCAAGAGGCGCCCTGAAACGAGGG 1164
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCATGTCATCCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rLlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCCCAACATTTAGGCTGGCGCAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGAGGGGGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGGCGCCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTCGGG 1584
QY 460 yGlyLleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGGTACAGCGCCCTGCCGAGGCCGATGGCTTCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGTGGCTGGATGGGTGCTGTCATGTCACCAACTCGGGGAGGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 31

US-10-123-292-143

; Sequence 143, Application US/10123292

; Publication No. US20030073211A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; TITLE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C32

; CURRENT APPLICATION NUMBER: US/10/123,292
; CURRENT FILING DATE: 2002-04-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-292-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-292-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGGTGGCCCTCTGCTGGCGGCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGCAGCGCGAGCGCGAGCGCGAGGCTGCGCAAGGCGGCGGCGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuArg 80
DB 386 GATGCCATCAGAGCTTCAGTGGGTGCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCAGATGACTGCTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaThrAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCTCGGCTGAGAGGATCATGACTGTTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyValLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTGGCAAGCAAGTAAACAAATGTTACAGACGACCTCTCTACCGCTGCTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTGCGGAGCGCGCAGTTGCGGGCGCGCTGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCCCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTGGCGCAGCGCTTC-CTGCCCCCGCGCGGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgGlnLeuPheValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CAGATCGGTACACGCTGGCTTCCACCTCTGCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280

DB 985 CTACTACAAGAGCGTGGGCGCGAGCGCGTCTGCTAGCTGGAGCAGCTGCTGCCCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCCAAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGAAAGCGCCCTTGAACAGCGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCATCTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAvalSerLe 380
DB 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGCCGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCGAGGGGCTTGGCCCGCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTTATCTCTTCAAGGGTGCCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGGCCCTTACTACCCCGAGCTGCGAGCTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGGCCGATGGCTGCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATACCGCTACTTGGCGCTCGACAGGCCAACTGACAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 32

US-10-123-903-143
; Sequence 143, Application US/10123903
; Publication No. US20030073212A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.

APPLICANT:	Tumas,Daniel
APPLICANT:	Watanabe,Colin K
APPLICANT:	Wood,William
APPLICANT:	Zhang, Zemin
TITLE OF INVENTION:	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
TITLE OF INVENTION:	ACIDS ENCODING THE SAME
FILE REFERENCE:	P3330R1C51
CURRENT APPLICATION NUMBER:	US/10/123,903
CURRENT FILING DATE:	2002-04-16
Prior Application removed -	See File Wrapper or Palm
NUMBER OF SEQ ID NOS:	550
SEQ ID NO	143
LENGTH:	1985
TYPE:	DNA
ORGANISM:	Homo Sapien
US-10-123-903-143	
Alignment Scores:	
Pred. No.:	3.35e-262
Score:	2792.00
Percent Similarity:	99.62%
Best Local Similarity:	99.62%
Query Match:	98.52%
DB:	15
	Gaps: 0
US-10-791-980-6 (1-520) x US-10-123-903-143 (1-1985)	
Qy	1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db	206 ATGTGTCGCGCGCTCTGTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy	21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db	266 GACGCCACGCCGCGGAGCGCGAGGCCAGGAGCTGGCCAAAGGAGCGGAGGCATTCCCTA 325
Qy	41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db	326 GAGAAGTAGTCGGATACCTCAATGAACAGAGTCCCAAGAGCTCCACCTCCACATTCGATTACG 385
Qy	61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db	386 GATGCCATTACAGACGTTTCAGTGGGTGTCACAGCTACCTGTCCAGCGCGTGTGGACCGC 445
Qy	81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db	446 GCCACCCCTGCGCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTTATGCG 505
Qy	101 AlaTyrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db	506 GCCTCGGCTGAGAGATCAGTACGTGTGTTGTAGACACCGAGCCAAATGAGGCGGTAAAG 565
Qy	121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db	566 AAACGCTTTGCAAGCAAGGTAACAAATGGTTACAAAGCAGCACCTCTCTTACCGCCTGGTG 625
Qy	141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
Db	625 AAATCGCCTGAGCATCTGCGGAGCGCGAGTTGCGGGGCGCGTGTGCGCCGCCCTTCAG 685
Qy	160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuThr 180
Db	686 TTGTGTGAGCAACGTCTCAGCGCTGGAGTCTTGGGAGGCCCCAGCCACAGCCCGCGCTGAC 745
Qy	180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db	746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy	200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db	806 CCAGGGGGGGCGCCCTGCGGACGCGCTTC-CTGCCCCCGCGGCGAAGCGCATCTTCGACCA 864
Qy	220 nAepGluArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240

```
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C65
; CURRENT APPLICATION NUMBER: US/10/124,819
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-819-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-124-819-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGTCGCGCGGTGGCCCTCTGCTGCGCGCCCTGCAGCTCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACGCCGCGAGCGCGAGCGCCAGGAGCTGCGCAAGAGCGCGAGGCAATTCCTA 325
QY 41 GluLysTrpGlyTrpLeuAsnGlnValProLysAlaProThrLysAlaProThrArgPheSer 60
DB 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACCTCGATTACAG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGTACCTGTCCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyraIa 100
DB 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATCGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGATCAGTACCTGTTGTGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlnAsnLysTrpTyrlsGlnHisLeuSerTyraArgLeuVal 140
DB 566 AAACGCTTTGCANAAGCAAGTAACAAATGGTACAAAGCAGCAGCTCTCCTACCGCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTCCGAGAGCGCGAGTTCGGGGCGCGTCCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGAGCAAGTCTCAGCGCTGAGTTCTGGAGGCGCCACAGCCAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAAGGGGACCAACAGATGGGCTGGGCAATGCCTTTGATGGC 805
```

```
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCTGCTGTCGTCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCCCTCACCCACTCGCCCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
DB 985 CTACTACAAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGCGCGTGA 1044
QY 280 nSerLeuTyrlsGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrlsSerProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrlsCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAATACTGCCACTCTCTCTCGATGCCACTACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCAATTTCTGGAGGTGGCAGCTCATGGCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLys 380
DB 1285 TCCACTGTCAGGAAAGATGGGTGGGCTGCCGCCCAACACTTGAAGGTGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrlsPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrlsVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrlsTrpProArgSerLeuGlnAspTrpG 460
DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGAAGCTTGCAGAGCTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTCAGGAGGTACGGGCGCCCTGCCGAGGCGCGCATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACGAGCGCAAACTGCAGGCGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGCGATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 34

US-10-124-822-143

; Sequence 143, Application US/10124822

; Publication No. US20030073214A1

```

; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; FILE REFERENCE: P333081C64
; CURRENT APPLICATION NUMBER: US/10/124,822
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-124-822-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-124-822-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGCGCGCGGTGGCCCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGGAGCGCGGAGGCCAGGAGCTGCGCAAGGAGCGCGAGGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGACAGGTCCCAAGGTCCTCCACCTCCACTCGATTCCAG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACCTGTCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCCCTGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTATTGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTGTTGCTAGACACCGGACCAAAATGAGCGGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACCGCTTTCGAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCCGAGCGCGGAGTTCGGGGGCGCCGTGCGCGCGCTTCCAG 685

```

```

160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
686 TTGTGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCGCCACACCCACAGCGCCGCTGAC 745
180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
746 ATCCGGCTCACCTTCTCCACAGGGGACCAACAGATGGGTGGGCAATGCTTTGATGGC 805
200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG 220
806 CAGGGGGCGCCCTGGCGCAGCGCTTC - CTGCCCCCGCCGCGGAGAGCGACACTTCGACCA 864
220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaH 240
865 AGATGAGCGCTGCTCCTGAGCGCGCGCGGGCGGCAACCTGTTCTGTTGTTGGCGCA 924
240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaP 260
925 CGAGATCGGTACACGCTTGGCCTCACCTCCAGCTCGCGCGCGCGCGCTCATGGCGCC 984
260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGAGACAGCTGCTGGCGCGCA 1044
280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuP 300
1045 GAGCCTGTATGGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
1105 CACTGACTTTGAGACCTGGGACTCTACAGCGCCCAAGGAGGCGCCCTGAAACGCGAGGG 1164
320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
1165 CCCTAAATACCTGCGCCTCTCTTCGATGCACTCCTAGACAGGCAACAGCAACTGTA 1224
340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCG 1284
360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
1285 TCCTACAGAAAGATGGGTGGGCTGCGCCCGCCCAATGAGGCTGCGGAGTGTCTATT 1344
380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGCGATGCTGGAGGTTCGCGGCGCCCAA 1404
400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGCGAGGGGCGCTGCGCCCGCCATCTGACGC 1464
420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
1465 CGCCCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCGCGCTACTAGT 1524
440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
1525 GCTGCGCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGAAAGTCTGCAGGACTGGGG 1584
460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
1585 AGGCATCTCTGAGGAGGTGAGCGCGCGCTGCGGAGGCGCGCTGCTCATCATCTTCTT 1644
480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645 CCGAGATGACCGCTACTGCGCGCTCGACAGCGCCAAACTGCAGGCAACACCTCGGGCGC 1704
500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCGCAACTCGGGGAGCGCCCTGTT 1764
520 e 520

```



```
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGAGGCCGCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGGCCAACTGCAGGCAACACACCTCGGGCG 1704

QY 500 gTPAlaThrGluLeuProTPMetGlyCysTPHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

QY 520 e 520
DB 1765 C 1765

RESULT 37
US-10-124-824-143
; Sequence 143, Application US/10124824
; Publication No. US2003007659A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC68
; CURRENT APPLICATION NUMBER: US/10/124,824
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-824-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-124-824-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGCTCGGCTCTGCTGCGGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCCGGAGCGCGGAGCCAGGAGCTGGCAGAGGCGGCGGCGCATTCCTA 325

QY 41 GluLysTyrglyTyTLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGGTCCCAAGCTCCCACTCGATTGAGC 385
```

```
QY 61 AspAlaIleAtrqAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGCTTTCAGTGGGTGTCCCACTACTCTGTGAGCGGCGGTGTGGACCCG 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyAla 100
DB 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGGC 505

QY 101 AlaTPAlaGluAtrqIleSerAspLeuPheAlaAtrqHisAtrqThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCAGACACCGGACCAAAATGAGGGGTGAG 565

QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyLysGlnHisLeuSerTyArgLeuVal 140
DB 566 AAACGCTTTGCNAGCAAGGTAACAATGGTTACAGACGACGACCTCTCTACCGCTGGTG 625

QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTCGGAGCGCGCAGTTGCGGGCGCGCTGCGCGCCCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGGCCACAGGCCCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACGATGGGCTGGGCAATGCCCTTTGATGC 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGCGAAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACCTGTTGCTGGTGTCTGCGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCTCGCCCGCGCGCGCGCGCTCATGGCGCC 984

QY 260 oTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044

QY 280 nSerLeuTyrglyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCGCGCGCGCGCGCTGAAACCGAGGG 1164

QY 320 yProLysTyrcysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCCTCAGTACAGAGGCAACAGCACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGAGGAAAGATGGGTGGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCAIT 1344

QY 380 uAenAspGlyAspPheTyPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404

QY 400 pProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCCAACAGCTGTGCGGGCAGGGGGCGCTGCCCGCCCATCTCTGAGC 1464
```

Qy	420	aAlaLeuPhePheProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCTCTCTGCGCGCCTCATCTCTCAAGGGTSCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGACGTGCAAGTGGAGCCCTACTACCCCGAAGCTGTGAGGACTGGGG	1584
Qy	460	yGlyLeProGluGlnValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTCAAGCGCGCCCTGCCAGGCGCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGCCGCTACTGGCGCCTCGACGAGCCCAACTGCAGGCAACCACTCGGSCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	

RESULT 38

```

US-10-127-825A-143
; Sequence 143, Application US/10127825A
; Publication No. US20030077710A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C84
; CURRENT APPLICATION NUMBER: US/10/127,825A
; CURRENT FILING DATE: 2002-04-22
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining prior application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550

```

```
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCCGTCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCTACAGCCGCCCAAGGAAGCGCCCTGAAACGAGGG 1164
Qy 320 YProLySerCyHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAAATACAGCCACTTCTTCGATGCCATCACTGTAGACAGGCNACAGCAACTGTA 1224
Qy 340 rIlePheLySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACACTGCAGGAAGATGGGTGGGCTGCGCCCAACATGAGGCTGGCGGAGTGTCATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLySerGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTCCATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgLeuIleLeuPheLySerGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGGTGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrPProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAGTGGAGCCCTACTACCCCGAAGTCTGAGGACTGGGG 1584
Qy 460 gGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrPArgLeuAspGlnAlaLyLeuGlnAlaThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 39

```
US-10-127-829A-143
; Sequence 143, Application US/10127829A
; Publication No. US2003007711A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
```

```
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RJC85
; CURRENT APPLICATION NUMBER: US/10/127,829A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-829A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-829A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGCTGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGCGAGGCCAGAGCTGCCNAGGAGCGGAGGCATTCTTA 325
Qy 41 GluLySerGlyTyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACATCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTCCAGCGGCTGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTCACTTGTTCGTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLySerTrpLysGlnHisLeuSerTyArgLeuVal 140
Db 566 AACGCTTTGCAAGCAAGGTAACAAATGGTACAGACGACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
```


QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCGCAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGGATACCTCAATGAACAGGTCCCAAGAGTCCCACTCCATCGATTACGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTCCAGCTTACCTGTACGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCTCGGCTGAGAGGATCAGTGTGTTTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAATGTTAAGACGACGACTCTCTTACCCTCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 NACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCTGCGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCCGCTCACCTCTTCACAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCACGCCCTC-CTGCCCCCGCGCGGAGGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
QY 240 eGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGGCGCGAGCGCTGTCTAGCTGGGACGCTGTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGCTGATGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnLysArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLeu 380
Db 1285 TCCACTGAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGCGGAGTGTCTATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTCGATGCTGAGGTTCCGGGGCCCCAA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGCGCAGGGGCTTGCCTCCGCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTACT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTTGCAGGAGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATCACCGCTACTGGCGCTCGACGAGGCCAAACTGCAGGCAACCCACTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTGTGGCATGCCAACTCGGAGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 41
US-10-127-839A-143
; Sequence 143, Application US/10127839A
; Publication No. US20030077713A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330P1C105
; CURRENT APPLICATION NUMBER: US/10/127,839A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17

```

; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-839A-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-839A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGTGTACTTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGCGAGCGCGAGGAGCTGCGCAAGGAGCGGAGGCATTCCTCTA 325
Qy 41 GluLysTyRGLyTyRLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCATGACACAGGTGCCCAAGCTCCCACTCCACTCGATTGCG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCCAAGCTACCTGTGCGGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyRAla 100
Db 446 GCCACCTTGGCAACCAAGGTAACTGTCCTGCGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTGAGAGCATCAGTGACTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyRLeysGlnHisLeuSerTyRArgLeuVal 140
Db 566 AAACGCTTTGGCAACCAAGGTAACTGTCCTGCGGGCGCGTGTGCGCGCTTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGCAGTTCCGGGGCGCGTGTGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGGCCCAAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyRAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGNCACACAGATGGGCTGGGCATTCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

```

; APPLICANT:	Gurney,Austin L.
; APPLICANT:	Sherwood,Steven
; APPLICANT:	Smith,Victoria
; APPLICANT:	Stewart,Timothy A.
; APPLICANT:	Tumas,Daniel
; APPLICANT:	Watanabe,Colin K
; APPLICANT:	Wood,William
; APPLICANT:	Zhang,Zemin
; TITLE OF INVENTION:	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
; FILE REFERENCE:	P333ORIC86
; CURRENT APPLICATION NUMBER:	US/10/127,901A
; CURRENT FILING DATE:	2002-10-15
; PRIOR APPLICATION NUMBER:	60/049911
; PRIOR FILING DATE:	1997-06-18
; PRIOR APPLICATION NUMBER:	60/056974
; PRIOR FILING DATE:	1997-08-26
; PRIOR APPLICATION NUMBER:	60/059113
; PRIOR FILING DATE:	1997-09-17
; PRIOR APPLICATION NUMBER:	60/059115
; PRIOR FILING DATE:	1997-09-17
; PRIOR APPLICATION NUMBER:	60/059117
; PRIOR FILING DATE:	1997-09-17
; PRIOR APPLICATION NUMBER:	60/059122
; PRIOR FILING DATE:	1997-09-17
; PRIOR APPLICATION NUMBER:	60/059184
; PRIOR FILING DATE:	1997-09-17
; PRIOR APPLICATION NUMBER:	60/059263
; PRIOR FILING DATE:	1997-09-18
; PRIOR APPLICATION NUMBER:	60/059352
; PRIOR FILING DATE:	1997-09-19
; PRIOR APPLICATION NUMBER:	60/059588
; PRIOR FILING DATE:	1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.	
; NUMBER OF SEQ ID NOS:	550
; SEQ ID NO 143	
; LENGTH:	1985
; TYPE:	DNA
; ORGANISM:	Homo Sapien
US-10-127-901A-143	
Alignment Scores:	
Pred. No.:	3,35e-262 Length: 1985
Score:	2792.00 Matches: 519
Percent Similarity:	99.62% Conservative: 0
Best Local Similarity:	99.62% Mismatches: 1
Query Match:	98.52% Indels: 2
DB:	15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-127-901A-143 (1-1985)	
Qy 1 MetValAlaArgValGlyLeuLeuEuaGalalaLeuLnfleuLeuTrrGlyHisLeu 20	
Db 206 ATGGTCGC CGCGGTGGCCCTCCTGTCGCCGCCCTGCAGCTGCTACTGTGGGGCCAACCTG 265	
Qy 21 AspAlaGlnProAlaGluAlaArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40	
Db 266 GAGCCCCAGCCC GCAGCGCGAGCGCGAGGCC CAGANGTGCCGCAAGAGGAGCGGAGGCATTTCCTA 325	
Qy 41 GluLyTyrcGlyTyrrbeuAnGluGlnValProlysAlaProThrSerThrArgrpheSer 60	
Db 326 GAGAAGTAGCGATACC TCAATA GAACAGGTCCCAAAGCTCC CACTCC ACTCGATT CAGC 385	
Qy 61 AspaLaile ArgAla PheGlnTrpValserGlnInleuProvalSer GlylWalLeuAspArg 80	
Db 386 GATGCCCATC AGACGCTTT CAGTGGSGTGTCC CAGTAGCTCAC CATACA CAGTTATGCG 445	
Qy 81 AlaThrLeuArgGlnMet ThrArg ProArg Cy sGly lVal Thr AspThr Asn Ser TyrAla 100	
Db 446 GCCACCCCTG GGCCAGATGA CTCTCCCGCTGCGGG GTTA CAGATACA CAGTTATGCG 505	
Qy 101 AlatrPa laGl uArg ileSe rAs pLeuP heAla argHi sAr gTh rL ysMe tAr gAg Ly s 120	


```
QY 340 rlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGG 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGGTGCCGCTACTACGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGTGCAGTGGAGGCTTACTACCCCGAAGTCTGCAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCGGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 44
US-10-131-813A-143
; Sequence 143, Application US/10131813A
; Publication No. US2003007716A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC139
; CURRENT APPLICATION NUMBER: US/10/131,813A
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
```

```
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-813A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-131-813A-143 (1-1985)
```

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGCGCGCTCTGCTGCGCGCTCTGCTGCGCGCTCTGCTGCGCGCTCTGCTGCGCG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGGCCCGAGCGCGGAGCGCGGAGCGCTGGCAAGAGGCGGAGCGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCCAACCTCCCATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCCAAGTACCTGTGAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGTAGACACCGGACCAAAATAGAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAGAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCCGAGCGCGGAGTTCGGGGGCGCGCTGCGGGCGGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCAGCGCTGAGTTCCTGGGAGGCGCCAGCCAGCCAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCCAAAGGGGACCAACGATGGGCTGGGCAATGCGCTTTGATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
```

Db 806 CAGGGGGCGCGCTGGCGACGCTTC-CTGCCCCGCGCGCGAGGCGACCTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGGTGGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 oTyrTrpLySerArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTAGCTGGACGACGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLySerProLeuGlyGlySerValAlaValGlnLeuProGlyLyLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTCGATGCCATCACTGTACAGGCAACGACACTGTA 1164
Qy 320 yProLySerTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTCTTCGATGCCATCACTGTACAGGCAACGACACTGTA 1224
Qy 340 rIlePheLySerGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLyGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTCAAGGGGGTGGATGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 gProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGCGAGGGGCGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLyGlyAlaArgTrpTyVa 440
Db 1465 CGCCCTCTTCTTCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCGCTGCGGAGGCGCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLySerLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGGCCAACTGCAAGGCAACACCTCTGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 45

US-10-131-818A-143

; Sequence 143, Application US/10131818A

; Publication NO. US2003007717A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C141
; CURRENT APPLICATION NUMBER: US/10/131,818A
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-818A-143

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-131-818A-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGTCGGCCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLyGluAlaGluAlaPheLeu	40
Db	266	GACCCCGAGCCCGGAGCGCGAGCTGCGCAAGAGCGGAGGCGGCGCATTCCTA	325
Qy	41	GluLySerGlyTyrLeuAsnGluGlnValProLyAlaProThrSerThrArgPheSer	60
Db	326	GAGAAATACGGATACCTCATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80

Db 386 GATGCCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCGACAGATGACTGTCCCGCTGGGGTTACAGATACCAACAGATTATGG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCCTGGTG 625
Qy 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGGGCCCTCGGCGACCGCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTGCTGCTGCTGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGGCGCGGACGCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyValGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTTCTCTTGATGCCATCACTGTAGACAGGCAACACAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGACCCCG 1284
Qy 360 gProLeuGlnLysArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGAATGGGTGGGCTGCGCCCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTTPArgPheAtqGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGTGCTGGAGGTTCGGGGGCCCCAA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCybArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACACAGCTGTCCGGGCGAGGGGCGCTGCCCGCCATCTCTGACG 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCGCGCGCTCTATCTCTTCAAGGGTGGCGCTACTAGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCCAAGTCTGCAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGCGGCGCTGCGAGGCCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCCAGGCCAAACTGCAGGCCAACACCTCGGGCG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 46
US-10-131-823A-143
; Sequence 143, Application US/10131823A
; Publication No. US2003007718A1
GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C143
; CURRENT APPLICATION NUMBER: US/10/131,823A
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA

; ORGANISM: Homo Sapien
US-10-131-823A-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-823A-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTCGGCGCGCTCGTCTCGTGGCGCGCTCGTCTCGTCTCGTCTCGTCTCGTCTCGTCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgGlyGlnGlnGlnGlnGlnGlnGlnGln 40
DB 266 GACGCCAGCCCGCGAGCGCGAGCGCGAGCGCGAGCGCGAGCGCGAGCGCGAGCGCGAGCGCG 325
QY 41 GluLysTrpGlyTrpLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCTCCAAAGCTCCACCTCCACTCGATTTCAGC 385
QY 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGCTGTTCGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATGCTCTCCCGCTCGCGGGTTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGTACGTGACTGTGTTCGTAGACACCGGACCAAAATGAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTAAACAGCAGCCTCTCTCCACGCTGTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 NACTGGCTGAGCACTGCGCGAGCGCGAGTTCGGGCGCGCTGCGCGCGCTTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCAGCGCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGCTCACCCTCTTCCNAGGAGCAACAAAGATGGCTGGGCATATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCTGGCGCACGCCCTTC-CTGCCCCCGCGCGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLysSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGTGCTCCCTGAGCGCGCGCGCGCGCGCAACCTGTGTGTGTGTGTGTGTG 924
QY 240 sGluLleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCACCCACTCGCCCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGCTGGGCGCGAGCGCGCTGTCTAGCTGGGAGCAGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGTT 1104
```

```
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnGl 320
DB 1105 CACTGACTTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
QY 320 YProLysTrpCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
DB 1165 CCCTAATACTGCCACTCTTCTTCGATGCTCATCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rLlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCACATGACAGAAAGATGGGTGGGCTGCCGCCCAACATTTAGGCTGGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTTACTTTCTAAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGCGCGGCGAGGGGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCTCTTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLePhePh 480
DB 1585 AGCATCCCTGAGAGGTGAGCGCGCTGCGCGCGCTGCGCGCGCTGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGGCAACCTGCAGGCAACCTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGTCCCTGGATGGGTCTGTGCATGTCACCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 47

US-10-131-824A-143

; Sequence 143, Application US/10131824A

; Publication No. US20030077719A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; TITLE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C126

```

; CURRENT APPLICATION NUMBER: US/10/131,824A
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 530
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-824A-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00        Matches:     519
Percent Similarity: 99.62%     Conservative: 0
Best Local Similarity: 99.62%   Mismatches:   1
Query Match:      98.52%       Indels:       2
DB:               15           Gaps:         0

US-10-791-980-6 (1-520) x US-10-131-824A-143 (1-1985)

Qy      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu 20
Db      206  ATGGTCGGCGCGCTCGCCCTCTCTGTGGCGGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265

Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GAGCCCGAGCCCGGAGCGCGGAGGCTCCGCAAGAGGAGCGGAGGCATTCCTA 325

Qy      41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCACCTCGATTCCAG 385

Qy      61  AspaAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCATCAGACGCTTTCAGTGGGGTGTCCCACTGACCTGTGCGCGCGTGTGGACCGC 445

Qy      81  AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446  GCCACCTCGCCGACAGATGACTGTCCTCCCGCTCGCGGGGTACAGATACCAACAGTTATGCG 505

Qy      101  AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506  GCCTGGGCTGAGAGGATCAGTGACTTGTTTGTGTAGACACCGGACCAAAATGAGCGGTAA 565

Qy      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGCTTTTGCAAGCAAGGTAAACAAATGGTACAGACGACGACCTCTCTCCACCGCTGGT 625

Qy      141  AsnTrpProGluHisLeu-ArgSerArgGlnPheGluAlaProCysAlaProProSerSe 160
Db      626  AACTGGCGCTGAGCACTGCCGAGCGCGGAGTTTCGGGGCGCGCTGCGCGCGCTTCCAG 685

Qy      160  rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180

```

```

Db      1765 C 1765
RESULT 48
US-10-131-830A-143
; Sequence 143, Application US/10131830A
; Publication No. US2003007720A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC137
; CURRENT APPLICATION NUMBER: US/10/131,830A
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-830A-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches:  1
Query Match:     98.52%      Indels:      2
DB:              15          Gaps:        0

US-10-791-980-6 (1-520) x US-10-131-830A-143 (1-1985)
QY      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db      206 ATGGTCGGCGCGCTCGGCTCTCTGCTGCGGCGCTGCAGCTGCTACTGTGGGCGCACCTG 265
QY      21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgGlyGlnGlnAlaGlnLeu 40

```

```

266 GACGCCAGCCCGCGGAGCGCGGAGCCAGGAGCTCGCAAGAGGAGCGGAGGATTCCTA 325
41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGACTCCCACTCCACTCGAATTCAGC 385
61  AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
81  AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGTACCAACAGTTATGCG 505
101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
506 GCCTGGGCTGAGAGGATCAGTGTCTTGTGTGTAGACACCGGACCAAAATGAGCGGTAA 565
121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
566 AAAGCGCTTTCAAAGCAGGTAACAATGGTACAAGCAGCACCTCTCTACCGCTGGTG 625
141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
626 AACTGGCTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCGTGGCGCGCTTCCAG 685
160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
686 TTGTGGAGCAACGTCTCAGCGCTGGAGTCTTGGAGAGCCCGCAGCCACAGGCCCCGCTGAC 745
180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrPalaMetProLeuMetAl 200
746 ATCGGCTCACCTTCTTCCAAAGGGGACCAACAATGGGTGGGCTGGCAATGCTTTGATGGC 805
200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGGCGGAGCGCACCTTCGACCA 864
220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
865 AGATAGCGCTGTGCTCCCTGAGCGCGCGCGGGGGCGCAACTGTTCGTGGTGGCTGGCGCA 924
240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCCGTGCA 1044
280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTTGAACGCGAGGG 1164
320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
1165 CCCTAAATACCTGCGCACCTCTCTTCGTATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
1285 TCCATGTCAGGAAAGATGGGTTCGGGCTGCCCGCCCAACATTGAGGTGTCGGCAGTGTCAIT 1344
380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
1345 GAATGATGGAGATTCTACTTCTTCNAAGGGGGTTCGATGCTGGAGGTTCCTCGGGGCCCCAA 1404

```



```

Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACCTTTCAGACCTGGGACTCTCAGCCCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCACCTCTCTTCGATGCCATCTAGTACAGGCAACGACAACTGTGA 1294
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCCAAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACACAGCTGTGGCGGCAGGGGCGCTGCCGCCCATCTGAGGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTCTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGI 460
Db 1525 GTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGCTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGAGGCGCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGGCCAACTGCAGGCCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGCTGCTGGCATGCGCAACTCGGGAGGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

```

RESULT 50

```

US-10-137-872A-143
; Sequence 143, Application US/10137872A
; Publication No. US2003007722A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: F330R1C150
; CURRENT APPLICATION NUMBER: US/10/137, 872A
; CURRENT FILING DATE: 2002-05-03
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-137-872A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-137-872A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGGCGGATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCATGAACAGCTCCCAAGCTCCACCTCCACTGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGCGGTTTTCAGTGGGTGTCCAGCTACTCTGTGAGCGGCGGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGGCTGCGGGGTTACAGATACCAACAGTTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGGATCAGTACTTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

```



```
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCCTCTCCTACCGCCCTGGTG 625
Qy 141 AantTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGGGCCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCCGGCTCACCTTCTTCAAGGGGACCAACAACGATGGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArTrpThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCTCGCGCAGCCCTTC-CTGCCCCCGCGCGGGAAGCGACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCGCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrLyAsArgLeuGlyArgAsAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCGTGGCGCGCGCGCGCTGCTAGCTGGAGCAGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyRgLyAsProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCCTACAGCCCCCAAGAAAGGGCGCTTGAACGCGAGG 1164
Qy 320 yProLyAsTyCyHisHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTTCTTCGATGCCATCTACTGTAGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTCATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyRgPhePheLysGlyGlyVargCystrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGTTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCGAGGGGACCTGCAAGTGGAGCCCTACTACCCCCGAAAGTGTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleLeuPhePh 480
Db 1585 AGGCATCTCTGAGGAGGTTCAGGGGCGCTTCCGAGGCGCGATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
```

```
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACACGCGCAAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 qTrpAlaThrGluLeuProTrpMetGlyCyTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGGTGCGCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 51
US-10-147-500-143
; Sequence 143, Application US/10147500
; Publication No. US2003007723A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1G325
; CURRENT APPLICATION NUMBER: US/10/147,500
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-500-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-500-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTCTGCTGCGCGCCCTGCTACTGTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGGCGGAGGCAATTCCTA 325
Qy 41 GluLysTyRgLyTrpLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGGATACCTCAATGAACAGGTCCCAAGAGTCCCACTCCCTCCATTCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGGTTTCAGTGGGTGTCCAGCTACTGTCCAGCGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyRAla 100
```

Db 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTGACTGTTGCTAGACACCGAGCAAAATAGAGCGTAA 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLysSerTrpArgLeuVal 140
 Db 566 AAACGCTTTCAGAACAGAGTAAACAATGGTACAAAGCAGCACCTCTCTACCGGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGGAGCGCCAGCCAGCCAGCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCACAAACGATGGGCTGGGCAATGCCCTTTGATGGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 806 CCAGGGGGCGCCCTGGCGACCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGTCCTCGAGCGCGCGCGGGCGCAACCTGTCGTGGTGGTGGCGCA 924
 Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CCAGATCGGTACACGCTTGGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 Db 985 CTACTACAAGGCTGGGCGCGGAGCGCGTGTCTAGCTGGGAGCGAGTGTGGCGGTGCA 1044
 Qy 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGAGCGCCCTTGAACCGAGGG 1164
 Qy 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
 Db 1165 CCTTAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCCCAACATTTAGGCTGGCGAGTGCAIT 1344
 Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
 Db 1345 GAATGATGGAGATTTCTACTTCTCAAGGGGGTTCGATGTGGAGGTTCGGGGGCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGGGAGGGGCTGCCCCCGCATCTTGACGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpTrpVa 440
 Db 1465 CGCCCTCTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTTACTACGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG 1584

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGTTCAGCGGCGCTCGCGAGGCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCAGATGACCGCTACTTGGCGCTCGACCGAGGCAAACTTCAGGGCAACCACTCGGGCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTCCCTGGATGGCTGCTGGATGCACTGCACCTCGGGAGGCGCTGT 1764
 Qy 520 e 520
 Db 1765 c 1765
 RESULT 52
 US-10-147-502-143
 ; Sequence 143, Application US/10147502
 ; Publication No. US2003007774A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: DeNovers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tamas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C326
 ; CURRENT APPLICATION NUMBER: US/10/147,502
 ; CURRENT FILING DATE: 2002-05-16
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 ; US-10-147-502-143
 Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: Gaps: 0
 US-10-791-980-6 (1-520) x US-10-147-502-143 (1-1985)
 Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGCGCGCTCGCGCTCTCTGTCGCGCCCTTCAGCTGCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCCGAGCCCGGAGCGCGGAGCTGCCAAGAGGCGGAGGCAATTCCTA 325
 Qy 41 GluLysTrpGlyTrpLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCCGATTCAGC 385

```
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGTACCTTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleSerMetArgArgLys 120
DB 506 GCTGGGCTGAGAGGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAGACACCTCTCTCCACCGCTGTGT 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCGCGAGCGGAGTTCGGGGCGCGTTCGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC -CTGCCCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLysSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTGTGCTGTCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTACACCTTGGCTTACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGCGTGGGCGCGCGCGCGCTGTCTAGCTGGGAGCGTGTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCGGAGAGCGCGCTGAAACGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeu 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCATCTGTAGACAGCAACAGCACTGT 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 qProLeuGlnArgTrpValGlyLeuProProLeuIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGGCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCGCCCGCCATCTCTGAGGC 1464
```

```
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTTGGCGCGCTCATCTCTTCAAGGGTGCCCGTACTACT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCGCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTCAGGAGGTGAGCGCGCCTGCCGAGGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCCAAACTGCAGGCCAACCCACTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCGTGT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 53

```
US-10-147-515-143
; Sequence 143, Application US/10147515
; Publication No. US2003007725A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C342
; CURRENT APPLICATION NUMBER: US/10/147,515
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-515-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-147-515-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGCGCGCGCTGGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGCGCCACCTG 265
```

```
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGlnAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGGAGCGGAGCGGAGCGAGCTGCGAGGAGGCGGAGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGATACCTCATGAACAGGTCCCAAGCTCCACCTCACTCATCGATTGACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACCTGTACGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGATACCTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGCGAGCGGCGAGTTTCGGGGCGCGCTTCGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGGTTCTGGAGGCGCCACGACACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCGCGCGCGCGGCGCAACTGTTGTTGGTGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTTCCCTGAGCGCGCGCGCGGCGCAACTGTTGTTGGTGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTGTCGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTGAAGCTGAGACTCTCCTACAGCCCGCAAGAGGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTTCTTCATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGCGAGCTGATGCCAACGCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGCGTGGCGTGGCGTGGCGTGGCGTGGCGTGGCGTGGCGT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
```

```
Db 1345 GAATGATGGAGATTCTTACTTTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTTCCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGAGTGAAGTGAGCCCTACTACCCCGAAGTCTGCAGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlelePhePh 480
Db 1585 AGCATCCCTGAGGAGTCAAGCGCGCTGCGGCGCGGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGAGATGACCGTACTTGGCGCTCGACACGAGGCAAACTGCAGGCAACCACTCGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGCAATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 54

```
US-10-147-517-143
; Sequence 143, Application US/10147517
; Publication No. US2003007726A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C337
; CURRENT APPLICATION NUMBER: US/10/147,517
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-517-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.82% Conservative: 0
Best Local Similarity: 99.82% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

Db	1225	CAITTTTAAAGGAGCCATTCTTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGAAAGATGGGTTCGGGCTGCCCCCAACATTGAGGCTCGGCAGTGTCTATT	1344
Qy	380	uAaAspGlyAspPheTyrPhePheIysGlyIAspCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTCGATGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysAspAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGCTCTCCACAGCTGTGTCCGGGCGAGGGGGCTGCCCCCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTCCCTCCTCTGCGCGCCCTCATCTCTTCAAGGGTGCCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGGCCGAGGGGAGCTGCAAGTGGAGGCCCTACTACCCCCGAAGCTGCAGGACTGGG	1584
Qy	460	YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTTCAGCGGGGCCCTGCGAGGCCCGATGGCTCCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACACAGGCCAAACTGCAGGCAACCACTCGGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e	520
Db	1765	C	1765
RESULT 55			
US-10-147-526-143			
; Sequence 143, Application US/10147526			
; Publication No. US2003007727A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Desnoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; TITLE OF INVENTION: ACIDS ENCODING THE SAME			
; FILE REFERENCE: F330RIC343			
; CURRENT APPLICATION NUMBER: US/10/147,526			
; CURRENT FILING DATE: 2002-05-17			
; Prior Application removed - See File wrapper or Palm			
; NUMBER OF SEQ ID NOS: 550			
; SEQ ID NO 143			
; LENGTH: 1985			
; TYPE: DNA			
; ORGANISM: Homo Sapien			
US-10-147-526-143			

Alignment Scores:

Pred. No.:	3,358-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.53%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-147-526-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuAraGAlaIeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCTCGGGCGCTCGCGCTCTGCTCTCGGGCCCTGTCAGTGTCTACTGTGTGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuAraGlySglnAlaGluAlaPheLeu	40
Db	266	GACGCCCGAGCCCGGAGCGGAGGCCAGAGCTGCGAAGGAGGCGGAGGCAATTCCTTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGCTACTCTCAGCGCGGTGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCACCGCCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe	160
Db	626	AACTGGCCCTGAGCATCTGCCGGAGCGCGCAGTTCCGGGGCGCGTGGCGCGCTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAACATGGGCTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCCGCGCGGGCGAAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGACGCCCGCGCGGGCGGCAACCTGTGTGTGTGGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCCGCGCGCGCTCATGTGGCGCC	984
Qy	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspPheValLeuAlaValGl	280
Db	985	CTACTTACAAGAGGCTGGGCGCGAGCGCGCTGCTCAGCTGGGACACAGTGTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATATGGGAAGCCCTAGGGGGCTCAGTGGCCCTCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACCTGACTTTGAGACTGGGACTCTCAGCGCCCCCAAGAAAGGGCGCTCTAAACGCCAGGG	1164

Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACCTCTTCATGCATCCTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTCTCGGAGGTGGCAGCTGATGGCNAAGTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGTTCGGCTGCCCCCAACATTGAGGCTCGGCAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCCAAGCTGTCCCGGGCAGGGGGCTGCCCCGCCCATCTGTACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrrVa	440
Db	1465	CGCCCTCTTCTTCCTCCTGCGCGCGCTCATCTCTTCAAGGGTGCCTGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrrProArgSerLeuGlnAspTTPGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAGTGGAGCCCTACTACCCCGAAGTCTGCAGNACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTCAGGAGGTTCAGCGCGCCCTGCGAGGCGCGATGGCTCCCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTTCGACCGCCAACTGCAGGCAACCACTCGGGCG	1704
Qy	500	gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	

RESULT 56

US-10-147-527-143
 ; Sequence 143, Application US/10147527
 ; Publication No. US2003007728A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zenin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; TITLE OF INVENTION: ACIDS ENCODING THE SAME
 ; FILE REFERENCE: P3330RLC353
 ; CURRENT APPLICATION NUMBER: US/10/147,527
 ; CURRENT FILING DATE: 2002-05-17
 ; Prior Application removed - See File Wrapper or Palm

/	APPLICANT:	Zhang, Zemin			
/	TITLE OF INVENTION:	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
/	TITLE OF INVENTION:	ACIDS ENCODING THE SAME			
/	FILE REFERENCE:	P3330R1C9			
/	CURRENT APPLICATION NUMBER:	US/10/121.041			
/	CURRENT FILING DATE:	2002-04-11			
/	Prior Application removed - See File Wrapper or Palm				
/	NUMBER OF SEQ ID NOS:	550			
/	SEQ ID NO 143				
/	LENGTH:	1985			
/	TYPE:	DNA			
/	ORGANISM:	Homo Sapien			
US-10-121-041-143					
 Alignment Scores:					
Pred. No.:	3.35e-262	Length:	1985		
Score:	2792.00	Matches:	519		
Percent Similarity:	99.62%	Conservative:	0		
Best Local Similarity:	99.62%	Mismatches:	1		
Query Match:	98.52%	Indels:	2		
DB:	15	Gaps:	0		
 US-10-791-980-6 (1-520) x US-10-121-041-143 (1-1985)					
Qy	1	MetValAlaArgValGlyLeuLeuAargAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20		
Db	206	ATGTCTCGCGCGTTCCTCTCTGCGGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265		
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu	40		
Db	266	GACGCCACGCCGCGGAGCGCGGAGCCAGAGCTGCGCAAGGAGGCGAGCATTCCTGA	325		
Qy	41	GluLysrTyGlyTyTyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60		
Db	326	GAGAAGTACGATACCTCAATGACAGGTTCCCCAAAGCTCCCACCTCCACTCGATTGAC	385		
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80		
Db	386	GATGCCATCAGAGCGTTTTCACTGGGTGTGCCAGCTACCCTGTGCGGGCGTGTGGACGCG	445		
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100		
Db	446	GCCACCTTCGCGCAGATGACTCTGTCCTCCGCTCGGGGTTCACAGATACCAACAGTTATCG	505		
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120		
Db	506	GCCTGGGCTGAGAGATCAGTGACTTGTGTGTGTGACACCCGACCAAATGAGCGTAAG	565		
Qy	121	LysArgPheAlaLysGlnGlyAsnLysrTpTyLysGlnHisLeuSerTyrArgLeuVal	140		
Db	566	AAACGCTTTGCMAACAAGGTAAACAATGGTACAGCAGCACCTCTCCTACCGCTGTGTG	625		
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160		
Db	626	AAC TGCGCTGAGCATCTGCGGAGCGCGCAGTTTCGGGCGCGCTGCGCGCCCTTCAG	685		
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180		
Db	686	TTGTGGAGCAACGTTCTACGCGCTGAGTGTCTGGAGGGCCCCAGCACAGCCCCCTGAC	745		
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetal	200		
Db	746	ATCCGGCTCACCTTCTTCCAAGGGGACCACACGATGGGCTGGGCAATGCCCTTTGATGC	805		
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspCl	220		
Db	806	CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCGCGCGGCGAAGCGCATTCGACCA	864		
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240		
Db	865	AGATGAGCCCTGGTCCCTGAGCGCGCGCGCGGGCGCAACCTGTTCTGTGTCTGCGCA	924		
Qy	240	sGluLleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260		


```
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C4
; CURRENT APPLICATION NUMBER: US/10/121,047
; CURRENT FILING DATE: 2002-04-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-121-047-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-121-047-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTGGCGCGGTCTCTGTCGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACCGCGGAGCGCGGAGCCGAGGAGCTGGCGAGGAGCGGAGGCAATCTCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerClyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCACAGTACCTGTGAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTGTCTCCCGCTGGGGGTACAGATACCAACAGATTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGGGTAG 565
QY 121 LysArgPheAlaLysGlnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTACAAATGGTACAGCAGCAGCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGSCCTTGAGCATCTCGCGGAGCCGGCAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCGCCAGCCACAGGCCCGCTGAC 745
```

```
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
DB 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGTGGGTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyLysHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCTTTC-CTGCCCGCGCGGAGGCGACCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATAGCGCTGCTGCTGAGCGCGCGCGCGCAACCTCTGCTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCACTCGCGCGCGCGGCGGTCTATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCAGCTGCCAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACCTTTGAGNACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCTCTGAAGCGCAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATATCGCCACTCTTCTTGGATGCTACCTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGACATTTCTGGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTCAGGMAAGATGGGTGGGCTGCCCGCCCAACATTTAGGCTCGCGCAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTGCGATGTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAAGGTGCCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCGCGAGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGAGCTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGAGGTACGGCGCTCTGCCAGGCGCCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACGAGCCAAACTGCAGGCAACACCTCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGTCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 60

US-10-123-215-143
 ; Sequence 143, Application US/10123215
 ; Publication No. US20030077780A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Cao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P33301C41
 ; CURRENT APPLICATION NUMBER: US/10/123,215
 ; CURRENT FILING DATE: 2002-04-15
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-123-215-143

Alignment Scores:

Pred. No.: 3,356-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-215-143 (1-1985)

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCGTTCGCGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCGCCGAGCCACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCCAAAGGGACACCAACATGGGCTGGGCAATGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCCCTGGGCGACGCTTC-CTGCCCGCGCGCGCGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGCTGTGTGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCCCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGCGAGCGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyTrpSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGGCGCTCGAAACGACGG 1164
 QY 320 yProLysTyTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAATATCTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGAGGAAAGATGGGTGGGCTGGGCTGCCCGCGCGCGCGCTCGCGAGTGTCTATT 1344
 QY 380 uAsnAspGlyAspPheTyTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGAGGGGGCGCTGCCCGCCATCTCGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
 DB 1465 CGCCCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpTyTrpArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCGAGGGGGATGCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
 DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCCCGATGGCTCCATCATCTTCT 1644
 QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTTGGGCGCTCGACCGAGCCCAACATGCGAGGCAACCACTCGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

```
Db 1705 CTGGCCACCGAGCTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 61
US-10-123-902-143
; Sequence 143, Application US/10123902
; Publication No. US2003007781A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C47
; CURRENT APPLICATION NUMBER: US/10/123,902
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-902-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-902-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGCTCGGCTCTCGTGTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGGAGCGCGGAGCGCAGAGCTGCGCAAGGAGCGGAGGCATTCCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCCAANGTCCCACTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACCGCTTTCAGTGGGTGTCCCAAGTACCTGTCTCAGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCAGATGACTGTCCCCCGCTGCGGGGTTTACAGATACCACACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
```

```
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATAGCGCGTAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTTGC CGGAGCGGAGTTCGGGGCGCGTGGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCCGCAGCAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCGCGCGGCGGAGCGACATTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCGCAACTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHiserProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACAGCTGTGGCCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGNAAGTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATATCTGCCACTTCTTCTGATGCAATCAGTGTAGACAGGCAACGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGCAAGAGTGGGTGGGCTGCCCGCGCGCGCGCAATTCAGGCTCGCGCAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGCGATGTGGAGGTTCGGGGGCCCCNA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGGAGGGGCGCTGCCCGCGCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCGCTCATCTCTTCAAGGGGTGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAGTGGAGCGCTACTACCCCGAGAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
```



```
Db      1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCGGAGCCGATGGCTCCATCATCTTCTT 1644
Qy      480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645 CCGAGATGACCGCTACTTGGGCGCTCGACCAAGGCGCAACTGAGGACACCACTCTCGGGCG 1704
Qy      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705 CTGGGCAACCGAGCTGCGCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy      520 e 520
Db      1765 C 1765

RESULT 62
US-10-123-908-143
; Sequence 143, Application US/10123908
; Publication No. US2003007782A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C44
; CURRENT APPLICATION NUMBER: US/10/123,908
; PRIORITY FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-908-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              15          Gaps:      0

US-10-791-980-6 (1-520) x US-10-123-908-143 (1-1985)
Qy      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db      206 ATGGTCGCGCGCTCGGCTCTGTCGCGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG 265
Qy      21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db      266 GACGCCACGCGCGGAGCGCGGAGCGGAGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
Qy      41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326 GAGAAAGTACGAGTACTCTCAGTAAACAGGTCCCCCAAGCTCCACCTCCACTCGATTACG 385
Qy      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
```

```
Db      386 GATGCCATCAGACGCGCTTTTCAGTGGGTGTCCTCAGTACCTGTTCAGCGGCGGTGTGGACCGC 445
Qy      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446 GCCACCTTGGCGCAATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTATTATGG 505
Qy      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCCGACCAAAATGAGGGCTAG 565
Qy      121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTACCGCTGTG 625
Qy      141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626 AACTGGCTTGAGCATCTCCGAGCGCGGAGTTCGGGGCGCGCTGCGGCGCCCTTCCAG 685
Qy      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCGCCCGACAGCCCGCTGAC 745
Qy      180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db      746 ATCCGCTCAGCTCTCTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTCATGC 805
Qy      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db      806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCGCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy      220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865 AGATGAGCGCTGTCTCCCTGAGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy      240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925 CGAGATCGGTCAACGCTTGGCGCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy      260 oTyrTyrIleArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db      985 CTACTACAAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGCGTGA 1044
Qy      280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGTT 1104
Qy      300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db      1105 CACTGACTTTGAGACCTGGGACTCTACAGCGCGCGCAAGGAAGGCGCGCTGAAACGACGG 1164
Qy      320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165 CCCTAAATACCTGCGCACCTCTCTCTTCGATGCGCATCCTGTGTAGACAGGCAACAGCACTGA 1224
Qy      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy      360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285 TCCACTCGAGAAAGATGGGTGGGCTGCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1344
Qy      380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGCGGCGCGCG 1404
Qy      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCGCTGCCCGCGCGCGCGCGCGCG 1464
Qy      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db      1465 CGCCCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGCT 1524
```

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
 QY 460 yGlyIleProGluGlnValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTCCCGAGGCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCCAACTGCGGCAACCCCTCGGGCCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCyTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765

RESULT 63

US-10-123-909-143
 ; Sequence 143, Application US/10123909
 ; Publication NO. US20030077783A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE OF INVENTION: ACIDS ENCODING THE SAME
 ; FILE REFERENCE: P33301C49
 ; CURRENT APPLICATION NUMBER: US/10/123,909
 ; CURRENT FILING DATE: 2002-04-16
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 ; US-10-123-909-143

Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-909-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGGCGGCTCGCCCTCTGCTGGCGCCCTGCGAGTGTCTGTGGGCGCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCCCGGAGCGCGGAGGCGCAGAGCTGCGCAAGGAGGCGGAGGCAATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGCTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGTTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCTGGGTGTAGAGGATCAGTGTCTTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProLuiHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTGCGGAGCGGCAAGTTCGGGGCGCCGTGCGCGCCCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCGTGGAGGCCCCAGCCACAGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCCCGCGGAGCGGAGCGACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCCCGCGCGGCAACCTGTTCGTGGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACCGCTTGGCCCTCACCTCCCGCGCGCGCGCGCTCATGGCGGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGAGCGCGCTGTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAAAGGCCCTGAAACCGCAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCTTAAATCTGCCACTCTCTTCGATGCCATCCTGATAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGGAGCTGATGCAACGTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 Db 1285 TCCACTCGAGGAAAGATGGTTCGGCTGCCCGCCCAACATTGAGGCTGCGGAGTGTCTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCTCGGGGCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGAGGGGGCTGCCCCGCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLeuGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCCCTCATCTCTTTCAAGGGTGCCTGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGTGCAGTGGAGCCCTACTACCCCGGAAGTCTCGAGACTGGGG 1584
QY 460 yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAGGCCAACTGCAGGCCAACCCCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 64

US-10-123-910-143
; Sequence 143, Application US/10123910
; Publication No. US2003007784A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C45
; CURRENT APPLICATION NUMBER: US/10/123,910
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-910-143

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-123-910-143 (1-1985)

QY 1 MetValAlaAraValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGGCGGTGGGCTCTCTGTCGGCGCCCTGCAGTCTGCTACTGTGGGGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGGAGCGCGGAGGCGGAGGAGCTGCGCAAGAGGCGGAGGCGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAenGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCGATTCAGTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCAAGCGCGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTCGGGGTTTACAGATACCAACAGTTATGCG 505
QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTTCGTAGACACCGGACCAAAATGAGGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCNAAGCAAGGTAACTGGTACACAGCAGCAGCTCTCTCCAGCCCTGGTG 625
QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTCAGCATCTCGCGAGCGGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACAACGCTCTCAGCGCTTGAGTTCTGGGAGGGCCCGGACACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGTGGGCAATGCCTTTGATGCG 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCGAGCGCGCGCGGCGGCGCAACCTGTTGCTGGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTTGGCTTCCACCTCTCGCCCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGCGCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAGGAGGCGCCCTGAAACCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATATCTGCCACTCTTCTTCATGTCCTCAGTGCCTCAGTGTAGACAGGCAACAGCAACTGA 1224
QY 340 xIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTGACAGCCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAenIleGluAlaAlaValSerLe 380

```

Db      1285  TCCACTGCAGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTCGCGAGTGCATT      1344
QY      380  uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy      400
Db      1345  GAATGATGGAGATTCTACTCTTCNAAGGGGGTCTGATCTGGAGGTTCGGGGGCCCA      1404
QY      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl      420
Db      1405  GCCAGTGTGGGTCTCCACACAGCTGTGCGGGCAGGGGGCTGCCCGGCCATCTGACGC      1464
QY      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaGlyTyrVa      440
Db      1465  CGCCCTCTCTTCCTGCTGCGCGCTCATCTCTTCAAGGGTGCCTACTACTG      1524
QY      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl      460
Db      1525  GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGG      1584
QY      460  yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh      480
Db      1585  AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCCGATGGCTCCATCATCTTCTT      1644
QY      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr      500
Db      1645  CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAAACTGAGGCAACCACTCGGGCG      1704
QY      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh      520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT      1764
QY      520  e 520
Db      1765  C 1765
```

```

RESULT 65
US-10-124-813-143
; Sequence 143, Application US/10124813
; Publication No. US2003007785A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filwaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC67
; CURRENT APPLICATION NUMBER: US/10/124,813
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-813-143
Alignment Scores: 3.35e-262 Length: 1985
Pred. No.: 2792.00 Matches: 519
Score:
```

```

Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 15 Indels: 2
DB: Gaps: 0
US-10-791-980-6 (1-520) x US-10-124-813-143 (1-1985)
QY      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTPrpGlyHisLeu 20
Db      206  ATGCTCGCGCGCTCGGCTCTCTGCTGCGCGCTCTGAGCTGCTACTGTGGGGCCACTG 265
QY      21  AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GAGCCCGCCCGCGGAGCGCGAGGAGGAGCTGCGCAAGGAGCGGAGGAGCATTCCTA 325
QY      41  GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTACG 385
QY      61  AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCCATCAGAGCGTTTCAGTGGGTGTCACGCTACCTGTGAGCGCGTGTGGACCG 445
QY      81  AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446  GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATG 505
QY      101  AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgAtgLys 120
Db      506  GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCCAAATGAGCGTA 565
QY      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGCTTTGCAAGCAAGGTACAAATGGTACAGCAGCACCCTCTCTACCGCCTGGTG 625
QY      141  AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCTTGAGCATCTGCGGAGCGCGAGTTTCGGGGCGCGTGCAGCGCTTCAG 685
QY      160  rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgTrpGlnProGlnAlaProLeuTh 180
Db      686  TTGTGGAGCAACGCTCTCAGCGCTGAGTTCTGAGGAGGAGGAGGAGGAGGAGGAGG 745
QY      180  rSerGlySerProSerSerLysGlyThrThrMetGlyTyrTrpAlaMetProLeuMetAl 200
Db      746  ATCGGCTCACCTCTTCCAAAGGGGACCAACACGATGGCTGGGCAATGCTTTGATGG 805
QY      200  aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db      806  CCAGGGGGCGCTTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGAGCGCATTCGACCA 864
QY      220  nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGTGCTCTGAGCCCGCGCGCGGCGGCAACCTGTTCGTGGTGTGGCG 924
QY      240  sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTACACGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCT 984
QY      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaVal 280
Db      985  CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGAGGAGGAGGAGGAGGAGGAG 1044
QY      280  nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCTGTATGGGAGGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY      300  eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db      1105  CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGAGGAGGAGGAGGAG 1164
QY      320  yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
```

```
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCACTCAGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rlePheLysGlySerHisPheTrpGluValAlaAlaPheGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCGG 1284
Qy 360 gProLeuGlnGluArGTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGATGGTGGCTGCCCCCAACATTGAGGTGGCGCAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCTGGGGCCCA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTTGCCTCCCGCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGGCGGCCCTTGCAGGCGCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGGCGCTCGACAGGCCAATCTGACGGCAACACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 66

```
; Sequence 143, Application US/10124817
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C56
; CURRENT APPLICATION NUMBER: US/10/124,817
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
```

```
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-817-143
Alignment Scores: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-124-817-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTGGGCTCTCTGTCGGCGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGGCATTCCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTGAGCGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGTCCTCCGCTGCGGGGTACAGATACCAACAGTTATGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGGTACAGCAGCAGCCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTACGATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCGCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCCTGAGCGCGCGCGGGCGCAACCTGTTGCTGCTGCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCTACCTGCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGGAGCGCTGCTCAGCTGGGAGCAGCTGCTGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGCTCCAGCTCCAGGAAGCTGTT 1104
```

```
Qy 300 eThraSPheGluThrTrpAspSerTy-SerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTAGAGCCCAAGAGGCCCTGAAAGCAGGG 1164
Qy 320 yProLysTyrcysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTTCGATGTCATCACTCTAGACAGGCAACAGCACTGA 1224
Qy 340 xIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCATGCTGATGCAACGTCCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGTGGGCTGCCCCCAACATTTGAGGCTGGCGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlycylArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGTTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlycylLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGGTCTCTCCACAGCTGTGCCGGGCAGGGGGCCTGCCCGGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CGCCCTCTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAGGTGCCCGCTACTAGT 1524
Qy 440 lIleAlaArgGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGSCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGCGGCGCCTGCCGGGCGCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspArgTyTyTyArgLeuAspGluAlaLysLeuGlnAlaThrThrSerGlyVaR 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGACGGCAACACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 67

```
US-10-125-922-143
; Sequence 143, Application US/10125922
; Publication No. US2003007787A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
```

```
; FILE REFERENCE: P3330R1C73
; CURRENT APPLICATION NUMBER: US/10/125,922
; CURRENT FILING DATE: 2002-04-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-125-922-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-125-922-143 (1-1985)
```

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGCTCGCGCGCTCGGCCTCTCTGTCGGCCCTGCAGCTGTACTGTGGGGCCACCCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGGAGGCTGCAGAGCTGCGAAGAGGCGGAGGCAATTCCTA 325
Qy 41 GlulysTyTyTyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTGTACGCGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyTyAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGCTTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyTyLysGlnHisLeuSerTyTyArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTACAAATGGTTACAAAGCAGCACCTCTCTTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGCGCGCCCTTCAG 685
Qy 160 rCysGlyValaThr-SerGlnArgTrpSerSerGlyVarProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGCCCCCAGGCCACAGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACACAAACGATGGGTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyValaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGACGCTGTGTCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGCTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGCGGCC 984
```



```
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAGAGGCTGGCGCGACGCGCTGCTCAGCTGGACGACGCTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTGGACCTGGGACTCTACAGCCCCCAAGGAGCGCCCTGAAACGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATAGTCCACTTCTCTTCGATGCCATCACTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTCGGCGAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCCAACAGCTGTGGCGGAGGGGCGCTGCCCGGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCGAAGTGTGACGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGAGGCCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCGAGGCCAACTGCAAGGCAACCCACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 68

US-10-125-924-143

; Sequence 143, Application US/10125924

; Publication No. US2003007788A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

```
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P33301C75
; CURRENT APPLICATION NUMBER: US/10/125,924
; CURRENT FILING DATE: 2002-04-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-125-924-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-125-924-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGGCGCGTCCGGCTCTCTGCTGGCGCGCTTCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCCCGGAGCGCGAGCAGGAGCTGGCGAAGAGCGGAGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTAGTACGATACCTCAATGAACAGGTCCCCAAGCTCCACACCTCCATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCATCAGAGCGTTTTCAGTGGGTGTCCAGACTACCTGTCCAGCGCGGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCCAGATCACTCGTCCCCGCTGCGGGGTTCACAGATACCAACAGTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCCTCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCGCCCGAGCCCGCTGCAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTCTTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGI 220
Db 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCCCGCGCGGAGCGGAGCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
```

Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGGGCGCAACCTGTTCTGTGGTGGCGCA 924
Qy 240 sGluileGlyHthrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCCCTACCCATCGCCCGCGCGCGGTCTATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAAGAGCTGGCGCGCGAGCGCTCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCNAGAGGGCGCTGAAACGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGTCCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTvpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCNAGAAAGATGGGTGGGTGCGGTGCGCCGCCAACATTGAGGCTGGCGAGTGTCA 1344
Qy 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCTTGCCTCCATCTTCAAGGGTGGCGCTAC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTAC 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGCGGCGCTTGGCGAGGCGCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCAGGCCAACACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 69
US-10-140-860-143
; Sequence 143, Application US/10140860
; Publication No. US2003007789A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Sherney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: F330R1C189
; CURRENT APPLICATION NUMBER: US/10/140, 860
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-860-143
Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-140-860-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGTCGCGCGCGTCGCGCTCTGCTGCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCGCGAGCTGCGAGGAGCGGAGGAGCGGAGGAGCTT 325
Qy 41 GlulysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGCTCCCCAAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCCGAGCTACTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCAGAGATGACTCTGCTCCCGCTGCGGGGTACAGATACCAACAGATTATCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTCTTAGACACACCGAGCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTACAGATCTGCGCGAGCGCGAGTTCGGGGCGCGGTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGGAGGCGCCAGCCAGGCGCCCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200

Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCTCTTTGATGC 805
Qy 200 aGlnGlyAlaProTPrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGACGCCCTTC-CTGGCCCGCGCGGGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTPrSerLeuSerArqArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGGGCAACCTGTTCGTGGTGCTGGCGCA 924
Qy 240 eGluLeGlyHisThrLeuLeuThriSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGGCTCACCCACTCGCGCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyrTyrLyArqLeuGlyArqAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGGACGCGCTGTCTAGCTGGGACGAGCTGTGGCGGTGA 1044
Qy 280 sSerLeuTyrGlyLyProLeuGlyGlySerValAlaValGlnLeuProGlyLyLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGGTCCAGCTCCCGAGGAAGCTGT 1104
Qy 300 eThrasPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTGAAACGACGG 1164
Qy 320 yProLyTyCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLyGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTPrValGlyLeuProProAenIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAGATGGTGGGCTGCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLyGlyVArqCyvTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCNA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCyvArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCGCCCGCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLyGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGGGGCGCTGCGGAGGGCCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLyLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAATGCGAGGCAACACACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCyvTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 70

US-10-142-417-143

; Sequence 143, Application US/10142417

Publication No. US20030077790A1
GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C232
; CURRENT APPLICATION NUMBER: US/10/142,417
; CURRENT FILING DATE: 2002-05-09
; Prior application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-417-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-417-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGGCGCGCTCGCCCTCTCTGCGCGCCCTGCGAGCTGCTACTGTGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCGAGGCTGCGCAAGGAGCGGAGGCATTTCCTA 325
Qy 41 GluLySTyrGlyTyrLeuAenGluValProLySalaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGTGTCCAGCTACTCTGTACGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCyvGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisThrThrLyMetArgArgLyS 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGCGGTAAAG 565
Qy 121 LysArgPheAlaLyGlnGlyAsnLyTrpTyrLyGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAGCTTTGCNAAGCAAGGTACAAATGGTACAGCAGCACCTCTCTCCACCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTTCGGCGCGCTTCAG 685

```
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTGGGAGGCGCCACAGGCGCCGCTGAC 745

QY 180 rSerGlySerProSerSerGlyThrThrThrMerGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGAATGCTTTGATGGC 805

QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGCGAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCCGTCACAGCTTGGCTCACCACCTCGCCCGCGCGCGCGGCTCATGGCGCC 984

QY 260 oTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTCGGCGTGCA 1044

QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAGAGGCGCCCTGAAACGCGAGG 1164

QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTCGGCTGCCCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344

QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCCAACAGCTGTGCGGGGAGGGGGCTGCCCCGCCATCTCAGCGC 1464

QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpTrpVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCCAGGGGAGCTCAAGTGGAGGCCCTTACTACCCCCGAATCTGCAGGACTGGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGGGCCCTGCGAGGGCCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGGCTTCGACCAAGGCCAAATGTCAGGCAACCCACCTCGGGCG 1704

QY 500 gTrpAlaThrGluLeuProTrpMerGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCCAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
```

QY 520 e 520
Db 1765 c 1765

RESULT 71
US-10-147-519-143
; Sequence 143, Application US/10147519
; Publication No. US2003007791A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: F3330R1C346
; CURRENT APPLICATION NUMBER: US/10/147,519
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-519-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-519-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGTACTGTGGGCGCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCGCGCGGAGCGCGAGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325

QY 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTCGATTACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGCTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
Db 446 GCCACCTTCGCCAGATGACTGTCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGGCGTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGGCTTTGCAAGCAAGGTAAACAATGGTACAAGCAGCACTCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCCTGAGCATCTGGCGGAGCGGAGTTTCGGGGCGCGCTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTACGCGCTGGAGTTCTGGAGGCGCCCGACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGCAATCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGCGCGCTCATGGCGCC 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCCGCTGGTCTCGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACACCTTGGCTTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGCTGGCGCGGACGCGCTGTCTAGCTGGGACGACGCTGGCGCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCGTGTATGGAAGCCCTAGGGGGCTCAGTGGCGGCTCCAGCTCCAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGGCGGCTGNAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATAGTCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCATTTCTGGAGGTGGGAGCTGATGCCACGCTCTAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
DB 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCAGTGTGGGTCTCCCAACAGCTGTGGCGGAGGGGGCTTGGCCCCGCATCTCGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGGCGGCTCATCTCTTCAAGGGTGGCGGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAAGTGTGACGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerClyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGGGCGGCTTGGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

DB 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAACTGCAGGCAACACCTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGGTGGCATGCCAACTCGGGAGCGCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 72
US-10-157-782-143
; Sequence 143, Application US/10157782
; Publication No. US2003007792A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C431
; CURRENT APPLICATION NUMBER: US/10/157,782
; CURRENT FILING DATE: 2002-05-29
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-157-782-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-157-782-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGTTCGCGCGCTCGGCTCTCTGTCGCGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACAGCCCGGAGCGCGGAGCCGAGGCTGCGCAAGGAGCGGAGGCATTCCTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATCAACAGGTCCCAAAAGCTCCACCTCCATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACGAGTACCTGTGTCAGCGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100

```
Db      446  GCGCCCTGGCCGACGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy      101  AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506  GCGTGGGTGAGAGGATCAGTGACTGTTTGTGTAGACACCGGACCAAAATGAGGGTAAG 565
Qy      121  LysArgPheAlaLysGlnClyAsnLysTTPYrLysGlnHisLysSerTyrArgLeuVal 140
Db      566  AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCGCTGGT 625
Qy      141  AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCTAGCATCTGCCGAGCGCGCAGTTCGGGGCGCGTGGCGCGCTTCAG 685
Qy      160  rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686  TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACAGGCGCGCTGAC 745
Qy      180  rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db      746  ATCCGGCTCACCTTCTTCAAGGGGACCACAAACGATGGCTGGGCAATGCCCTTTGATGCG 805
Qy      200  aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db      806  CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGGGGAGCGCACTTCGACCA 864
Qy      220  nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGTCCTCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGGCGCA 924
Qy      240  sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CAGATCGGTACACGCTTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGCGCGCC 984
Qy      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
Db      985  CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy      300  eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db      1105  CACTGACTTTGAGACTGGGACTCTCAGCCCCCAGAGAGGCCCTGGAACGACGAGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCCTAAATACTGCCACTCTTCCTCGATGCGCATCACTGTAGACAGGCAACAGCAACTGA 1224
Qy      340  rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTTAAAGGAGGCCAATTTCTGGAGGTGGCAGCTGATGCCAACGTCCTCAGAGCCCCG 1284
Qy      360  pProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGACGAAAGATGGGTGGGCTGCGCCCCCACAATTGAGGCTGGCGAGTGTCAAT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTTPArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTTCTACTCTTCAAAGGGGTGATGCTGGAGTTTCCGGGCCCCCAA 1404
Qy      400  sProValTTPGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db      1405  GCCAGTGGGGTCTCCCAACAGCTGTCCGGGAGGGGGCTGCCCCGCCATCCTGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465  CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
```

```
Db      1525  GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTGTGAGGACTGGG 1584
Qy      460  yGlylProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCTCAGGAGGTACGCGCGCTGCCGAGGCGCATGGCTCCATCATCTTCTT 1644
Qy      480  eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGGCGCTCGACCGCCAAACTGCAGGCAACACCTCGGGCGG 1704
Qy      500  gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGCCAACTCGGGGAGGCGCTGT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 73
US-10-152-395-143
; Sequence 143, Application US/10152395
; Publication No. US20030078377A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C405
; CURRENT APPLICATION NUMBER: US/10/152,395
; CURRENT FILING DATE: 2002-05-21
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-152-395-143

Alignment Scores:
Pred. No.:      3.35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              15          Gaps:        0

US-10-791-980-6 (1-520) x US-10-152-395-143 (1-1985)

Qy      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTTPGlyHisLeu 20
Db      206  ATGTCGCGCGCGCTCGCGCTCTCTGTCGCGCTCTGTCGCGCTCTGTCGCGCGCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACGCCAGCCCGCGGAGCGCGGAGGCGCAGGAGCTGCGAAGGAGGCGGCGATTCTCTA 325
Qy      41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```


Db 326 GAGAGTACCGATACCTCAATGAAACAGAGTCCCAAGCTCCCACTCCATCGATTGACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCTTTCAGTGGGTGTCCAGCTACCTGTGACGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
Db 446 GCCACCTCGCCGACAGATGACTCGTCCCGCTGGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIlysMetArgArgLys 120
Db 506 GCTGGGCTGAGAGGATCAGTGAATCTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTGTCAAGCAGGTAACAATGGTACAGCAGCCTCTCTACCGCTGGTG 625
Qy 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGCGCGCTGCGCGCTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCACGACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetal 200
Db 746 ATCCGCTCACCCTTCTTCAAGGGGACCAACGATGGGTGGGCAATGCCCTTGTATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGGGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGTGTGCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaP 260
Db 925 CGAGATCGGTACACCTTGGCTTCCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 ofTyrTrpYsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCTGGCGCGGACGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCCACAGCCCGGCGCGCGCGCGCTGAAACGCGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCAGTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 pProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerle 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTTAGGTGGCGGAGTGTCAAT 1344
Qy 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCATCTCTGACGC 1464

Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGGAGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCGCAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGCTGGCTGGCATGCCAATCGGGGAGCGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 74

US-10-125-926A-143
; Sequence 143, Application US/10125926A
; Publication No. US20030082686A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P333081C80
; CURRENT APPLICATION NUMBER: US/10/125,926A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.

```

; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-125-926A-143

```

Alignment Scores:

Pred. No.: Score: Percent Similarity: Best Local Similarity: Query Match: DB:	Argument Scores: 3.35e-262 2792.00 99.62% 99.62% 98.53% 15	
	Length: Matches: Conservative: Mismatches: Indels: Gaps:	1985 519 0 1 2 0

US-10-791-980-6 (1-520) x US-10-125-926A-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTTCGGCGCGTCCGCCCTCCTGCTCGCGGCCTCGAGCTGCTACTGTGGGCCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArGgLyGLyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCCAGCCCGCGAGCGCGGAGGCCAGAGCTGCGAAGGAGGCGGAGGCATTTCCTA	325
Qy	41	GlulysTyrrGlyTyrrLeuAsnGluGlnValProLysAlaProThrSerThrArGPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuproValserGlyValLeuAspArg	80
Db	386	GATGCCATCATGAGCGTTTCAGTGGGTGTCGCCAGCTACTCTGACGCGCGTGTTGGACC	445
Qy	81	AlaThrLeuArgGlnMetThrAtgPrOArGcYsgLyVAlThrAspThrAsnSerTyrrAla	100
Db	446	GCCACCTTGCCCAAGATGACTCTGTCGCCGTGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrylsMetArGArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTAGCTTGTGTTGTAGACACCGGACCAAAATGAGCGCGTA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrlsGlnHisLseuSerTyrrArgLeuVal	140
Db	566	AAAAGCTTTGCAAAGCAGGTTAACAAATGGTACNAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaproCysAlaproSerSe	160
Db	626	AAC TGCGCTGAGCATCTGCCGAGCCGCGAGTTCTCGGGCGCGTGCGCGCGCTTCCAG	685
Qy	160	rCyGglyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuth	180
Db	686	TTGTGGAGCAACGTCCTAGCGCTGGAGTTCTTGGAGAGGCCCCAGCCACAGGCCCGCTG	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal	200
Db	746	ATCCGGCTCACCTTCTTCCAAGGGAGCAACAACATGGCTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrPropheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCCGCGCGCGGCGAAAGCGACTTCG	864
Qy	220	naspGluArgTrpSerLeuSerArgArqGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGTGTCCTTGAGCCGCCCGCGGGCGCAACCTGTCTGGTGTCTGGCGCA	924
Qy	240	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalApr	260
Db	925	CGAGATCGGTACACAGCTTGCCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrrTyrlsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGGCCCGCAGCGCTCTCAGCTGGGACGACGTGTGGCCGTGCA	1044

Qy	280	nSerLeuTyrGlyVysProLeuGlyVysSerValAlaValGlnLeuProGlyVysLeuPh	300
Db	1045	GAGCCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGACTCCAGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyVArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTTTGACACTGGGACTCCTACAGCCCCCAAGGAAGGCGCCTGMAACGACGGG	1164
Qy	320	yProLysTyrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATATGCGCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CAITTTTAAAGGAGGCAATTTCTGGAGGTGGCAGCTGATGGCAAAGTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGTTCGGCTGCCGCCCAACATTGAGGCTGCGGCAGTGTCAAT	1344
Qy	380	aAsnAspGlyAspPheTyrPhePheLysGlyVArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGCCATCCTGACGC	1464
Qy	420	aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCCTCTGCGCGCCCTCACTCTCTTCAAGGGTGCCTGCTACGCT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGCTGCGAGACTGGGG	1584
Qy	460	yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGTCAAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTCTTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGCGCCTCGACGAGGCCAACTGCAGGCCAACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGCTCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e	520
Db	1765	c	1765
RESULT 75			
US-10-125-930A-143			
; Sequence 143, Application US/10125930A			
; Publication No. US20030082687A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Deanoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			

Db 1705 CTGGCCACCAGCTGCCCTGGATGGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

Qy 520 e 520

Db 1765 C 1765

RESULT 76

US-10-127-831A-143
; Sequence 143, Application US/10127831A
; Publication No. US20030082689A1

GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME

FILE REFERENCE: P3330R1C107
; CURRENT APPLICATION NUMBER: US/10/127,831A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien

US-10-127-831A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-831A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuGlnLeuLeuTrpGlyHisLeu 20

Db 206 ATGCTCGCGCGCTCGGCCCTCTCTGCTCGCGCCCTGCTGAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGlnAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGGAGCGCGGAGCCAGAGCTGCGCAAGAGGAGCGAGGAGGCTTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACCTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGCTCCAGCTACCTGTGACGGCGGTGTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGCTAGACACCCGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAAGCGTTTCAAAGCAAGGTAAATAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGATCTGCGGAGCGGAGATTGCGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGGAGGCCCGCCAGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTTATGGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyGlnAlaHisPheAspG 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCGCGCGCGCGGCGAGCGACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCCTGAGCGCGCGCGCGCGCAACCTGTTCTGCTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGAGCAGCGCTGCTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCTCTACGCCCCCAAGGAGGCGCGCTGAAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
Db 1165 CCCTAAATATCGCCACTCTTCTTCGATGCGCATCCTGTTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGCGGCTGCCCCCAACATTTAGAGGCTCGGCGAGTGTCTATT 1344

Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGCTGAGACACCGGACCAAAATGAGCGCTAAG 565
QY 121 LysArgPheAlaIysGlnGlyAsnLysTTPtTLYsGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGGCTTTGCAAGACAGGTAAACAATGTATACAGCAGCACTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCGTGCAGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCCGACGACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCGCTGGCGCACGCTTC -CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCACCCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCTGGGCGCGGACGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTAGACTGGAGCTCTTCTCGATGCTCATCTGTAGACAGGCAACGCACTGTA 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
Db 1165 CCTAAATACTGCCACTCTTCTTCGATGCTCATCTGTAGACAGGCAACGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerle 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGTGGCGGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTrpPheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGCTGATGCTGGAGGTTCGGGGGCCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGAGGGGCGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CCGCT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTrpTrpTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGCAGGAGCTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480

Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTCGAGGCGCGGCTCCATCATCTTCTT 1644
QY 480 eArgPheArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTTGGCGCTCGACCGAGGCCAAACTGCAGGCCAACCTCGGCGCG 1704
QY 500 gTrpAlaThrGluLeuLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 79
US-10-127-842A-143
; Sequence 143, Application US/10127842A
; Publication No. US20030082692A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C100
; CURRENT APPLICATION NUMBER: US/10/127,842A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-842A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0

Best Local Similarity: 99.52% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-842A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTTCGCGCGCTCGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGGGAGCCAGAGCTGCGCAAGAGGCGGAGGCACTTCTTA 325

QY 41 GlutylsTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAATACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCGATTGACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCAGCTTACCTGTGAGCGCGGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
DB 446 GCCACCTTGCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGTGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCCCGGAGCCGCGAGTTTCGGGGCGCGTTCGCGCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGAGGTTCTGGGAGGCGCCACAGGCGCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805

QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTGCTGGTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTACACGCTTGGCTTACCCACTGCGCGCGCGCGCGCTCATGCGGCC 984

QY 260 oTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGTCTAGCTGGGAGCAGCTGCTGGCGGTGCA 1044

QY 280 nSerLeuTrpGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAGGAAGCGCCCTGAAACCGCAGG 1164

QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
DB 1165 CCCTAAATACCTGCCACTCTTCTTCCATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCACACTGCAGAAAGATGGGTGGGCTGCCGCCNACATTTAGGCTCGGCGAGTGTATT 1344

QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTTCTTCAAAAGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCCAAGCTGTGCGGGGAGGGGCTGCCGCCCATCTCTGACGC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpYrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGCGGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGGTGAGCGCGCTGCGGAGCCCGATGGCTTCATCATCTCTTCTT 1644

QY 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCAAACTGCAGCAACACCCTCGGGCCG 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACAGAGTGGCTGGATGGGTGCTGTGCATGTCACCAACTCGGGAGCGCCCTGT 1764

QY 520 e 520
DB 1765 C 1765

RESULT 80
US-10-127-843A-143
; Sequence 143, Application US/10127843A
; Publication No. US20030082693A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P333081C99
; CURRENT APPLICATION NUMBER: US/10/127.843A
; CURRENT FILING DATE: 2002-04-22
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113


```
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC93
; CURRENT APPLICATION NUMBER: US/10/127,845A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-845A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-845A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db ATGGTGGCGGGCTGGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db GACGCCAGCCCGCGAGCGCGGAGGCGCAGAGCTGCGCAAGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db GAGAGGTACGGATACCTCAATGAACAGGTCCCCCAAGCTCCCACTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
; 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACTGTCTCAGCGGGGTGTTGGACGC 445
; 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
; 446 GCCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
; 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
; 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGTAAG 565
; 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
; 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCTCCGCTGGTG 625
; 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
; 626 AACTGGCTGAGCATCTGCCGAGCGCAGTTCGGGGCGCGTGGCGCGCGCTTCAG 685
; 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
; 686 TTGTGSAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
; 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
; 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGC 805
; 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
; 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
; 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
; 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTGTGTGTGTGTGTGTGTGT 924
; 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
; 925 CGAGATCGGTACACGCTTGGCTCACCCACTCCCGCGCGCGCGCGCTCATGCGGCC 984
; 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
; 985 CTACTACAAGAGGTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
; 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
; 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGT 1104
; 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
; 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGACGG 1164
; 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
; 1165 CCCTAAATACTGCGCACTCTTCTTCATGTCATCCTCCTGTAGACAGGCAACAGCACTGA 1224
; 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
; 1225 CATTTTAAAGGGAGCCATTCTCGGAGGTGGCAGCTGATGCGCAACGCTCTCAGAGCCCG 1284
; 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
; 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1344
; 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
; 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCTCCGGGGCCCA 1404
; 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
; 1405 GCCAGTGTGGGTCTCCACACAGCTGCGCGGCGAGGGGGCTGCCCGCGCATCTCTGACGC 1464
; 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
```

Db 1465 CCGCTCTTCTTCCCTCCTCTGCGCGCCTCATCTCTTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGAGCCCTACTACCCCGGAGTCTCAGACTGGGG 1584
QY 460 yGlyIleProGluGluValserGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCCCTGCGAGGCCGATGGCTCCATCATCTCTTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCTCGACGAGGCCAACTGCAGGCCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 82

US-10-127-846A-143
; Sequence 143, Application US/10127846A
; Publication No. US20030082695A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC94
; CURRENT APPLICATION NUMBER: US/10/127,846A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985

; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-846A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conserved: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-127-846A-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTGGCGCGCTCGGCCCTCTCTGTCGCGCCCTGACAGCTCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGGAGCGCGGAGCTGCGCAAGAGGCGGAGGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTGTGTTGTAGACACCGGACCAAAATGAGGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTTACCCCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAGATGGGCTGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgPheLeuValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGGGCGCAACCTGTTCGTGGTGTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHiserProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCCCTCACCACTCGCCCCCGCGCGCGCTCATGGCGCC 984
QY 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGTCCAGCTCCAGGAAAGCTGTT 1104

```
Qy 300 eThraSpheGluThrTrpAaspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACATTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCyshHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCTACTGTAGACGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGCTGCGAGCTGATGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGTGAGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATCGAGATTCTACTTCTTCAAAGGGGTCGATGCTGGAGTTCCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGGCAGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGGCCCTGCGGAGGCGCATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAAACTGAGGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTGCTGGATGCCAATCTCGGGAGGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 83

```
US-10-127-848A-143
; Sequence 143, Application US/10127848A
; Publication No. US20030082696A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; ACIDS ENCODING THE SAME
```

```
; FILE REFERENCE: P3330R1C106
; CURRENT APPLICATION NUMBER: US/10/127,848A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-848A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-127-848A-143 (1-1985)
```

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGCTCGCGCGCTCGGCTCTCTGCTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCGCGCGAGCGCGAGGCTGGCAAGGAGGCGGAGGCAATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGCTACTGTCCAGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCAGGCAAGGTAAACAAATGGTTACAGATACCAACAGATTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAGGCAAGGTAAACAAATGGTTACAGATACCAACAGATTATCGG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGAGGCTTCGGGGCGCGGCTTCGCAG 685
```


Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGGCACACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerSerGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCCCTTGTATGCG 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGGGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGCTGCTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGGCTTACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpTyrsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCGTGGCGCGCGCGCGCTGCTCAGCTGGGAGCGAGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTGTAGAGCTGGGACTCTACAGCCGCCCAAGGAGCGCCCTCGAAACGACGG 1164
Qy 320 yProLysTyrsHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTTCTTCTGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCTCCCAACATTTAGGCTGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyValGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGACGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 GCCTCTTCTTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 CTGGCCCGAGGGGAGCTGCAAGTGAGGCCCTTACTTACCCCGAGAGTCTGAGGAGTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCGAGGAGGTGAGCGGGCGCTTCCGAGGCGCGGATGGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCCAAATGCGAGGCAACACCTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520

Db 1765 C 1765

RESULT 84

US-10-127-849A-143
; Sequence 143, Application US/10127849A
; Publication No. US20030082697A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C103

; CURRENT APPLICATION NUMBER: US/10/127,849A
; CURRENT FILING DATE: 2002-04-23

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-127-849A-143

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-127-849A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuTrpGlyHisLeu 20

Db 206 ATGTCGCGCGCGCTCGGCTCTGTCGCGCGCTCTGTCGCGCGCTGTCGCGCGCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GACGCCAGCCGCGGAGCGCGGAGCGAGCTGGCGAAGGAGGCGGAGCATTCCTA 325
 Qy 41 GlulysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAAGTACGGATACCTCAATGAACAGTCCCAAGCTCCACCTCCACTCGATTGAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGACGGCGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTCGCCACAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGTGAGAGATCAGTGACTTGTGTCTAGACACCGGACCAAAATGAGCGCTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTTCGGCGCCGCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAAGTCTCAGCGCTGGAGTTCGGGAGGCCCCCAGGCACAGGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGCTCACCCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCGCTTTGATGGC 805
 Qy 200 agLingAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 806 CAGGGGGGGCCCTGGCGCACCCCTTC-CTGCCCGCGCGCGGAGCGACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
 Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTTCACCGCTTGGGCTCACCACACTGCGCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 Db 985 CTACTACAGAGCTGGGCGCGAGCGCGTCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGAAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTCGAAACCGAGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCTTAATACCTGCCACTTCTCTCGATGCCATCAGTGTAGACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheThrTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 Db 1285 TCACCTGCAGGAAGAATGGTGGGCTGCCCCCAACATTGAGCTGCGGCGAGTGTATT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400

Db 1345 GAATGATGAGATTTCCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCATCTCTGACGC 1464
 Qy 420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCTATCTTTCAGGGTGCCTGCTACTACGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGCATCTCTGAGAGGTGAGCGGCGCTCTGCGAGGCGCGATGGCTCCATCATCTTCT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCAGATGACCGTACTTGGCGCTCGACGAGGCAAACTGCAGGCAACCACTCGGCGCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCGACCGAGTGCCTGGATGGCTGCTGGCATGCCCACTCGGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 c 1765

RESULT 85
 ; US-10-127-850A-143
 ; Sequence 143, Application US/10127850A
 ; Publication No. US20030082698A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Deenoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C110
 ; CURRENT APPLICATION NUMBER: US/10/127,850A
 ; CURRENT FILING DATE: 2002-10-15
 ; PRIOR APPLICATION NUMBER: 60/049911
 ; PRIOR FILING DATE: 1997-06-18
 ; PRIOR APPLICATION NUMBER: 60/056974
 ; PRIOR FILING DATE: 1997-08-26
 ; PRIOR APPLICATION NUMBER: 60/059113
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059115
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059117
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059122
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059184
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059263
 ; PRIOR FILING DATE: 1997-09-18

; APPLICANT: Smith,Victoria
; APPLICANT: Stewart,Timothy A.
; APPLICANT: Tuman,Daniel
; APPLICANT: Watanabe,Colin K
; APPLICANT: Wood,William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C87
; CURRENT APPLICATION NUMBER: US/10/127,851A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-851A-143

Alignment Scores:

Pred. No.:	3.35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-127-851A-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGGCTCGGCTCTCTGCTGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCGCGAGCGGAGCCGAGAGCTGCGCAAGGAGCGGAGGCATTTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGAGCTCCACCTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCTCAGCGGGGTGTGGACGCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGCACGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGGAGTACGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGTAAAG	565

Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAAGCCTTTGCAAAAGCAAGGTACAAATGGTACAGCAGCACCTCTCTCTACCGGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACCTGGCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGAGCCCGCAGCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCGGCTCACCTTCTTCCAAGGGGACCACACGATGGGCTGGGCANTGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCTTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGAGCGCACCTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCCGCGGGCGCAACCTGTCTGTGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAACGCGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCGCACCTCTCTTCGTATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTCTGGAGGTGGAGCTGTAGGCAACGCTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTGGGCTGCCCGCTCCCCCAACATTGAGGCTGCGGCAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTCTGATGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCATCTCTGAGCG	1464
Qy	420	aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTACGCGCGCGCTGCCGAGGCCCGCATGCTCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500

Db 1645 CCAGATGACCGCTACTGCGGCTCGACAGGCCAACTGCAGGCCAACCCACCTCGGGCG 1704
 Qy 500 gtrpAlaThrGluLeuProTtpMetClyCysTtpHisAlaAenSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCGCCTGTT 1764

Qy 520 e 520
 Db 1765 C 1765

RESULT 87

US-10-128-684A-143
 ; Sequence 143, Application US/10128684A
 ; Publication No. US20030082700A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C118
 ; CURRENT APPLICATION NUMBER: US/10/128,684A
 ; CURRENT FILING DATE: 2002-04-23
 ; PRIOR APPLICATION NUMBER: 60/049911
 ; PRIOR FILING DATE: 1997-06-18
 ; PRIOR APPLICATION NUMBER: 60/056974
 ; PRIOR FILING DATE: 1997-08-26
 ; PRIOR APPLICATION NUMBER: 60/059113
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059115
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059117
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059122
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059184
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059263
 ; PRIOR FILING DATE: 1997-09-18
 ; PRIOR APPLICATION NUMBER: 60/059352
 ; PRIOR FILING DATE: 1997-09-19
 ; PRIOR APPLICATION NUMBER: 60/059588
 ; PRIOR FILING DATE: 1997-09-19
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 ; US-10-128-684A-143

Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservatives: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-128-684A-143 (1-1985)
 Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTtpGlyHisLeu 20
 Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCACGCTCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGGAGCGCGGAGCGGAGGCTGGCCNAGGAGGCGGAGGCAATTCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAenGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAAGCTCCCACTCCACTCGATTTCAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTtpValSerGlnLeuProValSerGlyValLeuLeuArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTGAGCGGCGTGTGGACCCG 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTGGCCAGATGACTCTCCCGCTGGGGGTTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTtpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCAGACACCGGACCAAAATGAGGCGTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTtpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCTCTCTACCGCTGGTG 625
 Qy 141 AsnTtpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTCCGAGGCGCGAGTTCCGGGCGCGCTCGCGCCCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTtpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCACAGCCAGGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTtpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCAGCTTCTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGC 805
 Qy 200 aGlnGlyAlaProTtpArgTtpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGGCGGAGGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTtpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGCTGCGGCA 924
 Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGCGCGC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAlaLeuLeuSerTtpAspAspValLeuAlaValGl 280
 Db 985 CTACTCAAGAGGCTGGGCGCGCGCTGCTGAGCTGGGACGAGCTGCTGGCGCTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTtpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTCGAAACCGAGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValaAspArgGlnGlnLeuThy 340
 Db 1165 CCCTAAATACGTGCCACTCTCTTCGTGATGCCATCTACTGTAGACAGGCAACAGCACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTtpGluValAlaAlaAspGlyAsnValSerGluProAr 360


```
QY 220 nAspGluArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCAACCTGCTGCTGCTGGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCACACGCTTGGCCCTCACCCACTCGCCCGCGCGCTCATGTCGGCC 984
QY 260 oTyTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGAGCAGCTGCTGGCCCTGCA 1044
QY 280 nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAG 1164
QY 320 yProLysTyTyCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTTCTCTTCATGCCATCCTGCTAGCAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCAATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCGCCCTCCCAACATTTAGGCTGCGGAGTGCA 1344
QY 380 uAenAspGlyAspPheTyPhePheLysGlyArgCysTrpAspPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCTGCGCCGCTCCTGAGCG 1464
QY 420 alaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CGCCCTCTTCTTCTTCTTCTGCGCGCTCATCTCTTCAAAGGTGCGCGCTACTAC 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTrpGI 460
Db 1525 GTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGGCGCCCTGCGAGGCCGATGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGAGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGCCAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTG 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 89

```
US-10-128-690A-143
; Sequence 143, Application US/10128690A
; Publication No. US20030082702A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
```

```
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P33301R1C122
; CURRENT APPLICATION NUMBER: US/10/128,690A
; CURRENT FILING DATE: 2002-04-23
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-690A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-128-690A-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTGCGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCCAAGGAGCGGAGCATTCCTCA 325
QY 41 GluLysTyTyGlyTyTyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGCTCCCAAGGCTCCCACTCCACTCGATTCCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCGCCAGCTACCTGTTCAGCGCGGTGTGGACGCC 445
```

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCCACAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAAAGCAAGGTAAACAAATGGTACAGCAGCACTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheClyValaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCCGAGCGGAGGTTTGGGGCGCGGTGGCGCGCGCTTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTACGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCAAGGGGACCAACATGGGCTGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGGCTGGCGACGCTTC-CTGCCCGCGCGCGGCGCAACTGTTGGTGGTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValLeuAlaHi 240
Db 865 AGATGAGCGCTGTTCCCTGAGCGCGCGCGCGGCGCAACTGTTGGTGGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTGGCTCACCACCTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 ofTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCTTGGCGCGCGCGCGCTGCTGCTGAGCTGGAGCGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGNACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCAIT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCGCTGCCCGCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgGluLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460

Db 1525 GCTGGCCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCTCCCTGAGAGGTCTAGCGCGCCCTGCGAGGCCGATGGGTCCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTTGGCGCTCGACAGGCCAACTGCAGGCAACCACTTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGTCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 c 1765
RESULT 90
US-10-128-691A-143
; Sequence 143, Application US/10128691A
; Publication No. US20030082703A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C123
; CURRENT APPLICATION NUMBER: US/10/128,691A
; PRIOR FILING DATE: 2002-04-23
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-691A-143

1

! CONVOY TITLES: 2002-01-23

```

; APPLICANT: Zhang, zemin
;
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEOTIC ACIDS ENCODING THE SAME
;
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
;
; FILE REFERENCE: P3330R1C134
;
; CURRENT APPLICATION NUMBER: US/10/131,819A
;
; CURRENT FILING DATE: 2002-04-24
;

```

[illegible]

RESULT 92

US-10-131-829A-143
; Sequence 143, Application US/10131829A
; Publication No. US20030082705A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C138
; CURRENT APPLICATION NUMBER: US/10/131,829A
; CURRENT FILING DATE: 2002-04-27
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-829A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-829A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGTCTGGCTCTGCTGCGCGCCTGCACCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGlnArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACCGCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGCGGCATTCCTA 325

QY 41 GluLysTrpGlyTrpLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCCAAGTACCTGTGTCAGGGCGGTGTGGACCC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
DB 446 GCCACCTGGCCAGATGACTGCTCCCGCTCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCCGAGCGCGAGTTCGGGGCGCGCTGGCGCCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCAGCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTCAAGGGGACCAACAGATGGGCTGGGAATGCTTGTATGTC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGTTGTCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGG 984
QY 260 cTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGGGCGCGCGCTGCTCAGCTGGGAGCGCTGCTGGCGTGA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGGAACCGCAGGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCATAAACTGCGCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
DB 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCGCCCAACATTCAGGTGGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheThrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATCGAGATTTCTACTTTCTTCAAGGGGGGTGATGCTGGAGGTTCGGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420


```
Db 985 CTACTACAAGAGCGCTGGCGCGACGCGCTGCTCAGCTGGGACGAGTGTCTGGCCGTGCA 1044
Qy 280 nSerLeuTyrGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGACCCCTAGGGGCTCAGTGGCGGTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgA:gpProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCGCCAAGGAAGGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTAGAGCCCG 1284
Qy 360 gProLeuGlnGluA:gtTpValGlyLeuProProhenlleGluAlaAlaValSerle 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyCysTrpArgPheArgGlyProIly 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAGGGGGTGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCCCTGCCCCGCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGAGCGGCGCCCTGCCGAGGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 94
US-10-146-729-143
; Sequence 143, Application US/10146729
; Publication No. US20030082708A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
```

```
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zenin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P330R1C318
; CURRENT APPLICATION NUMBER: US/10/146,729
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-146-729-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-146-729-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTGGCGCGCTGGGCTCTCTGTGGCGCCCTGACGTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCAGCCCGCGAGCGCGGAGCCAGAGCTGCCAAGGAGCGGAGGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCAAAAGTCCACACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACCGCTTTCAAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGTGGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGAGCGCATTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTGCTGGTGGTGGCGCA 924
```

```
Qy 240 sGluIeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCAACCACTCGCCGCGCGCGCGCTCAATGGCGCC 984
Qy 260 oTyTyriysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGACGCGCTCTCAGCTGGGACGACGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyriGlyysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyriSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTCAGACCTGGGACTCTCAGACGCCCAAGGAAGGCGCCCTGAACGCGAGG 1164
Qy 320 yProIysTyriCyHeHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACGGCAACGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProbsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyriPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCATGCTGGAGGTTCCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCyArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCGGCCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyriVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCCGCTACTAGT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyriTyriProArgSerLeuGlnAspTrpG1 460
Db 1525 GTTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyriTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCGCTACTGGCGCTCGACGAGGCCAACTGCAAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 95

```
US-10-146-791-143
; Sequence 143, Application US/10146791
; Publication NO. US20030082709A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
```

```
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C320
; CURRENT APPLICATION NUMBER: US/10/146,791
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-146-791-143
```

```
Alignment Scores: 3.35e-262 Length: 1985
Pred. No.: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

US-10-791-980-6 (1-520) X US-10-146-791-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGGCGCTCGGCCTCTGCTCGCGCCCTGCAGCTGTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACCCCGAGCCCGCGAGCGCGGAGCGCAGAGCTGCGAAGAGGGGAGGCGATTCCTA 325
Qy 41 GlulysTyriGlyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTCTGTGCGGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyriAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyriLysGlnHisLeuSerTyriArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGAGTCTGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTCTTGTGGAGGGCCCCAGCCACAGGCCCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAAGGGGACCAACAGTGGGCTGGGCAATGCCCTTGTATGGC 805
```


Db 686 ITGTGGAGCAACGCTCTCAGCGCTGAGGTTCTGGAGGCCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLySgLyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTTCTTCAAGGGGACACAAACGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTArpArpThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArpTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCCCTCACCACTCGCCCGCGCGCGCGCTCATGGGCGCC 984
Qy 260 oTyTrLySArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGGAGCGCGCTGCTCAGCTGGGACGACGTGTCGGCGTGCA 1044
Qy 280 nSerLeuTyArgLySProLeuGlyGlySerValAlaValGlnLeuProGlyLySLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCAAGAAAGGCGCCCTGAAACGCGAGGG 1164
Qy 320 yProLySvTyCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTTCTTCGATGCCATCTACTGTACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLySgLySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLeuLySgLyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTCTGCTGGAGGTTCCGGGCCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGCCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLySgLyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGCGCGCTGCCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLySLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGCGCGCTCGACAGGCAAACTGCAGGCAACCACTTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCySerTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCCAACCGAGTGGCTGATGGGCTGTGGCATGTCCACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520 |

Db 1765 C 1765
RESULT 97
US-10-147-508-143
; Sequence 143, Application US/10147508
; Publication No. US20030082711A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C330
; CURRENT APPLICATION NUMBER: US/10/147,508
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-508-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-147-508-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLySgLyAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGGAGCGCGGAGCGCGAGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325
Qy 41 GluLySvTyArgTyTrLeuAsnGluValProLySgAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACCGATACCTCAATGACAGGTCCCNAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGCTACCTGTCCAGCGCGGTGTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCCCTGGCGCAGATGACTGTCCTCCCGCTGGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLySvMetArgLyS 120
Db 506 GCTGGGCTGAGAGATCAGTACTGTTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLySgGlnGlyAsnLySvTyTrpTyLySgGlnHisLeuSerTyArgLeuVal 140

Db 566 AAACGCTTTTCAAGCAAGGTAAACAATGGTACAAGCAGCACCTCTCTTACCGCCTGGTG 625
Qy 141 AenTrrpGluHleu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGGAGCACTCTGGAGCGCGGAGTTTCGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnAtrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerGlyThrThrThrMetGlyTrrAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCCTTCTTCAAGGGGACCAACGATGGCTGGCAATCCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrrpAtrpThrProPheLeuProArgArgGlyGluAlaHiPheAspGl 220
Db 806 CCAGGGGGCGCTTGGCGCACCGCTTC-CTGCCCCCGCGGGGCAACCTTCTGCTGGTGGCGCA 864
Qy 220 nAspGluAtrpTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGCAACCTTCTGCTGGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTCAACGCTTGGCTTCAACCACTCGCGCGCGCGCGCTCATGCGCGC 984
Qy 260 oTrrYrLysAtrGluGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGCGCGGACCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGA 1044
Qy 280 nSerLeuTrpGlyLysPheLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGCTGGGACTCTTACAGCCGCCCAAGGAGCGCGCTTGAACACGAGG 1164
Qy 320 vProLysTrpCysHisSerPheAspAlaThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTTCTTGGATGCCATCTCTAGTGGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnAlaTrpValGlyLeuProProLeuGlnGlyAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCCCAACATTGAGGCTGGCGCATGTCTATT 1344
Qy 380 uAenAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACACACTGTGGCGGCGAGGGGCTTCCCCGCCATCTCAGCGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCGCGGAGGGGACTGCAAGTGGAGCCCTTACTACCCCCGAACTGTGAGGATGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCTTGGCGAGGCGCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCCAGGCCAAACTGCAGGCAACCACTTCGGGCGC 1704

Qy 500 gTrpAlaThrGluLeuProTrrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 98

US-10-147-512-143
; Sequence 143, Application US/10147512
; Publication No. US20030082712A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C332
; CURRENT APPLICATION NUMBER: US/10/147,512
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-512-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-512-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGGCGCGCTGGGCTCTGTCGGCGCCCTGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGGCATTCTCTTA 325
Qy 41 GlulysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACGACTACCTGTTCAGCGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATCGC 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCCTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGACCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCGAGCGCGCAGTTCGGGGCGCGTGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGTTCTGGGAGGCGCCAGCCAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTGCTGGTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 ofTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTGGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACCTGCCACTCTCTCTCGATGCCATCATCTGTAGACAGGCAACGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGCTGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTTCCACACACTGTGCGGGCAGGGGGCTTGGCCCCGCCATCTGAGCG 1464
QY 420 alaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTCAAGTGGAGCCCTACTACCCCCGGAAGTGTGAGGACTGGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCCCTCTGAGAGGTGAGCGGCCCTTCGCCGAGCCCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTGGCGCTCGACGAGGCCAAACTGCAGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGSCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 99
US-10-175-735-143
; Sequence 143, Application US/10175735
; Publication No. US20030082715A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Garritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C451
; CURRENT APPLICATION NUMBER: US/10/175,735
; CURRENT FILING DATE: 2002-06-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-175-735-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-175-735-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGTCAGCTGTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGCTGCGAGCTGCGAGAGGAGGCGGAGGCGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCATGAACAGGTCCCCAAGCTCCCACTCCACTCGATTACG 385

Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTCTGAGCGCGTGTGGACGCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCCCAGATGACTCGTCCCGCTGCGGGGTTCAGATATCCAAAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTTTCTGACACACCGACCACAAATGAGGCGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCCTACGCGCTGGT	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AAC'TGGCCTGAGCATCTCCCGGAGCGGCGAGTTGCGGGCGCGTGGCGCGCTTCACG	688
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGGAGGCCCCAGCCACAGAGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACTTCTTCCAAAGGGAGCCACAACAGATGGCTGGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACCGCCTTC-CTGCCCCCGCCGCGGCGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGGCGCAACCTGTCTGTGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGTGGCGCGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysrValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CAC'TGACTTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCA	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTTAAATACTGCCACTTCTCCTTCGATGCCATCACTGTAGCAGGCAACAGCAACTGT	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCACTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTGGGCTGCCCCCAACATTCAGGCTGCGGCAGTGCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGCATGCTGTGAGGTTCGCGGGCGCC	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyCylLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCATCTCTGACG	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440

```

Db 1465 CGCCCTCTTCTTCCTCTCTGGCGCGCCTCATCTCTTCAAGGGTGCCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGI 460
Db 1525 GCTGGCCGAGGGGAGTGAAGTGGAGCCCTACTACCCCGAAGTCTGCAGACTGGGG 1584
QY 460 yGlyleProGluGluValSerGlyAlaLeuProArgProAspGlyserIlelePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGCGCGCCCTGCCAGGCGCGATGGCTCCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCAAGGCCAAACTGCAGGCAACCACTCGGGCCG 1704
QY 500 gTTPAlaThrGluLeuProTrpMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTCTGGCATGCCAATCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 100
US-10-121-040-143
; Sequence 143, Application US/10121040
; Publication No. US20030082759A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C7
; CURRENT APPLICATION NUMBER: US/10/121,040
; CURRENT FILING DATE: 2002-04-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-121-040-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-121-040-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGIHisLeu 20
Db 206 ATGTCGCGCGCGCTGGCCCTCTCTGCGCGCCCTGCAGTGTCTACTGTGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40

```

Db 266 GACGCCAGCCGCGGAGCGCGAGGCTGCGCAAGGAGCGCGGATTCCTA 325
Qy 41 GlnlystYrGlyTyrLeuansGlnValProlysaAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACATTCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTACAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCACAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTGTGTGTGTGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGAAAGCAAGATTAACAAATGGTACAGACGACCTCTCTACCGGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGTTCGCGCGCTTCACG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGAGGTTCCTGGAGGGCGCCACAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTCCAGAGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProThrArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACAGCTTGGCTCACCACATCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGAGCCCGGAGAGGGCGCTGAAAGCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCGCCACACATTGAGGCTGGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400

Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTCGATGCTGGAGGTTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGCAAGGGGCTGCCCGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCCCTCATCTCTTCAAAGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGCGCGCTGCGAGCGCCGATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
Db 1645 CCNAGATGACCGTACTTGGCGCTCGACAGGCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 c 1765

RESULT 101
US-10-121-056-143
; Sequence 143, Application US/10121056
; Publication No. US20030082760A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deenoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C25
; CURRENT APPLICATION NUMBER: US/10/121,056
; CURRENT FILING DATE: 2002-04-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-121-056-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15

US-10-791-980-6 (1-520) x US-10-121-056-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGTGGCGCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACCGCCGCGAGCGCGAGCGCAGGAGCTGCGCAAGAGCGCGGAGCAATTCCTA 325
QY 41 GluLysTrpGlyTrpLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCATCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGACGTTTCAGTGGGTGTCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTACTGTTTGTGTAGACACCGGACCAAAATGAGGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGAGAGTAAACAAATGTTACAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTCTTCCAAAGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTTGGCGCAGCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGTTGGTGTGTCGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 cTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAAGGCTGGCGCGCGACGCGCTGTCTAGCTGGGACGAGCTGTGGCGCGTCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCGTGTATGGAAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTCAGCCCCCAAGGAGGGCGCCCTGAAACCGCAGGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
DB 1165 CCCTAAATACGCCACTCTTCTTCGATGCCATCTACTGTAGACGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTITTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCCTCAGAGCCCCG 1284
```

```
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGAGGANAAGATGGGTGGGCTGCCGCCCAACATTGAGGGTGGGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGAGGGGTGCGATGCTGGAGGTTCCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCGAGGGCCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 102

US-10-121-061-143

; Sequence 143, Application US/10121061

; Publication No. US20030082761A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330P1C24

; CURRENT APPLICATION NUMBER: US/10/121,061

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-121-061-143

Alignment Scores:

Pred. No.:	3.35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	99.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-121-061-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTGTCGCGCGGTTCGGCTCTCTGTGCGCGCCCTGCAGCTGTCTACTGTGGGCGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCCGGAGCGCGAGCCGAGAGCTGCGCAAGAGAGCGGAGGAGATTCCTTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAAAGCTCCCACTCCACTCGATTTCAG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCCACTGTCTCAAGCGCGCTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTCGCCACATGACTGTCTCCCGCTGCGGGGTTCAGATACCAACAGTTATGGC	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGCTGACGAGATCAGTACTTGTGTCTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAAACAAATGSGTACAAAGCAGCACCTCTCTACCGCCTGTGGT	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer	160
Db	626	AACTGGCTTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGGTGCGCGCGCTTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuThr	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCCTGGGAGGCCCCACGCCACAGCCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGCTCACCCTCTTCCAAGGGGACCACAAACATGGGCTGGGCAATGCTCTTGTATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln	220
Db	806	CNAGGGGGCGCCCTGGCGACGCTTC-CTGCCCGCGCGGCGAGCGGACCTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGTCCTCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTCTGCGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATTCGGTCAACGCTTGGCCCTCACCCACTCGCCCGCGCGCGCTCATATGGCGGC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln	280
Db	985	CTACTACAAGAGGCTGGGCGCGGACGCGCTGCTCAGCTGGGAGCGAGCTGCTGGCGGTGCA	104
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGATGGAAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCACAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGln	320
Db	1105	CACTGACTTTGAGACTCGGACTCTCAAGCCCCCAAGGAGGCGGCTGTAACACGCGAGG	1164

Qy	320	yProLysTyCyGHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATATGCGCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheHtrpGluValIaIaAspGlyAsnValSerGluProAr	360
Db	1225	CAITTTTAAAGGAGGACATTTCTGGAGAGTGGGAGCTGATGGCAACGCTCTCAGAGGCCCG	1284
Qy	360	gProLeuGlnGluArGTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGCCGAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyPhePheLysGlyArgCyStrpArgPheArgGlyProby	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCCAAGCTGTGCCGGGCGAGGGGCGCTGCCCGCCATCCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCCTCTGGCGCGCCTCATCTCTTCAAGGGTGCCTGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTCAGAGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCTCCCTGAGAGGCTCAGCGGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspAtqTyTTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTCGACAGGCCAATTCAGAGGCAACCCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCyStrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	a 520	
Db	1765	C 1765	
RESULT 103			
US-10-123-235-143			
; Sequence 143, Application US/10123235			
; Publication No. US20030082762A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Desnoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; FILE OF INVENTION: ACIDS ENCODING THE SAME			
; FILE REFERENCE: P3330R1C27			
; CURRENT APPLICATION NUMBER: US/10/123,235			
; CURRENT FILING DATE: 2002-04-15			
; Prior Application removed - See File Wrapper or Palm			
; NUMBER OF SEQ ID NOS: 550			

; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-235-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-235-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTGGCGCGGTGGCGCTCTGCTGGCGGCGCTGCAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGGCCCGCGCGAGCGCGAGGCCAGAGAGCTGCCGACGAGCGCGGAGCGGAGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCCACTCGATTGACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACCTGTGAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTGTCTCCCGCTGGGGTTACAGATACCAACAGTATTGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTGAGAGGATCAGTACATTGTTTGTAGACACCGGACCGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCGCTTTGCAAGCAAGGTAAACAAATGGTAAAGCAGCACCTCTCTTACCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTACGATCTCGGAGCGCGGAGTTCGGGGCGCGCTGGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACAGGCGCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCCCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCGCTGGCGCACGCCCTTC-CTGCGCGCGCGCGGAGCGGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTTCACGCTGGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
```

```
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCGCAAGGAAGCGCCCTTGAACCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCCACTCTTCTTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGCTGTCAGTGCACAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGAATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCATGTGCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGCTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 aProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCGCTGCCCGCCATCCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTCAGCGGCGCTGCCGAGGCGCGATGGCTCCATCATCTCTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTTGGCGCTCGACAGGCGCAACTGCAGGCAACACCATCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTTGGATGGGCTGTGGCATGCCAACTCGGGAGGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 104

US-10-124-818-143
; Sequence 143, Application US/10124818
; Publication No. US20030082763A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

```
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC62
; CURRENT APPLICATION NUMBER: US/10/124,818
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-818-143

Alignment Scores:
Pred. No.:      3,356-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              15          Gaps:      0

US-10-791-980-6 (1-520) x US-10-124-818-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGGTCTCTCTGCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGGAGCGGAGCCGAGAGCTGCGCAAGAGGCGGCGGCAATTCCTA 325
Qy 41 GlutysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCATGAACAGGTGCCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGAGCTACCTGTGCGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTTCGCGCAGATGACTGTCTCCCGCTGCGGGGTGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTpaAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGGTTCGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlnArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTCTTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCGCTTGGCGACGCCCTTC-CTGCCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGCTGCCGA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
```

```
Db 925 CGAGATCGGTACACAGCTTGGCCTCACCCACTCGCCGCGCGCGCGCTCATCGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGCGACGCGCTGCTCAGCTGGGAGCAGCTGTGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCGCCCAAGGAAGCGCGCTGAAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATATGCGCACTCTTCCTTCGATGCCATCCTGTTAGACAGGCAACAGCACTGA 1284
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAAGAAAGATGGGTGCGGCTGCGCCGCCCAACATTTGAGGCTGCGCAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCTGCGCGCCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGCTCTGAGGAGCTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACAGCGCGCCCTGCGGAGCGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCAAGGCCAAACTGCAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAATCTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 105
US-10-137-868-143
; Sequence 143, Application US/10137868
; Publication No. US20030082764A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
```


US-10-147-492-143
; Sequence 143, Application US/10147492
; Publication No. US20030082765A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForse, Laura

```
; APPLICANT: Desnovers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zenin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC347
; CURRENT APPLICATION NUMBER: US/10/147,492
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-492-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-492-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu 20
Db 206 ATGTGCGCGCGCTGGGCTCTCTGCGCGCCCTGCGAGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGGAGCCAGAGCTGCGCAGAGGCGGAGGCATTCTTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGAGCTACCTGTGCGCGCGTGTGGACGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTGCTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGCTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCCTTGCAAGCAAGGTAACAAATGGTACAGCAGACACCTCTCCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGCCAGATTGCGGGCGCGGTGGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGGAGGCCCAAGCTCGGAGCGCCCGCTGAC 745
```

```
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACGATGGGTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGGCGCAGCCTTC-CTGCCCGCGCGGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGCGCTGGTCCCTGAGCCCGCGCGGGCGCAACCTGTTCTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGCCCTCACCCACTGCCCCCGCGCGCGGCTCATGGGCGC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCAGCGCTCTCAGCTGGGACGACGTGTCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACCTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCCTGAAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACCTCTTCTTCGATGCATCCTCAGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAAAGATGGGTGCGGCTGCCCCCCCAACATTGAGGCTCGGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTTCTCAAAGGGGTGCGATGCTGGAGGTTCGCGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGGCGAGGGGCGCTGCCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTCAGAGAGTCCAGCGCGCCTGCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTTCGACCGGCCCAACTGCAGCGCAACCACTCTGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGTCGATGTCGAACCTCGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 107

US-10-158-782-143
; Sequence 143, Application US/10158782
; Publication No. US20030082766A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; CURRENT APPLICATION NUMBER: US/10/158,782
; CURRENT FILING DATE: 2002-05-30
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; Prior Application remove - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-158-782-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-158-782-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGGTCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACAGCCCGCGAGCGCGGAGCGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCACGACTACCTGTCCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGGAGTACGTGACTGTGTTGTACACCGGACCCAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCCAAGCAAGGTAACAAATGGTACAGCAGCAGCCTCTCTACCGCCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTACGATCTCGCGAGCCGGAGTTTCGGGGCGCGTTCGCCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGAGGCCCCACAGCCACAGGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTCCAAAGGGGACCAACGATGGGCTGGCAATGCTTGTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTTGGCGCACGCCCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCGCAACCTGTTCTGGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACGCTTGGCTTCCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCACAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAGAGGCGCCCTGAAACCGCAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACGTGCACACTCTCTCTCGATGCCATCCTATAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGAGCCATTCTGGGAGTGGCAGCTCATGGCAACGCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCCCTGCCCGCCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCGGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGAGGTGAGCGGCGCTGCGCGAGGGCCGATGGCTCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCCTCGACAGGCGCAAACTGCGAGGCAACCACTCGGGCGG 1704

```
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTrpHisAlaAdeSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 108
US-10-123-905-143
; Sequence 143, Application US/10123905
; Publication No. US20030087344A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Laureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C48
; CURRENT APPLICATION NUMBER: US/10/123.905
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-905-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-905-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCATGACAGGTCCCAAGCTCCACCTCCACCTCGATTACG 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACCTGTGCAGCGGCGTGTGGACGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
```

```
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAGCTTTGCNAAGCAAGGTACAAATGGTACAAAGCAGCACCTCTCTCAACCGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCCGCGGAGTTTCGGGGCGCGCTGCGCGCGCTTCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGAGCCCCAGCAGGCCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTTCTGTGGTGTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCTTCCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCACGCGCTGTCTCAGTGGGACGACGTGTGGCGGTGCA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCGCTGAACCGCAGG 1164

Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATATCTGCCACACTCTTCTTCGATGCCATCCTCTGTAGACAGGCAACAGCAACTGT 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGTATGGCAACCTCTCAGAGCCCCG 1284

Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACATCAGGAAAGATGGGTGCGGCTGCCCGCCCAACATTTGAGGCTGCGGCGAGTGTCA 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTCGATGTGGAGGTTCGCGGGCCCCCAA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCGCGCCCATCTGACGC 1464

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCTCTCTGCGCGCCTCATCTCTTCAAAGGGTCCCGCTACTACGT 1524

Qy 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTCCCCCGAAGTCTGCAAGAGCTGGGG 1584

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
```

Db 1585 AGGCATCCCTGAGGAGTTCAGCGGCGCCCTGCGGAGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eargAspAaPqTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAAACTGCAGGCAACACCTCGGGCGG 1704
Qy 500 gtrpAlaThrGluLeuProTirMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAATCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 109

US-10-123-907-143
; Sequence 143, Application US/10123907
; Publication No. US20030087345A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Bersini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC50
; CURRENT APPLICATION NUMBER: US/10/123,907
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-907-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-907-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGGCGGCTCGGCTCTCTGCTGCGGCGCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGGAGCGCGGAGCTGCGCAAGAGCGCGGAGCAATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACATTCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCATCAGAGCGTTCAGTGGGTGTCCAGCTACCTGTTCAGCGGCGGTGTTCAGCCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCCGCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGGCTGAGAGGATCAGTACCTTGTCTAGACACCGGACCAAAATGAGGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCGCGAGCGGCAGTTCGGGGCGCGCTGCGCGCCCTTCACG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyVArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCCTGGGAGGCCCCAGCCACAGGCCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
Db 746 ATCCGGCTCACCTTCTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyVArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGCTCCCTGAGCGCGCGCGGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr 260
Db 925 CGAGATCGGTACACCGCTTGGCCTCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGCGCGCTCTCAGCTGGGACGACGCTGTCGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTCAGACCTGGGACTCCTACAGCCCCCAAGGAGGGCGCCCTGAAACCGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCAATTTCTGGAGGTGGCAGCTGATGCGCAACGCTCTAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGCGGCTGCCCCCCCAACATTGAGGCTGCGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGCGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440

```
Db 1465 GCGCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTTCAAGGGTGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGGACTGCAAGTGTGAGCCCTACTACCCCGAAGTCTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGGGGGCCCTGCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCCTCGACGAGCCAAATCGCAGGCAACCACTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAAGAGTGGCTGGATGGGTCTGGTCATGCCAATCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 110
US-10-124-815-143
; Sequence 143, Application US/10124815
; Publication No. US20030087346A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumanabe, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC57
; CURRENT APPLICATION NUMBER: US/10/124,815
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-815-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-124-815-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGGCTGGGCTCTCTGCTGGCGCCCTGCAAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
```

```
Db 266 GAGCCCCAGCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGTGTCCCAAAAGCTCCCACTCCATCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGGTACTGTACAGCGCGGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATGACTGTGTCGCCGTGTGGGGCTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATAGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAAAGCAAGGTACAAATGGTACAAAGCAGCACCTCTCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGGTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGTGGAGGCCCGCAGCCAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCACACGATGGGTGGGCAATGCTTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCGCGCGCGCGGCGAAGCGACATTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlyArgGlyValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGGCGCAACTGTTCTGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCCTCACCACTCGCCCGCGCGCGCTCATGCGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCAGCGCTGTCTCAGCTGGGAGCAGCTGTGTCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGTCCAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCGCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCGCACCTCTTCTTCGATGCGCATCAGTGTAGACAGGGAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGCAGAAAGATGGGTGCGGCTGCCCGCCCAACATGAGGCTGCGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
```



```
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGCCATCTTGACGC 1464
QY 420 alaAlaPhePheProProLeuArgArgLeuLeuPheLeuGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lleAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCGAGGGGACTGCAGTGGAGCCCTACTACCCCGGAGTCTCAGGACTGGGG 1584
QY 460 YGlyLeProGluGluValserGlyAlaLeuProArgProAspGlySerileilePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCCGAGGCCGATGGCTCATCTCTTCT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCCTCGACGAGGCCAACTGCAGGCCAACCCCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 111
US-10-125-921A-143
; Sequence 143, Application US/10125921A
; Publication No. US20030087347A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: DeSini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC76
; CURRENT APPLICATION NUMBER: US/10/125,921A
; PRIORITY FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
```

```
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-125-921A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-125-921A-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGCTGCGCGCTGCACTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGGCCAGCCGCGGAGCGCGGAGCTGCCAGAGCTGCCAGGAGCGGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTCTAGACACCGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAGAGCAAGGTAAACAAATGGGTACAGCAGCACCTCTCTACCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCCGCGAGTTTCGGGGCGCGCTGCCGCGCGCTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCAGCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCGCTCACCTTTCTCAAGGGGACCAACAGATGGGCTGGGCAATGCGCTTGTATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGTTGCTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
```

```
Qy 260 oTyrTyrLysArgLeuGlyValArgAspAlaLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGGACCGCTGCTCAGCTGGACGACGCTGCGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValalaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGlnThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCyshisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValalaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCANAGGGGTGATGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 aProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGGCAGGGGCTGCCCGCCATCCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 GCCTCTCTTCTCTCTCTCTGGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGAGCTGGG 1584
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGCGGCGCTGCCAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGGCGCTCGACCGCCAAACTGCGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 112

US-10-125-928A-143

; Sequence 143, Application US/10125928A

; Publication No. US20030087349A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

```
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C77
; CURRENT APPLICATION NUMBER: US/10/125,928A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-125-928A-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-125-928A-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTGGGCTCTCTGTCGCGCCCTGCTGCTGCTGCTGCTGCTGCTGCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCG 325
Qy 41 GluLysTyrGlyTyrLeuLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGAGTACCTCAATGAACAGTCCCCAAAGCTCCCACTCCACCTCCATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGCTACCTGTGAGCGCGGTGTTGAGCCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaThrAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
```

Db 566 AAACGCTTTTCAAGCAAGGTATCAAAATGTTATCAAGCAGCACTCTCTTACCGCCTGGTG 625
Qy 141 AenTtpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCCTAGCATCTCGCGAGCCGCGAGTTCGGGGCGCCGTGCGCCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTpsSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerIysGlyThrThrThrMetGlyTtpAlaMetProLeuMetAl 200
Db 746 ATCCGCGCTCACCTTCTTCAAGGGGACCAACGATGGGCTGGCAATGCCCTTTCATGCG 805
Qy 200 aGlnGlyAlaProTtpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCCCGCGGCGCACTTCGACCA 864
Qy 220 nAspGluArgTtpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCACTTTCGTGGTCTCGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTACACGCTTGGCTCACCCACTCGCCGCGCGCGCTCATGGCGCC 984
Qy 260 ofTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTtpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCGTGGCGCGCGCGCTGTCTCAGCTGGGACGACGTCTCGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCATGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTtpAspSerTysSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGCGGACTCTTACAGCCGCCAAGAGGCGCCCTGAAACGCAAGG 1164
Qy 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTCCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTtpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCATTCTGGAGGTGCGACGTGATGCAACGCTCTCAGACCCCG 1284
Qy 360 gProLeuGlnGluArgTtpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAAGATGGTCCGCTGCCGCCCAACATTGAGGCTGCGGCGAGTCTCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheIysGlyIysArgCysTtpArgPheArgGlyProIy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 eProValTtpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCGCCCAATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgGluIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTGCGCGCGCTCATCTCTTCAAGGTGCGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTtpGl 460
Db 1525 GTGTGCCCGAGGGGAGCTCAAGTGGAGCCCTTACTACCCCGAAGCTCTCAGGAGCTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGAGGTCAGCGCGCTTCCGAGGCCGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTtpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTtpAlaThrGluLeuProTtpMetGlyCysTtpHiAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 113
US-10-127-821A-143
; Sequence 143, Application US/10127821A
; Publication No. US20030087350A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC92
; CURRENT APPLICATION NUMBER: US/10/127.821A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 143
; NUMBER OF SEQ ID NOS: 550
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-821A-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0


```
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-822A-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-822A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGGCGCGTTCCTGCTCGCGCGCTGCAGCTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgGlyGluAlaPheLeu 40
Db 266 GACGCCCGCGCGAGCGCGAGGCCAGGAGCTGCGCAAGAGCGCGAGGCATTTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGTTTCAGTGGGTGTCCTCCAGCTACCTGTGAGCGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTTTACAGATACCAACAGTTATGCG 505
QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgGlyLys 120
Db 506 GCTGGGCTGAGAGGATCAGTACATGTTTGTGTAGACACCGGACCAAAATGAGCGTAAAG 565
QY 121 LysArgPheAlaLysGlnLysAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCTTTGCAAGCAAGGTAAACAAATGGTACAGAGCAGCCTCTCTACCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGAGCAACGTCCTCAGCGCTGAGATTCTGGAGGCGCCACAGCCAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTCATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCGCTCGCGCAGCCCTTC-CTGGCCCGCGCGCGGCGGAGGCGCACTTCGACCA 864
```

```
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGTTGCTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTACACCGCTTGGCTTCACGCACCTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 cTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGCGAGCGCTGCTCAGCTGGGAGCGCTGCTGGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCGCCCAAGAGCGCGCTGAAACGCGCGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCGCACTCTCTTCGATGCCATCACTGTAGACAGGCAACACGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGTGCGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCGGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 CTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGGCTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyValLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCGAGGAGGTGAGCGGCGCTGCGGAGGGCCGATGGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCGCAAACTGCGAGGCAACACCTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCGCTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 115
US-10-127-824A-143
; Sequence 143, Application US/10127824A
; Publication No. US20030087352A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
```


Db 1525 GCTGGCCCGAGGGGACTCAGTGGAGGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGGAGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCGCTACTGCGGCTCGACCGAGCCAACTGCAGGCAACCCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGATGCCAACTCGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 116

US-10-127-826A-143
; Sequence 143, Application US/10127826A
; Publication No. US20030087353A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC90
; CURRENT APPLICATION NUMBER: US/10/127,826A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-826A-143

Alignment Scores:

Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-127-826A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpClyHisLeu 20
Db 206 ATGTGCGCGCGCGCGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGGAGCGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGAATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGACTACCTGTGAGCGCGGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATCAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGACACCTCTCTCCACCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysValaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGAGCGCGAGCTTGGGGCGCGCTGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGCGGAGCGCCCGCCAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCCCGCGCGCGCAACCTGTTCGTGGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCTTCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAGGCGCCCTGAAAGCGAGGG 1164

```
Qy 320 yProlystYrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACAGCCACTTCTTCGATGCCATCACTGTACAGAGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGCTCGGCCCTGCCCAACATTGAGGTGGCAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGCGGGGACTGCAAGTGGAGGCCCTACTACCCCGCAAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTTCCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGTCGCGCTCGACCGCCAAATGCGAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGATGGGCTGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 117
US-10-127-827A-143
; Sequence 143, Application US/10127827A
; Publication No. US20030087354A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Bersini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC83
; CURRENT APPLICATION NUMBER: US/10/127,827A
; CURRENT FILING DATE: 2002-10-16
; PRIOR APPLICATION NUMBER: 60/049911
```

```
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-827A-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-827A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGGCGGTGCGGCTCTCTGTCGGCCCTCGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGCGCGGAGCGCGGAGCGCAGAGCTGCGCAAGGAGGCGGAGGCGCATTCCTA 325
Qy 41 GlulysTyTrpGlyLeuLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCCACTCCGACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGCGCTTTCAGTGGGTGTCCAGCTACTCTGTGCGGGGCTTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyTrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGTCGCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTCTTAGACACCGGACCAAAATGAGGCGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTyTrArgLeuVal 140
Db 566 AACCGCTTTCGAAAGCAAGGTAAACAAATGGTACAGAGCAGCCCTCTCTCCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCGTGGAGGCGCCCGCAGCCAGGCGCCGCTGAC 745
```


Db 326 GAGAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCACCTCCATCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTCGGCTGAGAGATCAGTACCTGTTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCGCTTTCGAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTTCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCGGGAGGCCACGACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 agLinglyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGCGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCCTCAGCGCGCGCGCGCGCAACCTGTTCTGGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTAAGAGGCTGGCGCGCGCGCTGCTAGCTGGAGCAGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGGCGCTGAAACGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATCTGCCACTCTTCTTCGATGCCATCTACTGTAGACAGGCACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAGGAGGACCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATGAGCTCGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGTGCTGATGCTGGAGGTTCGGGGGCCCCAA 1404
Qy 400 pProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGGAAAGTCTGCAGGACTGGGG 1584
Qy 460 YGlvileProGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480
Db 1585 AGGATCCCTGAGAGAGTCAAGGGCGCTGCGGAGGCCCGATGGCTTCATCTCTTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 119
US-10-127-830A-143
; Sequence 143, Application US/10127830A
; Publication No. US20030087356A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C112
; CURRENT APPLICATION NUMBER: US/10/127, 830A
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19


```
; APPLICANT: Wood,William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C109
; CURRENT APPLICATION NUMBER: US/10/127,832A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-832A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-832A-143 (1-1985)
```

```
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGAGCGCGGAGTTTCGGGGCGCCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGAGCCCGCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGGGCGACGCGCTTC-CTGCCCGCGCGGGGAGGAGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalApr 260
Db 925 CGAGATCGGTACACGCTTGCGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGGACGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
Db 1165 CCCTAATACTGCGCATCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTTCTACTTCTTCAAAGGGGTTCGATGTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGCGGAGGGGCGCTGCCCGCCCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCTCTCTGGCGCGCCCTCATCTCTTCAAAGGGTCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTACGCGCGCTTCCGAGGCGCGGCTCCATCATCTCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGTACTTGGGCGCTCGACAGGCGCAACTGCGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
```


Db 1705 CTGGGCGACCGAGCTGCTGGATGGCTGCTGGCATGCCAACTCGGAGCGCCCTGTT 1764

Qy 520 e 520
Db 1765 c 1765

RESULT 121

US-10-127-833A-143
; Sequence 143, Application US/10127833A
; Publication No. US20030087358A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C95
; CURRENT APPLICATION NUMBER: US/10/127,833A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-833A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-833A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

Db 206 ATGTGCGCGCGCTCGGCTCTGCTGCGCGCCCTGCACTGCTACTGTGTGGCGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGCGCGAGCGCGAGCGAGAGCTGCGCAAGGAGCGCGAGGCAATTCCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCATGAAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTCAGTGGGTGTCACAGCTACCTGTGTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTGCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCAGACCCGACCCGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCCAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTACGATCTCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTGGAGAGGCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTCTCCAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAACCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGGAAGGGCCCTGAAACCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTGCGCACCTCTCTCGATGCGCATCACCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGAGCTGATGGCAACGCTCCAGAGCCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380

Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAATT 1344
Qy 380 uasnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGCGAGGGGCTGCCCCGCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGGCGCCCTGCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACACAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCCTGATGGGTGTGGTGCATGCCAACTCGGGGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 122

US-10-127-834A-143
; Sequence 143, Application US/10127834A
; Publication No. US20030087359A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC113
; CURRENT APPLICATION NUMBER: US/10/127,834A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-834A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-127-834A-143 (1-1985)
Qy 1 MetValalaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGATCGCGCGCTCGGCCCTCTCTCGCGGCCCTGCAGCTGTCTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGAGCGGAGCGCGGAGCGCAGAGCTGCGCAAGAGGCGGAGGCATTCTTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAATACGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTCTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACGCTTTGCCAAGCAAGGTAACAATGGTACAGCAGCACCTCTCTTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGAGAGGCCCCAGCACAGGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTCTTCCAAAGGGGACACACCAATGGGCTGGGCAATGCCCTTGTATGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCTTCCCGCGCGCGCGGCGCAACCTGTTCGGGTGTGTGGCGCA .924

```
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTGGCTCACCCTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyIysProLeuGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db 1045 GAGCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGAGTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAGCGCCCTGAAACCGAGG 1164
QY 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGT 1224
QY 340 rIlePheIysGlySerHisPheTrpGluValAlaIleAspGlyAsnValSerGluProAr 360
Db 1225 CATTITTAAGGAGCCATTTCTGGAGGTGGCAGTGTATGCCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheIysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyIysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCATCTTGAGCG 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGCTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCGCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGTACCGCTACTTGGCGCTCGACAGGCCAAGCTGCGAGGCAACCACTTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGAGGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 123

```
US-10-127-836A-143
; Sequence 143, Application US/10127836A
; Publication No. US20030087360A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
```

```
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Collin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P330R1C97
; CURRENT APPLICATION NUMBER: US/10/127,836A
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-836A-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Scores:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-127-836A-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTCTCGCGCCCTGCGAGCTGTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgIysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGCGCGAGCGCGAGGCTGCGCAAGGAGCGGCGGCGGCGCATTCCTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGGTGTCCAGCTACTCTGTGACGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
```


Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query March: 98.52% Indels: 2
Caps: 0

US-10-791-980-6 (1-520) x US-10-127-841A-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCTGGCCCTCTGCTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGlnArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCCCGGAGCGCGAGGCCAGGAGCTGGCAAGGAGCGGAGGCAATTCCTA 325
QY 41 GluLysTrpGlyTrpLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCGAGATGACTCGTCCCGCTGGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCTGGGCTGAGAGGATCAGTGAATGTTGTGTAGACACCGAGCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACTGGTACAGCAGCAGCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSetse 160
DB 626 AACTGGCCTGAGCATCTGCGGAGCGCGAGTTCTGGGCGCGCTGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCGCCGAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTTCATGCC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
DB 806 CCAGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgLysArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTGTGTGTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTACACGCTTGGCTTACCCACTTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGAGCGCGCTGCTCAGCTGGGAGCGGTGCTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAAGCCCTCAGGGGCTCAGTGGCGGTCCAGCTCCCGAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGACTCTCAGTGGGCTCAGTGGGCGGTCCAGCTCCCGAGGAAAGCTGT 1164
QY 320 yProLysTrpCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
```

```
DB 1165 CCCTAAATACTGCCACTCTTCTCTCGATGCCATCATCTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAlaPheGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTCGAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCAIT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGAGGGGGCTTGGCCCGCATCTCTGACCG 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
DB 1585 AGGCATCCTCAGGAGGTGACGGCGCTTGGCGAGGGCGGATGGCTCATCTCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCCAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGTGGATGCCAACTCGGGAGCGCGCTGT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 125

US-10-127-844A-143

Sequence 143 Application US/10127844A

Publication No. US20030087362A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Collin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C104
CURRENT APPLICATION NUMBER: US/10/127,844A
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26

```
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-844A-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-844A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCTGGCTCTCTGCGCGCTCTGAGTCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGCGGAGCGCAGGAGCTGCGCAAGAGGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGATTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTCTGGCTGAGAGGNTCAGTACCTGTTGTGTAGACACCGGACCAAAATGAGGGGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCTCTCCATCCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGCGCTGAGCATCTCGCGAGCGCGGAGTTCGGGGCGCGTGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCAGCGTGGAGTTCGGAGGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCGCTCACCTTCTTCAAGGGGACCAACGATGGGCTGGGCAATGCCTTTGATGCG 805
```

RESULT 126

US-10-128-687A-143

; Sequence 143, Application US/10128687A

; Publication No. US20030087363A1

Qy 520 e 520

Db 1765 c 1765

```
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCCTTC-CTGCCCGCGCGCGGAGCGCCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGTGGTCCCTGAGCGCGCGCGGGGCGCAACTGTTCTGTGTGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGCCCTACCCACTCGCCCGCGCGCGCTCATGTGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAGGCGCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCGCCTCTCTTCGATGCACTACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGACCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTCAGAGAAAGATGGGTGGCGCTGCCCGCCCAACATTTGAGGCTCGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGCGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGGTGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAGGTGGAGCGCTACTACCCCGAGTCTGCAGGAGCTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCCTCAGAGGTCAGCGCGCGCTGCCGAGGCGCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCGCGCCAAATGCAGGCAACCACTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGCTGTGGCATGCCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765
```



```

; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Defoige, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEOTIC
; FILE REFERENCE: P3330R1C115
; CURRENT APPLICATION NUMBER: US/10/128,687A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-687A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-128-687A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db 206 ATGTGCGCGCGCTCGGCTCTCTGTCGGCGCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGCGAGCGCGAGGCCAGAGCTCGCGCAAGAGCGCGGACCTTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCATCGATTACG 385
```

```

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGTGCGGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTGTGTAGACACCGGACCAAAATGAGGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCTTTTGCAAAACCAAGGTAACAAATGGTACACACCGGACCAAAATGAGGGCGTAAG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTCGAGCATCTCGGAGCGCGAGTTCGGGGCGCGTGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCACAGCCAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHis 240
Db 865 AGATGAGCGCTGGTCCCTCGAGCGCGCGCGGCGGCAACCTGTGTGTGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTGTATGGGAAGCGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCGCCCGGAGGAGGCGCTTGAACCGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACCTGCGCACCTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLue 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGGCGCTGCCCGCCCAACATTTAGGCTGGGAGTGTCTAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGTGATGTGTGGAGTTCGCGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
```

Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTCCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyTleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTCAGGAGGAGTACGCGCGCCCTGCCAGGCCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCyTrpHisAlaLysSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

US 10 128 688A 143
; Sequence 143, Application US/10128688A
; Publication No. US20030087364A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C125
; CURRENT APPLICATION NUMBER: US/10/128,688A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143

; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-688A-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-128-688A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGCGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGGAGGCGAGAGCTGCGAAGAGGCGGAGGCGATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGATCTGTCGCCGTTCGGGGTTACAGATACCAACAGATTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAAACAAATGGTACAAAGCAGACACCTCTCTACCGCGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGTTCGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTCGAGTTCGGGAGGCGCCCGCACACAGGCGCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACATGGGTGGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGAGCGCATTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGCGCAACCTGTTCTGTTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCCTCACCCACTCCCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

```
Db 1045 GAGCCTGTATGGAAGCCCTAGGGGCTCAGTGGCCGCTCCAGCTCCCAAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACTGGGATCTCTACAGCCCCNAGGAAGCGCCCTGAAACCGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTTCTGGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTGATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCCGGGCCCCAA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGGCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CCCCCTCTTCTTCTCTCTCGCGCCCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTTCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCCCTGCGAGGCGCCGATGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGCGCTCGACGAGCCCAACTGCGAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGAGGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 128
US-10-128-689A-143
; Sequence 143, Application US/10128689A
; Publication No. US20030087365A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
```

```
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C117
; CURRENT APPLICATION NUMBER: US/10/128,689A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-689A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-128-689A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGGCTCTCTGTCGCGCCCTCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGGCTGCGCAAGAGCGCGGAGGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCTCCAAAGCTCCACCTCCACCTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCAGCTACTCTGTCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGATTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCNAAGCAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGGAGTTCGGGCGCGCTGCGGCGCGCTTCAG 685
```



```
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-825A-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservativity: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-825A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGGTCTCTCTGTCGCGCGCTGAGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGGAGCGGAGCCGAGAGCTGCGCAAGGAGGCGGAGGCAATCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTCAGTGGGTGCCAGCTACCTGTGACGGGGGTGTGGACGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATGACTCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGGCTGAGAGATCAGTGACTTGTCTAGACACCGGACCAAAATGAGCGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGTAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGGAGCGCGAGTTCGGGGCGCGGTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyValArgProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTACGCGCTGAGTCTTGGGAGGCCCCAGCCAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTTCTCCAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGCGGCTCGCGCAGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCTGAGCGCGCGCGGGCGCAACCTGTTCTGTTGCTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
```

```
Db 925 CGAGATCGGTGCACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATCGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG 280
Db 985 CTACTACAAGAGCTGGCGCGACGCGCTGTCTCAGCTGGAGACGAGTGTGCGCCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGCAAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCGCACTCTTCTTCATGTCATCTAGTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rLlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGCGGCTGCCGCCCAACATTTAGGCTGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAAGATTTCTACTTCTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGCGCAGGGGGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTACTACTCTT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG 460
Db 1525 GCTGGCCGAGGGGAGTGCAGTGGAGCCCTACTCCCCCGAAGTCTCGAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlelePhePh 480
Db 1585 AGCATCCCTGAGAGGTACGCGCGCTCGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAAGGCCAAACTCGAGCAACACCTCGGGCCG 1704
Qy 500 gTTPAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCTGGATGGCTGGTGGCTGGCATGCCAATCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 131
US-10-230-417-143
; Sequence 143, Application US/10230417
; Publication No. US20030087385A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
```


RESULT 132
US-10-131-815A-143
; Sequence 143, Ap

QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLeuPheLeuArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGCTGCGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCGCGAGGGGACTGCAAGTGGAGCGCTTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 vGlyIleProGluGluValSerGlyAlaLeuProArgProArgGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGCTCATCATCTTCTT 1644
QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGTACCGCTACTGCGGCTCGACCAGGCCAACTGCAGGCAACCCACCTCGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 133

US-10-131-817A-143
; Sequence 143. Application US/10131817A
; Publication No. US20030092104A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C129
; CURRENT APPLICATION NUMBER: US/10/131,817A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-817A-143
Alignment Scores:
Pred. No.: 335e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-817A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGCGCGCTGCGGCTCTCTGTCGCGCCCTTCGACGTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGCAAGAGCGCGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGTCCACCTCCACATCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGAGTACCTGTTCAGCGCGGTGTGGACGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATCAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGACACCTCTCTACCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGAGCGGAGTTCGCGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCCTGGAGGCGCCACGACAGGCGCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACACAAACATGGGCTGGGCAATGCCCTTGTATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGGCGCACGCTTC-CTGCCCGCGCGCGGAGCGGCGCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCAACCTGTTGCTGTGTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCTCCACCTCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTCAAGAGGCTGGGCGCGGCTGCTCAGCTGGGACGACGCTGCTGGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

Db 626 AACTGGCCCTGAGCATCTGCCGAGCGCGCAGTTCCGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCyGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCACAGCCACGCGCTGAC 745
Qy 180 rSerGlySerProSerSerGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGGCCCGCGCGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGGGCAACCTGTTCGTGGTCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTACCCTACCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTy 280
Db 985 CTACTACAAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTy 300
Db 1045 GAGCTGTATGGAGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCACGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyTrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCGCGCGCGCGCGCGCGCGCGCGCG 1164
Qy 320 yProTy 340
Db 1165 CCTAAATACTGCTCCTCTCCATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1224
Qy 340 rIlePheLeuGlySerHisPhePhePhePhePhePhePhePhePhePhePhePhePhe 360
Db 1225 CATTTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAC 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCGAGAAAGATGGTGGGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1344
Qy 380 uAsnAspGlyAspPheTy 400
Db 1345 GAATGATGAGATTTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGCGGGCC 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCyAspAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheTyTyTyTyTyTyTyTyTyTy 440
Db 1465 CGCCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1524
Qy 440 lIleAlaArgGlyGlyLeuGlnValGluProTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 460
Db 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTTACTACCGCGCGCGCGCGCGCGCGCG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAAGAGGTGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1644
Qy 480 eArgAspAspArgTy 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCGCAACTGCGAGGCAACCACTTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 135

US-10-131-822A-143
; Sequence 143, Application US/10131822A
; Publication No. US20030092106A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zhenin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C127
; CURRENT APPLICATION NUMBER: US/10/131,822A
; PRIOR FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 143
; NUMBER OF SEQ ID NOS: 550
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-822A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.82% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-822A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCGCTGACGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCGCGAGCGGAGGCGCAGAGCTGCGCAAGAGGCGGAGGCATTCCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGACAGAGTCCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCACAGCTACCTGTGTCAGCGCGTGTGGACGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCGAGATACCTGCTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGATGAAATGGTACAGCAGCACCTCTCCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCGAGGCGGCGAGTTTGGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGSCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CAGGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTGGCTTCCACCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGGACCGCTGCTAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGATGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyr-SerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTGGAGCTGGGACTCTCAGACCCCAAGAGGCGCCCTGAAACGACGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCATGATGCCATCTGTAGNACAGCAACAGCACTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCGAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCATGTCAIT 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GATGATGGAGATTTCTACTTCTTCAAAGGGGTCCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCGCGGCGAGGGGCTGCCCCGCGCATCTGTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrPrArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTCTAGCGCGCTCGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACACGAGGCAAACTGCAGCAACACCTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGTGGCTGGATGGCTGCTGGCATGCGCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 136
US-10-131-828A-143
; Sequence 143, Application US/10131828A
; Publication No. US20030092107A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Denoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C140
; CURRENT APPLICATION NUMBER: US/10/131,828A
; CURRENT FILING DATE: 2002-04-24
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17


```
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-828A-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-828A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGGTCTCGGCTCTGCGCGCCCTGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGCGAGCGCGAGGAGCTGCGCAAGAGGCGGAGCGCATTCCTA 325
Qy 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGATACCTCATGACAGGTGCCAAAGCTCCACCTCCACCTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTGTGTGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTCGCGAGCGCGCAGTTCCGGGGCGCGTTCGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCGCCCGACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTCTTCCAGGGGACCAACAGTGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTTGGCGACGCTTC-CTGCGCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCGAGCGCGCGCGCGCAACCTGTTCGTGGTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
```

```
Db 925 CGAGATCGGTCAACACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGCGCGC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCCCTGAAACGACGG 1164
Qy 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACCTCTCTTCGATGCCATCCTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGCGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys 400
Db 1345 GAATGATGGAGATTCTACTTTCTTCAAGGGGGTGCATGTCTGGAGGTTCCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCGCTGCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1524
Qy 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCGCTTACTACCCCGGAAAGTCTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLePhePh 480
Db 1585 AGGATCCCTGAGAGGTTCAGCGCGCTCTCCAGGGCGCCCTGCCAGGGCCCATCTCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGGCGCTCGACCGGCAAACTGCGAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGCAGGAGTGGCTGGATGGGTGTCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 137
US-10-131-835A-143
; Sequence 143, Application US/10131835A
; Publication No. US20030092108A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deenoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
```



```
QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
|
|
|
Db 1645 CCGAGATGACCGCTACTGCGCCTCGACCGAGCCAACTGCGAGGCAACCTCGGGCG 1704
|
|
|
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAnSerGlySerAlaLeuPh 520
|
|
|
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCTGTT 1764
|
|
|
QY 520 e 520
|
|
|
Db 1765 C 1765
```

RESULT 138

```
US-10-137-864A-143
; Sequence 143, Application US/10137864A
; Publication No. US20030092110A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Dennoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C148
; CURRENT APPLICATION NUMBER: US/10/137,864A
; CURRENT FILING DATE: 2002-05-02
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-137-864A-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
```

```
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-137-864A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
|
|
|
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
|
|
|
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
|
|
|
Db 266 GACGCCACCGCGCGAGCGGAGCGGAGGAGCTGCGCAAGGAGCGGAGGAGCATTCCTTA 325
|
|
|
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
|
|
|
Db 326 GAGAAGTACGGATACCTCAATGACAGGTCCCCAAGGCTCCACCTCCACTCGATTCAGC 385
|
|
|
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
|
|
|
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCACAGCTACCTGTCCAGCGCGGTGTGGACCG 445
|
|
|
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
|
|
|
Db 446 GCCACCCCTGCCCGCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATCG 505
|
|
|
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
|
|
|
Db 506 CCCTGGGCTGAGAGGATCAGTGACTTTGTTGCTAGACACCGGACCCAAATAGGGCGTAAG 565
|
|
|
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
|
|
|
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAGCAGCACCTCTCTACCGCTGTGTG 625
|
|
|
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
|
|
|
Db 626 AACTGGCGCTGAGCATCTGCCGAGCGCGCATGTCGGGGCGCGGTGCGCGCGCTTCCAG 685
|
|
|
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
|
|
|
Db 686 TTGTGGAGCAACGCTCTAGCGCTGGAGTTCTGGGAGGCGCCACGACAGGCCCCCGCTGAC 745
|
|
|
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
|
|
|
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAACGATGGCTGGGCAATGCTTGTATGTC 805
|
|
|
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
|
|
|
Db 806 CCAGGGGGCGCCCTGCGCGCACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
|
|
|
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
|
|
|
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGGCGCAACTGTTGCTGGTGTGTCGCGCA 924
|
|
|
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
|
|
|
Db 925 CGAGATCGGTCAACGCTTGGCCTCACCACTCCCGCGCGCGCGCGCTCATGGCGCC 984
|
|
|
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
|
|
|
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGAGCGACGCTGCTGGCGCGTCA 1044
|
|
|
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
|
|
|
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
|
|
|
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
|
|
|
Db 1105 CACTGACTTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCCCTGAAACGACGG 1164
|
|
|
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
|
|
|
Db 1165 CCCTAAATACTGCGCACTCTTCTTCGTGATGTCATCACTGTGTAGACAGGCAACGACCACTGA 1224
```

Qy	340	rllpPheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTCTCGGAGGTGGCAGCTCATGGCAACGTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluAargTrpValGlyLeuProProAsnIleclulalaalalValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGGTGCGGCTGCCCCCAACATTAGAGCTCGGCAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCGCTGCCCGCCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGCCCGAGGGGACTGCAAGTGGAGCGCTACTACCCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	YgLYlIleProGlnIluValSerGlyAlaLeuProArgProAspGlySerllelePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTTCAGCGCGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCCTCGACCGAGGCCAACTGCAGGCAACACCTCGGGCGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTTGGATGGGCTGTGCGATGCCACTCGGGGAGCGCCCTGT	1764
Qy	520	e 520	
Db	1765	C 1765	

RESULT 139

```

RESUL1 139
; Sequence 143, Application US/10137869A
; Publication No. US20030092111A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C147
; CURRENT APPLICATION NUMBER: US/10/137,869A
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17

```

```
Db      806  CCAGGGGGCGCGCTGGCGACGCCCTTC-CTGGCCCGCGCGCGGAAGCGCACTTCGACCA 864
Qy      220  nAepGluArgTtpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGGTCTCTGAGCGCGCGCGCGCGCAACCTGTGTGTGTCTGGCGCA 924
Qy      240  sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTACACGCTTGGCTTCACCCACTCGCCCGCGCGCGCTCATGCGGCC 984
Qy      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGI 280
Db      985  CTACTACAAGAGCGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGTGCGCGTGA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCACGGAAGCTGT 1104
Qy      300  eThrAspPheGluThrTrpAspSerTyxSerProGlnGlyArgArgProGluThrGlnGI 320
Db      1105  CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACGACGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTTAATACTGCGCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCC 1284
Qy      360  pProLeuGlnGluArgTtpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTATT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db      1405  GCCAGTGGGGGTCTCCACAGCTGTGGCGGCAGGGGGCGCTGCCCGCCCATCTCTGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db      1465  CGCCCTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
Db      1525  GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGGTTCAGCGGCGCGCTGCCGAGGCGCGATGCTCTCATCTCTT 1644
Qy      480  eArgAspAspArgTyrTrpArgLeuAspGluAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGCGGCTTCGACAGGCGCAACTGACGGGCAACACTCTGGGCGG 1704
Qy      500  gTrpAlaThrGluLeuProTfMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCCAAGAGCTGCCCTGATGGGTGCTGTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy      520  e 520
Db      1765  C 1765
```

RESULT 140

US-10-147-523-143

; Sequence 143, Application US/10147523

; Publication No. US20030092113A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

```
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deanovers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; CURRENT APPLICATION NUMBER: US/10/147,523
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-523-143

Alignment Scores:
Pred. No.: 3,35e-262      Length: 1985
Score: 2792.00           Matches: 519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match: 98.52%           Indels: 2
DB: 15                    Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-523-143 (1-1985)
```

```
Qy      1  MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db      206  ATGTCGCGCGCGTGGCGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACCCCGAGCCCGGAGCGCGGAGGCTGGCAGAGGAGCGGAGCGGCGGCGCATTCCTA 325
Qy      41  GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTTCAGC 385
Qy      61  AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCAGAGCGTTTCAGTGGGTGTCCCGAGCTACCTGTTCAGCGGCGGTGTGGACCGC 445
Qy      81  AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446  GCCACCTTGGCCAGATGACTCTGCCCGCTTCGGGGTTACAGATACCAACAGATTATCGG 505
Qy      101  AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db      506  GCCTGGGCTGAGAGGATCAGTACTTGTTCGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGCTTTGCAAGCAAGGTAACAAAATGGTACAAAGCAGCACCTCTCTCCACCGCTGGTG 625
Qy      141  AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGCTTCGGCGCGCGCTTCAG 685
Qy      160  rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
```

```
Db      686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGGCACAGGCCCGCTGAC 745
Qy      180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db      746 ATCCGGCTCACCTTCTTCAAGGGGACACACAGCATGGCTGGCAATGCCTTTGATGGC 805
Qy      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db      806 CAGGGGGGGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGCGCAAGCGCACTTCGACCA 864
Qy      220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTCTGGTGTGCTGGCGCA 924
Qy      240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925 CGAGATCCGTACACGCTTGGCGCTCACCCACTCGCGCCGCGCGCGCGCTCATGGCGGCC 984
Qy      260 oTyTrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db      985 CTACTACAAGAGGCTGGGCGCGGACGCGCTGCTAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy      280 nSerLeuTyrgLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy      300 eThrAspPheGluThrTrpAspSerTyrsrProGlnGlyArgArgProGluThrGlnG1 320
Db      1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGGCGCCCTGAAACGCGAGG 1164
Qy      320 yProLysTyrcYsHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165 CCCTAAATACTGCCACTTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
Qy      360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285 TCCACTGTGAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGGAGTGTCA 1344
Qy      380 uAsnAspGlyAspPheTyPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGCCCCAA 1404
Qy      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCCCTGCCCGCCATCCTGACGC 1464
Qy      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db      1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Qy      440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrProArgSerLeuGlnAspTrpG1 460
Db      1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAAGGCTGGG 1584
Qy      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db      1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCT 1644
Qy      480 eArgAspAspArgTyTrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645 CCGAGATACCGCTACTGGCGGCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCCG 1704
Qy      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy      520 e 520
Db      1765 C 1765
```

RESULT 141

```
US-10-158-785-143
; Sequence 143, Application US/10158785
; Publication No. US20030092115A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C459
; CURRENT APPLICATION NUMBER: US/10/158,785
; CURRENT FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-158-785-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-158-785-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCGTCGGCCTCCTGCTGGCGGCCCTGCAGCTGTACTGTGGGGCCACTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCGAGCCCGGAGCGCGAGGCTGCGAAGGAGGGGAGGCAATTCCTA	325
Qy	41	GlulysTyrgLysTyrlLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACGGATACCTCATGAAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTGAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrIleuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla	100
Db	446	GCACCCCTGCGCAGATGACTCGTCCCCGTGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTCAGAGGATCAGTACTGTTTGTCTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTyTrpTyrlLysGlnHisLeuSerTyArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAAATAATGTTACAAAGCAGCACCTCTCTCCCGCGCTGTG	625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer-160
DB 625 AACTGGCCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCCTGAGCGCTGGAGTTCGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerSerGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTCCAGGGGACACACAGATGGCTGGGCATATGCTTTCATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCGCTGGCGCACGCTTC - CTGGCCCGCGCGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGTGTGCTGGCGCA 924
QY 240 sGluilleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGTACACGCTTGGCTTACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGCGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCGCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCGCGCGCGCGCGCGCTGAAACCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCATGCTCCATCATCTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCACCTGACGAAAGATGGTGGGCTGCGCCCGCGCGCGCGCGCGCTGAGGCTGGCGAGTGTCT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACACAGCTGTGGCGGCGAGGGGCGCTGCGCCCGCATCTCTGAGCG 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGCTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGGGCGCTGCGGAGGCGCGATGGCTCATCTTCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCGCAACTGCGAGGCAACCACTTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 c 1765
RESULT 142
US-10-121-051-143
; Sequence 143, Application US/10121051
; Publication No. US20030092147A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C6
; CURRENT APPLICATION NUMBER: US/10/121,051
; CURRENT FILING DATE: 2002-04-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-121-051-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-121-051-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuLeuLeuLeu 20
DB 206 ATGGTCGCGCGCTCGGCTCCTGTCGCGCCCTGCGAGCTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GACCGCCAGCGCGCGAGCGCGAGGCTGCGCAAGGAGCGGAGGCGCATTTCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCATGACAGGTCCCCAAGCTCCCACTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCTAGTGGGTCTCCAGCTACTGTGCGCGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCGCCAGATGACTCTGTCCTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

506	Db	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCGTAAAG	565
121	Qy	LYeaRgheAlaIyLSgInGlyASnLyETrpTyLySGLhIStIeuSerTyArArgLeuVal	140
566	Db	AAACGCTTTGCAAGCAAGGTACAAATGTGTACAAGCAGCACTCTCTCTACGCCCTGGTG	625
141	Qy	ASnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
626	Db	AACTGGCCTCAGCATCTGCCGAGCGCGCAGTTCCGGCGCGCGTGC	685
160	Qy	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
686	Db	TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTCTGGAGAGCCCAAGCCCGCTGAC	745
180	Qy	rSerGlySerProSerSerLySgLyThrThrMetGlyTrpAlaMetProLeuMetAl	200
746	Db	ATCCGGCTCACCTCTTCCAAAGGGGACCAACAAGATGGGCTGGGCAATGCCTTTGATGGC	805
200	Qy	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
806	Db	CCAGGGGGCGCCTTGGCGCACGCCCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA	864
220	Qy	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
865	Db	AGATGAGCGCTGGTCCCTGAGCCGCCCGCGGGGCGCAACTGTTCTGTGTGTGGCGCA	924
240	Qy	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
925	Db	CGAGATCGGTCAACAGCTTGGCTTCACCCCACTGGCCCGCGCGCGCTCATGCGCGCC	984
260	Qy	oTyTyLyEArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
985	Db	CTACTACAAGAGGCTGGCCCGCAGCGCTGCTCAGCTGGGACAAGCTGTGCGCGTGCA	1044
280	Qy	nSerLeuTyrgLyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
1045	Db	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGGTCCAGCTCCAGCAAGCTGTT	1104
300	Qy	eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGl	320
1105	Db	CACGTACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAACGCGAGG	1164
320	Qy	yProLysTyrcYshIsSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
1165	Db	CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGT	1224
340	Qy	rIlePheLySgLySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
1225	Db	CATTTTTAAAGGGAGCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
360	Qy	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
1285	Db	TCCACTGCAGAAAGATGGGTGGGCTGCCCGTCCCCCAACATTGAGGCTGGCGCAGTGCA	1344
380	Qy	uAsnAspGlyAspPheTyPhePheLySgLyGlyArgCysTrpArgPheArgGlyProLy	400
1345	Db	GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCA	1404
400	Qy	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
1405	Db	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCATCTCTGACGC	1464
420	Qy	aAlaLeuPhePheProProLeuArgLeuileLeuPheLySgLyAlaArgTyTrYrVa	440
1465	Db	CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT	1524
440	Qy	lLeuAlaRgGlyGlyLeuGlnValGluProTyTyTrProArgSerLeuGlnAspTrpGl	460
1525	Db	GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTTACCCCCGAAGCTGCGAGGACTGGG	1584
460	Qy	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh	480

Db	1585	AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCGGAGCGCGGATGGCTCCATCATCTCTCTT	1644
Qy	480	eArgAspAspArgTyTrtPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTCTGACACGAGGCAAACTGCAGGCAACACCTCGGGCGG	1704
Qy	500	gTtPAlaThrGluLeuProTtPMetGlyCysTtPHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGCGCACCGAGCTGCGCTGAGTGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 143			
US-10-121-042-143			
; Sequence 143, Application US/10121042			
; Publication No. US20030096386A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Desnoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; TITLE OF INVENTION: ACIDS ENCODING THE SAME			
; FILE REFERENCE: P3330R1C10			
; CURRENT APPLICATION NUMBER: US/10/121.042			
; CURRENT FILING DATE: 2002-04-11			
; Prior Application removed - See File Wrapper or Palm			
; NUMBER OF SEQ ID NOS: 550			
; SEQ ID NO 143			
; LENGTH: 1985			
; TYPE: DNA			
; ORGANISM: Homo Sapien			
US-10-121-042-143			
Alignment Scores:			
Pred. No.:			
Score:			
2792.00			
Length:			
3.35e-262			
Matches:			
2792.00			
Conservative:			
99.62%			
Mismatch:			
99.62%			
Indel:			
98.52%			
Query Match:			
15			
DB:			
US-10-791-980-6 (1-520) x US-10-121-042-143 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCGTCTGCTCTGCGGCCCTCTGCTGCGGCCCTGTCAGCTGTCTGCGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCGCCGCGAGCGCGAGGCGGAGAGTGGCAGAGGCGGAGGCGGAGGCGGAGGCGG	325
Qy	41	GluLysTrpGlyTyTrtPLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAACTACGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrtPValSerGlnLeuProValSerGlyValLeuAspArg	80

Db 386 GATGCCATCAGACGGCTTTTCAGTGGGTGTCCTCCAGCTACCTGTGACGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgGlyS 120
Db 506 GCTCGGCTGAGAGGATCAGTGACTGTTTGTGTAGACACCGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnClyHisLysTrrPyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTGTTTCAAGACGACACTCTCTACCGCTGGTG 625
Qy 141 AsnTrrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGTGGCGCCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTTCTCAAGGGGACCAACAAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrrArgTrrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGACGCCCTTC-CTGCCCGCGCGCGCAACCTGTTGTTGCTGGCGCA 864
Qy 220 nAspGluArgTrrSerLysSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCAACCTGTTGTTGCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCT 984
Qy 260 oTrrTrrLysArgLeuGlyArgAspAlaLeuLeuSerTrrAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCGTGGCGCGCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1044
Qy 280 nSerLeuTrrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGAGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrrAspSerTrrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTTGGACTTGGACTTGGACTTGGACTTGGACTTGGACTTGGACTTGGACTTGG 1164
Qy 320 yProLysTrrCysHisSerPheAspAlaThrValLeuAspGlyAsnValSerGluProAr 340
Db 1165 CCTAAATACTGCCACTCTTCTTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1224
Qy 340 rIlePheLysGlySerHisPheTrrPrrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrrPrrValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGGCGGCTGGCGGCTGGCGGCTGGCGGCTGGCGGCTGGCGG 1344
Qy 380 uAsnAspGlyAspPheTrrPhePheLysGlyLysArgCysTrrArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGGTGGATGCTGGAGGTTCGGGGGGCCCCAA 1404
Qy 400 sProValTrrPrrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACACAGCTGTGGCGGACGGGGGCTGGCGGCTGGCGGCTGGCGGCTGGCGG 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTrrTrrVa 440
Db 1465 CGCCCTTCTTTCCTCTCTGCGCGGCTCTATCTCTTCAAGGGTGGCGGCTACTAGCT 1524

Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTrrTrrProArgSerLeuGlnAspTrrGl 460
Db 1525 GCTGGCCCGGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGCTTCGACGAGCTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspPheArgTrrTrrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGGCCAACTGCGAGGCAACCACTCGGGCGG 1704
Qy 500 gTrrAlaThrGluLeuProTrrMetGlyCysTrrHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 144
US-10-123-912-143
; Sequence 143, Application US/10123912
; Publication No. US20030100087A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C55
; CURRENT APPLICATION NUMBER: US/10/123,912
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-912-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-123-912-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrPrrGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTGCTGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCCGGAGCGCGGAGGCTGCGCAAGGAGCGGCGGATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaIaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAAAGAGTCCCAAGCTCCACACCTCCACATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGAGTACCTGTTCAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCAGATCACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluAqlIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGACACCGGACCCAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCGAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGCGAGCGCGCAGTTCGGGGCGCGTTCGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerClyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGAGGTTCCTGGGAGGCGCCAGCGCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCAGAGGGGACACAAACGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCAGCGCTTC-CTGCGCGCGCGCGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgAlaArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGCGCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGAGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGTCCAGCTCCAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTCGAGACTGGGACTCCTACAGCCCCCAAGAGGCGCCCTGAAACGCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACATGCCACTCTTCCTTCGATGTCATCCTGATAGACAGCAACGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCGGCTGCCCCCAACATTCAGGCTGGGCGAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGACTGTCCCGGCGAGGGGCTGCCCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCGGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCGCTACTATCCCCCAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGlnValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGACGGCGCTGCGAGCGCGATGGCTCCATCTCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGGCGCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCGCTGGATGGCTGCTGGCATGCCAACTCGGAGGCGCGCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 145
US-10-192-007-143
; Sequence 143 Application US/10192007
; Publication No. US20030104544A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deanoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: F3330R1C281
; CURRENT APPLICATION NUMBER: US/10/192,007
; CURRENT FILING DATE: 2002-07-09
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19

[illegible][illegible]

; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090538
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091982

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-192-007-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCTCGGCTCTCTGTCGGCGCGCTCTGTCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGlyAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCGCGCGAGCGCGGAGCGCAGGAGCTGCGCAAGGAGCGCGGAGGCAATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGTCCCCAAAGCTCCACCTCCACTCGATTCAGC 385
Qy 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCGTTTTCAGTGGGTGTCCAGAGCTTACCTGTTCAGCGCGCTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCGAGTACGTCTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTGTAGACACCGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCCGAGCGCGAGGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACACAGTCTACAGCTGGAGTTCTGGGAGGCGCCACGACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGGCTTGGCGACGCTTC-CTGCCCCGCGCGCGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
```

```
Qy 260 oTyrTyrLysArgLeuGlyValArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGACACGCTGCTGGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyValArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCAAGGAAGCGCGCTGTAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuLeuTy 340
Db 1165 CCTAAATACTGCGCACTCTTCCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTCGAGGAAAGATGGGTTCGGGCTGCGCCCAACATTTAGGCTCGGCAGGTGTCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTCAAAAGGGGTGCGATGTGGAGGTTCGCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCGCCGCAATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTACTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCNAGTGGAGCCCTACTACCCCGAAGTCTGCGAGGCTGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCTCAGCGCGCCTGCGCGAGCCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACGCTACTTGGCGCCTCGACCGAGCCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCGTGGATGGGTGCTGTCATGCCAATCGGGGAGCGCTTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 146
US-10-194-359-143
; Sequence 143, Application US/10194359
; Publication No. US2003010454S1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven


```
; APPLICANT: Smith,Victoria
; APPLICANT: Stewart,Timothy A.
; APPLICANT: Tuma,Daniel
; APPLICANT: Watanabe,Colin K
; APPLICANT: Wood,William
; APPLICANT: Zhang,Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C315
; CURRENT APPLICATION NUMBER: US/10/194,359
; CURRENT FILING DATE: 2002-07-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-194-359-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-194-359-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGGCTGGGCTCTCTGCTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGGCCACAGCCCGGAGCGCGGAGCCAGGAGCTGCGCAAGGAGCGGAGGCATTTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProLysAlaProLysSerThrArgPheSer 60
DB 326 GAGAGTAGCGATACCTCAATGACAGCTGCCCAAGCTCCCACTCCACTCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACCTGTGTCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgGlySerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTGTGTGTCTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 NAATGGCTTGTAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGTTCGGCGCGCTTCACG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGATTCTGGGAGGCCCCAGCCACAGGCCCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
```

```
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGGGCGCAACCTGTTCTGCTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGTTCACACGCTTGGCTTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 cTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGGCGCGCGAGCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCGCAAGGAGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACACACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLue 380
DB 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGTGGCGCACTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCCGAGGGCCGATGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCAAACTGCAGGCAACCCACCTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGTCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 147
US-10-127-847A-143
; Sequence 143. Application US/10127847A
; Publication No. US20030119103A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
```



```
Db      1525  GTGGCCCCGAGGGGAGCTCAAGTGGAGGCCCTACTACCCCGAAGTCTCGAGGACTGGGG 1584
Qy      460  yGlytleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePheph 480
Db      1585  AGGCATCCCTGAGGAGCTCAGGGGCCCTGCGAGGCCGATGGCTCCATCATCTCTT 1644
Qy      480  eArgAspAspA-gTTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGCGGCTCGACCAAGCAACTGCAGGCCAACCAACCTCGGGCG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 148
US-10-137-866-143
; Sequence 143, Application US/10137866
; Publication No. US20030129689A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C151
; CURRENT APPLICATION NUMBER: US/10/137,866
; CURRENT FILING DATE: 2002-05-03
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-08-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059836
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062285
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062814
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063127
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063327
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063550
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063561
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063704
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063735
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063738
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/064248
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066453
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069212
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069278
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069334
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-16
; PRIOR APPLICATION NUMBER: 60/072320
; PRIOR FILING DATE: 1998-01-23
; PRIOR APPLICATION NUMBER: 60/073612
; PRIOR FILING DATE: 1998-02-04
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/081203
```

```
; PRIOR APPLICATION NUMBER: 60/091982

Alignment Scores:
Pred. No.:      3,35e-262          Length:      1985
Score:           2792.00          Matches:       519
Percent Similarity: 99.62%        Conservative:   0
Best Local Similarity: 99.62%     Mismatches:    1
Query Match:      98.52%         Indels:        2
DB:               16             Gaps:          0

US-10-791-980-6 (1-520) x US-10-137-866-143 (1-1985)

Qy      1 MetValAlaArgValGlyLeuLeuLeuAraAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db      206 ATGTGTCGGCGCTCGGCCCTCCTGCTCGCGCCCTGCAGCTGCTACTGTGGGGCACACCTG 265
Qy      21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgIysGluAlaGluAlaPheLeu 40
Db      266 GAGCCCCAGCCCGCGAGCGCGGAGGCGCAGAGCTGGCGCAAGGAGGCGGAGGCATTCCTTA 325
Qy      41 GluLysTyrGlyTVrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326 GAGAGTACGGATACCTCATATGAACAGTCCCCAAAGCTCCCACCTCCACTCGATTTCAGC 385
Qy      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTCAGCGCGGTGTTGGACCGC 445
Qy      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446 GCCACCCTGGCCGAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506 GCCTGGCTCAGAGGATCAGTGACTCTGTTTGTCTAGACACCGAGCCAAAATGAGGCGTAAAG 565
Qy      121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566 AAAGCCTTTGCCAAGCAAAGCTAACAAATGGTACAAGCAGCACCTCTCTCTACCGCTGGTG 625
Qy      141 AsnTrpProGluHisLeu - ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626 AACTGGCTCAGCATCTCGCGGAGCGCGCAGTTTCGGGGCGCGCTGCGCGCGCTTCGAC 685
Qy      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686 TTGTGGAGCAACGTCTCAGCGCTGGAGTCTTGGAGAGCCCGAGCCAGGCGCCCGCTGCAC 745
Qy      180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db      746 ATCGGCTCACCTTCTTCCAAGGGGACCACAACGATGGGCTGGGCAATGCCTTTGATGGC 805
Qy      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db      806 CCAAGGGGGCGCCCTGGCGCAGCGCTTC - CTGGCCCGCGCGGGGAGGCGCACTTCGACCA 864
Qy      220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865 AGATAGACGCTGTGTCCCTGAGCGCGCGCCCGCGCGCAACTGTGTCTGTGTGTGGCGCA 924
Qy      240 sGuilleGlyHieThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGTCGCGCC 984
Qy      260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db      985 CTACTACAGAGGCTGGGGCGCGACGCGCTGCTCAGCTGGGAGCACGTGCTGGCGCGTCA 1044
Qy      280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045 GACCTGTATGGGAAGCCCCCTAGGGGCTCAGTGGCGCTCAGCTCCGAGAAGCTGTT 1104
Qy      300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
```

Db 1105 CACTGACTTTGAGCCTGGGACTCTTACAGCCGCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProlyseTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACACAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrPduValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrrValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTCGCAGGAAGATGGTGGGCTGCCGCCCAACATTAGGCTGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrrPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrrPglyLeuProGlnLeuCysArgAlaGlyGlyLeuProArGHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCTTCCCGGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTrrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTrrTrrProArgSerLeuGlnAspTrrGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAAGTGTGACAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGTTCAGGGGCGCTTCCGAGGCCGATGGCTTCATCTTCTT 1644
Qy 480 eArgAspArgTrrTrrPrrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGGCCAACTGCGAGGCAACCCACCTCGGGCGG 1704
Qy 500 gTrrAlaThrGluLeuProTrrPrrMetGlyCysTrrPrrHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 149

US-10-146-726-143
; Sequence 143, Application US/10146726
; Publication No. US20030129690A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C308
; CURRENT APPLICATION NUMBER: US/10/146,726

; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-146-726-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-146-726-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrPglyHisLeu 20
Db 206 ATGGTCGCGCGGTTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGCTGCGCAAGGAGCGCGAGGCAATTCCTA 325
Qy 41 GluIysTyrGlyTrrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGTCCCAAGTCCACCTCCATCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGTACCTGTGTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCAAAATAGGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrrTrrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTGGCAAGCAGGTAAACAAATGGTACAGCAGCAGCCTCTCTACCGCCCTGGTG 625
Qy 141 AsnTrrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCGCGAGCGCGCAGTTGCGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCAGGCACAGGCCCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrMetGlyTrrPrrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrrPrrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrrSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGCAACCTGTTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCCTCACCACTTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrrLysArgLeuGlyArgAspAlaLeuLeuSerTrrPrrAspValLeuAlaValGl 280

```
Db 985 CTACTACAAGAGGCTGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlySerValalaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACCTTTGAGACTGGGACTCTCAGACCCCAAGAGAGGCCCTGAAACGACGAG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACGCAACTGTA 1224
Qy 140 illePheLysGlySerHisPheTrpGluValalaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 160 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1485 TCCACTTCCAGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGGACAGGGGGCTGCCGCCCATCTCCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGTGGCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCTGAGGAGGTGACGGGGCCCTGCCGAGGCCGATGCTCATCTCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAACTGACGCAACCACTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 150

US-10-146-727-143

; Sequence 143; Application US/10146727

; Publication No. US20030129691A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

```
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C312
; CURRENT APPLICATION NUMBER: US/10/146,727
; PRIORITY FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-146-727-143
```

Alignment Scores:

```
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-146-727-143 (1-1985)

```
Qy 1 MetValalaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGGCGTTCGCGCTCTGCTCGGCGCCCTGTCAGAGTGTCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCAGCCCGCGGAGCGCGAGCGCAGAGCTGCGAAGGGCGGAGGCGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACTGTCTGTCAGCGCGCTTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCACACCTGCGCCAGATGACTCGTCCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTCTTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACCGCTTTCAAAGCAAGGTACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGGAGCTTCGGGGCGCGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGGAGGCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGGGCCCTTGGCGCACGCGCTTC-CTGCCCCCGCGCGGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCTGAGCGCGCGCGCGCGCAACCTGTTCTGTGTGTGTGGCGCA 924
```



```
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTCAACAGCTGGCTCCACCCACTCGCGCGCGCGCGCTCATGGCGC 984
Qy 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGA 1044
Qy 280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db 1045 GAGCCTGTATGGAGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCGCCCAAGGAGCGCCCTGAAACCGAGG 1164
Qy 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCACCTCTTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGCAGCTGATGCCAACGCTCTAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheIysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGCTCATGTGTGAGGTTCCGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCCATTCCTG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTTACTACCGCCGAACTCTGCAGGACTGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTTCCGAGGCGCGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGTACCGCTACTTGGCGCTCGACAGGCGCAAACTGCGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGTGGCTGCTGGCATGCCAACTCGGGAGCGCGCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 151

```
US-10-146-788-143
; Sequence 143, Application US/10146788
; Publication No. US20030129693A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
```

```
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zenin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C322
; CURRENT APPLICATION NUMBER: US/10/146,788
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-146-788-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-146-788-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGCGCGCTGGCGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCNAGCCCGCGAGCGCGGAGCCAGAGCTGCGCAAGGAGCGCGGAGCATTCCTA 325
Qy 41 GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGATACCTCAATGAACAGGTCCCAAAAGTCCACACTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCTGTCGCCGCTCGGGGTTCAGATACCAACAGTTATGGC 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCCCGGAGCTTGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGAGGCGCCCGAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCCAGAGGGGACCAACAGATGGGCTGGGCAATGCGCTTTGATGGC 805
```



```
Db 686 TTGTGGAGCAAGCTCTCAGCGTGGAGTTCTGGAGGCCCGCCAGCCAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTCTTCCAGGGAGCCACCAAGATGGCTGGGCAATGCCCTTTGATGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC - CTGCCCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTCGTGCTGCGGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCGCTGGCGCGCGCGCGCTGCTCAGCTGGGAGCAGCTGTGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTGTAGACTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTCTCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTTPValGlyLeuProAsnIleGluAlaAlaValSerle 380
Db 1285 TCCACTGCAGGAAGAAGTGGTGGCGCTGCCCGCCCAACATTGAGGTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCA 1404
Qy 400 pProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CGCCCTCTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTTACCCCGGAGTCTGCAAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGCGCTGCGGAGGCCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCCAACTGCAGGCGCAACCACTCGGGCG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHiAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAAGGCTGGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
```

```
Db 1765 C 1765
RESULT 153
US-10-153-934-143
; Sequence 143, Application US/10153934
; Publication No. US20030129695A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C412
; CURRENT APPLICATION NUMBER: US/10/153,934
; CURRENT FILING DATE: 2002-05-22
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-153-934-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservat: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-153-934-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTTCGGCTCTCTGTCGCGCGCTGTCAGCTGTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCGCGCGGAGCGCGGAGCGAGCTGGCCAAAGGAGCGCGGAGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCCATCAGACGTTTCAGTGGGTGTCAGCTACCTGTCAGCGCGTGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTTCCTAGACACCGGACCAAAATGAGGGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
```

```
Db      566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCAACCGCCTGTGTG 625
Qy      141 AenTtpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626 AACTGGCTTGAGCAATCTCCGAGAGCCGAGTTCGGGGCGCGGTGCGCGCCGCTTCCAG 685
Qy      160 rCysGlyAlaThrSerGlnArgTtpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686 TTGTGGAGCAGCTCTCAGCGCTGAGTTCGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy      180 rSerGlySerProSerSerLysGlyThrThrMetGlyTtpAlaMetProLeuMetAl 200
Db      746 ATCCGGCTCACCTTCTTCCAGGGGACCACAAACGATGGCTGGGCAATGCCTTTGATGGC 805
Qy      200 aGlnGlyAlaProTtpArgTtpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db      806 CGAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGCGGCGAAGCGCACTTCAGCCA 864
Qy      220 nAspGluArgTtpSerLeuSerArgArgGlyValArgAenLeuPheValValLeuAlaHi 240
Db      865 AGATCAGCGCTGCTCCCTGAGCGCGCGCGGGGCGCACTGTTCGTGGTGTCTGGCGCA 924
Qy      240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy      260 cTyrtYrLysArgLeuGlyArgAspAlaLeuLeuSerTtpAspAspValLeuAlaValG1 280
Db      985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy      280 nSerLeuTyrtYrLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCAGCTCCAGGAAGCTGTT 1104
Qy      300 eThrAspPheGluThrTtpAspSerTyrtSerProGlnGlyArgArgProGluThrGlnG1 320
Db      1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy      320 yProLysTyrtCysHisSerSerPheAspAlaIleThrValaspArgGlnGlnLeuTy 340
Db      1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACGCAACTGTA 1224
Qy      340 rIlePheLysGlySerHisPheTtpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db      1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy      360 gProLeuGlnGluArgTtpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy      380 uAsnAspGlyAspPheTyrtPhePheLysGlyLysArgCysTtpArgPheArgGlyProLy 400
Db      1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400 sProValTtpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db      1405 GCCAGTGTGGGGTCTCCACACAGCTGTCCGGGAGGGGGCTGTCCCGCCCATCTCTGACGC 1464
Qy      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrtYrVa 440
Db      1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTTCAAGGTGTCGCTACTAGT 1524
Qy      440 lLeuAlaArgGlyLysLeuGlnValGluProTyrtYrtProArgSerLeuGlnAspTtpG1 460
Db      1525 GCTGGCCCGAGGGGACTGCAAGTGTGAGCCCTTACTACCCCGAAGTCTGCGAGGACTGGGG 1584
Qy      460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585 AGGCATCTCTGAGGAGGTACAGGGCGCCCTGCCAGGGCCCGATGGCTCCATCACTTCTT 1644
Qy      480 eArgAspAspArgTyrtTtpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCGAGGCAACCACTCGGGCGC 1704
```

```
Qy      500 gTtpAlaThrGluLeuProTtpMetGlyCysTtpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGCAATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy      520 e 520
Db      1765 C 1765
RESULT 154
US-10-807-143
; Sequence 143, Application US/10140807
; Publication No. US20030134354A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C174
; CURRENT APPLICATION NUMBER: US/10/140,807
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-807-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-140-807-143 (1-1985)
Qy      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTtpGlyHisLeu 20
Db      206 ATGTCTCGCGCGCTCGCCCTCTCTGCTCGCGCCCTCGAGCTGTCTACTGTGGGGCCACCTG 265
Qy      21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db      266 GAGCCCCAGCCCGCGGAGCGCGGAGGCGCAGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
Qy      41 GluLysTyrtYrtYrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326 GAGAAGTACGGATACCTCAATGAACAGGTCTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
Qy      61 AspAlaIleArgAlaPheGlnTtpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386 GATGCCATCAGAGCTTTCAGTGGGTGTCCAGCTACTGTTCAGCGGGGTGTGGACCGC 445
Qy      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrtAla 100
Db      446 GCCACCCCTGCGCCAGATGACTCTGTCGCCCGCTGCGGGGTTCACAGATACCAACAGATTATGCG 505
```

QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTAGAGGATCAGTGTCTGTTGTAGACACCGACCAAAATGAGGGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyIleLysTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACCGCTTTGCAAGCAAGGTAAACAAATGGTAAAGCAGCAGCTCTCTCCATCCGCGCTGGTG 625
QY 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSe 160
DB 626 AACTGGCTTGAGGATCTGCGGAGCGGCGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGGCGCCACAGCCAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGCAATGCCCTTTGATGCG 805
QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCTTGGCGCACGCCCTTC-CTGCCCGCGCGCGCGCGCGCTCATCGGCC 864
QY 220 nAspGluArgTTPSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCGCAACCTTGTGTGGTGTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCGCTCACCCACTCGCGCGCGCGCGCGCTCATCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCAAGAGGCGCCCTGAAACGACAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCTCTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
QY 360 pProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTTPArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 pProValTTPGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisPProAspAl 420
DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGGCGGAGGGGGCTTGGCCCCGCCATCTTCAGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
DB 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTTACTTACCCTCCCGAAGCTGTGCAGGACTGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTCTAGGAGGTTCAGCGGCGCTTCCGAGGGCCCGATGGCTCCATCATTTCTT 1644
QY 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGAGCCAAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGCCAACTCGGGAGGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 155
US-10-140-924-143
; Sequence 143, Application US/10140924
; Publication No. US20030134355A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C177
; CURRENT APPLICATION NUMBER: US/10/140,924
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-924-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-140-924-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
DB 206 ATGTCTCGCGCGCTGGCGCTCTCTGCGCGCTCTGAGCTGTCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCCAGCCCGCGGAGCGCGGAGGCTGCGCAAGGAGGCGGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATCACTCAATGAACAGGTGCCAAAGCTCCCACTCCACTCGATTGAGC 385

Db	1345	GAATGATGGAGATTTCTTACTTTCTTAAAGGGGGTCCGATGCTGGAGGTTCGGGGGCCCCAA	1400
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCCCGCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTCCCTCCTCTGCGCGCCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAAAGCTCGCAGACTGGGG	1584
Qy	460	YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGATCCCTGAGAGGTGAGCGGCCCTTGCAGGCGCGATGGCTCCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGTGGCGCTCGACACAGGCCAAACTGCAGGCAACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 157			
US-10-141-698-143			
; Sequence 143, Application US/10141698			
; Publication No. US20030134357A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Deonoyere, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; TITLE OF INVENTION: ACIDS ENCODING THE SAME			
; FILE REFERENCE: P3330R1C206			
; CURRENT APPLICATION NUMBER: US/10/141,698			
; CURRENT FILING DATE: 2002-05-08			
; Prior Application removed - See Palm or File wrapper			
; NUMBER OF SEQ ID NOS: 550			
; SEQ ID NO 143			
; LENGTH: 1985			
; TYPE: DNA			
; ORGANISM: Homo Sapien			
US-10-141-698-143			
Alignment Scores:			
Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	99.52%	Indels:	2
DB:	16	Gaps:	0

Pred. No.:	3.35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	99.52%	Indels:	2
DB:	16	Gaps:	0

US-10-791-980-6 (1-520) x US-10-141-702-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTGTGGCGCGTGGCGCTCTGTGTGGCGCCCTGCAGCTGTCTACTGTGGGCGACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGAGCGCGAGCGCAGAGCTGCGAAGGAGGCGGAGGCAATTCCTTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCCACTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTTCAGTGGGTGTCCCAAGTACTCTGTACAGCGCGTGTGTGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrIleSerTyrAla	100
Db	446	GCCACCTCTGCCCAATGACTGTCTCCCGCTTGCGGGGTTTACATACCAACAGTTATATGGC	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTCGGCTGAGAGGATCAGTGACTGTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGAACAGGTAAACAAATGGTTACAAAGCAGCACCTCTCTCTACCGCCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValProCysAlaProProSerSe	160
Db	626	AACTGGCTTGAGCATCTCCCGAGCCGGCAGTTCTGGGGCGCCGTGGCGCCGCTTCACAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTACGCGTGGAGTCTTGGGAGGCCCCCAGCCACAGCGCCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGGCTCACCTCTTCTCAAGGGGAGACCAACAGCATGGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200	agGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCCGCGGCGAAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCCGCGGCGCAACCTGTTCTGTGTCTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCCGTTACACAGCTTTGGGCTTACCCCACTCGCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuLeuSerTrpAspAspValLeuAlaValG	280
Db	985	CTACTTCAAGAGGCTGGGCGCGCAGCGCTGTCTAGCTGGGACGACGTCTGTGGCGTGC	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGTCCCAAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
Db	1105	CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTTGAAACGACGGG	1164

QY	320	yProLyTyrcYcshisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
DB	1165	CCCTAAATACTGCCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
QY	340	rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CAITTTTAAAGGAGGACCATTTCTGGGAGGTGGCAGCTGTAGTGGCAACGTCTCAGAGCCCGC	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
DB	1285	TCCACTGCAGGAAGATGGGTGGGCTGCCCCCCCACTGATGCGCTGCGCAGTGTCTT	1344
QY	380	uAsnAspGlyAspPheTyrcPhePheIysGlyArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGTTCGATGCTCGAGGTTCCGGGGCCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGTGGGTCTCCCAACAGCTGTGCCGGGAGGGGGCTGCCCCGCCCATCTCTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa	440
DB	1465	CGCCCTCTTCTTCCCTCTCTGGCGGCCCTCATCTCTTCAGGGTGCCTACTACGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyTrTyrcProArgSerLeuGlnAspTrpGl	460
DB	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCCCTGAGGAGGTCAAGCGGCGCCCTGCGGAGGCGCGATGGCTCCATCATCTTCTT	1644
QY	480	eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
DB	1645	CCGAGATGACCGCTACTGGCGCCCTCGACCAAGGCCAACTGCAGGCAACCACTCGGGCCG	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
DB	1705	CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
QY	520	a 520	
DB	1765	c 1765	

RESULT 159

US-10-141-704-143

; Sequence 143, Application US/10141704

; Publication No. US20030134359A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; TITLE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P33301C209

; CURRENT APPLICATION NUMBER: US/10/141,704

; CURRENT FILING DATE: 2002-05-08

; Prior Application removed - See Palm or File Wrapper

; NUMBER OF SEQ ID NOS: 550

```
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-704-143

Alignment Scores:
  Pred. No.:      3,35e-262      Length:      1985
  Score:          2792.00        Matches:     519
  Percent Similarity: 99.62%      Conservative: 0
  Best Local Similarity: 99.62%    Mismatches: 1
  Query Match:      98.52%        Indels:      2
  DB:               16           Gaps:        0

US-10-791-980-6 (1-520) x US-10-141-704-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCGGCTCTCTGCTGCGCGCTGACGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGAGCGCGGAGCGGAGCGGAGCGGAGCTGCGCAAGGAGCGGAGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGAGTCCCCAAGGCTCCCACTCCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACGAGCTACCTGTGAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCGCATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGTAACAATATGGTACAAAGCAGACCACTCTCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCAATCTCCGAGAGCGCGAGTTGCGGGCGCGCTGCGCGCTTCGAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACCAACGTTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGGCGCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCAAGGGGAGCCACAAACGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGGCTGGCGGCGAGCGCTTC-CTGCCCCGCGCGGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGGGCAACCTGTTGCTGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGGAGCGCGCTCTCAGCTGGGAGCGAGCTGGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
```

```
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTTGAACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATATCGCCACCTCTTCCTTCGATGCGCATCCTGTAGACAGGCAACGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGACGTGTAGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGGMAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTCGGCGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCATTCTTCAAAGGGGGTCTGATGCTGGAGGTTCGCGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGCAGGGGCGCTGCCCCGCCATCTCTGAGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCTCTCTCTGCGCGCTCATCTCTTCAAAGGCTGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGAGCTGCAAGTGGAGCGCTTACTACCCCGAAGTCTGCGGAGCTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480
Db 1585 AGCATCTCCTGAGGAGTCTCAGCGCGCTGCGGAGGCGCGATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCGCAAACTGCGAGCAACCACTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGCCAGCTGCTGGATGGGCTGCTGCGATGGGCTGCTGCGGAGCGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 160
US-10-142-421-143
; Sequence 143, Application US/10142421
; Publication No. US20030134360A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
```


APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tuma, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE OF INVENTION: ACIDS ENCODING THE SAME
FILE REFERENCE: P3330R1C241
CURRENT APPLICATION NUMBER: US/10/142,767
CURRENT FILING DATE: 2002-05-10
Prior Application removed - See Palm or File Wrapper
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 143
LENGTH: 1985
TYPE: DNA
ORGANISM: Homo Sapien
US-10-142-767-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-767-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTGGCGCGGTGGCTCTCTGTCGCGCGCTGACGTCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGACCGCGGAGCGCGAGGCGGAGGAGTGGCAAGAGGAGGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGAGTCCACACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGTACCTGTGACGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCGTGGGCTGAGAGGATCAGTCTGTTTGTGTAGACACCGGACCAAAATGAGGGGTAAAG 565
QY 121 LysArgPheAlaIleGlnGlyLeuLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGTGGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGGCCACAGGCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetal 200
DB 746 ATCCGGCTCACCTCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCGTTTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCCCGCGCGGCAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyValArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGGGGGCGCAACTGTTCGTGGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr 260
DB 925 CGAGATCGTTCACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCACGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACCTTCAGACCTGGGACTCTACAGCCCCCAAGGAGGCGCTGAAACAGCGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAAATACCTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGACGTGATGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerbe 380
DB 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyClyArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGCAGGGGGCTGCCCCCGCCATCTCTAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG 460
DB 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGCTGTCAGAGCTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCAGGAGGTGAGCGGGCGCTGCGAGGGCCCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATACCGCTACTGCGGCTCGACCGGCAAACTGCAGGCAACACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCGCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 163

US-10-143-033-143
; Sequence 143, Application US/10143033
; Publication No. US20030134363A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C246
; CURRENT APPLICATION NUMBER: US/10/143,033
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-143-033-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
Gaps: 0
16
US-10-791-980-6 (1-520) x US-10-143-033-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGCGAGCGCGAGGCCAGAGCTGCGCAGAGGCGCGAGGCAATTCCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCGATTTCAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGGTGTGGACGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGCTAGACACCGGACCAAAATCAGGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCGAAGCAAGGTAAACAAATGGTACAGGACGACCTCTCTACCGCGCTGGT 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160

Db 626 AACTGGCTGAGCATCTGCGGAGCCGCGAGTTTCGGGGCGCGCTGCGGCGCGCTTCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGTTCGTGGAGGCGCCAGCCAGCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACACATGGGTGGGCAATGCCCTTGTATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGGGCAGCGCTTC-CTGCCCCCGCGCGCGGAGGCGACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGTGTCTCCTGAGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCCTCACCCACTCGCCCGCGCGCGCTCATGTGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGGCGCTGAAACGCGAGGG 1164

Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAATACTGCCACTCTTCTTCGATGCGCATCACTGTAGACAGGCCACACGCAACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTCAGAAAGATGGGTGCGGCTGCCCGCCCAACATTTAGAGGCTGCGGAGGTTCGGGGCCCCNA 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCGGGGCCCCNA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGCGAGGGGCGCTGCCCGCGCATCTCGACGC 1464

Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCTCTTCAAGGGGTGCCCGCTACTACGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCCGAAGTCTGCAGGACTGGG 1584

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCCTGAGAGGTACGCGCGCGCTGCGAGGCGCGGCTGCTCATCTCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTTGGCGCTTCGACAGGCCAAACTGACGCAACACCTCGGGCG 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTCTGGCATGCCAATCTGGGGGAGCGCCCTGTT 1764
Oy 520 e 520
Db 1765 C 1765
RESULT 164
US-10-144-994-143
; Sequence 143, Application US/10144994
; Publication No. US20030134364A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P33301C257
; CURRENT APPLICATION NUMBER: US/10/144,994
; PRIOR FILING DATE: 2002-05-13
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059836
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062285
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062814
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063127
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063327
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063330
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063361
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063704
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063735
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063738
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064248
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066453
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069212
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069278
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069334
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-16
; PRIOR APPLICATION NUMBER: 60/072320
; PRIOR FILING DATE: 1998-01-23
; PRIOR APPLICATION NUMBER: 60/073612
; PRIOR FILING DATE: 1998-02-04
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081695
; PRIOR FILING DATE: 1998-04-14
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081818
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082999
; PRIOR FILING DATE: 1998-04-24
; PRIOR APPLICATION NUMBER: 60/083322

Db 1285 TCCACTGCGAGGAAGATGGTTCGGCTGCGCCCAACATTGAGGCTCGCGCATTCATT 1344
Qy 380 uAenAepGlyAepPheTyPhePheLysGlyAysCyvTtpAqgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTTTTCAAGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTtpGlyLeuProGlnLeuCyvArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCCGCATCTTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCAGGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTCGAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGCGGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAepAspArgTyTrpArgLeuAepGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTGCGCCTCGACAGGCCAAACTGCAAGGCCAACCCCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCyvTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 165

US-10-145-628-143
; Sequence 143, Application US/10145628
; Publication No. US20030134365A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P33301C271
; CURRENT APPLICATION NUMBER: US/10/145,628
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550.
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-628-143
Alignment Scores: 3.35e-262 Length: 1985
Pred. No.: 2792.00 Matches: 519
Score:

Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-628-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGGCGCGGTTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCCGGAGCGCGAGCGCGAGAGCTGCGCAAGGAGCGGAGGCATTCCTTA 325
Qy 41 GluLysTyTrGlyTyLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAATACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAepArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCyvGlyValThrAspThrAenSerTyAla 100
Db 446 GCCACCTGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGACACCGGACCAAAATAGGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAenLysTrpTyLysGlnHisLeuSerTyTrArgLeuVal 140
Db 566 AAACGCTTTCGCAAGCAGGTAACAAATGGTACAGCAGCAGCCTCTCTACCGCCTGGTG 625
Qy 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCyvAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCCTTCCAG 685
Qy 160 rCyvGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCAGCAGCAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACAGCTTGGCTTCCCACTCGCCCGCGCGCGCGGCTCATGGCGCC 984
Qy 260 oTyTrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyTrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTAGTGGCGCTCCAGCTCCCGAGGAACCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyTrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAGAGAGGCGCCCTGAAACGACGGG 1164
Qy 320 yProLysTyTrCyvHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340

```

Db 1165 CCCTAAATAGTCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaPheGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGCCACAGTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArGTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGGAGGTGCAIT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGGTCTCCACAGCTGTGGCGGGCAGGGGGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTrpTyVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTATACCCCGAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGGCCCTGCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAATCGAGGCACACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 166
; Sequence 143, Application US/10145746
; Publication No. US20030134366A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Collin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C269
; CURRENT APPLICATION NUMBER: US/10/145,746
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985

```

```

; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-746-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-746-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGCTGGCGCCCTGCAGCTGTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGAGCGCGGAGCGGAGGCCAGAGCTGCGAAGGAGCGGAGGCATTCCTA 325
Qy 41 GlulysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGTCCCCAAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCACACCTGCGCCAGATGACTCTGTCCTCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyLysGlnHisLeuSerTyArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyValaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCTCAGCGCTGGAGTTCCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAGCGACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGCGCAACCTGTTCTGTTGCTGGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCTACCCACTGCTGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGAGACGACGCTGTCGCGCTGCA 1044
Qy 280 nSerLeuTyTrpLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104

```



```
Oy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGCGAGG 1164
Oy 320 yProlystYrCyvHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCAGCTAGACAGGCAACAGCACTGTA 1224
Oy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGAGCTGATGCAACGTCTCAGAGCCCCG 1284
Oy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGCAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGAGTGTCAAT 1344
Oy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCyvTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Oy 400 sProValTrpGlyLeuProGlnLeuCyvArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 CCAAGTGGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGGCCATCTCTGACGC 1464
Oy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
Oy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 CTTGCTCTCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGG 1584
Oy 460 wIlyl;eThr;GluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGACGGGGCTCTCCAGAGGCCGATGGCTCCATCATCTTCTT 1644
Oy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGGCTCGACCGCCCAACTGCAGGCAACCACTCGGGCGG 1704
Oy 500 gTrpAlaThrGluLeuProTrpMetGlyCyvTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Oy 520 e 520
Db 1765 C 1765
```

RESULT 167

```
US-10-145-748-143
; Sequence 143, Application US/10145748
; Publication No. US20030134367A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deonoyers, Luc
; APPLICANT: Flivaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Geritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowaki, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhong, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; ACIDS ENCODING THE SAME
```

```
; FILE REFERENCE: P3330RIC283
; CURRENT APPLICATION NUMBER: US/10/145,748
; PRIOR FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-748-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-748-143 (1-1985)
```

```
Oy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGGTGCGGCTCTCTGCTGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTG 265
Oy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnGluArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGGAGCGCGGAGCGCAGAGGCTGCGCAAGAGGCGGAGGCAATTCCTA 325
Oy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTTCAGC 385
Oy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGGTTTCAAGTGGGTGCTCCAGCTACTGTCAGCGCGGTGTTGCGACCGC 445
Oy 81 AlaThrLeuArgGlnMetThrArgProArgCyvGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Oy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTTGCTAGACACCGGACCAAAATGAGCGCTAAG 565
Oy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTAAGTGGTACCAAGCAGCACCTCTCTTACCGGCTGGTG 625
Oy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGGAGTTGCGGGGCGCGCTGCGCGCGCGCTTCAG 685
Oy 160 rCyvGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTCTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGAGSCCCAGCCACAGCCCCGCTGAC 745
Oy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGCATGGGCTGGGCAATGCTTTGATGGC 805
Oy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGGCGCCCTGGCGGACGCTTC-CTGCCCGCGCGCGGCGGAGCGGCACTTCGACCA 864
Oy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCTCCCTGAGCGCGCGCGCGCGGCAACCTGTTCTGCTGGTGGCGCA 924
Oy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTTGGCTTCCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
```

```
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCGCTGGCGCGCGCGCTGCTAGCTGGGACGACGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGAGAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgTrpGluThrGlnG1 320
Db 1105 CACTGACCTTGGACCTGGGACTCTCTAGCGCCCAAGGAGGGCCCTGAAGCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATCTGCCACTCTCTTCGATGCCATCACTGTAGACGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATCGAGATTCTACTCTTCAAGGGGGTGGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGCTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 GCCTCTTCTTCCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGGACTGGG 1584
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGCGCTGCCAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGCGCGCTCGACCGCCAAACTGCGAGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGGCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 168

```
US-10-145-823-143
; Sequence 143, Application US/10145823
; Publication No. US20030134368A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
```

```
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC262
; CURRENT APPLICATION NUMBER: US/10/145,823
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-823-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	16	Gaps:	0

US-10-791-980-6 (1-520) x US-10-145-823-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCTGGGCTCTCTGTCGCGCGCTGCTACTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCGCCAGCGCGGAGCGGAGCGGAGCTGCGCAAGGAGGCGGAGGCAATCTCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACCGATACCTCAATGAACAGTCCCAAGCTCCACCTCCACTCGATTGAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTTCAGTGGGTCTCCAGCTACCTGTCAGCGCGTGTTCGACGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAACAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCCTGAGCATCTGCGCGAGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTCTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCCCAAGCCACAGCGCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrPalaMetProLeuMetal	200
Db	746	ATCCGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCGCTGCGGACCGCTTC-CTGCCCGCGCGGAGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240

```
Db      865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGCTGGCGCA 924
Qy      240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925 CAGATCGGTACACACCTTGGCCCTACCCACCTCGCCCGCGCGCGCTCATGCGGCC 984
Qy      260 oTyTyTyLeuArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db      985 CTACTACAAGAGCGTGGCGCGCGAGCGCTGCTCAGCTGGGACGAGTCTGCGCGTGA 1044
Qy      280 nSerLeuTyGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLeuLeuPh 300
Db      1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
Qy      300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG1 320
Db      1105 CACTGACTTTGAGACTGGGACTCTCCAGCCCTACAGCCCTCAAGGAAGCGCCCTGAAACGAGGG 1164
Qy      320 yProTyTyTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165 CCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy      340 rIlePheLeuGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225 CATTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCCTCAGAGCCCG 1284
Qy      360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db      1285 TCCACTGCAGGAAGAATGGTGGGGCTGCCCTCCCAACATGAGGGCTGGCGCATGTCAAT 1344
Qy      380 uAsnAspGlyAspPheTyPhePheLeuGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy      400 gProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLeuGlyAlaArgTyTyVa 440
Db      1465 CGCCCTCTTCTTCTCTCTCTGCGCGCTCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
Qy      440 lIleAlaArgGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTrpG1 460
Db      1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585 AGGCATCCCTGAGGAGGTGAGCGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy      480 eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLeuGlnAlaThrThrSerGlyAr 500
Db      1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLeuSerGlySerAlaLeuPh 520
Db      1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGTGGCATGCCAACTCGGGAGGCGCCCTGT 1764
Qy      520 e 520
Db      1765 C 1765
```

RESULT 169

```
US-10-145-826-143
; Sequence 143, Application US/10145826
; Publication No. US20030134369A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
```

```
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C284
; CURRENT APPLICATION NUMBER: US/10/145,826
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-145-826-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              16          Gaps:      0

US-10-791-980-6 (1-520) x US-10-145-826-143 (1-1985)
```

```
Qy      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db      206 ATGTGCGCGCGCTCGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGCCACCTG 265
Qy      21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db      266 GACGCCACAGCCCGCGGAGCGCGGAGGCTGCGCAAGGAGCGCGAGGCAATTCCTA 325
Qy      41 GluLySTyGlyTyTyLeuAsnGluGlnValProLySAlaProThrSerThrArgPheSer 60
Db      326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGCTCCACCTCCACTCGATTACG 385
Qy      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTACGCGGCGTGTGGACCGC 445
Qy      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db      446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATATACAGATACCAACAGTTATCG 505
Qy      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506 GCCTGGGCTGAGAGGATCAGTCACTTTGTTGCTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy      121 LysArgPheAlaLysGlnGlyAsnLysTrpTyLysGlnHisLeuSerTyArgLeuVal 140
Db      566 AAACGCTTTGCCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGTG 625
Qy      141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626 AACTGGGCTGAGCATCTGCGGAGCGCGAGTTCGCGGCGCGCTGCGCGCGCTTCAG 685
Qy      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686 TTGTGGAGCAACAGTCTCAGCGCTGGAGTTCGTGGAGGGCCCCCAGCCACAGGCCCTGAC 745
Qy      180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
```

```
Db      746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
Qy      200 aGlnGlyAlaProTTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db      806 CCAGGGGGCGCCCTGGCGACAGCCCTTC-CTGCCCCGCGCGCGCGAAGCGCACTTCGACCA 864
Qy      220 nAspGluArgTTrpSerLeuSerArgArgGlyValArgAsnLeuPheValValLeuAlaHi 240
Db      865 AGATAGAGCGCTGCTCCCTAGCCGCGCGGGGCGCAACCTTGTTGTTGGTGTGGCGCA 924
Qy      240 sGluLeGlyHisThrLeuGlyLeuThrHiserProAlaProArgAlaLeuMetAlaPr 260
Db      925 CCAGATCGGTACACGCTTGGCCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy      260 cTyrrTyrIysArgLeuGlyArgAsAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db      985 CTACTACAAAGAGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
Qy      280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db      1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCCGAGAAAGCTGTT 1104
Qy      300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db      1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCCCAAGAAAGGGCGCCCTGAAACGCGAGG 1164
Qy      320 yProIyetyrCyvHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCATCTGTAGACAGGCAACGCAACTGTA 1224
Qy      340 rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy      360 gProLeuGlnGluArgTTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285 TCCACTGCAGAAAGATGGTGGCGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCA 1344
Qy      380 uAsnAspG1VasPheTyrPhePheLeysGlyValArgCyvTrpArgPheArgGlyProLy 400
Db      1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400 sProValTrpGlyLeuProGlnLeuCyvArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTCGACGC 1464
Qy      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyVa 440
Db      1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAAGGGTGGCCGCTACTACGT 1524
Qy      440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrrProArgSerLeuGlnAspTrpG1 460
Db      1525 CTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGAAGTCTGCAAGGACTGGGG 1584
Qy      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585 AGGCATCCCTCAGGAGGTACGCGCGCCCTGCCGAGGCCCGATGGCTCCATCATCTTCTT 1644
Qy      480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db      1645 CCGAGATGACCGCTACTTGGCGCCTCGACAGGCGCAAACTGCGAGCAACCACTCGGGCCG 1704
Qy      500 qTrpAlaThrGluLeuProTrpMetGlyCyvTrpPheIalaAsnSerGlySerAlaLeuPh 520
Db      1705 CTGGGCCACCGAGTGCCTGGATGGGCTGTGGCTGTGGCACTGCCAACTCGGGAGCGCCCTGTT 1764
Qy      520 e 520
Db      1765 C 1765
```

RESULT 170

US-10-145-870-143

; Sequence 143, Application US/10145870

```
; Publication No. US20030134370A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deanoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C274
; CURRENT APPLICATION NUMBER: US/10/145,870
; PRIOR FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-870-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	16	Gaps:	0

US-10-791-980-6 (1-520) x US-10-145-870-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGCTCGGCCTCTCTGTCGCGCGCTGAGAGTGCTACTGTGGGGCCACTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgIysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGGAGCGCGAGGCTGCGCAAGGAGCGGAGGCAATTCCTA	325
Qy	41	GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer	60
Db	326	GAAGAATACCGATACCTCAATGAACAGGTCCCAAGTCTCCACCTCCACTCGATTGAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTACGGCGGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCyvGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgIys	120
Db	506	GCTTGGGCTGAGAGGATCAGTACTGTTTGTGTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaIysGlnGlyAsnIysTrpTyrIysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTACAAATGGTACAGCAGCACCTCTCTACCGCTGCTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTGCGGAGCGGAGGTTTCGGGGCGCGCTGCGCGCGCTTCCAG	685

```
QY 160 rCysGlyAlaThrSerGlnArgTpsSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCGCTGAC 745

QY 180 rSerGlySerProSerSerIysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGC 805

QY 200 aGlnGlyAlaProTpsTrpPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CACAGGGGGCGCTGGCGACGCTTC-CTGCCCCCGCGGGGCAACCTTGTGTGCTGTCGACCA 864

QY 220 nAspGluArgTpsSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGGGGCAACCTTGTGTGCTGTCGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984

QY 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGGCGCGACGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGCCCTTAGGGGCTCAGTGGCGCTCCAGTCCCAAGAAAGCTGTT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCGCCCAAGAGGCGCCCTGAAACGCGAGG 1164

QY 320 vProIysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTTCTCTTGGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTTCAGAGCCCG 1284

QY 360 gProLeuGlnGluArgTpsValGlyLeuProProbenlleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGTGCGGCACTGCATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCCGGGGGCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTTCCACAGCTGTGCGGGCAGGGGCTGCCCCCGCATCTCAGCGC 1464

QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GGTGCCCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGGAGTGTGCAAGGACTGGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCTCTGAGAGGTGAGCGGGCTTCCGAGGGCCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTGCGCGCTCGAACCGAGCAAACTGCAGGCAACCCACCTCGGGCGC 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACCGAGCTGCCCTGGATGGGCTGTGGATGCCAACTCGGGGAGCGCCCTGTT 1764
```

```
QY 520 e 520
Db 1765 C 1765

RESULT 171
US-10-145-876-143
; Sequence 143, Application US/10145876
; Publication No. US20030134371A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC304
; CURRENT APPLICATION NUMBER: US/10/145,876
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-876-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-876-143 (1-1985)
```

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGGCGCGCTCGGCTCTCTGTCGCGCCCTGAGCTGCTACTGTGGGCGCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGGAGCGCGAGGCTGCGCAAGGAGCGGAGGCGGAGCATTCCTTA 325

QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGGCTCCACCTCCGATTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACTCTGACGGCGGTGTGTGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
```

Qy 121 LysArgPheAlaIysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGACAGGTAAACAAATGGTACAGACAGACCTCTCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTCCGCGAGCCGCGAGTCTGGGCGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTACGCGCTGGAGTCTGGAGAGCCCGACAGCCCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGGCTTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnHisLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCGTGGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTTCACAGCTTGGCCTCACCACTGGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGCTGATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTGCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCGCTGATGCCAACGCTCAGAGCCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProProArgHisProAspAl 420
Db 1405 GCCAGTGGGGGTCTCCACAGCTGTCCGGGAGGGGGCTGCCCGCCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGGAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCGCCGATGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

Db 1645 CCGAGATGACCGCTACTGGCGCTCGAGCAGGCAAACTGCAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCTGGATGGCTGTCGCACTGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 172
US-10-145-959-143
; Sequence 143, Application US/10145959
; Publication No. US20030134372A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deenoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C281
; CURRENT APPLICATION NUMBER: US/10/145,959
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-959-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-959-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db 206 ATGTTCGGCGCGTGGCGCT 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCCAGCCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCGATTCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCTTTAGTGGGTGCCAGTACTGTCCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100

Db 446 GCCACCCCTGGCGCAGATGACTGTCCTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgIys 120
Db 506 GCTTGGCTGAGAGGATCAGTGTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACACAGCAGCCTCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGATTCTGGAGGCCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCGTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCTCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTGGAGCTGGGACTCTACAGCCCCCAGGAGCGCCCTGAAACCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCCAATTTCTGGAGGTGGCAGCTATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCCCCAACATTGAGGTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGTTCCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACACAGCTGTGCGGGCAGGGGGCCCTGCGCCCCCACTCTCGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460

Db 1525 GCTGCCCGGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGCTCTCGAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGGCCCTGCCGAGGCCCGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCCCAAACTGCAGGCAACCCACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 173
US-10-146-724-143
; Sequence 143, Application US/10146724
; Publication No. US2003013473A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C317
; CURRENT APPLICATION NUMBER: US/10/146,724
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-146-724-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-146-724-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGCGCGCTCGCGCTCTCTCGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCCGGAGCGCGGAGGCTGGCAGAGGAGGCGGAGGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60

QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGGAGCGCGAGGAGCTGGCGAAGGAGCGGAGGCATTCTCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTTCCAGCTACCTGTGAGCGGCGTGTGGACGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGATGACTGCTCCCGCTCGCGGGTTACAGATACCAACAGATTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCTCGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTAAAGCAGCACCTCTCTCCCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCGCGAGCGGCGAGTTCGGGGCGCGTGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCCCGCGCGGAGCGGAGCGCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGGACGCGCTGCTAGCTGGAGACGAGTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTCGGACTCTCTACAGCCCCCAAGGAGGCGCGCTCGAAAGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATCTGCCACTCTCTTCGATGCCATCTACTGTAGACGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTCATGGCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAGATGGTGGGCTCGCGCTCCCGCCCAACATTGAGGCTGGCGAGTGTCTATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyVarGysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTTCAAAGGGGTGATGTCTGGAGTTCCGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGGGCAAGGGGCTGGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCTCTTCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGCTCTGAGGACTGGGG 1584
QY 460 yGlyLeProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGCGCGCTCTCCGAGGCGCGATGCTCTCATCTCTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAACTGACGAGCAACCTCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 175
US-10-146-795-143
; Sequence 143, Application US/10146795
; Publication No. US20030134375A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C309
; CURRENT APPLICATION NUMBER: US/10/146,795
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-146-795-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2

DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-146-795-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGGCTCGCTCGCGCGCTCGAGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgGlyGlnAlaAlaPheLeu 40
Db 266 GAGCGCCAGCCCGGAGCGCGAGCGCGAGAGCTGCGCAAGAGGCGGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGGCCAGATGACTGTCCCCGCTGCGGGGTTACAGATACCACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCCAAATGAGCGGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTACCGGCTGG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGACATCTCGCGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACNAGTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGGCGCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAATGGCTGGCGCAATGCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGGCTGGCGACGCTTC-CTGCCCCGCGCGGCGAGGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCAACCTGTTCGTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGGACGCTGCTCAGCTGGGACGCGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGTCCAGCTCCACAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTCAGCCCCCAAGAGGCGCGCTGAAAGCGCAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTCTTCGTGATGCCATCCTGTAGACGGAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360

Db 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGAGCTGTATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGAGGGGGCTGCGCGCCATCTCGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAAGTCTGCAGAGGCTGGGG 1584
QY 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480
Db 1585 AGGATCCCTGAGAGGTCTAGCGGCGCTGCGGAGGCGCGATGGCTCCATCTCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGGCGCTCGACGAGGCGGCAACTGCAGGCAACACCTCGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCGCCAGAGTGGCTGGATGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 1764
QY 520 e 520
Db 1765 C 1765
RESULT 176
US-10-147-495-143
; Sequence 143, Application US/10147495
; Publication No. US20030134376A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Garritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: F3330R1C371
; CURRENT APPLICATION NUMBER: US/10/147,495
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-495-143


```
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P33301C372
; CURRENT APPLICATION NUMBER: US/10/147,504
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-504-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-504-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCGGCTCTCTGTCGGCGCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGCGAGCGCGAGCGCGAGAGCTGCGCAAGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GGAAGTACGGATACCTCATGAACAGGTCCCAAGCTCCCACTCCCTCCTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTGAGCTACCTGTCAGCGCGCTGTGGACCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGATGCTGCTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
Qy 101 AlaTyrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCGAACGAAGTAACAAATGGTACAGACGACCTCTCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTACGATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGTGAGTTCGTGGAGGCGCCGACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTGTATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCGCTGGCGACGCCCTTC-CTGCCCCGCGCGCGGCAAGCGCATTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValLeuAlaHis 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGGTGGCGCA 924
```

```
240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
925 CGAGATCGGTACACACGCTTGGCCTCACCACTCGCCCGCGCGCGCTCATGGCGCC 984
260 oTyrTyrIleArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
985 CTACTACAAGAGGCTGGGCGCGCGCTGCTAGCTGGGACGACGCTGCTGGCGCTGCA 1044
280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAAAGGCGCCCTGAAACGCGGG 1164
320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
1165 CCCTAAATACCTGCGCACCTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGT 1224
340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGCAGTGTCAAT 1344
380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
1345 GAATGATGGAGATTTCTACTTTCTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCAA 1404
400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
1405 GCCAGTGTGGGCTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCCGCCATCTGAGCGC 1464
420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
1465 CGCCCTCTCTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCGCTACTACCCCGAAAGTCTGCAAGGACTGGGG 1584
460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
1585 AGGCATCTCTGAGAGGAGTACGCGCGCGCTGCCAGGGCCGATGGCTCATCATCTTCTT 1644
480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645 CCGAGATGACCGCTACTTGGGCGCTCGACCAAGGCCAAACTGCAGGCAACACCTCGGGCGC 1704
500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
1705 CTGGGCCACCGAGTGGCTGGATGGGCTGCTGCATGCCAACTCGGAGGAGCGCCCTGT 1764
520 e 520
1765 C 1765

RESULT 179
US-10-147-506-143
; Sequence 143, Application US/10147506
; Publication No. US20030134379A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
```

```

; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C344
; CURRENT APPLICATION NUMBER: US/10/147,506
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-506-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00        Matches:    519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%    Mismatches: 1
Query Match:      98.52%        Indels:     2
DB:              16            Gaps:       0

US-10-791-980-6 (1-520) x US-10-147-506-143 (1-1985)

Qy      1 MetValAlaargValGlyIleuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db      206 ATGTTGCGCGCGTGGCCCTCTCTGTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265

Qy      21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266 GACGCCAGCCCGCGAGCGCGGAGGCGCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325

Qy      41 GluLysTyrglyTyrluAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326 GAGAAGTACGGATACCTCAATGAAACAGGTGCCCAAGCTCCACCTCCACTCGATTTCAGC 385

Qy      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACTCTGTACGGCGGTGTGGACCGC 445

Qy      81 AlaThrIeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyAla 100
Db      446 GCCACCTCTGGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGG 505

Qy      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506 GCCTGGGCTGAGAGNTCAGTGACTTGTTTGCTAGACACCGGACCAAAATGAGCGGTAG 565

Qy      121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrlLysGlnHisLeuSerTyArgLeuVal 140
Db      566 AAAACGCTTTGCCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCTGGT 625

Qy      141 AsnTrpProGluHisIeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626 AACTGGCTTGAGCATCTGCGGAGCCGGCAGTTTCGGGGCGCGGTGGCGCGCTTCCAG 685

Qy      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686 TTGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACGAGCCCCGCTGAC 745

Qy      180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db      746 ATCCGGCTCACCTCTTCCAAAGGGGACACAAACATATGGGTGGGCAATGCTTTTGTATGC 805

Qy      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgGlyGluAlaHisPheAspG 220

```

APPLICANT: Beresini, Maureen
APPLICANT: Deforge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P33301C331
CURRENT APPLICATION NUMBER: US/10/147,509
CURRENT FILING DATE: 2002-05-16
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059836
PRIOR FILING DATE: 1997-09-24
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062285
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062287
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062814
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/062816
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/063045
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/063082
PRIOR FILING DATE: 1997-10-31
PRIOR APPLICATION NUMBER: 60/063127
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/063327
PRIOR FILING DATE: 1997-10-27
PRIOR APPLICATION NUMBER: 60/063329
PRIOR FILING DATE: 1997-10-27
PRIOR APPLICATION NUMBER: 60/063550
PRIOR FILING DATE: 1997-10-28
PRIOR APPLICATION NUMBER: 60/063561
PRIOR FILING DATE: 1997-10-28
PRIOR APPLICATION NUMBER: 60/063704
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063733
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063735
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063738
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063755
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064248
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/064809
PRIOR FILING DATE: 1997-11-07
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065846
PRIOR FILING DATE: 1997-11-17
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/066453
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/066511
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/069212
PRIOR FILING DATE: 1997-12-11
PRIOR APPLICATION NUMBER: 60/069278
PRIOR FILING DATE: 1997-12-11
PRIOR APPLICATION NUMBER: 60/069334
PRIOR FILING DATE: 1997-12-11
PRIOR APPLICATION NUMBER: 60/069694
PRIOR FILING DATE: 1997-12-16
PRIOR APPLICATION NUMBER: 60/072320
PRIOR FILING DATE: 1998-01-23
PRIOR APPLICATION NUMBER: 60/073612
PRIOR FILING DATE: 1998-02-04
PRIOR APPLICATION NUMBER: 60/074086
PRIOR FILING DATE: 1998-02-09
PRIOR APPLICATION NUMBER: 60/074092
PRIOR FILING DATE: 1998-02-09
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-02-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081695
PRIOR FILING DATE: 1998-04-14
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081818
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082999
PRIOR FILING DATE: 1998-04-24
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085149
PRIOR FILING DATE: 1998-05-12
PRIOR APPLICATION NUMBER: 60/085323

✓	PRIOR FILING DATE:	1998-05-13
✓	PRIOR APPLICATION NUMBER:	60/085338
✓	PRIOR FILING DATE:	1998-05-13
✓	PRIOR APPLICATION NUMBER:	60/085339
✓	PRIOR FILING DATE:	1998-05-13
✓	PRIOR APPLICATION NUMBER:	60/085579
✓	PRIOR FILING DATE:	1998-05-15
✓	PRIOR APPLICATION NUMBER:	60/085697
✓	PRIOR FILING DATE:	1998-05-15
✓	PRIOR APPLICATION NUMBER:	60/085704
✓	PRIOR FILING DATE:	1998-05-15
✓	PRIOR APPLICATION NUMBER:	60/086414
✓	PRIOR FILING DATE:	1998-05-22
✓	PRIOR APPLICATION NUMBER:	60/086430
✓	PRIOR FILING DATE:	1998-05-22
✓	PRIOR APPLICATION NUMBER:	60/087106
✓	PRIOR FILING DATE:	1998-05-28
✓	PRIOR APPLICATION NUMBER:	60/088026
✓	PRIOR FILING DATE:	1998-06-04
✓	PRIOR APPLICATION NUMBER:	60/088730
✓	PRIOR FILING DATE:	1998-06-10
✓	PRIOR APPLICATION NUMBER:	60/088741
✓	PRIOR FILING DATE:	1998-06-10
✓	PRIOR APPLICATION NUMBER:	60/088810
✓	PRIOR FILING DATE:	1998-06-10
✓	PRIOR APPLICATION NUMBER:	60/088858
✓	PRIOR FILING DATE:	19/98-06-11
✓	PRIOR APPLICATION NUMBER:	60/089532
✓	PRIOR FILING DATE:	1998-06-17
✓	PRIOR APPLICATION NUMBER:	60/089599
✓	PRIOR FILING DATE:	1998-06-17
✓	PRIOR APPLICATION NUMBER:	60/089907
✓	PRIOR FILING DATE:	1998-06-18
✓	PRIOR APPLICATION NUMBER:	60/089947
✓	PRIOR FILING DATE:	1998-06-19
✓	PRIOR APPLICATION NUMBER:	60/090349
✓	PRIOR FILING DATE:	1998-06-23
✓	PRIOR APPLICATION NUMBER:	60/090429
✓	PRIOR FILING DATE:	1998-06-24
✓	PRIOR APPLICATION NUMBER:	60/090445
✓	PRIOR FILING DATE:	1998-06-24
✓	PRIOR APPLICATION NUMBER:	60/090538
✓	PRIOR FILING DATE:	1998-06-24
✓	PRIOR APPLICATION NUMBER:	60/090863
✓	PRIOR FILING DATE:	1998-06-26
✓	PRIOR APPLICATION NUMBER:	60/091360
✓	PRIOR FILING DATE:	1998-07-01
✓	PRIOR APPLICATION NUMBER:	60/091519
✓	PRIOR FILING DATE:	1998-07-02
✓	PRIOR APPLICATION NUMBER:	60/091982

Alignment Scores:		
Pred. No.:	3,356-262	1985
Score:	2792.00	Matches: 519
Percent Similarity:	99.62%	Conservative: 0
Best Local Similarity:	99.62%	Mismatches: 1
Query Match:	98.52%	Indels: 2
DB:	16	Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-509-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGTCTGGCCCTCTGTGCGGCCCTGCAGTGCTACTGTGGGGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgIysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCCGCGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluInValProIysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTAGCGATACCTCAATTGAACAGTCCCCAAAGCTCCACCTCCAATCGATTTCAGC	385

Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACTGTTCAGCGCGGTGTTCGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTCGCCACAGATGACTCGTCCCGCGTTCGGGGGTTCACAGATACCAACAGTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgIys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGCTAGACACCGGACCAAAATGAGCGGTAAAG	565
Qy	121	LysArgPheAlaLysGlnIysAsnLysTyrTrpIyryLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCCTTGCAAAGCAAGGTTAACAAAATGGTACAAAGCAGCACCTCTCTCTACCGCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGGCTGAGCATCTCGCGGAGCGCGCAGTTCCGGGCGCGGTGCGCGCGCTTCACG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTTGGAGACAAACGTCCTCAGCGCTGGAGTTCTGGAGAGCCCGCAGCCAGCGCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSerIysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTCTTCCAAAGGGGACCAACAACATGGGCTGGGCANTGCTTTGATGGC	805
Qy	200	gGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGCGCTTGGCGGCACGCCCTTC-CTAGCCCGCGCGCGGCGAAGCGCACCTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGACGCTGGTGCCTCTGAGCGCCCGCGCGGCGCAACGTGCTGTGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGCACGCGCTGCTCAGCTGGGACACAGCTGTGTGGCGGTCA	1044
Qy	280	nSerLeuTyrGlyIysProLeuGlyIysSerValAlaValGlnLeuProGlyIysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCGTCCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGGCGCCTCGAAGCGCAGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCCACCTTCTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGT	1224
Qy	340	rIlePheLeuGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGTTCGGGCTGCCCGCCCAACANTTGGGCTGGGCGAGTGTCTATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyIysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTCTTCAAAAGGGGTTCGATGCTGGAGCTGGGCGAGTGTCTATT	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCCAACAGCTGTGCCGGGAGGGGGCGCTGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpTrpVal	440

Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCAGGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTCGAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTTGGCGCTCGACAGGCCAACTGCAGGCCAACCCCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGCTGCTGGGCATGCCAACTCGGGAGGCGCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 181

US-10-147-510-143
; Sequence 143, Application US/10147510
; Publication No. US20030134381A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC370
; CURRENT APPLICATION NUMBER: US/10/147,510
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-510-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-510-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ARGGGTGGCGGGTGGCGCTCTCTGTCGGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GACGCCAGCCGCGAGCGCGAGGAGCTGCGCAAGAGAGCGCGAGGCATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAGCTCCCAACCTCCACCTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTCAGTGGGTGCCAGCTACCTGTCTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
Db 446 GCCACCTTCGCCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCCANAATAGGGGTAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCANAAGCAAGGTAACAAATGGTTACAGCAGCACCTCTCTACCGCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCCGAGCGCGCAGTTCGGGGCGCGTTCGGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGTTCTGGGAGGCCCCAGCCACAGGCCCTCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTCATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTTGAGCGCGCGCGCGGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCTCGCCCGCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAACTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGAGGCCCTCTGAACCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTCTCTTCGATGCCCTCCTCTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400

Db 1345 GAATGATGAGATTTCTACTTCTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCCCTGCCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLeuGlyGlyLeuTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAACTCTGCAGGACTGGGG 1584
QY 460 vGlyLeuProGluGluValSerGlyAlaLeuProArgProArgProArgSerLeuPhePhe 480
Db 1585 AGGCATCCCTGAGGAGGTCAGCGGGCCCTGCGGAGGCCGATGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAACTGCGAGGCAACACTCGGGCGG 1704
QY 500 gTPAlaThrGluLeuProTTPMetGlyCysTrpHisAlaLeuSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 182

US-10-147-511-143
; Sequence 143, Application US/10147511
; Publication No. US20030134382A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C356
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-511-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-511-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGCGCTCTCTCTCGCGCCCTCGAGCTGCTACTTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGGCTGCGCAAGGAGCGGCGGATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGCTCCCCAAAGCTCCACCTCCACTCGATTGAGC 385
QY 61 AspAlaLeuArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCAGCTACTGTCAGCGCGGTGTTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCCCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTPAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTCTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 625
QY 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCCGCGAGTTGCGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCGCAGCACAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGCGCGCAGCCTTC-CTGCCCCCGCGCGGCGGAGCGACTTCGACCA 864
QY 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTGTGTGTGTGTGTGTGT 924
QY 240 sGluLysGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTTCACAGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGAGCAGCTGTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGTGTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGCGCGCTCAAGCGCAGGG 1164
QY 320 YProLysTyrCysHisSerPheAspAlaLeuThrValAspArgGlnGlnLeuLeuTyr 340
Db 1165 CCTTAATATCTGCCACTCTCTCTTCGATGCCATCTACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rLysPheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGGAGGTGGCAGCTGTATGGCAAGCTCTCAGAGCCCCG 1284


```
QY 360 gProLeuGlnArgTrrpValGlyLeuProAenilleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGGTGGCCCCCAACATTGAGGCTGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGGTCTCCCAAGCTGTGGCGGGGAGGGGGCCCTGCCCCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTrrpVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
QY 440 lleuAlaArgGlyLeuGlnValGluProTrrpTrrpProArgSerLeuGlnAspTrrpGl 460
Db 1525 GCTGGCCCCAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyileProGluGluValSerGlyAlaLeuProArgProAspGlySerIleilePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGGGGCCCTGCGGAGGCCGATGGTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTrrpTrrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCCAACTGCAGGAGAACCCACCTCGGGCG 1704
QY 500 gTrrpAlaThrGluLeuProTrrpMetGlyCysTrrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGGCCCTGTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 183
US-10-147-529-143
; Sequence 143, Application US/10147529
; Publication No. US20030134383A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P33301C133
; CURRENT APPLICATION NUMBER: US/10/147,529
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-529-143
Alignment Scores:
```

```
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-147-529-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCCAGCCCGGAGCGCGGAGCCAGAGCTGCGCAAGAGCGCGAGGCAATTCCTA 325
QY 41 GluLysTrrpGlyTrrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGGTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCTGTGTGGACGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTCTAGACACCGGACCAAAATCAGGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrrpTrrpLysGlnHisLeuSerTrrpArgLeuVal 140
Db 566 AAACGCTTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625
QY 141 AsnTrrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCCTGAGCATCTGCCGAGCGCGGACGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGCGCCCGCCAGCAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGCGCAACCTGTTCTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCAGCTCCAGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrrpLysArgLeuGlyArgAspAlaLeuLeuSerTrrpAspAspValLeuAlaValGl 280
Db 985 CTACTCAAGAGGCTGGGGCGCGGACGCGCTGCTCAGTGGGACACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTrrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrrpAspSerTrrpProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGGCGCTCTGAAAGCGAGGG 1164
```

QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAACTGCGCACTCTTCCTTGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGTCCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGAAGTGGTCGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTCTTCAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGCAGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 sAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTCTTCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCCGAGGCCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAAACTGCGAGGCAACCACTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 184

US-10-152-397-143
; Sequence 143, Application US/10152397
; Publication No. US20030134384A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C380
; CURRENT APPLICATION NUMBER: US/10/152,397
; CURRENT FILING DATE: 2002-05-20
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-152-397-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-152-397-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGGAGGCCAGAGCTGCGCAAGGAGGCGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProIleAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTCTCCAGCTACTCTGACGCGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGGCGCAGATGACTCGTCCCGCTGGGGGTTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTGTGTTTCTAGACACCGGACCAANAATGAGCGGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAACAAATGGTTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCCTGAGCATCTGCGGAGCGGCGAGTTTGGGGCGCCGTCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThr-SerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTGGAGAGCCCCAGCCACAGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC -CTGCGCCCGCGCGGCGGAGCGACCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGTGTCTCTGAGCCCGCGCGGCGGCGCACTGTTCTGTGTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCTACCCACTCGCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGACGCTGCTCAGCTGGGACGACGCTGTGCGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

Db 1045 GAGCCTGTATGGAAAGCCCTTAGGGGGCTCACTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGAGGCCCTTGAAACCGAGGG 1164
Qy 320 yProLysTyrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 pProLeuGlnArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTCCGGCTGCCCCCCAACATTGAGGTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCCCCCCTATCTCTGACGC 1464
Qy 420 sAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCTATCTCTTCAAGGGTGGCGCTACTACTGT 1524
Qy 440 lIleAlaArgGlyGlyLeuGlnValIcluproTyrTyrProArgSerLeuGlnAspTTPG 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCGCTGCGGAGGCGCATGCTGCTCATCATCTTCTT 1644
Qy 480 eArgAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCTGACAGGCCCAAACTGACAGGCAACCACTCGGGCGG 1704
Qy 500 gTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 185
US-10-153-586-143
; Sequence 143, Application US/10153586
; Publication No. US20030134385A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C413
; CURRENT APPLICATION NUMBER: US/10/153,586
; PRIORITY FILING DATE: 2002-05-22
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-153-586-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-153-586-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGCAAGGAGCGCGAGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGCTCCCAAGGCTCCCACTCCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCACTGGGTGTCCAGAGTACCTGTGTCAGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCAGGAGTACCTGTCCTCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTTPAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTTGTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGAGCGGAGTCTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTGGGAGGCGCCCGCAGCCAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACATGGGCTGGGCAATGCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGCGCCCTGGGCGACGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGGCACTGTTGCTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
|||||

Db	925	CGAGATCGGTACACGCTTGGCGCTCACCCACTCGCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrrLyysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CAC TGACTTTCAGACCTGGGACTCCTACAGCGCCCAAGGAAGGCGCTCGAAACGACGGG	1164
Qy	320	yProLysTyrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTCGCCACTCTTCCTTCGATGCCATCAC TGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTTC TGAGGTTGGACGTGATGGCAACGCTCAGAGCCCGG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTC TACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGCGCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGCTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCATTCCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrrVa	440
Db	1465	CGCGCTCTTCTTCCTCTCGCGCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyLysLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCGCGAGGGGACGTGCAAGTGGAGCCCTACTACCGCCGAAGCTGACAGGACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh	480
Db	1585	AGGCATCCCTGAGGAGTTCAGCGCGCGCTGCGGAGCGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTCTGACCAAGCCCAACTGCGAGCAACACCACTCGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGTGCCTCGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e	520
Db	1765	C	1765

RESULT 186

US-10-158-786-143
; Sequence 143, Application US/10158786

; Publication No. US20

GENERAL INFORMATION:

Baker, Kevin P. APPLICANT

Beresini, Maureen APPLICANT

Berge, Laura APPLICANT

Desnoyers, Luc APPLICANT

Falvo, Rolf, Ellen APPLICANT

Gao, Wei-Qiang APPLICANT

Gerritsen, Mary E. APPLICANT

Goddard, Audrey APPLICANT

Godowski, Paul J. APPLICANT

Gurney, Austin L. APPLICANT

```
QY 220 nAppGluAtrpSerLeuSerArgArgArgGlyValValValLeuAlaHi 240
Db 865 AGATGAGCGTGTCTCTGAGCGCGCGCGCGCGCAACCTGTTCTGTGTGTGTGGCGCA 924
QY 240 sGluileGlyHieThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTGTGGCTCTACCCACTCGCGCGCGCGCGCTCATGTGGCGC 984
QY 260 oTyTrTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAGAGCTGGCGCGCGCGCGCTGCTCAGCTGGAGCAGCTGTGTGGCGGTGCA 1044
QY 280 nSerLeuTyGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGACACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGMAACGCGGG 1164
QY 320 yProTyTyCysHieSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAATAATGTCACCTCTCTCTTCGATGCCATCTAGCTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHiePheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGCGGCACTGTCATT 1344
QY 380 uAenAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCCGCATCTGACGC 1464
QY 420 alaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGI 460
Db 1525 GTGGCCCCAGGGGAGCTGCAAGTGGAGGCCCTACTACCCCGGAAGTCTGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGTCAAGGGCGCTTGGAGGCCCGATGGCTCATCTCTTCTT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCAAGCAAACTGAGGCAACCCACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 187

```
US-10-137-870-143
; Sequence 143, Application US/10137870
; Publication No. US20030138883A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
```

```
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC155
; CURRENT APPLICATION NUMBER: US/10/137,870
; CURRENT FILING DATE: 2002-05-03
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-137-870-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-137-870-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGCGCGCTCGGCTCTCTGTCGCGCGCTCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGAGCGCGGAGGCTGCGCAAGGAGCGGAGGCGCATTCCTA 325
QY 41 GluLysTyGlyTyLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGGCTCCACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGCTTTCAGTGGGTGTCCAGGCTACTGTGAGCGGCTGTGTGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATCGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTCACTTGTCTGTAGACACCGGACCAAAATCAGGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyLysGlnHisLeuSerTyArgLeuVal 140
Db 566 AAACGCTTGGCAAGAGCAAGGTAAATAATGGTACAGGAGCAGCTCTCTCCCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTCTTCTGGGAGGCGCCAGCCAGCCAGCGCTGAC 745
```

Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGACACAAACATGGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGly	220
Db	806	CCAGGGGGCGCTTGGCGCAGCCCTTC-CTGCCCGCGCGCGCAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCTGTTGTTGCTGGCGCA	924
Qy	240	sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalApr	260
Db	925	CGAGATCGGTCAACAGCTTGGCTCACCCATCTCGCGCGCGCGCGCGCTCATGGGGCC	984
Qy	260	oTyrrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGly	280
Db	985	CTACTACAAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCGCTGTATGGGAAGCCCTTAGGGGGTCTAGTGGCGTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGly	320
Db	1105	CACGTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAGGCGCTGTAAACGCAAGG	1164
Qy	320	yProLysTyrrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rLeuPheLysGlySerHisPheTrpGluValAlaAlaAspClyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTCTCTGGAGGTGGAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTGGGCTGCCGCCCCCAACATTGAGGCTGGGCGAGTGCATT	1344
Qy	380	uAsnAspGlyAspPheTyrrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCCAAGCTGTGCCGGGCAAGGGGCTCGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrrTyrrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpGly	460
Db	1525	GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTAGCCCCGAAGTCTGAGGAGCTGGG	1584
Qy	460	yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh	480
Db	1585	AGGCATCCCTGAGGAGTCAAGCGCGCTTGCAGGCGCGCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTTCSGACGAGCCAAATCTGAGGCAACCACTCGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e	520
Db	1765	C	1765

RESULT 188

```

US-10-140-018-143
; Sequence 143, Application US/10140018
; Publication No. US2003013885A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C158
; CURRENT APPLICATION NUMBER: US/10/140,018
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-018-143

```

RESULT 188

Db 626 AACTGGCTGAGCATCTGCGAGCGGAGTTCGGGGCGCGTTCGGCGCCCTTCCAG 685
Qy |||||
Db 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
|||
Db 686 TTGTGGAGGACGCTCTCAGCGCTGAGATTCTGGAGGCCCCACAGCCGCGCTGAC 745
|||
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
|||
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACACACAGATGGCTGGCAATGCTTTGATGGC 805
|||
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
|||
Db 806 CCAGGGGGCGCGCTGCGCACGCCCTTC-CTGCGCGCGCGCGGCGCACTTCGACCA 864
|||
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
|||
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTTGTGTGTGCTGGCGCA 924
|||
Qy 240 aGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
|||
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
|||
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
|||
Db 985 CTACTACAAGAGCGTGGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGCGTGA 1044
|||
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
|||
Db 1045 GAGCTGTATGGAGAGCCCTTAGGGGGCTCAGTGGCGGTCCAGTCCCGAGGAAGCTGT 1104
|||
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
|||
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGAGCGCCCTGAAACGCGAGG 1164
|||
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
|||
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACGGCAACAGCAACTGTA 1224
|||
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
|||
Db 1225 CATTTTTAAGAGGAGCCATTTCTGGAGGTGCGAGCTGATGGCAACGTCTCAGAGCCCCG 1284
|||
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
|||
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCA 1344
|||
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
|||
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGAGAGTTCCGGGGCCCCA 1404
|||
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
|||
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCGCCGCCCATCTCGACGC 1464
|||
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
|||
Db 1465 CGCCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1524
|||
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
|||
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAGTCTGCGAGGACTGGGG 1584
|||
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
|||
Db 1585 AGGCATCCCTGAGGAGGTGACGGCGCCCTGCGGAGGCCGATGCTCCATCATCTTCTT 1644
|||
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
|||
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCGAGGCAACCACTTCGGGCGG 1704
|||
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
|||

Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATCCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 189
US-10-140-021-143
; Sequence 143, Application US/10140021
; Publication No. US20030138886A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C167
; CURRENT APPLICATION NUMBER: US/10/140,021
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-021-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-140-021-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGATCGCGCGCTGCGGCTCTCTGCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCCGGAGCGCGGAGGCGAGAGCTGCGCAAGAGGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTAGCGATCATCTCAATGAACAGAGTCCCAAGAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGACTACTGTGTCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGTCGCCGCTGCGGGGTACAGATACCAACAGATTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
|||

Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGCGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCCTTTCAGAAAGCAAGTAAACAAATGGTACAGCAGCACCTCTCCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCCCGAGCGCCGACGTTCCGGGCGCGCTGGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGAGGCGCCAGCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACATGCGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGCTCACACGCTTGGCCCTCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGAGCAGCTGCTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTTGGGCTCTCTCAGCGCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATATGTCACCTCTCTCTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGTGGCGAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGTCAGAAAGATGGTGGGCTGCCCGCCCAACATGAGCGCTGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTCGATCTGGAGGTTCCGGGCGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGCGCAGGGGCGCTGCCCGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGTCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTATCCCGCAAGTCTGCGAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerLeilePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCCGAGGCGCGATGGCTCCATCATCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGAGATGACCGCTACTGGCGCCTCGACCGCCAAACTCGAGGCAACACCTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGCAATGCCAATCTGGGGGAGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 190
US-10-140-471-143
; Sequence 143, Application US/10140471
; Publication No. US2003013887A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C163
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-140-471-143
Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-140-471-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGGTCGCGCGCTCGGCGCTCTGTCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGGAGCGCGGAGCGCGAGCGCTGCGCAAGGAGCGGAGCGGCTTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCATGACAGCTGCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGTGTCCAGCTACCTGTCAGCGCGCTGTTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCGAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgIys 120
DB 506 GCGTGGGCTGAGAGGATCAGTCACTTGTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTTGCAAGACAGGTACAAATGGTACAGCAGCAGCTCTCTTACCAGCCCTGGTG 625
QY 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGTGGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
DB 746 ATCCGCTCACCTTCTTCNAGGGGACCAACAGATGGGCTGGCAATGCCCTTTGATGCG 805
QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTCGGCGACGCTTC-CTGCGCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCCACCATCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGCGTGGCGCGAGCGCGCTGTCTAGCTGGAGCAGCTGTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCGTGTATGGAAGCGCTTACGGGGCTCAGTGGCGCTCCAGTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTTCTACAGCGCCCAAGGAGGCGCGCTGAAACGCGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCTGTAGNACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
QY 360 gProLeuGlnArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
DB 1285 TCCACTGAGGAAAGATGGTGGGCTGCCCGCCCAACATGAGGCTGGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTTPArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCTGCTGGAGGTTCGGGGGCCCCAA 1404
QY 400 gProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCGCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGTGTGCCCGCTACTACGT 1524

QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAAATCGCAGGCAACCATCTCGGGCGG 1704
QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 191

US-10-140-922-143

; Sequence 143, Application US/10140922

; Publication No. US2003013889A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C179

; CURRENT APPLICATION NUMBER: US/10/140,922

; CURRENT FILING DATE: 2002-05-07

; Prior Application removed - See Palm or File Wrapper

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-140-922-143

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	16	Gaps:	0

US-10-791-980-6 (1-520) x US-10-140-922-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
DB 206 ATGTCGCGCGGTTCGCGCTCTCTGCGCGCTGCTGAGCTGTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGGAGCGCGGAGCTGGCGCAAGGAGCGGCGGCGGCGCATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluInValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCATGACAGGTCCCAAGCTCCACCTCCACATCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTTCAGTGGGTGCCAGCTACCTGTTCAGCGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATGATCTCTCCCGCTGCGGGTTACAGATACCAACAGATTATCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGATCAGTACCTGTGTGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGCACCTCTCTCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCCGAGCGGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnAlaProLeuTh 180
DB 686 TTGTGGACACGCTCTCAGCGCTGAGTTCGGGAGGCCCCCAGCCAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGCTCACCTCTTCCAAAGGACCCACAAACGATGGCTGGCAATGCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGCGCATCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACTGTTCGTGTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAGCGCCCTGAAACCGCAGG 1164
QY 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACCTGCCACTCTCTTCGATGCCATCACTGTAGACGGAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCGC 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLys 400
DB 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTCGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

DB 1405 GCCAGTGTGGGTTCTCCACAGCTGTCCGGGAGGGGGCTGCGCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluIleValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGAGCGCGGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCGCAACTGCAGGCAACCACTCGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGTCGATGCCAATCGGGGAGCGCGCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 192
US-10-145-631-143
; Sequence 143, Application US/10145631
; Publication No US20030138891A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C273
; CURRENT APPLICATION NUMBER: US/10/145, 631
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-631-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-631-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

1295	TCCACTGCAGGAAGATGGGTGGCGCTGCCCCCAACATTGAGCGCTCGCGCAGTGTCTATT	1344
QY	uAsnAAspGlyAspPheTyrPhePheLeysGlyGlyArgCysTrpArgPheArgGlyProLy	400
1345	GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTTCGGGGGCCCAA	1404
QY	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
1405	GCCAGTGTGGGGTCTCCACACAGCTGTGCCGGGCAAGGGGGCTGCCCGGCCCATCTCTGACGC	1464
QY	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLeysGlyAlaAArgTyrTyrVa	440
1465	GCGCCCTCTTCTCTCTCTGCGCGCCTCATCTCTTCAAGGGTGC CGCTACTACTAGT	1524
QY	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
1525	GCTGGCCCGAGGGGACGTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGCATCGGG	1584
QY	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
1585	AGGCATCCCTGAGGAGGTCAGGGCGCCCTGCCAGGCCGATGGCTCCCATCATCTTCTT	1644
QY	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
1645	CCGAGATGACCGCTACTTGGCGCCTCGACACAGGCCAAACTGCAGGCCAACCACTCGGGCGC	1704
QY	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
1705	CTGGGCCACCGAGCTGCCCTGGATGGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
QY	520 e 520	
1765	C 1765	
Db		

```

1 / APPLICANT: Baker, Kevin P.
2 / APPLICANT: Beresini, Maureen
3 / APPLICANT: DeForge, Laura
4 / APPLICANT: Desnoyers, Luc
5 / APPLICANT: Filvaroff, Ellen
6 / APPLICANT: Gao, Wei-Qiang
7 / APPLICANT: Gerritsen, Mary E.
8 / APPLICANT: Goddard, Audrey
9 / APPLICANT: Godowski, Paul J.
10 / APPLICANT: Gurney, Austin L.
11 / APPLICANT: Sherwood, Steven
12 / APPLICANT: Smith, Victoria
13 / APPLICANT: Stewart, Timothy A.
14 / APPLICANT: Tumas, Daniel
15 / APPLICANT: Watanabe, Colin K
16 / APPLICANT: Wood, William
17 / APPLICANT: Zhang, Zemin
18 / TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
19 / FILE OF INVENTION: ACIDS ENCODING THE SAME
20 / FILE REFERENCE: F3330R1C291
21 / CURRENT APPLICATION NUMBER: US/10/145,633
22 / CURRENT FILING DATE: 2002-05-14
23 / Prior Application removed - See File Wrapper or Palm
24 / NUMBER OF SEQ ID NOS: 550
25 / SEQ ID NO 143
26 / LENGTH: 1985
27 / TYPE: DNA
28 / ORGANISM: Homo Sapien
29 / US-10-145-633-143
30
31 Alignment Scores:
32 Pred. No.: 3,35e-262 Length: 1985
33 Score: 2792.00 Matches: 519
34 Percent Similarity: 99.62% Conservative: 0

```


; CURRENT APPLICATION NUMBER: US/10/140,274
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-274-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 99.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-274-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGTCTGCTGCGCGCGCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgGlyGlnAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGGAGCGCGAGGCTGCGCAAGGAGGCGGAGGCAATTCCTA 325
Qy 41 GlutylsTrpGlyLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGAGCTACCTGTGAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerThrAla 100
Db 446 GCCACCTTGGCGCAGATGATCTGCTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTCTAGACACCGGACCAAAATGAGCGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAAGCAGACACCTCTCCACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCGCGCAGTTTGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCAGCGCTGAGTTCTGGGAGGCCCCCAGCCACGAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCCTTGGGCGACGCTTC-CTGCCCGCGCGGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGCGCAACCTGTTCTGTGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrIleuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCCCTACCCACTCGCCCGCGCGCGCTCATGTGGCGCC 984
Qy 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280

Db 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyArgLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCACGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyArgHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTGCGCACTCTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGGAAAGATGGGTGCGGCTGCCCGCCCAACATTTGAGGCTGCGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGGCTGCCCGGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrpVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAAGGGTGCCTGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGACGAGTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGAGCGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGTACTTGGCGCTCGACCAAGGCGCAACTCGAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCCACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 196

US-10-140-019-143
; Sequence 143, Application US/10140019
; Publication No. US20030148423A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Oiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.

```
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC170
; CURRENT APPLICATION NUMBER: US/10/140,019
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - see file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-019-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-019-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGGTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGAGCGCGGAGCCAGAGCTGCCAAGAGCGCGGAGGCATTCTTA 325
Qy 41 GluLysTrpGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCACATGACTGCTCCCGCTGCGGGGTACAGATACCAACAGTTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGAGCCAAATGAGGCGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCTTTGCAAGCAAGGTAAACAAATGGTAAACAGCAGCCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCANTCTGCGGAGCGCGAGGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGAGCCACACAGTGGGCTGGGCAATGCCCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGGCGCTGGCGACGCCCTTC-CTGCCCCCGCGCGGAGCGGACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
```

```
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGGGCAACCTGTGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCACAGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrClyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCCGAAGAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCGCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGCGGCTGCCCCCAACATGAGGTGCGGACAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCGATGCTGGAGGTTCGCGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTTGGCGAGGCCCGATGGCTCCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTTGGCGCCTCGACAGGCCAAACTGCGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCGTGGATGGGTCTGTCGATGCCAATCTCGGAGCGCGCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 197
US-10-140-022-143
; Sequence 143, Application US/10140022
; Publication No. US20030148424A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
```

```
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C159
; CURRENT APPLICATION NUMBER: US/10/140,022
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-022-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-022-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGCGCGCTCGCTCGCGCGCTCGCTCGCGCGCTCGCTCGCTCGCTCGCTCGCT 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGGAGCGCGGAGCGCGGAGCGCGGAGCGCGGAGCGCGGAGCGCGGAGCG 325

Qy 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCAAGCTCCCAAGCTCC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGGTTTTCAGTGGGTGTCCTGAGCTACCTGTGAGCGGCGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTGCTCCCGCTCGCGGTTACAGATACCAAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGCTGAGAGGATCAGTGAATGTTTCTAGACACCGGACCAAAATGAGGCGTAA 565

Qy 121 LysArgPheAlaLysGlnGlnAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGACCTCTCCTACCGCTGTGT 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGGCGCGCAGTTTCGGGCGCGCTGCGCGCGCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACCTCTCAGCGCTCGAGTTCCTGGGAGGCGCCAGCCACAGGCGCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACACATGGGCTGGGCAATGCTTTGATGGC 805
```

RESULT 198

US-10-140-861-143
; Sequence 143, Application US/10140861
; Publication No. US20030148425A1

```
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGCTCACACGCTTGCGCTCACCGCTCGCGCGCGCGCGCGCGCGCGCGCGCG 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCGCGCGCGCTGCTCAGCTGGGACGACGTGTCGG 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValAlaGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTCGAAAACG 1164

Qy 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATATCTGCACCTCTCTTCGATGCCATCCTCTGTAGACAGGCAACAGCACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGTATGGCAGCTCTCAGAGCCCG 1284

Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAAAGATGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGG 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCGATGCTGGAGGTTCGGGGGCCCAA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGCGGCGAGGGGCTGCCCGCGCATCTGAGCG 1464

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGAGTGAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584

Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGAGTACCGCTACTGGCGCTCGACCAAGGCGCAACTCGAGGCAACCACTCGGCGCG 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765
```


[illegible]


```
Db 1645 CCGAGATGACCCCTACTGCGGCTCGACCGAGGCCAAATGTCAGGCAACACCTCGGGCGG 1704
Qy 500 gTrrAlaThrGluLeuProTrrPmetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 200
US-10-141-697-143
; Sequence 143, Application US/10141697
; Publication No. US20030148427A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Bersini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C202
; CURRENT APPLICATION NUMBER: US/10/141,697
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-697-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-141-697-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGGTGGGCTCTGCTGCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGGAGCGCGAGGCGAGGCTGCGCAAGGAGCGGCGGAGCATTCCTA 325
Qy 41 GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
```

```
Db 446 GCCACCCCTGCGCCAGATGACTGTCCTCCGCTCGGGGTTACAGATACCACAACTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTTCCTAGACACCGGACCAAAATGAGGGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCGCGAGCCGACGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrrPserSerGlyVargProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGAGGCCCCAGCCAGGCCCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrrPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyVargAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGCGCAACCTGTTCTGGTGGTGGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCTCTCAGCTGGGACGACGCTGCGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCNAGGAAGGGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCGCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGAGCTGATGGCAACGCTCCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGCAAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGGGCAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCTGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGGCCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGG 1584
```

```
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTCAAGCGCGCCCTGCCAGGCCCGATGGCTCATCTTCTT 1644

Qy 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACAGGCCAATACTGAGGCAACCACTCGGCGCG 1704

Qy 500 gTTPAlaThrGluLeuProTrpMetGlyCysTrpPheAlaAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACAGAGCTGCCCTGGATGGGCTGTGGCATGCCAATCGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 201
US-10-141-700-143
; Sequence 143, Application US/10141700
; Publication No. US20030148428A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC205
; CURRENT APPLICATION NUMBER: US/10/141,700
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-700-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-141-700-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGGTGGGCTCTCTGTCGGCGCCCTGACAGCTGCTACTTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGGAGCGCGGAGCGCAGGAGCTGCGCAAGAGGCGGAGGCGCATTCCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGGCTCCACCTCCATTCGATTTCAGC 385
```

```
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTACGGCGGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTGTAGACACCGGACCAAAATGAGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCGAAGCAAGGTAACAATGGTACAAGCAGCACCTCTCTACCGGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGCATGTTCCGGGCGCGCTGCGCGCGCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCGCCAGCCACAGGCCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGCAATGCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTGAGCGCGCGCGCGGCGCACTGTTCGTGTGTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACTGCCCGCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGNAACGCGAGG 1164

Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCGCACTCTTCTTCGATGCCATCAGCTGTAGACAGCAACAGCACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGAGCCATTTCTGGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTCAGGCTGGCGCAGTGTCTATT 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGTGTGGAGGTTCGGGGCCCCAA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGGCCATCTCTGACGC 1464
```

Qy	420	aAlaLeuPhePheProProLeuAArgLeuLeuPheLysGlyAlaAArgTyrTrpVa	440
Db	1465	CGCCCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTCCCGCTACTACGT	1524
Qy	440	lLeuAlaAArgGlyGlyLeuGlnValGluProTyrTyrProAArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProAArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGAGGTCAGCGGGCCCTCCGAGGGCCCATGGCTCCATCATCTTCTT	1644
Qy	480	eAArgAspAArgTyrTrpAArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAArg	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACCGCCAAACTGCAGCGCAACCACTCGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	

RESULT 202

```

US-10-141-705-143
; Sequence 143, Application US/10141705
; Publication No. US20030148429A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC201
; CURRENT APPLICATION NUMBER: US/10/141,705
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-705-143

```

Alignment Scores:

Pred. No.:	3,358-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	16	Gaps:	0

US-10-791-980-6 (1-520) X US-10-141-705-143 (1-1985)

Qy	1	Met	Val	Ala	Arg	Val	Gly	Leu	Leu	Leu	Arg	Ala	Leu	Cln	Leu	Leu	Leu	Trp	Gly	His	Ileu	20	
	Met	Val	Ala	Arg	Val	Gly	Leu	Leu	Leu	Arg	Ala	Leu	Cln	Leu	Leu	Leu	Trp	Gly	His	Ileu			
Db	206	ATG	TCT	CGC	GCG	CGT	CGC	GCT	CTC	TGT	CGC	GCC	TGC	GAG	CCT	TGC	TGT	TAC	TGT	GGG	CCC	ACCTG	265

Qy	21	AspAlaGlnProAlaGluAArgGlyGlyGlnGluLeuAArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCGAGCCCGGAGCGCGGAGGCCAGGAGCTGGCGCAAGGAGCGGAGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACCTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCCATCAGAGCTTTTCACTGGGTGTCCAGCTACTCTGTACGGGGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTCGCCAGATGACTCGTCCCGCTCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluAArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCCTGGGCTGAGAGGATCAGTGACTTGTTCCTAGACACCGGACCCAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGGCAAGCAAGGTAAACAATGGTACAAGCAGCACTCTCTCTACGGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu - ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTCGCGAGCCGGCAGTTCCGGCGCGCTGCGCGCGCTTCACG	685
Qy	160	rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTGGAGTCTTGGGAGGCCCCAGCCACAGGCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGACCAACAACATGGGCTGGGCATTCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrPropheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACCGCCTTC - CTGCCCGCGCGCGGCAAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGACGCTGTGTCCTGAGCGCCCGCCGCGGGCGCAACCTGTTCTGTGGTGTGGCGCA	924
Qy	240	aGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGCGCTCACCCACTCCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTCAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheLurThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CATGACTTTGAGACCTTGGGACTCTACAGCCCCCAAGGAAGGGCGCCCTGAAACGCAAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCAGTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGCAATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGGAAGATGGGTGCGGCTGCCCCCCCAACATTGAGGCTCGCGCAGTGTCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400

Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCCA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGGTCTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCCATCTCTGACGC 1464
 Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLeuPheLeuPheLeuPheLeuVa 440
 Db 1465 GCCT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGAGGCCCTACTACCCCGAAGTCTGCGAGGCTGGGG 1584
 Qy 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerLeuLeuPhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspArgTyrTyrArgLeuAspGlnAlaValSerGlyLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAACTGCGAGGCAACCTCTCGGGCCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaValSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGTCGCAACTCGGGGAGCGCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765

RESULT 203

US-10-141-753-143
 ; Sequence 143, Application US/10141753
 ; Publication No. US20030148430A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE OF INVENTION: ACIDS ENCODING THE SAME
 ; FILE REFERENCE: P3330R1C193
 ; CURRENT APPLICATION NUMBER: US/10/141,753
 ; CURRENT FILING DATE: 2002-05-08
 ; Prior Application removed - See Palm or File Wrapper
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-141-753-143
 Alignment Scores:
 Pred. No.: 3.35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-141-753-143 (1-1985)
 Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCCGGCGCTCGGCT 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGlyGluAlaGluAlaPheLeu 40
 Db 266 GAGCCCCAGCCCGGAGCGCGGAGCGCGAGCTGGCGCAAGAGGCGGAGGCGGATTCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAGTACCGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTGAGC 385
 Qy 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGCTACCTGTACGGCGGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTCTGGCCAGATGACTCGTCCCGCTGGGGGTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgLeuSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATAGAGCGTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
 Db 566 AAACGCTTTCAAAGCAAGGTAACAAATGTTACAAAGCAGCACCTCTCTACCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTGCGCGAGCGGCGAGTTTCGGGGCGCGCTGCGCGCGCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGAGGCCCGCAGCCAGCGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCTTTTGTATGGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 806 CCAGGGGGCGCCCTTGGCGCACCGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGCGCGCAACTGTTCTGTGTGTGGCGCA 924
 Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTGCACACGCTTGGCTCACCACTCCCGCGCGCGCGCGCTCATGCGGCC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspValLeuAlaValG1 280
 Db 985 CTACTACAAGAGGCTGGGGCGCGACGCGTGTCTGCTGGGACGAGCTGTGCGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGGCGCGCTGAAACGCGAGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAAATACTGCACTCTTCTCTTCGATGCTACCTGTAGACGAGGCAACAGCAACTGTA 1224
 Qy 340 rLlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360

Db 1225 CATTTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGCCAACGTCCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProAenIleGluAlaAalaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGGCGAGTGTCA 1344
QY 380 uAenAepGlyAapPheTyrPhePheLysGlyArgCysTyrPheArgPheArgProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAapAl 420
Db 1405 GCAGGTGGGGTCTCCCAAGTGTGGCGGAGGGGGCTGCCCCGCCATCTCGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGGCCCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yClyIleProGluGluValSerGlyAlaLeuProArgProAapGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCGGAGGCCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAapArgTyrTyrPheArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVa 500
Db 1645 CCGAGATGACCCCTACTGCGGCTCGACCGGCCAACTGCAAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAATCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 204

US-10-141-758-143
; Sequence 143, Application US/10141758
; Publication NO. US20030148431A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RJC194
; CURRENT APPLICATION NUMBER: US/10/141,758
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-758-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-141-758-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGTCAGCTCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCCAGCCCGGAGCGGAGGCGGAGAGCTGCCAAGAGGCGGAGGAGCANTTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCCAAGCTCCCACTCCACTCGATTCCAG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCAGACTACCTGTGAGCGGCGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGTACCTGCTCCCGCTGCGGGGTTCAGATACCAACAGTTATGGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAAAGCAAGTAAACAAATGTTACAAAGCAGACCTCTCTCCACCGCTGG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCCGAGCGCGCAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACCAACGTTCTCAGCGCTGGAGTTCCTGGAGGCGCCCGACCCAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACCGATGGGCTGGGCAATGCTTGTATGG 805
QY 200 aGlnGlyAlaProTyrPheLeuProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGCCCTGCGCGCACGCTTC-CTGCCCCCGCGCGCGCGCGCTCATGGCGCC 864
QY 220 nAspGluArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGTCGTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCCACCTCCTGCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAACCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCGCTGAAACGAGGG 1164

```
Oy 320 yProLysTyrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATCGCATCACTGTAGACGGCAACAGCACTGTA 1224
Oy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGAGCTGATGCAACGTCCTCAGAGCCCG 1284
Oy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGTCAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Oy 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATCGAGATTTCTACTTCTTCNAAGGGGTTCGATGCTGGAGGTTCCGGGGCCCA 1404
Oy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCCTGACGC 1464
Oy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 GCGCCTCTTCTTCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Oy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAGTGGAGCCCTATACCCCCCAAGTCTGCAGGACTGGGG 1584
Oy 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTTCAGCGGCGCTGCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Oy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTCGCGCCTCGACACGAGCCCAAACTGCAGGCAACCACTCGGGCG 1704
Oy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Oy 520 e 520
Db 1765 C 1765

RESULT 205
US-10-142-418-143
; Sequence 143, Application US/10142418
; Publication No. US20030148433A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C247
; CURRENT APPLICATION NUMBER: US/10/142,418
; CURRENT FILING DATE: 2002-05-10
; Prior Apploication removed - See File Wrapper or Palm
```

```
; NUMBER OF SEQ ID NOS: 550
```

```
; SEQ ID NO 143
```

```
; LENGTH: 1985
```

```
; TYPE: DNA
```

```
; ORGANISM: Homo Sapien
```

```
US-10-142-418-143
```

```
Alignment Scores:
```

```
Pred. No.: 3.35e-262 Length: 1985
```

```
Score: 2792.00 Matches: 519
```

```
Percent Similarity: 99.62% Conservative: 0
```

```
Best Local Similarity: 99.62% Mismatches: 1
```

```
Query Match: 98.52% Indels: 2
```

```
DB: 16 Gaps: 0
```

```
US-10-791-980-6 (1-520) x US-10-142-418-143 (1-1985)
```

```
Oy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
```

```
Db 206 ATGTCGCGCGCGTGGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
```

```
Oy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
```

```
Db 266 GAGCCCCAGGCCGCGAGCGCGGAGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
```

```
Oy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```

```
Db 326 GAGAAGTACGGATACCTCAATGAACAGTCCCCAAGCTCCACCTCCACTCGATTGAGC 385
```

```
Oy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
```

```
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTCTCCAGCTACCTGTTCAGCGCGCTGTTGACCGC 445
```

```
Oy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
```

```
Db 446 GCCACCTTGGCGCCAGATGACTCGTCCCCGCTGGGGGTTCACAGATACCAACAGTTATGCG 505
```

```
Oy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
```

```
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTTTGTCTAGACACCGGACCAANAATGAGCGGTAA 565
```

```
Oy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
```

```
Db 566 AAACGCTTTCAAAGCAAGGTACAAATGTTACAAAGCAGCACCTCTCTACCGCTGGTG 625
```

```
Oy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
```

```
Db 626 AACTGGCTTGAGCATCTTCCCGGAGCGGAGTTTGGGGCGCGCGTCCGCGCTTCCAG 685
```

```
Oy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
```

```
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCCTGGAGGCCCCCAGCCACAGGCCCGCTGAC 745
```

```
Oy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
```

```
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACGATGGGCTGGGCAATGCTTTGATGGC 805
```

```
Oy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
```

```
Db 806 CCAGGGGGCGCCCTTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGAGCGACATTCGACCA 864
```

```
Oy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
```

```
Db 865 AGATGAGCGTGGTCCCTGAGCGCGCGCGGGGGGCAACTGTTCGTGCTGGTGGCGCA 924
```

```
Oy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
```

```
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTGCGCGCGCGCGCGCTCATGGCGCC 984
```

```
Oy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValGl 280
```

```
Db 985 CTACTACAGAGGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGTGTGCGCGTGCA 1044
```



```
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGACCCCTAGGGGCTCAGTGGCGCTCCAGTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
QY 360 sProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTyrTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGCATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCCCTGCCCGGCATCTCTGACG 1464
QY 420 alaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CCCTCTCTTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCGGAGGGGACTCCAGTGGAGCCCTACTACCCCGGAGTCTGCAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCTGAGGAGTCCAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 qTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 206

US-10-142-420-143

; Sequence 143, Application US/10142420

; Publication No. US20030148434A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

```
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C235
; CURRENT APPLICATION NUMBER: US/10/142,420
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-142-420-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	16	Gaps:	0

US-10-791-980-6 (1-520) x US-10-142-420-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGCTCGGCTCTCTGCTGCGGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGCGAGCGCGAGCGGAGGCTGCGCAAGGAGCGGAGGAGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGTCCCACTCCACTCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCATCAGAGCGCTTTCAGTGGGTGTCCTCCAGTACCTGTGAGCGGCGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCGCAGATGACTGCTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCANAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCCNAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGGCCCTGGCGCAGCCCTTC-CTGCGCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCGAGCCCGCGCGGCGCAACCTGTTCTGGTGGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
```

Db 925 CGAGATCGGTACAGCGTTGGCCCTACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrlsArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCAGCGCGCTCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrlsGlyProLeuGlyGlySerValAlaValAlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrlsProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGACGCCCCNAGAGGGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrlsCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCAGTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProPheAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGANAGATGGTGGGCTGCCGCCCAACATTCAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrlsPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGCTGCCGCCCAATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgLeuIleLeuPheLysGlyAlaArgTyrlsVa 440
Db 1465 CGCCCTCTCTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCCGCTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrlsTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTTACTATCCCGCCAAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTTCCGAGGCCCATGGCTCCATCTCTTCT 1644
Qy 480 eArgAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCCAAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 207

US-10-142-422-143
; Sequence 143, Application US/10142422
; Publication No. US20030148435A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: F3330R1C226
; CURRENT APPLICATION NUMBER: US/10/142,422
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-422-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-422-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGCGCTCTCTGTCGCGCGCTGCTGAGCTGTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGGAGCGCGGAGCGCGAGCTGCGCAAGGAGCGGAGGCAATCTCTA 325
Qy 41 GluLysTyrlsGlyTyrlsLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGGTCTCCCAAGCTCCCACTCCATCTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGCTACTCTGTACGGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrlsAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACAGATACCAACAGTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACCCGACCCGAGCCGCGCTTCCAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrlsGlnHisLysSerTyrlsArgLeuVal 140
Db 566 AAAGCTTTGCAAGCAAGGTACAAATGTTACAAAGCAGCAGCCTCTCTCTACCGCTTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTCTTCGGAGGCGCCCGCAGCAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTTGTATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220

806	CCAGGGGGCGCCCTTGGCGCAGCCCTTC-CTGCCCGCGCGCGAGAGCGCACTTCGACCA	864
220	nAspGluArgTrpSerLeuSerA:ArgArgGlyYargAsmLeuPheValValLeuAlaHi	240
865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCTGGTGGTCTGGCGCA	924
240	sGluileGlyHisThrIleuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
925	CGAGATCGGTCAACAGCTTGCGCTCACCCACTCGCGCGCGCGCGCGCTCATYGGCGCC	984
260	oTyvTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1	280
985	CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGAGAGCAGCTGCTGGCGGTGCA	1044
280	nSerLeuTrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGTCTCAGCTCCAGGAAAGCTGT	1104
300	eThrAspPheGluThrTrpAspSerTyvSerProGlnGlyYargArgProGluThrGlnG1	320
1105	CACGTACTTTGAGACCTTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAAAGCGCAGG	1164
320	yProLysTyvCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
1165	CCCTAATACTGCCACCTTCTCTTCGATGCCCATCTACTGTAGCAGGCAACAGCAACTGT	1224
340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
1225	CATTTTAAAGGGAGCCATTCTCGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
1285	TCCACTGCAGAAAGATGGGTTCGGGCTGCCCCCAACATTGAGGCTCGCGCAGTGTCA	1344
380	uAsnAspGlyAspPheTyvPhePheLysGlyGlyYargCysTrpArgPheArgGlyProLy	400
1345	GNATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCA	1404
400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCGACGC	1464
420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyvTyvA	440
1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTACTACTAGT	1524
440	lLeuAlaArgGlyGlyLeuGlnValGluProTyvTrpProArgSerLeuGlnAspTrpG1	460
1525	GCTGGCCCGAGGGGATCGCAAGTGGAGCCCTACTACCCCGAAGCTCGCAGGACTGGG	1584
460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
1585	AGGCATCCCTGAGGAGGTACGCGCGCCCTCGCAGGGCCCGATGGCTCCATCATCTTCT	1644
480	eArgAspAspArgTyvTrpArgLeuAspGlnAlaLysIleuGlnAlaThrThrSerGlyAr	500
1645	CCGAGATGACCGCTACTTGGCGCCCTCGACCCAGGCCAACTGCAGGCAACCACTCTGGGCGC	1704
500	gTrpAlaThrGluLeuProTrpMetGlyCyvTrpHisAlaAsnSerGlySerAlaLeuPh	520
1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGSCATGCCAACTCGGGGAGCGCCCTGT	1764
520	e 520	
1765	C 1765	

RESULT 208

US-10-142-427-143

; Sequence 143, Application US/10142427

; Publication No. US20030148436A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

APPLICANT: Beresini, Maureen

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTTCTTCAAGGGACCAACAGATGGCTGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGGTGGTGGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACAGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGAGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTCGGACTCTACAGCCCCCAGAGAGGCCCTGAAACGCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCGCATCACTGTAGACAGGCAACAGCACTGA 1224
QY 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGTTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnArgTTPValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGAGNAAGATGGTGGCTGCGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGTCTGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACACAGCTGTGCCGGCAGGGGGCTGCCCGGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCCCTACTACGT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGG 1584
QY 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGACGGCGCCCTGCCGAGGGCCCATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCAACTGACGGCAACCACTCGGGCGG 1704
QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 209

US-10-142-760-143
; Sequence 143, Application US/10142760
; Publication No. US20030148437A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C239
; CURRENT APPLICATION NUMBER: US/10/142,760
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-760-143

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	16	Gaps:	0

US-10-791-980-6 (1-520) x US-10-142-760-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu	20
Db	206	ATGTCGCGCGCGTCGGCTCTCTGTCGCGCGCTGTCAGCTGCTACTGTGGGGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCGAGCCCGGAGCGCGGAGCGCAGAGCTGCGCAAGGAGCGGAGGATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACCGATACCTCATGACAGGTCCCCAAGCTCCACCTCCACTCGATTGAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCAGCGCGGTGTTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	CCACCTCCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCACTGACTGTTGCTAGACACCGGACCAAAATGAGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTTPTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAAACNAATGGTACAAAGCAGCACCTCTCTACCGCGCTGGT	625

QY 141 AenTrrProGluHisLeu-ArSertArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCCTGAGCATCTGCGGAGCGCGAGTTGCGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCGCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCCTTCTCCAGGGGACCAACAGATGGGCTGGGCATATGCCCTTTGATGC 805
QY 200 aGlnGlyAlaProTrrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCCGCGCGGCGGAGGCGCACTTCGACCA 864
QY 220 nAspGluArgTrrSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACAGCTTGGCTCACCACATCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTrrTrrLysArgLeuGlyArgAspAlaLeuLeuSerTrrAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGGCGCGCAGCGCTGTCTAGCTGGGACGAGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTrrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrrAspSerTrrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAGAGAGCGCCCTGAAACCGAGG 1164
QY 320 pProLysTrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCATCTGTAGACGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrrPgluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGTATGGCAACGCTCTCAGAGCCCG 1284
QY 360 pProLeuGlnArgTrrValGlyLeuProProAenIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGTCAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTrrPhePheLysGlyArgCysTrrArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTTCTTCAAGGGGGTGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrrPgluLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGCGAGGGGGCTGCCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrrTrrVa 440
DB 1465 GCCT 1524
QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTrrTrrProArgSerLeuGlnAspTrrPgl 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAGTCTGCGAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTrrTrrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCTCGACGAGCCAAACTGCGAGGCAACCACTCGGGCGG 1704
QY 500 gTrrAlaThrGluLeuProTrrMetGlyCysTrrPheHisAlaAenSerGlySerAlaLeuPh 520

DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 210
US-10-145-821-143
; Sequence 143, Application US/10145821
; Publication No. US20030148438A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C286
; CURRENT APPLICATION NUMBER: US/10/145,821
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-821-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-821-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrPglHisLeu 20
DB 206 ATGGTCGGCGCGTGGCGCTCTGCTGGCGCCCTGCTGAGCTGTACTGTGGGGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGCGGCGGCGGCGGCGGCGG 325
QY 41 GlulysTrrGlyTrrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCATGAACAGCTCCCAAGCTCCCACTCCATCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrrValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTGCTCCAGCTACCTGTGAGCGCGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTrrAla 100
DB 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTGGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

```
Db 506 GCGTGGCTGAGAGATCAGTACTTGTGTAGACACCGGACCAAAATGAGGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCCATCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCGAGAGCCGGAGTTCGGGGGGCGCGTCCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCACACGATGGGCTGGGCAATGCCCTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGGCGCAACTGTTCTGGTGTCTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACTGTTCTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 cTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAAAGGGCGCTGAAACGCGAGGG 1164
Qy 320 yProLysTyrCyHisHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAATACTGCCACTTCTCTCGATGCCATCAGTGTAGACAGGCACAGCAACTGTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAAACGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCGCTGCCCGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGCGCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480
```

```
Db 1585 AGGCATCCCTCAGGAGGTGAGGGGCGCCTGCCAGGCCCGCATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGGGCTTCGACCGCCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 211
US-10-152-531-143
; Sequence 143, Application US/10152531
; Publication No. US20030148439A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: DeNoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P330R1C378
; CURRENT APPLICATION NUMBER: US/10/152,531
; CURRENT FILING DATE: 2002-05-20
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-152-531-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-152-531-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTGGCGCGCTCGGCCTCTCTGTCGGCGCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
Qy 41 GluLysTrpGlyTyrLeuAsnGluValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATCTCAATGAACAGGTCCCCAAGCTCCCACTCCATTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
```


Db 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCTGCTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTCGGGGTTCAGATACCAACAGATTATGCG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTGGGCTGAGAGGATCAGTGACTGTGTGGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaGlyGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTGGCAAGCAAGTAAACAAATGGTAAACAGCAGCCTCTCCCTACCGCTGGTG 625
Qy 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGCAGTTCGGGGCGCGCTGGCGCCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATTCGGCTCACCTTCTTCAAGGGGACCACCAACGATGGGCTGGGCAATGCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCGCGCGCGGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGTTGCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCT 984
Qy 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCGTGGCGCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTCAGACCTGGGACTCTCAGACGCCCAAGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerPheAspAlaThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluPrAsr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGTAGCAACGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGGCGGAGTGCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTTPArgPheArgGlyProLys 400
Db 1345 GAATGATGGAGATTTCTACTTCTCAAAGGGGGTTCATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGGGCAGGGGCGCTGCGCCGCACTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgGluLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
Db 1525 CTTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACTACCCCGAAGCTTCGACGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGGCGCTCGACGAGCCAACTGACGAGCAACCACTCGGGCGG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 212

US-10-127-840A-143
; Sequence 143, Application US/10127840A
; Publication No. US20030153033A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C114
; CURRENT APPLICATION NUMBER: US/10/127,840A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA

; CURRENT APPLICATION NUMBER: US/10/142,424
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-424-143

Alignment Scores:
Pred. No.: 3,356-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-424-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
DB 206 ATGGTCGGCGGCTGGGCTCTCTGTCGGCGCTCTGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCGCGAGCGCGAGCGCCAGGAGCTGCGCAAGAGCGCGGAGGCATTCTCTA 325
QY 41 GluLysTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCACCTCCACATCGATTACG 385
QY 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCTTTGAGTGGGTGTCCTGAGCTGCTGAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTGCTCCCGCTGCGGGGTTACAGATACCAACAGATTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTCACTTGTGTGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAAAGGTAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCGTCCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCTGGAGGCGCCAGCCACAGGCGCCCGCTCAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTCTTCCAAAGGGGACCACCAACGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 eGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGGCTTGGCGCACGCTTC-CTGCCCCCGCGCGGAGCGCATTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCAACCTGTTCTGTTGGTGGTGGCGCA 924
QY 240 eGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280

DB 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGGAAGGCGCTTGAACCGCAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCTCCCCCAACATTGAGGCTGGCGAGTGTCT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTTCTTCAAAGGGGTGATGTCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGCAAGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyLeuProGluLeuValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGACGCGCGCTCTCCAGGCGCCGCTGCGGCAACCATCTCGGCG 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGGCGCAACTGCGGCAACCATCTCGGCGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGTGCCAATCTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 214
US-10-142-761-143
; Sequence 143, Application US/10142761
; Publication No. US20030157601A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.

;
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C237
; CURRENT APPLICATION NUMBER: US/10/142,765
; CURRENT FILING DATE: 2002-05-10
; Prior Applioication removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-765-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-765-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGGCTCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGGAGCGGCGGAGCGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTGCCAAAGCTCCACCTCCAGTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTACGCGGCGTGTGGACGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGACACCCGACCAAAATGAGGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTGCNAACAGAGGTAACAATGGTTACAGCAGACCTCTCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 NAATGGCCTGAGCATCTCGGAGCGCGAGCTGCGGCGCGCTGCGGCGCGCTTCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGAGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCACCAACGATGGCTGGGCAATGCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTTCTGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrIleArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCTCTACAGCCCAAGGAAGCGCGCTCAAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTTCGATGTCATCCTGTAGACAGGCAACAGCAACTGTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTCTTGGAGGTGGCAGCTGTAGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACATCGAGAAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTCGGCGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGGTCSATGTGTGGAGGTTCCGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAAGGGTGCCTACTACTGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTGTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480
Db 1585 AGGATCTCCTTGAGAGGTGAGCGCGCCTGCGGAGGCCCGATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACAGGCCAAACTGCAGGCAACCACTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGTCATGCCAATCTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520

Db 1765 c 1765

RESULT 217
US-10-142-887-143
; Sequence 143, Application US/10142887
; Publication No. US20030157605A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C212
; CURRENT APPLICATION NUMBER: US/10/142,887
; PRIORITY FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-887-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-887-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGGTGGCCCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325

QY 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACATCGATTACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGGGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTCGGGGTTCACAGATACCAACAGTTATGCG 505

QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTGGGCTGAGAGGATCAGTACCTGTTGTGTAGACACCGGACCAAAATGAGCGGTAA 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

Db 566 AAACCGCTTTGCAAGCAAGGTAAACAAATGGTAAAGCAGCAGCTCTCTCCACCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCGGAGGCCCCCAGCAGCAGCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGTGGCTGGCAATGCCCTTGTATGCG 805

QY 200 sGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGGCCCCCGCGCGAAGCGCACTTGGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGTGTGCTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlPr 260
Db 925 CGAGATCGGTCAACGCTTGGCCTCACCACTCGCGCGCGCGCGCTCATGGCGCC 984

QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
Db 985 TTACTACAGAGGCTGGCG 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCACAGGAAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACAGCGG 1164

QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCCATAAATACCTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGGAGGTGGCAGCTGATGGCAACGCTCTAGAGCCCG 1284

QY 360 sProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344

QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTTCTTCAAGGGGGTGCATGTCTGGAGGTTTCGGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTTGGCCCCGCCATCTCTGACGC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTAGCT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGGAGCTGTCAGGAGCTGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGGCCGATGGCTCCATCATCTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500

```
Db      1645  CCGAGATGACCGCTACTGGCGCTCGACCGCCAACTGCGAGGCGAAACCACCTCGGGCCG 1704
Qy      500  gTTPAlaThrGluLeuProTTPMetGlyCyTTPHiAlaAlaSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGTCGCAACTCGGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 218
US-10-142-888-143
; Sequence 143, Application US/10142888
; Publication No. US20030157606A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC227
; CURRENT APPLICATION NUMBER: US/10/142,888
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-888-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              17          Gaps:         0

US-10-791-980-6 (1-520) x US-10-142-888-143 (1-1985)

Qy      1  MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
Db      206  ATGGTTCGCGCGGTGGGCTCTCTGTGCGGCCCTGCGAGTCTACTGTGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GAGCGCCAGCCCGCGAGCGCGGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
Qy      41  GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAAGTACGAGATACCTCAATGAACAGGTCCCCAAAGTCTCCACCTCCACTCGATTACG 385
Qy      61  AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGGCGTGTGGACCGC 445
Qy      81  AlaThrLeuArgGlnMetThrArgProArgProCysGlyValThrAspThrAsnSerTyrAla 100
|||||
```

```
Db      446  GCCACCTTCGCCCGCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy      101  AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506  GCCTGGGCTGAGAGGATCAAGTACTTGTGCTAGACACCGGACCAAAATAGAGCGGTAA 565
Qy      121  LysArgPheAlaLysGlnGlyAsnLysTTPTyTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCTTACCGCCTGGTG 625
Qy      141  AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCCTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCCCTGCGCGCGCTTCCAG 685
Qy      160  rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686  TTGTGGAGCAACGTCTCAGCGCTGGAGTCTCTGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy      180  rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db      746  ATCGGCTCACCTTCTTCCAAGGGGACCACACGATGGGCTGGGCAATGCTTTGATGGC 805
Qy      200  aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db      806  CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCAAGCGACATTCGACCA 864
Qy      220  nAspGluArgTTPSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGCGGCGCNACTGTTCTGTGTGTGGCGCA 924
Qy      240  sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
Db      985  CTACTACAAGAGGTGGGCGCGCGCGCTGCTCAGCTGGAGACAGCTGTGGCGGTGCA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGGNAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db      1105  CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCGCTGAAACGCGAGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTTAAATATCTGCCACCTCTTCCCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy      360  gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTCAGAGAAAGATGGGTGGGCTGCCGCCCAACATTTAGGCTCGCGCAGTGTCAAT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTTPArgPheArgGlyPProLy 400
Db      1345  GAATGATGGAGATTCTACTTCTTCAAGGGGTGCGATGTGGAGGTTCGCGGGGCCCA 1404
Qy      400  sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisPProAspAl 420
Db      1405  GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGCAGGGGGCGCTGCCGCCCATCTCTGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db      1465  CGCCTCTTCTTCTCTCTCTGCGCGCCTCATCTCTTCAAGGGGTGCCCTACTACTAGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
Db      1525  GCTGGCCGAGGGGAGCTGCNAAGTGGAGCCCTACTACCCCGAAGTGTGCGAGGACTGGGG 1584
```

```
Qy 460 yGlylleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGCGCCCTGCGAGGCCGCGATGCTCCATCATCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIlysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCGCTACTGCGGCTCGACCGAGCCAACTGCGAGGCAACACCTCGGGCGG 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 219
US-10-143-034-143
; Sequence 143, Application US/10143034
; Publication No. US20030157607A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC233
; CURRENT APPLICATION NUMBER: US/10/143,034
; CURRENT FILING DATE: 2002-05-09
; Prior application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-143-034-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
Db: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-143-034-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ARGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCGAGCCCGCGAGCGCGGAGCCGAGAGCTGCGCAGGAGCGGAGGCATTCTCTA 325

Qy 41 GlutylsTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCCAAGCTCCACCTCGATTTCAGC 385
```

```
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCACTGGGTGTCCCGAGCTACCTGTGAGCGGCGTGTGTGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 CCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGTTTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTGTGTTTCTAGACACCGGACCCAAATGAGGGCTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTTACAAGCAGCACCTCTCTCCACCGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCCGCGAGTTCCGGGCGCGCTGCGCGCGCTTCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTCTTCCAAGGGGACCAACAACATGGGCTGGGCATGCTCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGCGCAACTGTTCTGGTGGTGGTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACACGCTTGGCCTCACCCACTCCGCCCGCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCNAGGAAGGCGCCCTGAACGCGAGGG 1164

Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCACTCACTGTAGACAGGCAACAGCAACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGAGAAAGATGGGTCCGGCTGCCCGCGCGCCCAACATTGAGGCTGCGGCGAGTGTCA 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGCGGGCCCCAA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCCAAGAGCTGTGCCGGGAGGGGGCGCTGCCCGGCCCATCTCGAGC 1464
```



```
QY 320 yProlystYrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATAGTCCACTCTCTCTCGATGTCATCTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLyGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGCAACGTCCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAenIleGluAlaAlaAvalSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGCTGGCTGCCCTCCCAACATTGAGGTGGCGAGTGTGATT 1344
QY 380 uAenAspGlyAspPheTrpPhePheLyGlyGlyArgCysTrpPheArgGlyProly 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCyAspAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCTTGGCCCGCATCTCAGCGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLyGlyAlaArgTrpVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCGCGCCCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCGCGGAGGGGACTGCAAGTGGAGGCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCGGATGCTGCATCATCTTCTT 1644
QY 480 eArgAspArgTrpTrpArgLeuAspGlnAlaLyLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCTCGACAGGCGCAACTGACAGGCAACCCCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGGATGCCAACTCGGGAGGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 223

```
US-10-144-992-143
; Sequence 143, Application US/10144992
; Publication No. US20030157611A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C259
; CURRENT APPLICATION NUMBER: US/10/144,992
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
```

```
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-144-992-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	2
Query Match:	98.52%	Indels:	1
DB:	17	Gaps:	0

US-10-791-980-6 (1-520) x US-10-144-992-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLyGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGAGCTGCGCAAGGAGGCGGAGGCATTCCTTA 325
QY 41 GluLyStYrGlyTrpLeuAenGluGlnValProLyAsAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCATGAAACAGGTCCCAAAAGTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCTGAGCTACCTGTACGCGCGTGTGTGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
Db 446 GCCACCTTGCAGGAGTACCTGTCCTGCGCTGCGGGGTACAGATACCAACAGTATTGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLyMetMetArgLyS 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLyGlnGlyAsnLyStYrLySglnHisLeuSerTrpArgLeuVal 140
Db 566 AACCGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCySgAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTAGCGCTGAGTTCGGAGGGCCCCCAGCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLySgLyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACACGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTTGGGCGCACGCGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGTCTTCCAGCGCGCGCGCGCGCAACCTGTTCGTGTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTrpTrpLySArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGAGCGGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
```

```
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValaValaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTAGGGGGCTCAGTGGCGGTCCAGTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTCAGACCTGGGACTCTCAGACCCCGAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACATGCCACTCTCTCTCGATGCTCCTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValaValaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCCATTTCTGGAGGTGGCGAGTGTGCGAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTTCCACAGCTGTGCCGGGAGGGGGCTTCCCCCGCCATCTTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GGTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCGAGGACTGGGG 1584
Qy 460 vGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGCGGGCCCTGCGGAGGGCCGATGGCTCCTCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGA CCGAGGCCAAATGCGAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 224

US-10-145-015-143

; Sequence 143, Application US/10145015

; Publication No. US20030157612A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

```
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C253
; CURRENT APPLICATION NUMBER: US/10/145,015
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-015-143
```

Alignment Scores:

```
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-145-015-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGGGCGTCGCGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCGCGGAGCGCGAGGCGAGAGTGGCGAAGGAGGCGGAGGCATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCCATCAGAGGGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTTGTCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAA CAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu - ArgSerArgGlnPheGlyAlaProCysAlaProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGCACTTCGGGGCGCGTGGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTAGCGCTGAGTTCCTGGGAGGCGCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGAC CACAACATGGGCTGGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTTGGCGCACGCTTC -CTGCCCGCGCGCGGAGCGGCGGCGCTTCACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
```



```
QY 180 rSerGlySerProSerSerLeuGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACACACGATGGGCTGGCAATGCCCTTGTATGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGGGCGCTGGCGCACGCCCTTC-CTGGCCCGCGCGGCAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTyrSerSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
Db 865 AGATGAGCCCTGGTCTTCCAGCGCGCGCGCGCGCAACCTGTGTGTGTGTGTGGCGCA 924
QY 240 eGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925-CCGAGATCGGTTCACACGCTTGGCTTCACCCCACTCGCCCGCGCGCGCTCATGGCGCG 984
QY 260 oTyrTyrLeuArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGGACCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLeuPhe 300
Db 1045 GAGCCTGTATGGAAGCCCTTGGGGGCTCAGTGGCGGCTCCAGCTCCCGAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCNAGGAAGCGGCCCTGAAACCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCCATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACACAGCTGTGGCGGCGAGGGGGCCCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCTTCTTCTGCGCGGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAACTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGGCGCTTGGCGAGGGCCGATGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGGCGCTCGACCGAGGCCAACTGCGAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
```

```
RESULT 227
US-10-145-629-143
; Sequence 143, Application US/10145629
; Publication No. US20030157616A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C264
; CURRENT APPLICATION NUMBER: US/10/145,629
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-629-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-629-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCCCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGAGCCCGGAGCGCGGAGCTGCCAAGAGCGGAGCGGAGCATTCCTA 325
QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTTCAGTGGGTGTCCAGAGTCACTGTCTGAGCGGGGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGTCGCCGCTGCCGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTAAAGCAGCAGCACCTCTCTCCGCGCTGTG 625
```

Qy 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db |||||
626 AACTGGCCCTGAGCATCTCCCGAGCCGCGAGTTCGGGGCGCGGTGGCGCGCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db |||||
686 TTGTGGAGCAAGCTCTAGCGCTGGAGTTCTGGAGGGCCCGAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerSerGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db |||||
746 ATCCGGCTCACCTTCTTCCAAAGGGGACCCACAACATGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db |||||
806 CCAGGGGGCCCTGGCGCAGCCCTTC-CTCCCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnPheValValLeuAlaHis 240
Db |||||
865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGGGCGCACTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db |||||
925 CGAGATCGGTACACGCTTGGCTCCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrrTyrrysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db |||||
985 CTACTACAAAGAGCTGGGCGCGAGCGCTCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrrGlyysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db |||||
1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGTCCCGAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGl 320
Db |||||
1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGGCGCGCTGAACGCGAGG 1164
Qy 320 yProlystTyrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db |||||
1165 CCTTAATACTGCACTCTCTCTCGATGCCATCACTGTAGACGGCACAGCAACTGTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db |||||
1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGTGTATGGCAAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db |||||
1285 TCCACTGCAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db |||||
1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db |||||
1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrrVa 440
Db |||||
1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTrpProArgSerLeuGlnAspTrpGl 460
Db |||||
1525 GCTGGCCCCAGGGGACCTGCAAGTGGAGCCCTTATACCCCCGAGTCTGCAAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db |||||
1585 AGGCATCCCTGAGGAGGTACGCGCGCTCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrrTrpArgLeuAspAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db |||||
1645 CCGAGATCACCCTACTCGCGCGCTCGACCGCCCAACTGACGGCAACCACTCTGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

Db 1705 CTGGGCCACCAGCTGCCCTGGATGGCTGCTGCATGCCAATCTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 228
US-10-145-630-143
; Sequence 143, Application US/10145630
; Publication No. US20030157617A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C272
; CURRENT APPLICATION NUMBER: US/10/145,630
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-630-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-630-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db |||||
206 ATGTCGCGCGCTCGGCCCTCTGTCGCGCCCTGCTGCGCGCCCTGCTGTCGAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db |||||
266 GAGCCCGAGCCGCGGAGCGCGGAGGCTGCGCAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
Qy 41 GlulysTyrrGlyTyrrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db |||||
326 GAGNAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCATCTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db |||||
386 GATGCCATCAGAGCGTTTCTAGTGGGTCTCCAGCTACTGTCAGCGCGCTTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrrAla 100
Db |||||
446 GCCACCTGCGCCAGATGACTCGTCCCCGCTGGCGGGTTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

Db	506	GCCTGGGCTGAGAGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG	565
Qy	121	LYSARGPHEALALYSGLNGLYASNLYSTPTPYLYSGNLHISLEUSERTYZARGLEUVAL	140
Db	566	AAACGCCTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGCACTCTCTCTACCGCGCTGGTG	625
Qy	141	ASNTRPPROGLUHISLEU-ARGSERARGGLNPHEGLYALAPROCYSLAPROPSERSE	160
Db	626	AACTGGCGCTGAGCATCTCCGGAGCGCGCAGTTCCGGGCGCGTGC	685
Qy	160	RCVSGLYALATHRSERGLNARGTRPSERSEGLYARGPROGLNPROGLNALAPROLEUTH	180
Db	686	TTGTGGAGCAACAGTCTCAGCGCTGGAGTCTGGAGAGCGCCAGCACAGCCCGCTGCAC	745
Qy	180	RSERGLYSERPROSERLYSGLYTHRTHRTHRMETGLYTRPALAMETPROLEUMETAL	200
Db	746	ATCCGGCTCACCTTCTTCCAAGGGAGCCACAAACGATGGCTGGGCATGCTTTGATGGC	805
Qy	200	AGNLGLYALAPROTRPARGTHRPROPHELEUPROARGGLYGLUALAHISPHASPGGL	220
Db	806	CCAGGGCGCGCTTGGCGCACGCGCTTC-CTGCCCGCGCGCGCAAGCGCACTTCGACCA	864
Qy	220	NASPGLUARGTRPSERLEUSERARGARGARGGLYARGASNLEUPHEVALVALLEUALAH	240
Db	865	AGATGACGCGTGGTCCCTGAGCCCGCGCGCGCGCAACCTGTTCGTGGTGTGGCGCA	924
Qy	240	SGLUILEGLYHISTHRLEUGLYLEUTHRHRHISERPROALAPROARGALALEUMETALAPR	260
Db	925	CGAGATCGGTACACAGCTTGGCTCACCCACTCCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	OTYTRYLYSARGLEUGLYARGASPALALEULEUSERTRPASPASPVALLEUALAVALGL	280
Db	985	CTACTACAGAGGCTGGGCGCAGCGCTGCTCAGCTGGGACGACGTGCTGGCGCTGCA	1044
Qy	280	NSERLEUTYRCGLYSPROLEUGLYGLYSERVALALAVAILNLEUPROGLYLYSLEUPH	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTCCAGGCAAGACTGTT	1104
Qy	300	ETHRASPHEGLUTHRTPRASPSTYRSERPROGLNGLYARGARGPROGLUTHRGLNG	320
Db	1105	CACTGACTTTTGAGACCTTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGCA	1164
Qy	320	YPROLYSTYRCYHISSESRPHEASPALALETHRVALIASPGLYASNVALSERGLUPROAR	340
Db	1165	CCCTAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	RLLEPHELYGLYSERHISPHETRPGLUVALALALASPGLYASNVALSERGLUPROAR	360
Db	1225	CAITTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	QPROLEUGLNGLUARGTRPVALGLYLEUPROPROASNILEGLUALALALAVALSERLE	380
Db	1285	TCCACTTCAGGAAGATGGGTGGGGCTGCCCGCCCCCAACATTTGAGGCTTCGGCAGTGT	1344
Qy	380	UASNASPGLYASPPHETYRPHETHELYSGLYLYVARGCYSTRPARGPHEARGGLYPROLY	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCA	1404
Qy	400	SPROVALTRPGLYLEUPROGLNLEUCYSARGALAGLYLYLEUPROARGHISPROASPAL	420
Db	1405	GCCAGTGTGGGTCTCCCAACAGCTGTGCCGGCAGGGGGCTGCCCGCCCATCTCGACGC	1464
Qy	420	AALALEUPHEPHEPROLEUARGARGLEULILEUPHELYSGLYALARGTYRTRYVA	440
Db	1465	CGCCCTCTTCTTCCCTCCTCTGGCGCGCCCTCATCTCTTCAAGGGGTGCCCGCTACTAC	1524
Qy	440	LLEUALAARGGLYGLYLEUGLNVALGLUPROTYRTRYRPROARGSERLEUGNASPTPGI	460
Db	1525	GCTGGCCCCGAGGGGACTGCNAGTGGAGCCCTACTACCCCCGAAAGTCTGAGGACTGGGG	1584
Qy	460	YGLYILEPROGLUGLUVALSERGLYALALEUPROARGTPROASPGLYSERILEILEPHEPH	480

```

Db 1585 AGGCATCCCTGAGAGAGTCAAGCGCGCCCTGCGCAGAGCCGATGGGTCCATCATCTCTTT 1644
Qy 480 eATGAsPAsArgTyrrTrrArgLeuAaspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAAGGCCAAACCTGCAGGCAACCACTTCGGGCG 1704
Qy 500 gTrrAlaThrGluLeuProTrrPrrMetGlyCysTrrPrrHisAlaAaspSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTCGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 229
US-10-145-747-143
; Sequence 143, Application US/10145747
; Publication No. US20030157618A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: DeNoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3310R1C300
; CURRENT APPLICATION NUMBER: US/10/145,747
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-747-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-747-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCTCGCGCGCTCGCGCTCTGTCTGCGCGCCCTGCAGTCTGCTACTGTGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGlnAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGAGCGCGAGGCCAGGAGTCCGCAAGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrrGlyTyrrLeuAenGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGAGTCCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrrPrrValSerGlnLeuProValSerGlyValLeuAaspArg 80

```

Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGACTACTGTCTACGCGCGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGCGGTAA 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAAGCCTTGGCAAGCAAGTAAATGGTACAGCAGCACCTCTCTACCGCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCCTGAGCATCTCGCGAGCGCGGAGTTCGGGGCGCGGTGCGCGCGCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCGCCAGCCACAGGCGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACTTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCCCTTTGATGGC 805
 Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGCGCGCGCTCATGGCGCC 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCGCAACTGTTCGTGGTGTCTGGCGCA 924
 Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGAGGCTGGCGCGCGCGCGCTGTCTAGCTGGGACGCGTGTGGCGGTGCA 1044
 Qy 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGCAAGAGCTGT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACTTGGACTCTCCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAAATACCTGCCACTCTTCTTCGATGCCATCACTGTAGACGGCAACGCACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CAITTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGGCGGAGTGCATT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGCGGGGCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGTCTCCACACGCTGTGCGGCGAGGGGGCTGCCCCGCCATCTCTGACGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGTCCCGCTACTAGGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCGAGGGGACTCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGACTGGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGCATCCCTGAGAGGTGAGCGGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCAGATGACCGCTACTGCGCGCTCGACGAGGCAAACTGCAGGCAACCACTCGGCGCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCAACGAGTCCCTGGATGGCTGCTGGCATGCCAACTGCCAGGAGGCCCTGT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 230
 US-10-145-752-143
 ; Sequence 143, Application US/10145752
 ; Publication No. US20030157619A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria A.
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P333081C292
 ; CURRENT APPLICATION NUMBER: US/10/145,752
 ; CURRENT FILING DATE: 2002-05-14
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 ; US-10-145-752-143
 Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 17 Gaps: 0
 US-10-791-980-6 (1-520) x US-10-145-752-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGCGCGTGGCGCTCTGCTGGCGCCCTCGAGCTGTACTGTGGGGCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACCCCGAGCCCGGAGCGCGGAGGCTGCGCAAGGAGCGGAGGCATTCCTA 325

Qy	41	GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGGTTTCAGTGGGTGCCAGCTACTCTGTACGGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTCTAGACACCGGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAAGCCTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSer	160
Db	626	AACTGGGCTGAGCATCTGCCGGAGCGCGCAGTTCCGGGCGCGGTGCGCGCGCTTCAG	685
Qy	160	xCysGlyAlaThrSerGlnArgTTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTCGAGGTCTTGGAGGCGCCAGCAGCGCCCGCTGC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAGGGGACCAACAACTGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGGCTTGGCGCACGCGCTTC-CTGCCCCGCGCGCGGCGAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHis	240
Db	865	AGATGAGCGTGTGTCCTGAGCCGCCCGCGGGCGCAACCTGTCTGTGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCCTCACCACTCCGCCCGCGCGCGGCTCATGGCGCC	984
Qy	260	oTyrTyIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGCTGGCGCGTCA	1044
Qy	280	nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCAGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACCTCTTCTTCGATGCCATCACTGTACACAGGCAACAGCAACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CAITTTTAAAGGGAGCCATTCTCTGGGAGGTGGACGTGTATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle	380
Db	1285	TCCACTGCAGGAAGATGGGTCCGGCTCCCGGCTCCCGCCCAACATTGAGGCTCGCGCAGTGCTATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGTTTCGGGGCCCA	1404

RESULT 231

US-10-145-754-143

00-10-143-734-143
: Sequence 143. Application US/10145754

Publication No. US20030157620A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P

REFUGEE: BAKER, ROYAL F.
; APPLICANT: Beresini, Maureen

APPLICANT: DeForge, Laura

APPLICANT: Desnoyers, Luc

APPLICANT: Filvaroff, Ellen

APPLICANT: Gao, Wei-Qiang

APPLICANT: Gerritsen, Mary E

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

APPLICANT: Stewart, Timothy

APPLICANT: Tumas, Daniel

APPLICANT: Watanabe, Colin K
APPLICANT: Wood William

APPLICANT: Wood, William

APPLICANT: Zhang Zemin

APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED

;
: TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

FILE REFERENCE: P3330R1C287

FILE REFERENCE: P3330RIC287
CURRENT APPLICATION NUMBER:

: CURRENT APPLICATION NUMBER: US/10/143,735
 : CURRENT FILING DATE: 2002-05-14

; CURRENT FILING DATE: 2002-03-15
 : Prior Application removed - See

: NUMBER OF SEQ ID NOS: 550
: FIRST APPLICATION removed - SEE THE NUMBER OF SEQUENCES

; SEQ ID NO 143

; LENGTH: 1985

TYPE: DNA

ORGANISM:

US-10-145-754-143

Alignment Scores:

Pred. No.:	3.35e-262	Length:	1985
------------	-----------	---------	------

Score:	2792.00	Matches:
--------	---------	----------

Percent Similarity: 99.62%

Best Local Similarity: 99.62%

Query Match: 98.52% Indels: 15

DB:	17	Gaps:
-----	----	-------

100 10 701 000 0 / 1 530) * 110 10 145 754 143 (1 - 1005)

Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	17	Gaps:	0
US-10-791-980-6 (1-520) x US-10-145-755-143 (1-1985)			
QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu	20
DB	206	ATGGTCGGCGCGTGGCCCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu	40
DB	266	GAGCGCCAGCCCGGAGCGCGGAGGCGGAGGAGTGGCAAGGAGCGGCGGAGCAATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTCAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
DB	386	GATGCCATCAGACGTTTCAGTGGGTCTCCAGCTACCTGTGAGCGGCGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTTGGCGCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG	505
QY	101	AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCTTGGGCTGAGAGATCATGTTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGAAAGCAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCCCTGGTG	625
QY	141	AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCCTGAGCATCTGCGGAGCGCGAGTTGCGGGCGCGTGGCGCGCCCTTCAG	685
QY	160	rcyGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCGCCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCATGCTTTGATGGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
DB	806	CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCCGCGCGGCGAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGGTGGCGCA	924
QY	240	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTACACGCTTGGCTCACCCACTGCGCGCGCGCGCGGCTCATGGCGCC	984
QY	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
DB	985	CTACTACAAGAGGCTGGGCGCGAGCGCGTGTCTAGCTGGGACGAGTGTGGCGGTGCA	1044
QY	280	nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
DB	1105	CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGAGGCGCCCTTGAAACCGAGGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340

DB	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCATCTAGACAGGCAACAGCAACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGGAGGCCAATTTCTGGGAGGTGGACGTGATGCAACGCTCTAGAGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe	380
DB	1285	TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGGAGTGTCAIT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly	400
DB	1345	GAATGATGGAGATTTTACTTCTTCAAGGGGGTGCATCTGGAGGTTCCCGGGGCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGGGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCATCTTGACGC	1464
QY	420	aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrpVa	440
DB	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl	460
DB	1525	GCTGGCGGAGGGGAGTGCAGTGGAGCCCTTACTACCCCGAGTCTGAGGAGCTGGGG	1584
QY	460	yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIlelePhePh	480
DB	1585	AGCATCTCTGAGGAGGTGAGCGGCGCTCCCGAGGCGCGATGCTCATCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
DB	1645	CCGAGATGACCGCTACTTGGCGCTCGACCGGCAAACTGCAGGCAACACCTCGGGCG	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
DB	1705	CTGGGCCACCGAGTGGCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGGCTGTT	1764
QY	520	e 520	
DB	1765	C 1765	
RESULT 233			
US-10-145-818-143			
; Sequence 143, Application US/10145818			
; Publication No. US20030157622A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Desnoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tamas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; FILE REFERENCE: P3330R1C290			
; CURRENT APPLICATION NUMBER: US/10/145,818			
; CURRENT FILING DATE: 2002-05-14			
; Prior Application removed - See File Wrapper or Palm			
; NUMBER OF SEQ ID NOS: 550			
; SEQ ID NO 143			
; LENGTH: 1985			

```
! TYPE: DNA
! ORGANISM: Homo Sapien
US-10-145-818-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-818-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db 206 ATGGTCGCGCGGTGGCGCTCTCTGTCGCGCGCTTGCAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGAGCGCGAGCGCCAGGAGCTGCGCAGGAGCGCGAGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTGTTTGTGTAGACACCGGACCCAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTGGCAGCAGGTAACTAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGTTCTGGGAGGCGCCACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCAGAGGAGCACCAACATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTTGGCGCAGCGCTTC-CTGCCCGCGCGCGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTGGCGGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCCTCACCATCTCGCCCGCGCGCGCGCTCATGGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGTT 1104
```

```
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCTGTAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAATATCTGCCACTCTTCTTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGCGGCTGCCCGCCCAACATTTAGAGCTCGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGCAGGGGCGCTGCCCGCCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGGTCCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrPrArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTACAGCGCGCTGCGCGAGCGCGCTGCTCATCTCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTGCGCGCTTCGACCAAGGCAAACTCGAGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACAGCTGCCCTGGATGGCTGCTGGCATGCCCACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765
```

RESULT 234

```
US-10-145-820-143
; Sequence 143, Application US/10145820
; Publication No. US20030157623A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
```


; FILE REFERENCE: P3330R1C276
; CURRENT APPLICATION NUMBER: US/10/145,820
; CURRENT FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059836
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062285
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062814
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063127
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063327
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063550
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063561
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063704
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063735
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063738
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064248
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066453
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069212
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069278
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069334
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-16
; PRIOR APPLICATION NUMBER: 60/072320
; PRIOR FILING DATE: 1998-01-23
; PRIOR APPLICATION NUMBER: 60/073612
; PRIOR FILING DATE: 1998-02-04
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081695
; PRIOR FILING DATE: 1998-04-14
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081818
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082999
; PRIOR FILING DATE: 1998-04-24
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/083545
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085149
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086414
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/086430
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/088026


```
QY      520 e 520
Db      1765 C 1765

RESULT 235
US-10-145-872-143
; Sequence 143, Application US/10145872
; Publication No. US20030157624A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC294
; CURRENT APPLICATION NUMBER: US/10/145,872
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-872-143

Alignment Scores:
Pred. No.: 3,356-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-872-143 (1-1985)

QY      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db      206 ATGGTCGGCGCGCTCGGCTCTCTGTCGCGCGCTGCAAGTCTACTGTGGGGCCACCTG 265

QY      21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266 GAGCGCCAGCCCGCGAGCGCGAGCGAGCTGCGCAAGAGCGCGAGCATTCCTA 325

QY      41 GlutylsTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326 GAGAAAGTACGGATACCTCAATGAACAGGTGCCCCAAAGCTCCACCTCCACTCGATTACG 385

QY      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386 GATGCCATCAGACCGCTTTTCAGTGGGTGTCCCAAGTACCTGTGTCAGCGCGTGTGGACCGC 445

QY      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446 GCCACCTTCGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

QY      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
```

```
QY      121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566 AAACGCTTTTGCAAAAGAGTAACAATGGTAAACAGCAGCACTCTCTCCACCGCTGGTG 625

QY      141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626 AACTGGCCTGAGCATCTCCGAGCGCGCAGTTCCGGGGCGCGTGGCGCGCTCCAG 685

QY      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGCCCGCTGAC 745

QY      180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db      746 ATCCGGCTCACCTCTTCCAAAGGGGACCACAAACGATGGGTGGGCAATGCTTTGATGGC 805

QY      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db      806 CCAGGGGCGGCTGGCGCACGCTTC-CTGCCCCCGCGCGCGGGAAGCGCACTTCGACCA 864

QY      220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGCGCAACCTGTTCTGCTGCTGCGCGCA 924

QY      240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984

QY      260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db      985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044

QY      280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045 GAGCGCTGATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104

QY      300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db      1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGAAAGCGCGCTCGAAACCGAGGG 1164

QY      320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
Db      1165 CCCTAATATCTGCCACTCTTCTTCGATGCTCATCTACTAGACAGCAACAGCAACTGTA 1224

QY      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGTGCAACAGTCTCAGAGCCCGC 1284

QY      360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerie 380
Db      1285 TCCACTCGAGAAAGATGGGTGGGCTGCGGCTGCCCGCCCAACATTAGGCTGGCGAGTGTCA 1344

QY      380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464

QY      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524

QY      440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db      1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAAGGACTGGGG 1584

QY      460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db      1585 AGGCATCCCTGAGGAGGTACGCGCGCGCTGCCCGGCGCGCGATGGCTCCATCATCTTCT 1644
```

```
Qy 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACGAGCCAACTGCGAGGCAACACCTCGGGCCG 1704
Qy 500 gTtpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACACGAGCTGCGCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 236
US-10-145-873-143
; Sequence 143, Application US/10145873
; Publication No. US20030157625A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C305
; CURRENT APPLICATION NUMBER: US/10/145,873
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-873-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-873-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGCGAGGCTGCGAGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTCCAGC 385
Qy 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCTGAGCGCGCTGTGGACCGC 445
```

```
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATGACTGTCCTCCCGCTGGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTACTGTTGTTTGTAGACACCGGACCAAAATAGGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAAACGCTTTGCAAAAGCAAGGTAACAAAATGGTACAAGCAGCACCTCTCTTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCCGTCGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTTGGCGCAGCGCTTC-CTGCCCGCGCGGCGAAGCGGACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCATCGCCCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysPheProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTCCAGCGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCCTCGAAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATATGTCACCTCTTCTTCGATGTCATCCTGTAGACNGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGACCATTTCTGGGAGGTGGCAGCTGTATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGCGAGGTGTCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAAGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGGAGGGGCTGCGCGCGCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
```

```
Db      1525  GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy      460  YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCTGAGGAGGTGAGCGGCGCCCTGCGAGGCCCGATGCTCATCATCTCTT 1644
Qy      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTTGGCGCTCGACCAGGCCAAACTGCAGGCAACCCACCTCGGGCG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCybTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGAITGGCTGTGGTATGCCAATCTCGGGAGGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 237
US-10-147-481-143
; Sequence 143, Application US/10147481
; Publication No. US20030157626A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C360
; CURRENT APPLICATION NUMBER: US/10/147,481
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-481-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:    98.52%      Indels:      2
DB:             17          Gaps:         0

US-10-791-980-6 (1-520) x US-10-147-481-143 (1-1985)

Qy      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db      206  ATGTGCGCGCGCTCGGCTCTCTGTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACGCCACCGCCGCGAGCGGAGCGGAGGCTGCGCAAGGAGCGGCGGCAATTCCTA 325
Qy      41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```

```
Db      326  GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACACCTCCATCGATTCAGC 385
Qy      61  AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTTACCTGTGAGCGGGCGTGTGTGACCGC 445
Qy      81  AlaThrLeuArgGlnMetThrArgProArgCybGlyValThrAspThrAsnSerTyrAla 100
Db      446  GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy      101  AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506  GCCTGGGCTGAGAGGATCAGTGACTTGTCTTAGACACCGGACCAAAATAGGGCGTAAAG 565
Qy      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AATCGCTTTGCAAGCAAGGTAACAATGGTACAGCAGCACCTCTCTCTACCGCTGGTG 625
Qy      141  AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGTGGCGCGCCTTCCAG 685
Qy      160  rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686  TTGTGGAGCAACGTCTCAGCGCTGGAGTTCCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy      180  rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db      746  ATCCGGCTCACTTCTTCCAAAGGGGACACAAACATGGGCTGGGCAATGCGCTTGTATGGC 805
Qy      200  aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db      806  CCAGGGGGCGCCCTGGGCGACGCCCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
Qy      220  nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGGTCCCTGAGCCGCGCGGGCGCAACCTGTTCTGTTGGTGTGTGGCGCA 924
Qy      240  sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTACACGCTTGGCCCTCACCCACTCCCGCGCGCGCGCGCTCATGCGCGCC 984
Qy      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db      985  CTACTACAGAGGCTGGGCGCGCGAGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTCCCGTCCAGGAAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db      1105  CACTGACTTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCGCTGAAACGCGAGG 1164
Qy      320  YProLysTyrCybHisSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
Db      1165  CCCTAAATACTGCCCACTCTTCTTCGATGCCATCCTGTAGACAGGCGACAGCAACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCGC 1284
Qy      360  gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTTAGAGGCTGCGGCAGTGTCAAT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTTCTCTTCTTCAAGGGGGTGTGATGTGGAGGTTTCCGGGGCCCCNA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
```

Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCCGCCATCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuLeuPheLeuGlyAlaArgTyrTyrVa 440
Db 1465 GCGCCCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTGTGCAAGGACTGGGG 1584
Qy 460 yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCTGCGAGGGCCGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTGCGCGCTCGACCAAGGCGCAAACTGAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGGCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 238

US-10-147-482-143
; Sequence 143, Application US/10147482
; Publication No. US20030157627A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C364
; CURRENT APPLICATION NUMBER: US/10/147,482
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-482-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatism: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-482-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
|||||

Db 206 ATGCTCGCGCGCTCGCCCTCTCTGCTGCGGCCCTGAGCTGTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCGCGCGAGCGCGAGGCGCAGAGCTGCGCAAGAGGCGGAGGATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCATCTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGCTTTCAGTGGGTGTCCAGACTACTGTACAGGGGGTGTTCGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGCTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGTTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGCGAGCGCGAGTTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTGGAGAGCCCGCCAGCCAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACGATGGGCTGGGCAATGCTTTTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCGCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTGCTGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCGCGCGCGCGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGTGGGGCGCGACGCGCTGCTCAGCTGGGAGCAGCGTGTGCGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG1 320
Db 1105 CACTGACTTTTGGAGCTGGGACTCTTACAGCGCCCAAGGAGGCGCGCTCAAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCGCACTCTTCTTCGATGCGCATCTACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCAATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnLysArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGCGGCTGCGCCCAACATTTGAGGCTGCGGCGTGTGCTATT 1344

Qy	380	waSaAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTCTTCAAAGGGGGTCGATGCTGGAGGTTCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGCTCTCCACACAGCTGTGCCGGGCAAGGGGGCTGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGC CGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGAGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGAGGTCAAGCGCGCCCTGCGAGGCGCGATGGCTCCCATCATCTTCCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGGCGCTCGACCAAGGCCAAACTGCAGGSCAACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGGCTCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	

RESULT 239

```

RES-10-147-503-143
; Sequence 143, Application US/10147503
; Publication No. US20030157628A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC335
; CURRENT APPLICATION NUMBER: US/10/147,503
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-503-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1

```


Db 1105 CACTGACCTTGAGACTGGGACTCTACAGCCCGCCCAAGGAGCGCCCTCGAAACCGAGGG 1164
Qy 320 YProlystYrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCACTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnLuarGtrPvalGlyvProProAsnleGluAlaAlaValSerle 380
Db 1285 TCCACTGCGAAGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyVgLyArGyCyvTrpArgPheArgGlyvProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCyvArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyTrPProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTTCAGCGGGCGCCCTGCCAGGGCCGATGGCTCCATCACTCTT 1644
Qy 480 eArgAspAspArgTyTrPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAATGCAGGCCAAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCystrPhHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCCCTGGATGGGCTGTGGCATCCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 241

US-10-152-401-143
; Sequence 143, Application US/10152401
; Publication No. US20030157630A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C385
; CURRENT APPLICATION NUMBER: US/10/152,401

; CURRENT FILING DATE: 2002-05-20
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-152-401-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
US-10-791-980-6 (1-520) x US-10-152-401-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGGTCGCAAGAGCGCGAGGCATTCTCTA 325
Qy 41 GluLysTyTrGlyTyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAAACAGGTCCCCAAAAGCTCCACCTCCACATCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTTCAGCGGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpLysGlnHisLeuSerTyArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCCTCTCTACCGCTTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGCAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCyGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCGGGAGGCCCCAGCCACAGGCCCTCGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGAACAACCAATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGCGCAAGCGCACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGCAACCTGTTCGTGGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCCTCACCACTCCGCCCGCGCGCGGCTCATGGCGCC 984
Qy 260 oTyTrTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280

Db 985 CTACTACAAGAGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLeuProLeuGlySerValAlaValGlnLeuProGlyLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACCTTGAGACCTGGGACTCCTACAGCCCCAGGAAGGCGCCCTGAAACGCAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACAGCCACTTCTCTCGATGCCACTCACTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTTCCACAGCTGTGCCGGGCAGGGGGCTGCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lIleuAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGACGGGCGCTTCCAGAGGCCCATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCCAACTCGAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 242
US-10-157-783-143
; Sequence 143, Application US/10157783
; Publication No. US20030157631A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C435
; CURRENT APPLICATION NUMBER: US/10/157,783
; CURRENT FILING DATE: 2002-05-29
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-157-783-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
US-10-791-980-6 (1-520) x US-10-157-783-143 (1-1985)
Qy 1 MetValalaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGCGCTCTCTGTCGCGCGCTGTCAGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGGAGCCAGAGCTGCGCAAGGAGGCGGAGGCATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCACGCTACCTGTCAGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTTGTTGCTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAAACAATGTGTACAGCAGCACCTCTCTCCCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTTCCAAGGGGACCAACAAGTGGGTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGGGCAGCGCTTC-CTGCCCGCGCGCGGAGGAGGCGACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTCTGTTCTGTTGTTGTTGGCGCA 924

```
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGTCAACGCTGGCTGCTACCCACTGCGCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 280
DB 985 CTACTACAAGAGCGCTGGCGCGCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1044
QY 280 nSerLeuTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 300
DB 1045 GAGCTGTATGGAAGCGCTTGGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1104
QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAGAGAGCGCGCTGAAACCGAGGG 1164
QY 320 yProTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 360
DB 1225 CATTTTAAAGGAGCGCACTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAAGATGGTGGCGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCCGGGGCCCA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCyenArgAlaGlyGlyLeuProArgHisProAsp 420
DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCATCTCTG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheTyTyTyTyTyTyTyTyTyTy 440
DB 1465 CGCCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyTyTyTyTyTyTyTyTyTyTyTyTyTy 460
DB 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTTACTACCCCGAAGTCTGCGAGCTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGAGGCGCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACCGAGCCAACTGCGAGGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCystrPheHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCACTCGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 243

```
US-10-158-792-143
; Sequence 143, Application US/10158792
; Publication No. US20030157632A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
```

```
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C460
; CURRENT APPLICATION NUMBER: US/10/158,792
; CURRENT FILING DATE: 2002-05-30
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-158-792-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
US-10-791-980-6 (1-520) x US-10-158-792-143 (1-1985)
```

```
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGTCGCGCGCTGGCTCTCTGTCGCGCGCTTGTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACGCCCGGAGCGCGGAGCCGAGAGCTGCGAAGAGGCGGAGGCATTCCTA 325
QY 41 GluTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 60
DB 326 GAGAAGTACGATACCTCAATGAACAGGTCTCCCAAAAGCTCCACCTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCy8GlyValThrAspThrAsnSerTyAla 100
DB 446 GCCACCTTGGCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGGCGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 140
DB 566 AAACGCTTTGCAAGAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGGAGCATCTCCCGGAGCGCGAGTCTGGGGCGCGCTGCGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCCGCCAGGCCCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCGGGCTCACTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGCG 805
```

```
QY 200 sGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
D 806 CCAGGGGGCGCCTGGCGACCCCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCAGACA 864
QY 220 nAspGluArgTTPSerLeuSerArgArgGlyValArgAsnLeuPheValValLeuAlaHi 240
D 865 AGATGAGCGCTGTCCTCGAGCGCGCGCGGGGCGCAACTGTTCTGTGTGTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
D 925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 cTyTyTyArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
D 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyTyGlyTyProLeuGlyGlySerValAlaValGlnLeuProGlyTyLeuPh 300
D 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG1 320
D 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGAG 1164
QY 320 yProTyTyTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
D 1165 CCCTAAATACTGCGCACTCTCTCTCGATGCGCATCACTGTAGACAGGCAACGCAACTGT 1224
QY 340 rIlePheTyGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
D 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCC 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
D 1285 TCCACTGAGGAAAGATGGTGGGCTGCCGCCCAACATTCAGGCTGGCGGAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyPhePheLeuGlyGlyArgCysTrpArgPheArgGlyProLy 400
D 1345 GAATATGGAGATTTCTACTTCTTCAAAGGGGGTCTGATCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
D 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCGCCATCTCAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheTyGlyAlaArgTyTyVa 440
D 1465 GCGCCTTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAAGGGTGGCGGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTrpProArgSerLeuGlnAspTrpG1 460
D 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTATACCCCCCAAGTCTGCAAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
D 1585 AGGCATCCTCAGGAGGTACGCGCGCCCTGCCGAGGCCCGCATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
D 1645 CCGAGATACCGCTACTCGCGCCTCGACAGGCCCAAACTGCAAGGCCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTTPMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
D 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
D 1765 C 1765
```

RESULT 244

US-10-158-462-143
; Sequence 143, Application US/10158462
; Publication No. US20030158104A1
; GENERAL INFORMATION:

```
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Beresini, Maureen  
; APPLICANT: DeForge, Laura  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Sherwood, Steven  
; APPLICANT: Smith, Victoria  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Watanabe, Colin K  
; APPLICANT: Wood, William  
; APPLICANT: Zhang, Zemin  
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; TITLE OF INVENTION: ACIDS ENCODING THE SAME  
; FILE REFERENCE: P3330R1C439  
; CURRENT APPLICATION NUMBER: US/10/158,462  
; CURRENT FILING DATE: 2002-05-29  
; NUMBER OF SEQ ID NOS: 550  
; SEQ ID NO 143  
; LENGTH: 1985  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
US-10-158-462-143
```

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-158-462-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
D 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
D 266 GAGCCCGAGCCCGGAGCGCGAGGCTGCGCAAGGAGCGGAGGATTCCTA 325
QY 41 GluLysTyTyGlyTyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
D 326 GAGAGTACGGATACCTCAATGACAGGTCCCCAAGCTCCACCTCCATCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
D 386 GATGCCATCAGAGGTTTCACTGGTGTCCAGCTACCTGTACGCGCGGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
D 446 GCCACCTCGCGCAGATGACTCGTCCCGCTGGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
D 506 GCTGGGCTGAGGAGTACAGTACTGTGTTTGTAGACACCGGACCAAAATAGGCGGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyTyLysGlnHisLeuSerTyArgLeuVal 140
D 566 AAACGCTTTCAAAAGCAAGGTAACAAATGGTTACAAGCAGCACCTCTCTACCGGCTGGT 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
D 626 AACTGGCCTGAGCATCTGCGGAGCGGCAAGTTCGGGGCGCGCTGCGCGCGCTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
D 180
```



```
Db      686  TTGTGGAGCAAGCTCTCAGGGCTGGAGTTCTGGGAGGGCCCCAGCCACAGGCCCGCGTGAC 745
Qy      180  rSerGlySerProSerSerGlyThrThrMetGlyTTrpAlaMetProLeuMetAl 200
Db      746  ATCCGGCTCACCTTCTTCAAGGGGACCACACGATGGGCTGGCAATGCCITTTGATGC 805
Qy      200  aGlnGlyAlaProTTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db      806  CCAGGGGGGGCGCTGGCGCACGCTTC - CTGGCCCGCGCGCGGGAAGCGCACTTCGACCA 864
Qy      220  nAspGluArgTTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
Db      865  AGATGAGCGCTGTCTCGAGCGCGCGCGCGCGCAACCTGTTCTGTGGTGGTGGCGCA 924
Qy      240  sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTCAACAGCTTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db      985  CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGACGCTGCGCGGTGCA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGAAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
Qy      300  eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db      1105  CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAGGAGGCGCTTGAACGCGAGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db      1165  CCCTAAATAGCTCCACTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGCCAACGTCCTCAGAGCCCCG 1284
Qy      360  gProLeuGlnGluArgTTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCAGGAAGATGGGTGGGCTGGCTGCCCCCAACATTGAGGTGGCGAGTGTCA 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400  sProValTTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCGCATCTGAGCG 1464
Qy      420  aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465  CGCCCTCTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGGTCTACTAGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db      1525  GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTTACTACCCCGAGTGTCCAGGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGSAGGTGAGCGGCGCTGCGGAGGCGCGATGCGTCCATCATCTTCT 1644
Qy      480  eArgAspAspArgTTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGGCGCTCGACGAGGCCAACTGCGAGGCAACACCTTCGGGCG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCCCAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy      520  e 520
Db      1765  C 1765
```

RESULT 245

US-10-143-035-143

; Sequence 143, Application US/10143035

; Publication No. US20030166071A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; CURRENT APPLICATION NUMBER: US/10/143, 035

; CURRENT FILING DATE: 2002-05-09

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-143-035-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985

Score: 2792.00 Matches: 519

Percent Similarity: 99.62% Conservative: 0

Best Local Similarity: 99.62% Mismatches: 1

Query Match: 98.52% Indels: 2

DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-143-035-143 (1-1985)

```
Qy      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTTrpGlyHisLeu 20
Db      206  ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACGCCACGCCCGCGGAGCGCGGAGCTGCCAAGAGGAGGAGGAGGAGGAGGAGGAGGAG 325
Qy      41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAGTACGATACCTCAATGAACAGGTCCCAAGAGTCCCACTCCATCGATTCAGC 385
Qy      61  AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCTGTGGACGCG 445
Qy      81  AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446  GCCACCTTGCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy      101  AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506  GCCTGGGCTGAGAGGATCAGTCACTTTGCTTGACACACCGGACCAAAATGAGGGCTAAG 565
Qy      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AACCGCTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCTCTACCGCTGTG 625
```


QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTGAGAGGATCAGTACCTGTTGTTGTAGACACCGGACCAAAATGAGGCGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGGCAAGGTAACTAAGTGAACAGCAGCAGCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGGGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCGGAGGCGCCACAGCCAGCCAGGCGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGCG 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGGGCGCTGGGCGACCCCTTC-CTGCCCCCGCGCGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATCAGCGCTGGTCCCTGAGCGCGCGCGCGCGCACTGTTCTGTTGCTGCGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTCAACGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCGCGCGTGA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAGCGCGCGCTGAAACGCGGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACGCGCACTCTCTTCGATGCGCATCACTGTAGACAGCAACGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGTGGCGGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCTTGGCCCCCCTATCTTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 GCGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyLysLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGGAAAGTCTGCGAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480

Db 1585 AGGCATCCTCAGGAGGTTCAGCGGCGCTTCGCGAGGCCCATCATCTCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCGGCCAAATGCGAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGATGGGCTGTGGCATGCCAACTCGGGAGGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 247
US-10-145-822-143
; Sequence 143, Application US/10145822
; Publication No. US20030166075A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C302
; CURRENT APPLICATION NUMBER: US/10/145,822
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-822-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-822-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGCGCGCCCTGCGAGTGTCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCCAGCCCGCGAGCGCGAGGCTGCGAAGGAGCGAGGAGGATTCCTA 325
QY 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCATCAGCGGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCGTGTTCGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCCCGCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTCTTCTAGACACCGGACCAAAATAGGCGGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCCAAAGCAAGGTAACAAATGGTTACAAGCAGCACCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCGCGAGCGGCGAGTTGCGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTTCTAGCCGCTGGAGTTCTGGAGAGGCCCCAGCCACAGGCCCTCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTTGAGCCCGCGCGCGGGCGCAACTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGCGAGCTGCTCAGCTGGGACGACGCTGTGGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTCAGACCTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACGCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGTGGAGCTGATGCAACGTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGCTGCCCGCCCAACATTAGCGTGGCGGAGTGTGATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTCTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 CCCAGTGTGGGTTCTCCACAGCTGTGCCGGGAGGGGCTGCGCGGCCCATCTTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440

Db 1465 CGCCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgTrpAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTGAGAGGTGAGCGGCGCCTGCGAGGCCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACCGAGGCAAACTGCAGGCAACCACTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCCTGGATGGCTGTGCTGCAACTGCCAAGTGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 248
US-10-145-824-143
; Sequence 143, Application US/10145824
; Publication No. US20030166076A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCES: P3330R1C280
; CURRENT APPLICATION NUMBER: US/10/145,824
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-145-824-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-824-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTGGCGCGCTCGGCGCTCTCTGCTGCGCGCCCTGAGCTGTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40

Db	266	GACGCCACCGCGGAGCGCGAGAGCCAGGAGCTGCCAAGAGGAGCGGAGGCATTCCTCA	325
Qy	41	GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCACAGCTACCTGTTCAGCGCGCTGTTCGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGACAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCTACCGCTCGTG	625
Qy	141	AsnTrpProGluHisLeuArgSerArgGlnPheGlyValProCysAlaProProSerSer	160
Db	626	AACTGGGCTGAGCATCTGCGGAGCGCGGACGTTGCGGCGCGCTGCGCGCGCTTCGAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTTGGAGAGCGCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSertysGlyThrThrThrMetGlyTrpAlaMetProLeuMetal	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGAGCCACAAACATGGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200	gAlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGly	220
Db	806	CCAGGGGGCGCCCTGGCGCAGCGCCTTC-CTCGCCCGCGCGCGGCGAAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGGGCTGTGCTCCAGCGCGCGCGGGGGCGACCTGTCTGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr	260
Db	925	CGAGATCGGTCAACGCTTGCGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGly	280
Db	985	CTACTACAAGAGGTGGCGCGCAGCGCTGCTCAGCTGGGAGCAGCGTGTGGCGCGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGly	320
Db	1105	CACGTGACTTTGAGACCTGGGACTCCTACAGCGCCCCCAAGGAAGCGCCCTGAAACGCAGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGAGCCATTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGGTTCGGGTGCCCTTCCAGCATTCAGGCGCTGGGCGAGTGCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLys	400
Db	1345	GAATGATGGAGATTCTACTCTTCAAAGGGGGTGCATGCTGAGGTTTCGGGGCGCCAA	1404

QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGACAGGGGGCTGTGCCCGCCATCTCTGACGC	1464
QY	420	aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCTCTCTGTGCCCGCCTCATCTCTTTCAAGGGTGCCCGCTACTACGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGGCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
QY	460	yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGTCAAGCGCGCCCTGCGAGGCGCGATGGCTCCATCATCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGCGCCTCGACAGGCCAATCTCAGGCAACCACTCGGGCCG	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGTGCCTCGATGGGCTGCTGGCATSCCAACTCGGGAGCGCCCTGTT	1764
QY	520	e 520	
Db	1765	C 1765	
RESULT 249			
US-10-145-827-143			
; Sequence 143, Application US/10145827			
; Publication No. US20030166077A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Deanoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; TITLE OF INVENTION: ACIDS ENCODING THE SAME			
; FILE REFERENCE: P3330R1C265			
; CURRENT APPLICATION NUMBER: US/10/145,827			
; CURRENT FILING DATE: 2002-05-14			
; Prior Application removed - See File Wrapper or Palm			
; NUMBER OF SEQ ID NOS: 550			
; SEQ ID NO 143			
; LENGTH: 1985			
; TYPE: DNA			
; ORGANISM: Homo Sapien			
US-10-145-827-143			

Alignment Scores:		
Pred. No.:	3,35e-262	Length:
Score:	2792.00	Matches:
Percent Similarity:	99.63%	Conservative:
Best Local Similarity:	99.63%	Mismatches:
Query Match:	98.52%	Indels:
DB:	17	Gaps:
US-10-791-980-6 (1-520)	x	US-10-145-827-143 (1-1985)

Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-869-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGGCTCTCTGCTCGCGCCCTGACGTCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuLeuArgGlyGlnAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCCGCGAGCGCGAGGCCAGGAGCTGCGCAAGGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuLeuGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgLys 120
DB 506 GCTCGGCTTGAGAGGATCAGTCTGTTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTGCAAGACAGTAACTGTTACAGACACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGACATCTGCGGAGCGCGAGTTGCGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCACACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTTGGCGCACGCTTC-CTGCCCCCGCGCGGAGGCGCATTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGTTGCTGGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTTCACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGCTTGGCGCGCGCGCTGCTGCTAGCTGGGACGACGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCGCCAGGAGGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
```

```
DB 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCATCTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1295 TCCACTGGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATCATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTTCCACAGCTGTGCCGGGCGAGGGGCTTGGCCCGCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGCTCATCTCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
DB 1645 CCGAGATACCGCTACTGCGCGCTCGACAGGCGCAAACTGCAGGCGCAACCCCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
```

Search completed: November 14, 2005, 14:43:53
Job time : 1743 secs

THIS PAGE BLANK (USPTO)